

Parma, 5 April 2011

Consolidated list of Article 13 health claims

List of references received by EFSA

Part 3

IDs 2001 – 3000

(This document contains the list of references for claims which the Commission has asked EFSA to prioritise in the evaluation.)

BACKGROUND

In accordance with Article 13 of Regulation (EC) No 1924/2006¹ Member States had provided the European Commission with lists of claims accompanied by the conditions applying to them and by references to the relevant scientific justification by 31 January 2008.

EFSA has received from the European Commission nine Access databases with a consolidated list of 4,185 main health claim entries with around 10,000 similar health claims. The similar health claims were accompanied by the conditions of use and scientific references. The nine Access databases were sent in three batches - in July 2008, in November 2008 and in December 2008.

Subsequently, EFSA combined the databases into one master database and re-allocated upon request of the Commission and Member States similar health claims which had been accidentally placed under a wrong main health claim entry (misplaced claims). During this process some Member States also identified a number of similar health claims which still needed to be submitted to EFSA (“missing claims”). These similar claims were also added to the database.

In March 2010, the European Commission forwarded to EFSA an addendum to the consolidated list containing an additional 452 main entry claims which have been added to the updated final database which was published on the EFSA website in May 2010 (containing 4,637 main entry claims).

The references to the scientific justifications provided by Member States were either included in the database or were provided in separate files. In addition, full-text copies of references were provided directly to EFSA from stakeholders. The deadline for submission of these references was end of 2008. EFSA wishes to acknowledge the full-text copies of relevant literature provided by stakeholders until that date. In some instances, references provided to EFSA were referring to papers which were submitted for publication. In case the publication had in the meanwhile taken place EFSA has included the correct citation in the list of references and this may result in some references carrying a 2009 or 2010 publication date.

¹ Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.

EFSA has screened all health claims on the list using six criteria established by the NDA Panel to identify claims for which EFSA considers sufficient information has been provided for evaluation and those for which more information or clarification is needed before evaluation can be carried out. The claims which had been sent back to the Commission and the Member States for further clarification in January 2009 were received back with additional information in November 2009.

Further information can be found on the EFSA website under the following link:
http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_article13.htm.

LIST OF REFERENCES

The present document compiles the lists of references for claims with ID numbers between 2001 and 3000 and which the Commission has asked EFSA to prioritise in the evaluation. The list takes into account references provided through different sources and those coming from misplaced or missing claims. The main health claim entries are sorted in ascending order of the ID number.

This document has been updated according to the progress of adoption of opinions related to Article 13 health claims. References for ID numbers which have been added to the document after the last update of 4 October 2010 have been highlighted in red font.

TABLE OF CONTENTS

Table of contents	3
ID 2001: “Bilberry (<i>Vaccinium myrtillus</i>) extract containing anthocyanins” and “Eye Health”	22
ID 2003: “ <i>Borago officinalis</i> (Common Name : Borage)” and “Skin health”	23
ID 2004: “ <i>Camellia sinensis</i> (Common Name : Tea)” and “Mental and cognitive health”	24
ID 2005: “ <i>Camellia sinensis</i> (Common Name : Tea)” and “Cognitive Performance: Focussed attention”	26
ID 2006: “ <i>Capsicum annum</i> (Common Name : Cayenne pepper)” and “Weight management”	29
ID 2007: “ <i>Carica papaya</i> (Common Name : Papaya)” and “Antioxidant activity”	31
ID 2010: “ <i>Carum carvi</i> (Common Name : Caraway)” and “Lactation”	31
ID 2013: “ <i>Cinnamomum cassia, zeylanicum</i> (Common Name : Cinnamon)” and “Glucose metabolism”	32
ID 2014: “ <i>Cinnamomum zeylanicum</i> BARK” and “Digestion”	33
ID 2017: “ <i>Cinnamomum zeylanicum</i> BARK” and “Cardiovascular”	35
ID 2018: “ <i>Cinnamomum zeylanicum</i> BARK” and “Genitourinary”	35
ID 2020: “ <i>Cinnamomum zeylanicum</i> BARK” and “Antioxidant”	36
ID 2021: “Cherries (<i>Prunus cerasus</i>), including Montmorency, Balaton or other sour/tart cherry varieties” and “Antioxidant support”	37
ID 2022: “Cherries (<i>Prunus cerasus</i>), including Montmorency, Balaton or other sour/tart cherry varieties” and “Joint support”	38
ID 2023: “Cherries (<i>Prunus cerasus</i>), including Montmorency, Balaton or other sour/tart cherry varieties” and “Cardiovascular / heart health support”	38
ID 2024: “Cherries (<i>Prunus cerasus, P. domestica</i>), including Montmorency, Balaton or other sour/tart cherry varieties” and “Brain/mental/cognitive health”	39
ID 2025: “ <i>Citrus paradisi</i> (Common Name : Grapefruit)” and “Antioxidant properties”	39
ID 2026: “ <i>Citrus aurantium</i> (Common Name : Bitter orange)” and “Metabolism of lipids/Weight management”	41
ID 2027: “ <i>Citrus aurantium</i> L. ssp. <i>Aurantium</i> (Common name: Bitter orange)” and “Respiratory health”	41
ID 2028: “ <i>Citrus limon</i> (Common Name: Lemon)” and “digestive health”	41
ID 2029: “ <i>Cucurbita pepo</i> (Common Name : Pumpkin)” and “Health of lower urinary tract”	42
ID 2031: “CoffeeSLENDER® Tablets made from an extract from green coffee beans (Svetol®) the active principle of which is: -5-caffeoylquinic acid or (Chlorogenic acid) =45%, Caffeine = 2%, 3- caffeoylquinic acid =10%” and “Weight loss and weight control in overweight adults Reduces glucose absorption from gut”	44
ID 2034: “ <i>Coriandrum sativum</i> FRUIT” and “Urinary”	45
ID 2035: “ <i>Coriandrum sativum</i> FRUIT” and “Cardiovascular”	46
ID 2037: “ <i>Coriandrum sativum</i> FRUIT” and “Immunity & antioxidant”	46
ID 2039: “ <i>Capsicum</i> Extract –with Capsaicin” and “Required for enhancing thermogenesis, increasing energy expenditure and enhancing loss of calories”	47
ID 2040: “ <i>Capsicum</i> Extract –with Capsaicin” and “Required for stimulating carbohydrate oxidation and burning carbohydrates”	48
ID 2041: “ <i>Capsicum</i> Extract –with Capsaicin” and “Required for fat oxidation and burns fat, leading to loss in body weight”	48

ID 2042: “Capsicum Extract –with Capsaicin” and “Required for reducing caloric intake”	48
ID 2043: “Capsicum Extract –with Capsaicin” and “Required for the reduction of oxidative stress”	48
ID 2044: “Capsicum Extract –with Capsaicin” and “Required for promotion of hair growth”	49
ID 2045: “Dioscorea villosa (Common Name : Wild Yam)” and “Menopause”	49
ID 2046: “Elettaria cardamomum SEED” and “Kidneys”	50
ID 2049: “Elderberry Sambucus nigra” and “Antioxidant properties”	50
ID 2050: “Fruit of Vaccinium myrtillus” and “Maintain eye health and function, through antioxidant and venous support action”	52
ID 2052: “Foeniculum vulgare ssp. Cappillaceum var. vulgare. DRIED FRUIT” and “Immunity. Antioxidant”	53
ID 2053: “Foeniculum vulgare ssp. Cappillaceum var. vulgare. DRIED FRUIT” and “Postpartum”	53
ID 2055: “Foeniculum vulgare Mill (Common name: Fennel)” and “Respiratory health”	54
ID 2056: “Foeniculi aetheroleum (Common name: Fennel oil)” and “Respiratory Health”	54
ID 2057: “Garcinia Cambogia (Common name: Carcinia gummi-gutta, gummi-gutta gum, brindleberry, Malabar, tamarind)” and “Weight management”	55
ID 2058: “Green Mate leaf extract (Ilex paragueariensis St.-Hil.)” and “Mild diuretic effect, drainage of excess water”	57
ID 2059: “Natural Grape Extract From red grape skin” and “Rich in polyphenols - Act as antioxidants - Antioxidant is a compound able to scavenge free radicals in the body and stop the oxidative chain reaction”	58
ID 2060: “Grape seed extract” and “Antioxidant activity”	58
ID 2061: “Natural Grape Extract From white grape skin Solvent free” and “Rich in polyphenols - Act as antioxidants - Antioxidant is a compound able to scavenge free radicals in the body and stop the oxidative chain reaction”	60
ID 2062: “Guarana” and “Guarana and mental performance”	60
ID 2063: “Guarana” and “Guarana and mental performance”	61
ID 2064: “Griffola fondosa (Common Name : Maitake)” and Immune health”	62
ID 2065: “GLA (example from Borago Officinalis, Primerose oil, Blackcurrant seed oil) and “Essential fatty acid of importance for a healthy skin”	63
ID 2068: “Hippophae rhamnoides (Common Name : Seabuckthorn)” and “Skin health”	64
ID 2069: “Illicium verum Hook. (Common name: Star anise)” and “Respiratory health”	64
ID 2070: “Ilex paraguariensis (Common Name : Yerba mate)” and “Weight management/Metabolism of lipids”	64
ID 2073: “Illicium verum (Common Name : Star anise)” and “Respiratory health”	65
ID 2075: “Lentinus edodes (Common Name : Shiitake)” and “Immune health”	66
ID 2076: “Linum usitatissimum (Common Name : flaxseed linseed)” and “Gut health”	67
ID 2080: “Lutein (example from tagetes E or Calendula Officinalis)” and “Antioxidant properties”	68
ID 2081: “Lycopene (fromTomato extract)” and “Antioxidant properties”	68
ID 2082: “Lycopene (fromTomato extract)” and “Antioxidant properties / protection of DNA”	70
ID 2083: “Lycium Barbarum (Common Name: Wolfberry)” and “Antioxidant properties”	71
ID 2087: “Melissa officinalis (Common Name : Lemon Balm)” and “Antioxidant properties”	72

ID 2090: “Matricaria recutita (Common Name : Chamomile” and “Antioxidant properties”	74
ID 2091: “Momordica charantia (Common Name : balsam pear, bitter melon, bitter gourd, ampalaya, karela (karola), fu kwa)” and “Glucose metabolism”	74
ID 2095: “Mung bean (Vigna Radiata)” and “Menopause”	75
ID 2096: “Meso-zeaxanthin (derived form lutein of plant extract like marigold ,spinach” and “Required for macular pigmentation in the eyes for helping in maintenance of health eye functions”	76
ID 2097: “Menthae piperitae aetheroleum (Common name: Peppermint oil)” and “Respiratory health”	77
ID 2098: “Oenothera biennis (Common Name : Evening Primrose)” and “Joint health”	77
ID 2103: “Paulinia cupana (Common Name : Guarana)” and “Cognitive performance”	77
ID 2104: “Phaseolus vulgaris (Common Name : White bean)” and “Glucose metabolism”	79
ID 2105: “Phaseolus vulgaris (Common Name : White bean)” and “Weight control”	80
ID 2106: “Plantago ovata/ispaghula” and “Cholesterol”	81
ID 2107: “Punica granatum (Common Name : Pomgranade)” and “Cardiovascular health”	82
ID 2108: “Petroselinum crispum (Common Name : Parsley)” and “Kidneys health”	83
ID 2109: “Piper nigrum FRUIT” and “Digestion”	83
ID 2115: “Piper nigrum FRUIT” and “Immunity & Antioxidant”	84
ID 2121: “Pimpinella anisum L. (Common name: Anise)” and “Respiratory Health”	85
ID 2122: “Punica granatum FRUIT & SEED” and “Digestion”	85
ID 2123: “Punica granatum FRUIT & SEED” and “Antioxidant & immunity”	86
ID 2124: “Raphanus sativus var niger (Common Name : Radish, Black radish, Japanese radish, Daikon)” and “Liver health”	87
ID 2125: “Rosmarinus officinalis (Common Name : Rosemary)” and “Antioxidant properties”	87
ID 2126: “Ribes nigrum (Common Name : Blackcurrant)” and “Muscles and joint health”	88
ID 2127: “Rubus fruticosus L. (Common name: Blackberry)” and “Respiratory health”	89
ID 2132: “Syzygium aramaticum. FLOWER BUD” and “Antioxidant”	89
ID 2133: “Sambucus nigra (Common Name : Elder)” and “Purification”	89
ID 2135: “Sambucus nigra (Common Name : Elder)” and “Glucose metabolism”	90
ID 2136: “Sambucus nigra (Common Name : Elderberry)” and “Antioxidative properties”	90
ID 2137: “Sambucus nigra (Common Name : Elderberry)” and “Respiratory health”	91
ID 2138: “Standardized Guarana extract PC102 Dry extract from seeds of Paullinia Cupana H. B. et Kunth, drug7native extract ratio (4.5-7) : 1, solvent of extraction Ethanol/Water , 11.0 - 13.0% of caffeine” and “For mental performance”	92
ID 2139: “Seed of Vitis vinifera (Grapeseed)” and “Circulatory health through antioxidant action”	92
ID 2140: “Soy Glycine max” and “Soy contains the phytoestrogens isoflavones that can function as either an estrogen agonist or antagonist”	92
ID 2141: “Sinapis alba (Common Name : White mustard)” and “Appetite/Digestion”	93
ID 2142: “Standardized tomato extract [Oleoresin extracted from ripe fruits of Licopersicum aesculentum, solvent of extraction Ethyl acetate, 5% lycopene” and “For antioxidant protection system/protection of DNA”	93
ID 2143: “Standardized tomato extract [Oleoresin extracted from ripe fruits of Licopersicum aesculentum, solvent of extraction Ethyl acetate, 5% lycopene” and “For skin health”	93

ID 2144: “Standardized grape seed extract [Dry extract from grape seeds of <i>Vitis vinifera</i> L. (Vitaceae), solvent of extraction Acetone/Water, 8.5 - 13.0% proanthocyanidins]” and “For antioxidant protection system”	94
ID 2146: “Standardized grape seed extract [Dry extract from grape seeds of <i>Vitis vinifera</i> L. (Vitaceae), solvent of extraction Acetone/Water, 8.5 - 13.0% proanthocyanidins]” and “For cardiovascular (heart/vessel) health”	94
ID 2147: “ <i>Salviae officinalis aetheroleum</i> (Common name: Sage oil)” and “Respiratory health”	95
ID 2149: “ <i>Thymus vulgaris/zygis</i> (Common Name : Thyme)” and “Health of the upper respiratory tract”	95
ID 2151: “ <i>Thymus vulgaris</i> (Common Name : Thyme)” and “Antioxidant properties”	97
ID 2153: “ <i>Vaccinium macrocarpon, oxycoccus</i> (Common Name: Cranberry)” and “Health of the lower urinary tract”	97
ID 2154: “ <i>Vaccinium macrocarpon</i> (Common Name : Cranberry)” and “Antioxidant properties”	101
ID2155: “ <i>Vaccinium macrocarpon</i> (Common Name: Cranberry)” and “Immune health”	102
ID 2156: “ <i>Vitis vinifera</i> (Common Name : Grape)” and “Antioxidant properties”	102
ID 2157: “ <i>Vitis vinifera</i> (Common Name : Grape)” and “Vein health”	103
ID 2158: “ <i>Vitis vinifera</i> (Common Name : Grape)” and “Skin health/Antioxidative properties”	105
ID 2159: “ <i>Vitis vinifera</i> (Common Name : Grape)” and “Heart health”	106
ID 2160: “VitaBerry® Antioxidant Fruit Blend” and “Excellent source of healthy fruit antioxidants”	106
ID 2162: “VitaBlue® Wild Blueberry Extract” and “Excellent source of healthy fruit antioxidants”	110
ID 2164: “VitaCurrant® Black Currant Extract 25% Anthocyanins” and “Excellent source of healthy fruit antioxidants”	113
ID 2165: “VitaCurrant® Black Currant Extract” and “Excellent source of healthy fruit antioxidants”	114
ID 2166: “VitaGrape® Grape Seed Extract 95% OPC” and “Excellent source of oligomeric proanthocyanidins known to help in the management of heart health”	117
ID 2167: “VitaGranate® Pomegranate Extract 40% Ellagic Acid” and “Excellent source of healthy fruit polyphenols known to help in the management of heart health”	119
ID 2169: “Zeaxanthin (from marigold/ capsicum extract / wolfberries fruit)” and “Required for macular pigmentation in the eyes for maintaining health eye functions”	120
ID 2173: “ZOTRIM®: Herbal food supplement/ingredient containing a proprietary* combination of extracts of three botanicals, <i>Ilex paraguariensis</i> (Yerba Mate) leaf extract, <i>Paullinia cupana</i> (Guarana) seed extract, and <i>Turnera aphrodisiaca</i> (Damiana) leaf extract” and “Helps lose excess weight, maintain a healthy weight. Supports healthy weight loss”	121
ID 2175: “ <i>Capsicum annum</i> (Common Name: Capsicum)” and “Stomach health”	122
ID 2178: “ <i>Balsamodendron mukul</i> (common name: Balsamodendron mukul)” and “Joint health”	124
ID 2179: “ <i>Eugenia jambolana</i> (common name: Eugenia jambolana)” and “Glucose metabolism”	124
ID 2181: “ <i>Emblica officinalis</i> (common name: <i>Emblica officinalis</i>)” and “Antioxidant properties”	125
ID 2186: “ <i>Salsa parrilha</i> (<i>Smilax officinalis</i>)” and “Digestive health”	127
ID 2187: “Combination of extracts from <i>Scutellaria baicalensis</i> (root) and <i>Acacia catechu</i> (heartwood) for use in food supplements only (UnivestinTM, LimbrelTM, FlavocoxidTM)” and “Joint health”	127
ID 2188: “Grapefrukt// <i>Citrus paradisi</i> (Common Name : Grapefruit)” and “Antioxidant properties”	128
ID 2191: “ <i>Ribes nigrum</i> (Common Name : Blackcurrant)” and “Muscles and joint health”	128
ID 2193: “Acerola” and “Antioxidant activity”	128

ID 2194: “Achillea millefolium L. (Common name: Yarrow)” and “Health of lower urinary tract”	130
ID 2195: “Achillea millefolium L. (Common name: Yarrow)” and “Respiratory health”	130
ID 2199: “Agrimonia eupatoria” and “Health of lower urinary tract”	130
ID 2200: “Agropyron repens - common name : Couch” and “Renal elimination / organism draining”	130
ID 2201: “Agropyron repens - common name : Couch” and “Control of weight”	130
ID 2202: “Alchemilla vulgaris” and “Joint health”	130
ID 2205: “Alchemilla xanthochlora ROTHM, syn. alchemilla vulgaris L. s.l. (Common name: Lady’s mantle)” and “Respiratory health”	130
ID 2207: “Allium cepa - common name: Onion” and “Renal elimination / Organism draining”	130
ID 2211: “Ammi visnaga” and “Respiratory health”	131
ID 2212: “Ananas comosus - common name: Bromelain, Pineapple” and “Vascular and Vein Health”	131
ID 2213: “Ananas comosus - common name: Bromelain, Pineapple” and “Digestion”	131
ID 2214: “Anethum graveolens - common name: dill” and “Renal elimination / organism draining”	131
ID 2216: “Anisi aetheroleum” and “Respiratory health”	132
ID 2217: “Apium graveolens (common name : celery)” and “Bladder health/ Health of urinary tract”	132
ID 2218: “Apium graveolens - common name : celery” and “Renal elimination / organism draining”	132
ID 2222: “Arctium lappa - common name : Burdock” and “Renal elimination / Organism draining”	133
ID 2223: “Armoracia rusticana” and “Intestinal health”	133
ID 2224: “Armorica rusticana - common name : Horseradish” and “Renal elimination / Organism draining” ...	134
ID 2226: “Ascophyllum nodosum - common name: ascophyllum” and “Control of weight”	134
ID 2227: “Ascophyllum nodosum - common name : ascophyllum” and “Constipation / Intestinal Health”	134
ID 2228: “Asparagus officinalis” and “Health of bladder and lower urinary tract”	134
ID 2230: “Avena sativum - common name : Oat” and “Constipation / Intestinal Health”	135
ID 2233: “Capsella bursa-pastoris” and “Urinary health”	135
ID 2235: “Cassia fistula - common name : caneficier” and “Constipation / Intestinal Health”	135
ID 2243: “Citrullus lunatus (Watermelon) extract - ACTI-08” and “Weight loss management carbohydrate & lipid metabolism improvement”	136
ID 2244: “Citrullus lunatus (Watermelon) extract - ACTI-08” and “Antioxidant properties”	136
ID 2246: “Cnicus benedictus” and “Respiratory health”	137
ID 2248: “Coleus forskohlii extract” and “body weight management - lipid metabolism”	137
ID 2253: “Cynara scolymus - common name: artichoke, globe artichoke” and “Renal elimination / organism draining”	138
ID 2254: “Eucalyptus globulus” and “Muscles and joint health”	138
ID 2255: “Filipendula ulmaria - common name: meadowsweet” and “Joint health”	138
ID 2256: “Fraxinus excelsior” and “Joint health”	139
ID 2257: “Fraxinus excelsior” and “Kidney health”	139
ID 2258: “Fraxinus ornus - common name: Manna” and “Constipation / Intestinal Health”	139
ID 2259: “Fucus vesiculosus” and “Thyroid function and production of hormone, energy metabolism”	139
ID 2260: “Fucus vesiculosus - common name: fucus, bladderwrack” and “Constipation / Intestinal Health”	140

ID 2261: “Ginkgo biloba [dry extract GK501 Pharmaton Dry extract from leaves of Ginkgo biloba L., drug/native extract ratio (35 - 45) : 1, solvent of extraction Acetone/Water, 6.0% terpene lactones, 24.5% ginkgoflavonoids]” and “For cognitive performance / blood circulation”	140
ID 2262: “Guava” and “Skin health”	145
ID 2263: “Guava” and “Antioxidative activity”	145
ID 2266: “Hedera helix” and “Urinary health”	147
ID 2267: “Hibiscus sabdariffa - common name: Hibiscus” and “Renal elimination / Organism draining”	147
ID 2272: “Hypericum perforatum” and “Respiratory health”	147
ID 2273: “Hypericum perforatum” and “Health of lower urinary tract”	147
ID 2274: “Hyssopus officinalis L. (Common name: Hyssop)” and “Respiratory health”	147
ID 2275: “Ilex paraguariensis - common name: yerba mate, maté, kali chaye” and “Renal elimination / organism draining”	148
ID 2276: “Ilex paragueariensis St.-Hil. - Green Mate leaf extract” and “Mild diuretic effect, drainage of excess water”	148
ID 2278: “Inula helenium” and “Pharyngeal and respiratory health”	148
ID 2280: “Inula helenium - common name: Elecampane” and “Renal elimination / Organism draining”	148
ID 2281: “Iris germanica L., Iris florentina auct., Iris pallida Lam. (Common name: Iris)” and “Respiratory health”	149
ID 2282: “Lagerstroemia speciosa extract” and “Blood glucose control - glucose metabolism”	149
ID 2285: “Lamium album - common name: white dead nettle” and “Renal elimination / organism draining” ...	150
ID 2292: “Levisticum officinale - common name: Lovage” and “Renal elimination / organism draining”	150
ID 2293: “Limonis aetheroleum” and “Respiratory health”	150
ID 2294: “Linum usitatissimum - common name: flaxseed” and “Control of weight”	150
ID 2296: “Lycopodium clavatum” and “Health of bladder and lower urinary tract”	151
ID 2297: “Malva sylvestris” and “Pharyngeal and respiratory health”	151
ID 2298: “Medicago sativa” and “Health of lower urinary tract”	151
ID 2303: “Melissa officinalis L. (Common name: Lemon balm)” and “Respiratory health”	151
ID 2304: “Melon extract (containing SOD) / Wheat Gliadin” and “Endogenous antioxidant enzyme; effects on immune system”	152
ID 2305: “Melon extract (containing SOD) / Wheat Gliadin” and “Endogenous antioxidant enzyme, protects skin from sun damage”	152
ID 2309: “Mentha x piperita L. (Common names: peppermint, mint)” and “Respiratory health”	152
ID 2310: “Menthae arvensis aetheroleum” and “Respiratory health”	153
ID 2311: “Myristica fragrans” and “Muscles and joint health”	153
ID 2314: “Ocimum basilicum - common name: Basil” and “Renal elimination / Organism draining”	153
ID 2315: “Ononis spinosa L. (Common name : Bugrane) “ and “Health of lower urinary tract”	153
ID 2318: “Phaseolus Vulgaris (Kidney bean) - Olea europa (Olive) - Rosemarinus officinalis (Rosemary) extracts - OXY-08” and “Weight loss management, fat metabolism & storage improvement”	153
ID 2319 : “Pimpinella saxifrage” and “Health of lower urinary tract”	154
ID 2320: “Pitanga” and “Skin health”	154
ID 2321: “Pitanga” and “Antioxidant activity”	156

ID 2322: “Populus nigra” and “Kidney health”	157
ID 2325: “Prunus mume (Plum) extract - INP-08” and “Weight loss management, acid base balancer”	158
ID 2326: “Prunus spinosa” and “Kidney health”	158
ID 2328: “Quercus robur” and “Health of the upper respiratory tract”	158
ID 2329: “Raphanus sativus - common name: radish, black radish, Japanese radish, Daikon” and “Digestion”	158
ID 2330: “Ribes nigrum - nom commun: blackcurrant” and “Renal Elimination / Draining organism”	158
ID 2331: “Ribes nigrum - nom commun: blackcurrant” and “Control of weight”	159
ID 2332: “Ribes nigrum L. (Common name: Blackcurrant)” and “Respiratory health”	159
ID 2333: “Rice vinegar extract - INRV-08” and “Weight loss management, acid base balancer”	159
ID 2334: “Rosa canica - common name : Cynorrhodon, Eglantier” and “Invigoration of the body”	160
ID 2335: “Rubus fruticosus” and “Glucose metabolism”	160
ID 2336: “Rubus idaeas (Raspberry) extract - BERI-08” and “Weight loss management, thermogenesis”	160
ID 2337: “Rubus idaeus - common name: Blackberry” and “Digestion”	161
ID 2338: “Rubus idaeus - common name: Blackberry” and “Renal elimination / Organism draining”	161
ID 2339: “Salvia triloba L. fil. (Common name: Greek sage)” and “Respiratory health”	161
ID 2340: “Salviae lavandulifoliae aetheroleum” and “Respiratory health”	161
ID 2342: “Sisymbrium officinale” and “Respiratory health”	162
ID 2344: “Triticum sativum” and “Resistance system”	162
ID 2345: “Undaria pinnatifidia” and “Body weight”	162
ID 2346: “Urtica dioica - common name: Stinging nettle” and “Renal Elimination / Organism draining”	162
ID 2348: “Valerian extract [Dry extract from roots of Valeriana officinalis L., drug/native extract ratio (3-6) : 1, solvent of extraction Ethanol/Water, min 0.3% valerenic acid]” and “For insomnia and mental health”..	163
ID 2351: “Verbascum thapsiforme” and “Pharyngeal and respiratory health”	163
ID 2352: “Verbascum thapsiforme” and “Bladder and Kidney Health”	164
ID 2355: “Veronica officinalis” and “Kidney health”	165
ID 2356: “Viola tricolor” and “Respiratory health”	165
ID 2362: “Garlic bulb (Allium sativum)” and “Body’s defence system against microorganism”	165
ID 2365: “Pumpkin seed (Cucurbita pepo)” and “Prostate/urinary tract”	165
ID 2368: “Combination of sweet fennel seed (Foeniculum dulce), mint leaf (Mentha piperita) and chamomile flower (Matricaria chamomilla)” and “Digestive system”	166
ID 2372: “Tomato extract containing lycopene” and “Cardio-vascular health”	166
ID 2373: “Tomato extract containing lycopene” and “Skin health”	171
ID 2374: “Tomato extract containing lycopene” and “Prostate health”	174
ID 2375: “Guarana seed (Paulina cupana fruit)” and “Invigoration of the body”	178
ID 2380: “Horseradish root (Armoracia rusticana)” and “Respiratory system health”	180
ID 2383: “Acorus Calamus (Sweet flag, sweet rush)” and “Invigoration of the body”	180
ID 2384: “Aegopodium podagraria” and “Digestive health”	181
ID 2386: “Alchemilla vulgaris (Lady's Mantle)” and “Invigoration the body”	181

ID 2388: “ <i>Andrographis paniculata</i> (Creat)” and “Purification”	181
ID 2391: “ <i>Angelica sinensis</i> (Angelica)” and “Invigoration the body”	181
ID 2392: “ <i>Angelica sinensis</i> (Angelica)” and “Metabolism in joints”	181
ID 2393: “ <i>Apium graveolens</i> (Celery)” and “Invigoration the body”	181
ID 2394: “ <i>Arctium lappa</i> (Burdock)” and “Joint health”	181
ID 2395: “ <i>Argyreia speciosa</i> ” and “Fertility”	181
ID 2396: “ <i>Ascophyllum nodosum</i> (seaweed)” and “Structure and function of the skin and mucous membranes”	182
ID 2398: “ <i>Avena sativa</i> (Green oat)” and “Digestive system, metabolism”	182
ID 2399: “ <i>Barbarea vulgaris</i> (Garden yellowrocket)” and “Physical and mental health”	182
ID 2400: “ <i>Berberis vulgaris</i> (Barberry)” and “Gastro-intestinal health”	182
ID 2401: “ <i>Beta vulgaris</i> ” and “Purification”	183
ID 2407: “ <i>Capparis spinosa</i> ” and “Liver health, appetite”	183
ID 2408: “ <i>Cassia fistula</i> ” and “Vein health”	183
ID 2409: “ <i>Centaurium erythraea</i> (Centaury)” and “Invigoration the body”	183
ID 2413: “ <i>Chamaenerion angustifolium</i> (Willow herb)” and “Digestive health”	183
ID 2414: “ <i>Chamaenerion angustifolium</i> (Willow herb)” and “Mental health”	183
ID 2415: “ <i>Chlorella pyrenoidosa</i> (Chlorella)” and “Digestive health / Liver health”	183
ID 2416: “ <i>Cichorium intybus</i> (Chicory)” and “Heart health / Vascular health”	184
ID 2417: “ <i>Comarum palustre</i> ” and “Joint health”	184
ID 2418: “ <i>Commiphora wightii</i> (Indian Bedellium, Guggal)” and “Joint, bone health”	184
ID 2427: “ <i>Crocus sativus</i> ” and “Fertility”	184
ID 2428: “ <i>Cyamopsis tetragonolobus</i> (Guar)” and “Weight management”	185
ID 2429: “ <i>Cyamopsis tetragonolobus</i> (Guar)” and “Blood glucose control”	185
ID 2430: “ <i>Cyperus scariosus</i> (Cyperus)” and “Digestive health”	185
ID 2431: “ <i>Daucus carota</i> (Carrot)” and “Eye health”	185
ID 2432: “ <i>Didymocarpus pedicellata</i> ” and “Kidneys health”	185
ID 2435: “ <i>Emblica officinalis</i> (Indian Gooseberry)” and “Respiratory health”	185
ID 2436: “ <i>Elytriga repens</i> ” and “Digestive health”	186
ID 2437: “ <i>Equisetum arvense</i> (Horsetail)” and “Invigoration of the body”	186
ID 2438: “ <i>Equisetum arvense</i> (Horsetail)” and “Skin, hair health”	186
ID 2439: “ <i>Equisetum arvense</i> (Horsetail)” and “Bone health”	186
ID 2441: “ <i>Euphrasia officinalis</i> (Eyebright)” and “Invigoration of the body”	186
ID 2442: “ <i>Fagopyrum esculentum</i> (Buckwheat)” and “Respiratory health”	186
ID 2444: “ <i>Filipendula ulmaria</i> (<i>Spiraea ulmaria</i>) (Meadowsweet)” and “Mental health / Relaxation”	186
ID 2455: “ <i>Justicia gendarussa</i> ” and “Health of lower urinary tract”	187
ID 2456: “ <i>Lathirus pratensis</i> ” and “Respiratory health”	187
ID 2457: “ <i>Ledebouriella seseloides</i> ” and “Skin health”	187
ID 2458: “ <i>Ledebouriella seseloides</i> ” and “Joint health”	187

ID 2459: “Leonurus quinquelobatus syn. L.villosus (motherwort)” and “Cardiovascular health”	187
ID 2461: “Medicago lupulina / M.satava” and “Glucose metabolism”	188
ID 2462: “Medicago lupulina / M.satava” and “Digestive health”	188
ID 2463: “Medicago lupulina / M.satava” and “Invigoration the body”	188
ID 2464: “Menyanthes trifoliata” and “Digestive health”	188
ID 2467: “Onopordon acanthium” and “Physical and mental performance”	188
ID 2468: “Orchis mascula” and “Fertility”	188
ID 2469: “Origanum vulgare” and “Health of the upper respiratory tract / Immune health”	188
ID 2472: “Origanum vulgare” and “Cardiovascular health”	189
ID 2473: “Origanum vulgare” and “Mental performance”	189
ID 2475: “Phoenix dactylifera (Date)” and “Antioxidant activity”	189
ID 2477: “Pinus pinaster (Maritime Pine)” and “Respiratory health”	189
ID 2480: “Polygonum arenastrum syn. aviculare (Knotweed)” and “Digestive health”	189
ID 2482: “Prunus amygdalus” and “Fertility”	189
ID 2485: “Ribes nigrum (Blackcurrant)” and “Invigoration the body”	189
ID 2486: “Rubus caesicus” and “Invigoration the body”	189
ID 2487: “Rubus idaeus (Raspberry)” and “Menstrual health”	190
ID 2488: “Salix alba (Willow)” and “Invigoration the body”	190
ID 2494: “Terminalia arjuna” and “Liver health”	190
ID 2496: “Trifolium pratense (Red Clover)” and “Heart health, cardiovascular health”	190
ID 2497: “Tussilago farfara (Coltsfoot)” and “Health of the upper respiratory tract / Immune health”	191
ID 2498: “Urtica dioica (Nettle)” and “Respiratory health”	191
ID 2499: ” Vaccinium macrocarpon, oxycoccus (Cranberry)” and “Heart health”	191
ID 2500: “Valeriana officinalis (Valerian)” and “Cardiovascular health”	192
ID 2501: “Valeriana officinalis (Valerian)” and “Digestive health”	192
ID 2504: “Zea mays (Maize)” and “Liver health”	192
ID 2505: “Zea mays (Maize)” and “Kidneys health”	192
ID 2508: “Name of Food product: Adhatoda vasica Description of food in terms of food legislation categories: Food supplement Was food on Irish market before 1st July 2007: No” and “Health benefits of food: Adhatoda vasica has antiinflammatory activity. Do benefits relate to a disease risk factor: No.Target group: Adults aged 18 years and over with some exceptions. If exceptions describe: Pregnant and lactating women, and children.”	192
ID 2510: “Name of Food product: psyllium seed (plantago ispaghula).Description of food in terms of food legislation categories: Food supplement.Was food on Irish market before 1st July 2007: No” and “Health benefits of food: bowel regularity; feeling of fullness; helps control blood levels of cholesterol.Do benefits relate to a disease risk factor: Yes.Target group: All of the general population including children and adults”	193
ID 2511: “Name of Food product: Terminalia arjuna.Description of food in terms of food legislation categories: Food supplement.Was food on Irish market before 1st July 2007: No” and “Health benefits of food: Terminalia arjuna possesses antioxidant activity..Do benefits relate to a disease risk factor: No.Target group: Adults aged 18 years and over with some exceptions.If exceptions describe: Pregnant and lactating women, and children”	193

ID 2514: “Ananas tige” and “Anti-inflammatoire”	194
ID 2515: “Ballota nigra L.” and “Antioxydant”	194
ID 2517: “Bardane racine” and “Anti-inflammatoire/anti-oxydant de la peau”	194
ID 2522: “Carotte racine” and “Anti-oxydant Photoprotection”	194
ID 2527: “Christe marine” and “Antioxydant”	195
ID 2528: “Christe marine” and “Diurétique”	195
ID 2530: “Chrysanthellum americanum” and “Antioxydant”	195
ID 2531: “Cosse de Haricot” and “Diurétique”	195
ID 2541: “Frêne Feuille” and “Système urinaire Diurétique”	195
ID 2552: “Levure de bière” and “Epiderme soigne l'acnée”	195
ID 2556: “Grifola frondosa (Maitake) thalle” and “Métabolisme des glucides antidiabétique, hypoglycémiant”	196
ID 2567: “Piloselle plante” and “Système urinaire Diurétique”	196
ID 2575: “Prêle” and “Anti-oxydant”	196
ID 2580: “Sauge sclérée plante” and “Anti-oxydant”	196
ID 2585: “Alfalfa” and “Système circulatoire Hypocholestérolémiant”	196
ID 2591: “Marjolaine feuille” and “Anti-oxydant”	197
ID 2596: “Chiendent rhizome plante” and “Système urinaire Diurétique, anti-inflammatoire des voies urinaires, prévention des calculs rénaux”	197
ID 2616: “Germe de blé” and “Anti-oxydant. Source de vitamine E”	197
ID 2618: “Germe de blé” and “Système circulatoire. Source d'oméga 3, anti-athérosclérose, diminue les triglycérides, réduit les risques de crises cardiaques”	197
ID 2620: “Argan” and “Anti-oxydant Anticancer”	197
ID 2622: “Cynorrhodon” and “Anti-asthénique, source de vitamine C”	198
ID 2628: “Bouleau pubescent” and “Diurétique”	198
ID 2629: “Chataigné” and “Astringent, anti-oxydant”	198
ID 2637: “Cranberry extract powder (Vaccinium macrocarpon)” and “natural antioxidant”	198
ID 2638: “blueberry extracts” and “can support maintainig of proper night vision”	199
ID 2639: “blueberry extracts” and “natural antioxidant”	199
ID 2640: “green tea extract (Camelia sinensis)” and “helps to keep normal cholesterol level”	199
ID 2641: “extract of Silybum marianum” and “antioxidant”	200
ID 2642: “extract of Gymnema sylvestre” and “helps to keep normal sugar level in organism”	200
ID 2643: “extrakt of Garcinia cambogie hydrodycitric acid” and “metabolism of fats”	201
ID 2647: “Boswellin (Bosellia serrata)” and “Metabolism of enzymes: Boswellin positively effects the enzyme 5-lipoxygenase, as well as the human leukocyte elastase (HLE)”	201
ID 2649: “ginger extract (Zingiberis officinale)” and “helps to maintai mobility of joints”	202
ID 2651: “Extract from Garcinia cambogia (60% HCA) - (-)-Hydroxycitric acid” and “HCA is an inhibitor of ATP-citrate lyase, which is involved in fatty acid synthesis”	204
ID 2652: “Extract from Aronia melanocarpa” and “antioxidant effects”	204
ID 2653: “Extract from the red grapes skin” and “antioxidant effects”	204

ID 2654: “Extract from Hibiscus Chinensis” and “antioxidant effects”	205
ID 2657: “green tea extract (Camelia sinensis)” and “helps to keep elasticity of vessels”	205
ID 2658: “nettle extract (Urtica dioica), dandelion extract (Taraxum officinale), birch extract (Betula pendula),parsley extract (Petroselinum crispum)” and “has diuretic effect , helps to maintain proper function of urinary system, diureticum”	205
ID 2660: “Evening primrose oil (Oenothera biennis) contains gamalinolenic acid” and “helps to maintain elasticity, tenderness and health of skin, structure and function of skin and mucose membrane”	206
ID 2661: “Evening primrose oil (Oenothera biennis) contains gamalinolenic acid” and “helps to keep normal blood cholesterol”	207
ID 2662: “Evening primrose oil (Oenothera biennis) contains gamalinolenic acid” and “helps to keep normal blood preassure	207
ID 2663: “extract of guarana (Paullinia cupana)” and “natural antioxidant”	208
ID 2664: “green tea extract (Camelia sinensis)” and “natural antioxidant”	208
ID 2665: “Mucuna pruriens” and “Metabolism of testosterone”	209
ID 2668: “Extract of olive leafs (oleuropein)” and “natural antioxidant protect organism from oxidative damage powerful antioxidants beneficial to human health”	209
ID 2672: “Ginseng, extract from root” and “Effective substances, ginsenosides”	210
ID 2673: “Ginseng, extract from root” and “Acting as antioxidants”	212
ID 2674: “Eucalyptol” and “Antiseptic properties”	212
ID 2675: “Menthol” and “Influence of nasal airflow”	213
ID 2676: “Ginseng ” and “Erection”	213
ID 2677: “Elder Flower (Sambucus nigra)” and “Supports body’s renal elimination of water”	213
ID 2680: “Valerian-hops combination (Humulus lupulus, Valeriana officinalis)” and “Sleep”	214
ID 2681: “Caraway fruit (Carum carvi)” and “Spasmolytic effect”	215
ID 2684: “Aniseed (Pimpinella anisum)” and “Stimulates secretion of all glands, including lacteal ones”	215
ID 2687: “Common Thyme (Thymus vulgaris, Thymus zygis)” and “Supports secretion of mucus in the upper respiratory tract”	216
ID 2690: “Lime Tree (Tilia cordata, Tilia platyphyllos)” and “Supports expectoration”	216
ID 2691: “Lime Tree (Tilia cordata, Tilia platyphyllos)” and “Supports body’s renal elimination of water”	216
ID 2692: “Fennel (Foeniculum vulgare)” and “Spasmolytic and carminative effect”	216
ID 2694: “German Chamomile (Matricaria/Chamomills recutita L.)” and “Spasmolytic effect”	217
ID 2696: “Peppermint (Mentha piperita)” and “Carminative effect”	217
ID 2699: “Goat’s rue (Galega officinalis)” and “Supports activity of lacteal glands”	217
ID 2701: “Chicory (Cichorium intybus L.)” and “Urinary elimination”	218
ID 2702: “Chicory (Cichorium intybus L.)” and “Slimming aid/ Weigth control”	218
ID 2703: “Carob (Ceratonica siliqua L.)” and “Satiety/ weight control”	219
ID 2704 : “Artichoke (leaf) Cynara scolymus” and “Health of lower urinary tract”	219
ID 2705: “Cherry Peduncle. Prunus avium, Prunus cerasus” and “Health of lower urinary tract”	219
ID 2707: “Guarana (seed) Paullinia cupana” and “Weight control and fat metabolism”	220
ID 2708: “Heather (blossoming top). Calluna vulgaris” and “Health of lower urinary tract”	221

ID 2709: “Mallow (leaf and flower) <i>Malva sylvestris</i> ” and “Pharyngeal health / Softening throat”	221
ID 2710: “Papaya (leaf) <i>Carica papaya</i> ” and “Body fat reduction”	222
ID 2713: “ <i>Pyrus malus</i> (Common Name Apple) extract powder containing polyphenols” and “Blood glucose control”	222
ID 2715: “ <i>Borago officinalis</i> - common name : Borage” and “Renal elimination / organism draining”	222
ID 2716: “ <i>Camellia sinensis</i> - common name : tea” and “Control of weight”	223
ID 2717: “ <i>Ribes nigrum</i> - nom commun : blackcurrant” and “Control of weight”	223
ID 2718: “ <i>Sambucus nigra</i> - common name : black elder, European elder” and “Control of weight”	223
ID 2719: “ <i>Armorica rusticana</i> - common name : Horseradish” and “Renal elimination / Organism draining” ...	223
ID 2722: “Alfalfa. (<i>Medicago sativa</i> L.)” and “Hair and nails health”	223
ID 2723: “Bamboo (<i>Bambusa arundinacea</i>)” and “Bones and joints health”	223
ID 2724: “Cocoa (<i>Theobroma cacao</i> L.)” and “Slimming / lipids metabolism”	224
ID 2725: “Cola (<i>Cola nitida</i>)” and “Weight control”	225
ID 2727: “Grape (<i>Vitis vinifera</i> L) ” and “Weight control”	225
ID 2728: “Grapefruit (<i>Citrus paradisi</i> Mact. = <i>C. decumana</i> L., <i>C. grandis</i> Osbeck ; <i>Citrus maxima</i>)” and “Purifying/ detoxifying properties”	226
ID 2730: “Larch tree (<i>Larix decidua</i>)” and “Immune health”	226
ID 2731: “Lithothamnium calcareum (calcium carbonate)” and “Bone health - mineralization”	227
ID 2733: “Nopal (<i>Opuntia ficus indica</i>)” and “Weight control”	227
ID 2734: “Purslane (<i>Portulaca oleracea</i> L.)” and “Antioxidant properties”	228
ID 2735: “Red Vine (<i>Vitis vinifera</i> L.)” and “Weight control/cellulitis”	229
ID 2736: “Sage (<i>Salvia lavandulaefolia</i> Vahl.)” and “Mental health/ cognitive functions”	229
ID 2739: “Corn silk (<i>Zea mays</i> L.)” and “Health of urinary and digestive function”	230
ID 2740: “Couchgrass (<i>Agropyron repens</i> L.)” and “Detoxification”	231
ID 2742: “Fennel (<i>Foeniculum vulgare</i>)” and “Urinary elimination - Detoxification”	232
ID 2743: “Papaya (<i>Carica papaya</i> L.)” and “Skin curves/Cellulitis”	233
ID 2744: “Turmeric (<i>Curcuma longa</i> L.)” and “Stimulation of appetite”	233
ID 2746: “Quinoa (<i>Chenopodium quinoa</i>)” and “Hair growth”	233
ID 2747: “Roquette (<i>Eruca sativa</i>): dry hydroethanolic extract ” and “Hair growth”	234
ID 2748: “Huile de carthame (safflower oil)” and “Skin care”	234
ID 2749: “Huile de noisettes : Hazel nut (<i>Corylus avellana</i>) oil” and “Skin care”	234
ID 2750: “Cassis : Dry extract of <i>Ribes Nigrum</i> fruit standardized at 7% of anthocyanosides” and “Eye health”	234
ID 2751: “Curcuma: <i>Curcuma longa</i> ” and “Liver lipids”	235
ID 2752: “Radis noir: <i>Raphanus niger</i> (Black radish)” and “Improve digestion/transit”	235
ID 2753 : “Sureau: Elder berry (dry aqueous extract)” and “Veinous system”	236
ID 2755: “Myrtille: Extract of <i>Vaccinum Myrtillus</i> (bilberries)” and “Hairs and nails care”	236
ID 2757: “ <i>Ascophyllum</i> (<i>Ascophyllum nodosum</i>) dry water extract” and “Action on fats”	237
ID 2758: “Spiruline (dry extract of <i>Spirulina maxima</i>)” and “Amino acid supplementation”	237

ID 2759: “Brocoli: Dry extract of concentrated Brassica oleracea inflorescences juice” and “Gastric acidities”	238
ID 2765: “Plante : Thé vert Camellia sinensis (Green tea)” and “Elimination rénale de l’eau”	238
ID 2767: “Plante: Frêne Fraxinus excelsior (ash)” and “Elimination rénale de l’eau – Fonctions d’élimination de l’organisme”	238
ID 2770: “Food supplement /Food ingredient: Whole cranberry powder from North American Cranberry (Vaccinium macrocarpon) Early Black species” and “Health of the lower urinary tract”	239
ID 2772: “Valerian extract [Dry extract from roots of Valeriana officinalis L., drug/native extract ratio(3 - 6): 1, solvent of extraction Ethanol/Water, min 0.3% valerenic acid]” and “For isomnia and mental health”	240
ID 2773: “Graines de brocoli et extraits de graines de brocoli: Sulforaphane” and “Santé de la prostate”	241
ID 2774: “Fumaria officinalis, fumitory, nom français : fumeterre” and “elimination”	242
ID 2778: “Artemisia vulgaris L. ; Common name : Armoise commune” and “appétit”	242
ID 2780: “Combretum micranthum G. Don; Common name: Kinkéliba” and “elimination”	242
ID 2782: “Equisetum arvense L.; Common name: Prêle des champs” and “élimination”	242
ID 2783: “ Equisetum arvense L. ; Common name : Prêle des champs; Common name : Armoise commune” and “ amincissement”	243
ID 2784: “Hieracium pilosella L.; Common name: Piloselle” and “élimination”	243
ID 2785: “Ononis spinosa L.; Common name: Bugrane ” and “élimination”	243
ID 2787: “Urtica dioica L.; Common name: Ortie dioïque” and “élimination”	243
ID 2788: “Zea mays L.; Common name: Maïs” and “amincissement”	243
ID 2792: “Ajuga extract” and “Trophism of skin and related tissues”	243
ID 2793: “Alfalfa” and “Cardiovascular system”	244
ID 2794: “Avocado-soy extract” and “Joints”	244
ID 2795: “Bilberry / flavonols + anthocyanidines” and “Antioxdativity Cardiovascular system”	245
ID 2796: “Bilberry and anthocyanins from blackcurrant” and “Eyes”	246
ID 2798: “Bilberry + pine bark” and “Musculoskeletal system”	247
ID 2800: “Bilberry + pine bark” and “Antioxdativity”	247
ID 2803: “Dandelion root extract” and “Cardiovascular system”	248
ID 2805: “Garlic” and “Carbohydrate metabolism and insulin sensitivity.”	248
ID 2807: “Ginkgo tree (Ginkgo biloba)” and “Cardiovascular system. Eyes. Ears”	248
ID 2808: “Ginseng” and “Physical performance and condition.”	249
ID 2809: “Ginseng” and “Mental state and performance”	249
ID 2812: “Green tea extract” and “Mental state and performance”	250
ID 2813: “Green tea extract” and “Mouth”	250
ID 2814: “Green tea, green tea extract” and “Cardiovascular system”	250
ID 2815: “Heather blossom extract” and “Mental state and performance”	250
ID 2816: “Dry extract of common horsetail summer shoots + dry extract of dandelion root” and “Fluid and electrolyte balance”	251
ID 2817: “Iceland moss extract (Cetraria islandica)” and “Antioxdativity”	251

ID 2819: “Jerusalem artichoke” and “Gut health”	251
ID 2820: “Jerusalem artichoke” and “Gut health”	252
ID 2821: “Nettle” and “Bone, nails, hair”	252
ID 2823: “Oregano (<i>Oreganum vulgare</i>)” and “Antioxidativity”	252
ID 2825: “Papaya” and “Digestion”	253
ID 2827: “Pine shoot (fresh) (<i>Picea abies</i>)” and “Respiratory passages”	254
ID 2829: “Roseroot (<i>Rhodiola rosea</i>)” and “Physical performance and condition. Antioxidativity”	254
ID 2830: “Suma (<i>Pfaffia paniculata</i>) –phospholipid compound” and “Mental state and performance Physical performance and condition.”	254
ID 2831: “ <i>Tribulus terrestris</i> ” and “Sexual organs and/or hormone activity”	255
ID 2832: “Wheat sprouts” and “Antioxidativity”	256
ID 2833: “Wheat sprouts” and “Eyes”	256
ID 2835: “Yerba mate extract (<i>Ilex paraguarensis</i>)” and “Antioxidativity”	256
ID 2844: “ <i>Brassica oleracea var italica</i> (broccoli)” and “Immune system”	257
ID 2845: “ <i>Brassica oleracea var italica</i> (broccoli)” and “Antioxidant properties and cell protection”	262
ID 2847: “ <i>Malva sylvestris</i> L. (Common name: Mallow)” and “-Respiratory health”	267
ID 2848: “Melissa extract [Dry extract from leaves of <i>Melissa officinalis</i> L., drug/native extract ratio (4 - 6) : 1, solvent of extraction Methanol/Water , min 1.8% rosmarinic acid]” and “-For mental health”	267
ID 2849: “Natural Grape Extract From grape seed Solvent free” and “-- Rich in polyphenols- Act as antioxidants - Antioxidant is a compound able to scavenge free radicals in the body and stop the oxidative chain reaction”	268
ID 2850: “ <i>Ocimum sanctum</i> LEAF” and “Antioxidant. Immunity”	268
ID 2854: “ <i>Bilberry Vaccinium myrtillus</i> ” and “Function as antioxidant”	269
ID 2855: “ <i>Blackcurrant Ribes nigrum</i> ” and “Antioxidant properties”	269
ID 2857: “ <i>Ecklonia cava</i> Kjellman (brown seaweed) extract” and “Antioxidant effects”	270
ID 2858: “ <i>Emblica officinalis</i> ” and “Immunity/digestion”	270
ID 2859: “Mangosteen (<i>Garcinia mangostana</i> L) fruits and extracts derived from the fruits” and “Immune support”	271
ID 2860: “Mangosteen (<i>Garcinia mangostana</i> L) fruits and extracts derived from the fruits” and “Antioxidant”	271
ID 2861: “Mangosteen (<i>Garcinia mangostana</i> L) fruits and extracts derived from the fruits” and “Control of blood lipids”	272
ID 2862: “Mangosteen (<i>Garcinia mangostana</i> L) fruits and extracts derived from the fruits” and “Regulation of inflammatory responses in the body”	272
ID 2865: “Polyphenols (from <i>Olea europaea</i> extract)” and “Antioxidant properties”	273
ID 2866: “Rosemary. <i>Rosmarinus officinalis</i> ” and “Antioxidant properties”	273
ID 2867: “ <i>Zingiber officinale</i> ” and “Blood sugar metabolism”	273
ID 2870: “Standardisierter Kartoffelextrakt” and “Sättigung/ Gewichtsmanagement / Förderung der CCK-Ausschüttung”	274
ID 2872: “Combination of Vitamin C, Selenium and Vitamin E” and “Anti-oxidant properties”	275
ID 2873: “Vitamin E acetate (D,L-alpha tocopherol acetate)” and “Health of the scalp”	276

ID 2874: “Vitamines du groupe B : B-group vitamins (especially vitamin B5 and vitamin B8)” and “Hairs and nails care”	276
ID 2875: “Vitamine B3” and “Hairs and nails care”.....	276
ID 2876: “Vitamine B8 (biotin)” and “Hair loss and regrowth”.....	276
ID 2877: “Vitamine B8 : Vitamin B8 or vitamin H (biotin)” and “Resistance and strength of the nails”	277
ID 2878: “Vitamine B5 (Pantothenic acid)” and “Skin care”	277
ID 2879: “Menaquinone-7 (MK-7, a form of vitamin K2)” and “Bone health”	278
ID 2880: “Menaquinone-7 (MK-7, a form of vitamin K2)” and “Cardiovascular Health”	281
ID 2881: “Folate/ Folic acid (Vitamin B9)” and “Cell division/multiplication: Nucleic acids and amino acids synthesis (such as in the gastrointestinal tract) “.....	282
ID 2882: “Folate/Folic acid” and “Effect on a normal pregnancy target group: women planning to become pregnant and pregnant”	283
ID 2884: “Calcium” and “Gut flora / Natural defences”.....	284
ID 2885: “Natural mineral water: Sulphates as Mg-, Na- salts: MgSO4, Na2SO4” and “Digestion/Intestinal tract”	284
ID 2886: “Natural mineral water: Hydrogencarbonates as Na- , Mg-, Ca-, salts: NaHCO3, Mg(HCO3)2,Ca(HCO3)2” and “Stomach acid in digestion”.....	284
ID 2887: “Sodium phosphate” and “Supports an increase in VO2max”	284
ID 2888: “zeaxantin” and “helps to preserve elasticity and permeabilityof capilars of retina and supports good blood circulation in eyes”	285
ID 2889: “Fer” and “lutte contre l'anémie/ la fatigue”	285
ID 2890: “Zinc” and “Le zinc est un élément ou cofacteur de différentes enzymes des métabolismes protéiques, glucidique et lipidiques ainsi que des acides nucléiques : alcool déshydrogénase, superoxyde dismutase, ADN polymérase, ARN polymérase, phosphatases alcalines, carboxy”.....	285
ID 2891: “Lactotripeptides” and “Blood pressure”	285
ID 2892: “Conjugated Linoleic acid (cis-9, trans-11 and trans-10, cis-12)” and “weight management, fat metabolism enhancement”.....	287
ID 2893: “Whey protein concentrate rich in alpha-lactalbumin” and “Cognition / memory”	288
ID 2894: “Potato protein isolate” and “satiety”	289
ID 2895: “Enova™ Oil (diacylglycerol oil of plant origin –Min 80% diacylglycerols)” and “Weight maintenance”	290
ID 2896: “Enova™ Oil (diacylglycerol oil of plant origin –Min 80% diacylglycerols)” and “Postprandial serum triglyceride”	291
ID 2897: “Essential fatty acid Linoleic Acid (LA - omega 6)” and “Brain development and maturation of neurosensorial functions”	291
ID 2898: “Essential fatty acid Linoleic Acid (LA - omega 6)” and “Growth and development and maintenance of body functions”	291
ID 2899: “Essential fatty acid Linoleic Acid (LA - omega 6)” and “Artery/Heart health”	292
ID 2900: “Fats” and “Cell growth/cell functioning and structure”	293
ID 2901: “Fats (containing EFA)” and “Essential fatty acids (EFA) supply”	293
ID 2902: “Fats (fatty acids higher than c-10)” and “Absorption of fat soluble vitamins”.....	293
ID 2903: “Isomaltulose (or trademark Palatinose)” and “Reduced speed of digestion and absorption results in lower glycemic response”.....	294

ID 2905: “Long-chain omega-3 (n-3) polyunsaturated fatty acids (LC omega-3 PUFA, LC n-3 PUFA) or docosahexaenoic acid or eicosapentaenoic acid or omega-3 fish oils” and “Building block for lipids in the retina’s photoreceptors; Eye Health”	295
ID 2906: “Low or reduced saturated fat (hard fat) or replacement of saturated fat with MUFA PUFA (soft fat) low cholesterol” and “Maintains healthy LDL cholesterol levels Arterial/Heart Health”	296
ID 2907: “Polyols” and “Remineralisation of teeth”	297
ID 2908: “Polyols” and “Low glyceemic properties”	298
ID 2909: “Sterols/ stanols and their esters” and “Heart health and artery health because of LDL cholesterol maintenance”	298
ID 2910: “Unsaturated fats/ fatty acids (poly and/or monounsaturates)” and “Blood cholesterol and artery/heart health”	299
ID 2911: “Unsaturated fats/fatty acids” and “Function of the cell membrane”	299
ID 2912: “Carbohydrates in dairy products” and “Foods with a low glyceemic index (GI) give a low and slow blood glucose response”	300
ID 2913: “L-methionine” and “Improvement of protein quality. Modulation of lipids metabolism”	300
ID 2914: “Long chain Omega 3 fatty acids” and “Normal immune system function”	300
ID 2915: “Olibra™/Fabulesse™ (Oil-in-water emulsion, containing 40% fractionated palm oil, 2,5% oats oil and water; no preservatives or stabilisers added.)” and “Fabulesse™ prolonges the feeling of satiety.”	300
ID 2916: “Indole-3-carbinol” and “Cell metabolism - positively affects the fission of cells their immunity and regeneration”	301
ID 2917: “Indole-3-carbinol” and “Induction of apoptosis of transformed and damaged cells”	301
ID 2919: “Formulated emulsion of palm oil, oat oil and water (Patent: WO 99/02041 Satiety Product)” and “Prolongs the feeling of satiety and contributes to a reduced calorie intake at the next meal. Less sensation of hunger between the meals and less need for snacking”	301
ID 2920: “Isomalt” and “Low glyceemic properties”	301
ID 2921: “Isomalt” and “Dental health - General”	302
ID 2922: “Inulin/oligofructose from chicory” and “Satiety”	302
ID 2923: “Galacto-oligosaccharides (GOS)” and “Calcium absorption”	303
ID 2925: “Alpha-cyclodextrin (a soluble dietary fiber)” and “Weight management”	304
ID 2926: “Alpha-cyclodextrin (a soluble dietary fiber)” and “Glucose homeostasis”	304
ID 2927: “Fibersol-2 (a resistant dextrin, i.e. a soluble dietary fiber)” and “Vascular/heart health;Blood lipids”	304
ID 2929: “Sunfiber (enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity In healthy people”	305
ID 2930: “Sunfiber (enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity In people with irritable bowel syndrom”	305
ID 2931: “Sunfiber (enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity In people receiving total or supplemental enteral nutrition”	305
ID 2932: “Sunfiber™ (syn.: Benefiber™) (enzymatically partially depolymerised guar gum)” and “Postprandial blood glucose”	306
ID 2933: “Hydroxypropyl methylcellulose (HPMC) Voedingsvezel” and “Verzadiging”	306
ID 2934: “CalorieControl Trim® Oat Bran 20%” and “Contribution to the maintenance of healthy blood cholesterol levels”	307

ID 2935: “CalorieControl Trim® Oat Bran” and “insulin_glucose response”	308
ID 2936: “Bifidobacterium breve BR 03 (DSM 16604)” and “Microflora / intestinal transit”	308
ID 2937: “Bifidobacterium breve BL 03 (DSM 16603)” and “Microflora / intestinal transit”	308
ID 2938: “Bifidobacterium breve BR 03 (DSM 16604) +Lactobacillus plantarum LP 01 (LMG P-21021)” and “Microflora / intestinal transit”	308
ID 2939: “Bifidobacterium infantis Bi1 (LMG P-17502), Bifidobacterium breve Bbr8 (LMG P-17501) and Bifidobacterium longum B110 (LMG P-17500)” and “he bacteria take part in the commensal gastrointestina flora. They survive in the gastrointestinal tract and counteract unwanted bacteria, promoting the intestinal healt”	308
ID 2940: “Bifidobacterium lactis BS 01 (LMG P-21384)” and “Intestinal transit”	309
ID 2941: “Bifidobacterium lactis BS 01 (LMG P-21384)+Lactobacillus rhamnosus LR 04 (DSM 16605)+Lactobacillus plantarum LP 02(LMG P-21020)” and “Natural defences / immune system / intestinal discomfort”	309
ID 2942: “Lactobacillus acidophilus bar 13 (CNCM-I-3857) and Bifidobacterium longum bar 33 (CNCM-I- 3858)- mix 1:1” and “immune modulation”	309
ID 2943: “Lactobacillus acidophilus K8 (LMG P-17503)” and “The strain takes part in the normal vaginal flora. It colonize the vagina. It counteract unwanted bacteria and yeasts, promoting the vaginal healt”	310
ID 2944: “Lactobacillus acidophilus LA 02 (LMG P-21381)+Lactobacillus plantarum LP 01 (LMG P- 21021)” and “Microflora / intestinal transit”	311
ID 2945: “Lactobacillus acidophilus LA1 (LMG P-21904)” and “Intestinal flora / gut health”	311
ID 2946: “Lactobacillus acidophilus P 18806” and “Benessere generale del tratto gastro-intestinale”	311
ID 2947: “Lactobacillus acidophilus P 18806” and “Rinforzo delle difese naturali”	312
ID 2948: “Lactobacillus acidophilus, Bifidobacterium (BB46); Bifidobacterium (BB02),Bifidobacterium Breve(Bbr8 LMG P-17501)CSL, Lactobacillus Rhamnosus ATC C53103 (LGG), Lactobacillus casei 101/37(Img P-17504), Lactobacillus delbrueckii spp bulgaricus AY/CSL (LMG P1” and “Intestinal microflora - Natural defences - immune response”	312
ID 2949: “Lactobacillus casei CNCM I-1572 DG” and “Intestinal flora”	312
ID 2950: “Lactobacillus crispatus P 17631” and “Benessere della microflora vaginale”	312
ID 2951: “Lactobacillus delbrueckii P18805” and “Benessere generale del tratto gastro-intestinale”	312
ID 2952: “Lactobacillus delbrueckii P18805” and “Rinforzo delle difese naturali”	313
ID 2953: “Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG-P 17224) and Streptococcus thermophilus 9Y/CSL (LMG-P 17225)” and “Intestinal microflora”	313
ID 2954: “Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG-P 17224) and Streptococcus thermophilus 9Y/CSL (LMG-P 17225)” and “Natural defence - immune response (Svolgono un'attività immunostimulante e immunomodulante verificato in individui adulti e bambini)”	314
ID 2955: “Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG-P 17224) and Streptococcus thermophilus 9Y/CSL (LMG-P 17225)” and “Lactose digestion”	315
ID 2956: “Lactobacillus gasseri P 17632” and “Benessere generale del tratto gastro-intestinale”	316
ID 2957: “Lactobacillus gasseri P 18137” and “Benessere della microflora vaginale”	316
ID 2958: “Lactobacillus gasseri P 18137” and “Benessere generale del tratto gastro-intestinale”	316
ID 2959: “Lactobacillus paracasei B21060” and “Funzione intestinale”	317
ID 2960: “Lactobacillus paracasei CNCM I 1687” and “Supports your natural (immune) defence system by increasing the IL-10 production and enanching NK cell activity in peripheral blood mononuclear cells	

(PBMC). Necessary to maintain the natural defences/helps to maintain a balanced immune system (increasing the IL-10 production and enhancing NK cell activity)	317
ID 2961: “Lactobacillus paracasei CNCM I 1687” and “Is a probiotic; contributes to a healthy digestive system by supporting the gut flora through an increased number of positive lactobacillus in the intestine; useful to maintain an healthy intestinal flora adhering to the mucosa; improves intestinal barrier function by competition (steric encumbrance) against pathogens; reduces gastro-intestinal discomfort; necessary to maintain a healthy digestive system by production of specific enzymes (e.g. beta-galactosidase)”	317
ID 2962: “Lactobacillus paracasei I1688” and “Rinforzo delle difese naturali”	318
ID 2963: “Lactobacillus paracasei I1688” and “Benessere generale del tratto gastro-intestinale”	318
ID 2964: “Lactobacillus paracasei LMG P-22043” and “Intestinal flora”	318
ID 2965: “Lactobacillus plantarum LP 01 (LMG P-21021)” and “Microflora / intestinal transit”	318
ID 2966: “Lactobacillus plantarum P 17630” and “Benessere del tratto intestinale”	319
ID 2967: “Lactobacillus plantarum P 17630” and “Benessere della microflora vaginale”	319
ID 2968: “Lactobacillus rhamnosus” and “Promotes the well being of the intestin improving skin, scalp and hair health.”	319
ID 2969: “Lactobacillus rhamnosus LR 04 (DSM 16605)” and “Microflora / intestinal transit”	319
ID 2970: “Lactobacillus salivarius I1794” and “Benessere generale del tratto gastro-intestinale”	320
ID 2971: “Lactobacillus salivarius I1794” and “Rinforzo delle difese naturali”	320
ID 2972: “PSMIX®, miscela di Lactobacillus paracasei I1688 e Lactobacillus salivarius I1794” and “Benessere generale del tratto gastro-intestinale”	320
ID 2973: “PSMIX®, miscela di Lactobacillus paracasei I1688 e Lactobacillus salivarius I1794” and “Rinforzo delle difese naturali”	321
ID 2974: “Streptococcus thermophilus LMG P 18807” and “Is a probiotic contributes to a healthy digestive system by supporting the gut flora through an increased number of positive lactobacillus in the intestine; useful to maintain an healthy intestinal flora adhering to the mucosa; improves intestinal barrier function by competition (steric encumbrance) against pathogens; reduces gastro-intestinal discomfort; necessary to maintain a healthy digestive system by production of specific enzymes (e.g. beta-galactosidase)”	321
ID 2975: “Streptococcus thermophilus LMG P 18807” and “Increases the immune defences/response by reducing the CD34+ cells. As recommended by PASSCLAIM, the functional capacity of the immune system has been assessed by: - measuring specific cell function in vivo e.g. production of cytokines or response to antigens - determining the incidence and severity of infection. Necessary to maintain the natural defences/helps to maintain a balanced immune system (reducing the CD34+ cells)”	321
ID 2976: “Yoghurt cultures (live)” and “Lactose digestion”	321
ID 2977: “Probiotic strain: Lactobacillus salivarius W24” and “Intestinal microbiota”	323
ID 2978: “Probiotic strain: Lactobacillus salivarius W24” and “Beneficially affects the oral ecology measured by increased numbers of positive lactobacilli in the oral microbiota”	324
ID 2979: “Probiotic strain: Lactobacillus salivarius W24” and “Gut barrier function”	324
ID 2980: “Probiotic strain: Lactobacillus salivarius W24” and “Balances/supports the immune system measured by increased levels of regulatory cytokines and sIgA”	325
ID 2981: “Probiotic strain: Lactobacillus casei W56” and “Intestinal microbiota”	325
ID 2982: “Probiotic strain: Lactobacillus casei W58” and “Gut barrier function”	326
ID 2983: “Probiotic strain: Lactobacillus casei W61” and “Balances/supports the immune system measured by increased levels of regulatory cytokines and sIgA”	326
ID 2984: “Probiotic strain: Lactococcus lactis W58” and “Intestinal microbiota”	326

ID 2985: “Probiotic strain: Lactococcus lactis W61” and “Gut barrier function”	327
ID 2986: “Probiotic strain: Lactococcus lactis W64” and “Balances/supports the immune system measured by increased levels of regulatory cytokines and sIgA”	328
ID 2987: “Probiotic strain: Bifidobacterium lactis W52 (Formerly known as Bifidobacterium infantis W52)” and “Intestinal microbiota”	328
ID 2988: “Probiotic strain: Bifidobacterium lactis W52 (Formerly known as Bifidobacterium infantis W52)” and “Gut barrier function”	329
ID 2989: “Probiotic strain: Bifidobacterium lactis W52 (Formerly known as Bifidobacterium infantis W52)” and “Balances/supports the immune system measured by increased levels of regulatory cytokines”	329
ID 2990: “Probiotic strain: Bifidobacterium lactis W52 (Formerly known as Bifidobacterium infantis W52)” and “Supports/maintains abdominal well-being and gastro-intestinal comfort measured by an improved intestinal passage”	330
ID 2991: “Probiotic strain: Lactobacillus salivarius LS-33” and “Intestinal microbiota”	330
ID 2992: Probiotic strain: “Bifidobacterium lactis BI-07 (Formerly known as Bifidobacterium infantis BI-07)” and “Promotes the restoration of the intestinal microbiota during and after antibiotic use measured by increased levels of bifidobacteria and reduced levels of non-beneficial bacteria in the intestine thereby improving a normal intestinal passage”	330
ID 2993: “Positively affects the immune response” and “Probiotic strain: Bifidobacterium lactis BI-07 (Formerly known as Bifidobacterium infantis BI-07)”	330
ID 2994: “Probiotic strain: Bifidobacterium lactis BI-04 (Formerly known as Bifidobacterium lactis BL-01 and Bifidobacterium longum BI-04)” and “Promotes the restoration of the intestinal microbiota during and after antibiotic use measured by enhanced levels of bifidobacteria in the intestine”	331
ID 2995: “Probiotic strain: Bifidobacterium lactis BI-04 (Formerly known as Bifidobacterium lactis BL-01 and Bifidobacterium longum BI-04)” and “Positively affects the immune response”	331
ID 2996: “Probiotic supplement: Winlove 500” and “Intestinal microbiota”	331
ID 2997: “Probiotic supplement: Lactobact omni FOS” and “Intestinal microbiota”	331
ID 2998: “Probiotic supplement: Lactobact omni FOS” and “Reduces stress-induced immune responses measured by the suppression of Th2 cytokines and increased levels of sIgA, thereby promoting resistance to viral infections”	331
ID 2999: “Probiotic strain: Lactobacillus acidophilus LA-5” and “Lactose intolerance”	332
ID 3000: “Probiotic strain: Lactobacillus acidophilus LA-5” and “Contributes to gastro-intestinal well-being measured by the improvement of natural bowel movements and a normal intestinal passage”	332

ID 2001: “Bilberry (*Vaccinium myrtillus*) extract containing anthocyanins” and “Eye Health”

- 1 *Vaccinium myrtillus* (bilberry). Monograph, 2001. *Altern Med Rev*, 6, 500-504.
- 2 *Herbal Remedies/ Heilpflanzen*. 2003. medpharm GmbH Scientific Publishers, Stuttgart.
- 3 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.
- 4 Barnes J, Anderson LA, Phillipson JD, 2002. Bilberry. In: *Herbal Medicine*. Pharmaceutical Press, London, 73-77.
- 5 Biesalski HK, Schrezenmeir J, Weber P, Weiss H, 1997. *Vitamine. Physiologie, Pathophysiologie*. Thieme, Stuttgart.
- 6 Bisset NG and Wichtl M, 2001. *Herbal Drugs and Phytopharmaceuticals* Medpharm Scientific Publishers, Stuttgart.
- 7 Bravetti G, 1989. Preventative medical treatment of senile cataract with vitamin E and *Vaccinium myrtillus* anthocyanosides: clinical evaluation. *Ann Ottal Clin Ocul* 109-116.
- 8 British Royal Air Force, 1966. Report der British Royal Air Force.
- 9 Canter PH and Ernst E, 2004. Anthocyanosides of *Vaccinium myrtillus* (bilberry) for night vision--a systematic review of placebo-controlled trials. *Surv Ophthalmol*, 49, 38-50.
- 10 Caselli L, 1985. Clinical and electroretinographic study on activity of anthocyanosides. *Arch Med Int*, 29-35.
- 11 Choi EH, Ok HE, Yoon Y, Magnuson BA, Kim MK, Chun HS, 2007. Protective effect of anthocyanin-rich extract from bilberry (*Vaccinium myrtillus* L.) against myelotoxicity induced by 5-fluorouracil. *Biofactors*, 29, 55-65.
- 12 Forte R, Iacobelli L, Tassone R, Gazzaniga D, Rispoli M, 1996. Fitotherapy and ophthalmology: considerations on dynamised myrtillus retinal effects with low luminance visual acuity. *Ann Ottal Clin Ocul*, 325-333.
- 13 Gloria E and Peria A, 1966. [Effect of anthocyanosides on the absolute visual threshold]. *Ann Ottalmol Clin Ocul*, 92, 595-607.
- 14 Jacques PF, Chylack LT, Jr., Hankinson SE, Khu PM, Rogers G, Friend J, Tung W, Wolfe JK, Padhye N, Willett WC, Taylor A, 2001. Long-term nutrient intake and early age-related nuclear lens opacities. *Arch Ophthalmol*, 119, 1009-1019.
- 15 Junemann G, 1967. [On the effect of anthocyanosides on hemeralopia following quinine poisoning]. *Klin Monatsbl Augenheilkd*, 151, 891-896.
- 16 Mayser HM and Wilhelm H, 2001. Effects of anthocyanosides on contrast vision. *Investigative Ophthalmology and Visual Science*, 348-B321
- 17 Mazza G, Kay CD, Cottrell T, Holub BJ, 2002. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. *J Agric Food Chem*, 50, 7731-7737.
- 18 Mills S, Bone K, Corrigan D, 2000. Bilberry fruit (*Vaccinium myrtillus* L.). In: *Principles and practice of phytotherapy: modern herbal medicine*. Churchill Livingstone, London, Edinburgh, 297-302.
- 19 Morazzoni P and Bombardelli E, 1996. *Vaccinium myrtillus* L. *Fitoterapia* 3-29.
- 20 Mowrey DB, 1993. Bilberry. In: *Next Generation Herbal Medicine*. McGraw-Hill, London, 14-24.
- 21 Murray MT, 1992. Bilberry. In: *The Healing Power of Herbs*. Prima Publishing, Roseville, California, 50-59.

- 22 Muth ER, Laurent JM, Jasper P, 2000. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. *Altern Med Rev*, 5, 164-173.
- 23 Nakaishi H, Matsumoto H, Tominaga S, Hirayama M, 2000. Effects of black current anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans. *Altern Med Rev*, 5, 553-562.
- 24 Newport A and Lockwood B, 2005. Use of nutraceuticals for eye health. *The Pharmaceutical Journal*, 275, 261-264.
- 25 Perossini M, Guidi G, Chiellini S, Siravo D, 1988. Diabetic and hypertensive retinopathy therapy with *Vaccinium myrtillus* anthocyanosides (Tegens) double-blind placebo-controlled clinical trial. *Ann Ottal Clin Ocul* 1173-1190
- 26 Repossi P, Malagola R, De Cadilhac C, 1987. The role of anthocyanosides on vascular permeability in diabetic retinopathy. *Ann Ottal Clin Ocul*, 113, 357-361.
- 27 Rose RC, Richer SP, Bode AM, 1998. Ocular oxidants and antioxidant protection. *Proc Soc Exp Biol Med*, 217, 397-407.
- 28 Sala D, Rolando M, Rossi PL, Pissarello L, 1979. Effect of anthocyanosides on visual performances at low illumination. *Minerva Oftalmol*, 283-285.
- 29 Scharrer A and Ober M, 1981. [Anthocyanosides in the treatment of retinopathies (author's transl)]. *Klin Monatsbl Augenheilkd*, 178, 386-389.
- 30 Varma SD, Mizuno A, Kinoshita JH, 1977. Diabetic cataracts and flavonoids. *Science*, 195, 205-206.
- 31 Wegmann R, Maeda K, Tronche P, Bastide P, 1969. [Effects of anthocyanosides on photoreceptors. Cytoenzymatic aspects]. *Ann Histochem*, 14, 237-256.
- 32 Yamakoshi J, Saito M, Kataoka S, Tokutake S, 2002. Procyanidin-rich extract from grape seeds prevents cataract formation in hereditary cataractous (ICR/f) rats. *J Agric Food Chem*, 50, 4983-4988.

ID 2003: “*Borago officinalis* (Common Name : Borage)” and “Skin health”

- 1 FDA (Food and Drug Administration).2004. Draft Guidance, Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act.
- 2 Gamma-linolenic acid (GLA). Monograph. 2004. *Alternative Medicine Review*, 9, 70-78.
- 3 Bahmer FA and Schafer J, 1992. [Treatment of atopic dermatitis with borage seed oil (Glandol)--a time series analytic study]. *Kinderarztl Prax*, 60, 199-202.
- 4 Berbis P, Hesse S, Privat Y, 1990. [Essential fatty acids and the skin]. *Allerg Immunol (Paris)*, 22, 225-231.
- 5 Boelsma E, Hendriks HF, Roza L, 2001. Nutritional skin care: health effects of micronutrients and fatty acids. *Am J Clin Nutr*, 73, 853-864.
- 6 Brosche T and Platt D, 2000. Effect of borage oil consumption on fatty acid metabolism, transepidermal water loss and skin parameters in elderly people. *Arch Gerontol Geriatr*, 30, 139-150.
- 7 Burger A and Wachter H, 1998. *Hunnius Pharmazeutisches Wörterbuch 8 Auflage*. Walter de Gruyter, Berlin, New York.
- 8 Chung S, Kong S, Seong K, Cho Y, 2002. Gamma-linolenic acid in borage oil reverses epidermal hyperproliferation in guinea pigs. *J Nutr*, 132, 3090-3097.
- 9 Europharma company and US Food and Drug Administration (FDA), 2002. Mails about Label Claims/ Disclaimers for products from the company EuroPharma.
- 10 Hahn A, 2006. *Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH*, Stuttgart.
- 11 Hendler SS and Rorvik D, 2001. *Physician Desk Reference for Nutritional supplement Thomson Healthcare*.

- 12 Henz BM, Jablonska S, van de Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk PG, Veenhuizen R, Muggli R, Raederstorff D, 1999. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. *Br J Dermatol*, 140, 685-688.
- 13 Muggli R, 2005. Systemic evening primrose oil improves the biophysical skin parameters of healthy adults. *Int J Cosmet Sci*, 27, 243-249.
- 14 Muggli R, 2007. Systemic evening primrose oil for irritated skin care. *Cosmetics Toiletries*, 122, 42-56.
- 15 Salvatore S, Pellegrini N, Brenna OV, Del Rio D, Frasca G, Brighenti F, Tumino R, 2005. Antioxidant characterization of some Sicilian edible wild greens. *J Agric Food Chem*, 53, 9465-9471.
- 16 Samson S, Rawlings AV, Guyonnet D, Lassel T, 2007. Improvements in stratum corneum barrier function from a probiotic yogurt containing borage oil, green tea polyphenols and vitamin E. *Journal of Investigative Dermatology*, 27, 65.
- 17 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag.
- 18 van Gool CJ, Thijs C, Henquet CJ, van Houwelingen AC, Dagnelie PC, Schrandt J, Menheere PP, van den brandt PA, 2003. Gamma-linolenic acid supplementation for prophylaxis of atopic dermatitis--a randomized controlled trial in infants at high familial risk. *Am J Clin Nutr*, 77, 943-951.
- 19 Wagner H and Wiesenauer M, 2003. *Phytotherapie: Phytopharmaka und pflanzliche Homöopathika* Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart
- 20 Ziboh VA, Miller CC, Cho Y, 2000. Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites. *Am J Clin Nutr*, 71, 361S-366S.

ID 2004: “Camellia sinensis (Common Name : Tea)” and “Mental and cognitive health”

- 1 Astill C, Birch MR, Dacombe C, Humphrey PG, Martin PT, 2001. Factors affecting the caffeine and polyphenol contents of black and green tea infusions. *J Agric Food Chem*, 49, 5340-5347.
- 2 BfR (Bundesinstitut für Risikobewertung), 2003. Getränke mit isoliertem L-Theanin. BgVV opinion dated of 05 JUN 2001 updated by BfR in August 2003.
- 3 Borzelleca JF, Peters D, Hall W, 2006. A 13-week dietary toxicity and toxicokinetic study with l-theanine in rats. *Food Chem Toxicol*, 44, 1158-1166.
- 4 Chan YC, Hosoda K, Tsai CJ, Yamamoto S, Wang MF, 2006. Favorable effects of tea on reducing the cognitive deficits and brain morphological changes in senescence-accelerated mice. *J Nutr Sci Vitaminol (Tokyo)*, 52, 266-273.
- 5 Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, Legleiter J, Marsh JL, Thompson LM, Lindquist S, Muchowski PJ, Wanker EE, 2006. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. *Hum Mol Genet*, 15, 2743-2751.
- 6 Feldheim W, 2001. Theanin - eine Verbindung besonderer Art im Tee. Wissenschaftlicher Informationsdienst Tee, Deutsches Tee-Institut, Hamburg.
- 7 Gardner EJ, Ruxton CH, Leeds AR, 2007. Black tea--helpful or harmful? A review of the evidence. *Eur J Clin Nutr*, 61, 3-18.
- 8 Haque AM, Hashimoto M, Katakura M, Tanabe Y, Hara Y, Shido O, 2006. Long-term administration of green tea catechins improves spatial cognition learning ability in rats. *J Nutr*, 136, 1043-1047.
- 9 Hiller K and Melzig MF, 2003. *Lexikon der Arzneipflanzen und Drogen*. Spektrum Akademischer Verlag, Heidelberg.
- 10 Hindmarch I, Quinlan PT, Moore KL, Parkin C, 1998. The effects of black tea and other beverages on aspects of cognition and psychomotor performance. *Psychopharmacology (Berl)*, 139, 230-238.

- 11 Hindmarch I, Rigney U, Stanley N, Quinlan P, Rycroft J, Lane J, 2000. A naturalistic investigation of the effects of day-long consumption of tea, coffee and water on alertness, sleep onset and sleep quality. *Psychopharmacology (Berl)*, 149, 203-216.
- 12 Hoppe HA, 1977. *Drogenkunde*. Ealter de Gruyter & Co, Berlin.
- 13 Juneja LR, Chu D, Okubo T, Nagato Y, Yokogoshi H, 1999. L-theanine - a unique amino acid of green tea and its relaxation effects in humans. *Trends in Food Sci.Technol.*, 10, 199-204.
- 14 Kakuda T, Nozawa A, Unno T, Okamura N, Okai O, 2000. Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. *Biosci Biotechnol Biochem*, 64, 287-293.
- 15 Kakuda T, Yanase H, Utsunomiya K, Nozawa A, Unno T, Kataoka K, 2000. Protective effect of gamma-glutamylethylamide (theanine) on ischemic delayed neuronal death in gerbils. *Neurosci Lett*, 289, 189-192.
- 16 Kakuda T, Nozawa A, Sugimoto A, Niino H, 2002. Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. *Biosci Biotechnol Biochem*, 66, 2683-2686.
- 17 Kimura R and Murata T, 1971. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. I. Central depressant effect of theanine. *Chem Pharm Bull (Tokyo)*, 19, 1257-1261.
- 18 Kimura R and Murata T, 1986. Effect of theanine on norepinephrine and serotonin levels in rat brain. *Chem Pharm Bull (Tokyo)*, 34, 3053-3057.
- 19 Kimura K, Ozeki M, Juneja LR, Ohira H, 2007. L-Theanine reduces psychological and physiological stress responses. *Biol Psychol*, 74, 39-45.
- 20 Kitaoka S, Hayashi H, Yokogoshi H, Suzuki Y, 1996. Transmural potential changes associated with the in vitro absorption of theanine in the guinea pig intestine. *Biosci Biotechnol Biochem*, 60, 1768-1771.
- 21 Kobayashi K, Nagato Y, Aoi N, Juneja LR, Kim M, Yamamoto T, Sugimoto S, 1998. Effects of L-Theanine on the release of alpha-brain waves in human volunteers. *Nippon Nōgei Kagakukai*, 72, 153-157.
- 22 Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, Awata S, Nagatomi R, Arai H, Tsuji I, 2006. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. *Am J Clin Nutr*, 83, 355-361.
- 23 Lu K, Gray MA, Oliver C, Liley DT, Harrison BJ, Bartholomeusz CF, Phan KL, Nathan PJ, 2004. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. *Hum Psychopharmacol*, 19, 457-465.
- 24 Nagasawa K, Aoki H, Yasuda E, Nagai K, Shimohama S, Fujimoto S, 2004. Possible involvement of group I mGluRs in neuroprotective effect of theanine. *Biochem Biophys Res Commun*, 320, 116-122.
- 25 Nathan PJ, Lu K, Gray M, Oliver C, 2006. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. *J Herb Pharmacother*, 6, 21-30.
- 26 Ozeki Y, Ogawa K, Ito N, 2003. Nonequilibrium relaxation analysis of Kosterlitz-Thouless phase transition. *Phys Rev E Stat Nonlin Soft Matter Phys*, 67, 026702.
- 27 Quinlan P, Lane J, Aspinall L, 1997. Effects of hot tea, coffee and water ingestion on physiological responses and mood: the role of caffeine, water and beverage type. *Psychopharmacology (Berl)*, 134, 164-173.
- 28 Quinlan PT, Lane J, Moore KL, Aspen J, Rycroft JA, O'Brien DC, 2000. The acute physiological and mood effects of tea and coffee: the role of caffeine level. *Pharmacol Biochem Behav*, 66, 19-28.
- 29 Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J, 2005. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. *J Neurosci*, 25, 8807-8814.
- 30 Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW, 2008. Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. *Psychopharmacology (Berl)*, 195, 569-577.
- 31 Schilcher H and Kammerer S, 2000. *Leitfaden Phytotherapie*. Urban & Fischer Verlag, München.

- 32 Scholz E and Bertram B, 1995. *Camellia sinensis* (L.) O. Kuntze, Der Teestrauch. *Zeitschrift Fur Phytotherapie*, 17, 235-250.
- 33 Schönfelder I and Schönfelder P, 2004. *Das neue Handbuch der Heilpflanzen: Botanik Arzneidrogen Wirkstoffe*. Wissenschaftliche Verlagsgesellschaft Hildeberg.
- 34 Scott D, Rycroft JA, Aspen J, Chapman C, Brown B, 2004. The effect of drinking tea at high altitude on hydration status and mood. *Eur J Appl Physiol*, 91, 493-498.
- 35 Shimbo M, Nakamura K, Jing Shi H, Kizuki M, Seino K, Inose T, Takano T, 2005. Green tea consumption in everyday life and mental health. *Public Health Nutr*, 8, 1300-1306.
- 36 Steptoe A and Wardle J, 1999. Mood and drinking: a naturalistic diary study of alcohol, coffee and tea. *Psychopharmacology (Berl)*, 141, 315-321.
- 37 Steptoe A, Gibson EL, Vuononvirta R, Williams ED, Hamer M, Rycroft JA, Erusalimsky JD, Wardle J, 2007. The effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind trial. *Psychopharmacology (Berl)*, 190, 81-89.
- 38 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag.
- 39 Unno T, Suzuki Y, Kakuda T, Hayakawa T, Tsuge H, 1999. Metabolism of theanine, gamma-glutamylethylamide, in rats. *J Agric Food Chem*, 47, 1593-1596.
- 40 Unno K, Takabayashi F, Yoshida H, Choba D, Fukutomi R, Kikunaga N, Kishido T, Oku N, Hoshino M, 2007. Daily consumption of green tea catechin delays memory regression in aged mice. *Biogerontology*, 8, 89-95.
- 41 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- 42 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.
- 43 Yamada T, Terashima T, Okubo T, Juneja LR, Yokogoshi H, 2005. Effects of theanine, r-glutamylethylamide, on neurotransmitter release and its relationship with glutamic acid neurotransmission. *Nutr Neurosci*, 8, 219-226.
- 44 Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T, 1998. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. *Neurochem Res*, 23, 667-673.

ID 2005: “Camellia sinensis (Common Name : Tea)” and “Cognitive Performance: Focussed attention”

- 1 Bastiaansen MC, Bocker KB, Brunia CH, de Munck JC, Spekreijse H, 2001. Event-related desynchronization during anticipatory attention for an upcoming stimulus: a comparative EEG/MEG study. *Clin Neurophysiol*, 112, 393-403.
- 2 Bastiaansen MC and Brunia CH, 2001. Anticipatory attention: an event-related desynchronization approach. *Int J Psychophysiol*, 43, 91-107.
- 3 Berger H, 1929. Ubre das elektroenkephalogram des menschen. *Arch.F.Psychiat.*, 87, 527-570.
- 4 Brice CF and Smith AP, 2002. Effects of caffeine on mood and performance: a study of realistic consumption. *Psychopharmacology (Berl)*, 164, 188-192.
- 5 Brown BB, 1970. Recognition of aspects of consciousness through association with EEG alpha activity represented by a light signal. *Psychophysiology*, 6, 442-452.
- 6 Cartwright RA, Roberts EAH, Wood DJ, 1954. Theanine an amino acid of N-ethyl amide present in tea. *J.Sci.Food Agric.*, 597-599.
- 7 Casimir J, Jadot J, Renard M, 1960. Separation and characterisation on N-ethyl-g-glutamine in *Xerocomus badius* (*Boletus ladius*). *Biochem.Biophys.Acta*, 39, 462-468.
- 8 Christopher G, Sutherland D, Smith A, 2005. Effects of caffeine in non-withdrawn volunteers. *Hum Psychopharmacol*, 20, 47-53.

- 9 Delmonte MM, 1984. Electro cortical activity and related phenomena associated with meditation practice: a literature review. *Int J Neurosci*, 24, 217-231.
- 10 Ekborg-Ott HK, Taylor A, Armstrong DW, 1997. Varietal differences in the total and enantiomeric composition of theanine in tea. *Journal of Agricultural and Food Chemistry*, 45, 353-363.
- 11 Finger A, Kuhr S, Engelhardt UH, 1992. Chromatography of tea constituents. *J Chromatogr*, 624, 293-315.
- 12 Foxe JJ, Simpson GV, Ahlfors SP, 1998. Parieto-occipital approximately 10 Hz activity reflects anticipatory state of visual attention mechanisms. *Neuroreport*, 9, 3929-3933.
- 13 Fredholm BB, Battig K, Holmen J, Nehlig A, Zwartau EE, 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev*, 51, 83-133.
- 14 Fu KM, Foxe JJ, Murray MM, Higgins BA, Javitt DC, Schroeder CE, 2001. Attention-dependent suppression of distracter visual input can be cross-modally cued as indexed by anticipatory parieto-occipital alpha-band oscillations. *Brain Res Cogn Brain Res*, 12, 145-152.
- 15 Gomez-Ramirez M, Higgins BA, Rycroft JA, Owen GN, Mahoney J, Shpaner M, Foxe JJ, 2007. The deployment of intersensory selective attention: a high-density electrical mapping study of the effects of theanine. *Clin Neuropharmacol*, 30, 25-38.
- 16 Juneja LR, Chu D, Okubo T, Nagato Y, Yokogoshi H, 1999. L-theanine - a unique amino acid of green tea and its relaxation effects in humans. *Trends in Food Sci.Technol.*, 10, 199-204.
- 17 Kamei T, Toriumi Y, Kimura H, Kimura K, 2001. Correlation between alpha rhythms and natural killer cell activity during yogic respiratory exercise. *Stress and Health*, 17, 141-145.
- 18 Kelly SP, Lalor EC, Reilly RB, Foxe JJ, 2005. Visual spatial attention tracking using high density SSVEP data for independent brain-computer communication. *IEEE Transactions on neural systems and rehabilitation engineering*, 13, 172-178.
- 19 Kim KS, Yum KS, Lee Y, 2001. Effect of changes in muscle tension and brain alpha wave activity induced by functional beverage on golf performance. *Proceedings of the International Symposium on Food, Nutrition and Health for the 21st Century*.
- 20 Kimura R and Murata T, 1971. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. I. Central depressant effect of theanine. *Chem Pharm Bull (Tokyo)*, 19, 1257-1261.
- 21 Kimura R and Murata T, 1986. Effect of theanine on norepinephrine and serotonin levels in rat brain. *Chem Pharm Bull (Tokyo)*, 34, 3053-3057.
- 22 Klimesch W, Doppelmayr M, Russegger H, Pachinger T, Schwaiger J, 1998. Induced alpha band power changes in the human EEG and attention. *Neurosci Lett*, 244, 73-76.
- 23 Kobayashi K, Nagato Y, Aoi N, Juneja LR, Kim M, Yamamoto T, Sugimoto S, 1998. Effects of L-Theanine on the release of alpha-brain waves in human volunteers. *Nippon-Nogeikagaku-Kaishi* 72, 153-157.
- 24 Konishi S and Takahashi E, 1966. Existence and synthesis of L-glutamic acid g-methylamide in tea plants. *Plant Cell Physiol*, 7, 171-175.
- 25 Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R, 2002. Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. *Sea-Air-Land. Psychopharmacology (Berl)*, 164, 250-261.
- 26 Lorist MM and Snel J, 1997. Caffeine effects on perceptual and motor processes. *Electroencephalogr Clin Neurophysiol*, 102, 401-413.
- 27 Millin DJ, Crispin DJ, Swaine D, 1969. Nonvolatile components of black tea and their contribution to the character of the beverage. *J.Agric.Food Chem.*, 17, 717-722.
- 28 Nagai Y, Sato H, Kashimura J, 2003. Effect of palatinose administration on alpha 1 brain waves in human volunteers. *Food Sci.Technol.Res*, 9, 357-360.
- 29 Nagashima Z, Nakagawa M, Tokumura H, Toriumi Y, 1957. Free amino acids in tea IV: quantitative changes in the manufacture of black and green tea. *J.Agric.Chem.Soc.Jpn.* , 31, 169- 173.

- 30 Nehlig A, 1999. Are we dependent upon coffee and caffeine? A review on human and animal data. *Neurosci Biobehav Rev*, 23, 563-576.
- 31 Oda S, Matsumoto T, Nakagawa K, Moriya K, 1999. Relaxation effects in humans of underwater exercise of moderate intensity. *Eur J Appl Physiol Occup Physiol*, 80, 253-259.
- 32 Passmore AP, Kondowe GB, Johnston GD, 1987. Renal and cardiovascular effects of caffeine: a dose-response study. *Clin Sci (Lond)*, 72, 749-756.
- 33 Ruijter J, Lorist MM, Snel J, 1999. The influence of different doses of caffeine on visual task performance. *Journal of Psychophysiology*, 13, 37-48.
- 34 Ruijter J, De Ruiter MB, Snel J, 2000. The effects of caffeine on visual selective attention to color: an ERP study. *Psychophysiology*, 37, 427-439.
- 35 Sakato Y, 1950. Studies on the chemical constituents of tea. A new amide - theanine. *Agri.Chem.Soc.Japan*, 23, 262-267.
- 36 Smith AP, Rusted JM, Eaton-Williams P, Savory M, Leathwood P, 1990. Effects of caffeine given before and after lunch on sustained attention. *Neuropsychobiology*, 23, 160-163.
- 37 Smith A, Sturgess W, Gallagher J, 1999. Effects of a low dose of caffeine given in different drinks on mood and performance. *Human Psychopharmacology - Clinical & Experimental*, 14, 473-482.
- 38 Smith A, 2002. Effects of caffeine on human behavior. *Food Chem Toxicol*, 40, 1243-1255.
- 39 Song CH, 2002. The effects of L-theanine containing functional beverage on mental relaxation and fatigue perception. *J.Korean Acad.Fam.Med.*, 23, 637-664.
- 40 Song C.H., Jung J.H., Oh J.S., Kim K.S., 2003. Effects of theanine on the release of alpha brain waves in adult males. *Korean J.Nutrition*, 36, 918-923.
- 41 Stoyva J and Kamiya J, 1968. Electrophysiological studies of dreaming as the prototype of a new strategy in the study of consciousness. *Psychol Rev*, 75, 192-205.
- 42 Terishima T, Takido J, Yokogoshi H, 1998. Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine. *Biosci.Biotechnol.Biochem*, 63, 615-618.
- 43 Travis F, Olson T, Egenes T, Gupta HK, 2001. Physiological patterns during practice of the Transcendental Meditation technique compared with patterns while reading Sanskrit and a modern language. *Int J Neurosci*, 109, 71-80.
- 44 Unno T, Suzuki Y, Kakuda T, Hayakawa T, Tsuge H, 1999. Metabolism of theanine, gamma-glutamylethylamide, in rats. *J Agric Food Chem*, 47, 1593-1596.
- 45 Vanni S, Revonsuo A, Hari R, 1997. Modulation of the parieto-occipital alpha rhythm during object detection. *J Neurosci*, 17, 7141-7147.
- 46 Walsh DH, 1974. Interactive effects of alpha feedback and instructional set on subjective state. *Psychophysiology*, 11, 428-435.
- 47 Wickremasinghe RL, 1978. Tea (in food research). *Advanced Food Research*, 24, 229-286.
- 48 Worden MS, Foxe JJ, Wang N, Simpson GV, 2000. Anticipatory biasing of visuospatial attention indexed by retinotopically specific alpha-band electroencephalography increases over occipital cortex. *J Neurosci*, 20, RC63:1-6.
- 49 Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T, 1998. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. *Neurochem Res*, 23, 667-673.
- 50 Yokogoshi H, Mochizuki M, Saitoh K, 1998. Theanine-induced reduction of brain serotonin concentration in rats. *Biosci Biotechnol Biochem*, 62, 816-817.

ID 2006: “Capsicum annum (Common Name : Cayenne pepper)” and “Weight management”

- 1 Barnes J, Anderson LA, Phillipson DJ, 2002. Herbal Medicines. Pharmaceutical Press, London.
- 2 Belza A and Jessen AB, 2005. Bioactive food stimulants of sympathetic activity: effect on 24-h energy expenditure and fat oxidation. *Eur J Clin Nutr*, 59, 733-741.
- 3 Belza A, Frandsen E, Kondrup J, 2007. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. *Int J Obes (Lond)*, 31, 121-130.
- 4 BHMA (British Herbal Medicine Association), 1996. British Herbal Pharmacopoeia. British Herbal Medicine Association, Exeter.
- 5 BHMA (British Herbal Medicine Association), 2006. British Herbal Compendium. British Herbal Medicine Association, Exeter.
- 6 Biggs DF and Ladenius RC, 1990. Capsaicin selectively reduces airway responses to histamine, substance P and vagal stimulation. *Eur J Pharmacol*, 175, 29-33.
- 7 Chevallier A, 2002. Encyclopedia of Herbal Medicine (DK Natural Health) Dorling Kindersley, London.
- 8 Cichewicz RH and Thorpe PA, 1996. The antimicrobial properties of chile peppers (*Capsicum* species) and their uses in Mayan medicine. *J Ethnopharmacol*, 52, 61-70.
- 9 Cordell GA and Araujo OE, 1993. Capsaicin: identification, nomenclature, and pharmacotherapy. *Ann Pharmacother*, 27, 330-336.
- 10 Felter HW and Lloyd JU, 1898. King's American dispensatory. Ohio Valley Co., Cincinnati.
- 11 Fugh-Berman A, 2005. The 5-minute Herb & Dietary supplement Consult. Lippincott Williams & Wilkins, New York.
- 12 Gonzalez R, Dunkel R, Koletzko B, Schusdziarra V, Allescher HD, 1998. Effect of capsaicin-containing red pepper sauce suspension on upper gastrointestinal motility in healthy volunteers. *Dig Dis Sci*, 43, 1165-1171.
- 13 Henderson DE, Slickman AM, Henderson SK, 1999. Quantitative HPLC determination of the antioxidant activity of capsaicin on the formation of lipid hydroperoxides of linoleic acid: a comparative study against BHT and melatonin. *J Agric Food Chem*, 47, 2563-2570.
- 14 Herr SM Ernst E and Young VSL, 2005. Herb-Drug Interaction Handbook. Church Street Books, Nassau, NY.
- 15 Hogaboam CM and Wallace JL, 1991. Inhibition of platelet aggregation by capsaicin. An effect unrelated to actions on sensory afferent neurons. *Eur J Pharmacol*, 202, 129-131.
- 16 Holzer P, Pabst MA, Lippe IT, 1989. Intra-gastric capsaicin protects against aspirin-induced lesion formation and bleeding in the rat gastric mucosa. *Gastroenterology*, 96, 1425-1433.
- 17 Hood VC, Cruwys SC, Urban L, Kidd BL, 2001. The neurogenic contribution to synovial leucocyte infiltration and other outcome measures in a guinea pig model of arthritis. *Neurosci Lett*, 299, 201-204.
- 18 Hornero-Mendez D and Minguez-Mosquera MI, 1998. Isolation and Identification of the Carotenoid Capsolutein from *Capsicum annum* as Cucurbitaxanthin A. *Journal of Agricultural and Food Chemistry*, 46, 4087-4090.
- 19 Institute for Natural Product Research, 2000. Capsicum monograph.
- 20 Jensen-Jarolim E, Gajdzik L, Haberl I, Kraft D, Scheiner O, Graf J, 1998. Hot spices influence permeability of human intestinal epithelial monolayers. *J Nutr*, 128, 577-581.
- 21 Jung MY, Kang HJ, Moon A, 2001. Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. *Cancer Lett*, 165, 139-145.
- 22 Kawada T, Hagihara K, Iwai K, 1986. Effects of capsaicin on lipid metabolism in rats fed a high fat diet. *J Nutr*, 116, 1272-1278.

- 23 Kawada T, Watanabe T, Takaishi T, Tanaka T, Iwai K, 1986. Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization. *Proc Soc Exp Biol Med*, 183, 250-256.
- 24 Kim JD, Kim JM, Pyo JO, Kim SY, Kim BS, Yu R, Han IS, 1997. Capsaicin can alter the expression of tumor forming-related genes which might be followed by induction of apoptosis of a Korean stomach cancer cell line, SNU-1. *Cancer letters* 120, 235-241.
- 25 Krishna De A, 2003. *Capsicum: The genus Capsicum*. CRC Press, Boca Raton.
- 26 Lejeune MP, Kovacs EM, Westerterp-Plantenga MS, 2003. Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. *Br J Nutr*, 90, 651-659.
- 27 Lim K, Yoshioka M, Kikuzato S, Kiyonaga A, Tanaka H, Shindo M, Suzuki M, 1997. Dietary red pepper ingestion increases carbohydrate oxidation at rest and during exercise in runners. *Med Sci Sports Exerc*, 29, 355-361.
- 28 McKenna DJ, Jones K, Hughes K, 2002. *Botanical Medicines: The Desk Reference for Major Herbal Supplements* Routledge, London.
- 29 Miller CH, Zhang Z, Hamilton SM, Teel RW, 1993. Effects of capsaicin on liver microsomal metabolism of the tobacco-specific nitrosamine NNK. *Cancer Lett*, 75, 45-52.
- 30 Molina-Torres J, Garcia-Chavez A, Ramirez-Chavez E, 1999. Antimicrobial properties of alkaloids present in flavouring plants traditionally used in Mesoamerica: affinin and capsaicin. *J Ethnopharmacol*, 64, 241-248.
- 31 Monsereenusorn Y, 1980. Effect of *Capsicum annum* on Blood Glucose Level. *Pharmaceutical Biology*, 18, 1 - 7.
- 32 Morre DJ, Chueh PJ, Morre DM, 1995. Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. *Proc Natl Acad Sci USA*, 92, 1831-1835.
- 33 Panossian A, Gabriellan E, Wagner H, 1996. Dose-dependent reversible effect of capsaicin on interleukin-1 α production is associated with the metabolism of arachidonic acid (leukotriene B4 and prostaglandin E2). *Phytomedicine*, 3, 169-174.
- 34 Reynolds JEF, 1996. *Martindale: The Extra Pharmacopoeia*. Pharmaceutical Press, London.
- 35 Tolan I, Ragoobirsingh D, Morrison EY, 2001. The effect of capsaicin on blood glucose, plasma insulin levels and insulin binding in dog models. *Phytother Res*, 15, 391-394.
- 36 Tsuchiya H, 2001. Biphasic membrane effects of capsaicin, an active component in *Capsicum* species. *J Ethnopharmacol*, 75, 295-299.
- 37 Tsuchiya H, 2001b. Erratum to "Biphasic membrane effects of capsaicin, an active component in *Capsicum* species". *J Ethnopharmacol*, 76, 313.
- 38 Uchida M, Yano S, Watanabe K, 1991. The role of capsaicin-sensitive afferent nerves in protective effect of capsaicin against absolute ethanol-induced gastric lesions in rats. *Jpn J Pharmacol*, 55, 279-282.
- 39 United States Pharmacopoeial Convention, 2006. *US Pharmacopoeia*.
- 40 Westerterp-Plantenga M, Diepvens K, Joosen AM, Berube-Parent S, Tremblay A, 2006. Metabolic effects of spices, teas, and caffeine. *Physiol Behav*, 89, 85-91.
- 41 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.
- 42 Williamson EM, 2004. *Potter's Herbal Cyclopaedia* The C.W. Daniel Company Ltd., Saffron Walden, UK.
- 43 Yeoh KG, Kang JY, Yap I, Guan R, Tan CC, Wee A, Teng CH, 1995. Chili protects against aspirin-induced gastroduodenal mucosal injury in humans. *Dig Dis Sci*, 40, 580-583.
- 44 Yoshioka M, St-Pierre S, Suzuki M, Tremblay A, 1998. Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women. *Br J Nutr*, 80, 503-510.

- 45 Yoshioka M, Doucet E, Drapeau V, Dionne I, Tremblay A, 2001. Combined effects of red pepper and caffeine consumption on 24 h energy balance in subjects given free access to foods. *Br J Nutr*, 85, 203-211.
- 46 Zhang Z, Huynh H, Teel RW, 1997. Effects of orally administered capsaicin, the principal component of capsicum fruits, on the in vitro metabolism of the tobacco-specific nitrosamine NNK in hamster lung and liver microsomes. *Anticancer Res*, 17, 1093-1098.

ID 2007: “Carica papaya (Common Name : Papaya)” and “Antioxidant activity”

- 1 AEFI (The Pharmacists' Spanish Association of the Industry), Monograph of papáin.
- 2 AFEPADI (Asociacion Espanola de Fabricantes de Preparados Alimenticios Especiales DyPM, 2003. Monograph of papáin.
- 3 Aruoma OI, Colognato R, Fontana I, Gartlon J, Migliore L, Koike K, Coecke S, Lamy E, Mersch-Sundermann V, Laurenza I, Benzi L, Yoshino F, Kobayashi K, Lee MC, 2006. Molecular effects of fermented papaya preparation on oxidative damage, MAP Kinase activation and modulation of the benzo[a]pyrene mediated genotoxicity. *Biofactors*, 26, 147-159.
- 4 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 5 Calzuola I, Gianfranceschi GL, Marsili V, 2006. Comparative activity of antioxidants from wheat sprouts, *Morinda citrifolia*, fermented papaya and white tea. *Int J Food Sci Nutr*, 57, 168-177.
- 6 Imao K, Wang H, Komatsu M, Hiramatsu M, 1998. Free radical scavenging activity of fermented papaya preparation and its effect on lipid peroxide level and superoxide dismutase activity in iron-induced epileptic foci of rats. *Biochem Mol Biol Int*, 45, 11-23.
- 7 Marotta F, Pavasuthipaisit K, Yoshida C, Albergati F, Marandola P, 2006. Relationship between aging and susceptibility of erythrocytes to oxidative damage: in view of nutraceutical interventions. *Rejuvenation Res*, 9, 227-230.
- 8 Marotta F, Weksler M, Naito Y, Yoshida C, Yoshioka M, Marandola P, 2006. Nutraceutical supplementation: effect of a fermented papaya preparation on redox status and DNA damage in healthy elderly individuals and relationship with GSTM1 genotype: a randomized, placebo-controlled, cross-over study. *Ann NY Acad Sci*, 1067, 400-407.
- 9 Mehdipour S, Yasa N, Dehghan G, Khorasani R, Mohammadirad A, Rahimi R, Abdollahi M, 2006. Antioxidant potentials of Iranian *Carica papaya* juice in vitro and in vivo are comparable to alpha-tocopherol. *Phytother Res*, 20, 591-594.
- 10 Osato JA, Santiago LA, Remo GM, Cuadra MS, Mori A, 1993. Antimicrobial and antioxidant activities of unripe papaya. *Life Sci*, 53, 1383-1389.
- 11 Rimbach G, Park YC, Guo Q, Moini H, Qureshi N, Saliou C, Takayama K, Virgili F, Packer L, 2000. Nitric oxide synthesis and TNF-alpha secretion in RAW 264.7 macrophages: mode of action of a fermented papaya preparation. *Life Sci*, 67, 679-694.

ID 2010: “Carum carvi (Common Name : Caraway)” and “Lactation”

- 1 Barthlott W, Groß E, Hölftje HD, Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz v, 2004. *HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe.: Einzelplatzversion/Windows/Up-Date* Springer, Heidelberg.
- 2 Brendler T, Gruenwald J, Jaenicke C, 2003. *Heilpflanzen (Herbal Remedies)* Taylor & Francis, Inc., Washington DC.

- 3 Hiller K and Melzig MF, 2003. Lexikon der Arzneipflanzen und Drogen. Spektrum Akademischer Verlag, Heidelberg.
- 4 Hoppe HA, 1975. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 5 Schönfelder I and Schönfelder P, 2004. Das neue Handbuch der Heilpflanzen: Botanik, Arzneidrogen, Wirkstoffe, Anwendungen Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 6 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2013: “Cinnamomum cassia, zeylanicum (Common Name : Cinnamon)” and “Glucose metabolism”

- 1 Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, Flanagan VP, Schoene NW, Graves DJ, 2004. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. *J Agric Food Chem*, 52, 65-70.
- 2 Anderson RA, 2008. Chromium and polyphenols from cinnamon improve insulin sensitivity. *Proceedings of the Nutrition Society*, 67, 48-53.
- 3 Bentley R and Trimen H, 1880. Medicinal Plants; being descriptions with original figures of the principal plants employed in medicine and an account of the characters, properties, and uses of their parts and products of medicinal value. Churchill, London.
- 4 Berrio LF, Polansky MM, Anderson RA, 1992. Insulin activity: stimulatory effects of cinnamon and Brewer's yeast as influenced by albumin. *Hormone research*, 37, 225-229.
- 5 Broadhurst CL, Polansky MM, Anderson RA, 2000. Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro. *J Agric Food Chem*, 48, 849-852.
- 6 Cao H, Polansky MM, Anderson RA, 2007. Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes. *Arch Biochem Biophys*, 459, 214-222.
- 7 Chase CK and McQueen CE, 2007. Cinnamon in diabetes mellitus. *Am J Health Syst Pharm*, 64, 1033-1035.
- 8 Grieve M, Cassia (Cinnamon). <http://botanical.com/botanical/mgmh/c/cassia31.html>.
- 9 Hlebowicz J, Darwiche G, Bjorgell O, Almer LO, 2007. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. *Am J Clin Nutr*, 85, 1552-1556.
- 10 Imparl-Radosevich J, Deas S, Polansky MM, Baedke DA, Ingebritsen TS, Anderson RA, Graves DJ, 1998. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. *Horm Res*, 50, 177-182.
- 11 Jarvill-Taylor KJ, Anderson RA, Graves DJ, 2001. A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. *J Am Coll Nutr*, 20, 327-336.
- 12 Kannappan S, Jayaraman T, Rajasekar P, Ravichandran MK, Anuradha CV, 2006. Cinnamon bark extract improves glucose metabolism and lipid profile in the fructose-fed rat. *Singapore Medical Journal*, 47, 858.
- 13 Khan A, Bryden NA, Polansky MM, Anderson RA, 1990. Insulin potentiating factor and chromium content of selected foods and spices. *Biological Trace Element Research*, 24, 183-188.
- 14 Khan A, Safdar M, Ali Khan MM, Khatkhat KN, Anderson RA, 2003. Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diabetes Care*, 26, 3215-3218.
- 15 Kim SH, Hyun SH, Choung SY, 2006. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. *Journal of Ethnopharmacology*, 104, 119-123.
- 16 Kim W, Khil LY, Clark R, Bok SH, Kim EE, Lee S, Jun HS, Yoon JW, 2006. Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4. *Diabetologia*, 49, 2437-2448.

- 17 Mang B, Wolters M, Schmitt B, Kelb K, Lichtinghagen R, Stichtenoth DO, Hahn A, 2006. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. *Eur J Clin Invest*, 36, 340-344.
- 18 MedicinesComplete, Cassia, <http://www.medicinescomplete.com/mc/herbals/2006/monographs.htm>
- 19 Pham AQ, Kourlas H, Pham DQ, 2007. Cinnamon Supplementation in Patients with Type 2 Diabetes Mellitus. *Pharmacotherapy*, 27, 595-599.
- 20 Preuss HG, Echard B, Polansky MM, Anderson R, 2006. Whole Cinnamon and Aqueous Extracts Ameliorate Sucrose-Induced Blood Pressure Elevations in Spontaneously Hypertensive Rats. *Journal of the American College of Nutrition*, 25, 144-150.
- 21 Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y, 2003. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. *Diabetes Res Clin Pract*, 62, 139-148.
- 22 Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y, 2004. Cinnamon extract prevents the insulin resistance induced by a high-fructose diet. *Horm Metab Res*, 36, 119-125.
- 23 Solomon TPJ and Blannin AK, 2007. Effects of short-term cinnamon ingestion on in vivo glucose tolerance. *Diabetes, Obesity and Metabolism*, 9, 895-901.
- 24 Subash Babu P, Prabuseenivasan S, Ignacimuthu S, 2007. Cinnamaldehyde—A potential antidiabetic agent. *Phytomedicine*, 14, 15-22.
- 25 Talpur N, Echard B, Ingram C, Bagchi D, Preuss H, 2005. Effects of a novel formulation of essential oils on glucose-insulin metabolism in diabetic and hypertensive rats: a pilot study. *Diabetes Obes Metab*, 7, 193-199.
- 26 Talpur N, Echard B, Ingram C, Bagchi D, Preuss H, 2005. Effects of a novel formulation of essential oils on glucose-insulin metabolism in diabetic and hypertensive rats: a pilot study. *Diabetes, Obesity and Metabolism*, 7, 193-199.
- 27 Vanschoonbeek K, Thomassen BJ, Senden JM, Wodzig WK, van Loon LJ, 2006. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. *J Nutr*, 136, 977-980.
- 28 Verspohl EJ, Bauer K, Neddermann E, 2005. Antidiabetic effect of *Cinnamomum cassia* and *Cinnamomum zeylanicum* in vivo and in vitro. *Phytother Res*, 19, 203-206.
- 29 Wang JG, Anderson RA, Graham GM, Chu MC, Sauer MV, Guarnaccia MM, Lobo RA, 2007. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. *Fertility and Sterility*, 88, 240-243.
- 30 WHO (World Health Organization), 1999. *Cortex Cinnamomi*. In: WHO Monographs on Selected Medicinal Plants. WHO, Geneva.
- 31 Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA, 2006. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. *J Int Soc Sports Nutr*, 3, 45-53.

ID 2014: “Cinnamomum zeylanicum BARK” and “Digestion”

- 1 A Guide to traditional herbal medicines: a sourcebook of accepted traditional uses of medicinal plants within Europe 2003. British Herbal Medicine Association.
- 2 Azumi S, Tanimura A, Tanamoto K, 1997. A novel inhibitor of bacterial endotoxin derived from cinnamon bark. *Biochem Biophys Res Commun*, 234, 506-510.
- 3 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.

- 4 BHMA (British Herbal Medicine Association), 2006. British Herbal Compendium. British Herbal Medicine Association, Exeter.
- 5 Billore KV, Yelne MB, Dennis TJ, Chaudhari BG, 2005. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 6 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.
- 7 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2006. HagerROM 2006. Hagers Handbuch der Drogen und Arzneistoffe Springer Medizin Verlag, Heidelberg.
- 8 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 9 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 10 Brendler T, Grünwald J, Jänicke C, 2003. Heilpflanzen - Herbal Remedies. CD-ROM. Medpharm Scientific Publishers.
- 11 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 12 Cahier de l'Agence, 1998. Médicaments à base de plantes: Cahiers de l'Agence no 3. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 13 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 14 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 15 Hiller K and Melzig MF, 2003. Lexikon der Arzneipflanzen und Drogen. Spektrum Akademischer Verlag.
- 16 Hoppe HA, 1975. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 17 Hoppe HA, 1977. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 18 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 19 Kapoor LD, 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton.
- 20 Kommission E, 1990. Monographie Cinnamomum spp.
- 21 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 22 Schönfelder I and Schönfelder P, 2004. Das neue Handbuch der Heilpflanzen: Botanik, Arzneidrogen, Wirkstoffe, Anwendungen Wissenschaftliche Verlagsgesellschaft.
- 23 Steinmetz E, 1957. Codex Vegetabilis. Litografia La Photograph, Padova.
- 24 WHO (World Health Organization), 1999. WHO Monographs on Selected Medicinal Plants. WHO, Geneva.
- 25 Wichtl M and Anton R, 1999. Plantes thérapeutiques : tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 26 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart.
- 27 Wichtl M and Anton R, 2003. Plantes thérapeutiques : tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 28 Wichtl M, 2004. Herbal Drugs and Phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart.
- 29 Yelne M, Sharma P, Dennis T, 2002. Database on Medicinal Plants Used in Ayurveda. Central Council for Research in Ayurveda & Siddha, Indian Ministry of Health and Family Welfare.

ID 2017: “Cinnamomum zeylanicum BARK” and “Cardiovascular”

- 1 Baratta MT, Dorman HJD, Deans SG, Figueiredo AC, Barroso JG, Ruberto G, 1998. Antimicrobial and antioxidant properties of some commercial essential oils. *Flavour and Fragrance Journal*, 13, 235-244.
- 2 Blumenthal M 122 BN, 1988. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Bradley P, 2006. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 4 Chericoni S, Prieto JM, Iacopini P, Cioni P, Morelli I, 2005. In vitro activity of the essential oil of *Cinnamomum zeylanicum* and eugenol in peroxy-nitrite-induced oxidative processes. *Journal of Agricultural and Food Chemistry*, 53, 4762-4765.
- 5 Dhuley JN, 1999. Anti-oxidant effects of cinnamon (*Cinnamomum verum*) bark and greater cardamom (*Amomum subulatum*) seeds in rats fed high fat diet. *Indian J Exp Biol*, 37, 238-242.
- 6 Gogte V, 2000. *Ayurvedic Pharmacology & Therapeutic Uses of Medicinal Plants*. Bharatiya Vidya Bhavan.
- 7 Indian Ministry of Health and Family Welfare, 2001. *The Ayurvedic Pharmacopoeia of India*. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 8 Kitazuru ER, Moreira AVB, Mancini-Filho J, Delincée H, Villavicencio A, 2004. Effects of irradiation on natural antioxidants of cinnamon (*Cinnamomum zeylanicum* N.). *Radiation Physics and Chemistry*, 71, 39-41.
- 9 Mancini-Filho J, Van-Koij A, Mancini DA, Cozzolino FF, Torres RP, 1998. Antioxidant activity of cinnamon (*Cinnamomum Zeylanicum*, Breyne) extracts. *Boll Chim Farm*, 137, 443-447.
- 10 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 11 Preuss HG, Echard B, Polansky MM, Anderson R, 2006. Whole cinnamon and aqueous extracts ameliorate sucrose-induced blood pressure elevations in spontaneously hypertensive rats. *J Am Coll Nutr*, 25, 144-150.
- 12 Sambaiah K and Srinivasan K, 1991. Effect of cumin, cinnamon, ginger, mustard and tamarind in induced hypercholesterolemic rats. *Nahrung*, 35, 47-51.
- 13 Sharma PC, Yelne MB, Dennis TJ, 2000. *Database on Medical Plants used in Ayurveda*.
- 14 Shobana S and Naidu KA, 2000. Antioxidant activity of selected Indian spices. *Prostaglandins Leukot Essent Fatty Acids*, 62, 107-110.
- 15 Suganthi R, Rajamani S, Ravichandran MK, Anuradha CV, 2005. Preventive action of food seasoning spices mixture on fructose-induced lipid abnormalities. *Asia Pac J Clin Nutr*, 14, 420-427.
- 16 WHO (World Health Organization), 1999. *WHO Monographs on Selected Medicinal Plants*. WHO, Geneva.
- 17 Wren RC, 1975. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. Health Science Press, Saffron Walden.

ID 2018: “Cinnamomum zeylanicum BARK” and “Genitourinary”

- 1 Afzal M, Khan NA, Ghufran A, Iqbal A, Inamuddin M, 2004. Diuretic and nephroprotective effect of Jawarish Zarooni Sada--a polyherbal unani formulation. *J Ethnopharmacol*, 91, 219-223.
- 2 Altschuler JA, Casella SJ, MacKenzie TA, Curtis KM, 2007. The effect of cinnamon on A1C among adolescents with type 1 diabetes. *Diabetes Care*, 30, 813-816.
- 3 Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, Flanagan VP, Schoene NW, Graves DJ, 2004. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. *Journal of Agricultural and Food Chemistry*, 52, 65-70.

- 4 Baratta MT, Dorman HJD, Deans SG, Figueiredo AC, Barroso JG, Ruberto G, 1998. Antimicrobial and antioxidant properties of some commercial essential oils. *Flavour and Fragrance Journal*, 13, 235-244.
- 5 Bradley P, 2006. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 6 Chericoni S, Prieto JA, Iacopini P, Cioni P, Morelli I, 2005. In vitro activity of the essential oil of *Cinnamomum zeylanicum* and eugenol in peroxynitrite-induced oxidative processes. *Journal of Agricultural and Food Chemistry*, 53, 4762-4765.
- 7 Dhuley JN, 1999. Anti-oxidant effects of cinnamon (*Cinnamomum verum*) bark and greater cardamom (*Amomum subulatum*) seeds in rats fed high fat diet. *Indian journal of experimental biology*, 37, 238-242.
- 8 Gogte VVM, 2000. *Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants*. Bharatiya Vidya Bhavan, Mumbai.
- 9 Indian Ministry of Health and Family Welfare, 2001. *The Ayurvedic Pharmacopoeia of India*. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 10 Kapoor LD, 1990. *Handbook of Ayurvedic Medicinal Plants*. CRC Press, Boca Raton.
- 11 Kitazuru ER, Moreira AVB, Mancini-Filho J, Delincee H, Villavicencio ALCH, 2004. Effects of irradiation on natural antioxidants of cinnamon (*Cinnamomum zeylanicum* N.). *Radiation Physics and Chemistry*, 71, 39-41.
- 12 Mancini-Filho J, Van-Koijj A, Mancini DAP, Cozzolino FF, Torres RP, 1998. Antioxidant activity of cinnamon (*Cinnamomum Zeylanicum*, Breyne) extracts. *Bollettino chimico-farmaceutico (Milano)*, 137, 443-447.
- 13 Murcia MA, Egea I, Romojaro F, Parras P, Jimenez AM, Martinez-Tome M, 2004. Antioxidant evaluation in dessert spices compared with common food additives. Influence of irradiation procedure. *Journal of Agricultural and Food Chemistry*, 52, 1872-1881.
- 14 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London.
- 15 Sharma PC, Yelne MB, Dennis TJ, 2000. *Database on Medical Plants used in Ayurveda*. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 16 Shobana S and Naidu KA, 2000. Antioxidant activity of selected Indian spices. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 62, 107-110.
- 17 Sitaram B, 2006. *Bhavaprakasa of Bhavamisra: Original Text Along With Commentary and Translation: Including Nighantu Portion*. Chaukhambha Orientalia, New Delhi.
- 18 WHO (World Health Organization), 1999. *WHO Monographs on Selected Medicinal Plants*. WHO (World Health Organization), Geneva.
- 19 Williamson EM, Evans FJ, Wren RC, 1988. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. CW Daniel Company Limited, Saffron Walden.

ID 2020: “Cinnamomum zeylanicum BARK” and “Antioxidant”

- 1 Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, Flanagan VP, Schoene NW, Graves DJ, 2004. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. *Journal of Agricultural and Food Chemistry*, 52, 65-70.
- 2 Baratta MT, Dorman HJD, Deans SG, Figueiredo AC, Barroso JG, Ruberto G, 1998. Antimicrobial and antioxidant properties of some commercial essential oils. *Flavour and Fragrance Journal*, 13, 235-244.
- 3 Chericoni S, Prieto JA, Iacopini P, Cioni P, Morelli I, 2005. In vitro activity of the essential oil of *Cinnamomum zeylanicum* and eugenol in peroxynitrite-induced oxidative processes. *Journal of Agricultural and Food Chemistry*, 53, 4762-4765.

- 4 Dhuley JN, 1999. Anti-oxidant effects of cinnamon (*Cinnamomum verum*) bark and greater cardamom (*Amomum subulatum*) seeds in rats fed high fat diet. *Indian journal of experimental biology*, 37, 238-242.
- 5 Kitazuru ER, Moreira AVB, Mancini-Filho J, Delincee H, Villavicencio ALCH, 2004. Effects of irradiation on natural antioxidants of cinnamon (*Cinnamomum zeylanicum* N.). *Radiation Physics and Chemistry*, 71, 39-41.
- 6 Mancini-Filho J, Van-Koijj A, Mancini DAP, Cozzolino FF, Torres RP, 1998. Antioxidant activity of cinnamon (*Cinnamomum Zeylanicum*, Breyne) extracts. *Bollettino chimico-farmaceutico(Milano)*, 137, 443-447.
- 7 Murcia MA, Egea I, Romojaro F, Parras P, Jimenez AM, Martinez-Tome M, 2004. Antioxidant evaluation in dessert spices compared with common food additives. Influence of irradiation procedure. *Journal of Agricultural and Food Chemistry*, 52, 1872-1881.
- 8 Shobana S and Naidu KA, 2000. Antioxidant activity of selected Indian spices. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 62, 107-110.

ID 2021: “Cherries (*Prunus cerasus*), including Montmorency, Balaton or other sour/tart cherry varieties” and “Antioxidant support”

- 1 Burkhardt S, Tan DX, Manchester LC, Hardeland R, Reiter RJ, 2001. Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (*Prunus cerasus*). *J Agric Food Chem*, 49, 4898-4902.
- 2 Chandra A, Nair MG, Iezzoni A, 1992. Evaluation and characterization of the anthocyanin pigments in tart cherries (*Prunus cerasus* L.). *J. Agric. Food Chem*, 40, 967-969.
- 3 Chandra A, Nair MG, Iezzoni AF, 1993. Isolation and stabilization of anthocyanins from tart cherries (*Prunus cerasus* L.). *J. Agric. Food Chem*, 41, 1062-1065.
- 4 Chandra A, Rana J, Li Y, 2001. Separation, identification, quantification, and method validation of anthocyanins in botanical supplement raw materials by HPLC and HPLC-MS. *J Agric Food Chem*, 49, 3515-3521.
- 5 Connolly DA, McHugh MP, Padilla-Zakour OI, Carlson L, Sayers SP, 2006. Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage. *Br J Sports Med*, 40, 679-683; discussion 683.
- 6 D-A-CH (Deutsche Gesellschaft für Ernährung - Österreichische Gesellschaft für Ernährung - Schweizerische Gesellschaft für Ernährungsforschung - Schweizerische Vereinigung für Ernährung), 2000. Referenzwerte für die Nährstoffzufuhr. Umschau Braus Verlag, Frankfurt am Main.
- 7 Halvorsen BL, Carlsen MH, Phillips KM, Bohn SK, Holte K, Jacobs DR, Jr., Blomhoff R, 2006. Content of redox-active compounds (ie, antioxidants) in foods consumed in the United States. *Am J Clin Nutr*, 84, 95-135.
- 8 Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D, 1993. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet*, 342, 1007-1011.
- 9 Kim DO, Heo HJ, Kim YJ, Yang HS, Lee CY, 2005. Sweet and sour cherry phenolics and their protective effects on neuronal cells. *J Agric Food Chem*, 53, 9921-9927.
- 10 Leveille GA, Bedford CL, Kraut CW, Lee YC, 1974. Nutrient composition of carrots, tomatoes and red tart cherries. *Fed Proc*, 33, 2264-2266.
- 11 Safari MR and Sheikh N, 2003. Effects of flavonoids on the susceptibility of low-density lipoprotein to oxidative modification. *Prostaglandins Leukot Essent Fatty Acids*, 69, 73-77.
- 12 Seeram NP, Momin RA, Nair MG, Bourquin LD, 2001. Cyclooxygenase inhibitory and antioxidant cyanidin glycosides in cherries and berries. *Phytomedicine*, 8, 362-369.

- 13 Seymour EM, Singer AAM, Bennink MR, Bolling SF, 2007. Cherry-enriched diets reduce metabolic syndrome and oxidative stress in lean Dahl-SS rats.(Presented in minisymposium 225, Dietary Bioactive Compounds: Chronic Disease Risk Reduction). *Experimental Biology* 225.
- 14 Tall JM and Raja SN, 2004. Dietary constituents as novel therapies for pain. *Clin J Pain*, 20, 19-26.
- 15 Wu X, Beecher GR, Holden JM, Haytowitz DB, Gebhardt SE, Prior RL, 2004. Lipophilic and hydrophilic antioxidant capacities of common foods in the United States. *J Agric Food Chem*, 52, 4026-4037.

ID 2022: “Cherries (*Prunus cerasus*), including Montmorency, Balaton or other sour/tart cherry varieties” and “Joint support”

- 1 Bezerra MM, Brain SD, Greenacre S, Jeronimo SM, de Melo LB, Keeble J, da Rocha FA, 2004. Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis. *Br J Pharmacol*, 141, 172-182.
- 2 Blau LW, 1950. Cherry diet control for gout and arthritis. *Tex Rep Biol Med*, 8, 309-311.
- 3 Jacob RA, Spinozzi GM, Simon VA, Kelley DS, Prior RL, Hess-Pierce B, Kader AA, 2003. Consumption of cherries lowers plasma urate in healthy women. *J Nutr*, 133, 1826-1829.
- 4 Kelley DS, Rasooly R, Jacob RA, Kader AA, Mackey BE, 2006. Consumption of Bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and women. *J Nutr*, 136, 981-986.
- 5 Tall JM, Seeram NP, Zhao C, Nair MG, Meyer RA, Raja SN, 2004. Tart cherry anthocyanins suppress inflammation-induced pain behavior in rat. *Behav Brain Res*, 153, 181-188.
- 6 Wang H, Nair MG, Strasburg GM, Chang YC, Booren AM, Gray JI, DeWitt DL, 1999. Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries. *J Nat Prod*, 62, 294-296.

ID 2023: “Cherries (*Prunus cerasus*), including Montmorency, Balaton or other sour/tart cherry varieties” and “Cardiovascular / heart health support”

- 1 Andriambelason E, Magnier C, Haan-Archipoff G, Lobstein A, Anton R, Beretz A, Stoclet JC, Andriantsitohaina R, 1998. Natural dietary polyphenolic compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. *J Nutr*, 128, 2324-2333.
- 2 Bak I, Lekli I, Juhasz B, Nagy N, Varga E, Varadi J, Gesztelyi R, Szabo G, Szendrei L, Bacskay I, Vecsernyes M, Antal M, Fesus L, Boucher F, de Leiris J, Tosaki A, 2006. Cardioprotective mechanisms of *Prunus cerasus* (sour cherry) seed extract against ischemia-reperfusion-induced damage in isolated rat hearts. *Am J Physiol Heart Circ Physiol*, 291, H1329-1336.
- 3 Bell DR and Gochenaur K, 2006. Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts. *J Appl Physiol*, 100, 1164-1170.
- 4 Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D, 1993. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet*, 342, 1007-1011.
- 5 Jayaprakasam B, Olson LK, Schutzki RE, Tai MH, Nair MG, 2006. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (*Cornus mas*). *J Agric Food Chem*, 54, 243-248.
- 6 Safari MR and Sheikh N, 2003. Effects of flavonoids on the susceptibility of low-density lipoprotein to oxidative modification. *Prostaglandins Leukot Essent Fatty Acids*, 69, 73-77.
- 7 Wang H, Nair MG, Strasburg GM, Chang YC, Booren AM, Gray JI, DeWitt DL, 1999. Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries. *J Nat Prod*, 62, 294-296.

ID 2024: “Cherries (*Prunus cerasus*, *P. domestica*), including Montmorency, Balaton or other sour/tart cherry varieties” and “Brain/mental/cognitive health”

- 1 Bouayed J, Rammal H, Dicko A, Younos C, Soulimani R, 2007. Chlorogenic acid, a polyphenol from *Prunus domestica* (Mirabelle), with coupled anxiolytic and antioxidant effects. *J Neurol Sci*, 262, 77-84.
- 2 Joseph JA, Denisova N, Villalobos-Molina R, Erat S, Strain J, 1996. Oxidative stress and age-related neuronal deficits. *Mol Chem Neuropathol*, 28, 35-40.
- 3 Joseph JA, Shukitt-Hale B, Denisova NA, Bielinski D, Martin A, McEwen JJ, Bickford PC, 1999. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. *J Neurosci*, 19, 8114-8121.
- 4 Lau FC, Shukitt-Hale B, Joseph JA, 2005. The beneficial effects of fruit polyphenols on brain aging. *Neurobiol Aging*, 26 Suppl 1, 128-132.

ID 2025: “*Citrus paradisi* (Common Name : Grapefruit)” and “Antioxidant properties”

- 1 Alvarez-Gonzalez I, Madrigal-Bujaidar E, Martino-Roaro L, Espinosa-Aguirre JJ, 2004. Antigenotoxic and antioxidant effect of grapefruit juice in mice treated with daunorubicin. *Toxicol Lett*, 152, 203-211.
- 2 Aviram M and B. F, 2003. Effects of flavonoids on the Oxidation of Low-Density Lipoprotein and Atherosclerosis. In: *Flavonoids in Health and Disease*. Rice-Evans C and Packer L (eds.). Marcel Dekker, New York, 165.
- 3 Benavente-García O, Castillo J, Marin FR, Ortuño A, Del Río JA, 1997. Uses and properties of Citrus flavonoids. *J. Agric. Food Chem*, 45, 4505-4515.
- 4 Blumberg JB and Halpner AD, 1999. Antioxidant status and function: relationships to aging and exercise. In: *Antioxidant Status, Diet, Nutrition, and Health*. Andreas M (ed.) CRC Press, Boca Raton, 251.
- 5 Brzozowski T, Konturek PC, Drozdowicz D, Konturek SJ, Zayachivska O, Pajdo R, Kwiecien S, Pawlik WW, Hahn EG, 2005. Grapefruit-seed extract attenuates ethanol-and stress-induced gastric lesions via activation of prostaglandin, nitric oxide and sensory nerve pathways. *World J Gastroenterol*, 11, 6450-6458.
- 6 Dembinski A, Warzecha Z, Konturek SJ, Ceranowicz P, Dembinski M, Pawlik WW, Kusnierz-Cabala B, Naskalski JW, 2004. Extract of grapefruit-seed reduces acute pancreatitis induced by ischemia/reperfusion in rats: possible implication of tissue antioxidants. *J Physiol Pharmacol*, 55, 811-821.
- 7 Giamperi L, Fraternali D, Bucchini A, Ricci D, 2004. Antioxidant activity of *Citrus paradisi* seeds glyceric extract. *Fitoterapia*, 75, 221-224.
- 8 Gorinstein S, Caspi A, Libman I, Katrich E, Lerner HT, Trakhtenberg S, 2004. Fresh israeli jaffa sweetie juice consumption improves lipid metabolism and increases antioxidant capacity in hypercholesterolemic patients suffering from coronary artery disease: studies in vitro and in humans and positive changes in albumin and fibrinogen fractions. *J Agric Food Chem*, 52, 5215-5222.
- 9 Gorinstein S, Leontowicz H, Leontowicz M, Krzeminski R, Gralak M, Martin-Belloso O, Delgado-Licon E, Haruenkit R, Katrich E, Park YS, Jung ST, Trakhtenberg S, 2004. Fresh Israeli Jaffa blond (Shamouti) orange and Israeli Jaffa red Star Ruby (Sunrise) grapefruit juices affect plasma lipid metabolism and antioxidant capacity in rats fed added cholesterol. *J Agric Food Chem*, 52, 4853-4859.
- 10 Gorinstein S, Zachwieja Z, Katrich E, Pawelzik E, Haruenkit R, Trakhtenberg S, Martin-Belloso O, 2004. Comparison of the contents of the main antioxidant compounds and the antioxidant activity of white grapefruit and his new hybrid. *LWT-Food Science and Technology*, 37, 337-343.
- 11 Gorinstein S, Leontowicz H, Leontowicz M, Drzewiecki J, Jastrzebski Z, Tapia MS, Katrich E, Trakhtenberg S, 2005. Red Star Ruby (Sunrise) and blond qualities of Jaffa grapefruits and their influence on plasma lipid levels and plasma antioxidant activity in rats fed with cholesterol-containing and cholesterol-free diets. *Life Sci*, 77, 2384-2397.

- 12 Gorinstein S, Caspi A, Libman I, Lerner HT, Huang D, Leontowicz H, Leontowicz M, Tashma Z, Katrich E, Feng S, Trakhtenberg S, 2006. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans. *J Agric Food Chem*, 54, 1887-1892.
- 13 Jagetia GC, Venkatesha VA, Reddy TK, 2003. Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow. *Mutagenesis*, 18, 337-343.
- 14 Jay M, Viricel M, Gonnet J, 2006. C-Glycosylflavonoids. In: *Flavonoides. Chemistry, Biochemistry and Applications*,. Andersen O and Markham K (eds.). CRC Taylor & Francis Group, Boca Raton.
- 15 Jeon SM, Bok SH, Jang MK, Kim YH, Nam KT, Jeong TS, Park YB, Choi MS, 2002. Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits. *Clinica Chimica Acta*, 317, 181-190.
- 16 Jung UJ, Lee MK, Park YB, Kang MA, Choi MS, 2006. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. *Int J Biochem Cell Biol*, 38, 1134-1145.
- 17 Juskiewicz J, Zdunczyk Z, Wróblewska M, Oszmianski J, Hernandez T, 2002. The response of rats to feeding with diets containing grapefruit flavonoid extract. *Food Research International*, 35, 201-205.
- 18 Kaliora AC, Dedoussis GV, Schmidt H, 2006. Dietary antioxidants in preventing atherogenesis. *Atherosclerosis*, 187, 1-17.
- 19 Kanno S, Shouji A, Asou K, Ishikawa M, 2003. Effects of naringin on hydrogen peroxide-induced cytotoxicity and apoptosis in P388 cells. *J Pharmacol Sci*, 92, 166-170.
- 20 Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliövaara M, Reunanen A, Hakulinen T, Aromaa A, 2002. Flavonoid intake and risk of chronic diseases. *Am J Clin Nutr*, 76, 560-568.
- 21 Kyle J and Duthie G, 2006. Flavonoids in Food. In: *Flavonoides. Chemistry, Biochemistry and Applications*. Andersen O and Markham K (eds.). CRC Taylor & Francis Group, Boca Raton.
- 22 Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN, 2000. Intake of flavonoids and lung cancer. *J Natl Cancer Inst*, 92, 154-160.
- 23 Lee CH, Jeong TS, Choi YK, Hyun BH, Oh GT, Kim EH, Kim JR, Han JI, Bok SH, 2001. Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. *Biochem Biophys Res Commun*, 284, 681-688.
- 24 Manthey JA, Grohmann K, Guthrie N, 2001. Biological properties of citrus flavonoids pertaining to cancer and inflammation. *Curr Med Chem*, 8, 135-153.
- 25 Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA, 2001. Flavonoids: a review of probable mechanisms of action and potential applications. *Am J Clin Nutr*, 74, 418-425.
- 26 Peterson JJ, Beecher GR, Bhagwat SA, Dwyer JT, Gebhardt SE, Haytowitz DB, Holden JM, 2006. Flavanones in grapefruit, lemons, and limes: A compilation and review of the data from the analytical literature. *Journal of food composition and analysis*, 19, 74-80.
- 27 Proteggente A, Rice-Evans C, Wiseman S, Put F, 2003. The relationship Between the Phenolic Composition and the Antioxidant Activity of Fruits and Vegetables. In: *Flavonoids in Health and Disease*. Rice-Evans C and Packer L (eds.). Marcel Dekker, New York.
- 28 Robards K, Prenzler PD, Tucker G, Swatsitang P, Glover W, 1999. Phenolic compounds and their role in oxidative processes in fruits. *Food Chemistry*, 66, 401-436.
- 29 Tirillini B, 2000. Grapefruit: the last decade acquisitions. *Fitoterapia*, 71 Suppl 1, S29-37.
- 30 Vanamala J, Leonardi T, Patil BS, Taddeo SS, Murphy ME, Pike LM, Chapkin RS, Lupton JR, Turner ND, 2006. Suppression of colon carcinogenesis by bioactive compounds in grapefruit. *Carcinogenesis*, 27, 1257-1265.
- 31 Vinson JA and Jang J, 2001. In Vitro and In Vivo Lipoprotein Antioxidant Effect of a Citrus Extract and Ascorbic Acid on Normal and Hypercholesterolemic Human Subjects. *J Med Food*, 4, 187-192.
- 32 Vinson JA, Liang X, Proch J, Hontz BA, Dancel J, Sandone N, 2002. Polyphenol antioxidants in citrus juices: in vitro and in vivo studies relevant to heart disease. *Adv Exp Med Biol*, 505, 113-122.

- 33 Wilcox LJ, Borradaile NM, Huff MW, 1999. Antiatherogenic properties of naringenin, a citrus flavonoid. *Cardiovascular Drug Reviews*, 17, 160-178.
- 34 Yu J, Wang L, Walzem RL, Miller EG, Pike LM, Patil BS, 2005. Antioxidant activity of citrus limonoids, flavonoids, and coumarins. *J Agric Food Chem*, 53, 2009-2014.
- 35 Zern TL and Fernandez ML, 2005. Cardioprotective effects of dietary polyphenols. *J Nutr*, 135, 2291-2294.

ID 2026: “Citrus aurantium (Common Name : Bitter orange)” and “Metabolism of lipids/Weight management”

- 1 Allison DB, Cutter G, Poehlman ET, Moore DR, Barnes S, 2005. Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain? *Int J Obes (Lond)*, 29, 443-446.
- 2 Bent S, Padula A, Neuhaus J, 2004. Safety and efficacy of citrus aurantium for weight loss. *Am J Cardiol*, 94, 1359-1361.
- 3 Coffey CS, Steiner D, Baker BA, Allison DB, 2004. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. *Int J Obes Relat Metab Disord*, 28, 1411-1419.
- 4 Dentali SJ, 2005. Comment on Citrus aurantium Minireview. *Exp Biol Med (Maywood)*, 230, 102-103.
- 5 Fugh-Berman A and Myers A, 2004. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. *Exp Biol Med (Maywood)*, 229, 698-704.
- 6 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A, 2004. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. *Clin Pharmacol Ther*, 76, 428-440.
- 7 Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB, 2006. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. *Obes Rev*, 7, 79-88.
- 8 Haller CA, Benowitz NL, Jacob P, 3rd, 2005. Hemodynamic effects of ephedra-free weight-loss supplements in humans. *Am J Med*, 118, 998-1003.
- 9 Preuss HG, DiFerdinando D, Bagchi M, Bagchi D, 2002. Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview. *J Med*, 33, 247-264.

ID 2027: “Citrus aurantium L. ssp. Aurantium (Common name: Bitter orange)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Kooperation Phytopharmaka, 1990-1995. *Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten)*. BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 4 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

ID 2028: “Citrus limon (Common Name: Lemon)” and “digestive health”

- 1 Bisset NG and Wichtl M, 2001. *Herbal Drugs and Phytopharmaceuticals* Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 2 Brendler T, Gruenwald J, Jaenicke C, 2003. *Herbal Remedies: Heilpflanzen*. Medpharm Scientific Publishers, Stuttgart, Germany.

3 Galliano Raspino M, 1996. Repertorio Fitoterapico. OEMF, Milan.

ID 2029: “Cucurbita pepo (Common Name : Pumpkin)” and “Health of lower urinary tract”

- 1 Monographie der Kommission E, Cucurbitae Peponis Semen (Kuerbissamen). 1985. Bundesanzeiger, 223.
- 2 Monographie der Kommission E, Cucurbitae Peponis Semen (Kuerbissamen). 1991. Bundesanzeiger, 11.
- 3 Bach D, 2000. Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe [B], 40, 437–443.
- 4 Berges R, Windeler J, Trampisch H, Senge T, 1995. Randomised, placebo-controlled, double-blind clinical trial of β -sitosterol in patients with benign prostatic hyperplasia. The Lancet, 345, 1529-1532.
- 5 Berges RR, Kassen A, Senge T, 2000. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int, 85, 842-846.
- 6 Bisset NG and Wichtl M, 2001. Herbal Drugs and Phytopharmaceuticals Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 7 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2006. HagerROM 2006. Hagers Handbuch der Drogen und Arzneistoffe Springer Medizin Verlag, Heidelberg.
- 8 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 9 Bombardelli E and Morazzoni P, 1997. Cucurbita pepo L. Fitoterapia, 68, 291-302.
- 10 Bradley P, 1992. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 11 Carbin B, Larsson B, Lindahl O, 1990. Treatment of benign prostatic hyperplasia with phytosterols. British Journal Of Urology, 66, 639-641.
- 12 Cruz R, Meurer C, Silva E, Schaefer C, Santos A, Bella Cruz A, Cechinel Filho V, 2006. Toxicity evaluation of Cucurbita maxima seed extract in mice. Pharmaceutical Biology, 44, 301-303.
- 13 de Queiroz-Neto A, Mataqueiro M, Santana A, Alessi A, 1994. Toxicologic evaluation of acute and subacute oral administration of Cucurbita maxima seed extracts to rats and swine Journal of Ethnopharmacology, 43, 45-51.
- 14 Eisenbrand G, Schreier P, Meyer AH, 2006. Römpp Lexikon Lebensmittelchemie. Thieme, Stuttgart.
- 15 Evira, 2007. Käyttöalueet: ärsytysrakko ja virtsaamisvaiivat. (positive monograph for the prevention of incontinence caused by an overactive bladder)2.
- 16 Fahim A, Abd-el Fattah A, Agha A, Gad M, 1995. Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis in rats. Pharmacol Res, 31, 73-79.
- 17 Fischer H, 2004. Harnwegsinfektionen. Verlagshaus Der Ärzte, Wien.
- 18 Friederich M, Theurer C, G S-S, 2000. Prosta Fink Forte capsules in the treatment of benign prostatic hyperplasia. Multicentric surveillance study in 2245 patients. Forsch Komplementarmed Klass Naturheilkd, 7, 200-204.
- 19 Fruhwirt G and Hermetter A, 2007. Seeds and oil of the Styrian oil Pumpkin: Components and biological activities. European Journal of Lipid Science and Technology, 109, 1128-1140.
- 20 Frutarom, 2006. EFLA 940 Pumpkin Seed Special Extract: New in vitro studies on the efficacy and mode of action in incontinence disorders.
- 21 Gossell-Williams M, Davis A, O'Connor N, 2006. Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. Journal of Medicinal Food 9, 284-286.
- 22 Hänsel R, Sticher O, Steinegger E, 2007. Pharmakognosie - Phytopharmazie. Springer Verlag, Heidelberg.

- 23 Hata K, 2005. Effects of Pumpkin Seed Extract on urinary bladder function in anesthetized rats. *Japanese Journal of Medicine and Pharmaceutical Science*, 54, 339-345.
- 24 Herr SM Ernst E and Young VSL, 2005. *Herb-Drug Interaction Handbook*. Church Street Books, Nassau.
- 25 Hojima Y, Pierce J, Pisano J, 1982. Pumpkin seed inhibitor of human factor XIIa (activated Hageman factor) and bovine trypsin. *Biochemistry*, 21, 3741-3746.
- 26 Kompek A, 2004. Wirkt Kürbis? Selektive Wirkung auf Reizblase, BPH und Inkontinenz. *ÖAZ*, 7, 654-656.
- 27 Kompek A, 2007. Wirkungsweise von Kürbis. *ÖAZ*, 19.
- 28 Kreuter M, 2000. *Der Medizinalkürbis Cucurbita pepo L.: Wirkstoffcharakteristik und pharmazeutische Anwendung*. TU Graz.
- 29 Kreuter M, 2000. Hormone Disbalance and Urinary Bladder Disease. *Phyto Novum*, Emil Flachsmann AG, Zürich.
- 30 Kubelka W and Länger R, 2001. *Pflanzliche Arzneispezialitäten aus Österreich 2001/2002*. Krause & Pachernegg Verlag, Gablitz.
- 31 Mansour E, Dworschak E, Lugasi A, Barna E, Gergely A, 1992. Nutritive value of pumpkin (*Cucurbita Pepo* Kakai 35) seed products. *J. Sci. Food Agric*, 61, 73-78.
- 32 Martindale W, 1993. *The extra pharmacopoeia*. Pharmaceutical Press, London.
- 33 Matzkin H and Soloway S, 1992. Immunohistochemical Evidence of the Existence and Localisation of Aromatase in Human Prostatic Tissues. *Prostate*, 21, 309-314.
- 34 Nitsch S, Egger H, Wutzl H, Maruna H, 1983. *Ernährungsheilkunde* 12.
- 35 Pahlow M, 1985. *Das große Buch der Heilpflanzen*. Urban & Fischer, Munchen.
- 36 Pittler M, 2000. Complementary therapies for treating benign prostatic hyperplasia. *Focus on Alternative and Complementary Therapies*, 25, 255-257.
- 37 Schiebel-Schlosser, 1998. Phytotherapy of BPH with pumpkin seeds - a multicentric clinical trial. *Zeitschrift für Phytotherapie*, 19, 71-76.
- 38 Schilcher H and Vahlensieck W, 2001. *Phytotherapie in der Urologie*. Hippokrates, Stuttgart.
- 39 Schmidlin C and Kreuter M, 2003. *Cucurbita pepo*, mögliche Einfluss auf hormonelle Ungleichgewicht bei Inkontinenz. *Phytotherapie*, 3, 16-18.
- 40 Sogabe H and Terado T, 2001. Clinical study of mixed processed foods containing of pumpkin seed extract and soybean germ extract on pollakiuria in night in elder women. *Japanese Journal of Medicine and Pharmaceutical Science*, 46, 727-737.
- 41 Sokeland J, 2004. The use of phytotherapeutic remedies in the treatment of prostate syndrome. *Zeitschrift für Phytotherapie*, 25, 20-26.
- 42 Sweetman S, 2002. *Martindale: The Complete Drug Reference*. Pharmaceutical Press, London.
- 43 Terrado T and al. e, 2004. Clinical Study of mixed processed foods containing pumpkin seed extract and soybean germ extract on pollikiuria in night in elderly men. *Japanese Journal of Medicine and Pharmaceutical Science*, 52, 551-561.
- 44 Tsai Y, Tong Y, Cheng J, Lee C, Yang F, Lee H, 2006. Pumpkin Seed Oil and Phytosterol-F Can Block Testosterone/Prazosin-Induced Prostate Growth in Rats. *Urologia Internationals*, 77, 269-274.
- 45 Vassiliou A, Neumann G, Condron R, Polya G, 1998. Purification and mass spectrometry-assisted sequencing of basic antifungal proteins from seeds of pumpkin (*Cucurbita maxima*). *Plant Science*, 134, 141-162.
- 46 Wichtl M and Anton R, 1999. *Cucurbitae semen - Graine de courge*. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 47 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

- 48 Wichtl M, 2002. Cucurbitae semen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 49 Williamson EM, 2004. Potter's Herbal Cyclopaedia The C.W. Daniel Company Ltd., Saffron Walden, UK.
- 50 Wilt T, Ishani A, Rutks I, MacDonald R, 1999. Phytotherapy for benign prostatic hyperplasia. *Phytopharmaka*, 165-177.
- 51 Wilt T, MacDonald R, Ishani A, 1999. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. *BJU International*, 83, 976-983.
- 52 Yanagisawa E, 2003. Study of Effectiveness of Mixed Processed Food containing Cucurbita Pepo Seed Extract and Soybean Seed Extract on Stress Urinary Incontinence in Women. *Japanese Journal of Medicine and Pharmaceutical Science*, 14, 313-322.
- 53 Zahradnik H, Schillfahrt R, Schoening R, Ebbinghaus K, Dunzendorfer U, 1980. Prostaglandin content in prostatic adenomas after treatment with a sterol. *Fortschr Med*, 92, 69-72.
- 54 Zhang X, Ouyang J, Zhang YS, Tayalla B, Zhou X, Zhou S, 1994. Effect of the extracts of pumpkin seeds on the urodynamics of rabbits: an experimental study. *J Tongji Med Univ* 14, 235-238.

ID 2031: “CoffeeSLENDER® Tablets made from an extract from green coffee beans (Svetol®) the active principle of which is: 5-caffeoylquinic acid or (Chlorogenic acid) =45%, Caffeine = 2%, 3-caffeoylquinic acid =10%” and “Weight loss and weight control in overweight adults Reduces glucose absorption from gut”

- 1 Arion WJ, Canfield WK, Ramos FC, Schindler PW, Burger HJ, Hemmerle H, Schubert G, Below P, Herling AW, 1997. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. *Arch Biochem Biophys*, 339, 315-322.
- 2 Azuma K, Ippoushi K, Nakayama M, Ito H, Higashio H, Terao J, 2000. Absorption of chlorogenic acid and caffeic acid in rats after oral administration. *J Agric Food Chem*, 48, 5496-5500.
- 3 Clifford MN, 1999. Chlorogenic acids and other cinnamates—nature, occurrence and dietary burden. *Journal of the Science of Food and Agriculture*, 79, 362-372.
- 4 Dellalibera O, Lemaire B, Lafay S, 2006. Le Svetol®, un extrait de café vert décaféiné, induit une perte de poids et augmente le ratio masse maigre sur masse grasse chez des volontaires en surcharge pondérale. *Phytotherapie*, 4, 194-197.
- 5 Greenberg JA, Boozer CN, Geliebter A, 2006. Coffee, diabetes, and weight control. *Am J Clin Nutr*, 84, 682-693.
- 6 Hemmerle H, Burger HJ, Below P, Schubert G, Rippel R, Schindler PW, Paulus E, Herling AW, 1997. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. *J Med Chem*, 40, 137-145.
- 7 Hirose M, Masuda A, Imaida K, Kagawa M, Tsuda H, Ito N, 1987. Induction of forestomach lesions in rats by oral administrations of naturally occurring antioxidants for 4 weeks. *Jpn J Cancer Res*, 78, 317-321.
- 8 Hossain MM, Huismans JW, Diehl JF, 1976. Mutagenicity studies on irradiated potatoes and chlorogenic acid; micronucleus test in rats. *Toxicology*, 6, 243-251.
- 9 Hsu CL, Huang SL, Yen GC, 2006. Inhibitory effect of phenolic acids on the proliferation of 3T3-L1 preadipocytes in relation to their antioxidant activity. *J Agric Food Chem*, 54, 4191-4197.
- 10 Johnston KL, Clifford MN, Morgan LM, 2003. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. *Am J Clin Nutr*, 78, 728-733.
- 11 Kitts DD and Wijewickreme AN, 1994. Effect of dietary caffeic and chlorogenic acids on in vivo xenobiotic enzyme systems. *Plant Foods Hum Nutr*, 45, 287-298.
- 12 Lafay S, Gil-Izquierdo A, Manach C, Morand C, Besson C, Scalbert A, 2006. Chlorogenic acid is absorbed in its intact form in the stomach of rats. *J Nutr*, 136, 1192-1197.

- 13 Lafay S, Morand C, Manach C, Besson C, Scalbert A, 2006. Absorption and metabolism of caffeic acid and chlorogenic acid in the small intestine of rats. *Br J Nutr*, 96, 39-46.
- 14 Mori H, Tanaka T, Shima H, Kuniyasu T, Takahashi M, 1986. Inhibitory effect of chlorogenic acid on methylazoxymethanol acetate-induced carcinogenesis in large intestine and liver of hamsters. *Cancer Lett*, 30, 49-54.
- 15 Olthof MR, Hollman PC, Katan MB, 2001. Chlorogenic acid and caffeic acid are absorbed in humans. *J Nutr*, 131, 66-71.
- 16 Shimoda H, Seki E, Aitani M, 2006. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. *BMC Complement Altern Med*, 6.
- 17 van Dam RM, 2006. Coffee and type 2 diabetes: from beans to beta-cells. *Nutr Metab Cardiovasc Dis*, 16, 69-77.
- 18 Welsch CA, Lachance PA, Wasserman BP, 1989. Dietary phenolic compounds: inhibition of Na⁺-dependent D-glucose uptake in rat intestinal brush border membrane vesicles. *J Nutr*, 119, 1698-1704.

ID 2034: “Coriandrum sativum FRUIT” and “Urinary”

- 1 Aggarwal BB and Shishodia S, 2006. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol*, 71, 1397-1421.
- 2 Bradley P, 2006. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 3 Chithra V and Leelamma S, 1999. Coriandrum sativum: mechanism of hypoglycemic action. *Food chemistry*, 67, 229-231.
- 4 Chithra V and Leelamma S, 1999. Coriandrum sativum changes the levels of lipid peroxides and activity of antioxidant enzymes in experimental animals. *Indian J Biochem Biophys*, 36, 59-61.
- 5 Chithra V and Leelamma S, 2000. Coriandrum sativum--effect on lipid metabolism in 1,2-dimethyl hydrazine induced colon cancer. *J Ethnopharmacol*, 71, 457-463.
- 6 Cortes-Eslava J, Gomez-Arroyo S, Villalobos-Pietrini R, Espinosa-Aguirre JJ, 2004. Antimutagenicity of coriander (*Coriandrum sativum*) juice on the mutagenesis produced by plant metabolites of aromatic amines. *Toxicol Lett*, 153, 283-292.
- 7 de Almeida Melo E, Mancini Filho J, Barbosa Guerra N, 2005. Characterization of antioxidant compounds in aqueous coriander extract (*Coriandrum sativum* L.). *LWT-Food Science and Technology*, 38, 15-19.
- 8 Gogte VVM, 2000. *Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants*. Bharatiya Vidya Bhavan, Mumbai.
- 9 Gray AM and Flatt PR, 1999. Insulin-releasing and insulin-like activity of the traditional anti-diabetic plant *Coriandrum sativum* (coriander). *Br J Nutr*, 81, 203-209.
- 10 Guerra NB, de Almeida Melo E, Filho JM, 2005. Antioxidant compounds from coriander (*Coriandrum sativum* L.) etheric extract. *Journal of Food Composition and Analysis*, 18, 193-199.
- 11 Hashim MS, Lincy S, Remya V, Teena M, Anila L, 2005. Effect of polyphenolic compounds from *Coriandrum sativum* on H₂O₂-induced oxidative stress in human lymphocytes. *Food chemistry*, 92, 653-660.
- 12 Indian Ministry of Health and Family Welfare, 2001. *The Ayurvedic Pharmacopoeia of India*. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 13 Kapoor LD, 1990. *Handbook of Ayurvedic Medicinal Plants*. CRC Press, Boca Raton.
- 14 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.

- 15 Ramadan MF, Kroh LW, Morsel JT, 2003. Radical scavenging activity of black cumin (*Nigella sativa* L.), coriander (*Coriandrum sativum* L.), and niger (*Guizotia abyssinica* Cass.) crude seed oils and oil fractions. *J Agric Food Chem*, 51, 6961-6969.
- 16 Ramadan MF and Moersel JT, 2006. Screening of the antiradical action of vegetable oils. *Journal of Food Composition and Analysis*, 19, 838-842.
- 17 Saeed S and Tariq P, 2007. Antibacterial activities of *Embllica officinalis* and *Coriandrum sativum* against Gram negative urinary pathogens. *Pak J Pharm Sci*, 20, 32-35.
- 18 Satyanarayana S, Sushruta K, Sarma GS, Srinivas N, Subba Raju GV, 2004. Antioxidant activity of the aqueous extracts of spicy food additives--evaluation and comparison with ascorbic acid in in-vitro systems. *J Herb Pharmacother*, 4, 1-10.
- 19 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 20 Sitaram B, 2006. Bhavaprakasa of Bhavamisra: Original Text Along With Commentary and Translation: Including Nighantu Portion. Chaukhambha Orientalia, New Delhi.
- 21 Wangensteen H, Samuelsen AB, Malterud KE, 2004. Antioxidant activity in extracts from coriander. *Food chemistry*, 88, 293-297.

ID 2035: “Coriandrum sativum FRUIT” and “Cardiovascular”

- 1 BHMA (British Herbal Medicine Association), 2006. British Herbal Compendium. British Herbal Medicine Association, Exeter.
- 2 Chithra V and Leelamma S, 1997. Hypolipidemic effect of coriander seeds (*Coriandrum sativum*): mechanism of action. *Plant Foods Hum Nutr*, 51, 167-172.
- 3 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 4 Lal AA, Kumar T, Murthy PB, Pillai KS, 2004. Hypolipidemic effect of *Coriandrum sativum* L. in triton-induced hyperlipidemic rats. *Indian J Exp Biol*, 42, 909-912.
- 5 Medhin DG, Hadhazy, Bakos P, Verzar-Petri G, 1986. Hypotensive effects of *Lupinus termis* and *Coriandrum sativum* in Anaesthetized Rats. A preliminary study. *Acta Pharm Hung*, 56, 59-63.
- 6 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 7 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.

ID 2037: “Coriandrum sativum FRUIT” and “Immunity & antioxidant”

- 1 Aggarwal BB and Shishodia S, 2006. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol*, 71, 1397-1421.
- 2 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 3 Chithra V and Leelamma S, 1999. *Coriandrum sativum* changes the levels of lipid peroxides and activity of antioxidant enzymes in experimental animals. *Indian J Biochem Biophys*, 36, 59-61.
- 4 Chithra V and Leelamma S, 2000. *Coriandrum sativum*--effect on lipid metabolism in 1,2-dimethyl hydrazine induced colon cancer. *J Ethnopharmacol*, 71, 457-463.

- 5 Cortes-Eslava J, Gomez-Arroyo S, Villalobos-Pietrini R, Espinosa-Aguirre JJ, 2004. Antimutagenicity of coriander (*Coriandrum sativum*) juice on the mutagenesis produced by plant metabolites of aromatic amines. *Toxicol Lett*, 153, 283-292.
- 6 de Almeida Melo E, Mancini Filho J, Barbosa Guerra N, 2005. Characterization of antioxidant compounds in aqueous coriander extract (*Coriandrum sativum* L.). *LWT-Food Science and Technology*, 38, 15-19.
- 7 Guerra NB, de Almeida Melo E, Filho JM, 2005. Antioxidant compounds from coriander (*Coriandrum sativum* L.) etheric extract. *Journal of Food Composition and Analysis*, 18, 193-199.
- 8 Hashim MS, Lincy S, Remya V, Teena M, Anila L, 2005. Effect of polyphenolic compounds from *Coriandrum sativum* on H₂O₂-induced oxidative stress in human lymphocytes. *Food Chemistry*, 92, 653-660.
- 9 Ramadan MF, Kroh LW, Morsel JT, 2003. Radical scavenging activity of black cumin (*Nigella sativa* L.), coriander (*Coriandrum sativum* L.), and niger (*Guizotia abyssinica* Cass.) crude seed oils and oil fractions. *J Agric Food Chem*, 51, 6961-6969.
- 10 Ramadan MF and Moersel JT, 2006. Screening of the antiradical action of vegetable oils. *Journal of Food Composition and Analysis*, 19, 838-842.
- 11 Satyanarayana S, Sushruta K, Sarma GS, Srinivas N, Subba Raju GV, 2004. Antioxidant activity of the aqueous extracts of spicy food additives--evaluation and comparison with ascorbic acid in in-vitro systems. *J Herb Pharmacother*, 4, 1-10.
- 12 Sharma PC, Yelne MB, Dennis TJ, Joshi A, Billore KV, 2005. Database on Medicinal Plants Used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Delhi.
- 13 Wangensteen H, Samuelsen AB, Malterud KE, 2004. Antioxidant activity in extracts from coriander. *Food Chemistry*, 88, 293-297.

ID 2039: “Capsicum Extract –with Capsaicin” and “Required for enhancing thermogenesis, increasing energy expenditure and enhancing loss of calories”

- 1 Belza A and Jessen AB, 2005. Bioactive food stimulants of sympathetic activity: effect on 24-h energy expenditure and fat oxidation. *Eur J Clin Nutr*, 59, 733-741.
- 2 Belza A, Frandsen E, Kondrup J, 2007. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. *Int J Obes (Lond)*, 31, 121-130.
- 3 Diepvens K, Westerterp KR, Westerterp-Plantenga MS, 2007. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. *Am J Physiol Regul Integr Comp Physiol*, 292, R77-85.
- 4 Henry CJ and Emery B, 1986. Effect of spiced food on metabolic rate. *Hum Nutr Clin Nutr*, 40, 165-168.
- 5 Kawada T, Watanabe T, Takaishi T, Tanaka T, Iwai K, 1986. Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization. *Proc Soc Exp Biol Med*, 183, 250-256.
- 6 Lejeune MP, Kovacs EM, Westerterp-Plantenga MS, 2003. Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. *Br J Nutr*, 90, 651-659.
- 7 Shin KO and Moritani T, 2007. The combined effects of capsaicin, green tea extract and chicken essence tablets on human autonomic nervous system activity. *J Nutr Sci Vitaminol (Tokyo)*, 53, 145-152.
- 8 Tsi D, Nah AK, Kiso Y, Moritani T, Ono H, 2003. Clinical study on the combined effect of capsaicin, green tea extract and essence of chicken on body fat content in human subjects. *J Nutr Sci Vitaminol (Tokyo)*, 49, 437-441.
- 9 Westerterp-Plantenga MS, Smeets A, Lejeune MP, 2005. Sensory and gastrointestinal satiety effects of capsaicin on food intake. *Int J Obes (Lond)*, 29, 682-688.

- 10 Yoshioka M, Lim K, Kikuzato S, Kiyonaga A, Tanaka H, Shindo M, Suzuki M, 1995. Effects of red-pepper diet on the energy metabolism in men. *J Nutr Sci Vitaminol (Tokyo)*, 41, 647-656.
- 11 Yoshioka M, St-Pierre S, Suzuki M, Tremblay A, 1998. Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women. *Br J Nutr*, 80, 503-510.

ID 2040: “Capsicum Extract –with Capsaicin” and “Required for stimulating carbohydrate oxidation and burning carbohydrates”

- 1 Lim K, Yoshioka M, Kikuzato S, Kiyonaga A, Tanaka H, Shindo M, Suzuki M, 1997. Dietary red pepper ingestion increases carbohydrate oxidation at rest and during exercise in runners. *Med Sci Sports Exerc*, 29, 355-361.
- 2 Yoshioka M, Lim K, Kikuzato S, Kiyonaga A, Tanaka H, Shindo M, Suzuki M, 1995. Effects of red-pepper diet on the energy metabolism in men. *J Nutr Sci Vitaminol (Tokyo)*, 41, 647-656.

ID 2041: “Capsicum Extract –with Capsaicin” and “Required for fat oxidation and burns fat, leading to loss in body weight”

- 1 Ahuja KD and Ball MJ, 2006. Effects of daily ingestion of chilli on serum lipoprotein oxidation in adult men and women. *Br J Nutr*, 96, 239-242.
- 2 Lejeune MP, Kovacs EM, Westerterp-Plantenga MS, 2003. Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. *Br J Nutr*, 90, 651-659.
- 3 Yoshioka M, Lim K, Kikuzato S, Kiyonaga A, Tanaka H, Shindo M, Suzuki M, 1995. Effects of red-pepper diet on the energy metabolism in men. *J Nutr Sci Vitaminol (Tokyo)*, 41, 647-656.
- 4 Yoshioka M, St-Pierre S, Suzuki M, Tremblay A, 1998. Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women. *Br J Nutr*, 80, 503-510.

ID 2042: “Capsicum Extract –with Capsaicin” and “Required for reducing caloric intake”

- 1 Westerterp-Plantenga MS, Smeets A, Lejeune MP, 2005. Sensory and gastrointestinal satiety effects of capsaicin on food intake. *Int J Obes (Lond)*, 29, 682-688.
- 2 Yoshioka M, Imanaga M, Ueyama H, Yamane M, Kubo Y, Boivin A, St-Amand J, Tanaka H, Kiyonaga A, 2004. Maximum tolerable dose of red pepper decreases fat intake independently of spicy sensation in the mouth. *Br J Nutr*, 91, 991-995.

ID 2043: “Capsicum Extract –with Capsaicin” and “Required for the reduction of oxidative stress”

- 1 Kempaiah RK and Srinivasan K, 2004. Influence of dietary curcumin, capsaicin and garlic on the antioxidant status of red blood cells and the liver in high-fat-fed rats. *Ann Nutr Metab*, 48, 314-320.
- 2 Lee CY, Kim M, Yoon SW, Lee CH, 2003. Short-term control of capsaicin on blood and oxidative stress of rats in vivo. *Phytother Res*, 17, 454-458.
- 3 Luqman S and Rizvi SI, 2006. Protection of lipid peroxidation and carbonyl formation in proteins by capsaicin in human erythrocytes subjected to oxidative stress. *Phytotherapy Research*, 20, 303-306.

ID 2044: “Capsicum Extract –with Capsaicin” and “Required for promotion of hair growth”

- 1 Harada N, Okajima K, Arai M, Kurihara H, Nakagata N, 2007. Administration of capsaicin and isoflavone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia. *Growth Horm IGF Res*, 17, 408-415.

ID 2045: “Dioscorea villosa (Common Name : Wild Yam)” and “Menopause”

- 1 Araghiniknam M, Chung S, Nelson-White T, Eskelson C, Watson RR, 1996. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. *Life Sci*, 59, PL147-157.
- 2 Bartram T, 1998. *Bartram's Encyclopedia of Herbal Medicine* Robinson Publishing London.
- 3 Haimov-Kochman R and Hochner-Celnikier D, 2005. Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us? *Acta Obstet Gynecol Scand*, 84, 972-979.
- 4 Higdon K, Scott A, Tucci M, Benghuzzi H, Tsao A, Puckett A, Cason Z, Hughes J, 2001. The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model. *Biomed Sci Instrum*, 37, 281-286.
- 5 Hudson TS, Standish L, Breed C, Bettenburg R, Dalen C, Noe J, O'Donnell T, Dibble E, 1998. Small clinical study on herbal formula for menopause. *Journal of naturopathic medicine*, 7, 73-77.
- 6 Jin UH, Kim DI, Lee TK, Lee DN, Kim JK, Lee IS, Kim CH, 2006. Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression. *J Ethnopharmacol*, 106, 333-343.
- 7 Komesaroff PA, Black CV, Cable V, Sudhir K, 2001. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. *Climacteric*, 4, 144-150.
- 8 Mills S and Bone K, 2000. *Principles and Practices of Phytotherapie (Modern Herbal Medecine)*. Churchill Livingstone, London, Edinburgh.
- 9 NLM (U.S. National Library of Medicine) and NIH (National Institutes of Health), Wild yam (*Dioscorea villosa*), <http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-wildyam.html>.
- 10 Reinhard-Hennch B, Strowitzki T, von Hagens C, 2006. [Complementary and alternative therapies for climacteric symptoms]. *Gynakol Geburtshilfliche Rundsch*, 46, 197-213.
- 11 Russell L, Hicks GS, Low AK, Shepherd JM, Brown CA, 2002. Phytoestrogens: a viable option? *Am J Med Sci*, 324, 185-188.
- 12 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 13 Wu WH, Liu LY, Chung CJ, Jou HJ, Wang TA, 2005. Estrogenic effect of yam ingestion in healthy postmenopausal women. *J Am Coll Nutr*, 24, 235-243.
- 14 Yen ML, Su JL, Chien CL, Tseng KW, Yang CY, Chen WF, Chang CC, Kuo ML, 2005. Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts. *Mol Pharmacol*, 68, 1061-1073.
- 15 Yin J, Tezuka Y, Kouda K, Le Tran Q, Miyahara T, Chen Y, Kadota S, 2004. In vivo antiosteoporotic activity of a fraction of *Dioscorea spongiosa* and its constituent, 22-O-methylprotodioscin. *Planta Med*, 70, 220-226.

ID 2046: “Elettaria cardamomum SEED” and “Kidneys”

- 1 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 2 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 3 Kapoor LD, 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton.
- 4 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 5 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 6 Sitaram B, 2006. Bhavaprakasa of Bhavamisra: Original Text Along With Commentary and Translation: Including Nighantu Portion. Chaukhambha Orientalia, New Delhi.

ID 2049: “Elderberry Sambucus nigra” and “Antioxidant properties”

- 1 Abuja PM, Murkovic M, Pfannhauser W, 1998. Antioxidant and Prooxidant Activities of Elderberry (*Sambucus nigra*) Extract in Low-Density Lipoprotein Oxidation. *Journal of Agricultural and Food Chemistry*, 46, 4091-4096.
- 2 Allen PC, 2003. Dietary supplementation with Echinacea and development of immunity to challenge infection with coccidia. *Parasitol Res*, 91, 74-78.
- 3 Awang DVC and Kindack DG, 1991. Herbal Medicine: Echinacea. *Can. Pharm. J*, 124, 512-516.
- 4 Bagchi D, Roy S, Patel V, He G, Khanna S, Ojha N, Phillips C, Ghosh S, Bagchi M, Sen CK, 2006. Safety and whole-body antioxidant potential of a novel anthocyanin-rich formulation of edible berries. *Mol Cell Biochem*, 281, 197-209.
- 5 Barnes J, Anderson LA, Gibbons S, Phillipson JD, 2005. Echinacea species (*Echinacea angustifolia* (DC.) Hell., *Echinacea pallida* (Nutt.) Nutt., *Echinacea purpurea* (L.) Moench): a review of their chemistry, pharmacology and clinical properties. *Journal of Pharmacy and Pharmacology*, 57, 929-954.
- 6 Bell DR and Gochenaur K, 2006. Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts. *J Appl Physiol*, 100, 1164-1170.
- 7 Blumenthal M, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 8 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs American Botanical Council, Austin, TX.
- 9 Borchers AT, Keen CL, Stern JS, Gershwin ME, 2000. Inflammation and Native American medicine: the role of botanicals. *Am J Clin Nutr*, 72, 339-347.
- 10 Bors W, Heller W, Michel C, Saran M, 1990. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. *Methods Enzymol*, 186, 343-355.
- 11 Bravo L, 1998. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. *Nutr Rev*, 56, 317-333.
- 12 Brinkeborn RM, Shah DV, Degenring FH, 1999. Echinaforce and other Echinacea fresh plant preparations in the treatment of the common cold. A randomized, placebo controlled, double-blind clinical trial. *Phytomedicine*, 6, 1-6.
- 13 Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG, 1997. Echinacea-induced cytokine production by human macrophages. *Int J Immunopharmacol*, 19, 371-379.

- 14 Cao G and Prior RL, 1999. Anthocyanins are detected in human plasma after oral administration of an elderberry extract. *Clin Chem*, 45, 574-576.
- 15 Cao G, Muccitelli HU, Sanchez-Moreno C, Prior RL, 2001. Anthocyanins are absorbed in glycosylated forms in elderly women: a pharmacokinetic study. *Am J Clin Nutr*, 73, 920-926.
- 16 Cundell DR, Matrone MA, Ratajczak P, Pierce JD, Jr., 2003. The effect of aerial parts of Echinacea on the circulating white cell levels and selected immune functions of the aging male Sprague-Dawley rat. *Int Immunopharmacol*, 3, 1041-1048.
- 17 Dorn M, Knick E, Lewith G, 1997. Placebo-controlled, double-blind study of Echinaceae pallidae radix in upper respiratory tract infections. *Complementary Therapies in Medicine*, 5, 40-42.
- 18 ESCOP (European Scientific cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. ESCOP and Georg Thieme Verlag, Exeter, Stuttgart, New York.
- 19 Gagliano Raspino M, 1996. Repertorio fitoterapico. Organizzazione Editoriale Medico Farmaceutica, Milan.
- 20 Garrow JS, James WPT, Ralph A, 2000. Human Nutrition and Dietetics. Churchill Livingstone, London, Edinburgh.
- 21 Hertog MGL, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic SI, Pekkarinen M, Simic BS, Toshima H, Feskens EJM, Hollman PCH, Katan MB, 1995. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. *Arch Intern Med*, 155, 381-386.
- 22 Kaack K and Austed T, 1998. Interaction of vitamin C and flavonoids in elderberry (*Sambucus nigra* L.) during juice processing. *Plant Foods Hum Nutr*, 52, 187-198.
- 23 Kuhnau J, 1976. The flavonoids. A class of semi-essential food components: their role in human nutrition. *World Rev Nutr Diet*, 24, 117-191.
- 24 Manach C, Regeat F, Texier O, Agullo G, Demigne C, Remesy C, 1996. Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. *Nutrition Research*, 16, 517-544.
- 25 Milbury PE, Cao G, Prior RL, Blumberg J, 2002. Bioavailability of elderberry anthocyanins. *Mech Ageing Dev*, 123, 997-1006.
- 26 Miyazawa T, Nakagawa K, Kudo M, Muraishi K, Someya K, 1999. Direct intestinal absorption of red fruit anthocyanins, cyanidin-3-glucoside and cyanidin-3,5-diglucoside, into rats and humans. *J Agric Food Chem*, 47, 1083-1091.
- 27 Murkovic M, Adam U, Pfannhauser W, 2000. Analysis of anthocyanine glycosides in human serum. *Fresenius J Anal Chem*, 366, 379-381.
- 28 Paganga G and Rice-Evans CA, 1997. The identification of flavonoids as glycosides in human plasma. *FEBS Lett*, 401, 78-82.
- 29 Ratty AK and Das NP, 1988. Effects of flavonoids on nonenzymatic lipid peroxidation: structure-activity relationship. *Biochem Med Metab Biol*, 39, 69-79.
- 30 Thole JM, Kraft TF, Sueiro LA, Kang YH, Gills JJ, Cuendet M, Pezzuto JM, Seigler DS, Lila MA, 2006. A comparative evaluation of the anticancer properties of European and American elderberry fruits. *J Med Food*, 9, 498-504.
- 31 Wang H, Cao G, Prior RL, 1997. Oxygen Radical Absorbing Capacity of Anthocyanins. *Journal of Agricultural and Food Chemistry*, 45, 304-309.
- 32 WHO (World Health Organisation), 1999. WHO monographs on selected medicinal plants. WHO, Geneva.
- 33 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- 34 Wichtl M, 2004. Herbal Drugs and Phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart.
- 35 Wu X, Gu L, Prior RL, McKay S, 2004. Characterization of anthocyanins and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capacity. *J Agric Food Chem*, 52, 7846-7856.

- 36 Youdim KA, Martin A, Joseph JA, 2000. Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress. *Free Radic Biol Med*, 29, 51-60.

ID 2050: “Fruit of *Vaccinium myrtillus*” and “Maintain eye health and function, through antioxidant and venous support action”

- 1 *Vaccinium myrtillus* (Bilberry). Monograph, 2001. *Altern Med Rev*, 6, 500-504.
- 2 Barnes J, Anderson LA, Phillipson JD, 2002. Bilberry. In: *Herbal Medicines. A guide for healthcare professionals*. Pharmaceutical Press, London, 73-77.
- 3 Bastide P, Rouher F, Tronche P, 1968. [Rhodopsin and anthocyanosides. Apropos of various experimental facts]. *Bull Soc Ophtalmol Fr*, 68, 801-807.
- 4 Bertuglia S, Malandrino S, Colantuoni A, 1995. Effect of *Vaccinium myrtillus* anthocyanosides on ischaemia reperfusion injury in hamster cheek pouch microcirculation. *Pharmacol Res*, 31, 183-187.
- 5 Bruneton J, 1999. Airelle myrtille. In: *Pharmacognosie, Phytochimie, Plantes médicinales*. Tech.& Doc. Lavoisier 361-363.
- 6 Choi EH, Ok HE, Yoon Y, Magnuson BA, Kim MK, Chun HS, 2007. Protective effect of anthocyanin-rich extract from bilberry (*Vaccinium myrtillus* L.) against myelotoxicity induced by 5-fluorouracil. *Biofactors*, 29, 55-65.
- 7 Cohen-Boulakia F, Valensi PE, Boulahdour H, Lestrade R, Dufour-Lamartinie JF, Hort-Legrand C, Behar A, 2000. In vivo sequential study of skeletal muscle capillary permeability in diabetic rats: effect of anthocyanosides. *Metabolism*, 49, 880-885.
- 8 Cooke D, Schwarz M, Boocock D, Winterhalter P, Steward WP, Gescher AJ, Marczyklo TH, 2006. Effect of cyanidin-3-glucoside and an anthocyanin mixture from bilberry on adenoma development in the ApcMin mouse model of intestinal carcinogenesis--relationship with tissue anthocyanin levels. *Int J Cancer*, 119, 2213-2220.
- 9 Delaveau P, 1984. Myrtille. *Le concours médical, Phytothérapie pratique*, 106, 4129-4130.
- 10 Dorvault F, 1995. Airelle. In: *L'officine*. Hazebroucq G (ed.) Vigot, 40.
- 11 Fursova A, Gesarevich OG, Gonchar AM, Trofimova NA, Kolosova NG, 2005. [Dietary supplementation with bilberry extract prevents macular degeneration and cataracts in senesce-accelerated OXYS rats]. *Adv Gerontol*, 16, 76-79.
- 12 Head KA, 2001. Natural therapies for ocular disorders, part two: cataracts and glaucoma. *Altern Med Rev*, 6, 141-166.
- 13 Ichianagi T, Shida Y, Rahman MM, Hatano Y, Konishi T, 2006. Bioavailability and tissue distribution of anthocyanins in bilberry (*Vaccinium myrtillus* L.) extract in rats. *J Agric Food Chem*, 54, 6578-6587.
- 14 Jayle GE, Aubry M, Gavini H, Braccini G, De la Baume C, 1965. [Study concerning the action of anthocyanoside extracts of *Vaccinium Myrtillus* on night vision]. *Ann Ocul (Paris)*, 198, 556-562.
- 15 Lala G, Malik M, Zhao C, He J, Kwon Y, Giusti MM, Magnuson BA, 2006. Anthocyanin-rich extracts inhibit multiple biomarkers of colon cancer in rats. *Nutr Cancer*, 54, 84-93.
- 16 Mazza G, Kay CD, Cottrell T, Holub BJ, 2002. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. *J Agric Food Chem*, 50, 7731-7737.
- 17 Mercier A, Perdriel G, Rozier J, Chevaleraud J, 1965. [Note concerning the action of anthocyanin glycosides on the human electroretinogram]. *Bull Soc Ophtalmol Fr*, 65, 1049-1053.
- 18 Mills S and Bone K, 2000. Bilberry fruit. In: *Principles and practice of Phytotherapy*. Churchill Livingstone, London, Edinburgh, 297-302.
- 19 Muth ER, Laurent JM, Jasper P, 2000. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. *Altern Med Rev*, 5, 164-173.

- 20 Nutranews. Science Nutrition Prévention et Santé, 2001. Prévenir le déclin de la vision lié au vieillissement. Mai 1-8.
- 21 Petlevski R., Hadzija M., Slijepcevic M., Juretic D., Petrik J., 2003 Glutathione S-transferases & malondialdehyde in the liver of NOD mice on short-term treatment with plant mixture extract P-9801091. Phytother Res, 17, 311-314.

ID 2052: “Foeniculum vulgare ssp. Cappillaceum var. vulgare. DRIED FRUIT” and “Immunity. Antioxidant”

- 1 Baliga MS, Jagetia GC, Rao SK, Babu K, 2003. Evaluation of nitric oxide scavenging activity of certain spices in vitro: a preliminary study. Nahrung, 47, 261-264.
- 2 Billore K, Yelne M, Dennis T, Chaudhari B, 2005. Database on Medicinal Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 3 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2005. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag Heidelberg.
- 4 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 5 Choi EM and Hwang JK, 2004. Antiinflammatory, analgesic and antioxidant activities of the fruit of Foeniculum vulgare. Fitoterapia, 75, 557-565.
- 6 De Marino S, Gala F, Borbone N, Zollo F, Vitalini S, Visioli F, Iorizzi M, 2007. Phenolic glycosides from Foeniculum vulgare fruit and evaluation of antioxidative activity. Phytochemistry, 68, 1805-1812.
- 7 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 8 Parejo I, Viladomat F, Bastida J, Schmeda-Hirschmann G, Burillo J, Codina C, 2004. Bioguided isolation and identification of the nonvolatile antioxidant compounds from fennel (Foeniculum vulgare Mill.) waste. J Agric Food Chem, 52, 1890-1897.
- 9 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 10 Ruberto G, Baratta MT, Deans SG, Dorman HJ, 2000. Antioxidant and antimicrobial activity of Foeniculum vulgare and Crithmum maritimum essential oils. Planta Med, 66, 687-693.
- 11 Satyanarayana S, Sushruta K, Sarma GS, Srinivas N, Subba Raju GV, 2004. Antioxidant activity of the aqueous extracts of spicy food additives--evaluation and comparison with ascorbic acid in in-vitro systems. J Herb Pharmacother, 4, 1-10.
- 12 Singh G, Maurya S, de Lampasona MP, Catalan C, 2006. Chemical constituents, antifungal and antioxidative potential of Foeniculum vulgare volatile oil and its acetone extract. Food control, 17, 745-752.

ID 2053: “Foeniculum vulgare ssp. Cappillaceum var. vulgare. DRIED FRUIT” and “Postpartum”

- 1 Albert-Puleo M, 1980. Fennel and anise as estrogenic agents. J Ethnopharmacol, 2, 337-344.
- 2 Billore K, Yelne M, Dennis T, Chaudhari B, 2005. Database on Medicinal Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 3 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 4 Devi K, Vanithakumari G, Anusya S, Mekala N, Malini T, Elango V, 1985. Effect of Foeniculum vulgare seed extract on mammary glands and oviducts of ovariectomised rats. Ancient Science of Life, 5.
- 5 Gogte V, 2000. Ayurvedic Pharmacology & Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan.

- 6 Hiller K and Melzig MF, 2003. Lexikon der Arzneipflanzen und Drogen. Spektrum Akademischer Verlag.
- 7 Hoppe HA, 1977. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 8 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 9 Malini T, Vanithakumari G, Megala N, Anusya S, Devi K, Elango V, 1985. Effect of *Foeniculum vulgare* Mill. seed extract on the genital organs of male and female rats. *Indian J Physiol Pharmacol*, 29, 21-26.
- 10 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 11 Schönfelder I and Schönfelder P, 2004. *Das neue Handbuch der Heilpflanzen: Botanik, Arzneidrogen, Wirkstoffe, Anwendungen* Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 12 Sitaram B, 2006. *Bhavaprakasa of Bhavamisra : Original Text Along With Commentary and Translation : Including Nighantu Portion*. Chaukhambha Orientalia, Varanasi, India.
- 13 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.
- 14 Yelne M, Sharma P, Dennis T, 2002. *Database on Medicinal Plants Used in Ayurveda*. Central Council for Research in Ayurveda & Siddha, Indian Ministry of Health and Family Welfare.

ID 2055: “*Foeniculum vulgare* Mill (Common name: Fennel)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, Texas.
- 3 ESCOP (European Scientific cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. ESCOP and Georg Thieme Verlag, Exeter, Stuttgart, New York.
- 4 Franke W, 1997. *Nutzpflanzenkunde*. Thieme, Stuttgart.
- 5 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.
- 6 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 7 Vogel G, 1990-1995. *Arzneipflanzen in der Phytotherapie. Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten. Kooperation Phytopharmaka*.
- 8 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.

ID 2056: “*Foeniculi aetheroleum* (Common name: Fennel oil)” and “Respiratory Health”

- 1 Blaschek W, Ebel S, Hackenthal E, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, Texas.
- 3 ESCOP (European Scientific cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. ESCOP and Georg Thieme Verlag, Exeter, Stuttgart, New York.
- 4 Franke W, 1997. *Nutzpflanzenkunde*. Thieme, Stuttgart.

- 5 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.
- 6 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- 7 Vogel G, 1990-1995. Arzneipflanzen in der Phytotherapie. Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten. Kooperation Phytopharmaka.
- 8 Wichtl M, 2004. Herbal Drugs and Phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart.

ID 2057: “Garcinia Cambogia (Common name: Carcinia gummi-gutta, gummi-gutta gum, brindleberry, Malabar, tamarind)” and “Weight management”

- 1 Allison DB, Fontaine KR, Heshka S, Mentore JL, Heymsfield SB, 2001. Alternative treatments for weight loss: a critical review. *Crit Rev Food Sci Nutr*, 41, 1-28; discussion 39-40.
- 2 No authors listed, 1992. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. *Am J Clin Nutr*, 55, 615S-619.
- 3 No authors listed, 1996. Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. *JAMA*, 276, 1907-1915.
- 4 Badmaev V and Majeed M, 1995. Open field, physician controlled, clinical evaluation of botanical weight loss formula citrin. *Nutracon 1995: Nutraceuticals, Dietary Supplements and Functional Foods*, Las Vegas.
- 5 Badmaev V, Majeed M, Conte AA, 2002. Open field, physician controlled clinical evaluation of a botanical weight loss formula based on *Garcinia cambogia* derived (-)hydroxycitric acid. *Nutraceuticals*, Jan/Feb, 10-14.
- 6 Bray GA, 1993. Use and abuse of appetite-suppressant drugs in the treatment of obesity. *Ann Intern Med*, 119, 707-713.
- 7 Burstein L, Kim KS, Delandshere G, 1989. Multilevel Investigations of Systematically Varying Slopes: Issues, Alternatives, and Consequences. Academic Press, New York.
- 8 Conte AA, 1993. A non-prescription alternative in weight reduction therapy. *Am. J. Bariatric Med.*, 3, 17-19.
- 9 Dempster AP, Laird NM, Rubin DB, 1977. Maximum likelihood from incomplete data via the EM algorithm. *Journal of the Royal Statistical Society. Series B (Methodological)*, 39, 1-38.
- 10 Downs BW, Bagchi M, Subbaraju GV, Shara MA, Preuss HG, Bagchi D, 2005. Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid. *Mutat Res*, 579, 149-162.
- 11 EMEA (European Medicines Agency)-CHMP (Committee on Human Medicinal Products), 2008. Guideline On Clinical Evaluation Of Medicinal Products Used In Weight Control.
- 12 Girola M, De Bernardi M, Conti S, 1996. Dose effect in lipid-lowering activity of a new dietary intetrator (chitosan, *Garcinia cambogia* extract, and chrome). *Acta Toxicol Ther*, 17, 25-40.
- 13 Graham JW, Hooper SM, Picnic AM, 1994. Analysis with missing data in drug prevention research. In: *Advances in Data Analysis for Prevention Intervention Research*. NIDA Research Monograph 142. Des Collins LM and Seats LA (eds.). US Dept of Health and Human Service, Washington DC.
- 14 Hayamizu K, Hirakawa H, Oikawa D, Nakanishi T, Takagi T, Tachibana T, Furuse M, 2003. Effect of *Garcinia cambogia* extract on serum leptin and insulin in mice. *Fitoterapia*, 74, 267-273.
- 15 Heymsfield SB, Wang Z, Visser M, Gallagher D, Pierson RN, 1992. Nutritional assessment by anthropometric and biochemical methods. In: *Modern Nutrition in Health and Disease*. Shils ME, Olson JA, Shike M (eds.). Lea & Febiger, Philadelphia, 812-841.
- 16 Heymsfield SB, Wang Z, Visser M, Gallagher D, Pierson RN, Jr., 1996. Techniques used in the measurement of body composition: an overview with emphasis on bioelectrical impedance analysis. *Am J Clin Nutr*, 64, 478S-484S.

- 17 Heymsfield SB, Wang ZM, Withers R, 1996. Multicomponent molecular-level models for body composition analysis. In: Human Body Composition. Roche AF, Heymsfield SB, Lohman TG (eds.). Human Kinetics, Champaign, 129-147.
- 18 Hobbs LS, 1994. Hydroxycitrate (HCA). In: The New Diet Pills. Pragmatic Press, 161–174.
- 19 Jellin JM, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter. Stockton.
- 20 Jena BS, Jayaprakasha GK, Singh RP, Sakariah KK, 2002. Chemistry and biochemistry of (-)-hydroxycitric acid from *Garcinia*. *J Agric Food Chem*, 50, 10-22.
- 21 Joyal SV, 2004. A perspective on the current strategies for the treatment of obesity. *Curr Drug Targets CNS Neurol Disord*, 3, 341-356.
- 22 Lewis YS and Neelakantan S, 1965. Hydroxycitric acid: the principal acid in the fruits of *Garcinia cambogia*. *Phytochemistry*, 4, 610-625.
- 23 Lowenstein JM, 1971. Effect of (-)-hydroxycitrate on fatty acid synthesis by rat liver in vivo. *J Biol Chem*, 246, 629-632.
- 24 Martius C and Maué R, 1941. Darstellung, physiologisches Verhalten und Bedeutung der (+)-Oxycitronensäure und ihrer Isomeren. *Z Physiol Chem*, 269, 33-40.
- 25 Murray F, 2004. Hydroxycitric acid: the weight is over. (found in fruit of *Garcinia cambogia*). *Better Nutrition for Today's Living*, 56, 34.
- 26 Nageswara Rao R and Sakariah KK, 1988. Lipid-lowering and antiobesity effect of (-) hydroxycitric acid. *Nutrition research*, 8, 209-212.
- 27 Niklson IA, Reimitz PE, Sennef C, 1997. Factors that influence the outcome of placebo-controlled antidepressant clinical trials. *Psychopharmacol Bull*, 33, 41-51.
- 28 Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ, 2002. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). *Mol Cell Biochem*, 238, 89-103.
- 29 Oluyemi KA, Omotuyi IO, Jimoh OR, Adesanya OA, Saalu CL, Josiah SJ, 2007. Erythropoietic and anti-obesity effects of *Garcinia cambogia* (bitter kola) in Wistar rats. *Biotechnol Appl Biochem*, 46, 69-72.
- 30 Pietrobelli A, Formica C, Wang Z, Heymsfield SB, 1996. Dual-energy X-ray absorptiometry body composition model: review of physical concepts. *Am J Physiol*, 271, E941-951.
- 31 Pittler MH and Ernst E, 2004. Dietary supplements for body-weight reduction: a systematic review. *Am J Clin Nutr*, 79, 529-536.
- 32 Preuss HG, Bagchi D, Bagchi M, Rao CVS, Satyanarayana S, Dey DK, 2004. Efficacy of a novel, natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX, niacin-bound chromium and *Gymnema sylvestre* extract in weight management in human volunteers: a pilot study. *Nutrition Research*, 24, 45-58.
- 33 Preuss HG, Garis RI, Bramble JD, Bagchi D, Bagchi M, Rao CV, Satyanarayana S, 2005. Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control. *Int J Clin Pharmacol Res*, 25, 133-144.
- 34 Roongpisuthipong C, Kantawan R, Roongpisuthipong W, 2007. Reduction of adipose tissue and body weight: effect of water soluble calcium hydroxycitrate in *Garcinia atroviridis* on the short term treatment of obese women in Thailand. *Asia Pac J Clin Nutr*, 16, 25-29.
- 35 Rothacker DQ and Waitman BE, 1997. Effectiveness of a *Garcinia cambogia* and natural caffeine combination in weight loss: a double-blind placebo-controlled pilot study. *Int J Obes*, 21, 53.
- 36 Russell-Aulet M, Wang J, Thornton J, Pierson Jr RN, 1991. Comparison of dual-photon absorptiometry systems for total-body bone and soft tissue measurements: dual-energy X-rays versus gadolinium 153. *J Bone Miner Res*, 6, 411-415.
- 37 Sullivan AC, Hamilton JG, Miller ON, Wheatley VR, 1972. Inhibition of lipogenesis in rat liver by (-)-hydroxycitrate. *Arch Biochem Biophys*, 150, 183-190.

- 38 Sullivan AC, Hamilton JG, Miller ON, Wheatley VR, 1972. Inhibition of lipogenesis in rat liver by (-)-hydroxycitrate. *Arch Biochem Biophys*, 150, 183-190.
- 39 Sullivan AC and Miller ON, 1974. The influence of (-)-hydroxycitrate on in vivo rates of hepatic glycogenesis: lipogenesis and cholesterol-genesis. *Fed Proc*, 33, 656.
- 40 Sullivan AC, Triscari J, Hamilton JG, Miller ON, 1974. Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. II. Appetite. *Lipids*, 9, 129-134.
- 41 Sullivan AC, Triscari J, Hamilton JG, Miller ON, Wheatley VR, 1974. Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. I. Lipogenesis. *Lipids*, 9, 121-128.
- 42 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag.
- 43 Thom E, 1996. Hydroxycitrate (HCA) in the treatment of obesity. *Int J Obes*, 20, 48.
- 44 van Loon LJ, van Rooijen JJ, Niesen B, Verhagen H, Saris WH, Wagenmakers AJ, 2000. Effects of acute (-)-hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans. *Am J Clin Nutr*, 72, 1445-1450.
- 45 Vasselli JR, Shane E, Boozer CN, Heymsfield SB, 1998. Garcinia cambogia extract inhibits body weight gain via increased energy expenditure (EE) in rats. *FASEB J*, 12, A505.
- 46 von Lippmann EO, 1883. Über eine neue, im Rübensaft vorkommende Säure. *Ber Dtsch Chem Ges*, 16, 1078-1081.
- 47 Watson JA, Fang M, Lowenstein JM, 1969. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. *Arch Biochem Biophys*, 135, 209-217.
- 48 Watson JA and Lowenstein JM, 1970. Citrate and the conversion of carbohydrate into fat. Fatty acid synthesis by a combination of cytoplasm and mitochondria. *J Biol Chem*, 245, 5993-6002.
- 49 Webster JD, Hesp R, Garrow JS, 1984. The composition of excess weight in obese women estimated by body density, total body water and total body potassium. *Hum Nutr Clin Nutr*, 38, 299-306.

ID 2058: “Green Mate leaf extract (*Ilex paraguariensis* St.-Hil.)” and “Mild diuretic effect, drainage of excess water”

- 1 Blumenthal M, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, Texas.
- 2 Gotz V and Kessler H, 1990. Mate-Tee als unterstützende Maßnahme bei Reduktionsdiäten. In: *Natur- und GanzheitsMedizin. Wissenschaft un Praxis*. Schattauer Verlagsgesellschaft mbH, Stuttgart, 252-258.
- 3 Lupi O, Semenovitch IJ, Treu C, Bottino D, Bouskela E, 2007. Evaluation of the effects of caffeine in the microcirculation and edema on thighs and buttocks using the orthogonal polarization spectral imaging and clinical parameters. *J Cosmet Dermatol*, 6, 102-107.
- 4 Neuhauser B, Beine S, Verwied SC, Luhrmann PM, 1997. Coffee consumption and total body water homeostasis as measured by fluid balance and bioelectrical impedance analysis. *Ann Nutr Metab*, 41, 29-36.
- 5 Newall CA, Anderson LA, Phillipson JD, 1996. *Herbal medicines: a guide for health-care professionals*. Pharmaceutical Press, London.
- 6 Rieg T, Steigele H, Schnermann J, Richter K, Osswald H, Vallon V, 2005. Requirement of intact adenosine A1 receptors for the diuretic and natriuretic action of the methylxanthines theophylline and caffeine. *J Pharmacol Exp Ther*, 313, 403-409.
- 7 Wemple RD, Lamb DR, McKeever KH, 1997. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. *Int J Sports Med*, 18, 40-46.

ID 2059: “Natural Grape Extract From red grape skin” and “Rich in polyphenols - Act as antioxidants - Antioxidant is a compound able to scavenge free radicals in the body and stop the oxidative chain reaction”

- 1 Monographie der Kommission E des BGA. *Chelidonii herba* (Schöllkraut). 1985.
- 2 Monographie der Kommission E des BGA. *Matricariae flos* (Kamillenblüten). 1990.
- 3 Monographie der Kommission E des BGA. *Liquiritiae radix* (Süßholzwurzel). 1991.
- 4 Bravo L, 1998. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. *Nutr Rev*, 56, 317-333.
- 5 Cao G, Booth SL, Sadowski JA, Prior RL, 1998. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. *Am J Clin Nutr*, 68, 1081-1087.
- 6 DGCCRF (Direction générale de la concurrence dlcedlrdf, Approved grape extract’s daily recommended intake.
- 7 DH (Department of Health), 5 A DAY health benefits. The health benefits of fruits and vegetables, http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/FiveADay/FiveADaygeneralinformation/DH_4002343.
- 8 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 9 Health Canada, 2008. Monograph Licorice.
- 10 Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*, 81, 230S-242S.
- 11 Middleton E, Jr., Kandaswami C, Theoharides TC, 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol Rev*, 52, 673-751.
- 12 Monagas M, Hernandez-Ledesma B, Gomez-Cordoves C, Bartolome B, 2006. Commercial Dietary Ingredients from *Vitis vinifera* L. Leaves and Grape Skins: Antioxidant and Chemical Characterization. *J Agric Food Chem*, 54, 319-327.
- 13 Santos-Buelga C and Scalbert A, 2000. Proanthocyanidins and tannin-like compounds: nature, occurrence, dietary intake and effects on nutrition and health. *Journal of the science of food and agriculture*, 80, 1094-1117.
- 14 Scalbert A, Johnson IT, Saltmarsh M, 2005. Polyphenols: antioxidants and beyond. *Am J Clin Nutr*, 81, 215S-217S.
- 15 Vitseva O, Varghese S, Chakrabarti S, Folts JD, Freedman JE, 2005. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. *J Cardiovasc Pharmacol*, 46, 445-451.
- 16 Yilmaz Y and Toledo RT, 2004. Major Flavonoids in Grape Seeds and Skins: Antioxidant Capacity of Catechin, Epicatechin, and Gallic Acid. *Journal of Agricultural and Food Chemistry*, 52, 255-260.

ID 2060: “Grape seed extract” and “Antioxidant activity”

- 1 Bagchi D, Bagchi M, Stohs SJ, Das DK, Ray SD, Kuszynski CA, Joshi SS, Pruess HG, 2000. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology*, 148, 187-197.
- 2 Balu M, Sangeetha P, Murali G, Panneerselvam C, 2006. Modulatory role of grape seed extract on age-related oxidative DNA damage in central nervous system of rats. *Brain Res Bull*, 68, 469-473.
- 3 Barden CA, Chandler HL, Lu P, Bomser JA, Colitz CM, 2008. Effect of grape polyphenols on oxidative stress in canine lens epithelial cells. *Am J Vet Res*, 69, 94-100.
- 4 Barrett M, 2004. *The Handbook of Clinically Tested Herbal Remedies*. Haworth Herbal Press, New York.

- 5 Carini M, Stefani R, Aldini G, Ozioli M, Facino RM, 2001. Procyanidins from *Vitis vinifera* seeds inhibit the respiratory burst of activated human neutrophils and lysosomal enzyme release. *Planta Med*, 67, 714-717.
- 6 Cheng M, Gao HQ, Xu L, Li BY, Zhang H, Li XH, 2007. Cardioprotective effects of grape seed proanthocyanidins extracts in streptozocin induced diabetic rats. *J Cardiovasc Pharmacol*, 50, 503-509.
- 7 Dulundu E, Ozel Y, Topaloglu U, Toklu H, Ercan F, Gedik N, Sener G, 2007. Grape seed extract reduces oxidative stress and fibrosis in experimental biliary obstruction. *J Gastroenterol Hepatol*, 22, 885-892.
- 8 Kalin R, Righi A, Del Rosso A, Bagchi D, Generini S, Cerinic MM, Das DK, 2002. Activin, a grape seed-derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. *Free Radic Res*, 36, 819-825.
- 9 Kar P, Laight D, Shaw KM, Cummings MH, 2006. Flavonoid-rich grapeseed extracts: a new approach in high cardiovascular risk patients? *Int J Clin Pract*, 60, 1484-1492.
- 10 Karthikeyan K, Bai BR, Devaraj SN, 2007. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. *Int J Cardiol*, 115, 326-333.
- 11 Kontek A, Campeanu R, Petrescu L, Rizea S, 1995. Effect of grape seed procyanidins on some vascular diseases Polyphenols 94.17. International Conference on Polyphenols, Palma de Mallorca, 23-27 May 1994, 399-400.
- 12 Li BY, Cheng M, Gao HQ, Ma YB, Xu L, Li XH, Li XL, You BA, 2008. Back-regulation of six oxidative stress proteins with grape seed proanthocyanidin extracts in rat diabetic nephropathy. *J Cell Biochem*, 104, 668-679.
- 13 Lu Y, Zhao WZ, Chang Z, Chen WX, Li L, 2004. Procyanidins from grape seeds protect against phorbol ester-induced oxidative cellular and genotoxic damage. *Acta Pharmacol Sin*, 25, 1083-1089.
- 14 Ma L, Gao HQ, Li BY, Ma YB, You BA, Zhang FL, 2007. Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma. *J Cardiovasc Pharmacol*, 49, 293-298.
- 15 Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R, 1994. Free radicals scavenging action and anti-enzyme activities of procyanidines from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung*, 44, 592-601.
- 16 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1996. Procyanidines from *Vitis vinifera* seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. *Planta Med*, 62, 495-502.
- 17 Maffei Facino R, Carini M, Aldini G, Calloni MT, Bombardelli E, Morazzoni P, 1998. Sparing effect of procyanidins from *Vitis vinifera* on vitamin E: in vitro studies. *Planta Med*, 64, 343-347.
- 18 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1999. Diet enriched with procyanidins enhances antioxidant activity and reduces myocardial post-ischaemic damage in rats. *Life Sci*, 64, 627-642.
- 19 Morin B, Narbonne JF, Ribera D, Badouard C, Ravanat JL, 2008. Effect of dietary fat-soluble vitamins A and E and proanthocyanidin-rich extract from grape seeds on oxidative DNA damage in rats. *Food Chem Toxicol*, 46, 787-796.
- 20 Natella F, Belelli F, Gentili V, Ursini F, Scaccini C, 2002. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. *J Agric Food Chem*, 50, 7720-7725.
- 21 Nuttall SL, Kendall MJ, Bombardelli E, Morazzoni P, 1998. An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. *J Clin Pharm Ther*, 23, 385-389.
- 22 Sano T, Oda E, Yamashita T, Naemura A, Ijiri Y, Yamakoshi J, Yamamoto J, 2005. Anti-thrombotic effect of proanthocyanidin, a purified ingredient of grape seed. *Thromb Res*, 115, 115-121.
- 23 Shafiee M, Carbonneau MA, Urban N, Descomps B, Leger CL, 2003. Grape and grape seed extract capacities at protecting LDL against oxidation generated by Cu²⁺, AAPH or SIN-1 and at decreasing

- superoxide THP-1 cell production. A comparison to other extracts or compounds. *Free Radic Res*, 37, 573-584.
- 24 Shao ZH, Hsu CW, Chang WT, Waypa GB, Li J, Li D, Li CQ, Anderson T, Qin Y, Schumacker PT, Becker LB, Hoek TL, 2006. Cytotoxicity induced by grape seed proanthocyanidins: role of nitric oxide. *Cell Biol Toxicol*, 22, 149-158.
 - 25 Sharma SD, Meeran SM, Katiyar SK, 2007. Dietary grape seed proanthocyanidins inhibit UVB-induced oxidative stress and activation of mitogen-activated protein kinases and nuclear factor-kappaB signaling in vivo SKH-1 hairless mice. *Mol Cancer Ther*, 6, 995-1005.
 - 26 Shi J, Yu J, Pohorly JE, Kakuda Y, 2003. Polyphenolics in grape seeds-biochemistry and functionality. *J Med Food*, 6, 291-299.
 - 27 Vigna GB, Costantini F, Aldini G, Carini M, Catapano A, Schena F, Tangerini A, Zanca R, Bombardelli E, Morazzoni P, Mezzetti A, Fellin R, Maffei Facino R, 2003. Effect of a standardized grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. *Metabolism*, 52, 1250-1257.
 - 28 Vogels N, Nijs IM, Westerterp-Plantenga MS, 2004. The effect of grape-seed extract on 24 h energy intake in humans. *Eur J Clin Nutr*, 58, 667-673.

ID 2061: “Natural Grape Extract From white grape skin Solvent free” and “Rich in polyphenols - Act as antioxidants - Antioxidant is a compound able to scavenge free radicals in the body and stop the oxidative chain reaction”

- 1 Bravo L, 1998. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. *Nutr Rev*, 56, 317-333.
- 2 Cao G, Booth SL, Sadowski JA, Prior RL, 1998. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. *Am J Clin Nutr*, 68, 1081-1087.
- 3 DGCCRF (Direction générale de la Concurrence, de la Consommation et de la Répression des Fraudes) Approved grape extract’s daily recommended intake.
- 4 DH (Department of Health), 5 A DAY health benefits. The health benefits of fruits and vegetables, http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/FiveADay/FiveADaygeneralinformation/DH_4002343.
- 5 Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*, 81, 230S-242S.
- 6 Middleton E, Jr., Kandaswami C, Theoharides TC, 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol Rev*, 52, 673-751.
- 7 Monagas M, Hernandez-Ledesma B, Gomez-Cordoves C, Bartolome B, 2006. Commercial Dietary Ingredients from *Vitis vinifera* L. Leaves and Grape Skins: Antioxidant and Chemical Characterization. *J Agric Food Chem*, 54, 319-327.
- 8 Scalbert A, Johnson IT, Saltmarsh M, 2005. Polyphenols: antioxidants and beyond. *Am J Clin Nutr*, 81, 215S-217S.
- 9 Yilmaz Y and Toledo RT, 2004. Major Flavonoids in Grape Seeds and Skins: Antioxidant Capacity of Catechin, Epicatechin, and Gallic Acid. *Journal of Agricultural and Food Chemistry*, 52, 255-260.

ID 2062: “Guarana” and “Guarana and mental performance”

- 1 Attele AS, Wu JA, Yuan CS, 1999. Ginseng pharmacology: multiple constituents and multiple actions. *Biochem Pharmacol*, 58, 1685-1693.
- 2 Bucci LR, 2000. Selected herbals and human exercise performance. *Am J Clin Nutr*, 72, 624S-636S.

- 3 Carlini EA, 2003. Plants and the central nervous system. *Pharmacol Biochem Behav*, 75, 501-512.
- 4 D'Angelo L, Grimaldi R, Caravaggi M, Marcoli M, Perucca E, Lecchini S, Frigo GM, Crema A, 1986. A double-blind, placebo-controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers. *J Ethnopharmacol*, 16, 15-22.
- 5 Ellis JM and Reddy P, 2002. Effects of Panax ginseng on quality of life. *Ann Pharmacother*, 36, 375-379.
- 6 Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB, 2007. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. *J Psychopharmacol*, 21, 65-70.
- 7 Katzung W, 1993. [Guarana--a natural product with high caffeine content]. *Med Monatsschr Pharm*, 16, 330-333.
- 8 Kennedy D, Haskell C, Pace S, Zangara A, Scholey AB, 2004. Psychoactive effects of a single dose of Paullinia cupana (Guarana) during intense mental demand. Poster presented at the Worldnutra Conference 2004, San Francisco, November 8-10. Worldnutra Conference, San Francisco.
- 9 Kennedy DO, Haskell CF, Wesnes KA, Scholey AB, 2004. Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax ginseng. *Pharmacol Biochem Behav*, 79, 401-411.
- 10 O'Hara M, Kiefer D, Farrell K, Kemper K, 1998. A review of 12 commonly used medicinal herbs. *Arch Fam Med*, 7, 523-536.
- 11 Vogler BK, Pittler MH, Ernst E, 1999. The efficacy of ginseng. A systematic review of randomised clinical trials. *Eur J Clin Pharmacol*, 55, 567-575.
- 12 WHO (World Health Organization), 1999. Radix Ginseng. In: WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva, pp 168-182.

ID 2063: “Guarana” and “Guarana and mental performance”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.
- 2 Brendler T, Grünwald J, Jänicke C, 2003. Heilpflanzen - Herbal Remedies. CD-ROM. Medpharm Scientific Publishers, Boca Raton.
- 3 Briggs C, 1992. Guarana. *Can Pharm J*, 125, 222-224.
- 4 Campos AR, Barros AI, Albuquerque FA, LK ML, Rao VS, 2005. Acute effects of guarana (Paullinia cupana Mart.) on mouse behaviour in forced swimming and open field tests. *Phytother Res*, 19, 441-443.
- 5 Carlini EA, 2003. Plants and the central nervous system. *Pharmacol Biochem Behav*, 75, 501-512.
- 6 Cauli O and Morelli M, 2005. Caffeine and the dopaminergic system. *Behav Pharmacol*, 16, 63-77.
- 7 Dansk Droge A/S, 2006. Guarana monograph.
- 8 Dorea JG and da Costa TH, 2005. Is coffee a functional food? *Br J Nutr*, 93, 773-782.
- 9 EBSCO Complementary and Alternative Review Board. Swedish Medical Center, Guarana (Paullinia cupana), http://www.swedish.org/body_frameset.cfm?id=1009.
- 10 Espinola EB, Dias RF, Mattei R, Carlini EA, 1997. Pharmacological activity of Guarana (Paullinia cupana Mart.) in laboratory animals. *J Ethnopharmacol*, 55, 223-229.
- 11 Franke W, 1997. *Nutzpflanzenkunde*. Thieme, Stuttgart.
- 12 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 13 Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB, 2007. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. *J Psychopharmacol*, 21, 65-70.
- 14 Hoppe HA, 1975. *Drogenkunde*. Ealter de Gruyter & Co, Berlin.

- 15 Houghton P, 1995. Herbal products, Part 7 Guarana. *Pharm J*, 254, 435-436.
- 16 Katzung W, 1993. Guarana - a natural product with high caffeine content. *Med Monatsschr Pharm*, 16, 330-333.
- 17 Kennedy D, Haskell C, Pace S, Zangara A, Scholey A, 2004. Psychoactive effects of a single dose *Paullinia cupana* (Guarana) during intense mental demand. *Worldnutra Conference 2004*, San Francisco.
- 18 Kennedy DO, Haskell CF, Wesnes KA, Scholey AB, 2004. Improved cognitive performance in human volunteers following administration of guarana (*Paullinia cupana*) extract: comparison and interaction with *Panax ginseng*. *Pharmacol Biochem Behav*, 79, 401-411.
- 19 Lorist MM and Tops M, 2003. Caffeine, fatigue, and cognition. *Brain Cogn*, 53, 82-94.
- 20 Magkos F and Kavouras SA, 2005. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. *Crit Rev Food Sci Nutr*, 45, 535-562.
- 21 Reynolds JEF, 1996. *Martindale: The Extra Pharmacopoeia*. Pharmaceutical Press, London.
- 22 Memorial Sloan-Kettering Cancer Center, *Paullinia cupana* (Guarana), <http://www.mskcc.org/mskcc/html/69248.cfm>
- 23 Miura T, Tataru M, Nakamura K, Suzuki I, 1998. Effect of guarana on exercise in normal and epinephrine-induced glycogenolytic mice. *Biol Pharm Bull*, 21, 646-648.
- 24 Mucignat-Caretta C, 1998. Changes in female cognitive performance after energetic drink consumption: a preliminary study. *Prog Neuropsychopharmacol Biol Psychiatry*, 22, 1035-1042.
- 25 Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M, 2003. Effects of caffeine on human health. *Food Addit Contam*, 20, 1-30.
- 26 Nehlig A, 2004. *Coffee, tea, chocolate, and the brain*. CRC Press, Boca Raton.
- 27 Pietta P and Pietta A, 1998. *Fitomedicine e Nutrienti*. GMR Press.
- 28 Smith A, 2002. Effects of caffeine on human behavior. *Food Chem Toxicol*, 40, 1243-1255.
- 29 Smith AP, 2005. Caffeine at work. *Hum Psychopharmacol*, 20, 441-445.
- 30 Steinmetz EF, 1957. *Codex Vegetabilis*. Litografia La Photograph, Padova.
- 31 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 32 van Wyk BE, 2005. *Handbuch der Nutzpflanzen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 33 Weckerle CS, Stutz MA, Baumann TW, 2003. Purine alkaloids in *Paullinia*. *Phytochemistry*, 64, 735-742.
- 34 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.

ID 2064: “Griffola fondosa (Common Name : Maitake)” and Immune health”

- 1 Bielenberg J, 1998. Die Süßholzwurzel. Wirkungen und Anwendungen unter dem Aspekt neuer pharmakologischer Erkenntnisse. *Z. Phytother.*, 19, 197-208.
- 2 Bielenberg J, 2001. Isoflavonoide als Mediatoren anti-inflammatorischer und antiallergischer Wirkungen der Süßholzwurzel. *Z. Phytother.*, 22, 289-293.
- 3 Brendler T, Gruenwald J, Jaenicke C, 2003. *Herbal Remedies: Heilpflanzen*. Medpharm Scientific Publishers, Stuttgart.
- 4 Gu CQ, Li J, Chao FH, 2006. Inhibition of hepatitis B virus by D-fraction from *Grifola frondosa*: synergistic effect of combination with interferon-alpha in HepG2 2.2.15. *Antiviral Res*, 72, 162-165.
- 5 Hobbs C, 1995. *Grifola frondosa* (Dicks. Fr.) S. F. Gray. In: *Medicinal Mushrooms - An exploration of tradition, healing & culture*. Botanica Press, Summertown, Tennessee, 110-115.

- 6 Kidd PM, 2000. The use of mushroom glucans and proteoglycans in cancer treatment. *Altern Med Rev*, 5, 4-27.
- 7 Klotter J, 2006. Immunostimulating effects of Maitake mushroom [beta]-glucan. *Townsend Letter for Doctors and Patients*, 275, 23.
- 8 Kodama N, Komuta K, Nanba H, 2002. Can maitake MD-fraction aid cancer patients? *Altern Med Rev*, 7, 236-239.
- 9 Kodama N, Kakuno T, Nanba H, 2003. Stimulation of the natural immune system in normal mice by polysaccharide from maitake mushroom. *Mycoscience*, 44, 257-261.
- 10 Kodama N, Komuta K, Nanba H, 2003. Effect of Maitake (*Grifola frondosa*) D-Fraction on the activation of NK cells in cancer patients. *J Med Food*, 6, 371-377.
- 11 Kodama N, Murata Y, Nanba H, 2004. Administration of a polysaccharide from *Grifola frondosa* stimulates immune function of normal mice. *J Med Food*, 7, 141-145.
- 12 Mayell M, 2001. Maitake extracts and their therapeutic potential. *Altern Med Rev*, 6, 48-60.
- 13 Murray MT, Maitake Gold 404 TM - the medicinal mushroom extract for cellular immune protection, http://www.doctormurray.com/media/system/NEW_PDF/Maitake%20for%20Immune%20Support.pdf.
- 14 Nie X, Shi B, Ding Y, Tao W, 2006. Preparation of a chemically sulfated polysaccharide derived from *Grifola frondosa* and its potential biological activities. *Int J Biol Macromol*, 39, 228-233.
- 15 Nono I, Ohno N, Ohsawa M, Oikawa S, Yadomae T, 1989. Modification of immunostimulating activities of grifolan by the treatment with (1----3)-beta-D-glucanase. *J Pharmacobiodyn*, 12, 671-680.
- 16 Skyie Lininger et al, 1998. Maitake (*Grifola frondosa*). In: *The Natural Pharmacy*. Prima Health, Roseville, CA, p. 288-289.
- 17 Vetvicka V and Vetvickova J, 2007. An Evaluation of the immunological activities of commercially available β 1, 3-glucans. *JANA*, 10, 25-31.
- 18 Wu MJ, Cheng TL, Cheng SY, Lian TW, Wang L, Chiou SY, 2006. Immunomodulatory properties of *Grifola frondosa* in submerged culture. *J Agric Food Chem*, 54, 2906-2914.

ID 2065: “GLA (example from *Borago Officinalis*, Primerose oil, Blackcurrant seed oil) and “Essential fatty acid of importance for a healthy skin”

- 1 Grattan C, Burton JL, Manku M, Stewart C, Horrobin DF, 1990. Essential-fatty-acid metabolites in plasma phospholipids in patients with ichthyosis vulgaris, acne vulgaris and psoriasis. *Clin Exp Dermatol*, 15, 174-176.
- 2 Horrobin DF, 1990. Post-viral fatigue syndrome, viral infections in atopic eczema, and essential fatty acids. *Med Hypotheses*, 32, 211-217.
- 3 Horrobin DF, 1993. Fatty acid metabolism in health and disease: the role of delta-6-desaturase. *Am J Clin Nutr*, 57, 732S-736S; discussion 736S-737S.
- 4 Lovell CR, Burton JL, Horrobin DF, 1981. Treatment of atopic eczema with evening primrose oil. *Lancet*, 1, 278.
- 5 Marshall RJ and Evans RW, 1990. Measurement of the Effects of Essential Fatty Acids on Human Skin Smoothness. In: *Omega-6 essential fatty acids: pathophysiology and roles in clinical medicine*. Horrobin DF (ed.) Wiley-Liss, New York, 81-98.
- 6 Morse PF, Horrobin DF, Manku MS, Stewart JC, Allen R, Littlewood S, Wright S, Burton J, Gould DJ, Holt PJ, et al., 1989. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response. *Br J Dermatol*, 121, 75-90.

- 7 van Gool CJ, Zeegers MP, Thijs C, 2004. Oral essential fatty acid supplementation in atopic dermatitis-a meta-analysis of placebo-controlled trials. *Br J Dermatol*, 150, 728-740.
- 8 Wright S and Burton JL, 1982. Oral evening-primrose-seed oil improves atopic eczema. *Lancet*, 2, 1120-1122.

ID 2068: “Hippophae rhamnoides (Common Name : Seabuckthorn)” and “Skin health”

- 1 Alicja Nocolak-Palczewska and Piotr Rykowski, 2003. Sea buckthorn *Hippophae rhamnoides* L. and its application in cosmetics. *Polish Journal of Cosmetology*, 35-43.
- 2 Erkkola R and Yang B, 2003. Sea buckthorn oils : Towards healthy mucous membranes. *AGROFood industry hi-tech*, 53-57.
- 3 Instytut Żywności i Żywienia (National Food and Nutrition Institute of Poland), 2007. Opinia Rokivium beauty skin formula. PD- 1801/osw/103/EM/07.
- 4 Yang B, Kalimo KO, Mattila LM, Kallio SE, Katajisto JK, Peltola OJ, Kallio HP, 1999. Effects of dietary supplementation with sea buckthorn (*Hippophae rhamnoides*) seed and pulp oils on atopic dermatitis. *J Nutr Biochem*, 10, 622-630.
- 5 Yang B, Kalimo KO, Tahvonen RL, Mattila LM, Katajisto JK, Kallio HP, 2000. Effect of dietary supplementation with sea buckthorn (*Hippophae rhamnoides*) seed and pulp oils on the fatty acid composition of skin glycerophospholipids of patients with atopic dermatitis. *J Nutr Biochem*, 11, 338-340.

ID 2069: “Illicium verum Hook. (Common name: Star anise)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, 1988. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 4 HealthCanada, 2006. *Monograph Hyssop*.
- 5 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.
- 6 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

ID 2070: “Ilex paraguariensis (Common Name : Yerba mate)” and “Weight management/Metabolism of lipids”

- 1 Andersen T and Fogh J, 2001. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. *J Hum Nutr Diet*, 14, 243-250.
- 2 Bisset NG and Wichtl M, 2001. *Herbal Drugs and Phytopharmaceuticals* Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 3 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 4 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.

- 5 Brendler T, Grünwald J, Jänicke C, 2003. Heilpflanzen - Herbal Remedies. CD-ROM. Medpharm Scientific Publishers, Boca Raton.
- 6 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 7 Cahier de l'Agence, 1998. Médicaments à base de plantes: Cahiers de l'Agence no 3. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 8 Dickel ML, Rates SM, Ritter MR, 2007. Plants popularly used for loosing weight purposes in Porto Alegre, South Brazil. J Ethnopharmacol, 109, 60-71.
- 9 Kilham C, 2005. Herbs to fight fat and diabetes. Functional Foods & Nutraceuticals, 26-28.
- 10 Knöss W and Haaf M, 2005. "Mate". Zeitschrift für Phytotherapie 26, 94-98.
- 11 Kovacs EM and Mela DJ, 2006. Metabolically active functional food ingredients for weight control. Obes Rev, 7, 59-78.
- 12 Lunceford N and Gugliucci A, 2005. Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea. Fitoterapia, 76, 419-427.
- 13 Martinet A, Hostettmann K, Schutz Y, 1999. Thermogenic effects of commercially available plant preparations aimed at treating human obesity. Phytomedicine, 6, 231-238.
- 14 Min B, McBride BF, Kardas MJ, Ismaili A, Sinha V, Kluger J, White CM, 2005. Electrocardiographic effects of an Ephedra-Free, multicomponent weight-loss supplement in healthy volunteers. Pharmacotherapy, 25, 654-659.
- 15 Pittler MH, Schmidt K, Ernst E, 2005. Adverse events of herbal food supplements for body weight reduction: systematic review. Obesity Reviews, 6, 93-111.
- 16 Schneider E, Scherer RA, Janssens MJJ, 2006. Argentinischer Mate-Tee: Verwendung--Verarbeitung--Geschmacksprofil. Deutsche Lebensmittel Rundschau, 102, 313-318.
- 17 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 18 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2073: “Illicium verum (Common Name : Star anise)” and “Respiratory health”

- 1 Hagers Handbuch der Drogen und Arzneistoffe. 2005. Springer Verlag GmbH & Co., Heidelberg.
- 2 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 3 Blumenthal M, 1988. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 4 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 5 Brendler T, Grünwald J, Jänicke C, 2003. Heilpflanzen - Herbal Remedies. CD-ROM. Medpharm Scientific Publishers, Boca Raton.
- 6 Foster S and Leung AY, 1996. Encyclopedia of common natural ingredients used in food, drug and cosmetics. Wiley-Interscience, New York.
- 7 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 8 Hoppe HA, 1975. Drogenkunde. Walter de Gruyter & Co, Berlin.

- 9 Kooperation Phytopharmaka, 1990-1995. Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten). BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 10 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 11 Steinmetz EF, 1957. Codex Vegetabilis. Litografia La Photograph, Padova.
- 12 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.
- 13 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 14 Wichtl M, 2004. Herbal Drugs and Phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart.
- 15 Yelne MB, Sharma PC, Dennis TJ, 2001. Database on Medicinal Plants Used in Ayurveda Central Council for Research in Ayurveda & Siddha.

ID 2075: “Lentinus edodes (Common Name : Shiitake)” and “Immune health”

- 1 Flynn V, 2001. Is the Shiitake mushroom an aphrodisiac and a cause of longevity? In: Science and cultivation of edible funghi. Maher, Rotterdam, 52.
- 2 Gerber, 1994. Dry extract of shii-ta-ke, immune system activator and general health agent. Cahiers de Biotherapies, 130, 83-89.
- 3 Gordon M, Bihari B, Goosby E, Gorter R, Greco M, Guralnik M, Mimura T, Rudinicki V, Wong R, Kaneko Y, 1998. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J Med, 29, 305-330.
- 4 Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K, 1999. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int J Immunopharmacol, 21, 531-540.
- 5 Hamuro J, Rollinghoff M, Wagner H, 1980. Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the beta(1 leads to 3) glucan-type lentinan and its analogues. Immunology, 39, 551-559.
- 6 Hanaue H, Tokuda Y, Machimura T, Kamijoh A, Kondo Y, Ogoshi K, Makuuchi H, Nakasaki H, Tajima T, Mitomi T, et al., 1989. Effects of oral lentinan on T-cell subsets in peripheral venous blood. Clin Ther, 11, 614-622.
- 7 Hobbs C, 1995. Lentinula edodes Shiitake. In: Medicinal Mushrooms: An Exploration of Tradition, Healing & Culture Hobbs C (ed.) Culinary Arts Ltd, Portland, 125-136.
- 8 Ladanyi A, Timar J, Lapis K, 1993. Effect of lentinan on macrophage cytotoxicity against metastatic tumor cells. Cancer Immunol Immunother, 36, 123-126.
- 9 Lee WH and Friedrich JA, 1997. Shiitake: the forest mushroom. In: Medicinal Benefits of Mushrooms: Healing for More Than 20 Centuries - their Effects on Cancer, Diabetes, Heart Disease and More. Lee WH and Friedrich JA (eds.). Keats Publishing, New Canaan, 29-32.
- 10 Lininger SW and Wright JV, 1998. Shiitake (Lentinan edodes). In: The natural pharmacy. Lininger SW and Wright JV (eds.). Prima Pub, Rocklin, 310-311.
- 11 Liu M, Li J, Kong F, Lin J, Gao Y, 1998. Induction of immunomodulating cytokines by a new polysaccharide-peptide complex from culture mycelia of Lentinus edodes. Immunopharmacology, 40, 187-198.
- 12 Matsuoka H, Seo Y, Wakasugi H, Saito T, Tomoda H, 1997. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res, 17, 2751-2755.

- 13 Miyaji CK, Poersch A, Ribeiro LR, Eira AF, Colus IM, 2006. Shiitake (*Lentinula edodes* (Berkeley) Pegler) extracts as a modulator of micronuclei induced in HEP-2 cells. *Toxicol In Vitro*, 20, 1555-1559.
- 14 Nakamura T, 1992. Shiitake (*Lentinus edodes*) dermatitis. *Contact Dermatitis*, 27, 65-70.
- 15 Ng ML and Yap AT, 2002. Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (*Lentinus edodes*). *J Altern Complement Med*, 8, 581-589.
- 16 Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K, 2006. [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. *Gan To Kagaku Ryoho*, 33 Suppl 1, 106-109.
- 17 Shida M and Uchida T, et al 1978. A (1/α3)-alpha-glucan isolated from the fruit bodies of *Lentinus edodes*. *Carbohydrate Research*, 60, 117-127.
- 18 Sia GM and Candlish JK, 1999. Effects of shiitake (*Lentinus edodes*) extract on human neutrophils and the U937 monocytic cell line. *Phytother Res*, 13, 133-137.
- 19 Soo D, The potential of funghi used in traditional chinese medicine: shiitake (*Lentinula edodes*), http://www.world-of-fungi.org/Mostly_Medical/Dawn_Soo/Dawn_Soo_SSM.htm.
- 20 Surenjav U and Zhang L, et al, 2006. Effects of molecular structure on antitumor activities of (1-3)-beta-D-glucans from different *Lentinus edodes*. *Carbohydrate Polymers*, 63, 97-104.
- 21 Suzuki F, Suzuki C, Shimomura E, Maeda H, Fujii T, Ishida N, 1979. Antiviral and interferon-inducing activities of a new peptidomannan, KS-2, extracted from culture mycelia of *Lentinus edodes*. *J Antibiot (Tokyo)*, 32, 1336-1345.
- 22 Suzuki M, Takatsuki F, Maeda YY, Hamuro J, Chihara G, 1994. Antitumor and immunological activity of lentinan in comparison with LPS. *Int J Immunopharmacol*, 16, 463-468.
- 23 Tani M, Tanimura H, Yamaue H, Tsunoda T, Iwahashi M, Noguchi K, Tamai M, Hotta T, Mizobata S, 1993. Augmentation of lymphokine-activated killer cell activity by lentinan. *Anticancer Res*, 13, 1773-1776.
- 24 Watanabe A, Kobayashi M, Hayashi S, Kodama D, Isoda K, Kondoh M, Kawase M, Tamesada M, Yagi K, 2006. Protection against D-galactosamine-induced acute liver injury by oral administration of extracts from *Lentinus edodes* mycelia. *Biol Pharm Bull*, 29, 1651-1654.
- 25 Yin G, Yu J, Li D, 1998. [Immune modulatory and therapeutic effect of lentinan on condyloma acuminatum]. *Zhongguo Zhong Xi Yi Jie He Za Zhi*, 18, 665-667.
- 26 Zheng R, Jie S, Hanchuan D, Moucheng W, 2005. Characterization and immunomodulating activities of polysaccharide from *Lentinus edodes*. *Int Immunopharmacol*, 5, 811-820.

ID 2076: “*Linum usitatissimum* (Common Name : flaxseed linseed)” and “Gut health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 3 Cahier de l'Agence, 1998. *Médicaments à base de plantes: Cahiers de l'Agence no 3*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Committee on Herbal Medicinal Products (HMPC) - Community Monographs, 2006. *Assessment report on Linum usitatissimum L.*
- 5 Dahl WJ, Lockert EA, Cammer AL, Whiting SJ, 2005. Effects of flax fiber on laxation and glycemic response in healthy volunteers. *J Med Food*, 8, 508-511.
- 6 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.

- 7 Hellemont J, 1988. *Fytotherapeutisch compendium*. Bohn, Scheltema & Holkema, Utrecht, the Netherlands.
- 8 Kritchevsky D, 1988. Dietary fiber. *Annu Rev Nutr*, 8, 301-328.
- 9 Schneemann BO and Tietyen J, 1994. Dietary Fiber. In: *Modern Nutrition in Health and Disease*. Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ (eds.). Lippincott Williams and Wilkins, Philadelphia 89-100.
- 10 Wichtl M and Anton R, 1999. *Plantes thérapeutiques : tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2080: “Lutein (example from tagetes E or Calendula Officinalis)” and “Antioxidant properties”

- 1 Aleman TS, Cideciyan AV, Windsor EA, Schwartz SB, Swider M, Chico JD, Sumaroka A, Pantelyat AY, Duncan KG, Gardner LM, Emmons JM, Steinberg JD, Stone EM, Jacobson SG, 2007. Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations. *Invest Ophthalmol Vis Sci*, 48, 1319-1329.
- 2 Bahrami H, Melia M, Dagnelie G, 2006. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. *BMC Ophthalmol*, 6, 23.
- 3 Coleman H and Chew E, 2007. Nutritional supplementation in age-related macular degeneration. *Curr Opin Ophthalmol*, 18, 220-223.
- 4 Dwyer JH, Navab M, Dwyer KM, Hassan K, Sun P, Shircore A, Hama-Levy S, Hough G, Wang X, Drake T, Merz CN, Fogelman AM, 2001. Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. *Circulation*, 103, 2922-2927.
- 5 Khachik F, Beecher GR, Smith JC, Jr., 1995. Lutein, lycopene, and their oxidative metabolites in chemoprevention of cancer. *J Cell Biochem Suppl*, 22, 236-246.
- 6 Kvangsakul J, Rodriguez-Carmona M, Edgar DF, Barker FM, Kopcke W, Schalch W, Barbur JL, 2006. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. *Ophthalmic Physiol Opt*, 26, 362-371.
- 7 Martin KR, Failla ML, Smith JC, Jr., 1996. Beta-carotene and lutein protect HepG2 human liver cells against oxidant-induced damage. *J Nutr*, 126, 2098-2106.
- 8 Shils ME, Shike M, Ross AC, Caballero B, Cousins R, 2006. *Modern Nutrition in Health and Disease*. Lippincott Williams & Wilkins, Baltimore, Philadelphia.
- 9 Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, Fobker M, Pauleikhoff D, 2007. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. *Exp Eye Res*, 84, 718-728.
- 10 Yeum KJ, Aldini G, Chung HY, Krinsky NI, Russell RM, 2003. The activities of antioxidant nutrients in human plasma depend on the localization of attacking radical species. *J Nutr*, 133, 2688-2691.

ID 2081: “Lycopene (from Tomato extract)” and “Antioxidant properties”

- 1 Agarwal S and Rao AV, 1998. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. *Lipids*, 33, 981-984.
- 2 Banhegyi G, 2005. [Lycopene--a natural antioxidant]. *Orv Hetil*, 146, 1621-1624.
- 3 Basu A and Imrhan V, 2007. Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. *Eur J Clin Nutr*, 61, 295-303.
- 4 Bilton R, Gerber M, Grolier P, Leoni C, 2001. *The White Book on Antioxidants in Tomatoes and Tomato Products and Their Health Benefits*. Tomato News/CMITI Sarl.

- 5 Blum A, Monir M, Wirsansky I, Ben-Arzi S, 2005. The beneficial effects of tomatoes. *Eur J Intern Med*, 16, 402-404.
- 6 Bruneton J, 1993. *Pharmacognosy, phytochemistry, medicinal plants*. Lavoisier, Paris.
- 7 Clinton SK, 1998. Lycopene: chemistry, biology, and implications for human health and disease. *Nutr Rev*, 56, 35-51.
- 8 Clinton SK, 2005. Tomatoes or lycopene: a role in prostate carcinogenesis? *J Nutr*, 135, 2057S-2059S.
- 9 Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA, 2004. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. *BJU Int*, 93, 1139-1150.
- 10 D'Odorico A, Martines D, Kiechl S, Egger G, Oberhollenzer F, Bonvicini P, Sturniolo GC, Naccarato R, Willett J, 2000. High plasma levels of alpha- and beta-carotene are associated with a lower risk of atherosclerosis: results from the Bruneck study. *Atherosclerosis*, 153, 231-239.
- 11 Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, 1995. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst*, 87, 1767-1776.
- 12 Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC, 2002. A prospective study of tomato products, lycopene, and prostate cancer risk. *J Natl Cancer Inst*, 94, 391-398.
- 13 Gomez-Aracena J, Sloots L, Garcia Rodriguez A, Van't Veer P, Gómez-Gracia E, García-Alcántara Á, Martín-Moreno JM, Kok F, Fernández-Crehuet Navajas J, 1997. Antioxidants in adipose tissue and myocardial infarction in a Mediterranean area. The Euramic study in Malaga. *Nutr Metab Cardiovasc Disease* 7, 376-382.
- 14 Iribarren C, Folsom AR, Jacobs JDR, Gross MD, Belcher JD, Eckfeldt JH, 1997. Association of Serum Vitamin Levels, LDL Susceptibility to Oxidation, and Autoantibodies Against MDA-LDL With Carotid Atherosclerosis A Case-Control Study. *Arteriosclerosis, thrombosis, and vascular biology*, 17, 1171-1177.
- 15 Klipstein-Grobusch K, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JCM, 2000. Serum carotenoids and atherosclerosis The Rotterdam Study. *Atherosclerosis*, 148, 49-56.
- 16 Kohlmeier L, Kark JD, Gomez-Gracia E, Martin BC, Steck SE, Kardinaal AF, Ringstad J, Thamm M, Masaev V, Riemersma R, Martin-Moreno JM, Huttunen JK, Kok FJ, 1997. Lycopene and myocardial infarction risk in the EURAMIC Study. *Am J Epidemiol*, 146, 618-626.
- 17 Kristenson M, Zieden B, Kucinskiene Z, Elinder LS, Bergdahl B, Elwing B, Abaravicius A, Razinkoviene L, Calkauskas H, Olsson AG, 1997. Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: concomitant cross sectional study of men aged 50. *BMJ*, 314, 629-633.
- 18 Lecerf JM, 2006. Tomate, lycopène et prévention cardiovasculaire. *Phytothérapie*, 4.
- 19 Lycopene. Monograph, 2003. *Altern Med Rev*, 8, 336-342.
- 20 Paetau I, Khachik F, Brown ED, Beecher GR, Kramer TR, Chittams J, Clevidence BA, 1998. Chronic ingestion of lycopene-rich tomato juice or lycopene supplements significantly increases plasma concentrations of lycopene and related tomato carotenoids in humans. *Am J Clin Nutr*, 68, 1187-1195.
- 21 Rissanen T, Voutilainen S, Nyyssonen K, Salonen R, Salonen JT, 2000. Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 20, 2677-2681.
- 22 Rissanen TH, Voutilainen S, Nyyssonen K, Salonen R, Kaplan GA, Salonen JT, 2003. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. *American Journal of Clinical Nutrition*, 77, 133.
- 23 Rissanen TH, Voutilainen S, Nyyssonen K, Lakka TA, Sivenius J, Salonen R, Kaplan GA, Salonen JT, 2007. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. *British Journal of Nutrition*, 85, 749-754.

- 24 Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H, 1997. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. *J Neurol Sci*, 152, 15-21.
- 25 Street DA, Comstock GW, Salkeld RM, Schuep W, Klag MJ, 1994. Serum antioxidants and myocardial infarction. Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? *Circulation*, 90, 1154-1161.
- 26 Tyssandier V, Feillet-Coudray C, Caris-Veyrat C, Guillard JC, Coudray C, Bureau S, Reich M, Amiot-Carlin MJ, Bouteloup-Demange C, Boirie Y, Borel P, 2004. Effect of tomato product consumption on the plasma status of antioxidant microconstituents and on the plasma total antioxidant capacity in healthy subjects. *J Am Coll Nutr*, 23, 148-156.
- 27 Van den Berg H, 1999. Carotenoid interactions. *Nutrition reviews*, 57, 1-10.
- 28 Visioli F, Riso P, Grande S, Galli C, Porrini M, 2003. Protective activity of tomato products on in vivo markers of lipid oxidation. *Eur J Nutr*, 42, 201-206.

ID 2082: “Lycopene (from Tomato extract)” and “Antioxidant properties / protection of DNA”

- 1 Agarwal S and Rao AV, 2000. Tomato lycopene and its role in human health and chronic diseases. *CMAJ*, 163, 739-744.
- 2 Astley SB and Elliott RM, 2005. How strong is the evidence that lycopene supplementation can modify biomarkers of oxidative damage and DNA repair in human lymphocytes? *J Nutr*, 135, 2071S-2073S.
- 3 Banhegyi G, 2005. [Lycopene--a natural antioxidant]. *Orv Hetil*, 146, 1621-1624.
- 4 Basu A and Imrhan V, 2007. Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. *Eur J Clin Nutr*, 61, 295-303.
- 5 Böhm V, Fröhlich K, Laske G, Hohbein J, 2006. Intestinal absorption of lycopene from different foods.
- 6 Davis CD, Swanson CA, Ziegler RG, Clevidence B, Dwyer JT, Milner JA, 2005. Executive summary report. *J Nutr*, 135, 2014S-2029S.
- 7 Gerster H, 1997. The potential role of lycopene for human health. *J Am Coll Nutr*, 16, 109-126.
- 8 Gruenwald J, 2003. Lycopene. The modern answer to urban wellness. *Nutra foods*, 2, 21-36.
- 9 Hadley CW, Clinton SK, Schwartz SJ, 2003. The consumption of processed tomato products enhances plasma lycopene concentrations in association with a reduced lipoprotein sensitivity to oxidative damage. *J Nutr*, 133, 727-732.
- 10 Hartal D and Danzig L, 2003. Tomato extract: A functional ingredient with health benefits. *Agro Food Industry Hi Tech*, 14, 18-24.
- 11 Heber D and Lu QY, 2002. Overview of mechanisms of action of lycopene. *Exp Biol Med (Maywood)*, 227, 920-923.
- 12 Klebanov GI, Kapitanov AB, Teselkin Yu O, Babenkova IV, Zhambalova BA, Lyubitsky OB, Nesterova OA, Vasil'eva OV, Popov IN, Lewin G, Vladimirov Yu A, 1998. The antioxidant properties of lycopene. *Membr Cell Biol*, 12, 287-300.
- 13 Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y, 1995. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. *Nutr Cancer*, 24, 257-266.
- 14 Levy J and Sharoni Y, 2004. The Functions of Tomato Lycopene and Its Role in Human Health. *The journal of the American Botanical Council*, 49-56.
- 15 Lugasi A, Hovari J, Biro L, Brandt S, Helyes L, 2004. [Factors influencing lycopene content of foods, and lycopene intake of Hungarian population]. *Magy Onkol*, 48, 131-136.

- 16 Matos HR, Marques SA, Gomes OF, Silva AA, Heimann JC, Di Mascio P, Medeiros MH, 2006. Lycopene and beta-carotene protect in vivo iron-induced oxidative stress damage in rat prostate. *Braz J Med Biol Res*, 39, 203-210.
- 17 Pool-Zobel BL, Bub A, Muller H, Wollowski I, Rechkemmer G, 1997. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. *Carcinogenesis*, 18, 1847-1850.
- 18 Porrini M, Riso P, Brusamolino A, Berti C, Guarnieri S, Visioli F, 2005. Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. *Br J Nutr*, 93, 93-99.
- 19 Rao AV and Agarwal S, 1998. Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. *Nutr Cancer*, 31, 199-203.
- 20 Rao AV and Agarwal S, 2000. Role of antioxidant lycopene in cancer and heart disease. *J Am Coll Nutr*, 19, 563-569.
- 21 Rao AV and Shen H, 2002. Effect of low dose lycopene intake on lycopene bioavailability and oxidative stress. *Nutrition Research*, 22, 1125-1131.
- 22 Rao LG, Guns E, Rao AV, 2003. Lycopene: its role in human health and disease. *Agro Food*, 7, 25-30.
- 23 The George Mateljan Foundation, Tomatoes, <http://whfoods.org/genpage.php?tname=foodspice&dbid=44>.
- 24 Tyssandier V, Feillet-Coudray C, Caris-Veyrat C, Guillard JC, Coudray C, Bureau S, Reich M, Amiot-Carlin MJ, Bouteloup-Demange C, Boirie Y, Borel P, 2004. Effect of tomato product consumption on the plasma status of antioxidant microconstituents and on the plasma total antioxidant capacity in healthy subjects. *J Am Coll Nutr*, 23, 148-156.
- 25 Visioli F, Riso P, Grande S, Galli C, Porrini M, 2003. Protective activity of tomato products on in vivo markers of lipid oxidation. *Eur J Nutr*, 42, 201-206.
- 26 Weisburger JH, 1998. Evaluation of the evidence on the role of tomato products in disease prevention. *Proc Soc Exp Biol Med*, 218, 140-143.
- 27 Zhao X, Aldini G, Johnson EJ, Rasmussen H, Kraemer K, Woolf H, Musaeus N, Krinsky NI, Russell RM, Yeum KJ, 2006. Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. *Am J Clin Nutr*, 83, 163-169.

ID 2083: “Lycium Barbarum (Common Name: Wolfberry)” and “Antioxidant properties”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. HagerROM 2004. *Hagers Handbuch der Drogen und Arzneistoffe*. Springer Verlag, Heidelberg.
- 2 Focks C and Bäcker M, 2006. *Leitfaden Chinesische Medizin*. Elsevier GmbH, Munchen.
- 3 Huang Y, Tan A, Shen Y, Lu J, 1998. [Scavenging effect of total flavonoids of lycium barbarum L on active oxygen radicals and inhibitory effects on heat output from L1210 cells]. *Wei Sheng Yan Jiu*, 27, 109-111, 115.
- 4 Huang Y, Lu J, Shen Y, 1999. [The protective effects of total flavonoids from Lycium Barbarum L. on lipid peroxidation of liver mitochondria and red blood cell in rats]. *Wei Sheng Yan Jiu*, 28, 115-116.
- 5 Huang LJ, Tian GY, Wang ZF, Dong JB, Wu MP, 2001. [Studies on the glycoconjugates and glycans from Lycium barbarum L in inhibiting low density lipoprotein (LDL) peroxidation]. *Yao Xue Xue Bao*, 36, 108-111.
- 6 Huang X, Yang M, Wu X, Yan J, 2003. [Study on protective action of lycium barbarum polysaccharides on DNA imparments of testicle cells in mice]. *Wei Sheng Yan Jiu*, 32, 599-601.
- 7 Li G, Yang J, Ren B, Wang Z, 2002. [Effect of lycium barbarum L on defending free radicals of mice caused by hypoxia]. *Wei Sheng Yan Jiu*, 31, 30-31.

- 8 Luo Q, Cai Y, Yan J, Sun M, Corke H, 2004. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from *Lycium barbarum*. *Life Sci*, 76, 137-149.
- 9 Luo Q, Li Z, Huang X, Yan J, Zhang S, Cai YZ, 2006. *Lycium barbarum* polysaccharides: Protective effects against heat-induced damage of rat testes and H₂O₂-induced DNA damage in mouse testicular cells and beneficial effect on sexual behavior and reproductive function of hemicastrated rats. *Life Sci*, 79, 613-621.
- 10 Ni H, Qing D, Kaisa S, Lu J, 2004. The study on the effect of LBP on cleaning hydroxygen free radical by EPR technique. *Journal of Chinese medicinal materials (Zhong yao cai)*, 27, 599.
- 11 Reid DP and Chou D, 1995. *A handbook of Chinese healing herbs*. Simon & Schuster, New York.
- 12 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 13 van Wyk BE, 2005. *Handbuch der Nutzpflanzen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 14 Wu SJ, Ng LT, Lin CC, 2004. Antioxidant activities of some common ingredients of traditional chinese medicine, *Angelica sinensis*, *Lycium barbarum* and *Poria cocos*. *Phytother Res*, 18, 1008-1012.
- 15 Wu H, Guo H, Zhao R, 2006. Effect of *Lycium barbarum* polysaccharide on the improvement of antioxidant ability and DNA damage in NIDDM rats. *Yakugaku Zasshi*, 126, 365-371.
- 16 Young G, Schreuder M, Lawrence RP, 2005. *Discovery of the Ultimate Superfood: How the Ningxia Wolfberry And 4 Other Foods Help Combat Heart Disease, Cancer, Chronic Fatigue, Depression, Diabetes And More;*. Life Sciences Pr.
- 17 Yu MS, Ho YS, So KF, Yuen WH, Chang RC, 2006. Cytoprotective effects of *Lycium barbarum* against reducing stress on endoplasmic reticulum. *Int J Mol Med*, 17, 1157-1161.
- 18 Zhang X, 1993. [Experimental research on the role of *Lycium barbarum* polysaccharide in anti-peroxidation]. *Zhongguo Zhong Yao Za Zhi*, 18, 110-112, 128.

ID 2087: “*Melissa officinalis* (Common Name : Lemon Balm)” and “Antioxidant properties”

- 1 Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M, 2003. *Melissa officinalis* extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. *Journal of Neurology Neurosurgery and Psychiatry*, 74, 863-866.
- 2 Allahverdiyev A, Duran N, Ozguven M, Koltas S, 2004. Antiviral activity of the volatile oils of *Melissa officinalis* L. against Herpes simplex virus type-2. *Phytomedicine*, 11, 657-661.
- 3 Ballard CG, O'Brien JT, Reichelt K, Perry EK, 2002. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: The results of a double-blind, placebo-controlled trial with *Melissa*. *Journal of Clinical Psychiatry*, 63, 553-558.
- 4 BHMA (British Herbal Medicine Association), 1983. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 5 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. *HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe*. Springer Verlag, Heidelberg.
- 6 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 7 Bolkent S, Yanardag R, Karabulut-Bulan O, Yesilyaprak B, 2005. Protective role of *Melissa officinalis* L. extract on liver of hyperlipidemic rats: A morphological and biochemical study. *Journal of Ethnopharmacology*, 99, 391-398.
- 8 Cerny A and Schmid K, 1999. Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study). *Fitoterapia*, 70, 221-228.
- 9 CKF (Commissie Keuring Fytoproducten), 2006. Master file *Melissae Folium*.
- 10 EMEA (The European Agency for the Evaluation of Medicinal Products), 2003. Working Party on Herbal Medicinal Products. Draft proposal for a core data for *Melissa* leaf. . EMEA/HMPWP/344/03.

- 11 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 12 European Council, 2005. Monograph Melissa leaf In: European Pharmacopoeia 5.0.
- 13 Ferreira A, Proenca C, Serralheiro MLM, Araujo MEM, 2006. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. *Journal of Ethnopharmacology*, 108, 31-37.
- 14 Gao LP, Wei HL, Zhao HS, Xiao SY, Zheng RL, 2005. Antiapoptotic and antioxidant effects of rosmarinic acid in astrocytes. *Pharmazie*, 60, 62-65.
- 15 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 16 Heilerova L, Buckova M, Tarapcik P, Silhar S, Labuda J, 2003. Comparison of Antioxidative Activity Data for Aqueous Extracts of Lemon Balm (*Melissa officinalis* L.), Oregano (*Origanum vulgare* L.), Thyme (*Thymus vulgaris* L.), and Agrimony (*Agrimonia eupatoria* L.) obtained by Conventional Methods and the DNA-Based Biosensor. *Czech J. Food Sci.*, 21, 78-84.
- 17 Hoppe HA, 1975. *Drogenkunde*. Ealter de Gruyter & Co, Berlin.
- 18 Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA, 2002. Modulation of mood and cognitive performance following acute administration of *Melissa officinalis* (lemon balm). *Pharmacology Biochemistry and Behavior*, 72, 953-964.
- 19 Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK, Wesnes KA, Scholey AB, 2003. Modulation of mood and cognitive performance following acute administration of single doses of *Melissa officinalis* (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. *Neuropsychopharmacology*, 28, 1871-1881.
- 20 Kennedy DO, Little W, Scholey AB, 2004. Attenuation of laboratory-induced stress in humans after acute administration of *Melissa officinalis* (lemon balm). *Psychosomatic Medicine*, 66, 607-613.
- 21 Kennedy DO, Little W, Haskell CF, Scholey AB, 2006. Anxiolytic effects of a combination of *Melissa officinalis* and *Valeriana officinalis* during laboratory induced stress. *Phytotherapy Research*, 20, 96-102.
- 22 Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J, 2004. Treatment of functional dyspepsia with a herbal preparation - A double-blind, randomized, placebo-controlled, multicenter trial. *Digestion*, 69, 45-52.
- 23 Muller SF and Klement S, 2006. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. *Phytomedicine*, 13, 383-387.
- 24 Qiao SL, Li WH, Tsubouchi R, Haneda M, Murakami K, Takeuchi F, Nisimoto Y, Yoshino M, 2005. Rosmarinic acid inhibits the formation of reactive oxygen and nitrogen species in RAW264.7 macrophages. *Free Radical Research*, 39, 995-1003.
- 25 Sadraei H, Ghannadi A, Malekshahi K, 2003. Relaxant effect of essential oil of *Melissa officinalis* and citral on rat ileum contractions. *Fitoterapia*, 74, 445-452.
- 26 Savino F, Cresi F, Castagno E, Silvestro L, Oggero R, 2005. A randomized double-blind placebo-controlled trial of a standardized extract of *Matricariae recutita*, *Foeniculum vulgare* and *Melissa officinalis* (ColiMil (R)) in the treatment of breastfed colicky infants. *Phytotherapy Research*, 19, 335-340.
- 27 Schemann M, Michel K, Zeller F, Hohenester B, Ruhl A, 2006. Region-specific effects of STW 5 (Iberogast (R)) and its components in gastric fundus, corpus and antrum. *Phytomedicine*, 13, 90-99.
- 28 Sibaevev A, Yuece B, Kelber O, Weiser D, Schirra J, Goeke B, Allescher HD, Storr M, 2006. STW 5 (Iberogast (R)) and its individual herbal components modulate intestinal electrophysiology of mice. *Phytomedicine*, 13, 80-89.
- 29 SMC (Swedish Medical Centre), 2006. *Herbs&Supplements: Lemon Balm, Melissa officinalis*
- 30 Steinmetz EF, 1957. *Codex Vegetabilis*. Litografia La Photograph, Padova.
- 31 Triantaphyllou K, Blekas G, Boskou D, 2001. Antioxidant properties of water extracts obtained from herbs of the species Lamiaceae. *International Journal of Food Sciences and Nutrition*, 52, 313-317.

- 32 UMM (University of Maryland Medical Centre), Lemon Balm <http://www.umm.edu/altmed/articles/lemon-balm-000261.htm>.
- 33 Werner RB, Goldberg A, Gruenwaid J, Hall T, Klein S, Translator P, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. The Journal of Alternative and Complementary Medicine, 4, 479-486.
- 34 Wheatley D, 2005. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. Journal of Psychopharmacology, 19, 414-421.
- 35 WHO (World Health Organization), 2002. Folium Melissa. In: WHO monographs on selected medicinal plants. WHO, Geneva.

ID 2090: “Matricaria recutita (Common Name : Chamomile” and “Antioxidant properties”

- 1 Avallone R, Zanolini P, Puia G, Kleinschnitz M, Schreier P, Baraldi M, 2000. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochem Pharmacol, 59, 1387-1394.
- 2 Bisset N and Wichtl M, 2001. Herbal Drugs and Phytopharmaceuticals Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 3 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.
- 4 Brendler T, Grünwald J, Jänicke C, 2003. Heilpflanzen - Herbal Remedies. CD-ROM. Medpharm Scientific Publishers, Boca Raton.
- 5 Campanini E, 2004. Dizionario di fitoterapia e piante medicinali. Tecniche nuove, Milano.
- 6 Pietta P and Pietta A, 1998. Fitomedicine e nutrienti. Giuseppe M. Riciutto Editore, Bussolengo (VR).

ID 2091: “Momordica charantia (Common Name : balsam pear, bitter melon, bitter gourd, ampalaya, karela (karola), fu kwa)” and “Glucose metabolism”

- 1 Albert-Puleo M, 1980. Fennel and anise as estrogenic agents. J Ethnopharmacol, 2, 337-344.
- 2 BHMA (British Herbal Medicine Association), 2006. British Herbal Compendium. British Herbal Medicine Association, Exeter.
- 3 Billore KV, Yelne MB, Dennis TJ, Chaudhari BG, 2005. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 4 Devi K, Vanithakumari G, Anusya S, Mekala N, Malini T, Elango V, 1985. Effect of Foeniculum vulgare seed extract on mammary glands and oviducts of ovariectomised rats. Ancient Science of Life, 5, 129-132.
- 5 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 6 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 7 Malini T, Vanithakumari G, Megala N, Anusya S, Devi K, Elango V, 1985. Effect of Foeniculum vulgare Mill. seed extract on the genital organs of male and female rats. Indian J Physiol Pharmacol, 29, 21-26.
- 8 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 9 Sitaram B, 2006. Bhavaprakasa of Bhavamisra : Original Text Along With Commentary and Translation : Including Nighantu Portion. Chaukhambha Orientalia, Varanasi, India.

ID 2095: “Mung bean (*Vigna Radiata*)” and “Menopause”

- 1 Albertazzi P and Purdie D, 2002. The nature and utility of the phytoestrogens: a review of the evidence. *Maturitas*, 42, 173-185.
- 2 Alexandersen P, Haarbo J, Breinholt V, Christiansen C, 2001. Dietary phytoestrogens and estrogen inhibit experimental atherosclerosis. *Climacteric*, 4, 151-159.
- 3 Azcoitia I, Moreno A, Carrero P, Palacios S, Garcia-Segura LM, 2006. Neuroprotective effects of soy phytoestrogens in the rat brain. *Gynecol Endocrinol*, 22, 63-69.
- 4 Beck V, Unterrieder E, Krenn L, Kubelka W, Jungbauer A, 2003. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. *J Steroid Biochem Mol Biol*, 84, 259-268.
- 5 Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A, 1998. Phyto-oestrogens: where are we now? *Br J Nutr*, 79, 393-406.
- 6 BMS (British Menopause Society), Fact Sheet: Alternative & Complementary Therapies, <http://www.thebms.org.uk/factdetail.php?id=3>.
- 7 Boue SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA, Cleveland TE, 2003. Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. *J Agric Food Chem*, 51, 2193-2199.
- 8 Brooks JD, Ward WE, Lewis JE, Hilditch J, Nickell L, Wong E, Thompson LU, 2004. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. *Am J Clin Nutr*, 79, 318-325.
- 9 Cassidy A and Griffin B, 1999. Phyto-oestrogens: a potential role in the prevention of CHD? *Proc Nutr Soc*, 58, 193-199.
- 10 Cassidy A and Faughnan M, 2000. Phyto-oestrogens through the life cycle. *Proc Nutr Soc*, 59, 489-496.
- 11 Cassidy A, Albertazzi P, Lise Nielsen I, Hall W, Williamson G, Tetens I, Atkins S, Cross H, Manios Y, Wolk A, Steiner C, Branca F, 2006. Critical review of health effects of soyabean phyto-oestrogens in postmenopausal women. *Proc Nutr Soc*, 65, 76-92.
- 12 Champ MM, 2002. Non-nutrient bioactive substances of pulses. *Br J Nutr*, 88 Suppl 3, S307-319.
- 13 D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A, Squadrito F, 2005. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. *Acta Obstet Gynecol Scand*, 84, 474-477.
- 14 Guthrie JR, Ball M, Murkies A, Dennerstein L, 2000. Dietary phytoestrogen intake in mid-life Australian-born women: relationship to health variables. *Climacteric*, 3, 254-261.
- 15 Haines C, James A, Sahota D, Chen ZY, Panesar N, Tomlinson B, Chow L, Benzie I, Husband A, 2006. Comparison between phytoestrogens and estradiol in the prevention of atheroma in ovariectomized cholesterol-fed rabbits. *Climacteric*, 9, 430-436.
- 16 Hallmans G, Zhang JX, Lundin E, Stattin P, Johansson A, Johansson I, Hulten K, Winkvist A, Aman P, Lenner P, Adlercreutz H, 2003. Rye, lignans and human health. *Proc Nutr Soc*, 62, 193-199.
- 17 Huang Y-W, Phillips J, Hunter L, 2007. Human Exposure to medicinal, dietary, and environmental estrogens. *Toxicological & Environmental Chemistry*, 89 (1), 141-160.
- 18 Jacobs MN and Lewis DF, 2002. Steroid hormone receptors and dietary ligands: a selected review. *Proc Nutr Soc*, 61, 105-122.
- 19 Kotsopoulos D, Dalais FS, Liang YL, McGrath BP, Teede HJ, 2000. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. *Climacteric*, 3, 161-167.
- 20 Kronenberg F and Fugh-Berman A, 2002. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. *Ann Intern Med*, 137, 805-813.

- 21 Kurzer MS, 2003. Phytoestrogen supplement use by women. *J Nutr*, 133, 1983S-1986S.
- 22 Li M, Poon P, Woo J, 2004. A pilot study of phytoestrogen content of soy foods and traditional Chinese medicines for women's health in Hong Kong. *Int J Food Sci Nutr*, 55, 201-205.
- 23 Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL, 2001. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. *J Agric Food Chem*, 49, 2472-2479.
- 24 Lund TD, Fleming DE, Dayton JR, Lephart ED, Salyer DL, 2003. Dietary soy phytoestrogens effects on retinal thickness in rats. *Nutr Neurosci*, 6, 47-51.
- 25 Madar Z and Stark AH, 2002. New legume sources as therapeutic agents. *Br J Nutr*, 88 Suppl 3, S287-292.
- 26 Mazur W and Adlercreutz H, Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment. Naturally occurring oestrogens in food. *Pure & Appl. Chem.*, 70 (9), 1759-1776.
- 27 Messina MJ, 1999. Legumes and soybeans: overview of their nutritional profiles and health effects. *Am J Clin Nutr*, 70, 439S-450S.
- 28 Milder IE, Arts IC, van de Putte B, Venema DP, Hollman PC, 2005. Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. *Br J Nutr*, 93, 393-402.
- 29 NAMS, 2000. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. *Menopause*, 7, 215-229.
- 30 Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C, Vesco K, Walker M, Bougatsos C, Nygren P, 2005. Management of menopause-related symptoms. *Evid Rep Technol Assess (Summ)*, 1-6.
- 31 Opas EE, Rutledge SJ, Vogel RL, Rodan GA, Schmidt A, 2004. Rat tail skin temperature regulation by estrogen, phytoestrogens and tamoxifen. *Maturitas*, 48, 463-471.
- 32 Panay N, 2007. Integrating phytoestrogens with prescription medicines--a conservative clinical approach to vasomotor symptom management. *Maturitas*, 57, 90-94.
- 33 Reddy K and Katan M, 2004. Diet, nutrition and the prevention of hypertension and cardiovascular disease. *Public Health Nutrition*, 7, 167-186.
- 34 Royal College of Obstetricians & Gynaecologists, 2006. Alternatives to HRT for Management of Symptoms of the Menopause. Scientific Advisory Committee, Opinion Paper 6.
- 35 Sator PG, Schmidt JB, Rabe T, Zouboulis CC, 2004. Skin aging and sex hormones in women -- clinical perspectives for intervention by hormone replacement therapy. *Exp Dermatol*, 13 Suppl 4, 36-40.
- 36 Vina J, Sastre J, Pallardo FV, Gambini J, Borras C, 2006. Role of mitochondrial oxidative stress to explain the different longevity between genders: protective effect of estrogens. *Free Radic Res*, 40, 1359-1365.
- 37 WHO (World Health Organisation), 1996. Programme of Research, Development & Research Training in Human Reproduction Research on the Menopause. *Progress in Reproductive Health Research*, 40, 1-8.
- 38 Wild CP, Andersson C, O'Brien NM, Wilson L, Woods JA, 2001. A critical evaluation of the application of biomarkers in epidemiological studies on diet and health. *Br J Nutr*, 86 Suppl 1, S37-53.
- 39 Wylie-Rosett J, 2005. Menopause, micronutrients, and hormone therapy. *Am J Clin Nutr*, 81, 1223S-1231S.

ID 2096: “Meso-zeaxanthin (derived form lutein of plant extract like marigold ,spinach” and “Required for macular pigmentation in the eyes for helping in maintenance of health eye functions”

- 1 Bone RA, Landrum JT, Cao Y, Howard AN, Alvarez-Calderon F, 2007. Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. *Nutrition & Metabolism*, 4, 12.
- 2 Thurnham DI, Tremel A, Howard AN, 2007. An intervention study in man with meso-zeaxanthin. *Br J Nutr*, (submitted).

ID 2097: “Menthae piperitae aetheroleum (Common name: Peppermint oil)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Mills S and Bone K, 2000. Principles and Practices of Phytotherapie: Modern Herbal Medecine. Churchill Livingstone, London, Edinburgh.
- 4 Monographie der Kommission E, Menthae piperitae aetheroleum (Pfefferminzöl).
- 5 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.
- 6 Vogel G, 1990-1995. Arzneipflanzen in der Phytotherapie. Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten. Kooperation Phytopharmaka.

ID 2098: “Oenothera biennis (Common Name : Evening Primrose)” and “Joint health”

- 1 Ernst E and Chrubasik S, 2000. Phyto-anti-inflammatories. A systematic review of randomized, placebo-controlled, double-blind trials. Rheum Dis Clin North Am, 26, 13-27.
- 2 Little C and Parsons T, 2001. Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev, CD002948.
- 3 Soeken KL, Miller SA, Ernst E, 2003. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. Rheumatology (Oxford), 42, 652-659.

ID 2103: “Paulinia cupana (Common Name : Guarana)” and “Cognitive performance”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.
- 2 Brendler T, Grünwald J, Jänicke C, 2003. Heilpflanzen - Herbal Remedies. CD-ROM. Medpharm Scientific Publishers, Boca Raton.
- 3 Briggs C, 1992. Guarana. Can Pharm J, 125, 222-224.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de L'Agence, 1998. Les Cahiers de l'agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Campos AR, Barros AI, Albuquerque FA, LK ML, Rao VS, 2005. Acute effects of guarana (Paullinia cupana Mart.) on mouse behaviour in forced swimming and open field tests. Phytother Res, 19, 441-443.
- 7 Carlini EA, 2003. Plants and the central nervous system. Pharmacol Biochem Behav, 75, 501-512.
- 8 Cauli O and Morelli M, 2005. Caffeine and the dopaminergic system. Behav Pharmacol, 16, 63-77.
- 9 Dansk Droge A/S, 2006. Guarana monograph.
- 10 Dorea JG and da Costa TH, 2005. Is coffee a functional food? Br J Nutr, 93, 773-782.
- 11 Espinola EB, Dias RF, Mattei R, Carlini EA, 1997. Pharmacological activity of Guarana (Paullinia cupana Mart.) in laboratory animals. J Ethnopharmacol, 55, 223-229.

- 12 EVIRA (Finnish Food Safety Authority), Guarana, http://www.evira.fi/portal/fi/elintarvikkeet/elintarviketietoa/energiajuomat/energiajuomien_piristavat_yhdisteet/.
- 13 Franke W, 1997. *Nutzpflanzenkunde*. Thieme, Stuttgart.
- 14 Haskell CF, Kennedy DO, Wesnes KA, Scholey AB, 2005. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. *Psychopharmacology (Berl)*, 179, 813-825.
- 15 Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB, 2007. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. *J Psychopharmacol*, 21, 65-70.
- 16 Hoppe HA, 1975. *Drogenkunde*. Ealter de Gruyter & Co, Berlin.
- 17 Houghton P, 1995. Herbal products, Part 7 Guarana. *Pharm J*, 254, 435-436.
- 18 Katzung W, 1993. Guarana - a natural product with high caffeine content. *Med Monatsschr Pharm*, 16, 330-333.
- 19 Kennedy D, Haskell C, Pace S, Zangara A, Scholey A, 2004. Psychoactive effects of a single dose Paullinia cupana (Guarana) during intense mental demand. *Worldnutra Conference 2004*, San Francisco.
- 20 Kennedy DO, Haskell CF, Wesnes KA, Scholey AB, 2004. Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax ginseng. *Pharmacol Biochem Behav*, 79, 401-411.
- 21 Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R, 2002. Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. *Sea-Air-Land. Psychopharmacology (Berl)*, 164, 250-261.
- 22 Lima WP, Carnevali LC, Jr., Eder R, Costa Rosa LF, Bacchi EM, Seelaender MC, 2005. Lipid metabolism in trained rats: effect of guarana (Paullinia cupana Mart.) supplementation. *Clin Nutr*, 24, 1019-1028.
- 23 Lorist MM and Tops M, 2003. Caffeine, fatigue, and cognition. *Brain Cogn*, 53, 82-94.
- 24 Magkos F and Kavouras SA, 2005. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. *Crit Rev Food Sci Nutr*, 45, 535-562.
- 25 Reynolds JEF, 1996. *Martindale: The Extra Pharmacopoeia*. Pharmaceutical Press, London.
- 26 Memorial Sloan-Kettering Cancer Center, Paullinia cupana (Guarana), <http://www.mskcc.org/mskcc/html/69248.cfm>
- 27 Miura T, Tatara M, Nakamura K, Suzuki I, 1998. Effect of guarana on exercise in normal and epinephrine-induced glycogenolytic mice. *Biol Pharm Bull*, 21, 646-648.
- 28 Mucignat-Caretta C, 1998. Changes in female cognitive performance after energetic drink consumption: a preliminary study. *Prog Neuropsychopharmacol Biol Psychiatry*, 22, 1035-1042.
- 29 Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M, 2003. Effects of caffeine on human health. *Food Addit Contam*, 20, 1-30.
- 30 Nehlig A, 2004. *Coffee, tea, chocolate, and the brain*. CRC Press, Boca Raton.
- 31 Oliveira CH, Moraes ME, Moraes MO, Bezerra FA, Abib E, De Nucci G, 2005. Clinical toxicology study of an herbal medicinal extract of Paullinia cupana, Trichilia catigua, Ptychopetalum olacoides and Zingiber officinale (Catuama) in healthy volunteers. *Phytother Res*, 19, 54-57.
- 32 Pietta P and Pietta A, 1998. *Fitomedicine e Nutrienti*. GMR Press.
- 33 Smith A, 2002. Effects of caffeine on human behavior. *Food Chem Toxicol*, 40, 1243-1255.
- 34 Smith AP, 2005. Caffeine at work. *Hum Psychopharmacol*, 20, 441-445.
- 35 Steinmetz EF, 1957. *Codex Vegetabilis*. Litografia La Photograph, Padova.
- 36 Swedish Medical Center, Guarana, http://www.swedish.org/body_frameset.cfm?id=1009.
- 37 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.

- 38 van Wyk BE, 2005. Handbuch der Nutzpflanzen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 39 Weckerle CS, Stutz MA, Baumann TW, 2003. Purine alkaloids in Paullinia. *Phytochemistry*, 64, 735-742.
- 40 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 41 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2104: “Phaseolus vulgaris (Common Name : White bean)” and “Glucose metabolism”

- 1 Bo-Linn GW, Santa Ana CA, Morawski SG, Fordtran JS, 1982. Starch blockers--their effect on calorie absorption from a high-starch meal. *N Engl J Med*, 307, 1413-1416.
- 2 Carlson GL, Li BU, Bass P, Olsen WA, 1983. A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man. *Science*, 219, 393-395.
- 3 Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG, 2007. A Dietary supplement containing standardized *Phaseolus vulgaris* extract influences body composition of overweight men and women. *Int J Med Sci*, 4, 45-52.
- 4 Garrow JS, Scott PF, Heels S, Nair KS, Halliday D, 1983. A study of 'starch blockers' in man using ¹³C-enriched starch as a tracer. *Hum Nutr Clin Nutr*, 37, 301-305.
- 5 Koike T, Koizumi Y, Tang L, Takahara K, Saitou Y, 2005. The anti-obesity effect and the safety of taking Phaseolamin™ 1600 diet. *J New Rem & Clin*, 54.
- 6 Layer P, Carlson GL, DiMagno EP, 1985. Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. *Gastroenterology*, 88, 1895-1902.
- 7 Layer P, Rizza RA, Zinsmeister AR, Carlson GL, DiMagno EP, 1986. Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus. *Mayo Clin Proc*, 61, 442-447.
- 8 Layer P, Zinsmeister AR, DiMagno EP, 1986. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology*, 91, 41-48.
- 9 Lee SC, Gepts PL, Whitaker JR, 2002. Protein structures of common bean (*Phaseolus vulgaris*) alpha-amylase inhibitors. *J Agric Food Chem*, 50, 6618-6627.
- 10 Marshall JJ and Lauda CM, 1975. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, *Phaseolus vulgaris*. *J Biol Chem*, 250, 8030-8037.
- 11 Pari L and Venkateswaran S, 2003. Effect of an aqueous extract of *Phaseolus vulgaris* on plasma insulin and hepatic key enzymes of glucose metabolism in experimental diabetes. *Pharmazie*, 58, 916-919.
- 12 Pari L and Venkateswaran S, 2004. Protective role of *Phaseolus vulgaris* on changes in the fatty acid composition in experimental diabetes. *J Med Food*, 7, 204-209.
- 13 Raubicheck C, 2006. Letter: Re Pharmachem's PHASE 2 STARCH NEUTRALIZER®: FDA -Accepted weight control and starch digestion claims.
- 14 Sawada S, Takeda Y, Tashiro M, 2002. Primary structures of alpha- and beta-subunits of alpha-amylase inhibitors from seeds of three cultivars of *Phaseolus* beans. *J Protein Chem*, 21, 9-17.
- 15 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 16 Thom E, 2000. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. *J Int Med Res*, 28, 229-233.
- 17 Udani J, Hardy M, Madsen DC, 2004. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. *Altern Med Rev*, 9, 63-69.
- 18 Watzl B and Leitzmann C, 1999. *Bioaktive Substanzen in Lebensmitteln*. Hippokrates, Stuttgart.
- 19 Watzl B and Rechkemmer G, 2001. Flavonoide. *Ernährungs-Umschau*, 48, 498-502.

ID 2105: “Phaseolus vulgaris (Common Name : White bean)” and “Weight control”

- 1 Boivin M, Zinsmeister AR, Go VL, DiMagno EP, 1987. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. *Mayo Clin Proc*, 62, 249-255.
- 2 Boivin M, Flourie B, Rizza RA, Go VL, DiMagno EP, 1988. Gastrointestinal and metabolic effects of amylase inhibition in diabetics. *Gastroenterology*, 94, 387-394.
- 3 Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG, 2007. A Dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. *Int J Med Sci*, 4, 45-52.
- 4 Elmadfa I and Leitzmann C, 1988. Ernährung des Menschen. Eugen Ulmer Verlag, Stuttgart.
- 5 Hahn A, Ströhle A, Wolters M, 2005. Ernährung–Physiologische Grundlagen, Prävention, Therapie. Wissenschaftliche Verlagsgesellschaft GmbH, Stuttgart.
- 6 Harikumar KB, Jesil AM, Sabu MC, Kuttan R, 2005. A preliminary assessment of the acute and subchronic toxicity profile of phase2: an alpha-amylase inhibitor. *Int J Toxicol*, 24, 95-102.
- 7 Jenkins DJ, Wolever TM, Taylor RH, Barker HM, Fielden H, 1980. Exceptionally low blood glucose response to dried beans: comparison with other carbohydrate foods. *Br Med J*, 281, 578-580.
- 8 Kasper H and Wild M, 2000. Ernährungsmedizin und Diätetik. Urban & Fischer, München.
- 9 Koike T, Koizumi Y, Tang L, Takahara K, Saitou Y, 2005. The anti-obesity effect and the safety of taking "Phaseolamin™ 1600tm diet. *J New Rem & Clin* 54, 1-16.
- 10 Layer P, Carlson GL, DiMagno EP, 1985. Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. *Gastroenterology*, 88, 1895-1902.
- 11 Layer P, Zinsmeister AR, DiMagno EP, 1986. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology*, 91, 41-48.
- 12 Le Berre-Anton V, Bompard-Gilles C, Payan F, Rouge P, 1997. Characterization and functional properties of the alpha-amylase inhibitor (alpha-AI) from kidney bean (Phaseolus vulgaris) seeds. *Biochim Biophys Acta*, 1343, 31-40.
- 13 Leitzmann C, Müller C, Michel P, Brehme U, Hahn A, Laube H, 2001. Ernährung in Prävention und Therapie. Hippokrates, Stuttgart.
- 14 Marshall JJ and Lauda CM, 1975. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, Phaseolus vulgaris. *J Biol Chem*, 250, 8030-8037.
- 15 Raubicheck C, 2006. Letter: Re Pharmachem's PHASE 2 STARCH NEUTRALIZER®: FDA -Accepted weight control and starch digestion claims.
- 16 Shivaraj B, Sharma KK, Pattabiraman TN, 1979. Natural plant enzyme inhibitors: Part VII--Alpha amylase inhibitors & amylases in plant tubers. *Indian J Biochem Biophys*, 16, 52-55.
- 17 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- 18 Tormo MA, Gil-Exojo I, Romero de Tejada A, Campillo JE, 2004. Hypoglycaemic and anorexigenic activities of an alpha-amylase inhibitor from white kidney beans (Phaseolus vulgaris) in Wistar rats. *Br J Nutr*, 92, 785-790.
- 19 Udani J, Hardy M, Madsen DC, 2004. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. *Altern Med Rev*, 9, 63-69.
- 20 van Wyk BE, 2005. Handbuch der Nutzpflanzen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2106: “Plantago ovata/ispaghula” and “Cholesterol”

- 1 Anderson JW, Zettwoch N, Feldman T, Tietyen-Clark J, Oeltgen P, Bishop CW, 1988. Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men. *Arch Intern Med*, 148, 292-296.
- 2 Anderson JW, Floore TL, Geil PB, O'Neal DS, Balm TK, 1991. Hypocholesterolemic effects of different bulk-forming hydrophilic fibers as adjuncts to dietary therapy in mild to moderate hypercholesterolemia. *Arch Intern Med*, 151, 1597-1602.
- 3 Anderson JW, Riddell-Mason S, Gustafson NJ, Smith SF, Mackey M, 1992. Cholesterol-lowering effects of psyllium-enriched cereal as an adjunct to a prudent diet in the treatment of mild to moderate hypercholesterolemia. *Am J Clin Nutr*, 56, 93-98.
- 4 Anderson JW, Allgood LD, Turner J, Oeltgen PR, Daggy BP, 1999. Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia. *Am J Clin Nutr*, 70, 466-473.
- 5 Anderson JW, Allgood LD, Lawrence A, Altringer LA, Jerdack GR, Hengehold DA, Morel JG, 2000. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. *Am J Clin Nutr*, 71, 472-479.
- 6 Bell LP, Hectorne K, Reynolds H, Balm TK, Hunninghake DB, 1989. Cholesterol-lowering effects of psyllium hydrophilic mucilloid. Adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. *JAMA*, 261, 3419-3423.
- 7 Bell LP, Hectorn KJ, Reynolds H, Hunninghake DB, 1990. Cholesterol-lowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia. *Am J Clin Nutr*, 52, 1020-1026.
- 8 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 9 Brown L, Rosner B, Willett WW, Sacks FM, 1999. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr*, 69, 30-42.
- 10 Davidson MH, Dugan LD, Burns JH, Sugimoto D, Story K, Drennan K, 1996. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. *Am J Clin Nutr*, 63, 96-102.
- 11 Davidson MH, Maki KC, Kong JC, Dugan LD, Torri SA, Hall HA, Drennan KB, Anderson SM, Fulgoni VL, Saldanha LG, Olson BH, 1998. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. *Am J Clin Nutr*, 67, 367-376.
- 12 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 13 Everson GT, Daggy BP, McKinley C, Story JA, 1992. Effects of psyllium hydrophilic mucilloid on LDL-cholesterol and bile acid synthesis in hypercholesterolemic men. *J Lipid Res*, 33, 1183-1192.
- 14 Jenkins DJ, Kendall CW, Vuksan V, Vidgen E, Parker T, Faulkner D, Mehling CC, Garsetti M, Testolin G, Cunnane SC, Ryan MA, Corey PN, 2002. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. *Am J Clin Nutr*, 75, 834-839.
- 15 Levin EG, Miller VT, Muesing RA, Stoy DB, Balm TK, LaRosa JC, 1990. Comparison of Psyllium Hydrophilic Mucilloid and Cellulose as Adjuncts to a Prudent Diet in the Treatment of Mild to Moderate Hypercholesterolemia. *Arch Intern Med*, 150, 1822-1827.
- 16 MacMahon M and Carless J, 1998. Ispaghula husk in the treatment of hypercholesterolaemia: a double-blind controlled study. *J Cardiovasc Risk*, 5, 167-172.
- 17 Matheson HB, Colon IS, Story JA, 1995. Cholesterol 7 alpha-hydroxylase activity is increased by dietary modification with psyllium hydrocolloid, pectin, cholesterol and cholestyramine in rats. *J Nutr*, 125, 454-458.

- 18 Neal GW and Balm TK, 1990. Synergistic effects of psyllium in the dietary treatment of hypercholesterolemia. *South Med J*, 83, 1131-1137.
- 19 Olson BH, Anderson SM, Becker MP, Anderson JW, Hunninghake DB, Jenkins DJ, LaRosa JC, Rippe JM, Roberts DC, Stoy DB, Summerbell CD, Truswell AS, Wolever TM, Morris DH, Fulgoni VL, 3rd, 1997. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. *J Nutr*, 127, 1973-1980.
- 20 Roberts DC, Truswell AS, Bencke A, Dewar HM, Farmakalidis E, 1994. The cholesterol-lowering effect of a breakfast cereal containing psyllium fibre. *Med J Aust*, 161, 660-664.
- 21 Spence JD, Huff MW, Heidenheim P, Viswanatha A, Munoz C, Lindsay R, Wolfe B, Mills D, 1995. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. *Ann Intern Med*, 123, 493-499.
- 22 Sprecher DL, Harris BV, Goldberg AC, Anderson EC, Bayuk LM, Russell BS, Crone DS, Quinn C, Bateman J, Kuzmak BR, Allgood LD, 1993. Efficacy of psyllium in reducing serum cholesterol levels in hypercholesterolemic patients on high- or low-fat diets. *Ann Intern Med*, 119, 545-554.
- 23 Stoy DB, LaRosa JC, Brewer BK, Mackey M, Meusing RA, 1993. Cholesterol-lowering effects of ready-to-eat cereal containing psyllium. *J Am Diet Assoc*, 93, 910-912.
- 24 Summerbell CD, Manley P, Barnes D, Leeds A, 1994. The effects of psyllium on blood lipids in hypercholesterolaemic subjects. *Journal of Human Nutrition and Dietetics*, 7, 147-151.
- 25 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 26 Wolever TM, Jenkins DJ, Mueller S, Boctor DL, Ransom TP, Patten R, Chao ES, McMillan K, Fulgoni V, 3rd, 1994(a). Method of administration influences the serum cholesterol-lowering effect of psyllium. *Am J Clin Nutr*, 59, 1055-1059.
- 27 Wolever TM, Jenkins DJ, Mueller S, Patten R, Relle LK, Boctor D, Ransom TP, Chao ES, McMillan K, Fulgoni V, 3rd, 1994(b). Psyllium reduces blood lipids in men and women with hyperlipidemia. *Am J Med Sci*, 307, 269-273.

ID 2107: “*Punica granatum* (Common Name : Pomgranade)” and “Cardiovascular health”

- 1 Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, Volkova N, Presser D, Attias J, Liker H, Hayek T, 2004. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. *Clin Nutr*, 23, 423-433.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Blumenthal M, 2003. *The ABC Clinical Guide to Herbs*. American Botanical Council, Austin, TX.
- 4 Fuhrman B, Volkova N, Aviram M, 2005. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. *J Nutr Biochem*, 16, 570-576.
- 5 Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA, 2000. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. *J Agric Food Chem*, 48, 4581-4589.
- 6 Langley P, 2000. Why a pomegranate? *BMJ*, 321, 1153-1154.
- 7 Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L, Derendorf H, 2006. Absorption, metabolism, and antioxidant effects of pomegranate (*Punica granatum* L.) polyphenols after ingestion of a standardized extract in healthy human volunteers. *J Agric Food Chem*, 54, 8956-8961.
- 8 Monographie der Kommission E, 1987. *Punica granatum* L. Bundesanzeiger Verlag; 15.10.1987.

- 9 Seeram NP, Schulman RN, Heber D, 2006. Pomegranates: ancient roots to modern medicine. Taylor & Francis - CRC Press, Boca Raton.
- 10 Sumner MD, Elliott-Eller M, Weidner G, Daubenmier JJ, Chew MH, Marlin R, Raisin CJ, Ornish D, 2005. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Am J Cardiol, 96, 810-814.
- 11 WHO/FAO (World Health Organization and Food and Agriculture Organization), 2003. Expert Report: Diet, nutrition and prevention of chronic diseases. Report of a Joint WHO/FAO Expert Consultation. WHO Technical Report Series 916.

ID 2108: “Petroselinum crispum (Common Name : Parsley)” and “Kidneys health”

- 1 Blumenthal M, 1994. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines The American Botanical Council, Austin.
- 2 Federal Republic of Germany, Indikationsliste nach § 109 a AMG.

ID 2109: “Piper nigrum FRUIT” and “Digestion”

- 1 Billore KV, Yelne MB, Dennis TJ, Chaudhari BG, 2005. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 2 Deans SG, 2001. Black Pepper, Piper nigrum. Medicinal and Aromatic Plants—Industrial Profiles. Phytochemistry, 58, 827-828.
- 3 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 4 Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S, 2005. Herb-drug interactions: a literature review. Drugs, 65, 1239-1282.
- 5 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 6 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India, Vol III. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 7 Jensen HR, Scott IM, Sims SR, Trudeau VL, Arnason JT, 2006. The effect of a synergistic concentration of a Piper nigrum extract used in conjunction with pyrethrum upon gene expression in Drosophila melanogaster. Insect Mol Biol, 15, 329-339.
- 8 Kapoor LD, 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton.
- 9 Khajuria A, Thusu N, Zutshi U, 2002. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine, 9, 224-231.
- 10 Lee SW, Rho MC, Park HR, Choi JH, Kang JY, Lee JW, Kim K, Lee HS, Kim YK, 2006. Inhibition of diacylglycerol acyltransferase by alkaloids isolated from the fruits of Piper longum and Piper nigrum. J Agric Food Chem, 54, 9759-9763.
- 11 Ononiwu IM, Ibeneme CE, Ebong OO, 2002. Effects of piperine on gastric acid secretion in albino rats. Afr J Med Med Sci, 31, 293-295.
- 12 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.

- 13 Sitaram B, 2006. Bhavaprakasa of Bhavamisra : Original Text Along With Commentary and Translation : Including Nighantu Portion. Chaukhambha Orientalia, Varanasi, India.
- 14 Srinivasan K, 2005. Spices as influencers of body metabolism: an overview of three decades of research. Food Research International, 38, 77-86.
- 15 Suresh D and Srinivasan K, 2007. Studies on the in vitro absorption of spice principles--curcumin, capsaicin and piperine in rat intestines. Food Chem Toxicol, 45, 1437-1442.
- 16 Williamson EM, 2002. Major Herbs of Ayurveda. Churchill Livingstone, London, Edinburgh.
- 17 Yelne M, Sharma P, Dennis T, 2002. Database on Medicinal Plants Used in Ayurveda. Central Council for Research in Ayurveda & Siddha, Indian Ministry of Health and Family Welfare.

ID 2115: “Piper nigrum FRUIT” and “Immunity & Antioxidant”

- 1 Billore KV, Yelne MB, Dennis TJ, Chaudhari BG, 2005. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 2 Chatterjee S, Niaz Z, Gautam S, Adhikari S, Variyar PS, Sharma A, 2007. Antioxidant activity of some phenolic constituents from green pepper (*Piper nigrum* L.) and fresh nutmeg mace (*Myristica fragrans*). Food Chemistry, 101, 515-523.
- 3 Chaudhry NM and Tariq P, 2006. Bactericidal activity of black pepper, bay leaf, aniseed and coriander against oral isolates. Pak J Pharm Sci, 19, 214-218.
- 4 Chun H, Shin DH, Hong BS, Cho WD, Cho HY, Yang HC, 2002. Biochemical properties of polysaccharides from black pepper. Biol Pharm Bull, 25, 1203-1208.
- 5 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 6 Gulcin I, 2005. The antioxidant and radical scavenging activities of black pepper (*Piper nigrum*) seeds. Int J Food Sci Nutr, 56, 491-499.
- 7 Kaleem M, Sheema, Sarmad H, Bano B, 2005. Protective effects of *Piper nigrum* and *Vinca rosea* in alloxan induced diabetic rats. Indian J Physiol Pharmacol, 49, 65-71.
- 8 Kapoor LD, 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton.
- 9 Karthikeyan J and Rani P, 2003. Enzymatic and non-enzymatic antioxidants in selected *Piper* species. Indian J Exp Biol, 41, 135-140.
- 10 Nalini N, Manju V, Menon VP, 2006. Effect of spices on lipid metabolism in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. J Med Food, 9, 237-245.
- 11 Natarajan KS, Narasimhan M, Shanmugasundaram KR, Shanmugasundaram ER, 2006. Antioxidant activity of a salt-spice-herbal mixture against free radical induction. J Ethnopharmacol, 105, 76-83.
- 12 Park IK, Lee SG, Shin SC, Park JD, Ahn YJ, 2002. Larvicidal activity of isobutylamides identified in *Piper nigrum* fruits against three mosquito species. J Agric Food Chem, 50, 1866-1870.
- 13 Pathak N and Khandelwal S, 2006. Modulation of cadmium induced alterations in murine thymocytes by piperine: oxidative stress, apoptosis, phenotyping and blastogenesis. Biochem Pharmacol, 72, 486-497.
- 14 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 15 Reddy SV, Srinivas PV, Praveen B, Kishore KH, Raju BC, Murthy US, Rao JM, 2004. Antibacterial constituents from the berries of *Piper nigrum*. Phytomedicine, 11, 697-700.
- 16 Ribeiro TS, Freire-de-Lima L, Previato JO, Mendonca-Previato L, Heise N, de Lima ME, 2004. Toxic effects of natural piperine and its derivatives on epimastigotes and amastigotes of *Trypanosoma cruzi*. Bioorg Med Chem Lett, 14, 3555-3558.

- 17 Selvendiran K, Thirunavukkarasu C, Singh JP, Padmavathi R, Sakthisekaran D, 2005. Chemopreventive effect of piperine on mitochondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. *Mol Cell Biochem*, 271, 101-106.
- 18 Selvendiran K, Prince Vijeya Singh J, Sakthisekaran D, 2006. In vivo effect of piperine on serum and tissue glycoprotein levels in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. *Pulm Pharmacol Ther*, 19, 107-111.
- 19 Suhaj M, 2006. Spice antioxidants isolation and their antiradical activity: a review. *Journal of Food Composition and Analysis*, 19, 531-537.
- 20 Vijayakumar RS, Surya D, Nalini N, 2004. Antioxidant efficacy of black pepper (*Piper nigrum* L.) and piperine in rats with high fat diet induced oxidative stress. *Redox Rep*, 9, 105-110.
- 21 Williamson EM, 2002. *Major Herbs of Ayurveda*. Churchill Livingstone, London, Edinburgh.
- 22 Yelne MB, Sharma PC, Dennis TJ, 2001. *Database on Medicinal Plants Used in Ayurveda* Central Council for Research in Ayurveda & Siddha.

ID 2121: “Pimpinella anisum L. (Common name: Anise)” and “Respiratory Health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Boskabady MH and Ramazani-Assari M, 2001. Relaxant effect of *Pimpinella anisum* on isolated guinea pig tracheal chains and its possible mechanism(s). *J Ethnopharmacol*, 74, 83-88.
- 4 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 5 Kooperation Phytopharmaka, 1990-1995. *Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten)*. BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 6 Pourgholami MH, Majzoob S, Javadi M, Kamalinejad M, Fanaee GH, Sayyah M, 1999. The fruit essential oil of *Pimpinella anisum* exerts anticonvulsant effects in mice. *J Ethnopharmacol*, 66, 211-215.
- 7 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.
- 8 Tabanca N, Bedir E, Kirimer N, Baser KH, Khan SI, Jacob MR, Khan IA, 2003. Antimicrobial compounds from *Pimpinella* species growing in Turkey. *Planta Med*, 69, 933-938.
- 9 Tirapelli CR, de Andrade CR, Cassano AO, De Souza FA, Ambrosio SR, da Costa FB, de Oliveira AM, 2007. Antispasmodic and relaxant effects of the hidroalcoholic extract of *Pimpinella anisum* (Apiaceae) on rat anococcygeus smooth muscle. *J Ethnopharmacol*, 110, 23-29.
- 10 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2122: “Punica granatum FRUIT & SEED” and “Digestion”

- 1 Billore KV, Yelne MB, Dennis TJ, Chaudhari BG, 2005. *Database on Medical Plants used in Ayurveda*. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 2 Gharzouli K, Khennouf S, Amira S, Gharzouli A, 1999. Effects of aqueous extracts from *Quercus ilex* L. root bark, *Punica granatum* L. fruit peel and *Artemisia herba-alba* Asso leaves on ethanol-induced gastric damage in rats. *Phytother Res*, 13, 42-45.

- 3 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 4 Kapoor LD, 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton.
- 5 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 6 Sitaram B, 2006. Bhavaprakasa of Bhavamisra : Original Text Along With Commentary and Translation : Including Nighantu Portion. Chaukhambha Orientalia, Varanasi, India.
- 7 Yelne MB, Sharma PC, Dennis TJ, 2001. Database on Medicinal Plants Used in Ayurveda Central Council for Research in Ayurveda & Siddha.

ID 2123: “Punica granatum FRUIT & SEED” and “Antioxidant & immunity”

- 1 Adhami VM and Mukhtar H, 2006. Polyphenols from green tea and pomegranate for prevention of prostate cancer. Free Radic Res, 40, 1095-1104.
- 2 Chidambara Murthy KN, Jayaprakasha GK, Singh RP, 2002. Studies on antioxidant activity of pomegranate (*Punica granatum*) peel extract using in vivo models. J Agric Food Chem, 50, 4791-4795.
- 3 Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA, 2000. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem, 48, 4581-4589.
- 4 Guo C, Yang J, Wei J, Li Y, Xu J, Jiang Y, 2003. Antioxidant activities of peel, pulp and seed fractions of common fruits as determined by FRAP assay. Nutrition Research, 23, 1719-1726.
- 5 Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, Wold AB, Haffner K, Baugerod H, Andersen LF, Moskaug O, Jacobs DR, Jr., Blomhoff R, 2002. A systematic screening of total antioxidants in dietary plants. J Nutr, 132, 461-471.
- 6 Karadeniz F, Burdurlu HS, Koca N, Soyer Y, 2005. Antioxidant activity of selected fruits and vegetables grown in Turkey. Turkish journal of agriculture and forestry, 29, 297-303.
- 7 Kaur G, Jabbar Z, Athar M, Alam MS, 2006. *Punica granatum* (pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe-NTA induced hepatotoxicity in mice. Food Chem Toxicol, 44, 984-993.
- 8 Kelawala NS and Ananthanarayan L, 2004. Antioxidant activity of selected foodstuffs. Int J Food Sci Nutr, 55, 511-516.
- 9 Lansky EP and Newman RA, 2007. *Punica granatum* (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol, 109, 177-206.
- 10 Li Y, Guo C, Yang J, Wei J, Xu J, Cheng S, 2006. Evaluation of antioxidant properties of pomegranate peel extract in comparison with pomegranate pulp extract. Food Chemistry, 96, 254-260.
- 11 Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L, Derendorf H, 2006. Absorption, metabolism, and antioxidant effects of pomegranate (*Punica granatum* L.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem, 54, 8956-8961.
- 12 Negi PS and Jayaprakasha GK, 2003. Antioxidant and Antibacterial Activities of *Punica granatum* Peel Extracts. Journal of Food Science, 68, 1473-1477.
- 13 Noda Y, Kaneyuki T, Mori A, Packer L, 2002. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin. J Agric Food Chem, 50, 166-171.
- 14 Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A, 2006. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res, 12, 4018-4026.

- 15 Reddy MK, Gupta SK, Jacob MR, Khan SI, Ferreira D, 2007. Antioxidant, antimalarial and antimicrobial activities of tannin-rich fractions, ellagitannins and phenolic acids from *Punica granatum* L. *Planta Med*, 73, 461-467.
- 16 Ricci D, Giamperi L, Bucchini A, Fraternali D, 2006. Antioxidant activity of *Punica granatum* fruits. *Fitoterapia*, 77, 310-312.
- 17 Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D, 2005. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. *J Nutr Biochem*, 16, 360-367.
- 18 Singh RP, Chidambaram Murthy KN, Jayaprakasha GK, 2002. Studies on the Antioxidant Activity of Pomegranate (*Punica granatum*) Peel and Seed Extracts Using in Vitro Models. *J Agric Food Chem*, 50, 81-86.
- 19 Sudheesh S and Vijayalakshmi NR, 2005. Flavonoids from *Punica granatum*--potential antiperoxidative agents. *Fitoterapia*, 76, 181-186.
- 20 Syed DN, Afaq F, Mukhtar H, 2007. Pomegranate derived products for cancer chemoprevention. *Semin Cancer Biol*, 17, 377-385.
- 21 Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP, 2003. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. *Angiogenesis*, 6, 121-128.
- 22 Wang RF, Xie WD, Zhang Z, Xing DM, Ding Y, Wang W, Ma C, Du LJ, 2004. Bioactive compounds from the seeds of *Punica granatum* (pomegranate). *J Nat Prod*, 67, 2096-2098.

ID 2124: “*Raphanus sativus* var *niger* (Common Name : Radish, Black radish, Japanese radish, Daikon)” and “Liver health”

- 1 Barillari J, Cervellati R, Costa S, Guerra MC, Speroni E, Utan A, Iori R, 2006. Antioxidant and choleric properties of *Raphanus sativus* L. sprout (Kaiware Daikon) extract. *J Agric Food Chem*, 54, 9773-9778.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. Radish *Raphani sativi radix*. In: *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX, p.193-194.
- 3 Bruneton J, 1999. Radis noir. In: *Pharmacognosie Phytochimie Plantes Médicinales*. Tec & Doc, Lavoisier, Paris.
- 4 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 5 Dorvault FLM, 1995. Radis noir. In: *L'Officine*. Vigot, Paris, 280.
- 6 Van Hellemont J, 1986. Monographie *Raphanus sativus*. In: *Compendium de Phytothérapie*. Association Pharmaceutique Belge, Bruxelles, 333-334.

ID 2125: “*Rosmarinus officinalis* (Common Name : Rosemary)” and “Antioxidant properties”

- 1 Aruoma OI, Spencer JP, Rossi R, Aeschbach R, Khan A, Mahmood N, Munoz A, Murcia A, Butler J, Halliwell B, 1996. An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provençal herbs. *Food Chem Toxicol*, 34, 449-456.
- 2 Bisset NG and Wichtl M, 2001. *Herbal Drugs and Phytopharmaceuticals* Medpharm GmbH Scientific Publishers, Stuttgart, Germany.

- 3 Bohm V, Netzel M, Kler A, Marx S, Weiss M, Geiss KR, 2004. Antioxidant capacity of human plasma and serum as affected by a single dose of a beverage rich in antioxidants-use of three different assay systems. *Journal of Food, Agriculture & Environment*, 2, 74-78.
- 4 Buckenhüskes HJ, 2005. Zur Diskussion über das Vorkommen biologisch aktiver Substanzen in Kräutern und Gewürzen. *Z. Arzn. Gew. Pfl*, 10, 172-179.
- 5 del Bano MJ, Lorente J, Castillo J, Benavente-Garcia O, del Rio JA, Ortuno A, Quirin KW, Gerard D, 2003. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of *Rosmarinus officinalis*. Antioxidant activity. *J Agric Food Chem*, 51, 4247-4253.
- 6 Schilcher H, Kammerer S, Wegener T, 2000. *Leitfaden Phytotherapie*. Urban & Fischer Verlag, München, Jena.
- 7 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 8 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 9 Youn J, Lee KH, Won J, Huh SJ, Yun HS, Cho WG, Paik DJ, 2003. Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis. *J Rheumatol*, 30, 1203-1207.

ID 2126: “Ribes nigrum (Common Name : Blackcurrant)” and “Muscles and joint health”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1975. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 3 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 5 Cahier de l'Agence, 1998. *Médicaments à base de plantes: Cahiers de l'Agence no 3*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 7 Fournier P, 1948. *Le livre des plantes médicinales et vénéneuses de France*. P. Lechevalier.
- 8 Garbacki N, Angenot L, Bassleer C, Damas J, Tits M, 2002. Effects of prodelphinidins isolated from *Ribes nigrum* on chondrocyte metabolism and COX activity. *Naunyn Schmiedebergs Arch Pharmacol*, 365, 434-441.
- 9 Garbacki N, Kinet M, Nusgens B, Desmecht D, Damas J, 2005. Proanthocyanidins, from *Ribes nigrum* leaves, reduce endothelial adhesion molecules ICAM-1 and VCAM-1. *J Inflamm (Lond)*, 2, 9.
- 10 Matsumoto H, Takenami E, Iwasaki-Kurashige K, Osada T, Katsumura T, Hamaoka T, 2005. Effects of blackcurrant anthocyanin intake on peripheral muscle circulation during typing work in humans. *Eur J Appl Physiol*, 94, 36-45.
- 11 Paris R and Myose H, 1981. *Précis de Matière Médicale, Tome II, Pharmacognosie spéciale*. Masson, Paris.
- 12 Rombi M, 1991. *Cent plantes médicinales*. Romart, Nice.
- 13 Schauenberg P and Paris F, 1977. *Guide des plantes médicinales. Analyse, description et utilisation de 400 plantes*. Lutterworth Press, Guildford.
- 14 Valnet J, 1976. *Phytothérapie. Traitement des maladies par les plantes*. Maloine Paris.
- 15 Van Hellemont J, 1986. *Compendium de phytothérapie*. Association Pharmaceutique Belge, Bruxelles.

- 16 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2127: “*Rubus fruticosus* L. (Common name: Blackberry)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Kooperation Phytopharmaka, 1990-1995. *Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten)*. BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 4 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.
- 5 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2132: “*Syzygium aromaticum*. FLOWER BUD” and “Antioxidant”

- 1 BHMA (British Herbal Medicine Association), 2003. *A Guide to traditional herbal medicines : a sourcebook of accepted traditional uses of medicinal plants within Europe*. British Herbal Medicine Association, Exeter.
- 2 Abdel-Wahhab MA and Aly SE, 2005. Antioxidant property of *Nigella sativa* (black cumin) and *Syzygium aromaticum* (clove) in rats during aflatoxicosis. *Journal of Applied Toxicology*, 25, 218-223.
- 3 Bradley P, 2006. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 4 Gulcin I, Sat IG, Beydemir S, Elmastas M, Kufrevioglu OI, 2004. Comparison of antioxidant activity of clove (*Eugenia caryophyllata* Thunb) buds and lavender (*Lavandula stoechas* L.). *Food Chemistry*, 87, 393-400.
- 5 Lee KG and Shibamoto T, 2001. Inhibition of malonaldehyde formation from blood plasma oxidation by aroma extracts and aroma components isolated from clove and eucalyptus. *Food and Chemical Toxicology*, 39, 1199-1204.
- 6 Lee KG and Shibamoto T, 2001. Antioxidant property of aroma extract isolated from clove buds [*Syzygium aromaticum* (L.) Merr. et Perry]. *Food Chemistry*, 74, 443-448.
- 7 Ponce AG, del Valle CE, Roura SI, 2004. Natural essential oils as reducing agents of peroxidase activity in leafy vegetables. *Lebensmittel-Wissenschaft Und-Technologie-Food Science and Technology*, 37, 199-204.
- 8 Wojdylo A, Oszmianski J, Czemerys R, 2007. Antioxidant activity and phenolic compounds in 32 selected herbs. *Food Chemistry*, 105, 940-949.

ID 2133: “*Sambucus nigra* (Common Name : Elder)” and “Purification”

- 1 AFSSAPS (Agence française de sécurité sanitaire des produits de santé), 1998. *Médicaments à base de plantes. Les cahiers de l'Agence n°3*. Agence du médicament, Paris.
- 2 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. *HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe*. Springer Verlag, Heidelberg.
- 3 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.

- 4 Brendler T, Gruenwald J, Jaenicke C, 1997. Herbal Remedies: Heilpflanzen. Deutscher Apotheker Verlag, Stuttgart.
- 5 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 6 Steinmetz EF, 1957. Codex Vegetabilis. Litografia La Photograph, Padova.
- 7 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- 8 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2135: “Sambucus nigra (Common Name : Elder)” and “Glucose metabolism”

- 1 Atkinson M, 1979. Herbs for Your Health. Dalesman Books, New York.
- 2 Gray AM, Abdel-Wahab YH, Flatt PR, 2000. The traditional plant treatment, *Sambucus nigra* (elder), exhibits insulin-like and insulin-releasing actions in vitro. *J Nutr*, 130, 15-20.
- 3 Matsui T, Ueda T, Oki T, Sugita K, Terahara N, Matsumoto K, 2001. alpha-Glucosidase inhibitory action of natural acylated anthocyanins. 1. Survey of natural pigments with potent inhibitory activity. *J Agric Food Chem*, 49, 1948-1951.

ID 2136: “Sambucus nigra (Common Name : Elderberry)” and “Antioxidative properties”

- 1 Abuja PM, Murkovic M, Pfannhauser W, 1998. Antioxidant and Prooxidant Activities of Elderberry (*Sambucus nigra*) Extract in Low-Density Lipoprotein Oxidation. *Journal of Agricultural and Food Chemistry*, 46, 4091-4096.
- 2 Bors W, Heller W, Michel C, Saran M, 1990. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. *Methods Enzymol*, 186, 343-355.
- 3 Bravo L, 1998. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. *Nutr Rev*, 56, 317-333.
- 4 Cao G and Prior RL, 1999. Anthocyanins are detected in human plasma after oral administration of an elderberry extract. *Clin Chem*, 45, 574-576.
- 5 Cao G, Muccitelli HU, Sanchez-Moreno C, Prior RL, 2001. Anthocyanins are absorbed in glycosylated forms in elderly women: a pharmacokinetic study. *Am J Clin Nutr*, 73, 920-926.
- 6 Hertog MGL, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic SI, Pekkarinen M, Simic BS, Toshima H, Feskens EJM, Hollman PCH, Katan MB, 1995. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. *Arch Intern Med*, 155, 381-386.
- 7 Jordheim M, Giske NH, Andersen ØM, 2007. Anthocyanins in Caprifoliaceae. *Biochemical Systematics and Ecology*, 35, 153-159.
- 8 Kaack K and Austed T, 1998. Interaction of vitamin C and flavonoids in elderberry (*Sambucus nigra* L.) during juice processing. *Plant Foods Hum Nutr*, 52, 187-198.
- 9 Kuhnau J, 1976. The flavonoids. A class of semi-essential food components: their role in human nutrition. *World Rev Nutr Diet*, 24, 117-191.
- 10 Lee J and Finn CE, 2007. Anthocyanins and other polyphenolics in American elderberry *Sambucus canadensis* and European elderberry *S. nigra* cultivars. *Journal of the Science of Food and Agriculture*, 87, 2665-2675.
- 11 Manach C, Regerat F, Texier O, Agullo G, Demigne C, Remesy C, 1996. Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. *Nutrition Research*, 16, 517-544.

- 12 Milbury PE, Cao G, Prior RL, Blumberg J, 2002. Bioavailability of elderberry anthocyanins. *Mech Ageing Dev*, 123, 997-1006.
- 13 Miyazawa T, Nakagawa K, Kudo M, Muraishi K, Someya K, 1999. Direct intestinal absorption of red fruit anthocyanins, cyanidin-3-glucoside and cyanidin-3,5-diglucoside, into rats and humans. *J Agric Food Chem*, 47, 1083-1091.
- 14 Murkovic M, Adam U, Pfannhauser W, 2000. Analysis of anthocyanine glycosides in human serum. *Fresenius J Anal Chem*, 366, 379-381.
- 15 Murkovic M, Muelleder U, Adam U, Pfannhauser W, 2001. Detection of anthocyanins from elderberry juice in human urine. *Journal of the Science of Food and Agriculture*, 81, 934-937.
- 16 Nakajima JI, Tanaka I, Seo S, Yamazaki M, Saito K, 2004. LC/PDA/ESI-MS Profiling and Radical Scavenging Activity of Anthocyanins in Various Berries. *J Biomed Biotechnol*, 2004, 241-247.
- 17 Netzel M, Strass G, Herbst M, Dietrich H, Bitsch R, Bitsch I, Frank T, 2005. The excretion and biological antioxidant activity of elderberry antioxidants in healthy humans. *Food Research International*, 38, 905-910.
- 18 Paganga G and Rice-Evans CA, 1997. The identification of flavonoids as glycosides in human plasma. *FEBS Lett*, 401, 78-82.
- 19 Raspino MG, 1996. *Repertorio fitoterapico*. Organizzazione Editoriale Medico Farmaceutica, Milano.
- 20 Ratty AK and Das NP, 1988. Effects of flavonoids on nonenzymatic lipid peroxidation: structure-activity relationship. *Biochem Med Metab Biol*, 39, 69-79.
- 21 Wang H, Cao G, Prior RL, 1997. Oxygen Radical Absorbing Capacity of Anthocyanins. *Journal of Agricultural and Food Chemistry*, 45, 304-309.
- 22 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 23 Wu X, Gu L, Prior RL, McKay S, 2004. Characterization of anthocyanins and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capacity. *J Agric Food Chem*, 52, 7846-7856.
- 24 Youdim KA, Martin A, Joseph JA, 2000. Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress. *Free Radic Biol Med*, 29, 51-60.

ID 2137: “Sambucus nigra (Common Name : Elderberry)” and “Respiratory health”

- 1 [Monographie der Kommission E. 1986. Bundesanzeiger, 50.](#)
- 2 [Bisset NG and Wichtl M, 2001. Herbal Drugs and Phytopharmaceuticals. Medpharm GmbH Scientific Publishers, Stuttgart, Germany.](#)
- 3 [Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2005. HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.](#)
- 4 [Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.](#)
- 5 [Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.](#)
- 6 [Brendler T, Grünwald J, Jänicke C, 2003. Herbal Remedies: Heilpflanzen, Version 5. Medpharm GmbH Scientific Publishers, Stuttgart.](#)
- 7 [Chibanguza G, Marz R, Sterner W, 1984. \[The effectiveness and toxicity of a plant secretolytic agent and its component drugs\]. *Arzneimittelforschung*, 34, 32-36.](#)
- 8 [Hoppe HA, 1975. Drogenkunde. Walter de Gruyter, Berlin.](#)

- 9 Kooperation Phytopharmaka, 1990–1995. Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten). BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 10 Schweizerisches Heilmittelinstitut Swissmedic, 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren, Annex 1.
- 11 Thom E, Zakay-Rones Z, Wollan T, Wadstein J, 2002. Randomised study on the efficacy and safety of an oral elderberry extract in the treatment of influenza A and B virus infection. *Antiviral research*, 53, A77.
- 12 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 13 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 14 Zakay-Rones Z, Varsano N, Zlotnik M, Manor O, Regev L, Schlesinger M, Mumcuoglu M, 1995. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (*Sambucus nigra* L.) during an outbreak of influenza B Panama. *J Altern Complement Med*, 1, 361-369.

ID 2138: “Standardized Guarana extract PC102 Dry extract from seeds of Paullinia Cupana H. B. et Kunth, drug:native extract ratio (4.5-7) : 1, solvent of extraction Ethanol/Water , 11.0 - 13.0% of caffeine” and “For mental performance”

- 1 Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB, 2007. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. *J Psychopharmacol*, 21, 65-70.

ID 2139: “Seed of Vitis vinifera (Grapeseed)” and “Circulatory health through antioxidant action”

- 1 Bouhamidi R, Prevost V, Nouvelot A, 1998. High protection by grape seed proanthocyanidins (GSPC) of polyunsaturated fatty acids against UV-C induced peroxidation. *C R Acad Sci III*, 321, 31-38.
- 2 Kim H, Deshane J, Barnes S, Meleth S, 2006. Proteomics analysis of the actions of grape seed extract in rat brain: technological and biological implications for the study of the actions of psychoactive compounds. *Life Sci*, 78, 2060-2065.
- 3 Sano A, Uchida R, Saito M, Shioya N, Komori Y, Tho Y, Hashizume N, 2007. Beneficial effects of grape seed extract on malondialdehyde-modified LDL. *J Nutr Sci Vitaminol (Tokyo)*, 53, 174-182.

ID 2140: “Soy Glycine max” and “Soy contains the phytoestrogens isoflavones that can function as either an estrogen agonist or antagonist”

- 1 Geller SE and Studee L, 2005. Botanical and dietary supplements for menopausal symptoms: what works, what does not. *J Womens Health (Larchmt)*, 14, 634-649.
- 2 Han KK, Soares JM, Jr., Haidar MA, de Lima GR, Baracat EC, 2002. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. *Obstet Gynecol*, 99, 389-394.
- 3 Kronenberg F and Fugh-Berman A, 2002. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. *Ann Intern Med*, 137, 805-813.
- 4 Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K, 1999. Hot flushes and other menopausal symptoms in relation to soy product intake in Japanese women. *Climacteric*, 2, 6-12.
- 5 Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L, 2006. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. *JAMA*, 295, 2057-2071.

- 6 Seidl MM and Stewart DE, 1998. Alternative treatments for menopausal symptoms. Systematic review of scientific and lay literature. *Can Fam Physician*, 44, 1299-1308.
- 7 Uesugi S, Watanabe S, Ishiwata N, Uehara M, Ouchi K, 2004. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. *Biofactors*, 22, 221-228.
- 8 Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA, 2000. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. *Menopause*, 7, 236-242.
- 9 Wangen KE, Duncan AM, Xu X, Kurzer MS, 2001. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. *Am J Clin Nutr*, 73, 225-231.

ID 2141: “Sinapis alba (Common Name : White mustard)” and “Appetite/Digestion”

- 1 Hänsel R and Sticher O, 2004. *Pharmakognosie - Phytopharmazie*. Springer Verlag, Berlin.
- 2 Pahlow M, 1985. *Das große Buch der Heilpflanzen*. Gräfe und Unzer, Munchen.
- 3 Wagner H, 1999. *Arzneidrogen und ihre Inhaltsstoffe, Pharmazeutische Biologie*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 4 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2142: “Standardized tomato extract [Oleoresin extracted from ripe fruits of *Lycopersicum esculentum*, solvent of extraction Ethyl acetate, 5% lycopene” and “For antioxidant protection system/protection of DNA”

- 1 Biesalski HK, 2000. The role of antioxidants in nutritional support. *Nutrition*, 16, 593-596.
- 2 Hadley P and Schwartz SJ, 2005. Lycopene. 421-434.
- 3 Levy J and Sharoni Y, 2004. The functions of tomato lycopene and its role in human health *HerbalGram*, 62, 49-56.
- 4 Stahl W and Sies H, 1996. Lycopene: a biologically important carotenoid for humans? *Arch Biochem Biophys*, 336, 1-9.

ID 2143: “Standardized tomato extract [Oleoresin extracted from ripe fruits of *Lycopersicum esculentum*, solvent of extraction Ethyl acetate, 5% lycopene” and “For skin health”

- 1 Biesalski HK, 2000. The role of antioxidants in nutritional support. *Nutrition*, 16, 593-596.
- 2 Fazekas Z, Gao D, Saladi RN, Lu Y, Lebowitz M, Wei H, 2003. Protective effects of lycopene against ultraviolet B-induced photodamage. *Nutr Cancer*, 47, 181-187.
- 3 Hadley P and Schwartz SJ, 2005. Lycopene.
- 4 Levy J and Sharoni Y, 2005. The functions of tomato lycopene and its role in human health. *Foods & Food Ingrid J Jpn*, 210, 49-58.
- 5 Stahl W and Sies H, 1996. Lycopene: a biologically important carotenoid for humans? *Arch Biochem Biophys*, 336, 1-9.
- 6 Stahl W, Heinrich U, Aust O, Tronnier H, Sies H, 2006. Lycopene-rich products and dietary photoprotection. *Photochem Photobiol Sci*, 5, 238-242.

ID 2144: “Standardized grape seed extract [Dry extract from grape seeds of *Vitis vinifera* L. (Vitaceae), solvent of extraction Acetone/Water, 8.5 - 13.0% proanthocyanidins]” and “For antioxidant protection system”

- 1 Bagchi D, Bagchi M, Stohs SJ, Das DK, Ray SD, Kuszynski CA, Joshi SS, Pruess HG, 2000. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology*, 148, 187-197.
- 2 Carini M, Stefani R, Aldini G, Ozioli M, Facino RM, 2001. Procyanidins from *Vitis vinifera* seeds inhibit the respiratory burst of activated human neutrophils and lysosomal enzyme release. *Planta Med*, 67, 714-717.
- 3 Kontek A, Campeanu R, Petrescu L, Rizea S, 1995. Effect of grape seed procyanidins on some vascular diseases. In: *Colloques de l'INRA*, No. 69. Polyphenols 94; 17th International Conference on Polyphenols, Palma de Mallorca, Spain, May 23-27, 1994. Brouillard R, Jay M, Scalbert A (eds.). INRA (Institut National de la Recherche Agronomique), Paris.
- 4 Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R, 1994. Free radicals scavenging action and anti-enzyme activities of procyanidines from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung*, 44, 592-601.
- 5 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1996. Procyanidines from *Vitis vinifera* seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. *Planta Med*, 62, 495-502.
- 6 Maffei Facino R, Carini M, Aldini G, Calloni MT, Bombardelli E, Morazzoni P, 1998. Sparing Effect of Procyanidins from *Vitis vinifera* on Vitamin E: In Vitro Studies. *Planta Medica*, 64, 343-347.
- 7 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1999. Diet enriched with procyanidins enhances antioxidant activity and reduces myocardial post-ischaemic damage in rats. *Life Sciences*, 64, 627-642.
- 8 Nuttall SL, Kendall MJ, Bombardelli E, Morazzoni P, 1998. An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. *J Clin Pharm Ther*, 23, 385-389.
- 9 Sano T, Oda E, Yamashita T, Naemura A, Ijiri Y, Yamakoshi J, Yamamoto J, 2005. Anti-thrombotic effect of proanthocyanidin, a purified ingredient of grape seed. *Thromb Res*, 115, 115-121.

ID 2146: “Standardized grape seed extract [Dry extract from grape seeds of *Vitis vinifera* L. (Vitaceae), solvent of extraction Acetone/Water, 8.5 - 13.0% proanthocyanidins]” and “For cardiovascular (heart/vessel) health”

- 1 Bagchi D, Bagchi M, Stohs SJ, Das DK, Ray SD, Kuszynski CA, Joshi SS, Pruess HG, 2000. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology*, 148, 187-197.
- 2 Carini M, Stefani R, Aldini G, Ozioli M, Facino RM, 2001. Procyanidins from *Vitis vinifera* seeds inhibit the respiratory burst of activated human neutrophils and lysosomal enzyme release. *Planta Med*, 67, 714-717.
- 3 Kontek A, Campeanu R, Petrescu L, Rizea S, 1995. Effect of grape seed procyanidins on some vascular diseases. In: *Colloques de l'INRA*, No. 69. Polyphenols 94; 17th International Conference on Polyphenols, Palma de Mallorca, Spain, May 23-27, 1994. Brouillard R, Jay M, Scalbert A (eds.). INRA (Institut National de la Recherche Agronomique), Paris.
- 4 Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R, 1994. Free radicals scavenging action and anti-enzyme activities of procyanidines from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung*, 44, 592-601.

- 5 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1996. Procyanidines from *Vitis vinifera* seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. *Planta Med*, 62, 495-502.
- 6 Maffei Facino R, Carini M, Aldini G, Calloni MT, Bombardelli E, Morazzoni P, 1998. Sparing effect of procyanidins from *Vitis vinifera* on vitamin E: in vitro studies. *Planta Med*, 64, 343-347.
- 7 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1999. Diet enriched with procyanidins enhances antioxidant activity and reduces myocardial post-ischaemic damage in rats. *Life Sci*, 64, 627-642.
- 8 Nuttall SL, Kendall MJ, Bombardelli E, Morazzoni P, 1998. An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. *J Clin Pharm Ther*, 23, 385-389.
- 9 Sano T, Oda E, Yamashita T, Naemura A, Ijiri Y, Yamakoshi J, Yamamoto J, 2005. Anti-thrombotic effect of proanthocyanidin, a purified ingredient of grape seed. *Thromb Res*, 115, 115-121.

ID 2147: “*Salviae officinalis aetheroleum* (Common name: Sage oil)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Hoppe HA, 1977. *Drogenkunde*. Ealter de Gruyter & Co, Berlin.
- 4 Kooperation Phytopharmaka, 1990-1995. *Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten)*. BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 5 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.
- 6 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 7 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.

ID 2149: “*Thymus vulgaris/zygis* (Common Name : Thyme)” and “Health of the upper respiratory tract”

- 1 Basch E, Ulbricht C, Hammerness P, Bevins A, Sollars D, 2004. Thyme (*Thymus vulgaris* L.), *thymol*. *J Herb Pharmacother*, 4, 49-67.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 3 BHMA (British Herbal Medicine Association), 1983. *British Herbal Pharmacopoeia* British Herbal Medicine Association, Bournemouth.
- 4 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. Thyme. British Herbal Medicine Association, Exeter.
- 5 Bisset NG and Wichtl M, 2001. *Herbal Drugs and Phytopharmaceuticals* Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 6 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. *HagerROM 2004*. *Hagers Handbuch der Drogen und Arzneistoffe*. Springer Verlag, Heidelberg.
- 7 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

- 8 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 9 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 10 Boskabady MH, Aslani MR, Kiani S, 2006. Relaxant effect of *Thymus vulgaris* on guinea-pig tracheal chains and its possible mechanism(s). *Phytother Res*, 20, 28-33.
- 11 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 12 Brendler T, Gruenwald J, Jaenicke C, 1997. Herbal Remedies: Heilpflanzen. Deutscher Apotheker Verlag, Stuttgart.
- 13 Brendler T, Grünwald J, Jänicke C, 2003. Heilpflanzen - Herbal Remedies. CD-ROM. Medpharm Scientific Publishers, Boca Raton.
- 14 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 15 Buechi S, Vogelín R, von Eiff MM, Ramos M, Melzer J, 2005. Open trial to assess aspects of safety and efficacy of a combined herbal cough syrup with ivy and thyme. *Forsch Komplementarmed Klass Naturheilkd*, 12, 328-332.
- 16 Cahier de l'Agence, 1998. Médicaments à base de plantes: Cahiers de l'Agence République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 17 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 18 Garnier G, Bézanger-Beauquesne L, Debraux G, Souèges R, Dol G, 1961. Ressources médicinales de la flore française. Vigot.
- 19 Health Canada, 2004. Monograph Thyme.
- 20 Hitokoto H, Morozumi S, Wauke T, Sakai S, Kurata H, 1980. Inhibitory effects of spices on growth and toxin production of toxigenic fungi. *Appl Environ Microbiol*, 39, 818-822.
- 21 Hoppe HA, 1975. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 22 Kooperation Phytopharmaka, 1990-1995. Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten). BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 23 Leung A and Foster S, 1996. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. John Wiley & Sons, New York.
- 24 Llewellyn GC, Burkett ML, Eadie T, 1981. Potential mold growth, aflatoxin production, and antimycotic activity of selected natural spices and herbs. *J Assoc Off Anal Chem*, 64, 955-960.
- 25 Mills S and Bone K, 2000. Principles and Practices of Phytotherapie: Modern Herbal Medecine. Churchill Livingstone, London, Edinburgh.
- 26 Mills S and Bone K Elsevier, 2005. The Essential Guide to Herbal Safety. Churchill Livingstone, London, Edinburgh.
- 27 Paris RR and Myose H, 1971. Précis de matière Médicale, Tome III. Masson, Paris.
- 28 Rombi M, 1991. Cent plantes médicinales. Romart, Nice.
- 29 Shapiro S and Guggenheim B, 1995. The action of thymol on oral bacteria. *Oral Microbiol Immunol*, 10, 241-246.
- 30 Steinmetz EF, 1957. Codex Vegetabilis. Litografia La Photograph, Padova.
- 31 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.
- 32 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.

- 33 Van den Broucke CO and Lemli JA, 1981. Pharmacological and chemical investigation of thyme liquid extracts. *Planta Med*, 41, 129-135.
- 34 Van den Broucke CO and Lemli JA, 1983. Spasmolytic activity of the flavonoids from *Thymus vulgaris*. *Pharm Weekbl Sci*, 5, 9-14.
- 35 Van Hellemont J, 1986. Compendium de phytothérapie. Association Pharmaceutique Belge, Bruxelles.
- 36 van Wyk BE, 2005. *Handbuch der Nutzpflanzen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 37 Vigo E, Cepeda A, Gualillo O, Perez-Fernandez R, 2004. In-vitro anti-inflammatory effect of *Eucalyptus globulus* and *Thymus vulgaris*: nitric oxide inhibition in J774A.1 murine macrophages. *J Pharm Pharmacol*, 56, 257-263.
- 38 WHO (World Health Organization), 1999. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.
- 39 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 40 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 41 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.
- 42 Williamson EM, Evans FJ, Wren RC, 1988. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. CW Daniel Company Limited, Saffron Walden.

ID 2151: “Thymus vulgaris (Common Name : Thyme)” and “Antioxidant properties”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. HagerROM 2004. *Hagers Handbuch der Drogen und Arzneistoffe*. Springer Verlag, Heidelberg.
- 2 Brendler T, Grünwald J, Jänicke C, 2003. *Heilpflanzen - Herbal Remedies*. CD-ROM. Medpharm Scientific Publishers, Boca Raton.
- 3 Gerhardt U, Hall G, Siewek F, 2006. *Handbuch Aromen und Gewürze*. Behring-Verlag, Hamburg.
- 4 Haraguchi H, Saito T, Ishikawa H, Date H, Kataoka S, Tamura Y, Mizutani K, 1996. Antiperoxidative components in *Thymus vulgaris*. *Planta Med*, 62, 217-221.
- 5 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 6 Zieschang P, 2002. *Lexikon der Heilpflanzen*. Tosa Verlag, Wien.

ID 2153: “Vaccinium macrocarpon, oxycoccus (Common Name: Cranberry)” and “Health of the lower urinary tract”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2004. Avis d'évaluation des justificatifs concernant l'allégation « contribue à diminuer la fixation de certaines bactéries E. coli sur les parois urinaires » pour un nectar/cocktail de jus de cranberry/canneberge. Maisons-Alfort, le 3 décembre 2004. Afssa-Saisine n° 2004-SA-214. Saisine liée n°2003-SA-0056 et 2003-SA-0352.
- 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2004. Avis relatif à l'évaluation des justificatifs concernant l'allégation « contribue à diminuer la fixation de certaines bactéries E.coli sur les parois des voies urinaires » et sur l'emploi de la « cranberry/canneberge » ou « Vaccinium macrocarpon » dans des jus concentrés, des compléments alimentaires et un cocktail/nectar de jus. Maisons-Alfort le 6 avril 2004. Afssa-Saisine n°2003-SA-0352, Saisine liée n°2003-SA-0056
- 3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2007. Avis relatif à l'évaluation des justificatifs concernant l'extension de l'allégation "contribue à diminuer la fixation de certaines bactéries E. coli sur les parois des voies urinaires", sur l'emploi de la "cranberry/canneberge" ou "Vaccinium macrocarpon" dans la canneberge fraîche et la canneberge congelée, la purée de canneberge, les canneberges

séchées/sucrées et les canneberges séchées/sucrées et aromatisées. Maisons-Alfort le 14 juin 2007. Afssa – Saisine n° 2006-SA-0256.

- 4 AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé), 2008. Good practice recommendations: diagnostics and antibiotherapy for community-acquired bacterial urinary infections in adults.
- 5 American Herbal Pharmacopoeia and Therapeutic Compendium, 2002. Cranberry Fruit. *Vaccinium Macrocarpon* Aiton. Standards of Analysis, Quality Control and Therapeutics. 1-26.
- 6 Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA, 1994. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. *JAMA*, 271, 751-754.
- 7 Bailey DT, Dalton C, Joseph Daugherty F, Tempesta MS, 2007. Can a concentrated cranberry extract prevent recurrent urinary tract infections in women? A pilot study. *Phytomedicine*, 14, 237-241.
- 8 Battle M, Martin T, Fulton J, 2001. Lactulose may help prevent urinary tract infections. *BMJ*, 323, 936.
- 9 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, 2003. HagerROM 2003. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.
- 10 Blumenthal M, 2003. The ABC Clinical Guide to Herbs. American Botanical Council, Austin, TX.
- 11 Bohbot JM, 2007. Results of a randomised, double-blind study on the prevention of recurrent cystitis with GynDelta. *The Gynaecologist's and Obstetrician's Journal*, Special issue from the C.C.D. laboratory.
- 12 Brigham and Women's Hospital, Cranberry, <http://healthlibrary.brighamandwomens.org/Search/19,Cranberry>.
- 13 Bruyere F, 2006. [Use of cranberry in chronic urinary tract infections]. *Med Mal Infect*, 36, 358-363.
- 14 CKF (Commissie Keuring Fytproducten), 2007. Master File *Fructus Vaccinii Macrocarpi*.
- 15 Cunningham DG, Vannozzi S, O'Shea E, Turk R, 2002. Analysis and Standardization of Cranberry Products. In: *Quality Management of Nutraceuticals*. Ho CT and Zheng QY (eds.). American Chemical Society, Washington, 151-166.
- 16 Cunningham DG, 2004. Letter to Gunter Haesaerts, GIKA France.
- 17 Cunningham DG, 2005. Letter to unknown recipient regarding proanthocyanidin value statement.
- 18 Di Martino P, Agniel R, David K, Templer C, Gaillard JL, Denys P, Botto H, 2006. Reduction of *Escherichia coli* adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial. *World J Urol*, 24, 21-27.
- 19 Donabedian H, 2006. Nutritional therapy and infectious diseases: a two-edged sword. *Nutr J*, 5, 21.
- 20 Fischer H, 2005. *Harnwegsinfektionen – Vorbeugen, Erkennen, Behandeln*. Verlagshaus der Ärzte, Wien.
- 21 Fleet JC, 1994. New support for a folk remedy: cranberry juice reduces bacteriuria and pyuria in elderly women. *Nutr Rev*, 52, 168-170.
- 22 Foda MM, Middlebrook PF, Gatfield CT, Potvin G, Wells G, Schillinger JF, 1995. Efficacy of cranberry in prevention of urinary tract infection in a susceptible pediatric population. *Can J Urol*, 2, 98-102.
- 23 Foo LY, Lu Y, Howell AB, Vorsa N, 2000. The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated *Escherichia coli* in vitro. *Phytochemistry*, 54, 173-181.
- 24 Foo LY, Lu Y, Howell AB, Vorsa N, 2000. A-Type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated *Escherichia coli*. *J Nat Prod*, 63, 1225-1228.
- 25 Foxman B, Geiger AM, Palin K, Gillespie B, Koopman JS, 1995. First-time urinary tract infection and sexual behavior. *Epidemiology*, 6, 162-168.
- 26 Franz C, 2007. Gutachten über gesundheitsbezogene Angaben zu Preiselbeeren bzw. die Vergleichbarkeit zwischen Preiselbeeren (*Vaccinium vitis-idaea*) und Cranberries (*V. macrocarpon*, *V. microcarpum*, *V. oxycoccus*).

- 27 Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CY, Pearle MS, 2005. Effect of cranberry juice consumption on urinary stone risk factors. *J Urol*, 174, 590-594; quiz 801.
- 28 Gika S.A.S. and Pharmatoka S.A.S., 2009. Updated synthesis of the files submitted by GIKA / PHARMATOKA SAS to the French Government 2002, 2006, 2008 on which the existing French health claim (dir.1946/2002) is based.
- 29 Goodine W, 2002. Regular drinking of cranberry-lingonberry juice concentrate reduced recurrent urinary tract infections in women. *Evid Based Nurs*, 5, 43.
- 30 Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA, 2006. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. *Clin Pharmacol Ther*, 79, 125-133.
- 31 Gupta K, Chou MY, Howell A, Wobbe C, Grady R, Stapleton AE, 2007. Cranberry products inhibit adherence of p-fimbriated *Escherichia coli* to primary cultured bladder and vaginal epithelial cells. *J Urol*, 177, 2357-2360.
- 32 Habash MB, Van der Mei HC, Busscher HJ, Reid G, 1999. The effect of water, ascorbic acid, and cranberry derived supplementation on human urine and uropathogen adhesion to silicone rubber. *Can J Microbiol*, 45, 691-694.
- 33 Harkins KJ, 2000. What's the use of cranberry juice? *Age Ageing*, 29, 9-12.
- 34 Harvard Medical School, Cranberry (*Vaccinium macrocarpon*), www.intelihealth.com.
- 35 Haverkorn MJ and Mandigers J, 1994. Reduction of bacteriuria and pyuria using cranberry juice. *JAMA*, 272, 590.
- 36 Henig YS and Leahy MM, 2000. Cranberry juice and urinary-tract health: science supports folklore. *Nutrition*, 16, 684-687.
- 37 Howell AB, Vorsa N, Der Marderosian A, Foo LY, 1998. Inhibition of the adherence of P-fimbriated *Escherichia coli* to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. *N Engl J Med*, 339, 1085-1086.
- 38 Howell AB, 2002. Cranberry proanthocyanidins and the maintenance of urinary tract health. *Crit Rev Food Sci Nutr*, 42, 273-278.
- 39 Howell AB and Foxman B, 2002. Cranberry juice and adhesion of antibiotic-resistant uropathogens. *JAMA*, 287, 3082-3083.
- 40 Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M, 2005. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. *Phytochemistry*, 66, 2281-2291.
- 41 Howell AB, 2007. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. *Mol Nutr Food Res*, 51, 732-737.
- 42 Hutchinson J, 2005. Do cranberries help prevent urinary tract infections? *Nurs Times*, 101, 38-40.
- 43 Jepson RG, Mihaljevic L, Craig J, 2004. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*, CD001321.
- 44 Jepson RG, Mihaljevic L, Craig J, 2004. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*, CD001321.
- 45 Jepson RG and Craig JC, 2007. A systematic review of the evidence for cranberries and blueberries in UTI prevention. *Mol Nutr Food Res*, 51, 738-745.
- 46 Jepson RG and Craig JC, 2008. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*, CD001321.
- 47 Johnson-White B, Buquo L, Zeinali M, Ligler FS, 2006. Prevention of nonspecific bacterial cell adhesion in immunoassays by use of cranberry juice. *Anal Chem*, 78, 853-857.
- 48 Kemper KJ, 1999. Cranberry (*Vaccinium macrocarpon*). Longwood Herbal Task Force and Center for Holistic Pediatric Education and Research.

- 49 Kiel RJ, Nashelsky J, Robbins B, Bondi S, 2003. Clinical inquiries. Does cranberry juice prevent or treat urinary tract infection? *J Fam Pract*, 52, 154-155.
- 50 Lavigne JP, Bourg G, Combescure C, Botto H, Sotto A, 2008. In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic *Escherichia coli* virulence after consumption of commercial *Vaccinium macrocarpon* (cranberry) capsules. *Clin Microbiol Infect*, 14, 350-355.
- 51 Leaver RB, 1996. Cranberry juice. *Prof Nurse*, 11, 525-526.
- 52 Leitao DP, Polizello AC, Ito IY, Spadaro AC, 2005. Antibacterial screening of anthocyanic and proanthocyanic fractions from cranberry juice. *J Med Food*, 8, 36-40.
- 53 Liu Y, Black MA, Caron L, Camesano TA, 2006. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of *Escherichia coli*. *Biotechnol Bioeng*, 93, 297-305.
- 54 Lowe FC and Fagelman E, 2001. Cranberry juice and urinary tract infections: what is the evidence? *Urology*, 57, 407-413.
- 55 Lynch DM, 2004. Cranberry for prevention of urinary tract infections. *Am Fam Physician*, 70, 2175-2177.
- 56 MayoClinic, Cranberry (*Vaccinium macrocarpon*) http://www.mayoclinic.com/health/cranberry/NS_patient-cranberry.
- 57 McMurdo MET, Bissett LY, Price RJG, Phillips G, Crombie IK, 2005. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. *Age Ageing*, 34, 256-261.
- 58 MedlinePlus, Cranberry (*Vaccinium macrocarpon*), <http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-cranberry.html>.
- 59 Mills S and Bone K, 2005. *The Essential Guide to Herbal Safety*. Churchill Livingstone, New York.
- 60 National Kidney Foundation, 2000. *Urinary Tract Infections*.
- 61 Natural Medicines Comprehensive Database, Cranberry Monograph, [http://www.naturaldatabase.com/\(S\(1qdhdb45brkz55510kmod55\)\)/nd/Search.aspx?cs=&s=ND&pt=100&id=958&ds=&name=Vaccinium+Macrocarpon+\(CRANBERRY\)&searchid=21570932](http://www.naturaldatabase.com/(S(1qdhdb45brkz55510kmod55))/nd/Search.aspx?cs=&s=ND&pt=100&id=958&ds=&name=Vaccinium+Macrocarpon+(CRANBERRY)&searchid=21570932).
- 62 Natural Standard Research Collaboration, Cranberry (*Vaccinium macrocarpon*), <http://www.naturalstandard.com/monographs/monoframeset.asp?monograph=/monographs/herbssupplement/s/patient-cranberry.asp%3Fprintversion%3Dtrue>.
- 63 Nazarko L, 1995. Infection control. The therapeutic uses of cranberry juice. *Nurs Stand*, 9, 33-35.
- 64 NCCAM (National Center for Complementary and Alternative Medicine), Herbs at a glance: Cranberry, <http://nccam.nih.gov/health/cranberry>.
- 65 Netzel M, Strass G, Herbst M, Dietrich H, Bitsch R, Bitsch I, Frank T, 2005. The excretion and biological antioxidant activity of elderberry antioxidants in healthy humans. *Food Research International*, 38, 905-910.
- 66 No authors listed, 2005. Cranberry and urinary tract infection. *Drug Ther Bull*, 43, 17-19.
- 67 Nowack R and Schmitt W, 2008. Cranberry juice for prophylaxis of urinary tract infections--conclusions from clinical experience and research. *Phytomedicine*, 15, 653-667.
- 68 Ofek I, Goldhar J, Sharon N, 1996. Anti-*Escherichia coli* adhesin activity of cranberry and blueberry juices. *Adv Exp Med Biol*, 408, 179-183.
- 69 Pizzorno JE and Murray MT, 1999. Section V: Pharmacology of natural medicines. *Vaccinium macrocarpon* (cranberry). In: *Textbook of Natural Medicine*. Pizzorno JE and Murray MT (eds.). Churchill Livingstone, Edinburgh, 1355-1364.
- 70 Puupponen-Pimia R, Nohynek L, Alakomi HL, Oksman-Caldentey KM, 2005. Bioactive berry compounds--novel tools against human pathogens. *Appl Microbiol Biotechnol*, 67, 8-18.
- 71 Raz R, Chazan B, Dan M, 2004. Cranberry juice and urinary tract infection. *Clin Infect Dis*, 38, 1413-1419.

- 72 Reid G, 2002. The role of cranberry and probiotics in intestinal and urogenital tract health. *Crit Rev Food Sci Nutr*, 42, 293-300.
- 73 Safarinejad MR, 2005. *Urtica dioica* for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. *J Herb Pharmacother*, 5, 1-11.
- 74 Schlager TA, Anderson S, Trudell J, Hendley JO, 1999. Effect of cranberry juice on bacteriuria in children with neurogenic bladder receiving intermittent catheterization. *J Pediatr*, 135, 698-702.
- 75 Sharon N and Ofek I, 2002. Fighting infectious diseases with inhibitors of microbial adhesion to host tissues. *Crit Rev Food Sci Nutr*, 42, 267-272.
- 76 Sobota AE, 1984. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. *J Urol*, 131, 1013-1016.
- 77 Stothers L, 2002. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. *Can J Urol*, 9, 1558-1562.
- 78 SupplementWatch, Cranberry, <http://www.supplementwatch.com>.
- 79 Suvarna R, Pirmohamed M, Henderson L, 2003. Possible interaction between warfarin and cranberry juice. *BMJ*, 327, 1454.
- 80 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 81 Terris MK, Issa MM, Tacker JR, 2001. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. *Urology*, 57, 26-29.
- 82 Turner A, Chen SN, Joike MK, Pendland SL, Pauli GF, Farnsworth NR, 2005. Inhibition of uropathogenic *Escherichia coli* by cranberry juice: a new antiadherence assay. *J Agric Food Chem*, 53, 8940-8947.
- 83 Urell.fr, From tradition to 36 mg PAC per day measured by DMAC, <http://www.urell.fr/en/zoom5.php>.
- 84 Veteran Affairs - Boston Healthcare System, Evaluation of Cran-Max for the Prevention of UTI in Spinal Cord Injured 17 Patients with Neurogenic Bladders.
- 85 Walker EB, Barney DP, Mickelsen JN, Walton RJ, Mickelsen RA, Jr., 1997. Cranberry concentrate: UTI prophylaxis. *J Fam Pract*, 45, 167-168.
- 86 Walling AD, 2002. Cranberry-Lingonberry Juice Can Prevent UTIs. *Am Fam Physician*, 65, 490-494.
- 87 Weeda E, 1999. *De Nederlandse oecologische flora set*. KNNV Uitgeverij, Gebonden.
- 88 WHO (World Health Organization), 2002. *WHO Monographs on Selected Medicinal Plants*.
- 89 Zafriri D, Ofek I, Adar R, Pocino M, Sharon N, 1989. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated *Escherichia coli* to eucaryotic cells. *Antimicrob Agents Chemother*, 33, 92-98.
- 90 Zheng W and Wang SY, 2003. Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries. *J Agric Food Chem*, 51, 502-509.

ID 2154: “*Vaccinium macrocarpon* (Common Name : Cranberry)” and “Antioxidant properties”

- 1 AFSSA(Agence Francaise de Securite Sanitaire des Aliments), AFFSA’s list of opinions related to human nutrition (FR), <http://www.afssa.fr/>.
- 2 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.
- 3 Duthie GG, Kyle JA, Jenkinson AM, Duthie SJ, Baxter GJ, Paterson JR, 2005. Increased salicylate concentrations in urine of human volunteers after consumption of cranberry juice. *J Agric Food Chem*, 53, 2897-2900.
- 4 Nowack R, 2003. Die amerikanische Cranberry (*Vaccinium macrocarpon* AITON). *Zeitschrift fur Phytotherapie*, 24, 40-46.

- 5 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- 6 Vinson JA, Su X, Zubik L, Bose P, 2001. Phenol antioxidant quantity and quality in foods: fruits. *J Agric Food Chem*, 49, 5315-5321.

ID2155: “Vaccinium macrocarpon (Common Name: Cranberry)” and “Immune health”

- 1 Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA, 1994. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. *JAMA*, 271, 751-754.
- 2 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.
- 3 Nowack R, 2003. Die amerikanische Cranberry (*Vaccinium macrocarpum* Aiton). *Zeitschrift für Phytotherapie*, 24, 40-46.
- 4 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- 5 Zhang L, Ma J, Pan K, Go VL, Chen J, You WC, 2005. Efficacy of cranberry juice on *Helicobacter pylori* infection: a double-blind, randomized placebo-controlled trial. *Helicobacter*, 10, 139-145.

ID 2156: “Vitis vinifera (Common Name : Grape)” and “Antioxidant properties”

- 1 Herbal Remedies/ Heilpflanzen, Version 5. 2003 Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 2 Bagchi D, Bagchi M, Stohs SJ, Das DK, Ray SD, Kuszynski CA, Joshi SS, Pruess HG, 2000. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology*, 148, 187-197.
- 3 Barrett M, 2004. The Handbook of Clinically Tested Herbal Remedies. Haworth Herbal Press, New York.
- 4 Berti F, Manfredi B, Mantegazza P, Rossoni G, 2003. Procyanidins from *Vitis vinifera* seeds display cardioprotection in an experimental model of ischemia-reperfusion damage. *Drugs Exp Clin Res*, 29, 207-216.
- 5 Blache D, Rustan I, Lesgards JF, 1997. Antioxidant properties of plant extracts and trans-resveratrol, a wine product, revealed in vitro et es vivo a biological test. *Lebensmittelchemie*, 51, 3.
- 6 Bombardelli E and Morazzoni P, 1995. *Vitis vinifera* L. *Fitoterapia*(Milano), 66, 291-317.
- 7 Bown D and Koziol C, 2001. DuMonts Grosse Kräuter- Enzyklopädie. DuMont Buchverlag, Köln, Germany.
- 8 Dekoninck WJ, Jocquet P, Jacquy J, Henriet M, 1978. Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. *Arzneimittelforschung*, 28, 1654-1657.
- 9 Dezsi L, Kis-Varga I, Nagy J, Komlodi Z, Karpati E, 2002. [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. *Acta Pharm Hung*, 72, 84-91.
- 10 Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, Friedmann A, Russmann DL, 1996. Therapeutic efficacy of vincamine in dementia. *Neuropsychobiology*, 34, 29-35.
- 11 Hagstadius S, Gustafson L, Risberg J, 1984. The effects of bromvincamine and vincamine on regional cerebral blood flow and mental functions in patients with multi-infarct dementia. *Psychopharmacology (Berl)*, 83, 321-326.
- 12 Hamann KF, Bernhold B, Sattler B, Iatraki L, 1979. Electronystagmographic study in rabbits on the vestibular effect of vincamine. *Arzneimittelforschung*, 29, 34-38.

- 13 Kar P, Laight D, Shaw KM, Cummings MH, 2006. Flavonoid-rich grapeseed extracts: a new approach in high cardiovascular risk patients? *Int J Clin Pract*, 60, 1484-1492.
- 14 Kidd PM, 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. *Altern Med Rev*, 4, 144-161.
- 15 Lu Y, Zhao WZ, Chang Z, Chen WX, Li L, 2004. Procyanidins from grape seeds protect against phorbol ester-induced oxidative cellular and genotoxic damage. *Acta Pharmacol Sin*, 25, 1083-1089.
- 16 McDaniel MA, Maier SF, Einstein GO, 2003. "Brain-specific" nutrients: a memory cure? *Nutrition*, 19, 957-975.
- 17 Mikus P, 1978. [Clinical, psychological and neurophysiological results of double-blind study on vincamine-cromesilate in patients with cerebro-vascular insufficiency (author's transl)]. *Arzneimittelforschung*, 28, 2165-2168.
- 18 Monagas M, Hernandez-Ledesma B, Gomez-Cordoves C, Bartolome B, 2006. Commercial dietary ingredients from *Vitis vinifera* L. leaves and grape skins: antioxidant and chemical characterization. *J. Agric. Food Chem*, 54, 319-327.
- 19 Orhan N, Aslan M, Orhan DD, Ergun F, Yesilada E, 2006. In-vivo assessment of antidiabetic and antioxidant activities of grapevine leaves (*Vitis vinifera*) in diabetic rats. *J Ethnopharmacol*, 108, 280-286.
- 20 Reinecke M, 1977. [Double-blind comparison of vincamine and placebo in patients with presbycusis (author's transl)]. *Arzneimittelforschung*, 27, 1294-1298.
- 21 Soares De Moura R, Costa Viana FS, Souza MA, Kovary K, Guedes DC, Oliveira EP, Rubenich LM, Carvalho LC, Oliveira RM, Tano T, Gusmao Correia ML, 2002. Antihypertensive, vasodilator and antioxidant effects of a *vinifera* grape skin extract. *J Pharm Pharmacol*, 54, 1515-1520.
- 22 Tesseris J, Roggen G, Caracalos A, Triandafillou D, 1975. Effects of vincamin on cerebral metabolism. *Eur Neurol*, 13, 195-202.
- 23 Thierry E, Otte G, Vander Eecken H, 1979. Comparative study of the clinical effect of vincamine versus papaverine given parenterally in the acute phase of stroke. *Arzneimittelforschung*, 29, 671-674.
- 24 van Wyk BE and Wink M, 2004. *Medicinal plants of the world*. Timber Press.

ID 2157: “*Vitis vinifera* (Common Name : Grape)” and “Vein health”

- 1 Bagchi D, Bagchi M, Stohs SJ, Das DK, Ray SD, Kuszynski CA, Joshi SS, Pruess HG, 2000. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology*, 148, 187-197.
- 2 Barrett M, 2004. *The Handbook of Clinically Tested Herbal Remedies*. Haworth Herbal Press, New York.
- 3 Beck H, 1997. Rotes Weinlaub von A bis Z. *PTA Heute*, 11(8), 792-796.
- 4 Blache D, Rustan I, Lesgards JF, 1997. Antioxidant properties of plant extracts and transresveratrol, a wine product, revealed in vitro et es vivo a biological test. *Lebensmittelchemie*, 51, 3.
- 5 Bombardelli E and Morazzoni P, 1995. *Vitis vinifera* L. *Fitoterapia*, 66, 291-317.
- 6 Bown D and Koziol C, 2001. *DuMont's große Kräuterenzyklopädie*. DuMont, Köln.
- 7 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 8 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. *Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 9 Carini M, Stefani R, Aldini G, Ozioli M, Facino RM, 2001. Procyanidins from *Vitis vinifera* seeds inhibit the respiratory burst of activated human neutrophils and lysosomal enzyme release. *Planta Med*, 67, 714-717.

- 10 Facino RM, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1999. Diet enriched with procyanidins enhances antioxidant activity and reduces myocardial post-ischæmic damage in rats. *Life Sci*, 64, 627-642.
- 11 Graf BA, Milbury PE, Blumberg JB, 2005. Flavonols, flavones, flavanones, and human health: epidemiological evidence. *J Med Food*, 8, 281-290.
- 12 Kalus U, Koscielny J, Grigorov A, Schaefer E, Peil H, Kiesewetter H, 2004. Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study. *Drugs R D*, 5, 63-71.
- 13 Kiesewetter H, Koscielny J, Kalus U, Vix JM, Peil H, Petrini O, van Toor BS, de Mey C, 2000. Efficacy of orally administered extract of red vine leaf AS 195 (*folia vitis viniferae*) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial. *Arzneimittelforschung*, 50, 109-117.
- 14 Kontek A, Campeanu R, Petrescu L, Rizea S, 1994. Effect of grape seed procyanidins on some vascular diseases. *Polyphenols 94*. 17. International Conference on Polyphenols, Palma de Mallorca (Espagne).
- 15 Lardos A and Kreuter MH, 2001. *Food Processing Japan*, 36(3), 50-53.
- 16 Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R, 1994. Free radicals scavenging action and anti-enzyme activities of procyanidines from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung*, 44, 592-601.
- 17 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1996. Procyanidines from *Vitis vinifera* seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. *Planta Med*, 62, 495-502.
- 18 Maffei Facino R, Carini M, Aldini G, Calloni MT, Bombardelli E, Morazzoni P, 1998. Sparing effect of procyanidins from *Vitis vinifera* on vitamin E: in vitro studies. *Planta Med*, 64, 343-347.
- 19 Monagas M, Hernandez-Ledesma B, Gomez-Cordoves C, Bartolome B, 2006. Commercial dietary ingredients from *Vitis vinifera* L. leaves and grape skins: antioxidant and chemical characterization. *J Agric Food Chem*, 54, 319-327.
- 20 Monsieur R and Van Snick G, 2006. [Efficacy of the red vine leaf extract AS 195 in Chronic Venous Insufficiency]. *Praxis (Bern 1994)*, 95, 187-190.
- 21 Nees S, Weiss DR, Reichenbach-Klinke E, Rampp F, Heilmeyer B, Kanbach J, Esperester A, 2003. Protective effects of flavonoids contained in the red vine leaf on venular endothelium against the attack of activated blood components in vitro. *Arzneimittelforschung*, 53, 330-341.
- 22 Nuttall SL, Kendall MJ, Bombardelli E, Morazzoni P, 1998. An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. *J Clin Pharm Ther*, 23, 385-389.
- 23 Orhan N, Aslan M, Orhan DD, Ergun F, Yesilada E, 2006. In-vivo assessment of antidiabetic and antioxidant activities of grapevine leaves (*Vitis vinifera*) in diabetic rats. *J Ethnopharmacol*, 108, 280-286.
- 24 Pharmacopée française IX, 1980. Monograph for the uses of *Vitis vinifera* L.
- 25 Pharmacopée française X, 1993. Vigne rouge, *vitis vinifera*.
- 26 Sano T, Oda E, Yamashita T, Naemura A, Ijiri Y, Yamakoshi J, Yamamoto J, 2005. Anti-thrombotic effect of proanthocyanidin, a purified ingredient of grape seed. *Thromb Res*, 115, 115-121.
- 27 Schaefer E, Peil H, Ambrosetti L, Petrini O, 2003. Oedema protective properties of the red vine leaf extract AS 195 (*Folia vitis viniferae*) in the treatment of chronic venous insufficiency. A 6-week observational clinical trial. *Arzneimittelforschung*, 53, 243-246.
- 28 van Wyk BE and Wink M, 2004. *Medicinal plants of the world*. Timber Press, Portland.

ID 2158: “Vitis vinifera (Common Name : Grape)” and “Skin health/Antioxidative properties”

- 1 Bagchi D, Bagchi M, Stohs S, Ray SD, Sen CK, Preuss HG, 2002. Cellular protection with proanthocyanidins derived from grape seeds. *Ann N Y Acad Sci*, 957, 260-270.
- 2 Bombardelli E and Morazzoni P, 1993. The flavonoids: New perspectives in biological activities and therapeutics. Milano, Italy: Indena Spa.
- 3 Bombardelli E and Morazzoni P, 1995. *Vitis vinifera* L. *Fitoterapia*, 66, 291-317.
- 4 Busserolles J, Gueux E, Balasinska B, Piriou Y, Rock E, Rayssiguier Y, Mazur A, 2006. In vivo antioxidant activity of procyanidin-rich extracts from grape seed and pine (*Pinus maritima*) bark in rats. *Int J Vitam Nutr Res*, 76, 22-27.
- 5 Carini M, Stefani R, Aldini G, Ozioli M, Facino RM, 2001. Procyanidins from *Vitis vinifera* seeds inhibit the respiratory burst of activated human neutrophils and lysosomal enzyme release. *Planta Med*, 67, 714-717.
- 6 Distante F, Bacci PA, Carrera M, 2006. Efficacy of a multifunctional plant complex in the treatment of the so-called 'cellulite': clinical and instrumental evaluation. *Int J Cosmet Sci*, 28, 191-206.
- 7 El Hindi T, Ehlers G, Demchuk M, Pfitzner I, 2004. Determination of the antioxidant capacity of an antioxidant combination using the fluoroscan assay in vitro and visualization of its effects using histological methods. *Arch Dermatol Res*, 296, 258-264.
- 8 Greul AK, Grundmann JU, Heinrich F, Pfitzner I, Bernhardt J, Ambach A, Biesalski HK, Gollnick H, 2002. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and proanthocyanidins. *Skin Pharmacol Appl Skin Physiol*, 15, 307-315.
- 9 Hexsel D, Orlandi C, Zechmeister do Prado D, 2005. Botanical extracts used in the treatment of cellulite. *Dermatol Surg*, 31, 866-872; discussion 872.
- 10 Jonadet M, Meunier MT, Bastide J, Bastide P, 1983. [Anthocyanosides extracted from *Vitis vinifera*, *Vaccinium myrtillus* and *Pinus maritimus*. I. Elastase-inhibiting activities in vitro. II. Compared angioprotective activities in vivo]. *J Pharm Belg*, 38, 41-46.
- 11 Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R, 1994. Free radicals scavenging action and anti-enzyme activities of procyanidines from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung*, 44, 592-601.
- 12 Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*, 81, 230S-242S.
- 13 Masquelier J, Dumon MC, Dumas J, 1981. Stabilisation du collagene par les oligomeres procyanidoliques. *Acta Therapeutica*, 7, 101-105.
- 14 Meunier M, Duroux E, Bastide P, 1989. Activite antiradicalaire d'oligomeres procyanidoliques et d'anthocyanosides vis-a-vis de l'anion superoxyde et vis-a-vis de la lipoperoxydation. *Plantes medicinales et phytotherapie*, 23, 267-274.
- 15 Moreno DA, Ilic N, Poulev A, Brasaemle DL, Fried SK, Raskin I, 2003. Inhibitory effects of grape seed extract on lipases. *Nutrition*, 19, 876-879.
- 16 Prieur C, Rigaud J, Cheynier V, Moutounet M, 1994. Oligomeric and polymeric procyanidins from grape seeds. *Phytochemistry*, 36, 781-784.
- 17 Ricardo da Silva JM, Rigaud J, Cheynier V, Cheminat A, Moutounet M, 1991. Procyanidin dimers and trimers from grape seeds. *Phytochemistry*, 30, 1259-1264.
- 18 Robert L, Godeau G, Gavignet-Jeanin C, Groult N, Six C, Robert A, 1990. Action des oligomeres procyanidoliques sur la permeabilite de la paroi vasculaire etude par morphologie quantitative. *Pathologie Biologie*, 38, 608-616.
- 19 Sangeetha P, Balu M, Haripriya D, Panneerselvam C, 2005. Age associated changes in erythrocyte membrane surface charge: Modulatory role of grape seed proanthocyanidins. *Exp Gerontol*, 40, 820-828.

- 20 Sano A, Yamakoshi J, Tokutake S, Tobe K, Kubota Y, Kikuchi M, 2003. Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. *Biosci Biotechnol Biochem*, 67, 1140-1143.
- 21 Sreemantula S, Nammi S, Kolanukonda R, Koppula S, Boini KM, 2005. Adaptogenic and nootropic activities of aqueous extract of *Vitis vinifera* (grape seed): an experimental study in rat model. *BMC Complement Altern Med*, 5, 1.
- 22 Vitseva O, Varghese S, Chakrabarti S, Folts JD, Freedman JE, 2005. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. *J Cardiovasc Pharmacol*, 46, 445-451.
- 23 Ward NC, Croft KD, Puddey IB, Hodgson JM, 2004. Supplementation with grape seed polyphenols results in increased urinary excretion of 3-hydroxyphenylpropionic Acid, an important metabolite of proanthocyanidins in humans. *J Agric Food Chem*, 52, 5545-5549.
- 24 Yamakoshi J, Otsuka F, Sano A, Tokutake S, Saito M, Kikuchi M, Kubota Y, 2003. Lightening effect on ultraviolet-induced pigmentation of guinea pig skin by oral administration of a proanthocyanidin-rich extract from grape seeds. *Pigment Cell Res*, 16, 629-638.
- 25 Yamakoshi J, Sano A, Tokutake S, Saito M, Kikuchi M, Kubota Y, Kawachi Y, Otsuka F, 2004. Oral intake of proanthocyanidin-rich extract from grape seeds improves chloasma. *Phytother Res*, 18, 895-899.
- 26 Zafirov D, Bredy-Dobrev G, Litchev V, Papisova M, 1990. Antiexudative and capillaritonic effects of procyanidines isolated from grape seeds (*V. Vinifera*). *Acta Physiol Pharmacol Bulg*, 16, 50-54.

ID 2159: “*Vitis vinifera* (Common Name : Grape)” and “Heart health”

- 1 Beck H, 1997. Rotes Weinlaub von A bis Z. *PTA heute*, 11, 792-796.
- 2 Blache D, Rustan I, Lesgards JF, 1997. Antioxidant properties of plant extracts and trans-resveratrol, a wine product, revealed in vitro et es vivo a biological test. *Lebensmittelchemie*, 51, 3.
- 3 Bombardelli E and Morazzoni P, 1995. *Vitis vinifera* L. *Fitoterapia*(Milano), 66, 291-317.

ID 2160: “VitaBerry® Antioxidant Fruit Blend” and “Excellent source of healthy fruit antioxidants”

- 1 Aaby K, Skrede G, Wrolstad RE, 2005. Phenolic composition and antioxidant activities in flesh and achenes of strawberries (*Fragaria ananassa*). *J Agric Food Chem*, 53, 4032-4040.
- 2 Ariga T, 2004. The antioxidative function, preventive action on disease and utilization of proanthocyanidins. *Biofactors*, 21, 197-201.
- 3 Asami DK, Hong YJ, Barrett DM, Mitchell AE, 2003. Comparison of the total phenolic and ascorbic acid content of freeze-dried and air-dried marionberry, strawberry, and corn grown using conventional, organic, and sustainable agricultural practices. *J Agric Food Chem*, 51, 1237-1241.
- 4 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.
- 5 Bagchi D, Roy S, Patel V, He G, Khanna S, Ojha N, Phillips C, Ghosh S, Bagchi M, Sen CK, 2006. Safety and whole-body antioxidant potential of a novel anthocyanin-rich formulation of edible berries. *Mol Cell Biochem*, 281, 197-209.
- 6 Beekwilder J, Hall RD, de Vos CH, 2005. Identification and dietary relevance of antioxidants from raspberry. *Biofactors*, 23, 197-205.
- 7 Beekwilder J, Jonker H, Meesters P, Hall RD, van der Meer IM, Ric de Vos CH, 2005. Antioxidants in raspberry: on-line analysis links antioxidant activity to a diversity of individual metabolites. *J Agric Food Chem*, 53, 3313-3320.

- 8 Boivin D, Blanchette M, Barrette S, Moghrabi A, Beliveau R, 2007. Inhibition of cancer cell proliferation and suppression of TNF-induced activation of NFkappaB by edible berry juice. *Anticancer Res*, 27, 937-948.
- 9 Caldwell CR, 2001. Oxygen radical absorbance capacity of the phenolic compounds in plant extracts fractionated by high-performance liquid chromatography. *Anal Biochem*, 293, 232-238.
- 10 Cao G, Alessio HM, Cutler RG, 1993. Oxygen-radical absorbance capacity assay for antioxidants. *Free Radic Biol Med*, 14, 303-311.
- 11 Cao G, Giovanoni M, Prior RL, 1996. Antioxidant capacity decreases during growth but not aging in rat serum and brain. *Arch Gerontol Geriatr*, 22, 27-37.
- 12 Cao G, Giovanoni M, Prior RL, 1996. Antioxidant capacity in different tissues of young and old rats. *Proc Soc Exp Biol Med*, 211, 359-365.
- 13 Cao G, Booth SL, Sadowski JA, Prior RL, 1998. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. *Am J Clin Nutr*, 68, 1081-1087.
- 14 Cao G and Prior RL, 1998. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. *Clin Chem*, 44, 1309-1315.
- 15 Cao G, Russell RM, Lischner N, Prior RL, 1998. Serum antioxidant capacity is increased by consumption of strawberries, spinach, red wine or vitamin C in elderly women. *J Nutr*, 128, 2383-2390.
- 16 Cao G and Prior RL, 1999. Measurement of oxygen radical absorbance capacity in biological samples. *Methods Enzymol*, 299, 50-62.
- 17 Cao G, Shukitt-Hale B, Bickford PC, Joseph JA, McEwen J, Prior RL, 1999. Hyperoxia-induced changes in antioxidant capacity and the effect of dietary antioxidants. *J Appl Physiol*, 86, 1817-1822.
- 18 Cao G and Prior RL, 2000. Postprandial increases in serum antioxidant capacity in older women. *J Appl Physiol*, 89, 877-883.
- 19 Crozier A, Burns J, Aziz AA, Stewart AJ, Rabiasz HS, Jenkins GI, Edwards CA, Lean ME, 2000. Antioxidant flavonols from fruits, vegetables and beverages: measurements and bioavailability. *Biol Res*, 33, 79-88.
- 20 Davalos A, Gomez-Cordoves C, Bartolome B, 2004. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. *J Agric Food Chem*, 52, 48-54.
- 21 Deyhim F, Patil BS, Villarreal A, Lopez E, Garcia K, Rios R, Garcia C, Gonzales C, Mandadi K, 2007. Cranberry juice increases antioxidant status without affecting cholesterol homeostasis in orchidectomized rats. *J Med Food*, 10, 49-53.
- 22 Freeman LM, Rush JE, Milbury PE, Blumberg JB, 2005. Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. *J Vet Intern Med*, 19, 537-541.
- 23 Gillespie KM, Chae JM, Ainsworth EA, 2007. Rapid measurement of total antioxidant capacity in plants. *Nat Protoc*, 2, 867-870.
- 24 Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, Wold AB, Haffner K, Baugherod H, Andersen LF, Moskaug O, Jacobs DR, Jr., Blomhoff R, 2002. A systematic screening of total antioxidants in dietary plants. *J Nutr*, 132, 461-471.
- 25 Halvorsen BL, Carlsen MH, Phillips KM, Bohn SK, Holte K, Jacobs DR, Jr., Blomhoff R, 2006. Content of redox-active compounds (ie, antioxidants) in foods consumed in the United States. *Am J Clin Nutr*, 84, 95-135.
- 26 Han C, Ding H, Casto B, Stoner GD, D'Ambrosio SM, 2005. Inhibition of the growth of premalignant and malignant human oral cell lines by extracts and components of black raspberries. *Nutr Cancer*, 51, 207-217.
- 27 He X and Liu RH, 2006. Cranberry phytochemicals: Isolation, structure elucidation, and their antiproliferative and antioxidant activities. *J Agric Food Chem*, 54, 7069-7074.

- 28 Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, Deemer EK, 2002. Development and validation of oxygen radical absorbance capacity assay for lipophilic antioxidants using randomly methylated beta-cyclodextrin as the solubility enhancer. *J Agric Food Chem*, 50, 1815-1821.
- 29 Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, Prior RL, 2002. High-throughput assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid handling system coupled with a microplate fluorescence reader in 96-well format. *J Agric Food Chem*, 50, 4437-4444.
- 30 Jaakola L, Maatta K, Pirttila AM, Torronen R, Karenlampi S, Hohtola A, 2002. Expression of genes involved in anthocyanin biosynthesis in relation to anthocyanin, proanthocyanidin, and flavonol levels during bilberry fruit development. *Plant Physiol*, 130, 729-739.
- 31 Jayaprakasha GK, Mandadi KK, Poulouse SM, Jadegoud Y, Nagana Gowda GA, Patil BS, 2007. Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from *Poncirus trifoliata* (L.) Raf. *Bioorg Med Chem*, 15, 4923-4932.
- 32 Juranic Z and Zizak Z, 2005. Biological activities of berries: from antioxidant capacity to anti-cancer effects. *Biofactors*, 23, 207-211.
- 33 Kahkonen MP, Hopia AI, Heinonen M, 2001. Berry phenolics and their antioxidant activity. *J Agric Food Chem*, 49, 4076-4082.
- 34 Kalt W, Forney CF, Martin A, Prior RL, 1999. Antioxidant capacity, vitamin C, phenolics, and anthocyanins after fresh storage of small fruits. *J Agric Food Chem*, 47, 4638-4644.
- 35 Kayano S, Yamada NF, Suzuki T, Ikami T, Shioaki K, Kikuzaki H, Mitani T, Nakatani N, 2003. Quantitative evaluation of antioxidant components in prunes (*Prunus domestica* L.). *J Agric Food Chem*, 51, 1480-1485.
- 36 Kayano S, Kikuzaki H, Ikami T, Suzuki T, Mitani T, Nakatani N, 2004. A new bipyrrole and some phenolic constituents in prunes (*Prunus domestica* L.) and their oxygen radical absorbance capacity (ORAC). *Biosci Biotechnol Biochem*, 68, 942-944.
- 37 Kelley DS, Rasooly R, Jacob RA, Kader AA, Mackey BE, 2006. Consumption of Bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and women. *J Nutr*, 136, 981-986.
- 38 Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM, 2005. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. *Pediatr Blood Cancer*, 44, 378-385.
- 39 Kikuzaki H, Kayano S, Fukutsuka N, Aoki A, Kasamatsu K, Yamasaki Y, Mitani T, Nakatani N, 2004. Abscisic acid related compounds and lignans in prunes (*Prunus domestica* L.) and their oxygen radical absorbance capacity (ORAC). *J Agric Food Chem*, 52, 344-349.
- 40 Kinnunen S, Hyyppa S, Lehmuskero A, Oksala N, Maenpaa P, Hanninen O, Atalay M, 2005. Oxygen radical absorbance capacity (ORAC) and exercise-induced oxidative stress in trotters. *Eur J Appl Physiol*, 95, 550-556.
- 41 Liu M, Li XQ, Weber C, Lee CY, Brown J, Liu RH, 2002. Antioxidant and antiproliferative activities of raspberries. *J Agric Food Chem*, 50, 2926-2930.
- 42 Lopez-Alarcon C and Lissi E, 2006. A novel and simple ORAC methodology based on the interaction of Pyrogallol Red with peroxy radicals. *Free Radic Res*, 40, 979-985.
- 43 Maatta-Riihinen KR, Kahkonen MP, Torronen AR, Heinonen IM, 2005. Catechins and procyanidins in berries of *vaccinium* species and their antioxidant activity. *J Agric Food Chem*, 53, 8485-8491.
- 44 Mazza G, Kay CD, Cottrell T, Holub BJ, 2002. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. *J Agric Food Chem*, 50, 7731-7737.
- 45 Meyers KJ, Watkins CB, Pritts MP, Liu RH, 2003. Antioxidant and antiproliferative activities of strawberries. *J Agric Food Chem*, 51, 6887-6892.

- 46 Miller ER, 3rd, Erlinger TP, Sacks FM, Svetkey LP, Charleston J, Lin PH, Appel LJ, 2005. A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: results from a randomized controlled feeding study. *Atherosclerosis*, 183, 175-182.
- 47 Moyer RA, Hummer KE, Finn CE, Frei B, Wrolstad RE, 2002. Anthocyanins, phenolics, and antioxidant capacity in diverse small fruits: vaccinium, rubus, and ribes. *J Agric Food Chem*, 50, 519-525.
- 48 Myhrstad MC, Carlsen H, Dahl LI, Ebihara K, Glemmestad L, Haffner K, Moskaug JO, Blomhoff R, 2006. Bilberry extracts induce gene expression through the electrophile response element. *Nutr Cancer*, 54, 94-101.
- 49 Nakatani N, Kayano S, Kikuzaki H, Sumino K, Katagiri K, Mitani T, 2000. Identification, quantitative determination, and antioxidative activities of chlorogenic acid isomers in prune (*Prunus domestica* L.). *J Agric Food Chem*, 48, 5512-5516.
- 50 Neto CC, 2007. Cranberry and its phytochemicals: a review of in vitro anticancer studies. *J Nutr*, 137, 186S-193S.
- 51 Olsson ME, Gustavsson KE, Andersson S, Nilsson A, Duan RD, 2004. Inhibition of cancer cell proliferation in vitro by fruit and berry extracts and correlations with antioxidant levels. *J Agric Food Chem*, 52, 7264-7271.
- 52 Olsson ME, Andersson CS, Oredsson S, Berglund RH, Gustavsson KE, 2006. Antioxidant levels and inhibition of cancer cell proliferation in vitro by extracts from organically and conventionally cultivated strawberries. *J Agric Food Chem*, 54, 1248-1255.
- 53 Pedersen CB, Kyle J, Jenkinson AM, Gardner PT, McPhail DB, Duthie GG, 2000. Effects of blueberry and cranberry juice consumption on the plasma antioxidant capacity of healthy female volunteers. *Eur J Clin Nutr*, 54, 405-408.
- 54 Pellegrini N, Serafini M, Colombi B, Del Rio D, Salvatore S, Bianchi M, Brighenti F, 2003. Total antioxidant capacity of plant foods, beverages and oils consumed in Italy assessed by three different in vitro assays. *J Nutr*, 133, 2812-2819.
- 55 Price JA, Sanny CG, Shevlin D, 2006. Application of manual assessment of oxygen radical absorbent capacity (ORAC) for use in high throughput assay of "total" antioxidant activity of drugs and natural products. *J Pharmacol Toxicol Methods*, 54, 56-61.
- 56 Prior RL and Cao G, 1999. In vivo total antioxidant capacity: comparison of different analytical methods. *Free Radic Biol Med*, 27, 1173-1181.
- 57 Prior RL and Cao G, 2000. Analysis of botanicals and dietary supplements for antioxidant capacity: a review. *J AOAC Int*, 83, 950-956.
- 58 Prior RL, 2003. Fruits and vegetables in the prevention of cellular oxidative damage. *Am J Clin Nutr*, 78, 570S-578S.
- 59 Prior RL, Hoang H, Gu L, Wu X, Bacchiocca M, Howard L, Hampsch-Woodill M, Huang D, Ou B, Jacob R, 2003. Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORAC(FL))) of plasma and other biological and food samples. *J Agric Food Chem*, 51, 3273-3279.
- 60 Prior RL, 2004. Plasma antioxidant measurements. *J Nutr*, 134, 3184S-3185S.
- 61 Prior RL, Wu X, Schaich K, 2005. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. *J Agric Food Chem*, 53, 4290-4302.
- 62 Prior RL, Gu L, Wu X, Jacob RA, Sotoudeh G, Kader AA, Cook RA, 2007. Plasma antioxidant capacity changes following a meal as a measure of the ability of a food to alter in vivo antioxidant status. *J Am Coll Nutr*, 26, 170-181.
- 63 Roberts WG, Gordon MH, Walker AF, 2003. Effects of enhanced consumption of fruit and vegetables on plasma antioxidant status and oxidative resistance of LDL in smokers supplemented with fish oil. *Eur J Clin Nutr*, 57, 1303-1310.

- 64 Roy S, Khanna S, Alessio HM, Vider J, Bagchi D, Bagchi M, Sen CK, 2002. Anti-angiogenic property of edible berries. *Free Radic Res*, 36, 1023-1031.
- 65 Sofic E, Sapcanin A, Tahirovic I, Gavrankapetanovic I, Jellinger K, Reynolds GP, Tatschner T, Riederer P, 2006. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. *J Neural Transm Suppl*, 39-43.
- 66 Stewart RJ, Askew EW, McDonald CM, Metos J, Jackson WD, Balon TW, Prior RL, 2002. Antioxidant status of young children: response to an antioxidant supplement. *J Am Diet Assoc*, 102, 1652-1657.
- 67 Stintzing FC, Stintzing AS, Carle R, Frei B, Wrolstad RE, 2002. Color and antioxidant properties of cyanidin-based anthocyanin pigments. *J Agric Food Chem*, 50, 6172-6181.
- 68 Sun J, Chu YF, Wu X, Liu RH, 2002. Antioxidant and antiproliferative activities of common fruits. *J Agric Food Chem*, 50, 7449-7454.
- 69 Tomer DP, McLeman LD, Ohmine S, Scherer PM, Murray BK, O'Neill KL, 2007. Comparison of the total oxyradical scavenging capacity and oxygen radical absorbance capacity antioxidant assays. *J Med Food*, 10, 337-344.
- 70 Valentova K, Stejskal D, Bednar P, Vostalova J, Cihalik C, Vecerova R, Koukalova D, Kolar M, Reichenbach R, Sknouril L, Ulrichova J, Simanek V, 2007. Biosafety, antioxidant status, and metabolites in urine after consumption of dried cranberry juice in healthy women: a pilot double-blind placebo-controlled trial. *J Agric Food Chem*, 55, 3217-3224.
- 71 Walton MC, Lentle RG, Reynolds GW, Kruger MC, McGhie TK, 2006. Anthocyanin absorption and antioxidant status in pigs. *J Agric Food Chem*, 54, 7940-7946.
- 72 Wang SY and Lin HS, 2000. Antioxidant activity in fruits and leaves of blackberry, raspberry, and strawberry varies with cultivar and developmental stage. *J Agric Food Chem*, 48, 140-146.
- 73 Wu X, Pittman HE, 3rd, Prior RL, 2006. Fate of anthocyanins and antioxidant capacity in contents of the gastrointestinal tract of weanling pigs following black raspberry consumption. *J Agric Food Chem*, 54, 583-589.
- 74 Yan X, Murphy BT, Hammond GB, Vinson JA, Neto CC, 2002. Antioxidant activities and antitumor screening of extracts from cranberry fruit (*Vaccinium macrocarpon*). *J Agric Food Chem*, 50, 5844-5849.
- 75 Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D, 2007. Berry anthocyanins as novel antioxidants in human health and disease prevention. *Mol Nutr Food Res*, 51, 675-683.
- 76 Zheng W and Wang SY, 2003. Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries. *J Agric Food Chem*, 51, 502-509.

ID 2162: “VitaBlue® Wild Blueberry Extract” and “Excellent source of healthy fruit antioxidants”

- 1 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.
- 2 Bagchi D, Roy S, Patel V, He G, Khanna S, Ojha N, Phillips C, Ghosh S, Bagchi M, Sen CK, 2006. Safety and whole-body antioxidant potential of a novel anthocyanin-rich formulation of edible berries. *Mol Cell Biochem*, 281, 197-209.
- 3 Bradham RR and Gangemi JD, 2000. The medicinal potential of blueberries. A new nutraceutical for South Carolina farmers. *J S C Med Assoc*, 96, 300-303.
- 4 Caldwell CR, 2001. Oxygen radical absorbance capacity of the phenolic compounds in plant extracts fractionated by high-performance liquid chromatography. *Anal Biochem*, 293, 232-238.
- 5 Cao G, Alessio HM, Cutler RG, 1993. Oxygen-radical absorbance capacity assay for antioxidants. *Free Radic Biol Med*, 14, 303-311.

- 6 Cao G, Giovanoni M, Prior RL, 1996(a). Antioxidant capacity in different tissues of young and old rats. *Proc Soc Exp Biol Med*, 211, 359-365.
- 7 Cao G, Giovanoni M, Prior RL, 1996(b). Antioxidant capacity decreases during growth but not aging in rat serum and brain. *Archives of Gerontology and Geriatrics*, 22, 27-37.
- 8 Cao G, Booth SL, Sadowski JA, Prior RL, 1998(a). Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. *Am J Clin Nutr*, 68, 1081-1087.
- 9 Cao G and Prior RL, 1998(b). Comparison of different analytical methods for assessing total antioxidant capacity of human serum. *Clin Chem*, 44, 1309-1315.
- 10 Cao G and Prior RL, 1999(a). Measurement of oxygen radical absorbance capacity in biological samples. *Methods Enzymol*, 299, 50-62.
- 11 Cao G, Shukitt-Hale B, Bickford PC, Joseph JA, McEwen J, Prior RL, 1999(b). Hyperoxia-induced changes in antioxidant capacity and the effect of dietary antioxidants. *J Appl Physiol*, 86, 1817-1822.
- 12 Cao G and Prior RL, 2000. Postprandial increases in serum antioxidant capacity in older women. *J Appl Physiol*, 89, 877-883.
- 13 Davalos A, Gomez-Cordoves C, Bartolome B, 2004. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. *J Agric Food Chem*, 52, 48-54.
- 14 Freeman LM, Rush JE, Milbury PE, Blumberg JB, 2005. Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. *J Vet Intern Med*, 19, 537-541.
- 15 Gillespie KM, Chae JM, Ainsworth EA, 2007. Rapid measurement of total antioxidant capacity in plants. *Nat Protoc*, 2, 867-870.
- 16 Halvorsen BL, Carlsen MH, Phillips KM, Bohn SK, Holte K, Jacobs DR, Jr., Blomhoff R, 2006. Content of redox-active compounds (ie, antioxidants) in foods consumed in the United States. *Am J Clin Nutr*, 84, 95-135.
- 17 Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, Deemer EK, 2002(a). Development and validation of oxygen radical absorbance capacity assay for lipophilic antioxidants using randomly methylated beta-cyclodextrin as the solubility enhancer. *J Agric Food Chem*, 50, 1815-1821.
- 18 Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, Prior RL, 2002(b). High-throughput assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid handling system coupled with a microplate fluorescence reader in 96-well format. *Journal of Agricultural and Food Chemistry*, 50, 4437-4444.
- 19 Huang D, Ou B, Prior RL, 2005. The chemistry behind antioxidant capacity assays. *J Agric Food Chem*, 53, 1841-1856.
- 20 Jayaprakasha GK, Mandadi KK, Poulouse SM, Jadegoud Y, Nagana Gowda GA, Patil BS, 2007. Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from *Poncirus trifoliata* (L.) Raf. *Bioorg Med Chem*, 15, 4923-4932.
- 21 Kalt W, Forney CF, Martin A, Prior RL, 1999. Antioxidant capacity, vitamin C, phenolics, and anthocyanins after fresh storage of small fruits. *J Agric Food Chem*, 47, 4638-4644.
- 22 Kay CD and Holub BJ, 2002. The effect of wild blueberry (*Vaccinium angustifolium*) consumption on postprandial serum antioxidant status in human subjects. *Br J Nutr*, 88, 389-398.
- 23 Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM, 2005. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. *Pediatr Blood Cancer*, 44, 378-385.
- 24 Kinnunen S, Hyyppa S, Lehmuskero A, Oksala N, Maenpaa P, Hanninen O, Atalay M, 2005. Oxygen radical absorbance capacity (ORAC) and exercise-induced oxidative stress in trotters. *Eur J Appl Physiol*, 95, 550-556.
- 25 Lopez-Alarcon C and Lissi E, 2006. A novel and simple ORAC methodology based on the interaction of Pyrogallol Red with peroxy radicals. *Free Radic Res*, 40, 979-985.

- 26 Mazza G, Kay CD, Cottrell T, Holub BJ, 2002. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. *J Agric Food Chem*, 50, 7731-7737.
- 27 Miller ER, 3rd, Erlinger TP, Sacks FM, Svetkey LP, Charleston J, Lin PH, Appel LJ, 2005. A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: results from a randomized controlled feeding study. *Atherosclerosis*, 183, 175-182.
- 28 Moyer RA, Hummer KE, Finn CE, Frei B, Wrolstad RE, 2002. Anthocyanins, phenolics, and antioxidant capacity in diverse small fruits: vaccinium, rubus, and ribes. *J Agric Food Chem*, 50, 519-525.
- 29 Price JA, Sanny CG, Shevlin D, 2006. Application of manual assessment of oxygen radical absorbent capacity (ORAC) for use in high throughput assay of "total" antioxidant activity of drugs and natural products. *J Pharmacol Toxicol Methods*, 54, 56-61.
- 30 Prior RL and Cao G, 1999. In vivo total antioxidant capacity: comparison of different analytical methods. *Free Radic Biol Med*, 27, 1173-1181.
- 31 Prior RL and Cao G, 2000. Analysis of botanicals and dietary supplements for antioxidant capacity: a review. *J AOAC Int*, 83, 950-956.
- 32 Prior RL, 2003(a). Fruits and vegetables in the prevention of cellular oxidative damage. *Am J Clin Nutr*, 78, 570S-578S.
- 33 Prior RL, Hoang H, Gu L, Wu X, Bacchiocca M, Howard L, Hampsch-Woodill M, Huang D, Ou B, Jacob R, 2003(b). Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORAC(FL))) of plasma and other biological and food samples. *J Agric Food Chem*, 51, 3273-3279.
- 34 Prior RL, 2004. Plasma antioxidant measurements. *J Nutr*, 134, 3184S-3185S.
- 35 Prior RL, Wu X, Schaich K, 2005. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. *J Agric Food Chem*, 53, 4290-4302.
- 36 Prior RL, Gu L, Wu X, Jacob RA, Sotoudeh G, Kader AA, Cook RA, 2007. Plasma antioxidant capacity changes following a meal as a measure of the ability of a food to alter in vivo antioxidant status. *J Am Coll Nutr*, 26, 170-181.
- 37 Rababah TM, Ereifej KI, Howard L, 2005. Effect of ascorbic acid and dehydration on concentrations of total phenolics, antioxidant capacity, anthocyanins, and color in fruits. *J Agric Food Chem*, 53, 4444-4447.
- 38 Roberts WG, Gordon MH, Walker AF, 2003. Effects of enhanced consumption of fruit and vegetables on plasma antioxidant status and oxidative resistance of LDL in smokers supplemented with fish oil. *Eur J Clin Nutr*, 57, 1303-1310.
- 39 Sofic E, Sapcanin A, Tahirovic I, Gavrankapetanovic I, Jellinger K, Reynolds GP, Tatschner T, Riederer P, 2006. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. *J Neural Transm Suppl*, 39-43.
- 40 Stewart RJ, Askew EW, McDonald CM, Metos J, Jackson WD, Balon TW, Prior RL, 2002. Antioxidant status of young children: response to an antioxidant supplement. *J Am Diet Assoc*, 102, 1652-1657.
- 41 Stintzing FC, Stintzing AS, Carle R, Frei B, Wrolstad RE, 2002. Color and antioxidant properties of cyanidin-based anthocyanin pigments. *J Agric Food Chem*, 50, 6172-6181.
- 42 Tomer DP, McLeman LD, Ohmine S, Scherer PM, Murray BK, O'Neill KL, 2007. Comparison of the total oxyradical scavenging capacity and oxygen radical absorbance capacity antioxidant assays. *J Med Food*, 10, 337-344.
- 43 Ueda Y, Le Nguyen TD, Inoue H, Kunii D, Yamamoto S, Azuma M, 2004. Relationship between smoking habits and serum oxygen radical absorbance capacity and dietary intake in Japanese adults. *Clin Exp Pharmacol Physiol*, 31 Suppl 2, S35-36.
- 44 Walton MC, Lentle RG, Reynolds GW, Kruger MC, McGhie TK, 2006. Anthocyanin absorption and antioxidant status in pigs. *J Agric Food Chem*, 54, 7940-7946.
- 45 Yi W, Fischer J, Krewer G, Akoh CC, 2005. Phenolic compounds from blueberries can inhibit colon cancer cell proliferation and induce apoptosis. *J Agric Food Chem*, 53, 7320-7329.

- 46 Zheng W and Wang SY, 2003. Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries. *J Agric Food Chem*, 51, 502-509.

ID 2164: “VitaCurren[®] Black Currant Extract 25% Anthocyanins” and “Excellent source of healthy fruit antioxidants”

- 1 Bell DR and Gochenaur K, 2006. Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts. *J Appl Physiol*, 100, 1164-1170.
- 2 Canter PH and Ernst E, 2004. Anthocyanosides of *Vaccinium myrtillus* (bilberry) for night vision--a systematic review of placebo-controlled trials. *Surv Ophthalmol*, 49, 38-50.
- 3 Kahkonen MP and Heinonen M, 2003. Antioxidant activity of anthocyanins and their aglycons. *J Agric Food Chem*, 51, 628-633.
- 4 Karlsen A, Retterstol L, Laake P, Paur I, Kjolsrud-Bohn S, Sandvik L, Blomhoff R, 2007. Anthocyanins inhibit nuclear factor-kappaB activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. *J Nutr*, 137, 1951-1954.
- 5 Maatta K, Kamal-Eldin A, Torronen R, 2001. Phenolic compounds in berries of black, red, green, and white currants (*Ribes* sp.). *Antioxid Redox Signal*, 3, 981-993.
- 6 Matsumoto H, Inaba H, Kishi M, Tominaga S, Hirayama M, Tsuda T, 2001. Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms. *J Agric Food Chem*, 49, 1546-1551.
- 7 McGhie TK and Walton MC, 2007. The bioavailability and absorption of anthocyanins: towards a better understanding. *Mol Nutr Food Res*, 51, 702-713.
- 8 Nakaishi H, Matsumoto H, Tominaga S, Hirayama M, 2000. Effects of black current anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans. *Altern Med Rev*, 5, 553-562.
- 9 Nielsen IL, Dragsted LO, Ravn-Haren G, Freese R, Rasmussen SE, 2003. Absorption and excretion of black currant anthocyanins in humans and watanabe heritable hyperlipidemic rabbits. *J Agric Food Chem*, 51, 2813-2820.
- 10 Park SJ, Shin WH, Seo JW, Kim EJ, 2007. Anthocyanins inhibit airway inflammation and hyperresponsiveness in a murine asthma model. *Food Chem Toxicol*, 45, 1459-1467.
- 11 Prior RL and Wu X, 2006. Anthocyanins: structural characteristics that result in unique metabolic patterns and biological activities. *Free Radic Res*, 40, 1014-1028.
- 12 Ramirez-Tortosa C, Andersen OM, Gardner PT, Morrice PC, Wood SG, Duthie SJ, Collins AR, Duthie GG, 2001. Anthocyanin-rich extract decreases indices of lipid peroxidation and DNA damage in vitamin E-depleted rats. *Free Radic Biol Med*, 31, 1033-1037.
- 13 Rechner AR and Kroner C, 2005. Anthocyanins and colonic metabolites of dietary polyphenols inhibit platelet function. *Thromb Res*, 116, 327-334.
- 14 Slimestad R and Solheim H, 2002. Anthocyanins from black currants (*Ribes nigrum* L.). *J Agric Food Chem*, 50, 3228-3231.
- 15 Talavera S, Felgines C, Texier O, Besson C, Manach C, Lamaison JL, Remesy C, 2004. Anthocyanins are efficiently absorbed from the small intestine in rats. *J Nutr*, 134, 2275-2279.
- 16 Tsuda T, Horio F, Osawa T, 2000. The role of anthocyanins as an antioxidant under oxidative stress in rats. *Biofactors*, 13, 133-139.
- 17 Viljanen K, Kylli P, Kivikari R, Heinonen M, 2004. Inhibition of protein and lipid oxidation in liposomes by berry phenolics. *J Agric Food Chem*, 52, 7419-7424.

- 18 WHO/FAO (World Health Organization and Food and Agriculture Organization), 1982. Evaluation of certain food additives and contaminants. Twenty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives WHO Technical Report Series, No. 683.
- 19 Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D, 2007. Berry anthocyanins as novel antioxidants in human health and disease prevention. *Molecular Nutrition & Food Research*, 51.

ID 2165: “VitaCurren[®] Black Currant Extract” and “Excellent source of healthy fruit antioxidants”

- 1 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.
- 2 Bagchi D, Roy S, Patel V, He G, Khanna S, Ojha N, Phillips C, Ghosh S, Bagchi M, Sen CK, 2006. Safety and whole-body antioxidant potential of a novel anthocyanin-rich formulation of edible berries. *Mol Cell Biochem*, 281, 197-209.
- 3 Boivin D, Blanchette M, Barrette S, Moghrabi A, Beliveau R, 2007. Inhibition of cancer cell proliferation and suppression of TNF-induced activation of NFkappaB by edible berry juice. *Anticancer Res*, 27, 937-948.
- 4 Breinholt VM, Nielsen SE, Knuthsen P, Lauridsen ST, Daneshvar B, Sorensen A, 2003. Effects of commonly consumed fruit juices and carbohydrates on redox status and anticancer biomarkers in female rats. *Nutr Cancer*, 45, 46-52.
- 5 Caldwell CR, 2001. Oxygen radical absorbance capacity of the phenolic compounds in plant extracts fractionated by high-performance liquid chromatography. *Anal Biochem*, 293, 232-238.
- 6 Cao G, Alessio HM, Cutler RG, 1993. Oxygen-radical absorbance capacity assay for antioxidants. *Free Radic Biol Med*, 14, 303-311.
- 7 Cao G, Giovanoni M, Prior RL, 1996. Antioxidant capacity decreases during growth but not aging in rat serum and brain. *Arch Gerontol Geriatr*, 22, 27-37.
- 8 Cao G, Giovanoni M, Prior RL, 1996. Antioxidant capacity in different tissues of young and old rats. *Proc Soc Exp Biol Med*, 211, 359-365.
- 9 Cao G, Booth SL, Sadowski JA, Prior RL, 1998. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. *Am J Clin Nutr*, 68, 1081-1087.
- 10 Cao G and Prior RL, 1998. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. *Clin Chem*, 44, 1309-1315.
- 11 Cao G and Prior RL, 1999. Measurement of oxygen radical absorbance capacity in biological samples. *Methods Enzymol*, 299, 50-62.
- 12 Cao G, Shukitt-Hale B, Bickford PC, Joseph JA, McEwen J, Prior RL, 1999. Hyperoxia-induced changes in antioxidant capacity and the effect of dietary antioxidants. *J Appl Physiol*, 86, 1817-1822.
- 13 Cao G and Prior RL, 2000. Postprandial increases in serum antioxidant capacity in older women. *J Appl Physiol*, 89, 877-883.
- 14 Davalos A, Gomez-Cordoves C, Bartolome B, 2004. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. *J Agric Food Chem*, 52, 48-54.
- 15 Degenhardt A, Knapp H, Winterhalter P, 2000. Separation and purification of anthocyanins by high-speed countercurrent chromatography and screening for antioxidant activity. *J Agric Food Chem*, 48, 338-343.
- 16 Ehala S, Vaher M, Kaljurand M, 2005. Characterization of phenolic profiles of Northern European berries by capillary electrophoresis and determination of their antioxidant activity. *J Agric Food Chem*, 53, 6484-6490.

- 17 Farombi EO, Hansen M, Ravn-Haren G, Moller P, Dragsted LO, 2004. Commonly consumed and naturally occurring dietary substances affect biomarkers of oxidative stress and DNA damage in healthy rats. *Food Chem Toxicol*, 42, 1315-1322.
- 18 Freeman LM, Rush JE, Milbury PE, Blumberg JB, 2005. Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. *J Vet Intern Med*, 19, 537-541.
- 19 Gillespie KM, Chae JM, Ainsworth EA, 2007. Rapid measurement of total antioxidant capacity in plants. *Nat Protoc*, 2, 867-870.
- 20 Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, Wold AB, Haffner K, Baugerod H, Andersen LF, Moskaug O, Jacobs DR, Jr., Blomhoff R, 2002. A systematic screening of total antioxidants in dietary plants. *J Nutr*, 132, 461-471.
- 21 Halvorsen BL, Carlsen MH, Phillips KM, Bohn SK, Holte K, Jacobs DR, Jr., Blomhoff R, 2006. Content of redox-active compounds (ie, antioxidants) in foods consumed in the United States. *Am J Clin Nutr*, 84, 95-135.
- 22 Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, Deemer EK, 2002. Development and validation of oxygen radical absorbance capacity assay for lipophilic antioxidants using randomly methylated beta-cyclodextrin as the solubility enhancer. *J Agric Food Chem*, 50, 1815-1821.
- 23 Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, Prior RL, 2002. High-throughput assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid handling system coupled with a microplate fluorescence reader in 96-well format. *J Agric Food Chem*, 50, 4437-4444.
- 24 Huang D, Ou B, Prior RL, 2005. The chemistry behind antioxidant capacity assays. *J Agric Food Chem*, 53, 1841-1856.
- 25 Jayaprakasha GK, Mandadi KK, Poulouse SM, Jadegoud Y, Nagana Gowda GA, Patil BS, 2007. Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from *Poncirus trifoliata* (L.) Raf. *Bioorg Med Chem*, 15, 4923-4932.
- 26 Kalt W, Forney CF, Martin A, Prior RL, 1999. Antioxidant capacity, vitamin C, phenolics, and anthocyanins after fresh storage of small fruits. *J Agric Food Chem*, 47, 4638-4644.
- 27 Kapasakalidis PG, Rastall RA, Gordon MH, 2006. Extraction of polyphenols from processed black currant (*Ribes nigrum* L.) residues. *J Agric Food Chem*, 54, 4016-4021.
- 28 Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM, 2005. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. *Pediatr Blood Cancer*, 44, 378-385.
- 29 Kinnunen S, Hyypää S, Lehmuskero A, Oksala N, Maenpää P, Hanninen O, Atalay M, 2005. Oxygen radical absorbance capacity (ORAC) and exercise-induced oxidative stress in trotters. *Eur J Appl Physiol*, 95, 550-556.
- 30 Landbo AK, Pinelo M, Vikbjerg AF, Let MB, Meyer AS, 2006. Protease-assisted clarification of black currant juice: synergy with other clarifying agents and effects on the phenol content. *J Agric Food Chem*, 54, 6554-6563.
- 31 Lopez-Alarcon C and Lissi E, 2006. A novel and simple ORAC methodology based on the interaction of Pyrogallol Red with peroxy radicals. *Free Radic Res*, 40, 979-985.
- 32 Maatta K, Kamal-Eldin A, Torronen R, 2001. Phenolic compounds in berries of black, red, green, and white currants (*Ribes* sp.). *Antioxid Redox Signal*, 3, 981-993.
- 33 Matsumoto H, Nakamura Y, Hirayama M, Yoshiki Y, Okubo K, 2002. Antioxidant activity of black currant anthocyanin aglycons and their glycosides measured by chemiluminescence in a neutral pH region and in human plasma. *J Agric Food Chem*, 50, 5034-5037.
- 34 Miller ER, 3rd, Erlinger TP, Sacks FM, Svetkey LP, Charleston J, Lin PH, Appel LJ, 2005. A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: results from a randomized controlled feeding study. *Atherosclerosis*, 183, 175-182.

- 35 Morillas-Ruiz J, Zafrilla P, Almar M, Cuevas MJ, Lopez FJ, Abellan P, Villegas JA, Gonzalez-Gallego J, 2005. The effects of an antioxidant-supplemented beverage on exercise-induced oxidative stress: results from a placebo-controlled double-blind study in cyclists. *Eur J Appl Physiol*, 95, 543-549.
- 36 Moyer RA, Hummer KE, Finn CE, Frei B, Wrolstad RE, 2002. Anthocyanins, phenolics, and antioxidant capacity in diverse small fruits: vaccinium, rubus, and ribes. *J Agric Food Chem*, 50, 519-525.
- 37 Olsson ME, Gustavsson KE, Andersson S, Nilsson A, Duan RD, 2004. Inhibition of cancer cell proliferation in vitro by fruit and berry extracts and correlations with antioxidant levels. *J Agric Food Chem*, 52, 7264-7271.
- 38 Pinelo M, Landbo AK, Vikbjerg AF, Meyer AS, 2006. Effect of clarification techniques and rat intestinal extract incubation on phenolic composition and antioxidant activity of black currant juice. *J Agric Food Chem*, 54, 6564-6571.
- 39 Price JA, Sanny CG, Shevlin D, 2006. Application of manual assessment of oxygen radical absorbent capacity (ORAC) for use in high throughput assay of "total" antioxidant activity of drugs and natural products. *J Pharmacol Toxicol Methods*, 54, 56-61.
- 40 Prior RL and Cao G, 1999. In vivo total antioxidant capacity: comparison of different analytical methods. *Free Radic Biol Med*, 27, 1173-1181.
- 41 Prior RL and Cao G, 2000. Analysis of botanicals and dietary supplements for antioxidant capacity: a review. *J AOAC Int*, 83, 950-956.
- 42 Prior RL, 2003. Fruits and vegetables in the prevention of cellular oxidative damage. *Am J Clin Nutr*, 78, 570S-578S.
- 43 Prior RL, Hoang H, Gu L, Wu X, Bacchiocca M, Howard L, Hampsch-Woodill M, Huang D, Ou B, Jacob R, 2003. Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORAC(FL))) of plasma and other biological and food samples. *J Agric Food Chem*, 51, 3273-3279.
- 44 Prior RL, Wu X, Schaich K, 2005. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. *J Agric Food Chem*, 53, 4290-4302.
- 45 Prior RL, Gu L, Wu X, Jacob RA, Sotoudeh G, Kader AA, Cook RA, 2007. Plasma antioxidant capacity changes following a meal as a measure of the ability of a food to alter in vivo antioxidant status. *J Am Coll Nutr*, 26, 170-181.
- 46 Rababah TM, Ereifej KI, Howard L, 2005. Effect of ascorbic acid and dehydration on concentrations of total phenolics, antioxidant capacity, anthocyanins, and color in fruits. *J Agric Food Chem*, 53, 4444-4447.
- 47 Roberts WG, Gordon MH, Walker AF, 2003. Effects of enhanced consumption of fruit and vegetables on plasma antioxidant status and oxidative resistance of LDL in smokers supplemented with fish oil. *Eur J Clin Nutr*, 57, 1303-1310.
- 48 Sofic E, Sapcanin A, Tahirovic I, Gavrankapetanovic I, Jellinger K, Reynolds GP, Tatschner T, Riederer P, 2006. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. *J Neural Transm Suppl*, 39-43.
- 49 Stewart RJ, Askew EW, McDonald CM, Metos J, Jackson WD, Balon TW, Prior RL, 2002. Antioxidant status of young children: response to an antioxidant supplement. *J Am Diet Assoc*, 102, 1652-1657.
- 50 Stintzing FC, Stintzing AS, Carle R, Frei B, Wrolstad RE, 2002. Color and antioxidant properties of cyanidin-based anthocyanin pigments. *J Agric Food Chem*, 50, 6172-6181.
- 51 Tomer DP, McLeman LD, Ohmine S, Scherer PM, Murray BK, O'Neill KL, 2007. Comparison of the total oxyradical scavenging capacity and oxygen radical absorbance capacity antioxidant assays. *J Med Food*, 10, 337-344.
- 52 Ueda Y, Le Nguyen TD, Inoue H, Kunii D, Yamamoto S, Azuma M, 2004. Relationship between smoking habits and serum oxygen radical absorbance capacity and dietary intake in Japanese adults. *Clin Exp Pharmacol Physiol*, 31 Suppl 2, S35-36.

- 53 Viljanen K, Kylli P, Kivikari R, Heinonen M, 2004. Inhibition of protein and lipid oxidation in liposomes by berry phenolics. *J Agric Food Chem*, 52, 7419-7424.
- 54 Walton MC, Lentle RG, Reynolds GW, Kruger MC, McGhie TK, 2006. Anthocyanin absorption and antioxidant status in pigs. *J Agric Food Chem*, 54, 7940-7946.
- 55 WHO/FAO (World Health Organization and Food and Agriculture Organization), 1982. Evaluation of certain food additives and contaminants. Twenty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives WHO Technical Report Series, No. 683.
- 56 Wu X, Gu L, Prior RL, McKay S, 2004. Characterization of anthocyanins and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capacity. *J Agric Food Chem*, 52, 7846-7856.
- 57 Xiong S, Melton LD, Eastal AJ, Siew D, 2006. Stability and antioxidant activity of black currant anthocyanins in solution and encapsulated in glucan gel. *J Agric Food Chem*, 54, 6201-6208.
- 58 Young JF, Nielsen SE, Haraldsdottir J, Daneshvar B, Lauridsen ST, Knuthsen P, Crozier A, Sandstrom B, Dragsted LO, 1999. Effect of fruit juice intake on urinary quercetin excretion and biomarkers of antioxidative status. *Am J Clin Nutr*, 69, 87-94.
- 59 Young JF, Nielsen SE, Haraldsdottir J, Daneshvar B, Lauridsen ST, Knuthsen P, Crozier A, Sandstrom B, Dragsted LO, 2000. [Polyphenolic antioxidants in fruit juice. Urinary excretion and effects on biological markers for antioxidative status]. *Ugeskr Laeger*, 162, 1388-1392.
- 60 Zadernowski R, Naczek M, Nesterowicz J, 2005. Phenolic acid profiles in some small berries. *J Agric Food Chem*, 53, 2118-2124.

ID 2166: “VitaGrape® Grape Seed Extract 95% OPC” and “Excellent source of oligomeric proanthocyanidins known to help in the management of heart health”

- 1 Bagchi D, Bagchi M, Stohs S, Ray SD, Sen CK, Preuss HG, 2002. Cellular protection with proanthocyanidins derived from grape seeds. *Ann NY Acad Sci*, 957, 260-270.
- 2 Bogs J, Downey MO, Harvey JS, Ashton AR, Tanner GJ, Robinson SP, 2005. Proanthocyanidin synthesis and expression of genes encoding leucoanthocyanidin reductase and anthocyanidin reductase in developing grape berries and grapevine leaves. *Plant Physiol*, 139, 652-663.
- 3 Devi A, Jolitha AB, Ishii N, 2006. Grape seed proanthocyanidin extract (GSPE) and antioxidant defense in the brain of adult rats. *Med Sci Monit*, 12, BR124-129.
- 4 El-Alfy AT, Ahmed AA, Fatani AJ, 2005. Protective effect of red grape seeds proanthocyanidins against induction of diabetes by alloxan in rats. *Pharmacol Res*, 52, 264-270.
- 5 Erlejman AG, Fraga CG, Oteiza PI, 2006. Procyanidins protect Caco-2 cells from bile acid- and oxidant-induced damage. *Free Radic Biol Med*, 41, 1247-1256.
- 6 Faria A, Calhau C, de Freitas V, Mateus N, 2006. Procyanidins as antioxidants and tumor cell growth modulators. *J Agric Food Chem*, 54, 2392-2397.
- 7 Feng Y, Liu YM, Leblanc MH, Bhatt AJ, Rhodes PG, 2007. Grape seed extract given three hours after injury suppresses lipid peroxidation and reduces hypoxic-ischemic brain injury in neonatal rats. *Pediatr Res*, 61, 295-300.
- 8 Fridrich D, Kern M, Fritz J, Pahlke G, Kohler N, Winterhalter P, Marko D, 2007. The epidermal growth factor receptor and human topoisomerases represent potential cellular targets of oligomeric procyanidins. *Mol Nutr Food Res*, 51, 192-200.
- 9 Fujii H, Nakagawa T, Nishioka H, Sato E, Hirose A, Ueno Y, Sun B, Yokozawa T, Nonaka G, 2007. Preparation, characterization, and antioxidative effects of oligomeric proanthocyanidin-L-cysteine complexes. *J Agric Food Chem*, 55, 1525-1531.

- 10 Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, Haytowitz D, Gebhardt S, Prior RL, 2004. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. *J Nutr*, 134, 613-617.
- 11 Houde V, Grenier D, Chandad F, 2006. Protective effects of grape seed proanthocyanidins against oxidative stress induced by lipopolysaccharides of periodontopathogens. *J Periodontol*, 77, 1371-1379.
- 12 Hu H and Qin YM, 2006. Grape seed proanthocyanidin extract induced mitochondria-associated apoptosis in human acute myeloid leukaemia 14.3D10 cells. *Chin Med J (Engl)*, 119, 417-421.
- 13 Iriti M and Faoro F, 2006. Grape phytochemicals: a bouquet of old and new nutraceuticals for human health. *Med Hypotheses*, 67, 833-838.
- 14 Katiyar SK, 2007. UV-induced immune suppression and photocarcinogenesis: chemoprevention by dietary botanical agents. *Cancer Lett*, 255, 1-11.
- 15 Kaur M, Singh RP, Gu M, Agarwal R, Agarwal C, 2006. Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. *Clin Cancer Res*, 12, 6194-6202.
- 16 Kim H, Hall P, Smith M, Kirk M, Prasain JK, Barnes S, Grubbs C, 2004. Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. *J Nutr*, 134, 3445S-3452S.
- 17 Kim YJ, Park HJ, Yoon SH, Kim MJ, Leem KH, Chung JH, Kim HK, 2005. Anticancer effects of oligomeric proanthocyanidins on human colorectal cancer cell line, SNU-C4. *World J Gastroenterol*, 11, 4674-4678.
- 18 Liu YN, Shen XN, Yao GY, 2006. [Effects of grape seed proanthocyanidins extracts on experimental diabetic nephropathy in rats]. *Wei Sheng Yan Jiu*, 35, 703-705.
- 19 Mantena SK and Katiyar SK, 2006. Grape seed proanthocyanidins inhibit UV-radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling in human epidermal keratinocytes. *Free Radic Biol Med*, 40, 1603-1614.
- 20 Mantena SK, Baliga MS, Katiyar SK, 2006a. Grape seed proanthocyanidins induce apoptosis and inhibit metastasis of highly metastatic breast carcinoma cells. *Carcinogenesis*, 27, 1682-1691.
- 21 Meeran SM and Katiyar SK, 2007. Grape seed proanthocyanidins promote apoptosis in human epidermoid carcinoma A431 cells through alterations in Cdk1-Cdk-cyclin cascade, and caspase-3 activation via loss of mitochondrial membrane potential. *Exp Dermatol*, 16, 405-415.
- 22 Nomoto H, Iigo M, Hamada H, Kojima S, Tsuda H, 2004. Chemoprevention of colorectal cancer by grape seed proanthocyanidin is accompanied by a decrease in proliferation and increase in apoptosis. *Nutr Cancer*, 49, 81-88.
- 23 Prior RL and Gu L, 2005. Occurrence and biological significance of proanthocyanidins in the American diet. *Phytochemistry*, 66, 2264-2280.
- 24 Puiggros F, Llopiz N, Ardevol A, Blade C, Arola L, Salvado MJ, 2005. Grape seed procyanidins prevent oxidative injury by modulating the expression of antioxidant enzyme systems. *J Agric Food Chem*, 53, 6080-6086.
- 25 Ray SD, Parikh H, Bagchi D, 2005. Proanthocyanidin exposure to B6C3F1 mice significantly attenuates dimethylnitrosamine-induced liver tumor induction and mortality by differentially modulating programmed and unprogrammed cell deaths. *Mutat Res*, 579, 81-106.
- 26 Sangeetha P, Balu M, Haripriya D, Panneerselvam C, 2005. Age associated changes in erythrocyte membrane surface charge: Modulatory role of grape seed proanthocyanidins. *Exp Gerontol*, 40, 820-828.
- 27 Schmidt BM, Erdman JW, Jr., Lila MA, 2006. Differential effects of blueberry proanthocyanidins on androgen sensitive and insensitive human prostate cancer cell lines. *Cancer Lett*, 231, 240-246.
- 28 Shao ZH, Hsu CW, Chang WT, Waypa GB, Li J, Li D, Li CQ, Anderson T, Qin Y, Schumacker PT, Becker LB, Hoek TL, 2006. Cytotoxicity induced by grape seed proanthocyanidins: role of nitric oxide. *Cell Biol Toxicol*, 22, 149-158.

- 29 Sharma SD, Meeran SM, Katiyar SK, 2007. Dietary grape seed proanthocyanidins inhibit UVB-induced oxidative stress and activation of mitogen-activated protein kinases and nuclear factor-kappaB signaling in in vivo SKH-1 hairless mice. *Mol Cancer Ther*, 6, 995-1005.
- 30 Shi J, Yu J, Pohorly JE, Kakuda Y, 2003. Polyphenolics in grape seeds-biochemistry and functionality. *J Med Food*, 6, 291-299.
- 31 Terra X, Valls J, Vitrac X, Merrillon JM, Arola L, Ardevol A, Blade C, Fernandez-Larrea J, Pujadas G, Salvado J, Blay M, 2007. Grape-seed procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by inhibiting NFkB signaling pathway. *J Agric Food Chem*, 55, 4357-4365.
- 32 Weber HA, Hodges AE, Guthrie JR, O'Brien BM, Robaugh D, Clark AP, Harris RK, Algaier JW, Smith CS, 2007. Comparison of proanthocyanidins in commercial antioxidants: grape seed and pine bark extracts. *J Agric Food Chem*, 55, 148-156.
- 33 Zhang XY, Li WG, Wu YJ, Gao MT, 2005. Amelioration of doxorubicin-induced myocardial oxidative stress and immunosuppression by grape seed proanthocyanidins in tumour-bearing mice. *J Pharm Pharmacol*, 57, 1043-1052.
- 34 Zhang XY, Bai DC, Wu YJ, Li WG, Liu NF, 2005a. Proanthocyanidin from grape seeds enhances anti-tumor effect of doxorubicin both in vitro and in vivo. *Pharmazie*, 60, 533-538.
- 35 Zhang XY, Li WG, Wu YJ, Zheng TZ, Li W, Qu SY, Liu NF, 2005b. Proanthocyanidin from grape seeds potentiates anti-tumor activity of doxorubicin via immunomodulatory mechanism. *Int Immunopharmacol*, 5, 1247-1257.
- 36 Zhang XY, Li WG, Wu YJ, Bai DC, Liu NF, 2005c. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells. *Can J Physiol Pharmacol*, 83, 309-318.

ID 2167: “VitaGranate® Pomegranate Extract 40% Ellagic Acid” and “Excellent source of healthy fruit polyphenols known to help in the management of heart health”

- 1 Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B, 2000. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. *Am J Clin Nutr*, 71, 1062-1076.
- 2 Aviram M and Dornfeld L, 2001. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. *Atherosclerosis*, 158, 195-198.
- 3 Aviram M, Dornfeld L, Kaplan M, Coleman R, Gaitini D, Nitecki S, Hofman A, Rosenblat M, Volkova N, Presser D, Attias J, Hayek T, Fuhrman B, 2002. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. *Drugs Exp Clin Res*, 28, 49-62.
- 4 Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, Volkova N, Presser D, Attias J, Liker H, Hayek T, 2004. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. *Clin Nutr*, 23, 423-433.
- 5 Damas J, Rémacle-Volon G, Adam A, 1989. Some cardiovascular and hematological changes induced in the rat by activation of Hageman factor with ellagic acid. *Adv Exp Med Biol*, 247A, 461-465.
- 6 de Nigris F, Williams-Ignarro S, Lerman LO, Crimi E, Botti C, Mansueto G, D'Armiento FP, De Rosa G, Sica V, Ignarro LJ, Napoli C, 2005. Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. *Proc Natl Acad Sci U S A*, 102, 4896-4901.
- 7 de Nigris F, Williams-Ignarro S, Botti C, Sica V, Ignarro LJ, Napoli C, 2006. Pomegranate juice reduces oxidized low-density lipoprotein downregulation of endothelial nitric oxide synthase in human coronary endothelial cells. *Nitric Oxide*, 15, 259-263.

- 8 de Nigris F, Balestrieri ML, Williams-Ignarro S, D'Armiento FP, Fiorito C, Ignarro LJ, Napoli C, 2007. The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. *Nitric Oxide*, 17, 50-54.
- 9 de Nigris F, Williams-Ignarro S, Sica V, Lerman LO, D'Armiento FP, Byrns RE, Casamassimi A, Carpentiero D, Schiano C, Sumi D, Fiorito C, Ignarro LJ, Napoli C, 2007. Effects of a pomegranate fruit extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis. *Cardiovasc Res*, 73, 414-423.
- 10 Esmailzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L, 2004. Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia. *J Med Food*, 7, 305-308.
- 11 Esmailzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L, 2006. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. *Int J Vitam Nutr Res*, 76, 147-151.
- 12 Ignarro LJ, Byrns RE, Sumi D, de Nigris F, Napoli C, 2006. Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. *Nitric Oxide*, 15, 93-102.
- 13 Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, Aviram M, 2001. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. *J Nutr*, 131, 2082-2089.
- 14 Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, Cass B, Bojanowski MW, Gingras D, Beliveau R, 2005. Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. *Carcinogenesis*, 26, 821-826.
- 15 No authors listed, 2005. Juice from the "jewel of winter" could be good for the heart. *Harv Heart Lett*, 16, 7.
- 16 No authors listed, 2007. Pomegranates for the prostate and the heart: seeds of hope. *Harv Mens Health Watch*, 11, 4-5.
- 17 Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN, 2006. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. *J Control Release*, 113, 189-207.
- 18 Ratnoff OD, Everson B, Embury P, Ziats NP, Anderson JM, Emanuelson MM, Malemud CJ, 1991. Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates. *Proc Natl Acad Sci U S A*, 88, 10740-10743.
- 19 Schubert SY, Neeman I, Resnick N, 2002. A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. *FASEB J*, 16, 1931-1933.
- 20 Sumner MD, Elliott-Eller M, Weidner G, Daubenmier JJ, Chew MH, Marlin R, Raisin CJ, Ornish D, 2005. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. *Am J Cardiol*, 96, 810-814.
- 21 Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP, 2003. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. *Angiogenesis*, 6, 121-128.
- 22 Yang L, Leung KY, Cao Y, Huang Y, Ratnayake WM, Chen ZY, 2005. Alpha-linolenic acid but not conjugated linolenic acid is hypocholesterolaemic in hamsters. *Br J Nutr*, 93, 433-438.
- 23 Yu YM, Chang WC, Wu CH, Chiang SY, 2005. Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid. *J Nutr Biochem*, 16, 675-681.
- 24 Yu YM, Wang ZH, Liu CH, Chen CS, 2007. Ellagic acid inhibits IL-1beta-induced cell adhesion molecule expression in human umbilical vein endothelial cells. *Br J Nutr*, 97, 692-698.

ID 2169: "Zeaxanthin (from marigold/ capsicum extract / wolfberries fruit" and "Required for macular pigmentation in the eyes for maintaining health eye functions"

- 1 Lutein and zeaxanthin. Monograph, 2005. *Altern Med Rev*, 10, 128-135.

- 2 Delcourt C, Carriere I, Delage M, Barberger-Gateau P, Schalch W, 2006. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. *Invest Ophthalmol Vis Sci*, 47, 2329-2335.
- 3 Dorey CK, Granata L, Nichols CR, Cheng KM, Craft NE, 2005. Dietary modulation of lens zeaxanthin in quail. *Exp Eye Res*, 81, 464-477.
- 4 Hartmann D, Thurmann PA, Spitzer V, Schalch W, Manner B, Cohn W, 2004. Plasma kinetics of zeaxanthin and 3'-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. *Am J Clin Nutr*, 79, 410-417.
- 5 Kim SR, Nakanishi K, Itagaki Y, Sparrow JR, 2006. Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. *Exp Eye Res*, 82, 828-839.
- 6 Kvansakul J, Rodriguez-Carmona M, Edgar DF, Barker FM, Kopcke W, Schalch W, Barbur JL, 2006. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. *Ophthalmic Physiol Opt*, 26, 362-371.
- 7 Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, Vom Hagen F, Nawroth P, Brownlee M, Hammes HP, 2006. Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. *Diabetologia*, 49, 1089-1096.
- 8 Mishra LC, Singh BB, Dagenais S, 2000. Scientific basis for the therapeutic use of *Withania somnifera* (ashwagandha): a review. *Altern Med Rev*, 5, 334-346.
- 9 SanGiovanni JP, Chew EY, Clemons TE, Ferris FL, Gensler G, Lindblad AS, 2007. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. *Arch Ophthalmol*, 125, 1225-1232.
- 10 Schalch W, 2004. Profiles of macular optical density in subpopulations of supplementation trial with lutein and zeaxanthin. *FASEBJ*, 18, Abstract N°.367.1, A532.
- 11 Schalch W, Cohn W, Barker FM, Kopcke W, Mellerio J, Bird AC, Robson AG, Fitzke FF, van Kuijk FJ, 2007. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study. *Arch Biochem Biophys*, 458, 128-135.
- 12 Thomson LR, Toyoda Y, Delori FC, Garnett KM, Wong ZY, Nichols CR, Cheng KM, Craft NE, Dorey CK, 2002. Long term dietary supplementation with zeaxanthin reduces photoreceptor death in light-damaged Japanese quail. *Exp Eye Res*, 75, 529-542.
- 13 Wenzel AJ, Gerweck C, Barbato D, Nicolosi RJ, Handelman GJ, Curran-Celentano J, 2006. A 12-wk egg intervention increases serum zeaxanthin and macular pigment optical density in women. *J Nutr*, 136, 2568-2573.
- 14 Whitehead AJ, Mares JA, Danis RP, 2006. Macular pigment: a review of current knowledge. *Arch Ophthalmol*, 124, 1038-1045.
- 15 WHO (World Health Organization), 2005. Evaluation of Certain Food Additives. Sixty-third report of the Joint FAO/WHO Expert Committee on Food Additives. WHO, Geneva.
- 16 Zeavision, 2004. Qualified Health Claim - Lutein and Eye Diseases Docket No. 2004Q-0180; .

ID 2173: “ZOTRIM®: Herbal food supplement/ingredient containing a proprietary* combination of extracts of three botanicals, *Ilex paraguariensis* (Yerba Mate) leaf extract, *Paullinia cupana* (Guarana) seed extract, and *Turnera aphrodisiaca* (Damiana) leaf extract” and “Helps lose excess weight, maintain a healthy weight. Supports healthy weight loss”

- 1 Andersen T and Fogh J, 2001. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. *J Hum Nutr Diet*, 14, 243-250.
- 2 Baker G and Leeds AR, 2002. Energy intake from snacks while viewing television, and the effect on this of a herbal preparation. 3rd Health and Nutrition Conference, London.
- 3 Ruxton CHS, 2004. Efficacy of Zotrim: a herbal weight loss preparation. *Nutrition and Food Science*, 34, 25-28.

- 4 Ruxton CHS and Gardner EJ, 2005. A review of the efficacy and safety of key ingredients of over-the-counter products for weight management. *British Food Journal*, 107, 111-125.
- 5 Ruxton CHS, Hinton F, Evans CEL, 2005. Effects of an over-the-counter herbal weight management product (Zotrim?) on weight and waist circumference in a sample of overweight women: a consumer study. *Nutrition & Food Science*, 35, 303-314.
- 6 Ruxton CHS, Kirkwood L, McMillan B, John DS, Evans CEL, 2007. Effectiveness of a herbal supplement (Zotrim?) for weight management. *British Food Journal*, 109, 416-428.

ID 2175: “Capsicum annum (Common Name: Capsicum)” and “Stomach health”

- 1 Barnes J, Anderson LA, Phillipson DJ, 2002. *Herbal Medicines*. Pharmaceutical Press, London.
- 2 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 3 BHMA (British Herbal Medicine Association), 2006. *British Herbal Compendium*. British Herbal Medicine Association, Exeter.
- 4 Biggs DF and Ladenius RC, 1990. Capsaicin selectively reduces airway responses to histamine, substance P and vagal stimulation. *Eur J Pharmacol*, 175, 29-33.
- 5 Chevallier A, 2002. *Encyclopedia of Herbal Medicine (DK Natural Health)*. Dorling Kindersley, London.
- 6 Cichewicz RH and Thorpe PA, 1996. The antimicrobial properties of chile peppers (*Capsicum* species) and their uses in Mayan medicine. *J Ethnopharmacol*, 52, 61-70.
- 7 Commission on Human Medicines, 2006. *British Pharmacopoeia 2007, Vol I*. Health Ministers UK, London.
- 8 Cordell GA and Araujo OE, 1993. Capsaicin: identification, nomenclature, and pharmacotherapy. *Ann Pharmacother*, 27, 330-336.
- 9 Council of Europe, 2002. *European Pharmacopoeia*.
- 10 Felter HW and Lloyd JU, 1898. *King’s American dispensatory*. Ohio Valley Co., Cincinnati.
- 11 Fugh-Berman A, 2005. *The 5-minute Herb & Dietary supplement Consult*. Lippincott Williams & Wilkins, New York.
- 12 Gonzalez R, Dunkel R, Koletzko B, Schusdziarra V, Allescher HD, 1998. Effect of capsaicin-containing red pepper sauce suspension on upper gastrointestinal motility in healthy volunteers. *Dig Dis Sci*, 43, 1165-1171.
- 13 Henderson DE, Slickman AM, Henderson SK, 1999. Quantitative HPLC determination of the antioxidant activity of capsaicin on the formation of lipid hydroperoxides of linoleic acid: a comparative study against BHT and melatonin. *J Agric Food Chem*, 47, 2563-2570.
- 14 Herr SM Ernst E and Young VSL, 2005. *Herb-Drug Interaction Handbook*. Church Street Books, Nassau, NY
- 15 Hogaboam CM and Wallace JL, 1991. Inhibition of platelet aggregation by capsaicin. An effect unrelated to actions on sensory afferent neurons. *Eur J Pharmacol*, 202, 129-131.
- 16 Holzer P, Pabst MA, Lippe IT, 1989. Intragastric capsaicin protects against aspirin-induced lesion formation and bleeding in the rat gastric mucosa. *Gastroenterology*, 96, 1425-1433.
- 17 Hood VC, Cruwys SC, Urban L, Kidd BL, 2001. The neurogenic contribution to synovial leucocyte infiltration and other outcome measures in a guinea pig model of arthritis. *Neurosci Lett*, 299, 201-204.
- 18 Hornero-Mendez D and Minguez-Mosquera MI, 1998. Isolation and Identification of the Carotenoid Capsolutein from *Capsicum annum* as Cucurbitaxanthin A. *Journal of Agricultural and Food Chemistry*, 46, 4087-4090.
- 19 Institute for Natural Product Research, 2000. *Capsicum monograph*.

- 20 Jensen-Jarolim E, Gajdzik L, Haberl I, Kraft D, Scheiner O, Graf J, 1998. Hot spices influence permeability of human intestinal epithelial monolayers. *J Nutr*, 128, 577-581.
- 21 Jung MY, Kang HJ, Moon A, 2001. Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. *Cancer Lett*, 165, 139-145.
- 22 Kawada T, Hagihara K, Iwai K, 1986. Effects of capsaicin on lipid metabolism in rats fed a high fat diet. *J Nutr*, 116, 1272-1278.
- 23 Kawada T, Watanabe T, Takaishi T, Tanaka T, Iwai K, 1986. Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization. *Proc Soc Exp Biol Med*, 183, 250-256.
- 24 Kim JD, Kim JM, Pyo JO, Kim SY, Kim BS, Yu R, Han IS, 1997. Capsaicin can alter the expression of tumor forming-related genes which might be followed by induction of apoptosis of a Korean stomach cancer cell line, SNU-1. *Cancer letters*, 120, 235-241.
- 25 Krishna De A, 2003. *Capsicum: The genus Capsicum*. CRC Press, Boca Raton (Florida).
- 26 McKenna DJ, Jones K, Hughes K, 2002. *Botanical Medicines: The Desk Reference for Major Herbal Supplements*. Routledge, London.
- 27 Miller CH, Zhang Z, Hamilton SM, Teel RW, 1993. Effects of capsaicin on liver microsomal metabolism of the tobacco-specific nitrosamine NNK. *Cancer Lett*, 75, 45-52.
- 28 Molina-Torres J, Garcia-Chavez A, Ramirez-Chavez E, 1999. Antimicrobial properties of alkamides present in flavouring plants traditionally used in Mesoamerica: affinin and capsaicin. *J Ethnopharmacol*, 64, 241-248.
- 29 Monsereenusorn Y, 1980. Effect of *Capsicum annum* on Blood Glucose Level. *Pharmaceutical Biology*, 18, 1 - 7.
- 30 Morre DJ, Chueh PJ, Morre DM, 1995. Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. *Proc Natl Acad Sci U S A*, 92, 1831-1835.
- 31 Panossian A, Gabrielan E, Wagner H, 1996. Dose-dependent reversible effect of capsaicin on interleukin-1 α production is associated with the metabolism of arachidonic acid (leukotriene B4 and prostaglandin E2). *Phytomedicine*, 3, 169-174.
- 32 Reynolds JEF, 1996. *Martindale: The Extra Pharmacopoeia*. Pharmaceutical Press, London.
- 33 Tolan I, Ragoobirsingh D, Morrison EY, 2001. The effect of capsaicin on blood glucose, plasma insulin levels and insulin binding in dog models. *Phytother Res*, 15, 391-394.
- 34 Tsuchiya H, 2001. Biphasic membrane effects of capsaicin, an active component in *Capsicum* species. *J Ethnopharmacol*, 75, 295-299.
- 35 Tsuchiya H, 2001b. Erratum to "Biphasic membrane effects of capsaicin, an active component in *Capsicum* species". *J Ethnopharmacol*, 76, 313.
- 36 Uchida M, Yano S, Watanabe K, 1991. The role of capsaicin-sensitive afferent nerves in protective effect of capsaicin against absolute ethanol-induced gastric lesions in rats. *Jpn J Pharmacol*, 55, 279-282.
- 37 United States Pharmacopoeial Convention, 2006. *US Pharmacopoeia*. United States Pharmacopoeial Convention, Rockville, Md
- 38 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.
- 39 Williamson EM, 2004. *Potter's Herbal Cyclopaedia* The C.W. Daniel Company Ltd., Saffron Walden, UK.
- 40 Yeoh KG, Kang JY, Yap I, Guan R, Tan CC, Wee A, Teng CH, 1995. Chili protects against aspirin-induced gastroduodenal mucosal injury in humans. *Dig Dis Sci*, 40, 580-583.
- 41 Zhang Z, Huynh H, Teel RW, 1997. Effects of orally administered capsaicin, the principal component of capsicum fruits, on the in vitro metabolism of the tobacco-specific nitrosamine NNK in hamster lung and liver microsomes. *Anticancer Res*, 17, 1093-1098.

ID 2178: “Balsamodendron mukul (common name: Balsamodendron mukul)” and “Joint health”

- 1 Ayurvedic Formulary of India, Part I. 2000. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homoeopathy, New Dehli, India.
- 2 Indian Materia Medica, Vol I. 2002.
- 3 Bagul MS, Srinivasa H, Kanaki NS, Rajani M, 2005. Research Letter-Anti-inflammatory activity of two Ayurvedic formulations containing guggul. *Indian Journal of Pharmacology*, 37, 399-400.
- 4 Francis JA, Raja SN, Nair MG, 2004. Bioactive terpenoids and guggulsteroids from *Commiphora mukul* gum resin of potential anti-inflammatory interest. *Chem Biodivers*, 1, 1842-1853.
- 5 Gupta SS, 1994. Prospects and perspectives of natural plants products in medicine. *Indian J Pharmacol*, 26.
- 6 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 7 Kimura I, Yoshikawa M, Kobayashi S, Sugihara Y, Suzuki M, Oominami H, Murakami T, Matsuda H, Doiphode VV, 2001. New triterpenes, myrrhanol A and myrrhanone A, from guggul-gum resins, and their potent anti-inflammatory effect on adjuvant-induced air-pouch granuloma of mice. *Bioorg Med Chem Lett*, 11, 985-989.
- 8 Matsuda H, Morikawa T, Ando S, Oominami H, Murakami T, Kimura I, Yoshikawa M, 2004. Absolute stereostructures of polypodane-type triterpenes, myrrhanol A and myrrhanone A, from guggul-gum resin (the resin of *Balsamodendron mukul*). *Chem Pharm Bull (Tokyo)*, 52, 1200-1203.
- 9 Shah Biren N, Nayak BS, Seth AK, Jalalpure SS, Patel KN, Patel MA, Mishra AD, 2006. Search for medicinal plants as a source of anti-inflammatory and anti-arthritis agents - A review. *Pharmacognosy Magazine*, 2, 77-86.
- 10 Simpson MD, 2005. Complementary approaches to arthritis. *Pharmacist*, 24, 520-525.
- 11 Singh BB, Mishra LC, Vinjamury SP, Aquilina N, Singh VJ, Shepard N, 2003. The effectiveness of *Commiphora mukul* for osteoarthritis of the knee: an outcomes study. *Altern Ther Health Med*, 9, 74-79.
- 12 WHO (World Health Organization), 2007. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.

ID 2179: “Eugenia jambolana (common name: Eugenia jambolana)” and “Glucose metabolism”

- 1 Indian Materia Medica, Vol I. 2002.
- 2 Bnouham M, Ziyat A, Mekhfi H, Tahri A, Legssyer A, 2006. Medicinal plants with potential antidiabetic activity – A review of ten years of herbal medicine research (1990-2000). *Int J diabetes & Metabolism*, 14, 1-25.
- 3 Grover JK, Vats V, Rathi SS, Dawar R, 2001 Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. *J Ethnopharmacol*, 76, 233-238.
- 4 Helmstädter A, 2007. Antidiabetic drugs used in Europe prior to the discovery of insulin. *Pharmazie*, 62, 717-720.
- 5 Henriette Kress, *Eugenia jambolana*, <http://www.henriettesherbal.com/eclectic/usdisp/eugenia-jamb.html>.
- 6 Himalaya Herbal Healthcare, *Syzygium cuminii*, www.himalayahealthcare.com/herbfinder/h_syzygi.htm.
- 7 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India, Vol II. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 8 Jung M, Park M, Lee HC, Kang YH, Kang ES, Kim SK, 2006. Antidiabetic agents from medicinal plants. *Curr Med Chem* 13 1203-1218.

- 9 Mhaskar, E. B, J.F. C, Kirtikar and Basu's Illustrated Indian Medicinal Plants-their usage in Ayurveda and Unani Medicines.
- 10 Rathi SS, Grover JK, Vikrant V, Biswas NR, 2002. Prevention of experimental diabetic cataract by Indian Ayurvedic plant extracts. *Phytother Res*, 16, 774-777.
- 11 Ratsimamanga SU, *Eugenia jambolana* (monograph).
- 12 Ravi K, Ramachandran B, Subramanian S, 2004. Effect of *Eugenia Jambolana* seed kernel on antioxidant defense system in streptozotocin-induced diabetes in rats. *Life Sci*, 75, 2717-2731.
- 13 Ravi K, Ramachandran B, Subramanian S, 2004. Protective effect of *Eugenia jambolana* seed kernel on tissue antioxidants in streptozotocin-induced diabetic rats. *Biol Pharm Bull*, 27, 1212-1217.
- 14 Ravi K, Sekar DS, Subramanian S, 2004. Hypoglycemic activity of inorganic constituents in *Eugenia jambolana* seed on streptozotocin-induced diabetes in rats. *Biol Trace Elem Res*, 99, 145-155.
- 15 Sagrawat H, Mann AS, Kharya MD, 2006. Pharmacological potential of *Eugenia jambolana*: A review. *Pharmacognosy Mag.*, 2, 96-105.
- 16 Shalam M, Harish MS, Farhana SA, 2006. Prevention of dexamethasone and fructoseinduced insulin resistance in rats by SH-01D, a herbal preparation. *Indian J Pharmacol*, 38, 419-422.
- 17 Sridhar SB, Sheetal UD, Pai MRS, Shastri MS, 2005. Preclinical evaluation of the antidiabetic potential effect of *Eugenia jambolana* seed powder in streptozotocin-diabetic rats. *Braz J Med Biol Res*, 38, 463-468.
- 18 Vikrant V, Grover JK, Tandon N, Rathi SS, Gupta N, 2001. Treatment with extracts of *Mormodica charantia* and *Eugenia jambolana* Prevents hyperglycemia and hyperinsulinemia in fructose fed rats. *J Ethnopharmacol*, 76, 139-143.

ID 2181: “*Emblca officinalis* (common name: *Emblca officinalis*)” and “Antioxidant properties”

- 1 Bajpai M, Pande A, Tewari SK, Prakash D, 2005. Phenolic contents and antioxidant activity of some food and medicinal plants. *Int J Food Sci Nutr*, 56, 287-291.
- 2 Bhattacharya A, Chatterjee A, Ghosal S, Bhattacharya SK, 1999. Antioxidant activity of active tannoid principles of *Emblca officinalis* (amla). *Indian J Exp Biol*, 37, 676-680.
- 3 Bhattacharya A, Ghosal S, Bhattacharya SK, 2000a. Antioxidant activity of tannoid principles of *Emblca officinalis* (amla) in chronic stress induced changes in rat brain. *Indian J Exp Biol*, 38, 877-880.
- 4 Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S, 2000b. Antioxidant activity of *Bacopa monniera* in rat frontal cortex, striatum and hippocampus. *Phytother Res*, 14, 174-179.
- 5 Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S, 2002. Effect of bioactive tannoid principles of *Emblca officinalis* on ischemia-reperfusion-induced oxidative stress in rat heart. *Phytomedicine*, 9, 171-174.
- 6 Caldecott T, 2008. Amalaki. <http://www.toddcaldcott.com/amalaki.html>.
- 7 Calixto JB, Santos AR, Cechinel Filho V, Yunes RA, 1998. A review of the plants of the genus *Phyllanthus*: their chemistry, pharmacology, and therapeutic potential. *Med Res Rev*, 18, 225-258.
- 8 Chaudhuri RK, 2002. *Emblca* cascading antioxidant: a novel natural skin care ingredient. *Skin Pharmacol Appl Skin Physiol*, 15, 374-380.
- 9 Chawla YK, Dubey P, Singh R, Nundy S, Tandon BN, 1982. Treatment of dyspepsia with Amalaki (*Emblca officinalis* Linn.)--an Ayurvedic drug. *Indian J Med Res*, 76 Suppl, 95-98.
- 10 Chemexcil, 1992. Selected Medicinal Plants of India: A Monograph of Identity, Safety and Clinical Usage. Pharmaceuticals and Cosmetics Export Promotion Council, Bombay.
- 11 Ghosal S, Tripathi VK, Chauhan S, 1996. Active constituents of *Emblca Officinalis*: Part 1- The chemistry and antioxidative effects of two new hydrolysable tannins, emblicanin A and B. *Indian journal of chemistry. Sect. B: Organic chemistry, including medical chemistry*, 35, 941-948.

- 12 Haque R, Bin-Hafeez B, Ahmad I, Parvez S, Pandey S, Raisuddin S, 2001. Protective effects of *Emblica officinalis* Gaertn. in cyclophosphamide-treated mice. *Hum Exp Toxicol*, 20, 643-650.
- 13 Indian Ministry of Health and Family Welfare, 2001. Amalaki. In: *The Ayurvedic Pharmacopoeia of India*, Vol I. Government of India, New Dehli, India.
- 14 Jacob A, Pandey M, Kapoor S, Saroja R, 1988. Effect of the Indian gooseberry (amla) on serum cholesterol levels in men aged 35-55 years. *Eur J Clin Nutr*, 42, 939-944.
- 15 Kaur C and Kapoor HC, 2002. Anti-oxidant activity and total phenolic content of some Asian vegetables. *International Journal of Food Science & Technology*, 37, 153-161.
- 16 Kerala Agricultural University, Medicinal Plants. <http://www.kau.edu/pop/medicinalplants.htm>
- 17 Khanom F, Kayahara H, Tadasa K, 2000. Superoxide-scavenging and prolyl endopeptidase inhibitory activities of Bangladeshi indigenous medicinal plants. *Biosci Biotechnol Biochem*, 64, 837-840.
- 18 Khopde SM, Priyadarsini KI, Mohan H, Gawandi VB, Satav JG, Yakhmi JV, Banavaliker MM, Biyani MK, Mittal JP, 2001. Characterizing the antioxidant activity of amla (*Phyllanthus emblica*) extract. *Curr Sci*, 81, 185-190.
- 19 Kumaran A and Karunakaran RJ, 2006. Nitric oxide radical scavenging active components from *Phyllanthus emblica* L. *Plant Foods Hum Nutr*, 61, 1-5.
- 20 Manjunatha S, Jaryal AK, Bijlani RL, Sachdeva U, Gupta SK, 2001. Effect of Chyawanprash and vitamin C on glucose tolerance and lipoprotein profile. *Indian J Physiol Pharmacol*, 45, 71-79.
- 21 Nadkharni A, 2002. *Emblica officinalis*. In: *Indian Materia Medica*.
- 22 Naik GH, Priyadarsini KI, Bhagirathi RG, Mishra B, Mishra KP, Banavalikar MM, Mohan H, 2005. In vitro antioxidant studies and free radical reactions of triphala, an ayurvedic formulation and its constituents. *Phytother Res*, 19, 582-586.
- 23 Naik GH, Priyadarsini KI, Mohan H, 2006. Free radical scavenging reactions and phytochemical analysis of triphala, an ayurvedic formulation. *Current Sci*, 90, 1100-1106.
- 24 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 25 Pozharitskaya ON, Ivanova SA, Shikov AN, Makarov VG, 2007. Separation and evaluation of free radical-scavenging activity of phenol components of *Emblica officinalis* extract by using an HPTLC-DPPH* method. *J Sep Sci*, 30, 1250-1254.
- 26 Rajak S, Banerjee SK, Sood S, Dinda AK, Gupta YK, Gupta SK, Maulik SK, 2004. *Emblica officinalis* causes myocardial adaptation and protects against oxidative stress in ischemic-reperfusion injury in rats. *Phytother Res*, 18, 54-60.
- 27 Rani P, Meena Unni K, Karthikeyan J, 2004. Evaluation of antioxidant properties of berries *Indian Journal of Clinical Biochemistry*, 19, 103-110.
- 28 Rao TP, Sakaguchi N, Juneja LR, Wada E, Yokozawa T, 2005. Amla (*Emblica officinalis* Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats. *J Med Food*, 8, 362-368.
- 29 RRL and IDMA, 1999. *Indian Herbal Pharmacopoeia*. Joint publication of Indian Drugs Manufacturer's Association and Regional Research Laboratory Jammu-Tawi.
- 30 Sabu MC and Kuttan R, 2002. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. *J Ethnopharmacol*, 81, 155-160.
- 31 Sai Ram M, Neetu D, Deepti P, Vandana M, Ilavazhagan G, Kumar D, Selvamurthy W, 2003. Cytoprotective activity of Amla (*Emblica officinalis*) against chromium (VI) induced oxidative injury in murine macrophages. *Phytother Res*, 17, 430-433.
- 32 Scartezzini P and Speroni E, 2000. Review on some plants of Indian traditional medicine with antioxidant activity. *J Ethnopharmacol*, 71, 23-43.

- 33 Scartezzini P, Antognoni F, Raggi MA, Poli F, Sabbioni C, 2006. Vitamin C content and antioxidant activity of the fruit and of the Ayurvedic preparation of *Emblica officinalis* Gaertn. *J Ethnopharmacol*, 104, 113-118.
- 34 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda.
- 35 Shishoo CJ, Shah SA, Rathod IS, Patel SG, 1998. Quality assurance of Chyavanprash through determination of free radical scavenging activity. *Indian journal of pharmaceutical sciences*, 60, 179-181.
- 36 Suryanarayana P, Kumar PA, Saraswat M, Petrash JM, Reddy GB, 2004. Inhibition of aldose reductase by tannoid principles of *Emblica officinalis*: implications for the prevention of sugar cataract. *Mol Vis*, 10, 148-154.
- 37 Unander DW, Webster GL, Blumberg BS, 1990. Records of usage or assays in *Phyllanthus* (Euphorbiaceae). I. Subgenera *Isocladius*, *Kirganelia*, *Cicca* and *Emblica*. *J Ethnopharmacol*, 30, 233-264.
- 38 Vasant L and Frawley D, 1986. *Special Oriental Herbs*. In: *The yoga of herbs: an ayurvedic guide to herbal medicine*. Lotus Press, Tokyo.
- 39 Williamson EM, 2002. *Major Herbs of Ayurveda*. Churchill Livingstone, London, Edinburgh.
- 40 Yokozawa T, Kim HY, Kim HJ, Okubo T, Chu DC, Juneja LR, 2007a. Amla (*Emblica officinalis* Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. *Br J Nutr*, 97, 1187-1195.
- 41 Yokozawa T, Kim HY, Kim HJ, Tanaka T, Sugino H, Okubo T, Chu DC, Juneja LR, 2007b. Amla (*Emblica officinalis* Gaertn.) attenuates age-related renal dysfunction by oxidative stress. *J Agric Food Chem*, 55, 7744-7752.

ID 2186: “Salsa parrilha (*Smilax officinalis*)” and “Digestive health”

- 1 Bartram T, 1995. *Encyclopedia of herbal medicine*. Grace Publishers, Dorset.
- 2 Blumenthal M, 1988. Sarsaparilla root. In: *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Hobbs C, 1988. Sarsaparilla, a literature review. *HerbalGram* 17, 10-15.
- 4 Leung AY and Foster S, 1996. *Encyclopedia of common natural ingredients used in food, drugs, and cosmetics*. John Wiley & Sons, New York.
- 5 Mindell E, 1992. *Earl Mindell’s herb bible*. Simon & Shuster, New York.
- 6 Newall CA, Anderson LA, Phillipson JD, 1996. *Herbal Medicines: A Guide for Health-care Professionals*. The Pharmaceutical Press, London.

ID 2187: “Combination of extracts from *Scutellaria baicalensis* (root) and *Acacia catechu* (heartwood) for use in food supplements only (Univestin™, Limbrel™, Flavocoxid™)” and “Joint health”

- 1 Burnett BP, Jia Q, Zhao Y, Levy RM, 2007. A medicinal extract of *Scutellaria baicalensis* and *Acacia catechu* acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. *J Med Food*, 10, 442-451.
- 2 Butenko IG, Gladchenko SV, Galushko SV, 1993. Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from *Scutellaria baicalensis* georgy roots. *Agents Actions*, 39 Spec No, C49-51.
- 3 Huang WH, Lee AR, Yang CH, 2006. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of *Scutellaria baicalensis* GEORGI. *Biosci Biotechnol Biochem*, 70, 2371-2380.
- 4 Kim YS, Unpublished. Double-blind, randomized, placebo controlled, comparative study to assess the safety and efficacy of Univestin K and the efficacy of Univestin K vs. Glucosamin in the adults suffering from arthritis.

- 5 Levy R, Saikovskiy R, Schmidt E, Khokhlov A, 2007. Safety, efficacy and acceptability of flavocoxid (Limbrel™) compared with naproxen in subjects with osteoarthritis of the knee: a pilot study. *Osteoarthritis and Cartilage*, 15 (suppl B), 91.
- 6 Naik GH, Priyadarsini KI, Satav JG, Banavalikar MM, Sohoni DP, Biyani MK, Mohan H, 2003. Comparative antioxidant activity of individual herbal components used in Ayurvedic medicine. *Phytochemistry*, 63, 97-104.
- 7 Qi J, 2003. Generating and screening a natural product library for cyclooxygenase and lipooxygenase dual inhibitors. *Studies Nat. Prod. Chem.*, 29, 643-718.
- 8 Sampalis JS, 2003. Safety and efficacy of a proprietary plant-derived anti-inflammatory in humans: a randomized, double-blind, placebo-controlled trial. Final Protocol, Unigen Pharmaceuticals Inc.
- 9 Shao ZH, Vanden Hoek TL, Li CQ, Schumacker PT, Becker LB, Chan KC, Qin Y, Yin JJ, Yuan CS, 2004. Synergistic effect of *Scutellaria baicalensis* and grape seed proanthocyanidins on scavenging reactive oxygen species in vitro. *Am J Chin Med*, 32, 89-95.
- 10 Unigen Pharmaceuticals, 2006. Specifications of the combination of extracts from *Scutellaria baicalensis* (root) and *Acacia catechu* (heartwood).
- 11 Van Loon IM, 1998. The Golden Root: Clinical Applications of *Scutellaria baicalensis* Georgi flavonoids as Modulators of the Inflammatory Response. *Alternative Medicine Review*, 3, 472-480.
- 12 Zhang YP, 2006. Wonderful effects of *Radix Scutellariae* in treating painful joints. *Shanghai Journal of Traditional Chinese Medicine*, 40, 50-51.

ID 2188: “Grapefruit//*Citrus paradisi* (Common Name : Grapefruit)” and “Antioxidant properties”

- 1 Sharamon S, Baginski J, Hessová L, 1997. *Zázračná síla grapefruitu*. Pragma, Prague.

ID 2191: “*Ribes nigrum* (Common Name : Blackcurrant)” and “Muscles and joint health”

- 1 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 2 Garbacki N, Angenot L, Bassleer C, Damas J, Tits M, 2002. Effects of prodelfinidins isolated from *Ribes nigrum* on chondrocyte metabolism and COX activity. *Naunyn Schmiedebergs Arch Pharmacol*, 365, 434-441.
- 3 Garbacki N, Kinet M, Nusgens B, Desmecht D, Damas J, 2005. Proanthocyanidins, from *Ribes nigrum* leaves, reduce endothelial adhesion molecules ICAM-1 and VCAM-1. *J Inflamm (Lond)*, 2, 9.
- 4 Matsumoto H, Takenami E, Iwasaki-Kurashige K, Osada T, Katsumura T, Hamaoka T, 2005. Effects of blackcurrant anthocyanin intake on peripheral muscle circulation during typing work in humans. *Eur J Appl Physiol*, 94, 36-45.

ID 2193: “Acerola” and “Antioxidant activity”

- 1 Bhathena SJ and Velasquez MT, 2002. Beneficial role of dietary phytoestrogens in obesity and diabetes. *Am J Clin Nutr*, 76, 1191-1201.
- 2 Brouwer IA, Van Dusseldorp M, West CE, Meyboom S, Thomas CMG, Duran M, Van Het Hof KH, Eskes T, Hautvast T, Steegers-Theunissen RPM, 1999. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. *The Journal of Nutrition*, 129, 1135-1139.

- 3 Ceriello A and Motz E, 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arterioscler Thromb Vasc Biol*, 24, 816-823.
- 4 Clifford MN, 1985. Chlorogenic acids. In: *Coffee*. Vol 1. Chemistry. Clarke RJ and Macrae R (eds.). Elsevier Applied Science Publications, London.
- 5 Clifford MN, 1999. Chlorogenic acids and other cinnamates—nature, occurrence and dietary burden. *Journal of the Science of Food and Agriculture*, 79, 362-372.
- 6 Clifford MN, 2000. Chlorogenic acids and other cinnamates—nature, occurrence, dietary burden, absorption and metabolism. *Journal of the Science of Food and Agriculture*, 80, 1033-1043.
- 7 Hanamura T, Hagiwara T, Kawagishi H, 2005. Structural and functional characterization of polyphenols isolated from acerola (*Malpighia emarginata* DC.) fruit. *Biosci Biotechnol Biochem*, 69, 280-286.
- 8 Harats D, Chevion S, Nahir M, Norman Y, Sagee O, Berry EM, 1998. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. *Am J Clin Nutr*, 67, 240-245.
- 9 Hassimotto NM, Genovese MI, Lajolo FM, 2005. Antioxidant activity of dietary fruits, vegetables, and commercial frozen fruit pulps. *J Agric Food Chem*, 53, 2928-2935.
- 10 Hwang J, Hodis HN, Sevanian A, 2001. Soy and alfalfa phytoestrogen extracts become potent low-density lipoprotein antioxidants in the presence of acerola cherry extract. *J Agric Food Chem*, 49, 308-314.
- 11 Kawaguchi M, Tanabe H, Nagamine K, 2007. Isolation and characterization of a novel flavonoid possessing a 4,2"-glycosidic linkage from green mature acerola (*Malpighia emarginata* DC.) fruit. *Biosci Biotechnol Biochem*, 71, 1130-1135.
- 12 Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM, 1996. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. *N Engl J Med*, 334, 1156-1162.
- 13 Lecerf JM, 1997. Nutrition, antioxydants et athéroclérose. *Rev Fr Endocrinol Clin*, 38, 119-141.
- 14 Lecerf JM, 1999. Les antioxydants et les autres éléments protecteurs dans les jus de fruits et légumes. Pasteur Institute-Lille.
- 15 Lecerf J, 2006. Functional claims of article 13: Polyphenols in juices. Pasteur Institute-Lille.
- 16 Manach C, Scalbert A, Morand C, Remesy C, Jimenez L, 2004. Polyphenols: food sources and bioavailability. *Am J Clin Nutr*, 79, 727-747.
- 17 Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*, 81, 230S-242S.
- 18 Mezadri T, Fernandez-Pachon MS, Villano D, Garcia-Parrilla MC, Troncoso AM, 2006. [The acerola fruit: composition, productive characteristics and economic importance]. *Arch Latinoam Nutr*, 56, 101-109.
- 19 Ruxton CH, Gardner EJ, Walker D, 2006. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. *Int J Food Sci Nutr*, 57, 249-272.
- 20 Scalbert A and Williamson G, 2000. Dietary intake and bioavailability of polyphenols. *J Nutr*, 130, 2073S-2085S.
- 21 Tucker KL, Selhub J, Wilson PW, Rosenberg IH, 1996. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. *J Nutr*, 126, 3025-3031.
- 22 Wakabayashi H, Fukushima H, Yamada T, Kawase M, Shirataki Y, Satoh K, Tobe T, Hashimoto K, Kurihara T, Motohashi N, Sakagami H, 2003. Inhibition of LPS-stimulated NO production in mouse macrophage-like cells by Barbados cherry, a fruit of *Malpighia emarginata* DC. *Anticancer Res*, 23, 3237-3241.

ID 2194: “Achillea millefolium L. (Common name: Yarrow)” and “Health of lower urinary tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2195: “Achillea millefolium L. (Common name: Yarrow)” and “Respiratory health”

- 1 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.

ID 2199: “Agrimonia eupatoria” and “Health of lower urinary tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2200: “Agropyron repens - common name : Couch” and “Renal elimination / organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 3 Cahier de l'Agence, 1998. Médicaments à base de plantes: Cahiers de l'Agence no 3. République Française, Ministère de l'Emploi et de la Solidarité, Paris.

ID 2201: “Agropyron repens - common name : Couch” and “Control of weight”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de L'Agence, 1998. Les Cahiers de l'agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.

ID 2202: “Alchemilla vulgaris” and “Joint health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2205: “Alchemilla xanthochlora ROTHM, syn. alchemilla vulgaris L. s.l. (Common name: Lady’s mantle)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Natural Medicines Comprehensive Database, Alchemilla, www.naturaldatabase.com.

ID 2207: “Allium cepa - common name: Onion” and “Renal elimination / Organism draining”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.

ID 2211: “Ammi visnaga” and “Respiratory health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2212: “Ananas comosus - common name: Bromelain, Pineapple” and “Vascular and Vein Health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 3 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.

ID 2213: “Ananas comosus - common name: Bromelain, Pineapple” and “Digestion”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 3 Grabovac V and Bernkop-Schnurch A, 2006. Improvement of the intestinal membrane permeability of low molecular weight heparin by complexation with stem bromelain. *Int J Pharm*, 326, 153-159.
- 4 Hale LP, 2004. Proteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of mice. *Int Immunopharmacol*, 4, 255-264.
- 5 Hale LP, Greer PK, Trinh CT, Gottfried MR, 2005. Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. *Clin Immunol*, 116, 135-142.
- 6 Malamud A and Wilson KT, 2000. Treatment of gastrointestinal infections. *Curr Opin Gastroenterol*, 16, 51-55.
- 7 University of Maryland Medical Centre, Bromelain, <http://www.umm.edu/altmed/articles/bromelain-000289.htm>.
- 8 WHFOODS, Pineapple, <http://www.whfoods.com/genpage.php?tname=foodspice&dbid=34>.

ID 2214: “Anethum graveolens - common name: dill” and “Renal elimination / organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de L'Agence, 1998. Les Cahiers de l'agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.

ID 2216: “Anisi aetheroleum” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Boskabady MH and Ramazani-Assari M, 2001. Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). J Ethnopharmacol, 74, 83-88.
- 4 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 5 Kooperation Phytopharmaka, 1990-1995. Arzneipflanzen in der Phytotherapie (Indikationsgegliedertes Kompendium von Arzneipflanzen gemäss Monographien der Kommission E mit Darstellung von Kombinationsmöglichkeiten). BAH, BPI, VRH, Gesellschaft für Phytotherapie.
- 6 Pourgholami MH, Majzoob S, Javadi M, Kamalinejad M, Fanaee GH, Sayyah M, 1999. The fruit essential oil of Pimpinella anisum exerts anticonvulsant effects in mice. J Ethnopharmacol, 66, 211-215.
- 7 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.
- 8 Tabanca N, Bedir E, Kirimer N, Baser KH, Khan SI, Jacob MR, Khan IA, 2003. Antimicrobial compounds from Pimpinella species growing in Turkey. Planta Med, 69, 933-938.
- 9 Tirapelli CR, de Andrade CR, Cassano AO, De Souza FA, Ambrosio SR, da Costa FB, de Oliveira AM, 2007. Antispasmodic and relaxant effects of the hidroalcoholic extract of Pimpinella anisum (Apiaceae) on rat anococcygeus smooth muscle. J Ethnopharmacol, 110, 23-29.
- 10 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2217: “Apium graveolens (common name : celery)” and “Bladder health/ Health of urinary tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2218: “Apium graveolens - common name : celery” and “Renal elimination / organism draining”

- 1 Anton R and Wichtl M, 2003. Plantes thérapeutiques (2 e édition française). Tec&Doc, Paris, 692.
- 2 Barnes J, Anderson LA, Phillipson JD, 2003. Herbal Medicines. Pharmaceutical Press, London.
- 3 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. Plantes médicinales des régions tempérées. Maloine, Paris.
- 4 Blumenthal M, 1998. The complete German commission E monographs. Thieme, Stuttgart.
- 5 Bradley P, 1992. British Herbal Compendium. British Herbal Medicine Association, Exeter.
- 6 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 7 Cahiers de L'Agence, 1998. Les Cahiers de l'agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 8 Crellin JK and Philpott J, 1990. A Reference Guide to Medicinal Plants. Duke University Press, Durham, London.
- 9 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- 10 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.

- 11 Hellemont JV, 1986. Compendium de Phytothérapie. APB Service Scientifique.
- 12 Leung AY and Foster S, 1996. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. John Wiley & Sons, New York.
- 13 Mills S and Bone K, 2000. Principles and Practices of Phytothérapie: Modern Herbal Medecine. Churchill Livingstone, London, Edinburgh.
- 14 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 15 Wren RC, 1988. Potter's New Cyclopaedia of Botanical Drugs and Preparations. The C.W. Daniel Company Limited, Essex.
- 16 Пилат Т and Иванов А, 2002. Антишлак. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 582- 584.

ID 2222: “Arctium lappa - common name : Burdock” and “Renal elimination / Organism draining”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. Les plantes dans la thérapeutique moderne. Maloine, Paris.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 4 Cahiers de l'Agence, 1997. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- 7 Foster S and Leung AY, 1996. Encyclopedia of common natural ingredients used in food, drug and cosmetics. Wiley-Interscience, New York
- 8 Mills S and Bone K Elsevier, 2005. The Essential Guide to Herbal Safety. Churchill Livingstone, London, Edinburgh.
- 9 Moatti R and Musarella P, 1993. Le guide complet des plantes pour se soigner. Editions du Rocher, Monaco
- 10 Valnet J, 1983. Phytothérapie. Traitement des maladies par les plantes. Livre de Poche / Maloine, Paris.
- 11 Van Hellemont J, 1986. Compendium de phytothérapie. Association Pharmaceutique Belge, Bruxelles.
- 12 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 13 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 14 Wichtl M, 2004. Herbal Drugs and Phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart.

ID 2223: “Armoracia rusticana” and “Intestinal health”

- 1 **Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.**

ID 2224: “Armorica rusticana - common name : Horseradish” and “Renal elimination / Organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.

ID 2226: “Ascophyllum nodosum - common name: ascophyllum” and “Control of weight”

- 1 Etude clinique: Evaluation de l'efficacité de gélules « ventre plat » par mesures centimétriques.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2227: “Ascophyllum nodosum - common name : ascophyllum” and “Constipation / Intestinal Health”

- 1 Etude clinique : Evaluation de l'efficacité de gélules « ventre plat » par mesures centimétriques.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 4 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 5 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 6 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2228: “Asparagus officinalis” and “Health of bladder and lower urinary tract”

- 1 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 2 Indian Ministry of Health and Family Welfare, 2004. The Ayurvedic Pharmacopoeia of India, Vol IV. Government of India, New Dehli, India.
- 3 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

- 4 Kapoor LD, 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton.
- 5 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 6 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 7 Sitaram B, 2006. Bhavaprakasa of Bhavamisra: Original Text Along With Commentary and Translation: Including Nighantu Portion. Chaukhambha Orientalia, New Delhi.
- 8 Williamson EM, 2002. Major Herbs of Ayurveda. Churchill Livingstone, London, Edinburgh.

ID 2230: “Avena sativum - common name : Oat” and “Constipation / Intestinal Health”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 4 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2233: “Capsella bursa-pastoris” and “Urinary health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2235: “Cassia fistula - common name : caneficier” and “Constipation / Intestinal Health”

- 1 Abo KA and Adeyemi AA, 2002. Seasonal accumulation of anthraquinones in leaves of cultivated Cassia podocarpa Guill et Perr. Afr J Med Med Sci, 31, 171-173.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 4 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 5 Elujoba AA, Ajulo OO, Iweibo GO, 1989. Chemical and biological analyses of Nigerian Cassia species for laxative activity. J Pharm Biomed Anal, 7, 1453-1457.
- 6 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.

ID 2243: “Citrullus lunatus (Watermelon) extract - ACTI-08” and “Weight loss management carbohydrate & lipid metabolism improvement”

- 1 Edwards AJ, Vinyard BT, Wiley ER, Brown ED, Collins JK, Perkins-Veazie P, Baker RA, Clevidence BA, 2003. Consumption of watermelon juice increases plasma concentrations of lycopene and beta-carotene in humans. *J Nutr*, 133, 1043-1050.
- 2 Fisler JS and Warden CH, 2006. Uncoupling proteins, dietary fat and the metabolic syndrome. *Nutr Metab (Lond)*, 3, 38.
- 3 Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I, 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. *Journal of Clinical Investigation*, 114, 1752-1761.
- 4 Micol V, 2007. ACTISOD®: the second generation antioxidant for weight management.
- 5 Micol V, Larson H, Edeas B, Ikeda T, 2007. Watermelon extract stimulates antioxidant enzymes and improves glycemic and lipid metabolism. *Agro Food Industry Hi Tech*, 18, 22.
- 6 Ninapharm, ACTISOD® - Ingredient description, composition certificate.
- 7 Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M, 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*, 404, 787-790.
- 8 Richeux F, 2006. Evaluation of acute oral toxicity in rats. Up and down procedure. Test LD50. TAO425-PH-06/0013.

ID 2244: “Citrullus lunatus (Watermelon) extract - ACTI-08” and “Antioxidant properties”

- 1 Alscher RG, Erturk N, Heath LS, 2002. Role of superoxide dismutases (SODs) in controlling oxidative stress in plants. *Journal of Experimental Botany*, 53, 1331-1341.
- 2 Edwards AJ, Vinyard BT, Wiley ER, Brown ED, Collins JK, Perkins-Veazie P, Baker RA, Clevidence BA, 2003. Consumption of watermelon juice increases plasma concentrations of lycopene and beta-carotene in humans. *J Nutr*, 133, 1043-1050.
- 3 Micol V, Larson H, Edeas B, Ikeda T, 2007. Watermelon extract stimulates antioxidant enzymes and improves glycemic and lipid metabolism. *Agro Food Industry Hi Tech*, 18, 22.
- 4 Ninapharm, ACTISOD® - Ingredient description, composition certificate. NINAPH-ACTI-08.
- 5 Ninapharm, Supplementation with ACTISOD® offers an Internal skin protection and regeneration in a double blind, placebo-controlled study.
- 6 Ninapharm, ACTISOD® Antioxidant actions.
- 7 Ninapharm, ACTISOD® An Innovative Anti-ageing. For beverages.
- 8 Ninapharm, Localization and antioxidant capacity of ACTISOD® in a cellular system.
- 9 Ninapharm, ACTISOD® bioavailability.
- 10 Ninapharm, Protective action against cell damage.
- 11 Ninapharm, Cell activating action.
- 12 Ninapharm, Collagen productivity in normal human fibroblasts.
- 13 Ninapharm, Comparison of lycopene composition.
- 14 Ninapharm, Lycopene absorption.
- 15 Ninapharm, Anti-oxidative activity SOD-like mechanism and DDPH radical scavenging activity.
- 16 Ninapharm, Antiradical effects of ACTISOD® against the hydrogen peroxide.

- 17 Richeux F, 2006. Evaluation of acute oral toxicity in rats. Up and down procedure. Test LD50.
- 18 Rougier Y, Pouyssegur V, Edeas B, Nasu M, Séité P, 2006. Vieillesse tissulaire, stress oxydatif et tests spécifiques : rappels et synthèse pratique. Intérêt de la Recherche-Préventive pour une supplémentation nutritionnelle novatrice (extrait de *Citrullus lanatus*) favorisant la régulation anti-radicalaire au niveau mitochondrial. Entretiens de Bichat Thérapeutique. Table Ronde.

ID 2246: “Cnicus benedictus” and “Respiratory health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2248: “Coleus forskohlii extract” and “body weight management - lipid metabolism”

- 1 *Coleus forskohlii*. Monograph. 2006. Altern Med Rev, 11, 47-51.
- 2 Allen DO, Ahmed B, Naseer K, 1986. Relationships between cyclic AMP levels and lipolysis in fat cells after isoproterenol and forskolin stimulation. J Pharmacol Exp Ther, 238, 659-664.
- 3 Badmaev V, Majeed M, Conte AA, Parker JE, 2002. Diterpene forskolin (*Coleus forskohlii*, Benth.): A possible new compound for reduction of body weight by increasing lean body mass. Nutraceuticals, March/April, 6-7.
- 4 Battochio AP, Sartori MS, Coelho CA, 2005. Water-soluble extract of *Coleus barbatus* modulates weight gain, energy utilization and lipid metabolism in secondary biliary cirrhosis: an experimental study in young rats. Acta Cir Bras, 20, 229-236.
- 5 Bhagwat AM, Joshi B, Joshi AS, 2004. A randomized double-blind clinical trial to investigate the efficacy and safety of ForsLean in increasing lean body mass.
- 6 Bruneton J, 1993. Pharmacognosy, phytochemistry, medicinal plants. Lavoisier, Paris.
- 7 Daly JW, 1984. Forskolin, adenylate cyclase, and cell physiology: an overview. Adv Cyclic Nucleotide Protein Phosphorylation Res, 17, 81-89.
- 8 Ding X and Staudinger JL, 2005. Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J Pharmacol Exp Ther, 312, 849-856.
- 9 Enoksson S, Blaak E, Arner P, 1997. Forskolin potentiates isoprenaline-induced glycerol output and local blood flow in human adipose tissue in vivo. Pharmacol Toxicol, 81, 214-218.
- 10 Godard MP, Johnson BA, Richmond SR, 2005. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res, 13, 1335-1343.
- 11 Han LK, Morimoto C, Yu RH, Okuda H, 2005. Effects of *Coleus forskohlii* on fat storage in ovariectomized rats. Yakugaku Zasshi, 125, 449-453.
- 12 Hänsel R, Sticher O, Steinegger E, 2007. Pharmakognosie - Phytopharmazie. Springer Verlag, Heidelberg.
- 13 Joost HG and Steinfeldt HJ, 1987. Forskolin inhibits insulin-stimulated glucose transport in rat adipose cells by a direct interaction with the glucose transporter. Mol Pharmacol, 31, 279-283.
- 14 Kamath MS, 2005. Efficacy and safety of ForsLean in increasing lean body mass in obese subjects. Department of Ayurvedic Medicine, Kasturba Medical College, Manipal, India.
- 15 Krieder R, Henderson S, Magu B, 2002. Effects of *Coleus forskohlii* extract supplementation on body composition and markers of health in sedentary overweight females. Memphis, TN: Exercise and Sports Nutrition Laboratory, Department of Human Movement Science and Education, University of Memphis [for Sabinsa Corporation]
- 16 Litosch I, Hudson TH, Mills I, Li SY, Fain JN, 1982. Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes. Mol Pharmacol, 22, 109-115.

- 17 Likhoba CW, Simmonds MS, Paton AJ, 2006. Plectranthus: a review of ethnobotanical uses. J Ethnopharmacol, 103, 1-24.
- 18 Mills I, Moreno FJ, Fain JN, 1984. Forskolin inhibition of glucose metabolism in rat adipocytes independent of adenosine 3',5'-monophosphate accumulation and lipolysis. Endocrinology, 115, 1066-1069.
- 19 Morimoto C, Kameda K, Tsujita T, Okuda H, 2001. Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells. J Lipid Res, 42, 120-127.
- 20 Okuda H, Morimoto C, Tsujita T, 1992. Relationship between cyclic AMP production and lipolysis induced by forskolin in rat fat cells. J Lipid Res, 33, 225-231.
- 21 Seamon KB, Padgett W, Daly JW, 1981. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA, 78, 3363-3367.
- 22 Tsuguyoshi A, 2001. Clinical report on root extract of perilla plant (Coleus forskohlii) ForsLean in reducing body fat. Asano Institute Tokyo, Japan.

ID 2253: “Cynara scolymus - common name: artichoke, globe artichoke” and “Renal elimination / organism draining”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2254: “Eucalyptus globulus” and “Muscles and joint health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2255: “Filipendula ulmaria - common name: meadowsweet” and “Joint health”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 4 Hocking PM, Robertson GW, Gentle MJ, 2005. Effects of non-steroidal anti-inflammatory drugs on pain-related behaviour in a model of articular pain in the domestic fowl. Res Vet Sci, 78, 69-75.

- 5 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 6 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2256: “Fraxinus excelsior” and “Joint health”

- 1 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Depoërs P, Ledoux F, Meurin P, 1998. *La phytothérapie entre science et traditions*. Amyris, Paris.
- 4 Jellin JM, Gregory P, Batz F, 2000. *Natural Medicines Comprehensive Database*. Pharmacists Letter, Stockton.
- 5 Kostova I and Iossifova T, 2007. Chemical components of *Fraxinus* species. *Fitoterapia*, 78, 85-106.

ID 2257: “Fraxinus excelsior” and “Kidney health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Depoërs P, Ledoux F, Meurin P, 2002. *La phytothérapie entre science et tradition*. Amyris, Paris.
- 5 Jellin JM, Gregory P, Batz F, 2000. *Natural Medicines Comprehensive Database*. Pharmacists Letter, Stockton.
- 6 Kostova I and Iossifova T, 2007. Chemical components of *Fraxinus* species. *Fitoterapia*, 78, 85-106.

ID 2258: “Fraxinus ornus - common name: Manna” and “Constipation / Intestinal Health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.

ID 2259: “Fucus vesiculosus” and “Thyroïde function and production of hormone, energy metabolism”

- 1 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 2 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, 2003. *HagerROM 2003. Hagers Handbuch der Drogen und Arzneistoffe*. Springer Verlag, Heidelberg.
- 3 Bradley P, 1993. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.

- 4 Morel J-M, Perrey F, Lejeune R, Goetz P, 2005. Monographie médicalisée. Phytothérapie, 5, 218-221.
- 5 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2260: “Fucus vesiculosus - common name: fucus, bladderwrack” and “Constipation / Intestinal Health”

- 1 BHMA (British Herbal Medicine Association), 1996. British Herbal Pharmacopoeia. British Herbal Medicine Association, Exeter.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Boni U and Patri G, 1977. Quercia marina. In: Scoprire, Riconoscere, Usare le Erbe. Fabbri Editori, Milan, 670-671.
- 4 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 5 Briand X, 1989. Les algues marines : médicaments de la mer et aliment « santé ». La lettre phytothérapique, supplément n° 14, 9-15, 24-26.
- 6 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 7 Bruneton J, 1999. Polysaccharides des algues. In: Pharmacognosie internationales M (ed.) Tec & Doc, Lavoisier, Paris, 45-60.
- 8 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 9 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 10 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2261: “Ginkgo biloba [dry extract GK501 Pharmaton Dry extract from leaves of Ginkgo biloba L., drug/native extract ratio (35 - 45) : 1, solvent of extraction Acetone/Water, 6.0% terpene lactones, 24.5% ginkgoflavonoids]” and “For cognitive performance / blood circulation”

- 1 Ahlemeyer B and Krieglstein J, 2003. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry, 36 Suppl 1, S8-14.
- 2 Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d'Arbigny P, 1993. Effect of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther, 15, 549-558.
- 3 Ginkgo leaf, 2005. In: European Pharmacopoeia 5.0. Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM), Strasbourg, 1657-1658.
- 4 No authors listed, 2007. Ginkgo biloba-Extrakt. Antidementiva, 21, 41.
- 5 No authors listed, 2007. Ginkgo biloba-Extrakt. Deutsche Apotheker Zeitung 21, 40-47.
- 6 Arnould T, Michiels C, Janssens D, Berna N, Remacle J, 1998. Effect of Ginkor Fort on hypoxia-induced neutrophil adherence to human saphenous vein endothelium. J Cardiovasc Pharmacol, 31, 456-463.
- 7 Arrigo A, 1986. Treatment of chronic cerebrovascular insufficiency with Ginkgo biloba extract. Therapiewoche, 36, 5208-5218.

- 8 Bauer U, 1984. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. *Arzneimittelforschung*, 34, 716-720.
- 9 Bent S, Goldberg H, Padula A, Avins AL, 2005. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. *J Gen Intern Med*, 20, 657-661.
- 10 Birks J, Grimley Evans J, Van Dongen M, 2003. Ginkgo Biloba for Cognitive Impairment and Dementia. *The Cochrane Library* 4.
- 11 Birks J and Grimley Evans J, 2005. Ginkgo Biloba for Cognitive Impairment and Dementia. *The Cochrane Library*, 4.
- 12 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. The American Botanical Council, Austin, TX.
- 13 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 14 Blumenthal M, 2002. Ginkgo biloba L. In: *The ABC Clinical Guide to Herbs*. American Botanical Council, Austin, TX.
- 15 Brautigam MRH, 1998. Treatment of age-related memory complaints with Ginkgo biloba extract: a randomized double blind placebo-controlled study. *Phytomedicine*, 5.
- 16 Brendler T, Gruenwald J, Jaenicke C, 2003. *Herbal Remedies - Heilpflanzen (CD-Rom)*. Medpharm Scientific Publishers, Stuttgart.
- 17 Burns NR, Bryan J, Nettelbeck T, 2006. Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults. *Hum Psychopharmacol*, 21, 27-37.
- 18 Caballero B, Allen L, Prentice A, 2005. *Encyclopedia of Human Nutrition*. Elsevier, Oxford.
- 19 Carlson JJ, Farquhar JW, DiNucci E, Ausserer L, Zehnder J, Miller D, Berra K, Hagerty L, Haskell WL, 2007. Safety and efficacy of a ginkgo biloba-containing dietary supplement on cognitive function, quality of life, and platelet function in healthy, cognitively intact older adults. *J Am Diet Assoc*, 107, 422-432.
- 20 Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R, 1999. Ginkgo biloba extract increases ocular blood flow velocity. *J Ocul Pharmacol Ther*, 15, 233-240.
- 21 Cieza A, Maier P, Poppel E, 2003. Effects of Ginkgo biloba on mental functioning in healthy volunteers. *Arch Med Res*, 34, 373-381.
- 22 CKF (Commissie Keuring Fytoproducten), 2006. Master file: Ginkgo Folium.
- 23 Cockle SM, Kimber S, Hindmarch I, 2000. The effects of Ginkgo biloba extract (LI 1370) supplementation on activities of daily living in free living older volunteers: a questionnaire survey. *Hum Psychopharmacol*, 15, 227-235.
- 24 DeFeudis FV, 1998. *Ginkgo biloba extract (EGb 761): from chemistry to the clinic*. Ullstein Medical, Weisbaden.
- 25 Dimpfel W, Kler A, Kriesl E, Lehnfeld R, Keplinger-Dimpfel IK, 2006. Neurophysiological characterization of a functionally active drink containing extracts of ginkgo and ginseng by source density analysis of the human EEG. *Nutr Neurosci*, 9, 213-224.
- 26 Erdinçler DS, Karakoc Y, Toplan S, Önen S, Sukyasyan A, Beger T, Demiroglu C, 1996. The effect of ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability. *Clinical Hemorheology and Microcirculation*, 16, 271-276.
- 27 Ernst E, 1999. Herbal medications for common ailments in the elderly. *Drugs Aging*, 15, 423-428.
- 28 Ernst E and Pittler MH, 1999. Ginkgo biloba for Dementia. A systematic review of double-blind, placebo controlled trials. *Clinical Drug Invest*, 17.

- 29 Ernst E, 2002. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. *Ann Intern Med*, 136, 42-53.
- 30 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 31 Grassel E, 1992. Effect of Ginkgo-biloba extract on mental performance. Double-blind study using computerized measurement conditions in patients with cerebral insufficiency. *Fortschr Med*, 110, 73-76.
- 32 Guinot P, Caffrey E, Lambe R, Darragh A, 1989. Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers. *Haemostasis*, 19, 219-223.
- 33 Halama P, Bartsch G, Meng G, 1988. Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Ginkgo biloba extract. *Fortschr Med*, 106, 408-412.
- 34 Hilton M and Stuart E, 2005. Ginkgo biloba for tinnitus. *The Cochrane Library*, 4.
- 35 Hofferberth B, 1989. The effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome. A double-blind study against placebo. *Arzneimittelforschung*, 39, 918-922.
- 36 Hofferberth B, 1994. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. *Human Psychopharmacology: Clinical and Experimental*, 9, 215-222.
- 37 Horsch S and Walther C, 2004. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD)--a review based on randomized, controlled studies. *Int J Clin Pharmacol Ther*, 42, 63-72.
- 38 Issing W, Klein P, Weiser M, 2005. The homeopathic preparation Vertigoheel versus Ginkgo biloba in the treatment of vertigo in an elderly population: a double-blinded, randomized, controlled clinical trial. *J Altern Complement Med*, 11, 155-160.
- 39 Izzo AA and Ernst E, 2001. Interactions between herbal medicines and prescribed drugs: a systematic review. *Drugs*, 61, 2163-2175.
- 40 Jacoby D and Mohler ER, 3rd, 2004. Drug treatment of intermittent claudication. *Drugs*, 64, 1657-1670.
- 41 Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ, 2005. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol*, 59, 425-432.
- 42 Jung F, Mrowietz C, Kiesewetter H, Wenzel E, 1990. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. *Arzneimittelforschung*, 40, 589-593.
- 43 Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R, 1996. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Pharmacopsychiatry*, 29, 47-56.
- 44 Kennedy DO, Scholey AB, Wesnes KA, 2000. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. *Psychopharmacology (Berl)*, 151, 416-423.
- 45 Kennedy DO, Scholey AB, Wesnes KA, 2002. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. *Physiology and Behavior*, 75, 739-751.
- 46 Kleijnen J and Knipschild P, 1992. Ginkgo biloba for cerebral insufficiency. *Br J Clin Pharmacol*, 34, 352-358.
- 47 Kohler S, Funk P, Kieser M, 2004. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. *Blood Coagul Fibrinolysis*, 15, 303-309.
- 48 Koltringer P, Langsteger W, Klima G, Reisecker F, Eber O, 1993. Hemorheologic effects of Ginkgo biloba extract EGb 761. Dose-dependent effect of EGb 761 on microcirculation and viscoelasticity of blood. *Fortschr Med*, 111, 170-172.

- 49 Krieglstein J, Ausmeier F, El-Abhar H, Lippert K, Welsch M, Rupalla K, Henrich-Noack P, 1995. Neuroprotective effects of Ginkgo biloba constituents. *European Journal of Pharmaceutical Sciences*, 3, 39-48.
- 50 Kudolo GB, 2000. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic beta-cell function in response to glucose loading in normal glucose tolerant individuals. *J Clin Pharmacol*, 40, 647-654.
- 51 Kurz A and Van Baelen B, 2004. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the Cochrane collaboration. *Dement Geriatr Cogn Disord*, 18, 217-226.
- 52 Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, 1997. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. *JAMA*, 278, 1327-1332.
- 53 Le Bars PL and Kastelan J, 2000. Efficacy and safety of a Ginkgo biloba extract. *Public Health Nutr*, 3, 495-499.
- 54 Le Bars PL, Kieser M, Itil KZ, 2000. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761® in dementia. *Dement Geriatr Cogn Disord*, 11, 230-237.
- 55 Lee EJ, Chen HY, Wu TS, Chen TY, Ayoub IA, Maynard KI, 2002. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rats. *J Neurosci Res*, 68, 636-645.
- 56 Maier P, Pösl M, Pöppel E, 2003. Ginkgo - Wundermittel für ältere Golfspieler? *Leistungssport*, 5.
- 57 McKenna DJ, Jones K, Hughes K, 2001. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. *Altern Ther Health Med*, 7, 70-86, 88-90.
- 58 Mehlsen J, Drabaek H, Wiinberg N, Winther K, 2002. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. *Clin Physiol Funct Imaging*, 22, 375-378.
- 59 Mix JA and Crews WD, Jr., 2000. An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. *J Altern Complement Med*, 6, 219-229.
- 60 Mix JA and Crews WD, Jr., 2002. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. *Hum Psychopharmacol*, 17, 267-277.
- 61 Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG, 2000. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. *Drugs*, 59, 1057-1070.
- 62 Nathan PJ, Ricketts E, Wesnes K, Mrazek L, Greville W, Stough C, 2002. The acute nootropic effects of Ginkgo biloba in healthy older human subjects: a preliminary investigation. *Hum Psychopharmacol*, 17, 45-49.
- 63 NIH (National Institute of Health), Drugs and Supplements - Ginkgo (Ginkgo biloba L.), <http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-ginkgo.html>.
- 64 O'Hara M, Kiefer D, Farrell K, Kemper K, 1998. A review of 12 commonly used medicinal herbs. *Arch Fam Med*, 7, 523-536.
- 65 Oken BS, Storzbach DM, Kaye JA, 1998. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. *Arch Neurol*, 55, 1409-1415.
- 66 Persson J, Bringlov E, Nilsson LG, Nyberg L, 2004. The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy volunteers. *Psychopharmacology (Berl)*, 172, 430-434.
- 67 Peters H, Kieser M, Holscher U, 1998. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial. *Vasa*, 27, 106-110.
- 68 Pittler MH and Ernst E, 2000. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. *Am J Med*, 108, 276-281.
- 69 Pittler MH and Ernst E, 2005. Complementary therapies for peripheral arterial disease: systematic review. *Atherosclerosis*, 181, 1-7.

- 70 Rai GS, Shovlin C, Wesnes KA, 1991. A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment. *Curr Med Res Opin*, 12, 350-355.
- 71 Rejali D, Sivakumar A, Balaji N, 2004. Ginkgo biloba does not benefit patients with tinnitus: a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. *Clin Otolaryngol Allied Sci*, 29, 226-231.
- 72 Rigney U, Kimber S, Hindmarch I, 1999. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. *Phytother Res*, 13, 408-415.
- 73 Santos RF, Galduroz JC, Barbieri A, Castiglioni ML, Ytaya LY, Bueno OF, 2003. Cognitive performance, SPECT, and blood viscosity in elderly non-demented people using Ginkgo biloba. *Pharmacopsychiatry*, 36, 127-133.
- 74 Scholey A, Kennedy D, Wesnes K, 2005. The psychopharmacology of herbal extracts: issues and challenges. *Psychopharmacology (Berl)*, 179, 705-707; author reply 708-711.
- 75 Schweizer J and Hautmann C, 1999. Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIIb. A randomised, double-blind, multicentric clinical trial. *Arzneimittelforschung*, 49, 900-904.
- 76 SMC (Swedish Medical Center), Ginkgo, <http://healthlibrary.epnet.com/GetContent.aspx?token=af362d97-4f80-4453-a175-02cc6220a387&chunkiid=21740>.
- 77 Smith PF, Maclennan K, Darlington CL, 1996. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). *J Ethnopharmacol*, 50, 131-139.
- 78 Soholm B, 1998. Clinical improvement of memory and other cognitive functions by Ginkgo biloba: review of relevant literature. *Adv Ther*, 15, 54-65.
- 79 Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R, 2002. Ginkgo for memory enhancement: a randomized controlled trial. *JAMA*, 288, 835-840.
- 80 Stough C, Clarke J, Lloyd J, Nathan PJ, 2001. Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. *Int J Neuropsychopharmacol*, 4, 131-134.
- 81 Sun B, 2003. Effects of extract of Ginkgo biloba on spasms of the basilar artery and cerebral microcirculatory perfusion in rats with subarachnoid hemorrhage. *Clinical Hemorheology and Microcirculation*, 29, 231-238.
- 82 Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H, 1986. Treatment of cerebral aging disorders with Ginkgo biloba extract. A longitudinal multicenter double-blind drug vs. placebo study. *Presse Med*, 15, 1583-1587.
- 83 UMMC (University of Maryland Medical Center), Ginkgo biloba, <http://www.umm.edu/altmed/articles/ginkgo-biloba-000247.htm>.
- 84 Vesper J and Hänsgen KD, 1994. Efficacy of Ginkgo Biloba in 90 outpatients with cerebral insufficiency caused by old age. *Phytomedicine*, 1, 9-16.
- 85 Wesnes K, Simmons D, Rook M, Simpson P, 1987. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. *Human Psychopharmacology: Clinical and Experimental*, 2.
- 86 Wesnes KA, Ward T, McGinty A, Petrini O, 2000. The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy middle-aged volunteers. *Psychopharmacology*, 152, 353-361.
- 87 Wesnes KA, Ward T, McGinty A, Petrini O, 2000. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. *Psychopharmacology (Berl)*, 152, 353-361.
- 88 Wettstein A, 1999. Cholinesterase inhibitor and ginkgo extracts in therapy of dementia. A comparison of effectiveness based on controlled studies. *Fortschr Med*, 117, 48-49.

- 89 Wettstein A, 2000. Cholinesterase inhibitors and Ginkgo extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. *Phytomedicine*, 6, 393-401.
- 90 WHO (World Health Organization), 2007. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.
- 91 Winther K, Randløv C, Rein E, Mehlsen J, 1998. Effects of Ginkgo biloba extract on cognitive function and blood pressure in elderly subjects. *Current Therapeutic Research*, 59, 881-888.
- 92 Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C, 2004. Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular diseases. *Cardiovasc Drug Rev*, 22, 309-319.

ID 2262: “Guava” and “Skin health”

- 1 Aust O, Stahl W, Sies H, Tronnier H, Heinrich U, 2005. Supplementation with tomato-based products increases lycopene, phytofluene, and phytoene levels in human serum and protects against UV-light-induced erythema. *Int J Vitam Nutr Res*, 75, 54-60.
- 2 Cesarini JP, Michel L, Maurette JM, Adhoute H, Bejot M, 2003. Immediate effects of UV radiation on the skin: modification by an antioxidant complex containing carotenoids. *Photodermatol Photoimmunol Photomed*, 19, 182-189.
- 3 Eichler O, Sies H, Stahl W, 2002. Divergent optimum levels of lycopene, beta-carotene and lutein protecting against UVB irradiation in human fibroblastst. *Photochem Photobiol*, 75, 503-506.
- 4 Greul AK, Grundmann JU, Heinrich F, Pfitzner I, Bernhardt J, Ambach A, Biesalski HK, Gollnick H, 2002. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and proanthocyanidins. *Skin Pharmacol Appl Skin Physiol*, 15, 307-315.
- 5 Heinrich U, Gartner C, Wiebusch M, Eichler O, Sies H, Tronnier H, Stahl W, 2003. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. *J Nutr*, 133, 98-101.
- 6 Ribaya-Mercado JD, Garmyn M, Gilchrest BA, Russell RM, 1995. Skin lycopene is destroyed preferentially over beta-carotene during ultraviolet irradiation in humans. *J Nutr*, 125, 1854-1859.
- 7 Rodriguez-Amaya DB, 1999. Latin American food sources of carotenoids. *Arch Latinoam Nutr*, 49, 74S-84S.
- 8 Stahl W, Heinrich U, Wiseman S, Eichler O, Sies H, Tronnier H, 2001. Dietary tomato paste protects against ultraviolet light-induced erythema in humans. *J Nutr*, 131, 1449-1451.
- 9 Stahl W and Sies H, 2002. Carotenoids and protection against solar UV radiation. *Skin Pharmacol Appl Skin Physiol*, 15, 291-296.
- 10 Stahl W, Heinrich U, Aust O, Tronnier H, Sies H, 2006. Lycopene-rich products and dietary photoprotection. *Photochem Photobiol Sci*, 5, 238-242.
- 11 Stahl W and Sies H, 2007. Carotenoids and flavonoids contribute to nutritional protection against skin damage from sunlight. *Mol Biotechnol*, 37, 26-30.

ID 2263: “Guava” and “Antioxidative activity”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris.
- 2 Bhathena SJ and Velasquez MT, 2002. Beneficial role of dietary phytoestrogens in obesity and diabetes. *Am J Clin Nutr*, 76, 1191-1201.

- 3 Brouwer IA, van Dusseldorp M, West CE, Meyboom S, Thomas CMG, Duran M, Hof KHV, Eskes TKAB, Hautvast JGAJ, Steegers-Theunissen RPM, 1999. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. *J Nutr*, 129, 1135-1139.
- 4 Ceriello A and Motz E, 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arteriosclerosis Thrombosis and Vascular Biology*, 24, 816-823.
- 5 Clifford MN, 1985. Chlorogenic acids. In: *Coffee*. Clarke RJ and Macrae R (eds.). Elsevier, London, 153-202.
- 6 Clifford MN, 1999. Chlorogenic acids and other cinnamates - nature, occurrence and dietary burden. *Journal of the Science of Food and Agriculture*, 79, 362-372.
- 7 Clifford MN, 2000. Chlorogenic acids and other cinnamates - nature, occurrence, dietary burden, absorption and metabolism. *Journal of the Science of Food and Agriculture*, 80, 1033-1043.
- 8 Harats D, Chevion S, Nahir M, Norman Y, Sagee O, Berry EM, 1998. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. *Am J Clin Nutr*, 67, 240-245.
- 9 Jimenez-Escrig A, Rincon M, Pulido R, Saura-Calixto F, 2001. Guava fruit (*Psidium guajava* L.) as a new source of antioxidant dietary fiber. *Journal of Agricultural and Food Chemistry*, 49, 5489-5493.
- 10 Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM, 1996. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. *N Engl J Med*, 334, 1156-1162.
- 11 Kuskoski EM, Asuero AG, Morales MT, Fett R, 2006. Wild fruits and pulps of frozen fruits: antioxidant activity, polyphenols and anthocyanins. *Ciência Rural*, 36, 1283-1287.
- 12 Lecerf JM, 1997. Nutrition, antioxydants et athéroclérose. *Rev Fr Endocrinol Clin*, 38, 119-141.
- 13 Lecerf JM, 1999. Les antioxydants et les autres éléments protecteurs dans les jus de fruits et de légumes. Pasteur Institute-Lille.
- 14 Lecerf JM, 2006. Functional Claims of Article 13: Polyphenols in Juices. References and Scientific Evidences. Pasteur Institute-Lille.
- 15 Manach C, Scalbert A, Morand C, Remesy C, Jimenez L, 2004. Polyphenols: food sources and bioavailability. *Am J Clin Nutr*, 79, 727-747.
- 16 Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*, 81, 230s-242s.
- 17 Miesan KH and Mohamed S, 2001. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. *Journal of Agricultural and Food Chemistry*, 49, 3106-3112.
- 18 Rodriguez-Amaya DB, 1999. Latin American food sources of carotenoids. *Archivos Latinoamericanos De Nutricion*, 49, 74s-84s.
- 19 Ruxton CHS, Gardner EJ, Walker D, 2006. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. *International Journal of Food Sciences and Nutrition*, 57, 249-272.
- 20 Scalbert A and Williamson G, 2000. Dietary intake and bioavailability of polyphenols. *J Nutr*, 130, 2073s-2085s.
- 21 Thaipong K, Boonprakob U, Cisneros-Zevallos L, Byrne DH, 2005. Hydrophilic and lipophilic antioxidant activities of guava fruits. *Southeast Asian Journal of Tropical Medicine and Public Health*, 36, 254-257.
- 22 Tucker KL, Selhub J, Wilson PWF, Rosenberg IH, 1996. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. *J Nutr*, 126, 3025-3031.

ID 2266: “Hedera helix” and “Urinary health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2267: “Hibiscus sabdariffa - common name: Hibiscus” and “Renal elimination / Organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2272: “Hypericum perforatum” and “Respiratory health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2273: “Hypericum perforatum” and “Health of lower urinary tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2274: “Hyssopus officinalis L. (Common name: Hyssop)” and “Respiratory health”

- 1 Hyssop. 2006. Health Products and Food Branch of Health Canada, the Natural Health Products Directorate (NHPD).
- 2 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 3 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- 7 Eberwein E and Vogel G, 1990. Arzneipflanzen in der Phytotherapie. Kooperation Phytopharmaka, Berlin.
- 8 Valnet J, 1983. Phytothérapie. Traitement des maladies par les plantes. Livre de Poche / Maloine, Paris.
- 9 Van Hellemont J, 1986. Compendium de phytothérapie. Association Pharmaceutique Belge, Bruxelles.
- 10 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2275: “Ilex paraguariensis - common name: yerba mate, maté, kali chaye” and “Renal elimination / organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 3 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 4 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 5 Paris R and Myose H, 1981. Précis de Matière Médicale, Tome II, Pharmacognosie spéciale. Masson, Paris.
- 6 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 7 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2276: “Ilex paragueariensis St.-Hil. - Green Mate leaf extract” and “Mild diuretic effect, drainage of excess water”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Götz V and Kessler H, 1990. Mate-Tee als unterstützende Maßnahme bei Reduktionsdiäten. Natur- und GanzheitsMedizin, 3, 252-258.
- 3 Neuhauser Berthold M, Beine S, Verwied SC, Luhrmann PM, 1997. Coffee consumption and total body water homeostasis as measured by fluid balance and bioelectrical impedance analysis. Annals of Nutrition and Metabolism, 41, 29-36.
- 4 Newall CA, Anderson LA, Phillipson JD, 1996. Herbal medicines: a guide for health-care professionals. Pharmaceutical Press, London.
- 5 Rieg T, Steigele H, Schnermann J, Richter K, Osswald H, Vallon V, 2005. Requirement of intact adenosine A1 receptors for the diuretic and natriuretic action of the methylxanthines theophylline and caffeine. J Pharmacol Exp Ther, 313, 403-409.
- 6 Wemple RD, Lamb DR, McKeever KH, 1997. Caffeine vs caffeine-free sports drinks: Effects on urine production at rest and during prolonged exercise. International Journal of Sports Medicine, 18, 40-46.

ID 2278: “Inula helenium” and “Pharyngeal and respiratory health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.
- 2 Rubine H, 2001. Ālante helēniju. Ārstniecības augu avīze, 2, 7.

ID 2280: “Inula helenium - common name: Elecampane” and “Renal elimination / Organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.

- 2 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Rubine H, 2001. Ālante helēniju. Ārstniecības augu avīze, 2, 7.
- 5 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2281: “*Iris germanica* L., *Iris florentina* auct., *Iris pallida* Lam. (Common name: Iris)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Eberwein E and Vogel G, 1990. Arzneipflanzen in der Phytotherapie. Kooperation Phytopharmaka, Berlin.
- 4 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.
- 5 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2282: “*Lagerstroemia speciosa* extract” and “Blood glucose control - glucose metabolism”

- 1 Fukushima M, Matsuyama F, Ueda N, Egawa K, Takemoto J, Kajimoto Y, Yonaha N, Miura T, Kaneko T, Nishi Y, Mitsui R, Fujita Y, Yamada Y, Seino Y, 2006. Effect of corosolic acid on postchallenge plasma glucose levels. Diabetes Research and Clinical Practice, 73, 174-177.
- 2 Hattori K, Sukenobu N, Sasaki T, Takasuga S, Hayashi T, Kasai R, Yamasaki K, Hazeki O, 2003. Activation of insulin receptors by lagerstroemin. Journal of Pharmacological Sciences, 93, 69-73.
- 3 Hayashi T, Maruyama H, Kasai R, Hattori K, Takasuga S, Hazeki O, Yamasaki K, Tanaka T, 2002. Ellagitannins from *Lagerstroemia speciosa* as activators of glucose transport in fat cells. Planta Medica, 68, 173-175.
- 4 Judy WV, Hari SP, Stogsdill WW, Judy JS, Naguib YMA, Passwater R, 2003. Antidiabetic activity of a standardized extract (Glucosol) from *Lagerstroemia speciosa* leaves in Type II diabetics - A dose-dependence study. Journal of Ethnopharmacology, 87, 115-117.
- 5 Klein G, Kim JK, Himmeldirk K, Cao Y, Chen XZ, 2007. Antidiabetes and anti-obesity activity of *Lagerstroemia speciosa*. Evidence-Based Complementary and Alternative Medicine, 4, 401-407.
- 6 Li YS, Kim J, Li J, Liu F, Liu XQ, Himmeldirk K, Ren YL, Wagner TE, Chen XZ, 2005. Natural anti-diabetic compound 1,2,3,4,6-penta-O-galloyl-D-glucopyranose binds to insulin receptor and activates insulin-mediated glucose transport signaling pathway. Biochemical and Biophysical Research Communications, 336, 430-437.
- 7 Liu XQ, Kim J, Li YS, Li J, Liu F, Chen XZ, 2005. Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells. J Nutr, 135, 165-171.
- 8 Miura T, Itoh Y, Kaneko T, Ueda N, Ishida T, Fukushima M, Matsuyama F, Seino Y, 2004. Corosolic acid induces GLUT4 translocation in genetically type 2 diabetic mice. Biological & Pharmaceutical Bulletin, 27, 1103-1105.

- 9 Miura T, Ueda N, Yamada K, Fukushima M, Ishida T, Kaneko T, Matsuyama F, Seino Y, 2006. Antidiabetic effects of corosolic acid in KK-Ay diabetic mice. *Biological & Pharmaceutical Bulletin*, 29, 585-587.
- 10 Ulbricht C, Basch E, Weissner W, Hackman D, 2006. An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration. *Expert Opinion on Drug Safety*, 5, 719-728.

ID 2285: “*Lamium album* - common name: white dead nettle” and “Renal elimination / organism draining”

- 1 Bradley P, 2006. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 2 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Chabrol E, Charonnat R, Maximin M, Waitz R, Porin J, 1931. L'action cholérétique des composées. *CR Soc Biol*, 108, 1100-1102.
- 5 Fournier P, 1948. *Le livre des plantes médicinales et vénéneuses de France*. Lechevalier, Paris.
- 6 Friley J, Lamier blanc. In: *Les simples et autres plantes médicinales*. CNPMAI (Conservatoire National des Plantes à Parfum, Médicinales, Aromatiques et Industrielles de Milly-la-Forêt), 73.
- 7 Paris R and Moyse H, 1961. Labiées médicinales diverses. In: *Abrégé de matière médicale. Matières premières d'origine végétale*. Vigot, Paris, 142.
- 8 Van Hellemont J, 1986. *Compendium de phytothérapie*. Association Pharmaceutique Belge, Bruxelles.
- 9 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 10 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2292: “*Levisticum officinale* - common name: Lovage” and “Renal elimination / organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.

ID 2293: “*Limonis aetheroleum*” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.

ID 2294: “*Linum usitatissimum* - common name: flaxseed” and “Control of weight”

- 1 Blumenthal M, 2000. *Herbal Medicine: Expanded Commission E Monographs* American Botanical Council.
- 2 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.

- 3 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 4 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2296: “Lycopodium clavatum” and “Health of bladder and lower urinary tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2297: “Malva sylvestris” and “Pharyngeal and respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Hiller K and Melzig MF, 2003. Lexikon der Arzneipflanzen und Drogen. Spektrum Akademischer Verlag, Heidelberg.
- 4 Hoppe HA, 1977. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 5 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.
- 6 Schönfelder I and Schönfelder P, 2004. Das neue Handbuch der Heilpflanzen: Botanik, Arzneidrogen, Wirkstoffe, Anwendungen Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 7 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 8 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2298: “Medicago sativa” and “Health of lower urinary tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2303: “Melissa officinalis L. (Common name: Lemon balm)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.
- 3 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2304: “Melon extract (containing SOD) / Wheat Gliadin” and “Endogenous antioxidant enzyme; effects on immune system”

- 1 Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E, 1999. Immunity and probiotics. *Immunol Today*, 20, 387-390.
- 2 Dugas B, Dugas N, Conti M, Calenda A, Pino P, Thomas Y, Mazier D, Vouldoukis I, 2003. Wheat gliadin promotes the interleukin-4-induced IgE production by normal human peripheral mononuclear cells through a redox-dependent mechanism. *Cytokine*, 21, 270-280.
- 3 He Y, Vemulapalli R, Schurig GG, 2002. Recombinant *Ochrobactrum anthropi* expressing *Brucella abortus* Cu,Zn superoxide dismutase protects mice against *B. abortus* infection only after switching of immune responses to Th1 type. *Infect Immun*, 70, 2535-2543.
- 4 Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, Mahler O, 2003. Cu/Zn superoxide dismutase plays important role in immune response. *J Immunol*, 170, 2993-3001.
- 5 Rahman H, Rocco R, Latorre J, Tabassum V, 2005. The effects of a specialized superoxide dismutase nutritional supplement for HIV patients on HAART. The 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Abstract no. MoPe11.11C10.
- 6 Vouldoukis I, Conti M, Kolb JP, Calenda A, Mazier D, Dugas B, 2003. Induction of Th1-dependent immunity by an orally effective melon superoxide dismutase extract. *Curr Trends Immunol*, 5, 141-145.

ID 2305: “Melon extract (containing SOD) / Wheat Gliadin” and “Endogenous antioxidant enzyme, protects skin from sun damage”

- 1 Albicini M, Kick J, Hauser B, Ehrmann U, Leverve X, Radermacher P, Speit G, Muth CM, 2005. The Orally Effective Mixture of Sod and Gliadin Glisodin® Protects Against Oxidative DNA Damage. 11th Congress of the European Shock Society, Vienna.
- 2 Laverdet C, 2003. Glisodin Sun Pilot Trial: an open study conducted in France on 15 patients presenting fragile skin, hypersensitivity to the sun or even problems of sun disease.
- 3 Laverdet C, Pomarede N, Oliveres-Ghouti C, 2005. Glisodin and Exposure to the Sun: an open study conducted in France on 150 patients by 40 dermatologists.
- 4 Mac-Mary S, Sainthillier JM, Creidi P, Series JP, Vix F, Humbert P, 2005. Evaluation of the Effect of GliSODin® on the Intensity of Actinic Erythema Induced with Radiation. CARD (Annual Congress of Dermatological Research), Brest.
- 5 Mac-Mary S, Sainthillier JM, Courderotmasuyer C, Creidi P, Humbert P, 2007. Could a photobiological test be a suitable method to assess the anti-oxidant effect of a nutritional supplement Glisodin? *Eur J Dermatol*, 17, 254-255.

ID 2309: “Mentha x piperita L. (Common names: peppermint, mint)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Mills S and Bone K, 2000. *Principles and Practices of Phytotherapy: Modern Herbal Medicine*. Churchill Livingstone, London, Edinburgh.
- 3 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.

ID 2310: “*Menthae arvensis aetheroleum*” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Eberwein E and Vogel G, 1990. Arzneipflanzen in der Phytotherapie. Kooperation Phytopharmaka, Berlin.

ID 2311: “*Myristica fragrans*” and “Muscles and joint health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, 2003. HagerROM 2003. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.

ID 2314: “*Ocimum basilicum* - common name: Basil” and “Renal elimination / Organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.

ID 2315: “*Ononis spinosa* L. (Common name : Bugrane) “ and “Health of lower urinary tract”

- 1 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 2 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.
- 3 Villalobos MA, De La Cruz JP, Martin-Romero M, Carmona JA, Smith-Agreda JM, Sanchez de la Cuesta F, 1998. Effect of dietary supplementation with evening primrose oil on vascular thrombogenesis in hyperlipemic rabbits. *Thromb Haemost*, 80, 696-701.

ID 2318: “*Phaseolus Vulgaris* (Kidney bean) - *Olea europa* (Olive) - *Rosemarinus officinalis* (Rosemary) extracts - OXY-08” and “Weight loss management, fat metabolism & storage improvement”

- 1 Cecil KM, Lin A, Ross BD, Egelhoff JC, 2002. Methylsulfonylmethane observed by in vivo proton magnetic resonance spectroscopy in a 5-year-old child with developmental disorder: effects of dietary supplementation. *J Comput Assist Tomogr*, 26, 818-820.
- 2 Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG, 2007. A dietary supplement containing standardized *Phaseolus vulgaris* extract influences body composition of overweight men and women. *Int J Med Sci*, 4, 45-52.
- 3 Ebisuzaki K, 2003. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. *Anticancer Res*, 23, 453-458.
- 4 Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF, 2006. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. *Osteoarthritis Cartilage*, 14, 286-294.
- 5 Koike T, Koizumi Y, Tang L, Takahara K, Saitou Y, 2005. The Anti-obesity Effect and the Safety of Taking "Phaseolamin 1600 Diet". *J New Rem & Clin*, 54.

- 6 Landa M, 2006. Letter to Charles J. Raubicheck (Frommer Lawrence & Haug LLP): PHASE-2® (Phaseolus vulgaris) Pharmachem Laboratories, Inc. Structure/Function Claims. Department of Health and Human Services, U.S.A.
- 7 Layer P, Zinsmeister AR, DiMugno EP, 1986. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology*, 91, 41-48.
- 8 Marshall JJ and Lauda CM, 1975. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, *Phaseolus vulgaris*. *J Biol Chem*, 250, 8030-8037.
- 9 Micol V, Blanes C, Caturla N, Laporta O, Edeas B, 2005. Synergetic mixed nutritional ingredients enhance and maintain weight loss in humans. *AgroFOOD Indus High Tech*, 5, 13-16.
- 10 Ninapharm, 2008. OXYLIA®. Ingredient description, composition certificate.
- 11 Ninapharm, 2008. Ingredient mechanisms of actions: OXYLIA® a powerful and safe balancing diet supplement.
- 12 Ninapharm, 2008. OXYLIA®. Certificate of non toxicity - Test LD5.
- 13 Ninapharm, 2008. OXYLIA® enhances and maintains weight loss in humans.
- 14 Ninapharm, 2008. OXYLIA®. Reduction of calorie absorption study done on rats.
- 15 Ninapharm, 2008. SOD-like activity of OXYLIA®.
- 16 Pari L and Venkateswaran S, 2003. Effect of an aqueous extract of *Phaseolus vulgaris* on the properties of tail tendon collagen of rats with streptozotocin-induced diabetes. *Braz J Med Biol Res*, 36, 861-870.
- 17 Raubicheck CJ, 2006. Letter to Mitchell Skop (Pharmachem Laboratories, Inc.): Pharmachem's PHASE-2 STARCH NEUTRALIZER®. FDA-Accepted Weight Control and Starch Digestion Claims. Frommer Lawrence & Haug LLP.
- 18 Rougier Y, 2005. Solutions Minceur et Contrôle durable du poids - Intérêt scientifique d'une nouvelle génération de compléments nutritionnels respectant les S.L.I.M. data. *Entretiens de Bichat Thérapeuthique*, 125-131.
- 19 Santimone M, Koukikolo R, Moreau Y, Le Berre V, Rouge P, Marchis-Mouren G, Desseaux V, 2004. Porcine pancreatic alpha-amylase inhibition by the kidney bean (*Phaseolus vulgaris*) inhibitor (alpha-AI1) and structural changes in the alpha-amylase inhibitor complex. *Biochim Biophys Acta*, 1696, 181-190.
- 20 Tatsutaka Y, Takayo S, Tooru S, 2006. Safety and weight reduction effects of foods containing *Phaseolus vulgaris*. *Eastern Medicine*, 21, 41-47.
- 21 Venkateswaran S, Pari L, Saravanan G, 2002. Effect of *Phaseolus vulgaris* on circulatory antioxidants and lipids in rats with streptozotocin-induced diabetes. *J Med Food*, 5, 97-103.

ID 2319 : “Pimpinella saxifrage” and “Health of lower urinary tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. *Natural Medicines Comprehensive Database*. Pharmacists Letter, Stockton.

ID 2320: “Pitanga” and “Skin health”

- 1 Alaluf S, Heinrich U, Stahl W, Tronnier H, Wiseman S, 2002. Dietary carotenoids contribute to normal human skin color and UV photosensitivity. *J Nutr*, 132, 399-403.
- 2 Anstey AV, 2002. Systemic photoprotection with alpha-tocopherol (vitamin E) and beta-carotene. *Clin Exp Dermatol*, 27, 170-176.
- 3 Antille C, Tran C, Sorg O, Saurat JH, 2004. Topical beta-carotene is converted to retinyl esters in human skin ex vivo and mouse skin in vivo. *Exp Dermatol*, 13, 558-561.

- 4 Bando N, Hayashi H, Wakamatsu S, Inakuma T, Miyoshi M, Nagao A, Yamauchi R, Terao J, 2004. Participation of singlet oxygen in ultraviolet-a-induced lipid peroxidation in mouse skin and its inhibition by dietary beta-carotene: an ex vivo study. *Free Radic Biol Med*, 37, 1854-1863.
- 5 Battistutta D, Williams DL, Green A, 2000. Effectiveness of daily sunscreen application and b-carotene intake for prevention of photaging: A community-based randomised trial. 13th Int. Congress on Photobiology, July 1-6, 2000, Abstr. 58, San Francisco.
- 6 Boelsma E, Hendriks HF, Roza L, 2001. Nutritional skin care: health effects of micronutrients and fatty acids. *Am J Clin Nutr*, 73, 853-864.
- 7 Britton G, Liaaen-Jensen S, Pfander H, Carotenoids. Volume 4: Natural Functions. Birkhäuser, Basel.
- 8 Cesarini JP, Michel L, Maurette JM, Adhoute H, Bejot M, 2003. Immediate effects of UV radiation on the skin: modification by an antioxidant complex containing carotenoids. *Photodermatol Photoimmunol Photomed*, 19, 182-189.
- 9 Chew BP and Park JS, 2004. Carotenoid action on the immune response. *J Nutr*, 134, 257S-261S.
- 10 Eicker J, Kurten V, Wild S, Riss G, Goralczyk R, Krutmann J, Berneburg M, 2003. Betacarotene supplementation protects from photoaging-associated mitochondrial DNA mutation. *Photochem Photobiol Sci*, 2, 655-659.
- 11 Freyre MR, Baigorria CM, Rozycki VR, Bernardi CM, Charpentier M, 2000. [Suitability of wild underexploited vegetables from the Argentine Chaco as a food resource]. *Arch Latinoam Nutr*, 50, 394-399.
- 12 Fuller CJ, Faulkner H, Bendich A, Parker RS, Roe DA, 1992. Effect of beta-carotene supplementation on photosuppression of delayed-type hypersensitivity in normal young men. *Am J Clin Nutr*, 56, 684-690.
- 13 Garmyn M, Ribaya-Mercado JD, Russel RM, Bhawan J, Gilchrest BA, 1995. Effect of beta-carotene supplementation on the human sunburn reaction. *Exp Dermatol*, 4, 104-111.
- 14 Gollnick H, Hopfenmuller W, Hemmes C, Chun S, Schmid C, Sundermeier K, Biesalski HK, 1996. Systemic beta carotene plus topical UV-sunscreen are an optimal protection against harmful effects of natural UV-sunlight: results of the Berlin-Eilath study. *European Journal of Dermatology*, 6, 219-238.
- 15 Greul AK, Grundmann JU, Heinrich F, Pfitzner I, Bernhardt J, Ambach A, Biesalski HK, Gollnick H, 2002. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and proanthocyanidins. *Skin Pharmacol Appl Skin Physiol*, 15, 307-315.
- 16 Guercio-Hauer C, Macfarlane DF, Deleo VA, 1994. Photodamage, photoaging and photoprotection of the skin. *Am Fam Physician*, 50, 327-332, 334.
- 17 Heinrich U, Gartner C, Wiebusch M, Eichler O, Sies H, Tronnier H, Stahl W, 2003. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. *J Nutr*, 133, 98-101.
- 18 Heinrich U, Tronnier H, Stahl W, Bejot M, Maurette JM, 2006. Antioxidant supplements improve parameters related to skin structure in humans. *Skin Pharmacol Physiol*, 19, 224-231.
- 19 Herraiz LA, Hsieh WC, Parker RS, Swanson JE, Bendich A, Roe DA, 1998. Effect of UV exposure and beta-carotene supplementation on delayed-type hypersensitivity response in healthy older men. *J Am Coll Nutr*, 17, 617-624.
- 20 Hughes DA, 1999. Effects of carotenoids on human immune function. *Proc Nutr Soc*, 58, 713-718.
- 21 Hughes DA, 2001. Dietary carotenoids and human immune function. *Nutrition*, 17, 823-827.
- 22 Köpcke W and Krutmann J, 2008. Protection from Sunburn with b-Carotene - A Meta-analysis. *Photochemistry and Photobiology*, 84, 284-288.
- 23 Lee J, Jiang S, Levine N, Watson RR, 2000. Carotenoid supplementation reduces erythema in human skin after simulated solar radiation exposure. *Proc Soc Exp Biol Med*, 223, 170-174.
- 24 Mathews-Roth MM, Pathak MA, Parrish J, Fitzpatrick TB, Kass EH, Toda K, Clemens W, 1972. A clinical trial of the effects of oral beta-carotene on the responses of human skin to solar radiation. *J Invest Dermatol*, 59, 349-353.

- 25 McArdle F, Rhodes LE, Parslew RA, Close GL, Jack CI, Friedmann PS, Jackson MJ, 2004. Effects of oral vitamin E and beta-carotene supplementation on ultraviolet radiation-induced oxidative stress in human skin. *Am J Clin Nutr*, 80, 1270-1275.
- 26 Miquel J, Ramirez-Bosca A, Ramirez-Bosca JV, Alperi JD, 2006. Menopause: a review on the role of oxygen stress and favorable effects of dietary antioxidants. *Arch Gerontol Geriatr*, 42, 289-306.
- 27 Obermuller-Jevic UC, Francz PI, Frank J, Flaccus A, Biesalski HK, 1999. Enhancement of the UVA induction of haem oxygenase-1 expression by beta-carotene in human skin fibroblasts. *FEBS Lett*, 460, 212-216.
- 28 O'Connor I and O'Brien N, 1998. Modulation of UVA light-induced oxidative stress by beta-carotene, lutein and astaxanthin in cultured fibroblasts. *J Dermatol Sci*, 16, 226-230.
- 29 Offord EA, Gautier JC, Avanti O, Scaletta C, Runge F, Kramer K, Applegate LA, 2002. Photoprotective potential of lycopene, beta-carotene, vitamin E, vitamin C and carnosic acid in UVA-irradiated human skin fibroblasts. *Free Radic Biol Med*, 32, 1293-1303.
- 30 Postaire E, Jungmann H, Bejot M, Heinrich U, Tronnier H, 1997. Evidence for antioxidant nutrients-induced pigmentation in skin: results of a clinical trial. *Biochem Mol Biol Int*, 42, 1023-1033.
- 31 Rodriguez-Amaya DB, 1999. Latin American food sources of carotenoids. *Arch Latinoam Nutr*, 49, 74S-84S.
- 32 Skoog ML, Ollinger K, Skogh M, 1997. Microfluorometry using fluorescein diacetate reflects the integrity of the plasma membrane in UVA-irradiated cultured skin fibroblasts. *Photodermatol Photoimmunol Photomed*, 13, 37-42.
- 33 Someya K, Totsuka Y, Murakoshi M, Kitano H, Miyazawa T, 1994. The effect of natural carotenoid (palm fruit carotene) intake on skin lipid peroxidation in hairless mice. *J Nutr Sci Vitaminol (Tokyo)*, 40, 303-314.
- 34 Stahl W, Heinrich U, Jungmann H, Sies H, Tronnier H, 2000. Carotenoids and carotenoids plus vitamin E protect against ultraviolet light-induced erythema in humans. *Am J Clin Nutr*, 71, 795-798.
- 35 Stahl W and Sies H, 2007. Carotenoids and flavonoids contribute to nutritional protection against skin damage from sunlight. *Mol Biotechnol*, 37, 26-30.
- 36 Trekli MC, Riss G, Goralczyk R, Tyrrell RM, 2003. Beta-carotene suppresses UVA-induced HO-1 gene expression in cultured FEK4. *Free Radic Biol Med*, 34, 456-464.
- 37 Wei RR, Wamer WG, Lambert LA, Kornhauser A, 1998. beta-Carotene uptake and effects on intracellular levels of retinol in vitro. *Nutr Cancer*, 30, 53-58.
- 38 Wertz K, Seifert N, Hunziker PB, Riss G, Wyss A, Lankin C, Goralczyk R, 2004. Beta-carotene inhibits UVA-induced matrix metalloprotease 1 and 10 expression in keratinocytes by a singlet oxygen-dependent mechanism. *Free Radic Biol Med*, 37, 654-670.
- 39 Wertz K, Hunziker PB, Seifert N, Riss G, Neeb M, Steiner G, Hunziker W, Goralczyk R, 2005. beta-Carotene interferes with ultraviolet light A-induced gene expression by multiple pathways. *J Invest Dermatol*, 124, 428-434.
- 40 Wertz K, Seifert N, Hunziker PB, Riss G, Wyss A, Hunziker W, Goralczyk R, 2006. Beta-carotene interference with UVA-induced gene expression by multiple pathways. *Pure and Applied Chemistry*, 78, 1539-1550.
- 41 Wolf C, Steiner A, Honigsmann H, 1988. Do oral carotenoids protect human skin against ultraviolet erythema, psoralen phototoxicity, and ultraviolet-induced DNA damage? *J Invest Dermatol*, 90, 55-57.

ID 2321: “Pitanga” and “Antioxidant activity”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris.

- 2 Bhathena SJ and Velasquez MT, 2002. Beneficial role of dietary phytoestrogens in obesity and diabetes. *Am J Clin Nutr*, 76, 1191-1201.
- 3 Brouwer IA, van Dusseldorp M, West CE, Meyboom S, Thomas CM, Duran M, van het Hof KH, Eskes TK, Hautvast JG, Steegers-Theunissen RP, 1999. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. *J Nutr*, 129, 1135-1139.
- 4 Ceriello A and Motz E, 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arterioscler Thromb Vasc Biol*, 24, 816-823.
- 5 Clifford MN, 1985. Chlorogenic acids. In: *Coffee*. Clarke RJ and Macrae R (eds.). Elsevier, London, 153-202.
- 6 Clifford MN, 1999. Chlorogenic acids and other cinnamates-nature, occurrence and dietary burden. *J Sci Food Agric*, 79, 362-372.
- 7 Clifford MN, 2000. Chlorogenic acids and other cinnamates-nature, occurrence, dietary burden, absorption and metabolism. *Journal of the Science of Food and Agriculture*, 80, 1033-1043.
- 8 Freyre MR, Baigorria CM, Rozycki VR, Bernardi CM, Charpentier M, 2000. Suitability of wild underexploited vegetables from the Argentine Chaco as a food resource. *Arch Latinoam Nutr*, 50, 394-399.
- 9 Harats D, Chevion S, Nahir M, Norman Y, Sagee O, Berry EM, 1998. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. *Am J Clin Nutr*, 67, 240-245.
- 10 Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM, 1996. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. *N Engl J Med*, 334, 1156-1162.
- 11 Lecerf JM, 1997. Nutrition, antioxydants et athéroclérose. *Rev Fr Endocrinol Clin*, 38, 119-141.
- 12 Lecerf J, 1999. Les antioxydants et les autres éléments protecteurs dans les jus de fruits et légumes. Pasteur Institute-Lille.
- 13 Lecerf JM, 2006. Functional Claims of Article 13: Polyphenols in Juices. Pasteur Institute-Lille.
- 14 Lima V, Melo EA, Lima DE, 2002. Total phenolics and carotenoids in surinam cherry. *Scientia Agricola*, 59, 447-450.
- 15 Manach C, Scalbert A, Morand C, Remesy C, Jimenez L, 2004. Polyphenols: food sources and bioavailability. *Am J Clin Nutr*, 79, 727-747.
- 16 Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*, 81, 230S-242S.
- 17 Miquel J, Ramirez-Bosca A, Ramirez-Bosca JV, Alperi JD, 2006. Menopause: a review on the role of oxygen stress and favorable effects of dietary antioxidants. *Arch Gerontol Geriatr*, 42, 289-306.
- 18 Rodriguez-Amaya DB, 1999. Latin American food sources of carotenoids. *Arch Latinoam Nutr*, 49, 74S-84S.
- 19 Ruxton CH, Gardner EJ, Walker D, 2006. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. *Int J Food Sci Nutr*, 57, 249-272.
- 20 Scalbert A and Williamson G, 2000. Dietary intake and bioavailability of polyphenols. *J Nutr*, 130, 2073S-2085S.
- 21 Tucker KL, Selhub J, Wilson PW, Rosenberg IH, 1996. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. *J Nutr*, 126, 3025-3031.

ID 2322: “Populus nigra” and “Kidney health”

- 1 Jellin JM, Gregory P, Batz F, 2000. *Natural Medicines Comprehensive Database*. Pharmacists Letter, Stockton.

ID 2325: “Prunus mume (Plum) extract - INP-08” and “Weight loss management, acid base balancer”

- 1 No authors listed, 2007. Clinical trial randomized -double blind placebo controlled study supplement 1/urine pH measure, 2/ weight loss supplement, 3/ blood fluidity. Medica Center Osaka in collaboration with MIREI International.
- 2 Chuda Y, Ono H, Ohnishi-Kameyama M, Matsumoto K, Nagata T, Kikuchi Y, 1999. Mumefural, citric acid derivative improving blood fluidity from fruit-juice concentrate of Japanese apricot (*Prunus mume* Sieb. et Zucc). *J Agric Food Chem*, 47, 828-831.
- 3 Dogasaki C, Murakami H, Nishijima M, Ohno N, Yadomae T, Miyazaki T, 1994. Biological activity and structural characterization of alkaline-soluble polysaccharides from the kernels of *Prunus mume* Sieb. et Zucc. *Biol Pharm Bull*, 17, 386-390.
- 4 Kim TK, Cha MR, Kim SJ, Kim SY, Jeon KI, Park HR, Park E, Lee SC, 2005. Antioxidative Activity of Methanol Extract from *Prunus mume* Byproduct. *Cancer Prev Res*, 10, 251-256.
- 5 Ninapharm, 2008. INNER7+® - Plum. Composition certificate.
- 6 Ninapharm, 2008. INNER7+® - Plum. Ingredient description, mechanisms of actions.
- 7 Ninapharm, 2008. INNER7+® - Plum. *Prunus mume* extract rich in citric acid.
- 8 Ninapharm, 2008. INNER7+® - Plum. Certificate of non toxicity - Test LD50.
- 9 Son SS, Ji WD, Chung HC, 2003. Optimum condition for acetic acid fermentation using mume (*Prunus mume* Sieb. et Zucc) fruits. *J Korean Soc Food Sci Nutr*, 32, 544-548.
- 10 Utsunomiya H, Yamakawa T, Kamei J, Kadonosono K, Tanaka S, 2005. Anti-hyperglycemic effects of plum in a rat model of obesity and type 2 diabetes, Wistar fatty rat. *Biomed Res*, 26, 193-200.

ID 2326: “Prunus spinosa” and “Kidney health”

- 1 Jellin JM, Gregory P, Batz F, 2000. *Natural Medicines Comprehensive Database*. Pharmacists Letter, Stockton.

ID 2328: “Quercus robur” and “Health of the upper respiratory tract”

- 1 Jellin JM, Gregory P, Batz F, 2000. *Natural Medicines Comprehensive Database*. Pharmacists Letter, Stockton.

ID 2329: “Raphanus sativus - common name: radish, black radish, Japanese radish, Daikon” and “Digestion”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.

ID 2330: “Ribes nigrum - nom commun: blackcurrant” and “Renal Elimination / Draining organism”

- 1 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.

- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 4 Leclerc H, 1994. Précis de phytothérapie: essais de thérapeutique par les plantes françaises. Masson, Paris.
- 5 Musarella P and Moatti R, 1993. Le guide complet des plantes pour se soigner. Editions du Rocher, Paris.
- 6 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 7 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2331: “Ribes nigrum - nom commun: blackcurrant” and “Control of weight”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2332: “Ribes nigrum L. (Common name: Blackcurrant)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. Hagers Enzyklopädie der Arzneistoffe und Drogen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren.

ID 2333: “Rice vinegar extract - INRV-08” and “Weight loss management, acid base balancer”

- 1 No authors listed, 2007. INNER7+® - Rice Vinegar Extract. Clinical trial randomized -double blind placebo controlled study supplement: 1/ 24h net acid excretion & urine ph measure-2/ weight loss supplement. Medica Center Osaka in collaboration with MIREI International.
- 2 Fushimi T, Kishi M, Oshima Y, Tsukamoto Y, Ito A, 2005. Investigation of Safety of Drinks Containing Vinegar. Journal of Urban Living Health Association, 49, 267-278.
- 3 Gerber J, Hutchins A, Johnston C, 2006. Impact of daily vinegar consumption on body composition and insulin sensitivity in overweight, healthy adults. FASEB J, 20, A579.
- 4 Johnston CS, Kim CM, Buller AJ, 2004. Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance or type 2 diabetes. Diabetes Care, 27, 281-282.
- 5 Johnston CS and Buller AJ, 2005. Vinegar and peanut products as complementary foods to reduce postprandial glycemia. J Am Diet Assoc, 105, 1939-1942.
- 6 Leeman M, Ostman E, Bjorck I, 2005. Vinegar dressing and cold storage of potatoes lowers postprandial glycaemic and insulinaemic responses in healthy subjects. Eur J Clin Nutr, 59, 1266-1271.
- 7 Ninapharm, 2008. INNER7+® - Rice Vinegar Extract. Ingredient description, composition certificate.
- 8 Ninapharm, 2008. INNER7+® - Rice Vinegar Extract. Natural acetic acid source.
- 9 Ninapharm, 2008. INNER7+® - Rice Vinegar Extract. Inhibitory effects and its constituents on α -glucosidase activity.

- 10 Ninapharm, 2008. INNER7+® - Rice Vinegar Extract. Bibliographic report on beneficial effects of metabolism.
- 11 Ninapharm, 2008. INNER7+® - Rice Vinegar Extract. Certificate of non toxicity.
- 12 Ostman E, Granfeldt Y, Persson L, Bjorck I, 2005. Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects. Eur J Clin Nutr, 59, 983-988.

ID 2334: “Rosa canica - common name : Cynorrhodon, Eglantier” and “Invigoration of the body”

- 1 Boullard B, 2001. Plantes médicinales du monde: Réalités & Croyances. Paris, Estem.
- 2 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Daels-Rakotoarison DA, Gressier B, Trotin F, Brunet C, Luyckx M, Dine T, Bailleul F, Cazin M, Cazin JC, 2002. Effects of Rosa canina fruit extract on neutrophil respiratory burst. Phytother Res, 16, 157-161.
- 5 Girre L, 2001. Les plantes et les médicaments : L'origine végétale de nos médicaments. Delachaux et Niestlé, Lausanne.
- 6 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 7 Leclerc H, 1976. Les tonique astringents. In: Précis de phytothérapie. Essais de thérapeutique par les plantes françaises. Masson, Paris.
- 8 Leung AY and Foster S, 1996. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. John Wiley & Sons, New York.
- 9 No authors listed, 2001. Encyclopédie des plantes médicinales. Larousse, Paris.
- 10 Salminen JP, Karonen M, Lempa K, Liimatainen J, Sinkkonen J, Lukkarinen M, Pihlaja K, 2005. Characterisation of proanthocyanidin aglycones and glycosides from rose hips by high-performance liquid chromatography-mass spectrometry, and their rapid quantification together with vitamin C. J Chromatogr A, 1077, 170-180.
- 11 Schauenberg P and Paris F, 1977. Guide des plantes médicinales. Analyse, description et utilisation de 400 plantes. Lutterworth Press, Guildford.
- 12 Van Hellemont J, 1986. Compendium de Phytothérapie. Association Pharmaceutique Belge, Bruxelles.
- 13 WHO and FAO (World Health Organization and Food and Agriculture Organization), 2004. Vitamin and mineral requirements in human nutrition.
- 14 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2335: “Rubus fruticosus” and “Glucose metabolism”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2336: “Rubus idaeas (Raspberry) extract - BERI-08” and “Weight loss management, thermogenesis”

- 1 Bertrand PP, 2004. Real-time detection of serotonin release from enterochromaffin cells of the guinea-pig ileum. Neurogastroenterol Motil, 16, 511-514.
- 2 Braun T, Volland P, Kunz L, Prinz C, Gratzl M, 2007. Enterochromaffin cells of the human gut: sensors for spices and odorants. Gastroenterology, 132, 1890-1901.

- 3 Hofer D, Puschel B, Drenckhahn D, 1996. Taste receptor-like cells in the rat gut identified by expression of alpha-gustducin. *Proc Natl Acad Sci USA*, 93, 6631-6634.
- 4 Li Y, Hao Y, Zhu J, Owyang C, 2000. Serotonin released from intestinal enterochromaffin cells mediates luminal non-cholecystokinin-stimulated pancreatic secretion in rats. *Gastroenterology*, 118, 1197-1207.
- 5 Lindemann B, 2001. Receptors and transduction in taste. *Nature*, 413, 219-225.
- 6 Lucas F and Sclafani A, 1996. Capsaicin attenuates feeding suppression but not reinforcement by intestinal nutrients. *Am J Physiol*, 270, R1059-1064.
- 7 Morimoto C, Satoh Y, Hara M, Inoue S, Tsujita T, Okuda H, 2005. Anti-obese action of raspberry ketone. *Life Sci*, 77, 194-204.
- 8 Phillips RJ and Powley TL, 1996. Gastric volume rather than nutrient content inhibits food intake. *Am J Physiol*, 271, R766-769.
- 9 Rougier Y and Pouyssegur V, 2007. De 50 ans de régime minceur à l'émergence de la minceur santé. Les réponses d'une synergie pluridisciplinaire prometteuse : Index SLIM data Chrononutrition et Neuronutrition. Présentation d'un extrait alimentaire novateur (*Rubus Idaeus*) ciblant la Neuronutrition. *Entretiens de Bichat Thérapeutique*, 111-118.

ID 2337: “*Rubus idaeus* - common name: Blackberry” and “Digestion”

- 1 **Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.**

ID 2338: “*Rubus idaeus* - common name: Blackberry” and “Renal elimination / Organism draining”

- 1 Wichtl M and Anton R, 1999. *Rubi idaei folium*. In: *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2339: “*Salvia triloba* L. fil. (Common name: Greek sage)” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.
- 3 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2340: “*Salviae lavandulifoliae aetheroleum*” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2007. *Hagers Enzyklopädie der Arzneistoffe und Drogen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1988. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Eberwein E and Vogel G, 1990. *Arzneipflanzen in der Phytotherapie*. Kooperation Phytopharmaka, Berlin.
- 4 Swissmedic (Schweizerisches Heilmittelinstitut), 2007. *Anleitung zum Einreichen von Zulassungsgesuchen für Husten- und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren*.

ID 2342: “Sisymbrium officinale” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, 2003. HagerROM 2003. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.

ID 2344: “Triticum sativum” and “Resistance system”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2345: “Undaria pinnatifidia” and “Body weight”

- 1 Undaria-P® - Frequently Asked Questions, <http://www.undaria.eu/english/faq.htm>.

ID 2346: “Urtica dioica - common name: Stinging nettle” and “Renal Elimination / Organism draining”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1975. Les plantes dans la thérapeutique moderne. Maloine, Paris.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. Plantes médicinales des régions tempérées. Maloine, Paris.
- 3 BHMA (British Herbal Medicine Association), 1996. British Herbal Pharmacopoeia. British Herbal Medicine Association, Exeter.
- 4 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 5 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 6 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 7 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 8 EMEA (European Medicines Agency), 2007. Opinion of the Committee on Herbal Medicinal Products on a Community Herbal Monograph on *Foeniculum vulgare* Miller subsp. *vulgare* var. *dulce* (Miller) Thellung, fructus. EMEA/HMPC/280074/2007.
- 9 ESCOP (The European Scientific Cooperative on Phytotherapy), 1997. ESCOP Monographs on the Medicinal Uses of Plant Drugs.
- 10 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *Urticae folium / herba-radix*. In: ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart, 521-535.
- 11 Fournier P, 1948. Le livre des plantes médicinales et vénéneuses de France. Lechevalier, Paris.
- 12 Hiller K and Melzig MF, 2003. Lexikon der Arzneipflanzen und Drogen. Spektrum Akademischer Verlag, Heidelberg.
- 13 Hoppe HA, 1977. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 14 Koch E, 2001. Extracts from fruits of saw palmetto (*Sabal serrulata*) and roots of stinging nettle (*Urtica dioica*): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. *Planta Med*, 67, 489-500.
- 15 Leclerc H, 1976. Les toniques astringents. In: Précis de phytothérapie: essais de thérapeutique par les plantes françaises. Masson, Paris.

- 16 Leung AY and Foster S, 2003. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. Wiley-Interscience, New York.
- 17 Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, Avdeichuk J, Golubev G, Melnik K, Elenberger N, Engelmann U, 2005. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial. *World J Urol*, 23, 139-146.
- 18 Popa G, Hagele-Kaddour H, Walther C, 2005. Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. *MMW Fortschr Med*, 147, 103-108.
- 19 Safarinejad MR, 2005. *Urtica dioica* for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. *J Herb Pharmacother*, 5, 1-11.
- 20 Schauenberg P and Paris F, 1977. *Guide des plantes médicinales*. Delachaux & Niestle, Lausanne.
- 21 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 22 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 23 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.
- 24 Yarnell E, 2002. Botanical medicines for the urinary tract. *World J Urol*, 20, 285-293.

ID 2348: “Valerian extract [Dry extract from roots of *Valeriana officinalis* L., drug/native extract ratio (3-6) : 1, solvent of extraction Ethanol/Water, min 0.3% valerenic acid]” and “For insomnia and mental health”

- 1 Cerny A and Schmid K, 1999. Tolerability and efficacy of valerian/lemon balm in healthy volunteers. *Fitoterapia*, 70, 221-228.
- 2 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 3 Leathwood PD, Chauffard F, Heck E, Munoz-Box R, 1982. Aqueous extract of valerian root (*Valeriana officinalis* L.) improves sleep quality in man. *Pharmacol Biochem Behav*, 17, 65-71.
- 4 Schwander J and Mann C, 1999. The pupil unrest index as a measure of sleep restoration in patients with psychophysiological insomnia.
- 5 WHO (World Health Organization), 1999. *Radix Valerianae*. In: *WHO Monographs on Selected Medicinal Plants*. WHO (World Health Organization), Geneva.

ID 2351: “*Verbascum thapsiforme*” and “Pharyngeal and respiratory health”

- 1 No authors listed, 1985. *Résumé de Phytothérapie*. Herboristerie.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 3 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. *Verbascum thapsus* L., *Verbascum phlomoides* L. et *Verbascum thapsiforme* Schrad. In: *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 4 BHMA (British Herbal Medicine Association), 1983. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 5 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.

- 6 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 7 Boni U and Patri G, 1977. Scoprire, Riconoscere, Usare le Erbe. Fabbri Editori, Milan.
- 8 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 9 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 10 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 11 Capasso F, Gaginella TS, Grandolini G, Izzo AA, 2003. Phytotherapy: a quick reference to herbal medicine. Springer Verlag, Heidelberg.
- 12 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- 13 Fournier P, 1948. Le livre des plantes médicinales et veneneuses de France. Lechevalier, Paris.
- 14 Garnier G, Bézanger-Beauquesne L, Debraux G, Souèges R, Dol G, 1961. Ressources medicinales de la flore française. Vigot, Paris.
- 15 Hostettmann K, 2001. Tout savoir sur les plantes médicinales des montagnes. Favre, Lausanne.
- 16 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.
- 17 Leclerc H, 1976. Précis de phytothérapie. Masson, Paris.
- 18 Mességué M, 1972. C'est la nature qui a raison. Robert Laffont, Paris.
- 19 Mills S and Bone K, 2000. Principles and Practices of Phytotherapie: Modern Herbal Medecine. Churchill Livingstone, London, Edinburgh.
- 20 Morel JM, 1992. Nouveau guide de phytothérapie. Grancher, Paris.
- 21 Palaiseul J, 1999. Nos grand-mères savaient - la vérité sur les plantes et la vie naturelle. Robert Laffont, Paris.
- 22 Paris R and Moyses H, 1981. Précis de Matière Médicale. Masson, Paris.
- 23 PDR health, Mullein, http://www.pdrhealth.com/drug_info/nmdrugprofiles/herbaldrugs/101980.shtml.
- 24 Rombi M, Robert D, Guedon D, Rosier-Sala C, Renzacci E, 2007. 120 plantes médicinales : composition, mode d'action et intérêt thérapeutique ... de l'Ail à la Vigne rouge. Alpen Editions, Monaco.
- 25 Totalmédia Inc, PasseportSanté.net, <http://www.passeportsante.net>.
- 26 Turker AU and Camper ND, 2002. Biological activity of common mullein, a medicinal plant. J Ethnopharmacol, 82, 117-125.
- 27 Turker AU and Gurel E, 2005. Common mullein (*Verbascum thapsus* L.): recent advances in research. Phytother Res, 19, 733-739.
- 28 Valnet J, 1983. Phytothérapie. Traitement des maladies par les plantes. Maloine, Paris.
- 29 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2352: “Verbascum thapsiforme” and “Bladder and Kidney Health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2355: “Veronica officinalis” and “Kidney health”

- 1 Jellin JM, Gregory P, Batz F, 2000. Natural Medicines Comprehensive Database. Pharmacists Letter, Stockton.

ID 2356: “Viola tricolor” and “Respiratory health”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, 2003. HagerROM 2003. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.

ID 2362: “Garlic bulb (Allium sativum)” and “Body’s defence system against microorganism”

- 1 Adetumbi M, Javor GT, Lau BH, 1986. Allium sativum (garlic) inhibits lipid synthesis by Candida albicans. Antimicrob Agents Chemother, 30, 499-501.
- 2 Ghannoum MA, 1988. Studies on the anticandidal mode of action of Allium sativum (garlic). J Gen Microbiol, 134, 2917-2924.
- 3 Ghannoum MA, 1990. Inhibition of Candida adhesion to buccal epithelial cells by an aqueous extract of Allium sativum (garlic). J Appl Bacteriol, 68, 163-169.
- 4 Iwalokun BA, Ogunledun A, Ogbolu DO, Bamiro SB, Jimi-Omojola J, 2004. In vitro antimicrobial properties of aqueous garlic extract against multidrug-resistant bacteria and Candida species from Nigeria. J Med Food, 7, 327-333.
- 5 Lemar KM, Turner MP, Lloyd D, 2002. Garlic (Allium sativum) as an anti-Candida agent: a comparison of the efficacy of fresh garlic and freeze-dried extracts. J Appl Microbiol, 93, 398-405.
- 6 Lemar KM, Muller CT, Plummer S, Lloyd D, 2003. Cell death mechanisms in the human opportunistic pathogen Candida albicans. J Eukaryot Microbiol, 50 Suppl, 685-686.
- 7 Lemar KM, Passa O, Aon MA, Cortassa S, Muller CT, Plummer S, O'Rourke B, Lloyd D, 2005. Allyl alcohol and garlic (Allium sativum) extract produce oxidative stress in Candida albicans. Microbiology, 151, 3257-3265.
- 8 Motsei ML, Lindsey KL, van Staden J, Jager AK, 2003. Screening of traditionally used South African plants for antifungal activity against Candida albicans. J Ethnopharmacol, 86, 235-241.
- 9 Shuford JA, Steckelberg JM, Patel R, 2005. Effects of fresh garlic extract on Candida albicans biofilms. Antimicrob Agents Chemother, 49, 473.
- 10 Yamada Y and Azuma K, 1977. Evaluation of the in vitro antifungal activity of allicin. Antimicrob Agents Chemother, 11, 743-749.

ID 2365: “Pumpkin seed (Cucurbita pepo)” and “Prostate/urinary tract”

- 1 Berges RR, Windeler J, Trampisch HJ, Senge T, 1995. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet, 345, 1529-1532.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Gossell-Williams M, Davis A, O'Connor N, 2006. Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. J Med Food, 9, 284-286.

- 4 Lans C, 2007. Ethnomedicines used in Trinidad and Tobago for reproductive problems. *J Ethnobiol Ethnomed*, 3, 13.
- 5 Tsai YS, Tong YC, Cheng JT, Lee CH, Yang FS, Lee HY, 2006. Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. *Urol Int*, 77, 269-274.
- 6 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.

ID 2368: “Combination of sweet fennel seed (*Foeniculum dulce*), mint leaf (*Mentha piperita*) and chamomile flower (*Matricaria chamomilla*)” and “Digestive system”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.

ID 2372: “Tomato extract containing lycopene” and “Cardio-vascular health”

- 1 Agarwal S and Rao AV, 1998. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. *Lipids*, 33, 981-984.
- 2 Agarwal S and Rao AV, 2000. Tomato lycopene and its role in human health and chronic diseases. *CMAJ*, 163, 739-744.
- 3 Ahuja KD, Pittaway JK, Ball MJ, 2006. Effects of olive oil and tomato lycopene combination on serum lycopene, lipid profile, and lipid oxidation. *Nutrition*, 22, 259-265.
- 4 Andersen LF, Jacobs DR, Jr., Gross MD, Schreiner PJ, Dale Williams O, Lee DH, 2006. Longitudinal associations between body mass index and serum carotenoids: the CARDIA study. *Br J Nutr*, 95, 358-365.
- 5 Arab L and Steck S, 2000. Lycopene and cardiovascular disease. *Am J Clin Nutr*, 71, 1691S-1695S; discussion 1696S-1697S.
- 6 Araujo FB, Barbosa DS, Hsin CY, Maranhao RC, Abdalla DS, 1995. Evaluation of oxidative stress in patients with hyperlipidemia. *Atherosclerosis*, 117, 61-71.
- 7 Aviram M and Fuhrman B, 1998. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. *Mol Cell Biochem*, 188, 149-159.
- 8 Balestrieri ML, De Prisco R, Nicolaus B, Pari P, Moriello VS, Strazzullo G, Iorio EL, Servillo L, Balestrieri C, 2004. Lycopene in association with alpha-tocopherol or tomato lipophilic extracts enhances acyl-platelet-activating factor biosynthesis in endothelial cells during oxidative stress. *Free Radic Biol Med*, 36, 1058-1067.
- 9 Bansal P, Gupta SK, Ojha SK, Nandave M, Mittal R, Kumari S, Arya DS, 2006. Cardioprotective effect of lycopene in the experimental model of myocardial ischemia-reperfusion injury. *Mol Cell Biochem*, 289, 1-9.
- 10 Biesalski HK, 2000. The role of antioxidants in nutritional support. *Nutrition*, 16, 593-596.
- 11 Blum A, Monir M, Wirsansky I, Ben-Arzi S, 2005. The beneficial effects of tomatoes. *Eur J Intern Med*, 16, 402-404.
- 12 Blum A, Merai M, Karem A, Blum N, Ben-Arzi S, Wirsansky I, Khazim K, 2006. Effects of tomatoes on the lipid profile. *Clin Invest Med*, 29, 298-300.
- 13 Blum A, Monir M, Khazim K, Peleg A, Blum N, 2007. Tomato-rich (Mediterranean) diet does not modify inflammatory markers. *Clin Invest Med*, 30, E70-74.
- 14 Bobak M, Hense HW, Kark J, Kuch B, Vojtisek P, Sinnreich R, Gostomzyk J, Bui M, von Eckardstein A, Junker R, Fobker M, Schulte H, Assmann G, Marmot M, 1999. An ecological study of determinants of coronary heart disease rates: a comparison of Czech, Bavarian and Israeli men. *Int J Epidemiol*, 28, 437-444.

- 15 Bohm V and Bitsch R, 1999. Intestinal absorption of lycopene from different matrices and interactions to other carotenoids, the lipid status, and the antioxidant capacity of human plasma. *Eur J Nutr*, 38, 118-125.
- 16 Bose KS and Agrawal BK, 2007. Effect of lycopene from cooked tomatoes on serum antioxidant enzymes, lipid peroxidation rate and lipid profile in coronary heart disease. *Singapore Med J*, 48, 415-420.
- 17 Bramley PM, 2000. Is lycopene beneficial to human health? *Phytochemistry*, 54, 233-236.
- 18 Briviba K, Schnabele K, Rechkemmer G, Bub A, 2004. Supplementation of a diet low in carotenoids with tomato or carrot juice does not affect lipid peroxidation in plasma and feces of healthy men. *J Nutr*, 134, 1081-1083.
- 19 Bub A, Barth S, Watzl B, Briviba K, Herbert BM, Luhrmann PM, Neuhauser-Berthold M, Rechkemmer G, 2002. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in R-allele-carrier but not in QQ homozygous elderly subjects on a tomato-rich diet. *Eur J Nutr*, 41, 237-243.
- 20 Bub A, Barth SW, Watzl B, Briviba K, Rechkemmer G, 2005. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice. *Br J Nutr*, 93, 291-297.
- 21 Canene-Adams K, Campbell JK, Zaripheh S, Jeffery EH, Erdman JW, Jr., 2005. The tomato as a functional food. *J Nutr*, 135, 1226-1230.
- 22 Carpenter KL, Hardwick SJ, Albarani V, Mitchinson MJ, 1999. Carotenoids inhibit DNA synthesis in human aortic smooth muscle cells. *FEBS Lett*, 447, 17-20.
- 23 Carroll YL, Corridan BM, Morrissey PA, 2000. Lipoprotein carotenoid profiles and the susceptibility of low density lipoprotein to oxidative modification in healthy elderly volunteers. *Eur J Clin Nutr*, 54, 500-507.
- 24 Chopra M, O'Neill ME, Keogh N, Wortley G, Southon S, Thurnham DI, 2000. Influence of increased fruit and vegetable intake on plasma and lipoprotein carotenoids and LDL oxidation in smokers and nonsmokers. *Clin Chem*, 46, 1818-1829.
- 25 Clarke R and Armitage J, 2002. Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials. *Cardiovasc Drugs Ther*, 16, 411-415.
- 26 Das S, Otani H, Maulik N, Das DK, 2005. Lycopene, tomatoes, and coronary heart disease. *Free Radic Res*, 39, 449-455.
- 27 De Pablo P, Dietrich T, Karlson EW, 2007. Antioxidants and other novel cardiovascular risk factors in subjects with rheumatoid arthritis in a large population sample. *Arthritis Rheum*, 57, 953-962.
- 28 Engelhard YN, Gazer B, Paran E, 2006. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-I hypertension: a double-blind, placebo-controlled pilot study. *Am Heart J*, 151, 100.
- 29 Ferreira AL, Salvadori DM, Nascimento MC, Rocha NS, Correa CR, Pereira EJ, Matsubara LS, Matsubara BB, Ladeira MS, 2007. Tomato-oleoresin supplement prevents doxorubicin-induced cardiac myocyte oxidative DNA damage in rats. *Mutat Res*, 631, 26-35.
- 30 Frederiksen H, Rasmussen SE, Schroder M, Bysted A, Jakobsen J, Frandsen H, Ravn-Haren G, Mortensen A, 2007. Dietary supplementation with an extract of lycopene-rich tomatoes does not reduce atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits. *Br J Nutr*, 97, 6-10.
- 31 Fuhrman B, Elis A, Aviram M, 1997. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. *Biochem Biophys Res Commun*, 233, 658-662.
- 32 Fuhrman B, Volkova N, Rosenblat M, Aviram M, 2000. Lycopene synergistically inhibits LDL oxidation in combination with vitamin E, glabridin, rosmarinic acid, carnosic acid, or garlic. *Antioxid Redox Signal*, 2, 491-506.
- 33 Gianetti J, Pedrinelli R, Petrucci R, Lazzarini G, De Caterina M, Bellomo G, De Caterina R, 2002. Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis. *Am Heart J*, 143, 467-474.
- 34 Hadley P and Schwartz SJ, 2005. Lycopene. *Encyclopedia of Dietary Supplements*, 421-434.

- 35 Hak AE, Stampfer MJ, Campos H, Sesso HD, Gaziano JM, Willett W, Ma J, 2003. Plasma carotenoids and tocopherols and risk of myocardial infarction in a low-risk population of US male physicians. *Circulation*, 108, 802-807.
- 36 Hak AE, Ma J, Powell CB, Campos H, Gaziano JM, Willett WC, Stampfer MJ, 2004. Prospective study of plasma carotenoids and tocopherols in relation to risk of ischemic stroke. *Stroke*, 35, 1584-1588.
- 37 Heber D and Lu QY, 2002. Overview of mechanisms of action of lycopene. *Exp Biol Med (Maywood)*, 227, 920-923.
- 38 Heber D, 2004. Vegetables, fruits and phytoestrogens in the prevention of diseases. *J Postgrad Med*, 50, 145-149.
- 39 Hininger IA, Meyer-Wenger A, Moser U, Wright A, Southon S, Thurnham D, Chopra M, Van Den Berg H, Olmedilla B, Favier AE, Roussel AM, 2001. No significant effects of lutein, lycopene or beta-carotene supplementation on biological markers of oxidative stress and LDL oxidizability in healthy adult subjects. *J Am Coll Nutr*, 20, 232-238.
- 40 Hozawa A, Jacobs DR, Jr., Steffes MW, Gross MD, Steffen LM, Lee DH, 2007. Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) study. *Clin Chem*, 53, 447-455.
- 41 Hsiao G, Wang Y, Tzu NH, Fong TH, Shen MY, Lin KH, Chou DS, Sheu JR, 2005. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. *J Lab Clin Med*, 146, 216-226.
- 42 Ito Y, Kurata M, Suzuki K, Hamajima N, Hishida H, Aoki K, 2006. Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. *J Epidemiol*, 16, 154-160.
- 43 Kaliora AC, Dedoussis GV, Schmidt H, 2006. Dietary antioxidants in preventing atherogenesis. *Atherosclerosis*, 187, 1-17.
- 44 Kardinaal AF, Kok FJ, Ringstad J, Gomez-Aracena J, Mazaev VP, Kohlmeier L, Martin BC, Aro A, Kark JD, Delgado-Rodriguez M, et al., 1993. Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC Study. *Lancet*, 342, 1379-1384.
- 45 Kawashima A, Madarame T, Koike H, Komatsu Y, Wise JA, 2007. Four week supplementation with mixed fruit and vegetable juice concentrates increased protective serum antioxidants and folate and decreased plasma homocysteine in Japanese subjects. *Asia Pac J Clin Nutr*, 16, 411-421.
- 46 Kiokias S and Gordon MH, 2003. Dietary supplementation with a natural carotenoid mixture decreases oxidative stress. *Eur J Clin Nutr*, 57, 1135-1140.
- 47 Klipstein-Grobusch K, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JCM, 2000. Serum carotenoids and atherosclerosis: The Rotterdam Study. *Atherosclerosis*, 148, 49-56.
- 48 Kohlmeier L, Kark JD, Gomez-Gracia E, Martin BC, Steck SE, Kardinaal AF, Ringstad J, Thamm M, Masaev V, Riemersma R, Martin-Moreno JM, Huttunen JK, Kok FJ, 1997. Lycopene and myocardial infarction risk in the EURAMIC Study. *Am J Epidemiol*, 146, 618-626.
- 49 Krinsky NI and Johnson EJ, 2005. Carotenoid actions and their relation to health and disease. *Mol Aspects Med*, 26, 459-516.
- 50 Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE, Etherton TD, 2002. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. *Am J Med*, 113 Suppl 9B, 71S-88S.
- 51 Lee DK, Grantham RN, Mannion JD, Trachte AL, 2006. Carotenoids enhance phosphorylation of Akt and suppress tissue factor activity in human endothelial cells. *J Nutr Biochem*, 17, 780-786.
- 52 Levy J and Sharoni Y, 2004. The functions of tomato lycopene and its role in human health. *HerbalGram*, 62, 49-56.

- 53 Linseisen J, Hoffmann J, Riedl J, Wolfram G, 1998. Effect of a single oral dose of antioxidant mixture (vitamin E, carotenoids) on the formation of cholesterol oxidation products after ex vivo LDL oxidation in humans. *Eur J Med Res*, 3, 5-12.
- 54 Liu M-L, Ylitalo K, Nuotio I, Salonen R, Salonen JT, Taskinen M-R, 2002. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in symptomatic members of familial combined hyperlipidemia families. *Stroke*, 33, 1255-1260.
- 55 Liu X, Qu D, He F, Lu Q, Wang J, Cai D, 2007. Effect of lycopene on the vascular endothelial function and expression of inflammatory agents in hyperhomocysteinemic rats. *Asia Pac J Clin Nutr*, 16 Suppl 1, 244-248.
- 56 Lo HM, Hung CF, Tseng YL, Chen BH, Jian JS, Wu WB, 2007. Lycopene binds PDGF-BB and inhibits PDGF-BB-induced intracellular signaling transduction pathway in rat smooth muscle cells. *Biochem Pharmacol*, 74, 54-63.
- 57 Martin KR, Wu D, Meydani M, 2000. The effect of carotenoids on the expression of cell surface adhesion molecules and binding of monocytes to human aortic endothelial cells. *Atherosclerosis*, 150, 265-274.
- 58 Maruyama C, Imamura K, Oshima S, Suzukawa M, Egami S, Tonomoto M, Baba N, Harada M, Ayaori M, Inakuma T, Ishikawa T, 2001. Effects of tomato juice consumption on plasma and lipoprotein carotenoid concentrations and the susceptibility of low density lipoprotein to oxidative modification. *J Nutr Sci Vitaminol (Tokyo)*, 47, 213-221.
- 59 Matulka RA, Hood AM, Griffiths JC, 2004. Safety evaluation of a natural tomato oleoresin extract derived from food-processing tomatoes. *Regul Toxicol Pharmacol*, 39, 390-402.
- 60 McDevitt TM, Tchao R, Harrison EH, Morel DW, 2005. Carotenoids normally present in serum inhibit proliferation and induce differentiation of a human monocyte/macrophage cell line (U937). *J Nutr*, 135, 160-164.
- 61 McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL, 2001. Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS). *J Am Coll Cardiol*, 38, 1788-1794.
- 62 Misra R, Mangi S, Joshi S, Mittal S, Gupta SK, Pandey RM, 2006. LycoRed as an alternative to hormone replacement therapy in lowering serum lipids and oxidative stress markers: a randomized controlled clinical trial. *J Obstet Gynaecol Res*, 32, 299-304.
- 63 Moore EH, Napolitano M, Prosperi A, Avella M, Suckling KE, Bravo E, Botham KM, 2003. Incorporation of lycopene into chylomicron remnant-like particles enhances their induction of lipid accumulation in macrophages. *Biochem Biophys Res Commun*, 312, 1216-1219.
- 64 Most MM, 2004. Estimated phytochemical content of the dietary approaches to stop hypertension (DASH) diet is higher than in the Control Study Diet. *J Am Diet Assoc*, 104, 1725-1727.
- 65 Neyestani TR, Shariat-Zadeh N, Gharavi A, Kalayi A, Khalaji N, 2007. The opposite associations of lycopene and body fat mass with humoral immunity in type 2 diabetes mellitus: a possible role in atherogenesis. *Iran J Allergy Asthma Immunol*, 6, 79-87.
- 66 Osganian SK, Stampfer MJ, Rimm E, Spiegelman D, Manson JE, Willett WC, 2003. Dietary carotenoids and risk of coronary artery disease in women. *Am J Clin Nutr*, 77, 1390-1399.
- 67 Polidori MC, Savino K, Alunni G, Freddio M, Senin U, Sies H, Stahl W, Mecocci P, 2002. Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. *Free Radic Biol Med*, 32, 148-152.
- 68 Pool-Zobel BL, Bub A, Muller H, Wollowski I, Rechkemmer G, 1997. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. *Carcinogenesis*, 18, 1847-1850.
- 69 Porrini M and Riso P, 2000. Lymphocyte lycopene concentration and DNA protection from oxidative damage is increased in women after a short period of tomato consumption. *J Nutr*, 130, 189-192.

- 70 Porrini M, Riso P, Oriani G, 2002. Spinach and tomato consumption increases lymphocyte DNA resistance to oxidative stress but this is not related to cell carotenoid concentrations. *Eur J Nutr*, 41, 95-100.
- 71 Rao AV and Agarwal S, 1998. Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. *Nutr Cancer*, 31, 199-203.
- 72 Rao AV and Agarwal S, 2000. Role of antioxidant lycopene in cancer and heart disease. *J Am Coll Nutr*, 19, 563-569.
- 73 Rao AV, 2002. Lycopene, tomatoes, and the prevention of coronary heart disease. *Exp Biol Med (Maywood)*, 227, 908-913.
- 74 Rao AV, Ray MR, Rao LG, 2006. Lycopene. *Adv Food Nutr Res*, 51, 99-164.
- 75 Rao AV and Rao LG, 2007. Carotenoids and human health. *Pharmacol Res*, 55, 207-216.
- 76 Riso P, Pinder A, Santangelo A, Porrini M, 1999. Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? *Am J Clin Nutr*, 69, 712-718.
- 77 Riso P, Visioli F, Erba D, Testolin G, Porrini M, 2004. Lycopene and vitamin C concentrations increase in plasma and lymphocytes after tomato intake. Effects on cellular antioxidant protection. *Eur J Clin Nutr*, 58, 1350-1358.
- 78 Riso P, Visioli F, Grande S, Guarnieri S, Gardana C, Simonetti P, Porrini M, 2006. Effect of a tomato-based drink on markers of inflammation, immunomodulation, and oxidative stress. *J Agric Food Chem*, 54, 2563-2566.
- 79 Rissanen T, Voutilainen S, Nyyssonen K, Salonen R, Salonen JT, 2000. Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. *Arterioscler Thromb Vasc Biol*, 20, 2677-2681.
- 80 Rissanen TH, Voutilainen S, Nyyssonen K, Lakka TA, Sivenius J, Salonen R, Kaplan GA, Salonen JT, 2001. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. *Br J Nutr*, 85, 749-754.
- 81 Rissanen T, Voutilainen S, Nyyssonen K, Salonen JT, 2002. Lycopene, atherosclerosis, and coronary heart disease. *Exp Biol Med (Maywood)*, 227, 900-907.
- 82 Rissanen TH, Voutilainen S, Nyyssonen K, Salonen R, Kaplan GA, Salonen JT, 2003. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. *Am J Clin Nutr*, 77, 133-138.
- 83 Rowley K, O'Dea K, Su Q, Jenkins AJ, Best JD, 2003. Low plasma concentrations of diet-derived antioxidants in association with microalbuminuria in Indigenous Australian populations. *Clin Sci (Lond)*, 105, 569-575.
- 84 Rowley K, Walker KZ, Cohen J, Jenkins AJ, O'Neal D, Su Q, Best JD, O'Dea K, 2003. Inflammation and vascular endothelial activation in an Aboriginal population: relationships to coronary disease risk factors and nutritional markers. *Med J Aust*, 178, 495-500.
- 85 Sesso HD, Liu S, Gaziano JM, Buring JE, 2003. Dietary lycopene, tomato-based food products and cardiovascular disease in women. *J Nutr*, 133, 2336-2341.
- 86 Sesso HD, Buring JE, Norkus EP, Gaziano JM, 2004. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. *Am J Clin Nutr*, 79, 47-53.
- 87 Sesso HD, Buring JE, Norkus EP, Gaziano JM, 2005. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in men. *Am J Clin Nutr*, 81, 990-997.
- 88 Sesso HD, 2006. Carotenoids and cardiovascular disease: what research gaps remain? *Curr Opin Lipidol*, 17, 11-16.
- 89 Shao A and Hathcock JN, 2006. Risk assessment for the carotenoids lutein and lycopene. *Regul Toxicol Pharmacol*, 45, 289-298.
- 90 Silaste ML, Alfthan G, Aro A, Kesaniemi YA, Horkko S, 2007. Tomato juice decreases LDL cholesterol levels and increases LDL resistance to oxidation. *Br J Nutr*, 98, 1251-1258.

- 91 Stahl W and Sies H, 1996. Lycopene: a biologically important carotenoid for humans? *Arch Biochem Biophys*, 336, 1-9.
- 92 Stahl W and Sies H, 2005. Bioactivity and protective effects of natural carotenoids. *Biochim Biophys Acta*, 1740, 101-107.
- 93 Sukanuma H and Inakuma T, 1999. Protective effect of dietary tomato against endothelial dysfunction in hypercholesterolemic mice. *Biosci Biotechnol Biochem*, 63, 78-82.
- 94 Tavani A, Gallus S, Negri E, Parpinel M, La Vecchia C, 2006. Dietary intake of carotenoids and retinol and the risk of acute myocardial infarction in Italy. *Free Radic Res*, 40, 659-664.
- 95 The Research Institute of Public Health - University of Kuopio (Finland), Lycopene and heart diseases, <http://www.uku.fi/nutritionepidemiologists/lycopene.htm>
- 96 Torbergesen AC and Collins AR, 2000. Recovery of human lymphocytes from oxidative DNA damage; the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect. *Eur J Nutr*, 39, 80-85.
- 97 Upritchard JE, Sutherland WH, Mann JI, 2000. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. *Diabetes Care*, 23, 733-738.
- 98 van Herpen-Broekmans WM, Klopping-Ketelaars IA, Bots ML, Kluit C, Princen H, Hendriks HF, Tijburg LB, van Poppel G, Kardinaal AF, 2004. Serum carotenoids and vitamins in relation to markers of endothelial function and inflammation. *Eur J Epidemiol*, 19, 915-921.
- 99 Visioli F, Riso P, Grande S, Galli C, Porrini M, 2003. Protective activity of tomato products on in vivo markers of lipid oxidation. *Eur J Nutr*, 42, 201-206.
- 100 Voutilainen S, Nurmi T, Mursu J, Rissanen TH, 2006. Carotenoids and cardiovascular health. *Am J Clin Nutr*, 83, 1265-1271.
- 101 Walfisch S, Walfisch Y, Kirilov E, Linde N, Mnitentag H, Agbaria R, Sharoni Y, Levy J, 2007. Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. *Eur J Cancer Prev*, 16, 298-303.
- 102 Weisburger JH, 2002. Lycopene and tomato products in health promotion. *Exp Biol Med (Maywood)*, 227, 924-927.
- 103 Willcox JK, Catignani GL, Lazarus S, 2003. Tomatoes and cardiovascular health. *Crit Rev Food Sci Nutr*, 43, 1-18.

ID 2373: “Tomato extract containing lycopene” and “Skin health”

- 1 Alaluf S, Heinrich U, Stahl W, Tronnier H, Wiseman S, 2002. Dietary carotenoids contribute to normal human skin color and UV photosensitivity. *J Nutr*, 132, 399-403.
- 2 Aust O, Stahl W, Sies H, Tronnier H, Heinrich U, 2005. Supplementation with tomato-based products increases lycopene, phytofluene, and phytoene levels in human serum and protects against UV-light-induced erythema. *Int J Vitam Nutr Res*, 75, 54-60.
- 3 Bhuvaneswari V, Velmurugan B, Balasenthil S, Ramachandran CR, Nagini S, 2001. Chemopreventive efficacy of lycopene on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. *Fitoterapia*, 72, 865-874.
- 4 Black HS, 1998. Radical interception by carotenoids and effects on UV carcinogenesis. *Nutr Cancer*, 31, 212-217.
- 5 Bohm V and Bitsch R, 1999. Intestinal absorption of lycopene from different matrices and interactions to other carotenoids, the lipid status, and the antioxidant capacity of human plasma. *Eur J Nutr*, 38, 118-125.

- 6 Carini M, Stefani R, Aldini G, Ozioli M, Facino RM, 2001. Procyanidins from *Vitis vinifera* seeds inhibit the respiratory burst of activated human neutrophils and lysosomal enzyme release. *Planta Med*, 67, 714-717.
- 7 Cesarini JP, Michel L, Maurette JM, Adhoute H, Bejot M, 2003. Immediate effects of UV radiation on the skin: modification by an antioxidant complex containing carotenoids. *Photodermatol Photoimmunol Photomed*, 19, 182-189.
- 8 Comsiock GW, Helzlsouer KJ, Bush TL, 1991. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. *Am J Clin Nutr*, 53, 260S-264S.
- 9 Dorgan JF, Boakye NA, Fears TR, Schleicher RL, Helsel W, Anderson C, Robinson J, Guin JD, Lessin S, Ratnasingham LD, Tangrea JA, 2004. Serum carotenoids and alpha-tocopherol and risk of nonmelanoma skin cancer. *Cancer Epidemiol Biomarkers Prev*, 13, 1276-1282.
- 10 Eichler O, Sies H, Stahl W, 2002. Divergent optimum levels of lycopene, beta-carotene and lutein protecting against UVB irradiation in human fibroblastst. *Photochem Photobiol*, 75, 503-506.
- 11 El Hindi T, Ehlers G, Demchuk M, Pfitzner I, 2004. Determination of the antioxidant capacity of an antioxidant combination using the fluoroscan assay in vitro and visualization of its effects using histological methods. *Arch Dermatol Res*, 296, 258-264.
- 12 Facino RM, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1999. Diet enriched with procyanidins enhances antioxidant activity and reduces myocardial post-ischaemic damage in rats. *Life Sci*, 64, 627-642.
- 13 Fazekas Z, Gao D, Saladi RN, Lu Y, Lebowohl M, Wei H, 2003. Protective effects of lycopene against ultraviolet B-induced photodamage. *Nutr Cancer*, 47, 181-187.
- 14 Greul AK, Grundmann JU, Heinrich F, Pfitzner I, Bernhardt J, Ambach A, Biesalski HK, Gollnick H, 2002. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and proanthocyanidins. *Skin Pharmacol Appl Skin Physiol*, 15, 307-315.
- 15 Greul AK, Grundmann JU, Heinrich F, Pfitzner I, Bernhardt J, Ambach A, Biesalski HK, Gollnick H, 2002. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and proanthocyanidins. *Skin Pharmacol Appl Skin Physiol*, 15, 307-315.
- 16 Heinrich U, Gartner C, Wiebusch M, Eichler O, Sies H, Tronnier H, Stahl W, 2003. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. *J Nutr*, 133, 98-101.
- 17 Heinrich U, Tronnier H, Stahl W, Bejot M, Maurette JM, 2006. Antioxidant supplements improve parameters related to skin structure in humans. *Skin Pharmacol Physiol*, 19, 224-231.
- 18 Khachik F, Carvalho L, Bernstein PS, Muir GJ, Zhao DY, Katz NB, 2002. Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. *Experimental Biology and Medicine*, 227, 845-851.
- 19 Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R, 1994. Free radicals scavenging action and anti-enzyme activities of procyanidines from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung*, 44, 592-601.
- 20 Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P, 1996. Procyanidines from *Vitis vinifera* seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. *Planta Med*, 62, 495-502.
- 21 Maffei Facino R, Carini M, Aldini G, Calloni MT, Bombardelli E, Morazzoni P, 1998. Sparing effect of procyanidins from *Vitis vinifera* on vitamin E: in vitro studies. *Planta Med*, 64, 343-347.
- 22 Matulka RA, Hood AM, Griffiths JC, 2004. Safety evaluation of a natural tomato oleoresin extract derived from food-processing tomatoes. *Regul Toxicol Pharmacol*, 39, 390-402.
- 23 Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry Dt, Holly EA, Sagebiel RW, Potischman N, 2004. Diet and melanoma in a case-control study. *Cancer Epidemiol Biomarkers Prev*, 13, 1042-1051.

- 24 Nishino H, 1997. Cancer prevention by natural carotenoids. *J Cell Biochem Suppl*, 27, 86-91.
- 25 Nishino H, 1998. Cancer prevention by carotenoids. *Mutat Res*, 402, 159-163.
- 26 Nishino H, Murakoshi M, Ii T, Takemura M, Kuchide M, Kanazawa M, Mou XY, Wada S, Masuda M, Ohsaka Y, Yogosawa S, Satomi Y, Jinno K, 2002. Carotenoids in cancer chemoprevention. *Cancer Metastasis Rev*, 21, 257-264.
- 27 Nishino H, Murakoshi M, Mou XY, Wada S, Masuda M, Ohsaka Y, Satomi Y, Jinno K, 2005. Cancer prevention by phytochemicals. *Oncology*, 69 Suppl 1, 38-40.
- 28 Nuttall SL, Kendall MJ, Bombardelli E, Morazzoni P, 1998. An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. *J Clin Pharm Ther*, 23, 385-389.
- 29 Offord EA, Gautier JC, Avanti O, Scaletta C, Runge F, Kramer K, Applegate LA, 2002. Photoprotective potential of lycopene, beta-carotene, vitamin E, vitamin C and carnolic acid in UVA-irradiated human skin fibroblasts. *Free Radic Biol Med*, 32, 1293-1303.
- 30 Paetau I, Rao D, Wiley ER, Brown ED, Clevidence BA, 1999. Carotenoids in human buccal mucosa cells after 4 wk of supplementation with tomato juice or lycopene supplements. *Am J Clin Nutr*, 70, 490-494.
- 31 Pool-Zobel BL, Bub A, Muller H, Wollowski I, Rechkemmer G, 1997. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. *Carcinogenesis*, 18, 1847-1850.
- 32 Porrini M and Riso P, 2000. Lymphocyte lycopene concentration and DNA protection from oxidative damage is increased in women after a short period of tomato consumption. *J Nutr*, 130, 189-192.
- 33 Porrini M, Riso P, Oriani G, 2002. Spinach and tomato consumption increases lymphocyte DNA resistance to oxidative stress but this is not related to cell carotenoid concentrations. *Eur J Nutr*, 41, 95-100.
- 34 Postaire E, Jungmann H, Bejot M, Heinrich U, Tronnier H, 1997. Evidence for antioxidant nutrients-induced pigmentation in skin: results of a clinical trial. *Biochem Mol Biol Int*, 42, 1023-1033.
- 35 Rao AV and Agarwal S, 1998. Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. *Nutr Cancer*, 31, 199-203.
- 36 Ribaya-Mercado JD, Garmyn M, Gilchrest BA, Russell RM, 1995. Skin lycopene is destroyed preferentially over beta-carotene during ultraviolet irradiation in humans. *J Nutr*, 125, 1854-1859.
- 37 Richelle M, Bortlik K, Liardet S, Hager C, Lambelet P, Baur M, Applegate LA, Offord EA, 2002. A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste. *J Nutr*, 132, 404-408.
- 38 Riso P, Pinder A, Santangelo A, Porrini M, 1999. Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? *Am J Clin Nutr*, 69, 712-718.
- 39 Riso P, Visioli F, Erba D, Testolin G, Porrini M, 2004. Lycopene and vitamin C concentrations increase in plasma and lymphocytes after tomato intake. Effects on cellular antioxidant protection. *Eur J Clin Nutr*, 58, 1350-1358.
- 40 Shao A and Hathcock JN, 2006. Risk assessment for the carotenoids lutein and lycopene. *Regul Toxicol Pharmacol*, 45, 289-298.
- 41 Sies H and Stahl W, 2003. Non-nutritive bioactive constituents of plants: lycopene, lutein and zeaxanthin. *Int J Vitam Nutr Res*, 73, 95-100.
- 42 Sies H and Stahl W, 2004. Nutritional protection against skin damage from sunlight. *Annu Rev Nutr*, 24, 173-200.
- 43 Smit N, Vicanova J, Cramers P, Vrolijk H, Pavel S, 2004. The combined effects of extracts containing carotenoids and vitamins E and C on growth and pigmentation of cultured human melanocytes. *Skin Pharmacol Physiol*, 17, 238-245.
- 44 Stahl W, von Laar J, Martin HD, Emmerich T, Sies H, 2000. Stimulation of gap junctional communication: comparison of acyclo-retinoic acid and lycopene. *Arch Biochem Biophys*, 373, 271-274.

- 45 Stahl W, Heinrich U, Wiseman S, Eichler O, Sies H, Tronnier H, 2001. Dietary tomato paste protects against ultraviolet light-induced erythema in humans. *J Nutr*, 131, 1449-1451.
- 46 Stahl W, Ale-Agha N, Polidori MC, 2002. Non-antioxidant properties of carotenoids. *Biol Chem*, 383, 553-558.
- 47 Stahl W and Sies H, 2002. Carotenoids and protection against solar UV radiation. *Skin Pharmacol Appl Skin Physiol*, 15, 291-296.
- 48 Stahl W and Sies H, 2003. Antioxidant activity of carotenoids. *Mol Aspects Med*, 24, 345-351.
- 49 Stahl W and Sies H, 2005. Bioactivity and protective effects of natural carotenoids. *Biochim Biophys Acta*, 1740, 101-107.
- 50 Stahl W, Heinrich U, Aust O, Tronnier H, Sies H, 2006. Lycopene-rich products and dietary photoprotection. *Photochem Photobiol Sci*, 5, 238-242.
- 51 Torbergson AC and Collins AR, 2000. Recovery of human lymphocytes from oxidative DNA damage; the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect. *Eur J Nutr*, 39, 80-85.
- 52 Vainio H and Rautalahti M, 1998. An international evaluation of the cancer preventive potential of carotenoids. *Cancer Epidemiol Biomarkers Prev*, 7, 725-728.
- 53 Visioli F, Riso P, Grande S, Galli C, Porrini M, 2003. Protective activity of tomato products on in vivo markers of lipid oxidation. *Eur J Nutr*, 42, 201-206.
- 54 Walfisch Y, Walfisch S, Agbaria R, Levy J, Sharoni Y, 2003. Lycopene in serum, skin and adipose tissues after tomato-oleoresin supplementation in patients undergoing haemorrhoidectomy or peri-anal fistulotomy. *Br J Nutr*, 90, 759-766.
- 55 Walfisch S, Walfisch Y, Kirilov E, Linde N, Mnitentag H, Agbaria R, Sharoni Y, Levy J, 2007. Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. *Eur J Cancer Prev*, 16, 298-303.
- 56 Wright TI, Spencer JM, Flowers FP, 2006. Chemoprevention of nonmelanoma skin cancer. *J Am Acad Dermatol*, 54, 933-946; quiz 947-950.

ID 2374: “Tomato extract containing lycopene” and “Prostate health”

- 1 Agarwal S and Rao AV, 1998. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. *Lipids*, 33, 981-984.
- 2 Amir H, Karas M, Giat J, Danilenko M, Levy R, Yermiahu T, Levy J, Sharoni Y, 1999. Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. *Nutr Cancer*, 33, 105-112.
- 3 Ansari MS, Gupta NP, Hemal AK, 2002. Chemoprevention of carcinoma prostate: a review. *Int Urol Nephrol*, 34, 207-214.
- 4 Ansari MS and Gupta NP, 2003. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. *BJU Int*, 92, 375-378; discussion 378.
- 5 Ansari MS and Gupta NP, 2004a. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. *Urol Oncol*, 22, 415-420.
- 6 Ansari MS and Gupta NP, 2004b. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. *BJU Int*, 94, 678.
- 7 Ansari MS and Ansari S, 2005a. Lycopene and prostate cancer. *Future Oncol*, 1, 425-430.
- 8 Ansari MS and Sgupta NP, 2005b. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. *BJU Int*, 95, 453.

- 9 Astley SB and Elliott RM, 2005. How strong is the evidence that lycopene supplementation can modify biomarkers of oxidative damage and DNA repair in human lymphocytes? *J Nutr*, 135, 2071S-2073S.
- 10 Barber NJ, Zhang X, Zhu G, Pramanik R, Barber JA, Martin FL, Morris JD, Muir GH, 2006. Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. *Prostate Cancer Prostatic Dis*, 9, 407-413.
- 11 Basu A and Imrhan V, 2007. Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. *Eur J Clin Nutr*, 61, 295-303.
- 12 Bhuvaneswari V, Velmurugan B, Balasenthil S, Ramachandran CR, Nagini S, 2001. Chemopreventive efficacy of lycopene on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. *Fitoterapia*, 72, 865-874.
- 13 Bohm V and Bitsch R, 1999. Intestinal absorption of lycopene from different matrices and interactions to other carotenoids, the lipid status, and the antioxidant capacity of human plasma. *Eur J Nutr*, 38, 118-125.
- 14 Boileau TW, Clinton SK, Erdman JW, Jr., 2000. Tissue lycopene concentrations and isomer patterns are affected by androgen status and dietary lycopene concentration in male F344 rats. *J Nutr*, 130, 1613-1618.
- 15 Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW, Jr., Clinton SK, 2003. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. *J Natl Cancer Inst*, 95, 1578-1586.
- 16 Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, Kim HS, Christov-Tzelkov K, van Breemen R, 2002. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. *Exp Biol Med (Maywood)*, 227, 886-893.
- 17 Breinholt V, Lauridsen ST, Daneshvar B, Jakobsen J, 2000. Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. *Cancer Lett*, 154, 201-210.
- 18 Campbell JK, Canene-Adams K, Lindshield BL, Boileau TW, Clinton SK, Erdman JW, Jr., 2004. Tomato phytochemicals and prostate cancer risk. *J Nutr*, 134, 3486S-3492S.
- 19 Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, Torner JC, Cantor KP, 1999. Family history and prostate cancer risk in a population-based cohort of Iowa men. *Cancer Epidemiol Biomarkers Prev*, 8, 53-60.
- 20 Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, van Breemen R, Ashton D, Bowen PE, 2001. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. *J Natl Cancer Inst*, 93, 1872-1879.
- 21 Cohen JH, Kristal AR, Stanford JL, 2000. Fruit and vegetable intakes and prostate cancer risk. *J Natl Cancer Inst*, 92, 61-68.
- 22 Di Mascio P, Kaiser S, Sies H, 1989. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. *Arch Biochem Biophys*, 274, 532-538.
- 23 Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ, 1999. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. *Cancer Res*, 59, 1225-1230.
- 24 Gann PH and Khachik F, 2003. Tomatoes or lycopene versus prostate cancer: is evolution anti-reductionist? *J Natl Cancer Inst*, 95, 1563-1565.
- 25 Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, 1995. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst*, 87, 1767-1776.
- 26 Giovannucci E, 1999. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. *J Natl Cancer Inst*, 91, 317-331.
- 27 Giovannucci E, 2002. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. *Exp Biol Med (Maywood)*, 227, 852-859.

- 28 Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC, 2002. A prospective study of tomato products, lycopene, and prostate cancer risk. *J Natl Cancer Inst*, 94, 391-398.
- 29 Giovannucci E, 2005. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. *J Nutr*, 135, 2030S-2031S.
- 30 Hadley CW, Miller EC, Schwartz SJ, Clinton SK, 2002. Tomatoes, lycopene, and prostate cancer: progress and promise. *Exp Biol Med (Maywood)*, 227, 869-880.
- 31 Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, Schoenberg JB, Silverman DT, Brown LM, Pottner LM, Liff J, Schwartz AG, Fraumeni JF, Jr., Hoover RN, 1999. Dietary factors and risks for prostate cancer among blacks and whites in the United States. *Cancer Epidemiol Biomarkers Prev*, 8, 25-34.
- 32 Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, Hunziker PB, Hunziker W, Goralczyk R, Wertz K, 2005. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. *FASEB J.*, 19, 272-274.
- 33 Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y, 2007. Lycopene and other carotenoids inhibit estrogenic activity of 17beta-estradiol and genistein in cancer cells. *Breast Cancer Res Treat*, 104, 221-230.
- 34 Hsing AW, Comstock GW, Abbey H, Polk BF, 1990. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. *J Natl Cancer Inst*, 82, 941-946.
- 35 Ito Y, Kurata M, Suzuki K, Hamajima N, Hishida H, Aoki K, 2006. Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. *J Epidemiol*, 16, 154-160.
- 36 Jain MG, Hislop GT, Howe GR, Ghadirian P, 1999. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. *Nutr Cancer*, 34, 173-184.
- 37 Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y, 2000. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. *Nutr Cancer*, 36, 101-111.
- 38 Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT, 1997. A case-control study of diet and prostate cancer. *Br J Cancer*, 76, 678-687.
- 39 Key TJ, Allen NE, Spencer EA, Travis RC, 2002. The effect of diet on risk of cancer. *Lancet*, 360, 861-868.
- 40 Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeny L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E, 2007. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. *Am J Clin Nutr*, 86, 672-681.
- 41 Kim L, Rao AV, Rao LG, 2002. Effect of lycopene on prostate LNCaP cancer cells in culture. *J Med Food*, 5, 181-187.
- 42 Kim HS, Bowen P, Chen L, Duncan C, Ghosh L, Sharifi R, Christov K, 2003. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. *Nutr Cancer*, 47, 40-47.
- 43 Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, Urban DA, Crawford ED, Hayes RB, 2006. A prospective study of lycopene and tomato product intake and risk of prostate cancer. *Cancer Epidemiology Biomarkers & Prevention*, 15, 92-98.
- 44 Klipstein-Grobusch K, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JC, 2000. Serum carotenoids and atherosclerosis. The Rotterdam Study. *Atherosclerosis*, 148, 49-56.
- 45 Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, John EM, Howe GR, Dreon DM, West DW, Paffenbarger RS, 2000. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. *Cancer Epidemiology Biomarkers & Prevention*, 9, 795-804.

- 46 Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP, Jr., 2001. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. *Cancer Epidemiol Biomarkers Prev*, 10, 861-868.
- 47 Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP, Jr., 2002. Effects of lycopene supplementation in patients with localized prostate cancer. *Exp Biol Med (Maywood)*, 227, 881-885.
- 48 Kucuk O, 2002a. Cancer chemoprevention. *Cancer Metastasis Rev*, 21, 189-197.
- 49 Kucuk O, 2002b. Chemoprevention of prostate cancer. *Cancer Metastasis Rev*, 21, 111-124.
- 50 Le Marchand L, Hankin JH, Kolonel LN, Wilkens LR, 1991. Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene. *Am J Epidemiol*, 133, 215-219.
- 51 Limpens J, Schroder FH, de Ridder CM, Bolder CA, Wildhagen MF, Obermuller-Jevic UC, Kramer K, van Weerden WM, 2006. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. *J Nutr*, 136, 1287-1293.
- 52 Livny O, Kaplan I, Reifen R, Polak-Charcon S, Madar Z, Schwartz B, 2002. Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. *J Nutr*, 132, 3754-3759.
- 53 Lu QY, Hung JC, Heber D, Go VL, Reuter VE, Cordon-Cardo C, Scher HI, Marshall JR, Zhang ZF, 2001. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. *Cancer Epidemiol Biomarkers Prev*, 10, 749-756.
- 54 Matos HR, Di Mascio P, Medeiros MH, 2000. Protective effect of lycopene on lipid peroxidation and oxidative DNA damage in cell culture. *Arch Biochem Biophys*, 383, 56-59.
- 55 Mills PK, Beeson WL, Phillips RL, Fraser GE, 1989. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. *Cancer*, 64, 598-604.
- 56 Mohanty NK, Saxena S, Singh UP, Goyal NK, Arora RP, 2005. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. *Urol Oncol*, 23, 383-385.
- 57 Moller P and Loft S, 2006. Dietary antioxidants and beneficial effect on oxidatively damaged DNA. *Free Radic Biol Med*, 41, 388-415.
- 58 Muller N, Alteheld B, Stehle P, 2003. Tomato products and lycopene supplements: mandatory components in nutritional treatment of cancer patients? *Curr Opin Clin Nutr Metab Care*, 6, 657-660.
- 59 Nahum A, Hirsch K, Danilenko M, Watts CK, Prall OW, Levy J, Sharoni Y, 2001. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. *Oncogene*, 20, 3428-3436.
- 60 No authors listed, 2005. Does fruit and vegetable intake protect against cancer? *CA: A Cancer Journal for Clinicians*, 55, 69-70.
- 61 Nomura AM, Stemmermann GN, Lee J, Craft NE, 1997. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. *Cancer Epidemiol Biomarkers Prev*, 6, 487-491.
- 62 Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM, 2000. Prostate cancer and dietary carotenoids. *Am J Epidemiol*, 151, 119-123.
- 63 Pastori M, Pfander H, Boscoboinik D, Azzi A, 1998. Lycopene in Association with [alpha]-Tocopherol Inhibits at Physiological Concentrations Proliferation of Prostate Carcinoma Cells. *Biochemical and Biophysical Research Communications*, 250, 582-585.
- 64 Pool-Zobel BL, Bub A, Muller H, Wollowski I, Rechkemmer G, 1997. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. *Carcinogenesis*, 18, 1847-1850.
- 65 Porrini M and Riso P, 2000. Lymphocyte lycopene concentration and DNA protection from oxidative damage is increased in women after a short period of tomato consumption. *J Nutr*, 130, 189-192.

- 66 Porrini M, Riso P, Oriani G, 2002. Spinach and tomato consumption increases lymphocyte DNA resistance to oxidative stress but this is not related to cell carotenoid concentrations. *Eur J Nutr*, 41, 95-100.
- 67 Rao AV and Agarwal S, 1998. Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. *Nutr Cancer*, 31, 199-203.
- 68 Rao LG, Mackinnon ES, Josse RG, Murray TM, Strauss A, Rao AV, 2007. Lycopene consumption decreases oxidative stress and bone resorption markers in postmenopausal women. *Osteoporos Int*, 18, 109-115.
- 69 Riso P, Pinder A, Santangelo A, Porrini M, 1999. Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? *Am J Clin Nutr*, 69, 712-718.
- 70 Riso P, Visioli F, Erba D, Testolin G, Porrini M, 2004. Lycopene and vitamin C concentrations increase in plasma and lymphocytes after tomato intake. Effects on cellular antioxidant protection. *Eur J Clin Nutr*, 58, 1350-1358.
- 71 Siler U, Barella L, Spitzer V, Schnorr J, Lein M, Goralczyk R, Wertz K, 2004. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. *FASEB J*, 18, 1019-1021.
- 72 Siler U, Herzog A, Spitzer V, Seifert N, Denelavas A, Hunziker PB, Barella L, Hunziker W, Lein M, Goralczyk R, Wertz K, 2005. Lycopene effects on rat normal prostate and prostate tumor tissue. *J Nutr*, 135, 2050S-2052S.
- 73 Stahl W, von Laar J, Martin HD, Emmerich T, Sies H, 2000. Stimulation of gap junctional communication: comparison of acyclo-retinoic acid and lycopene. *Arch Biochem Biophys*, 373, 271-274.
- 74 Torbergson AC and Collins AR, 2000. Recovery of human lymphocytes from oxidative DNA damage; the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect. *Eur J Nutr*, 39, 80-85.
- 75 Tzonou A, Signorello LB, Laggiou P, Wu J, Trichopoulos D, Trichopoulou A, 1999. Diet and cancer of the prostate: a case-control study in Greece. *Int J Cancer*, 80, 704-708.
- 76 van Breemen RB, 2005. How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia? *J Nutr*, 135, 2062S-2064S.
- 77 Visioli F, Riso P, Grande S, Galli C, Porrini M, 2003. Protective activity of tomato products on in vivo markers of lipid oxidation. *Eur J Nutr*, 42, 201-206.
- 78 Vogt TM, Mayne ST, Graubard BI, Swanson CA, Sowell AL, Schoenberg JB, Swanson GM, Greenberg RS, Hoover RN, Hayes RB, Ziegler RG, 2002. Serum lycopene, other serum carotenoids, and risk of prostate cancer in US Blacks and Whites. *Am J Epidemiol*, 155, 1023-1032.
- 79 Walfisch S, Walfisch Y, Kirilov E, Linde N, Mnitentag H, Agbaria R, Sharoni Y, Levy J, 2007. Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. *Eur J Cancer Prev*, 16, 298-303.
- 80 Weisburger JH, 1998. Evaluation of the evidence on the role of tomato products in disease prevention. *Proc Soc Exp Biol Med*, 218, 140-143.
- 81 Wu K, Erdman JW, Jr., Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroot V, Willett WC, Giovannucci E, 2004. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. *Cancer Epidemiol Biomarkers Prev*, 13, 260-269.
- 82 Zhao X, Aldini G, Johnson EJ, Rasmussen H, Kraemer K, Woolf H, Musaeus N, Krinsky NI, Russell RM, Yeum KJ, 2006. Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. *Am J Clin Nutr*, 83, 163-169.

ID 2375: “Guarana seed (Paulina cupana fruit)” and “Invigoration of the body”

- 1 Andersen T and Fogh J, 2001. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. *J Hum Nutr Diet*, 14, 243-250.

- 2 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2004. HagerROM 2004. Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.
- 3 Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL, 2001. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. *Int J Obes Relat Metab Disord*, 25, 316-324.
- 4 Brendler T, Grünwald J, Jänicke C, 2003. Herbal Remedies - Heilpflanzen (CD-Rom). Medpharm Scientific Publishers, Stuttgart.
- 5 Briggs C, 1992. Guarana. *Can Pharm J*, 125, 222-224.
- 6 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 7 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 8 Campos AR, Barros AI, Albuquerque FA, LK ML, Rao VS, 2005. Acute effects of guarana (*Paullinia cupana* Mart.) on mouse behaviour in forced swimming and open field tests. *Phytother Res*, 19, 441-443.
- 9 Carlini EA, 2003. Plants and the central nervous system. *Pharmacol Biochem Behav*, 75, 501-512.
- 10 Cauli O and Morelli M, 2005. Caffeine and the dopaminergic system. *Behav Pharmacol*, 16, 63-77.
- 11 Dansk Droge A/S, 2006. Guarana monograph.
- 12 Dorea JG and da Costa TH, 2005. Is coffee a functional food? *Br J Nutr*, 93, 773-782.
- 13 Espinola EB, Dias RF, Mattei R, Carlini EA, 1997. Pharmacological activity of Guarana (*Paullinia cupana* Mart.) in laboratory animals. *J Ethnopharmacol*, 55, 223-229.
- 14 Galduroz JC and Carlini Ede A, 1994. Acute effects of the *Paulinia cupana*, "Guarana" on the cognition of normal volunteers. *Sao Paulo Med J*, 112, 607-611.
- 15 Galduroz JC and Carlini EA, 1996. The effects of long-term administration of guarana on the cognition of normal, elderly volunteers. *Sao Paulo Med J*, 114, 1073-1078.
- 16 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for Herbal Medicines. Thomson Reuters, Montvale.
- 17 Haskell CF, Kennedy DO, Wesnes KA, Scholey AB, 2005. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. *Psychopharmacology (Berl)*, 179, 813-825.
- 18 Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB, 2007. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. *J Psychopharmacol*, 21, 65-70.
- 19 Hoppe HA, 1977. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 20 Houghton P, 1995. Herbal products. Part 7. Guarana. *Pharm J*, 254, 435-436.
- 21 Katzung W, 1993. Guarana - a natural product with high caffeine content. *Med Monatsschr Pharm*, 16, 330-333.
- 22 Kennedy D, Haskell C, Pace S, Zangara A, Scholey AB, 2004. Psychoactive effects of a single dose *Paullinia cupana* (Guarana) during intense mental demand. *Worldnutra Conference 2004*, San Francisco.
- 23 Kennedy DO, Haskell CF, Wesnes KA, Scholey AB, 2004. Improved cognitive performance in human volunteers following administration of guarana (*Paullinia cupana*) extract: comparison and interaction with *Panax ginseng*. *Pharmacol Biochem Behav*, 79, 401-411.
- 24 Lima WP, Carnevali LC, Jr., Eder R, Costa Rosa LF, Bacchi EM, Seelaender MC, 2005. Lipid metabolism in trained rats: effect of guarana (*Paullinia cupana* Mart.) supplementation. *Clin Nutr*, 24, 1019-1028.
- 25 Lorist MM and Tops M, 2003. Caffeine, fatigue, and cognition. *Brain Cogn*, 53, 82-94.
- 26 Magkos F and Kavouras SA, 2005. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. *Crit Rev Food Sci Nutr*, 45, 535-562.
- 27 Memorial Sloan-Kettering Cancer Center, Information About Herbs, Botanicals and Other Products, <http://www.mskcc.org/mskcc/html/69248.cfm>.

- 28 Miura T, Tatara M, Nakamura K, Suzuki I, 1998. Effect of guarana on exercise in normal and epinephrine-induced glycogenolytic mice. *Biol Pharm Bull*, 21, 646-648.
- 29 Mucignat-Caretta C, 1998. Changes in female cognitive performance after energetic drink consumption: a preliminary study. *Prog Neuropsychopharmacol Biol Psychiatry*, 22, 1035-1042.
- 30 Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M, 2003. Effects of caffeine on human health. *Food Addit Contam*, 20, 1-30.
- 31 Nehlig A, 2004. *Coffee, tea, chocolate, and the brain*. CRC Press, Boca Raton.
- 32 Pietta P and Pietta A, 1998. *Fitomedicine e nutrienti*. Giuseppe M. Riciutto Editore, Bussolengo.
- 33 Quinlan PT, Lane J, Moore KL, Aspen J, Rycroft JA, O'Brien DC, 2000. The acute physiological and mood effects of tea and coffee: the role of caffeine level. *Pharmacol Biochem Behav*, 66, 19-28.
- 34 Reynolds JEF, 1996. *Martindale: The Extra Pharmacopoeia*. Pharmaceutical Press, London.
- 35 Santa Maria A, Lopez A, Diaz MM, Munoz-Mingarro D, Pozuelo JM, 1998. Evaluation of the toxicity of guarana with in vitro bioassays. *Ecotoxicol Environ Saf*, 39, 164-167.
- 36 SMC (Swedish Medical Center), Monographs prepared by EBSCO Complementary and Alternative Review Board, http://www.swedish.org/body_frameset.cfm?id=1009.
- 37 Smith A, 2002. Effects of caffeine on human behavior. *Food Chem Toxicol*, 40, 1243-1255.
- 38 Smith AP, 2005. Caffeine at work. *Hum Psychopharmacol*, 20, 441-445.
- 39 Steinmetz EF, 1957. *Codex Vegetabilis*. Published by the author, Amsterdam.
- 40 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 41 Van Wyk BE, 2005. *Handbuch der Nutzpflanzen*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 42 Weckerle CS, Stutz MA, Baumann TW, 2003. Purine alkaloids in Paullinia. *Phytochemistry*, 64, 735-742.
- 43 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 44 Wichtl M, 2002. *Teedrogen und Phytopharmaka*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 45 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.

ID 2380: “Horseradish root (*Armoracia rusticana*)” and “Respiratory system health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Brendler T, Jaenicke C, Gruenwald J, Tapellini D, 2000. *PDR for herbal medicines*. Medical Economics, Montvale.
- 3 Goos KH, Albrecht U, Schneider B, 2006. [Efficacy and safety profile of a herbal drug containing nasturtium herb and horseradish root in acute sinusitis, acute bronchitis and acute urinary tract infection in comparison with other treatments in the daily practice/results of a prospective cohort study]. *Arzneimittelforschung*, 56, 249-257.
- 4 Walther J, 1959. [Treatment of diseases of the respiratory tract with an extract from *Cochlearia armoracia* (horseradish)]. *Medizinische*, 4, 78-79.

ID 2383: “Acorus Calamus (Sweet flag, sweet rush)” and “Invigoration of the body”

- 1 Rubine H, 2000 *Kalme smaržīgā. Ārstniecības augu avīze*, 1, 1.
- 2 Чиков ПС, 1974. *Лекарственные растения СССР и их применение*. М: Медицина, 22- 23.

ID 2384: “Aegopodium podagraria” and “Digestive health”

- 1 Pētersone A, 1976. Gārša. Ārstniecības augi, 1, 238.

ID 2386: “Alchemilla vulgaris (Lady's Mantle)” and “Invigoration the body”

- 1 Rubine H, 2001. Raskrēsliņš parastais. Ārstniecības augu avīze, 2, 49.
- 2 Skutelis A, Pakalns D, Mikažans V, Fatare I, 2005. Arstniecības augu farmakoloģija. Z/S Vecpavuli, Rīga.

ID 2388: “Andrographis paniculata (Creat)” and “Purification”

- 1 Mitra SK, Expert Report on PartySmart. HerbalScience Group LLC.
- 2 No authors listed, PartySmart - Product Monograph. HerbalScience Group LLC.

ID 2391: “Angelica sinensis (Angelica)” and “Invigoration the body”

- 1 Austin DF, 2002. Plant Resources of South-East Asia. No 12.2. Medicinal and Poisonous Plants 2. Economic Botany, 56, 297-297.
- 2 Bensky D and Gamble A, 2004. Chinese Herbal Medicine: Materia Medica. Eastland Press.
- 3 eFloras.org, Angelica sinensis, http://www.efloras.org/florataxon.aspx?flora_id=2&taxon_id=200015389.

ID 2392: “Angelica sinensis (Angelica)” and “Metabolism in joints”

- 1 NIH (National Institute of Health), Drugs and Supplements - Dong quai (Angelica sinensis [Oliv.] Diels), Chinese angelica, <http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-dongquai.html#skip>

ID 2393: “Apium graveolens (Celery)” and “Invigoration the body”

- 1 Skutelis A, Pakalns D, Mikažans V, Fatare I, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.

ID 2394: “Arctium lappa (Burdock)” and “Joint health”

- 1 Пилат ТЛ and Иванов АА, 2002. Фиторевматит. In: Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 619- 620.
- 2 Пилат ТЛ and Иванов АА, 2002. Суставные травы. In: Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 617-619.

ID 2395: “Argyreia speciosa” and “Fertility”

- 1 Agrawal HSK and Kulkarni KS, 2003. Efficacy and safety of Speman in patients with oligospermia: an open clinical study. Indian Journal of Clinical Practice, 14, 29-31.
- 2 Mukherjee K, Tripathi A, Kulkarni KS, 2003. Evaluation of the efficacy of Speman in the management of male subfertility. Indian Journal of Clinical Practice, 13, 29-31.

- 3 Singh I, Pandey RN, Sarkar S, Kulkarni KS, 2003. Efficacy of Speman in the treatment of male subfertility. Indian Journal of Clinical Practice, 14, 31-33.

ID 2396: “Ascophyllum nodosum (seaweed)” and “Structure and function of the skin and mucous membranes”

- 1 Cousens R, 1984. Estimation of annual production by the intertidal brown alga *Ascophyllum nodosum*. Botanica Marina, 27, 217-227.
- 2 Pavia H and Brock E, 2000. Extrinsic factors influencing phlorotannin production in the brown alga *Ascophyllum nodosum*. Marine Ecology Progress Series, 193, 285-294.
- 3 Santelices B and Ojeda FP, 1984. Effects of canopy removal on the understory algal community structure of coastal forest of *Macrocystis pyrifera* from Southern South America. Marine Ecology Progress Series, 14, 165-173.
- 4 Sharp GJ, 1986. *Ascophyllum nodosum* and its harvesting in Eastern Canada. In: Case studies of seven commercial seaweed resources. FAO Technical Report 281. 3-46.
- 5 Yan X, Nagata T, Fan X, 1998. Antioxidative activities in some common seaweeds. Plant Foods Hum Nutr, 52, 253-262.

ID 2398: “Avena sativa (Green oat)” and “Digestive system, metabolism”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. The American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 3 Rubine H, 2002. Auzas sējas. Ārstniecības augu avīze, 3, 1.
- 4 Rubine H and Eniņa V, 2004. Sējas auza. Ārstniecības augi. Apgāds Zvaigzne ABC.
- 5 Skutelis A and Pakalns D, 2005. Ārstniecības augu farmakoloģija. Rīga.
- 6 Пилат ТЛ and Иванов АА, 2002. Слабительные травы. In: ПЗ2 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 597-598.
- 7 Пилат ТЛ and Иванов АА, 2002. Желудочные нейтральные / Желудочные щелочные. In: ПЗ2 Биологически активные добавки к пище (теория, производство, применение). Авваллон., Москва, 602-604.

ID 2399: “Barbarea vulgaris (Garden yellowrocket)” and “Physical and mental health”

- 1 Pētersone A, 1976. Zvērene. Ārstniecības augi, 1, 226.
- 2 Plants For A Future, *Barbarea vulgaris*, <http://www.pfaf.org/database/plants.php?Barbarea+vulgaris>.

ID 2400: “Berberis vulgaris (Barberry)” and “Gastro-intestinal health”

- 1 Иванов Л and Антишляк АА, 2002 ПЗ2 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва.

ID 2401: “Beta vulgaris” and “Purification”

- 1 Miške I and Brutane D, 2004. Bietes. Dzīvības elementi. Nordik, Rīga.

ID 2407: “Capparis spinosa” and “Liver health, appetite”

- 1 Baijal R, Patel N, Kolhapure SA, 2004. Evaluation of efficacy and safety of Liv. 52 DS tablets in acute viral hepatitis: a prospective, double-blind, randomized, placebo-controlled, phase III clinical trial. *Medicine*, 12, 41-53.
- 2 Kolhapure SA and Mitra SK, 2004. Meta-analysis of 50 Phase III clinical trials in evaluation of efficacy and safety of Liv. 52 in infective hepatitis. *Medicine*, 12, 51-61.

ID 2408: “Cassia fistula” and “Vein health”

- 1 Reddy SS, Nagabushanam M, Ramanuja Rao M, 1984. Role of Pilex tablets and ointment in the treatment of piles and fissures. *Probe*, 23, 213.
- 2 Sahu M and Pankaj S, 2001. Clinical study of Pilex combination therapy vs conventional ayurvedic therapy in the management of haemorrhoids. *Indian Practitioner*, 54, 799-805.
- 3 Tripathi A, 2000. Comparative evaluation of Pilex with Daflon in haemorrhoids. *Antiseptic*, 97, 317.

ID 2409: “Centaurium erythraea (Centauray)” and “Invigoration the body”

- 1 Plants For A Future, *Centaurium erythraea*, <http://www.pfaf.org/database/plants.php?Centaurium+erythraea>.

ID 2413: “Chamaenerion angustifolium (Willow herb)” and “Digestive health”

- 1 Rubine H, 2001. Ugunspuķe šaurlapu. *Ārstniecības augu avīze*, 2, 55.
- 2 Skutelis A, Pakalns D, Mikažans V, Fatare I, 2005. *Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.*

ID 2414: “Chamaenerion angustifolium (Willow herb)” and “Mental health”

- 1 Rubine H, 2001. Ugunspuķe šaurlapu. *Ārstniecības augu avīze*, 2, 55.
- 2 Skutelis A, Pakalns D, Mikažans V, Fatare I, 2005. *Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.*

ID 2415: “Chlorella pyrenoidosa (Chlorella)” and “Digestive health / Liver health”

- 1 Kerem M, Salman B, Pasaoglu H, Bedirli A, Alper M, Katircioglu H, Atici T, Percin EF, Ofluoglu E, 2008. Effects of microalgae *Chlorella* species crude extracts on intestinal adaptation in experimental short bowel syndrome. *World J Gastroenterol*, 14, 4512-4517.
- 2 Northcote DH, Goulding KJ, Horne RW, 1958. The chemical composition and structure of the cell wall of *Chlorella pyrenoidosa*. *Biochem J*, 70, 391-397.
- 3 Shibata S, Hayakawa K, Egashira Y, Sanada H, 2007. Hypocholesterolemic mechanism of *Chlorella*: *Chlorella* and its indigestible fraction enhance hepatic cholesterol catabolism through up-regulation of cholesterol 7 α -hydroxylase in rats. *Biosci Biotechnol Biochem*, 71, 916-925.

ID 2416: “Cichorium intybus (Chicory)” and “Heart health / Vascular health”

- 1 Rubine H and Eniņa V, 2004. Parastais cigoriņš. Ārstniecības augi. Apgāds Zvaigzne ABC. 84-86.
- 2 Зюзук Б and Куцик Р, 2002. Цикорий дикий (Цикорий обыкновенный) Cichorium intybus L.. Аналитический обзор.

ID 2417: “Comarum palustre” and “Joint health”

- 1 Кьюсев ПА, 2000. Полный справочник лекарственных растений. ЭКСМО-ПРЕСС, Москва.
- 2 Rubine H, 2002 Vārnkāja purva. Ārstniecības augu avīze, 3, 55.

ID 2418: “Commiphora wighti (Indian Bedellium, Guggal)” and “Joint, bone health”

- 1 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 2 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.
- 3 Herbal Monograph, Indian Bedellium. Himalaya, http://www.himalayadirect.com/shopcontent.asp?type=h_commip
- 4 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 5 Mills S and Bone K, 2005. The Essential Guide to Herbal Safety. Churchill Livingstone, London, Edinburgh.
- 6 Pole S, 2006. Ayurvedic Medicine: The Principles of Traditional Practice. Churchill Livingstone, London, Edinburgh.
- 7 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 8 Singh BB, Mishra LC, Vinjamury SP, Aquilina N, Singh VJ, Shepard N, 2003. The effectiveness of Commiphora mukul for osteoarthritis of the knee: an outcomes study. Altern Ther Health Med, 9, 74-79.
- 9 Srikantha Murthy KR, 2006. Bhavaprakasa of Bhavamisra. Chowkhamba Krishnadas Academy, Varanasi.
- 10 Srivastava N, Sath R, Jain BK, Kolhapure SA, 2005. Evaluation and comparative clinical efficacy and safety of rumalaya forte in patients suffering from osteoarthritis of the knee. Indian Journal of Clinical Practice, 16, 19- 30.
- 11 Srivastava RN, Sharma VD, Mahendra A, 2005. Evaluation of the clinical efficacy and safety of Rumalaya forte and glucosamine and chondroitin combination, in patients suffering from osteoarthritis of the knee. Medicine Update, 12, 43-50.
- 12 Upadhyay L, Tripathi K, Kolhapure SA, 2004. Clinical evaluation of the efficacy of JT-2000 (Rumalaya forte) in management of osteoarthritis - a double-blind placebo-controlled trial. Medicine Update, 11, 31-36.

ID 2427: “Crocus sativus” and “Fertility”

- 1 Garg SK, 2002. Clinical Evaluation of Tentex Royal in Erectile Dysfunction. Antiseptic, 99, 161-162.
- 2 Gopumadhavan S, Rafiq M, Venkataranganna MV, Kulkarni KS, Mitra SK, 2003. Assessment of Tentex royal for sexual activity in an experimental model. Indian Journal of Clinical Practice, 13, 23-26.

- 3 Mohan, 2002. Efficacy of Tentex Royal in the management of erectile dysfunction in diabetics. Capsule, XLI, 2.

ID 2428: “*Cyamopsis tetragonolobus* (Guar)” and “Weight management”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
2 Burton-Freeman B, 2000. Dietary fiber and energy regulation. J Nutr, 130, 272S-275S.
3 Facts and Comparisons, 1993. Guar Gum. In: The Lawrence Review of Natural Products. J. B. Lippincott Co, St. Louis.
4 Kovacs EM, Westerterp-Plantenga MS, Saris WH, Goossens I, Geurten P, Brouns F, 2001. The effect of addition of modified guar gum to a low-energy semisolid meal on appetite and body weight loss. Int J Obes Relat Metab Disord, 25, 307-315.

ID 2429: “*Cyamopsis tetragonolobus* (Guar)” and “Blood glucose control”

- 1 Facts and Comparisons, 1993. Guar Gum. In: The Lawrence Review of Natural Products. J. B. Lippincott Co, St. Louis.

ID 2430: “*Cyperus scariosus* (Cyperus)” and “Digestive health”

- 1 *Cyperus rotundus* Linn. In: Selected Medical Plants of India. 428-429.
2 Jagtap AG, Shirke SS, Phadke AS, 2004. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol, 90, 195-204.
3 MDidea, *Cyperus scariosus* or *Cyperus rotundus*, an old famous Sedge from ancient Egypt and China, <http://www.mdidea.com/products/proper/proper057.html>.
4 Wikipedia, *Cyperus rotundus*, http://en.wikipedia.org/wiki/Cyperus_rotundus.

ID 2431: “*Daucus carota* (Carrot)” and “Eye health”

- 1 Пилат ТЛ and Иванов АА, 2002. Витамины для глаз. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 515-516.

ID 2432: “*Didymocarpus pedicellata*” and “Kidneys health”

- 1 Bhatnagar V, Agarwal S, Gupta S, Kolhapure S, 2004. Effect of Cystone on pediatric urolithiasis with special reference to urinary excretion of calculogenesis inhibitors. Medicine Update, 11, 47-54.
2 Chatterjee B, 1982. Role of Cystone in various urinary disorders. Probe, XXII, 27- 30.
3 Deepak Verma, Pendse AK, Singh PP, 1989. Hyperoxaluria in urolithiasis and Cystone Therapy. The Antiseptic (): (), 86, 257.
4 Gajjar AK, 1987. Experience with Cystone in Urolithiasis. Probe, XXVI, 127-128.

ID 2435: “*Emblia officinalis* (Indian Gooseberry)” and “Respiratory health”

- 1 101 Herbs, *Emblia officinalis*, http://www.101herbs.com/emblica_officialis.html.

ID 2436: “Elytriga repens” and “Digestive health”

- 1 Rubine H, 2001. Vārpata ložņu. Ārstniecības augu avīze, 2.

ID 2437: “Equisetum arvense (Horsetail)” and “Invigoration of the body”

- 1 Do Monte FH, dos Santos JG, Jr., Russi M, Lanziotti VM, Leal LK, Cunha GM, 2004. Antinociceptive and anti-inflammatory properties of the hydroalcoholic extract of stems from Equisetum arvense L. in mice. Pharmacol Res, 49, 239-243.
- 2 Dos Santos JG, Jr., Blanco MM, Do Monte FH, Russi M, Lanziotti VM, Leal LK, Cunha GM, 2005. Sedative and anticonvulsant effects of hydroalcoholic extract of Equisetum arvense. Fitoterapia, 76, 508-513.
- 3 Dos Santos JG, Jr., Hoffmann Martins do Monte F, Marcela Blanco M, Maria do Nascimento Bispo Lanziotti V, Damasseno Maia F, Kalyne de Almeida Leal L, 2005. Cognitive enhancement in aged rats after chronic administration of Equisetum arvense L. with demonstrated antioxidant properties in vitro. Pharmacol Biochem Behav, 81, 593-600.
- 4 Rubine H, 2000. Kosa tīruma. Ārstniecības augu avīze, 1, 28.

ID 2438: “Equisetum arvense (Horsetail)” and “Skin, hair health”

- 1 Rubine H, 2000. Kosa tīruma. Ārstniecības augu avīze, 1, 28.

ID 2439: “Equisetum arvense (Horsetail)” and “Bone health”

- 1 Rubine H, 2000. Kosa tīruma. Ārstniecības augu avīze, 1, 28.

ID 2441: “Euphrasia officinalis (Eyebright)” and “Invigoration of the body”

- 1 EMEA (European Medicines Agency) Committee for Veterinary Medicinal Products, 1999. Euphrasia officinalis. Summary report. EMEA/MRL/667/99-FINAL.
- 2 Rubine H and Enina V, 2004. Stavais zibulis. Arstniecības augi. Leteikumi arstniecības augu vaksana un lietošana. ABC, Zvaigzne.

ID 2442: “Fagopyrum esculentum (Buckwheat)” and “Respiratory health”

- 1 Rubine H, 2001. Griki. Ārstniecības augu avīze.

ID 2444: “Filipendula ulmaria (Spiraea ulmaria) (Meadowsweet)” and “Mental health / Relaxation”

- 1 Blumenthal M, Goldberg A, Brinckmann J, 2000. Meadowsweet. In: Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX, 253-255.
- 2 Rubine H, 2000. Vīgrieze lielziedu, vīgrieze parastā. Ārstniecības augu avīze, 1.
- 3 Skutelis A, Pakalns D, Mikažans V, Fatore I, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.

ID 2455: “Justicia gendarussa” and “Health of lower urinary tract”

- 1 Plants For A Future, Justicia gendarussa, <http://www.pfaf.org/database/plants.php?Justicia+gendarussa>.

ID 2456: “Lathirus pratensis” and “Respiratory health”

- 1 Pētersone A, 1976. Dedestīņas. Ārstniecības augi, 1, 168.

ID 2457: “Ledebouriella seseloides” and “Skin health”

- 1 Tierra M, Upper respiratory system, <http://planetherbs.com/research-articles-2.html>

ID 2458: “Ledebouriella seseloides” and “Joint health”

- 1 Fogarty JE, 1977. A Barefoot Doctors Manual: the American Translation of the Official Chinese Paramedical Manual. Running Pr, Philadelphia.
- 2 Israel Program for Scientific Translation, 1968. Flora of the USSR. Gantner Verlag, Jerusalem.
- 3 Kunkel G, 1984. Plants for Human Consumption: an Annotated Checklist of the Edible Phanerogams and Ferns. Lubrecht & Cramer Ltd, Monticello, N.Y.
- 4 Пилат Т and Иванов А, 2002. Фиторевматит. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 619- 620.
- 5 Reid BE, 1977. Famine Foods of the Chiu-Huang Pen-ts'ao. Southern Materials Centre, Taipei.
- 6 Stuart GA, 1911. Chinese Materia Medica. Presbyterian Mission Press, Shanghai.
- 7 Tanaka T and Nakao S, 1976. Tanaka's Encyclopaedia of Edible Plants of the World. Keigaku Pub Co, Yugaku-sha.
- 8 Yeung HC, 1985. Handbook of Chinese Herbs and Formulas. Institute of Chinese Medicine, Los Angeles.

ID 2459: “Leonurus quinquelobatus syn. L.villosus (motherwort)” and “Cardiovascular health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. Motherwort herb. In: The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX, 267-269.
- 2 Rubine H, 2002 Vārnkāja purva. Ārstniecības augu avīze, 3, 55.
- 3 Skutelis A and Pakalns D, 2005. Ārstniecības augur farmakoloģija. Rīga.
- 4 Пилат Т and Иванов А, 2002. Сонные. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 490-491.
- 5 Пилат Т and Иванов А, 2002. Успокаивающие травы. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 491-494.
- 6 Пилат Т and Иванов А, 2002. Фитогипертонит. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 558-560.

ID 2461: “Medicago lupulina / M.sativa” and “Glucose metabolism”

- 1 Gray AM and Flatt PR, 1997. Pancreatic and extra-pancreatic effects of the traditional anti-diabetic plant, *Medicago sativa* (lucerne). *Br J Nutr*, 78, 325-334.
- 2 Pētersone A, 1976. Lucerna. *Ārstniecības augi*.
- 3 Swanston-Flatt SK, Day C, Bailey CJ, Flatt PR, 1990. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. *Diabetologia*, 33, 462-464.

ID 2462: “Medicago lupulina / M.sativa” and “Digestive health”

- 1 Pētersone A, 1976. Lucerna. *Ārstniecības augi*.

ID 2463: “Medicago lupulina / M.sativa” and “Invigoration the body”

- 1 Pētersone A, 1976. Lucerna. *Ārstniecības augi*, 1, 386.

ID 2464: “Menyanthes trifoliata” and “Digestive health”

- 1 Rubine H, 2000. *Pelašķis parastais*. *Ārstniecības augu avīze*, 1, 48.

ID 2467: “Onopordon acanthium” and “Physical and mental performance”

- 1 Pētersone A, 1976. *Baltdadzis*. *Ārstniecības augi*, 1, 131.

ID 2468: “Orchis mascula” and “Fertility”

- 1 Agrawal HSK and Kulkarni KS, 2003. Efficacy and safety of Speman in patients with Oligospermia: an open clinical study. *Indian Journal of Clinical Practice*, 14, 29-31.
- 2 Mukherjee K, Tripathi A, Kulkarni KS, 2003. Evaluation of the efficacy of Speman in the management of male subfertility. *Indian Journal of Clinical Practice*, 13, 29-31.
- 3 Singh I, Pandey RN, Sarkar S, Kulkarni KS, 2003. Efficacy of Speman in the treatment of male subfertility. *Indian Journal of Clinical Practice*, 14, 31-33.

ID 2469: “Origanum vulgare” and “Health of the upper respiratory tract / Immune health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 *Plants For A Future*, *Origanum vulgare*, <http://www.pfaf.org/database/plants.php?Origanum+vulgare2>.
- 3 Rubine H, 2001. *Raudene parastā*. *Ārstniecības augu avīze*, 2.
- 4 Skutelis A, Pakalns D, Mikažans V, Fatare I, 2005. *Ārstniecības augu farmakoloģija*. Z/S Vecpāvuli, Rīga.

ID 2472: “Origanum vulgare” and “Cardiovascular health”

- 1 Пилат Т and Иванов А, 2002. Фитоклимаксные. In: ПЗ2 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 625- 626.
- 2 Пилат Т and Иванов А, 2002. Лактогон. In: ПЗ2 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 627- 628.

ID 2473: “Origanum vulgare” and “Mental performance”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. Oregano. In: The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX, 358-359.
- 2 Skutelis A, Pakalns D, Mikažans V, Fatāre I, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.

ID 2475: “Phoenix dactylifera (Date)” and “Antioxidant activity”

- 1 No authors listedm, PartySmart - Product Monograph. HerbalScience Group LLC.
- 2 Mitra SK, Expert Report on PartySmart. HerbalScience Group LLC.

ID 2477: “Pinus pinaster (Maritime Pine)” and “Respiratory health”

- 1 Rubine H, 2000. Priede parastā. Ārstniecības augu avīze, 1, 43.

ID 2480: “Polygonum arenastrum syn. aviculare (Knotweed)” and “Digestive health”

- 1 Rubine H, 2001. Pūplaksis trejlapu. Ārstniecības augu avīze, 2, 48.

ID 2482: “Prunus amygdalus” and “Fertility”

- 1 Gopumadhavan S, Rafiq M, Venkataranganna MV, Kulkarni KS, Mitra SK, 2003. Assessment of Tentex royal for sexual activity in an experimental model. Indian Journal of Clinical Practice, 13, 23-26.
- 2 Kulkarni SK and Garg V, 2002. Clinical Evaluation of Tentex Royal in Erectile Dysfunction. The Antiseptic, 99, 161-162.
- 3 Mohan, 2002. Efficacy of Tentex Royal in the management of erectile dysfunction in diabetics. Capsule, XLI, 2.

ID 2485: “Ribes nigrum (Blackcurrant)” and “Invigoration the body”

- 1 Rubine H and Eniņa V, 2004. Parastā upene. Ārstniecības augi. Apgāds Zvaigzne ABC. 290-292.
- 2 Skutelis A and Pakalns D, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.

ID 2486: “Rubus caesicus” and “Invigoration the body”

- 1 Pētersone A, 1976. Kazenes. Ārstniecības augi. 305.

- 2 Rubine H and Eniņa V, 2004. Zilganā kazene un melnā cūcene. Ārstniecības augi. Apgāds Zvaigzne, 141-142.

ID 2487: “Rubus idaeus (Raspberry)” and “Menstrual health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. Raspberry leaf. In: The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX, 366.
- 2 Rubine H and Eniņa V, 2004. Meža avene. In: Ārstniecības augi. Apgāds Zvaigzne ABC, 59-60.
- 3 Skutelis A and Pakalns D, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.

ID 2488: “Salix alba (Willow)” and “Invigoration the body”

- 1 Rubine H, 2000. Vītols, baltais. Ārstniecības augu avīze, 1, 60.

ID 2494: “Terminalia arjuna” and “Liver health”

- 1 Baijal R, Patel N, Kolhapure SA, 2004. Evaluation of efficacy and safety of Liv. 52 DS tablets in acute viral hepatitis: a prospective, double-blind, randomized, placebo-controlled, phase III clinical trial. *Medicine*, 12, 41-53.
- 2 Kolhapure SA and Mitra SK, 2004. Meta-analysis of 50 Phase III clinical trials in evaluation of efficacy and safety of Liv. 52 in infective hepatitis. *Medicine*, 12, 51-61.

ID 2496: “Trifolium pratense (Red Clover)” and “Heart health, cardiovascular health”

- 1 Atkinson C, Oosthuizen W, Scollen S, Loktionov A, Day NE, Bingham SA, 2004. Modest protective effects of isoflavones from a red clover-derived dietary supplement on cardiovascular disease risk factors in perimenopausal women, and evidence of an interaction with ApoE genotype in 49-65 year-old women. *J Nutr*, 134, 1759-1764.
- 2 Blakesmith SJ, Lyons-Wall PM, George C, Joannou GE, Petocz P, Samman S, 2003. Effects of supplementation with purified red clover (*Trifolium pratense*) isoflavones on plasma lipids and insulin resistance in healthy premenopausal women. *Br J Nutr*, 89, 467-474.
- 3 Campbell MJ, Woodside JV, Honour JW, Morton MS, Leathem AJ, 2004. Effect of red clover-derived isoflavone supplementation on insulin-like growth factor, lipid and antioxidant status in healthy female volunteers: a pilot study. *Eur J Clin Nutr*, 58, 173-179.
- 4 Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T, 2001. The effect of isoflavones extracted from red clover (*Rimostil*) on lipid and bone metabolism. *Menopause*, 8, 259-265.
- 5 Geller SE and Studee L, 2006. Soy and red clover for mid-life and aging. *Climacteric*, 9, 245-263.
- 6 Hidalgo LA, Chedraui PA, Morocho N, Ross S, San Miguel G, 2005. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. *Gynecol Endocrinol*, 21, 257-264.
- 7 Howes JB, Sullivan D, Lai N, Nestel P, Pomeroy S, West L, Eden JA, Howes LG, 2000. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. *Atherosclerosis*, 152, 143-147.

- 8 Howes JB, Tran D, Brillante D, Howes LG, 2003. Effects of dietary supplementation with isoflavones from red clover on ambulatory blood pressure and endothelial function in postmenopausal type 2 diabetes. *Diabetes Obes Metab*, 5, 325-332.
- 9 Knudson Schult TM, Ensrud K, Blackwellc T, Ettingerd B, Wallacee R, Tice JA, 2004. Effect of isoflavones on lipids and bone turnover markers in menopausal women. *Maturitas*, 48, 209-218.
- 10 Nestel PJ, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron JD, West L, 1999. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. *J Clin Endocrinol Metab*, 84, 895-898.
- 11 Nestel P, Cehun M, Chronopoulos A, DaSilva L, Teede H, McGrath B, 2004. A biochanin-enriched isoflavone from red clover lowers LDL cholesterol in men. *Eur J Clin Nutr*, 58, 403-408.
- 12 Rubine H, 2001. Āboliņš. Ārstniecības augu avīze, 2, 5.
- 13 Rubine H and Eniņa V, 2004. Āboliņi. Ārstniecības augi. . Apgāds Zvaigzne ABC, 31-32.
- 14 Skutelis A, Pakalns D, Mikažans V, Fatare I, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.
- 15 Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, Ruggeri P, Campo GM, Calapai G, Caputi AP, Squadrito G, 2002. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. *Atherosclerosis*, 163, 339-347.
- 16 Teede HJ, McGrath BP, DeSilva L, Cehun M, Fassoulakis A, Nestel PJ, 2003. Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women. *Arterioscler Thromb Vasc Biol*, 23, 1066-1071.

ID 2497: “Tussilago farfara (Coltsfoot)” and “Health of the upper respiratory tract / Immune health”

- 1 Пилат Т and Иванов А, 2002. Фитокашель. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 567- 568.
- 2 Пилат Т and Иванов А, 2002. Фитоангин. In: П32 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 573- 574

ID 2498: “Urtica dioica (Nettle)” and “Respiratory health”

- 1 Rubine H, 2000. Nātre lielā. Ārstniecības augu avīze, 1, 371.
- 2 Skutelis A, Pakalns D, Mikažans V, Fatare I, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.

ID 2499: ” Vaccinium macrocarpon, oxycoccus (Cranberry)” and “Heart health”

- 1 Kemper KJ, 1999. Cranberry (*Vaccinium macrocarpon*). *The Longwood Herbal Task Force. The Center for Holistic Pediatric Education and Research*, 1-14.
- 2 Kruse-Elliott K, 2005. Cranberry juice modulates atherosclerotic vascular dysfunction. *Congress of the International Union of Physiological Sciences, San Diego, March 31-April 5 2005*.
- 3 Lila MA, 2004. Anthocyanins and Human Health: An In Vitro Investigative Approach. *J Biomed Biotechnol*, 2004, 306-313.
- 4 Wilson T, Porcari JP, Harbin D, 1998. Cranberry extract inhibits low density lipoprotein oxidation. *Life Sci*, 62, PL381-386.

ID 2500: “Valeriana officinalis (Valerian)” and “Cardiovascular health”

- 1 Пилат Т and Иванов А, 2002. Успокаивающие травы. In: ПЗ2 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 491- 494.

ID 2501: “Valeriana officinalis (Valerian)” and “Digestive health”

- 1 Rubine H, 2001. Baldriāns parastais. Ārstniecības augu avīze, 1, 55pp.
- 2 Skutelis A and Pakalns D, 2005. Ārstniecības augu farmakoloģija. Z/S Vecpāvuli, Rīga.

ID 2504: “Zea mays (Maize)” and “Liver health”

- 1 Rubine H and Eniņa V, 2004. Parastā kukurūza. Ārstniecības augi. [In Latvian]. Apgāds Zvaigzne ABC, 152-153.
- 2 Skutelis A and Pakalns D, 2005. Ārstniecības augu farmakoloģija. [In Latvian]. 136.
- 3 Пилат ТЛ and Иванов АА, 2002. Антишлак. ПЗ2 Биологически активные добавки к пище (теория, производство, применение). М. Авваллон. [In Russian]. 582-584, 587-590.

ID 2505: “Zea mays (Maize)” and “Kidneys health”

- 1 Maksimovic Z, Dobric S, Kovacevic N, Milovanovic Z, 2004. Diuretic activity of Maydis stigma extract in rats. Pharmazie, 59, 967-971.
- 2 Rubine H and Eniņa V, 2004. Parastā kukurūza. Ārstniecības augi. Apgāds Zvaigzne ABC., 152-153.
- 3 Skutelis A and Pakalns D, 2005. Ārstniecības augu farmakoloģija. . Z/S Vecpovuli, Rīga.
- 4 Velazquez DVO, Xavier HS, Batista JEM, de Castro-Chaves C, 2005. Zea mays L. extracts modify glomerular function and potassium urinary excretion in conscious rats. Phytomedicine, 12, 363-369.
- 5 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 6 Пилат ТЛ and Иванов АА, 2002. Антишлак. In: ПЗ2 Биологически активные добавки к пище (теория, производство, применение). Авваллон, Москва, 582-584.

ID 2508: “Name of Food product: Adhatoda vasica Description of food in terms of food legislation categories: Food supplement Was food on Irish market before 1st July 2007: No” and “Health benefits of food: Adhatoda vasica has antiinflammatory activity. Do benefits relate to a disease risk factor: No.Target group: Adults aged 18 years and over with some exceptions. If exceptions describe: Pregnant and lactating women, and children.”

- 1 Bhattacharyya D, Pandit S, Jana U, Sen S, Sur TK, 2005. Hepatoprotective activity of Adhatoda vasica aqueous leaf extract on D-galactosamine-induced liver damage in rats. Fitoterapia, 76, 223-225.
- 2 Chakraborty A and Brantner AH, 2001. Study of alkaloids from Adhatoda vasica Nees on their antiinflammatory activity. Phytother Res, 15, 532-534.
- 3 Dhuley JN, 1999. Antitussive effect of Adhatoda vasica extract on mechanical or chemical stimulation-induced coughing in animals. J Ethnopharmacol, 67, 361-365.
- 4 Jahangir T, Khan TH, Prasad L, Sultana S, 2006. Reversal of cadmium chloride-induced oxidative stress and genotoxicity by Adhatoda vasica extract in Swiss albino mice. Biol Trace Elem Res, 111, 217-228.

- 5 Kumar A, Ram J, Samarth RM, Kumar M, 2005. Modulatory influence of *Adhatoda vasica* Nees leaf extract against gamma irradiation in Swiss albino mice. *Phytomedicine*, 12, 285-293.

ID 2510: “Name of Food product: psyllium seed (*Plantago ispaghula*).Description of food in terms of food legislation categories: Food supplement.Was food on Irish market before 1st July 2007: No” and “Health benefits of food: bowel regularity; feeling of fullness; helps control blood levels of cholesterol.Do benefits relate to a disease risk factor: Yes.Target group: All of the general population including children and adults”

- 1 Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, 2006. HagerROM 2006. Hagers Handbuch der Drogen und Arzneistoffe Springer Medizin Verlag, Heidelberg.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 EMEA (European Medicines Agency) HMPC (Committee on Herbal Medicinal Products), 2006. Community Herbal Monograph on *Plantago Ovata* Forssk., *Seminis tegumentum*.
- 4 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 5 Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A, Gonzalez-Huix F, Riera J, Gonzalez-Lara V, Dominguez-Abascal F, Gine JJ, Moles J, Gomollon F, Gassull MA, 1999. Randomized clinical trial of *Plantago ovata* seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). *Am J Gastroenterol*, 94, 427-433.
- 6 McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M, 1998. Psyllium is superior to docusate sodium for treatment of chronic constipation. *Aliment Pharmacol Ther*, 12, 491-497.
- 7 Odes HS and Madar Z, 1991. A double-blind trial of a celandin, aloe vera and psyllium laxative preparation in adult patients with constipation. *Digestion*, 49, 65-71.
- 8 Ramkumar D and Rao SS, 2005. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. *Am J Gastroenterol*, 100, 936-971.
- 9 Rodriguez-Moran M, Guerrero-Romero F, Lazcano-Burciaga G, 1998. Lipid- and glucose-lowering efficacy of *Plantago Psyllium* in type II diabetes. *J Diabetes Complications*, 12, 273-278.
- 10 Scheppach W, Luehrs H, Melcher R, Gostner A, Schaubert J, Kudlich T, Weiler F, Menzel T, 2004. Antiinflammatory and anticarcinogenic effects of dietary fibre. *Clinical Nutrition Supplements* 1, 8.

ID 2511: “Name of Food product: Terminalia arjuna.Description of food in terms of food legislation categories: Food supplement.Was food on Irish market before 1st July 2007: No” and “Health benefits of food: Terminalia arjuna possesses antioxidant activity..Do benefits relate to a disease risk factor: No.Target group: Adults aged 18 years and over with some exceptions.If exceptions describe: Pregnant and lactating women, and children”

- 1 Bharani A, Ahirwar LK, Jain N, 2004. *Terminalia arjuna* reverses impaired endothelial function in chronic smokers. *Indian Heart J*, 56, 123-128.
- 2 Devi RS, Narayan S, Vani G, Shyamala Devi CS, 2007. Gastroprotective effect of *Terminalia arjuna* bark on diclofenac sodium induced gastric ulcer. *Chem Biol Interact*, 167, 71-83.
- 3 Devi RS, Narayan S, Vani G, Srinivasan P, Mohan KV, Sabitha KE, Devi CS, 2007. Ulcer protective effect of *Terminalia arjuna* on gastric mucosal defensive mechanism in experimental rats. *Phytother Res*, 21, 762-767.

- 4 Gauthaman K, Maulik M, Kumari R, Manchanda SC, Dinda AK, Maulik SK, 2001. Effect of chronic treatment with bark of Terminalia arjuna: a study on the isolated ischemic-reperfused rat heart. *J Ethnopharmacol*, 75, 197-201.
- 5 Gupta R, Singhal S, Goyle A, Sharma VN, 2001. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. *J Assoc Physicians India*, 49, 231-235.
- 6 Manna P, Sinha M, Sil PC, 2006. Aqueous extract of Terminalia arjuna prevents carbon tetrachloride induced hepatic and renal disorders. *BMC Complement Altern Med*, 6, 33.
- 7 Manna P, Sinha M, Pal P, Sil PC, 2007. Arjunolic acid, a triterpenoid saponin, ameliorates arsenic-induced cyto-toxicity in hepatocytes. *Chem Biol Interact*, 170, 187-200.
- 8 Manna P, Sinha M, Sil PC, 2007. Phytomedicinal activity of Terminalia arjuna against carbon tetrachloride induced cardiac oxidative stress. *Pathophysiology*, 14, 71-78.
- 9 Raghavan B and Kumari SK, 2006. Effect of Terminalia arjuna stem bark on antioxidant status in liver and kidney of alloxan diabetic rats. *Indian J Physiol Pharmacol*, 50, 133-142.
- 10 Sivalokanathan S, Ilayaraja M, Balasubramanian MP, 2006. Antioxidant activity of Terminalia arjuna bark extract on N-nitrosodiethylamine induced hepatocellular carcinoma in rats. *Mol Cell Biochem*, 281, 87-93.

ID 2514: “Ananas tige” and “Anti-inflammatoire”

- 1 Brien S, Lewith G, Walker A, Hicks SM, Middleton D, 2004. Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies. *Evid Based Complement Alternat Med*, 1, 251-257.
- 2 Hale LP, Greer PK, Sempowski GD, 2002. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. *Clin Immunol*, 104, 183-190.
- 3 Walker AF, Bundy R, Hicks SM, Middleton RW, 2002. Bromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adults. *Phytomedicine*, 9, 681-686.

ID 2515: “Ballota nigra L.” and “Antioxidant”

- 1 Citoglu GS, Coban T, Sever B, Iscan M, 2004. Antioxidant properties of Ballota species growing in Turkey. *J Ethnopharmacol*, 92, 275-280.
- 2 Vrchovska V, Spilkova J, Valentao P, Sousa C, Andrade PB, Seabra RM, 2007. Antioxidative properties and phytochemical composition of Ballota nigra infusion. *Food Chemistry* 105, 1396-1403.

ID 2517: “Bardane racine” and “Anti-inflammatoire/anti-oxidant de la peau”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Lin CC, Lu JM, Yang JJ, Chuang SC, Ujii T, 1996. Anti-inflammatory and radical scavenge effects of Arctium lappa. *Am J Chin Med*, 24, 127-137.

ID 2522: “Carotte racine” and “Anti-oxidant Photoprotection”

- 1 Bruneton J, 1993. Pharmacognosy, phytochemistry, medicinal plants. Lavoisier, Paris.
- 2 Hoppe HA, 1975. Drogenkunde. Walter de Gruyter, Berlin.

- 3 Tapiero H, Townsend DM, Tew KD, 2004. The role of carotenoids in the prevention of human pathologies. *Biomed Pharmacother*, 58, 100-110.
- 4 WHO and FAO (World Health Organization and Food and Agriculture Organization), 2004. Vitamin and mineral requirements in human nutrition.

ID 2527: “Christe marine” and “Antioxydant”

- 1 Ruberto G, Baratta MT, Deans SG, Dorman HJ, 2000. Antioxydant and antimicrobienne activité de *Foeniculum vulgare* and *Crithmum maritimum* huiles essentielles. *Planta Med*, 66, 687-693.

ID 2528: “Christe marine” and “Diurétique”

- 1 Cunsolo F, Ruberto G, Amico V, Piattelli M, 1993. Bioactives métabolites de fennel marine Sicilienne, *Crithmum maritimum*. *J Nat Prod*, 56, 1598-1600.

ID 2530: “Chrysanthellum americanum” and “Antioxydant”

- 1 Amos S, Binda L, Adamu M, Vongtau HO, Abbah J, Omogbai EK, Akah PA, Bukar BB, Wambebe C, Gamaniel K, 2003. Effet de l'extrait aqueux de *Chrysanthellum indicum* sur la mobilisation du calcium et l'activation de la veine portale de rat. *J Ethnopharmacol*, 88, 57-62.

ID 2531: “Cosse de Haricot” and “Diurétique”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2541: “Frêne Feuille” and “Système urinaire Diurétique”

- 1 Kostova I and Iossifova T, 2007. Composés chimiques de *Fraxinus* espèces. *Fitoterapia*, 78, 85-106.
- 2 Ledoux F, Meurin P, Depoërs P, 2002. *La Phytothérapie entre Science et Tradition*. Amyris, Bruxelles.

ID 2552: “Levure de bière” and “Epiderme soigne l'acnée”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2556: “Grifola frondosa (Maitake) thalle” and “Métabolisme des glucides antidiabétique, hypoglycémiant”

- 1 Horio H and Ohtsuru M, 2001. Maitake (*Grifola frondosa*) improve glucose tolerance of experimental diabetic rats. *J Nutr Sci Vitaminol (Tokyo)*, 47, 57-63.
- 2 Konno S, Tortorelis DG, Fullerton SA, Samadi AA, Hettiarachchi J, Tazaki H, 2001. A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients. *Diabet Med*, 18, 1010.
- 3 Preuss HG, Echard B, Bagchi D, Perricone NV, Zhuang C, 2007. Enhanced insulin-hypoglycemic activity in rats consuming a specific glycoprotein extracted from maitake mushroom. *Mol Cell Biochem*, 306, 105-113.

ID 2567: “Piloselle plante” and “Système urinaire Diurétique”

- 1 Beaux D, Fleurentin J, Mortier F, 1999. Effect of extracts of *Orthosiphon stamineus* Benth, *Hieracium pilosella* L., *Sambucus nigra* L. and *Arctostaphylos uva-ursi* (L.) Spreng. in rats. *Phytother Res*, 13, 222-225.
- 2 Ledoux F, Meurin P, Depoërs P, 2002. *La Phytothérapie entre Science et Tradition*. Amyris, Bruxelles.

ID 2575: “Prêle” and “Anti-oxidant”

- 1 Guilherme dos Santos J, Jr., Hoffmann Martins do Monte F, Marcela Blanco M, Maria do Nascimento Bispo Lanziotti V, Damasseno Maia F, Kalyne de Almeida Leal L, 2005. Cognitive enhancement in aged rats after chronic administration of *Equisetum arvense* L. with demonstrated antioxidant properties in vitro. *Pharmacol Biochem Behav*, 81, 593-600.
- 2 Oh H, Kim DH, Cho JH, Kim YC, 2004. Hepatoprotective and free radical scavenging activities of phenolic petrosins and flavonoids isolated from *Equisetum arvense*. *J Ethnopharmacol*, 95, 421-424.

ID 2580: “Sauge sclarée plante” and “Anti-oxidant”

- 1 Miliauskasa G, Venskutonis PR, van Beek TA, 2004. Screening of radical scavenging activity of some medicinal and aromatic plant extracts. *Food Chemistry*, 85, 231-237.
- 2 Orhana I, Kartalb M, Nazc Q, Ejazc A, Yilmazd G, Kan Y, Konuklugil B, Şenera B, Choudharyc MI, 2007. Antioxidant and anticholinesterase evaluation of selected Turkish *Salvia* species. *Food Chemistry* 103, 1247-1254.
- 3 Tepe B, Sokmen M, Askin Akpulat H, Sokmen A, 2006. Screening of the antioxidant potentials of six *Salvia* species from Turkey. *Food Chemistry*, 95, 200-204.

ID 2585: “Alfalfa” and “Système circulatoire Hypcholestérolémiant”

- 1 Esper E, Barichello AW, Chan EK, Matts JP, Buchwald H, 1987. Synergistic lipid-lowering effects of alfalfa meal as an adjuvant to the partial ileal bypass operation. *Surgery*, 102, 39-51.
- 2 Malinow MR, McLaughlin P, Naito HK, Lewis LA, McNulty WP, 1978. Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys. *Atherosclerosis*, 30, 27-43.
- 3 Malinow MR, McLaughlin P, Stafford C, Livingston AL, Kohler GO, 1980. Alfalfa saponins and alfalfa seeds. Dietary effects in cholesterol-fed rabbits. *Atherosclerosis*, 37, 433-438.
- 4 Malinow MR, 1983. Experimental models of atherosclerosis regression. *Atherosclerosis*, 48, 105-118.

ID 2591: “Marjolaine feuille” and “Anti-oxidant”

- 1 el-Ashmawy IM, el-Nahas AF, Salama OM, 2005. Protective effect of volatile oil, alcoholic and aqueous extracts of *Origanum majorana* on lead acetate toxicity in mice. *Basic Clin Pharmacol Toxicol*, 97, 238-243.
- 2 Jun WJ, Han BK, Yu KW, Kim MS, Chang HS, Kim HY, Hong YC, 2001. Antioxidant effects of *Origanum majorana* L. on superoxide anion radicals. *Food Chemistry* 75, 439-444.
- 3 Ninfali P, Mea G, Giorgini S, Rocchi M, Bacchiocca M, 2005. Antioxidant capacity of vegetables, spices and dressings relevant to nutrition. *Br J Nutr*, 93, 257-266.

ID 2596: “Chiendent rhizome plante” and “Système urinaire Diurétique, anti-inflammatoire des voies urinaires, prévention des calculs rénaux”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2616: “Germe de blé” and “Anti-oxidant. Source de vitamine E”

- 1 Paranich VA, Cherevko OI, Frolova NA, Paranich AV, 2000. [The effect of wheat germ oil on the antioxidant system of animals]. *Lik Sprava*, 40-44.

ID 2618: “Germe de blé” and “Système circulatoire. Source d'oméga 3, anti-arthérosclérose, diminue les triglycérides, réduit les risques de crises cardiaques”

- 1 Alessandri C, Pignatelli P, Loffredo L, Lenti L, Del Ben M, Carnevale R, Perrone A, Ferro D, Angelico F, Violi F, 2006. Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with mild hypercholesterolemia. *Arterioscler Thromb Vasc Biol*, 26, 2577-2578.
- 2 Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J, 2006. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. *Atherosclerosis*, 189, 19-30.
- 3 McKenney JM and Sica D, 2007. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. *Pharmacotherapy*, 27, 715-728.
- 4 Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM, 2004. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. *J Nutr*, 134, 2991-2997.

ID 2620: “Argan” and “Anti-oxidant Anticancer”

- 1 Bennani H, Drissi A, Giton F, Kheuang L, Fiet J, Adlouni A, 2007. Antiproliferative effect of polyphenols and sterols of virgin argan oil on human prostate cancer cell lines. *Cancer Detect Prev*, 31, 64-69.
- 2 Drissi A, Girona J, Cherki M, Godas G, Derouiche A, El Messal M, Saile R, Kettani A, Sola R, Masana L, Adlouni A, 2004. Evidence of hypolipemiant and antioxidant properties of argan oil derived from the argan tree (*Argania spinosa*). *Clin Nutr*, 23, 1159-1166.
- 3 Drissi A, Bennani H, Giton F, Charrouf Z, Fiet J, Adlouni A, 2006. Tocopherols and saponins derived from *Argania spinosa* exert, an antiproliferative effect on human prostate cancer. *Cancer Invest*, 24, 588-592.

- 4 Khallouki F, Younos C, Soulimani R, Oster T, Charrouf Z, Spiegelhalter B, Bartsch H, Owen RW, 2003. Consumption of argan oil (Morocco) with its unique profile of fatty acids, tocopherols, squalene, sterols and phenolic compounds should confer valuable cancer chemopreventive effects. *Eur J Cancer Prev*, 12, 67-75.

ID 2622: “Cynorrhodon” and “Anti-asthénique, source de vitamine C”

- 1 Daels-Rakotoarison DA, Gressier B, Trotin F, Brunet C, Luyckx M, Dine T, Bailleul F, Cazin M, Cazin JC, 2002. Effects of *Rosa canina* fruit extract on neutrophil respiratory burst. *Phytother Res*, 16, 157-161.
- 2 Salminen JP, Karonen M, Lempa K, Liimatainen J, Sinkkonen J, Lukkarinen M, Pihlaja K, 2005. Characterisation of proanthocyanidin aglycones and glycosides from rose hips by high-performance liquid chromatography-mass spectrometry, and their rapid quantification together with vitamin C. *J Chromatogr A*, 1077, 170-180.
- 3 WHO and FAO (World Health Organization and Food and Agriculture Organization), 2004. Vitamin and mineral requirements in human nutrition.

ID 2628: “Bouleau pubescent” and “Diurétique”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Capasso F, Gaginella TS, Grandolini G, Izzo AA, 2003. *Phytotherapy: a quick reference to herbal medicine*. Springer, Berlin.
- 4 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 5 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 6 Valnet J, 1983. *Phytothérapie. Traitement des maladies par les plantes. Livre de Poche / Maloine*, Paris.
- 7 Van Hellemont J, 1986. *Compendium de phytothérapie*. Association Pharmaceutique Belge, Bruxelles.
- 8 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2629: “Chataîgné” and “Astringent, anti-oxidant”

- 1 Calliste CA, Trouillas P, Allais DP, Duroux JL, 2005. *Castanea sativa* Mill. leaves as new sources of natural antioxidant: an electronic spin resonance study. *J Agric Food Chem*, 53, 282-288.
- 2 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2637: “Cranberry extract powder (*Vaccinium macrocarpon*)” and “natural antioxidant”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), AFSSA's list of opinions related to human nutrition (FR), <http://www.afssa.fr/>.
- 2 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.

- 3 Di Martino P, Agniel R, David K, Templer C, Gaillard JL, Denys P, Botto H, 2006. Reduction of *Escherichia coli* adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial. *World J Urol*, 24, 21-27.
- 4 Duthie GG, Kyle JA, Jenkinson AM, Duthie SJ, Baxter GJ, Paterson JR, 2005. Increased salicylate concentrations in urine of human volunteers after consumption of cranberry juice. *J Agric Food Chem*, 53, 2897-2900.
- 5 Hutchinson J, 2005. Do cranberries help prevent urinary tract infections? *Nurs Times*, 101, 38-40.
- 6 Jepson RG, Mihaljevic L, Craig J, 2004. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*, CD001321.
- 7 Nowack R, 2003. Die amerikanische Cranberry (*Vaccinium macrocarpum* Aiton). *Zeitschrift für Phytotherapie*, 24, 40-46.
- 8 Reid G, Hsieh J, Potter P, Mighton J, Lam D, Warren D, Stephenson J, 2001. Cranberry juice consumption may reduce biofilms on uroepithelial cells: pilot study in spinal cord injured patients. *Spinal Cord*, 39, 26-30.
- 9 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 10 Vvedenskaya IO, Rosen RT, Guido JE, Russell DJ, Mills KA, Vorsa N, 2004. Characterization of flavonols in cranberry (*Vaccinium macrocarpon*) powder. *J Agric Food Chem*, 52, 188-195.

ID 2638: “blueberry extracts” and “can support maintainig of proper night vision”

- 1 Bagchi D, Sen CK, Bagchi M, M. A, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry* 69, 75-80.
- 2 Newport A and Lockwood B, 2005. Use of nutraceuticals for eye health *The Pharmaceutical Journal* 275, 261-264.

ID 2639: “blueberry extracts” and “natural antioxidant”

- 1 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.

ID 2640: “green tea extract (*Camelia sinensis*)” and “helps to keep normal cholesterol level”

- 1 Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM, 2004. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. *J Pharmacol Exp Ther*, 308, 767-773.
- 2 Hamblin T, 2006. Natural products and the treatment of leukemia. *Leuk Res*, 30, 649-650.
- 3 Kazi A, Smith DM, Daniel K, Zhong S, Gupta P, Bosley ME, Dou QP, 2002. Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. *In Vivo*, 16, 397-403.
- 4 Kemberling JK, Hampton JA, Keck RW, Gomez MA, Selman SH, 2003. Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. *J Urol*, 170, 773-776.
- 5 Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC, Zhao J, 2003. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. *Arch Intern Med*, 163, 1448-1453.
- 6 Moyers SB and Kumar NB, 2004. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. *Nutr Rev*, 62, 204-211.

- 7 Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J, 2005. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. *J Neurosci*, 25, 8807-8814.
- 8 Skrzydlewska E, Ostrowska J, Farbiszewski R, Michalak K, 2002. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. *Phytomedicine*, 9, 232-238.
- 9 Yokozawa T, Nakagawa T, Kitani K, 2002. Antioxidative activity of green tea polyphenol in cholesterol-fed rats. *J Agric Food Chem*, 50, 3549-3552.

ID 2641: “extract of *Silybum marianum*” and “antioxidant”

- 1 Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM, 2007. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. *Invest New Drugs*, 25, 139-146.
- 2 Herbmed, Clinical trials of *Silybum Marianum*, <http://www.herbmed.org/Herbs/Herb120.htm>.
- 3 Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ, 2006. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. *Clin Cancer Res*, 12, 2944-2950.
- 4 Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M, 2006. The efficacy of *Silybum marianum* (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. *Phytother Res*, 20, 1036-1039.
- 5 Mayer KE, Myers RP, Lee SS, 2005. Silymarin treatment of viral hepatitis: a systematic review. *J Viral Hepat*, 12, 559-567.
- 6 Rambaldi A, Jacobs BP, Iaquinto G, Gluud C, 2005. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. *Cochrane Database Syst Rev*, CD003620.

ID 2642: “extract of *Gymnema sylvestre*” and “helps to keep normal sugar level in organism”

- 1 *Gymnema sylvestre* Monograph. 1999 *Altern Med Rev*, 4, 46-47.
- 2 Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER, 1990. Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *J Ethnopharmacol*, 30, 295-300.
- 3 Grover JK, Yadav S, Vats V, 2002. Medicinal plants of India with anti-diabetic potential. *J Ethnopharmacol*, 81, 81-100.
- 4 Luo H, Kashiwagi A, Shibahara T, Yamada K, 2007. Decreased bodyweight without rebound and regulated lipoprotein metabolism by gymnemate in genetic multifactor syndrome animal. *Mol Cell Biochem*, 299, 93-98.
- 5 Ogawa Y, Sekita K, Umemura T, Saito M, Ono A, Kawasaki Y, Uchida O, Matsushima Y, Inoue T, Kanno J, 2004. [*Gymnema sylvestre* leaf extract: a 52-week dietary toxicity study in Wistar rats]. *Shokuhin Eiseigaku Zasshi*, 45, 8-18.
- 6 Persaud SJ, Al-Majed H, Raman A, Jones PM, 1999. *Gymnema sylvestre* stimulates insulin release in vitro by increased membrane permeability. *J Endocrinol*, 163, 207-212.
- 7 Porchezian E and Dobriyal RM, 2003. An overview on the advances of *Gymnema sylvestre*: chemistry, pharmacology and patents. *Pharmazie*, 58, 5-12.
- 8 Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B, 1990. Use of *Gymnema sylvestre* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. *J Ethnopharmacol*, 30, 281-294.

- 9 Shapiro K and Gong WC, 2002. Natural products used for diabetes. *J Am Pharm Assoc (Wash)*, 42, 217-226.
- 10 Shimizu K, Iino A, Nakajima J, Tanaka K, Nakajyo S, Urakawa N, Atsuchi M, Wada T, Yamashita C, 1997. Suppression of glucose absorption by some fractions extracted from *Gymnema sylvestre* leaves. *J Vet Med Sci*, 59, 245-251.

ID 2643: “extrakt of *Garcinia cambogiae* hydroxycitric acid” and “metabolism of fats”

- 1 Jena BS, Jayaprakasha GK, Singh RP, Sakariah KK, 2002. Chemistry and biochemistry of (-)-hydroxycitric acid from *Garcinia*. *J Agric Food Chem*, 50, 10-22.
- 2 Mattes RD and Bormann L, 2000. Effects of (-)-hydroxycitric acid on appetitive variables. *Physiol Behav*, 71, 87-94.
- 3 Tomita K, Okuhara Y, Shigematsu N, Suh H, Lim K, 2003. (-)-hydroxycitrate ingestion increases fat oxidation during moderate intensity exercise in untrained men. *Biosci Biotechnol Biochem*, 67, 1999-2001.
- 4 Westerterp-Plantenga MS and Kovacs EM, 2002. The effect of (-)-hydroxycitrate on energy intake and satiety in overweight humans. *Int J Obes Relat Metab Disord*, 26, 870-872.

ID 2647: “Boswellin (*Boswellia serrata*)” and “Metabolism of enzymes: Boswellin positively effects the enzyme 5-lipoxygenase, as well as the human leukocyte elastase (HLE)”

- 1 Ammon HP, Safayhi H, Mack T, Sabieraj J, 1993. Mechanism of antiinflammatory actions of curcumine and boswellic acids. *J Ethnopharmacol*, 38, 113-119.
- 2 Ammon HP, 2006. Boswellic acids in chronic inflammatory diseases. *Planta Med*, 72, 1100-1116.
- 3 *Boswellia serrata*. Monograph, 1998. *Altern Med Rev*, 3, 306-307.
- 4 Banno N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y, Nishimura R, Kimura Y, Suzuki T, 2006. Anti-inflammatory activities of the triterpene acids from the resin of *Boswellia carterii*. *J Ethnopharmacol*, 107, 249-253.
- 5 Basch E, Boon H, Davies-Heerema T, Foppo I, Hashmi S, Hasskarl J, Sollars D, Ulbricht C, 2004. *Boswellia*: an evidence-based systematic review by the Natural Standard Research Collaboration. *J Herb Pharmacother*, 4, 63-83.
- 6 Fan AY, Lao L, Zhang RX, Wang LB, Lee DY, Ma ZZ, Zhang WY, Berman B, 2005. Effects of an acetone extract of *Boswellia carterii* Birdw. (Burseraceae) gum resin on rats with persistent inflammation. *J Altern Complement Med*, 11, 323-331.
- 7 Fan AY, Lao L, Zhang RX, Zhou AN, Wang LB, Moudgil KD, Lee DY, Ma ZZ, Zhang WY, Berman BM, 2005. Effects of an acetone extract of *Boswellia carterii* Birdw. (Burseraceae) gum resin on adjuvant-induced arthritis in lewis rats. *J Ethnopharmacol*, 101, 104-109.
- 8 Frank A and Unger M, 2006. Analysis of frankincense from various *Boswellia* species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. *J Chromatogr A*, 1112, 255-262.
- 9 Herbmed, *Boswellia serrata*, <http://www.herbmed.org/herblist.asp?varLetter=B&varName=Scientific>.
- 10 Huang M-T, Badmaev V, Ding Y, Liu Y, Xie J-G, Ho C-T, 2000. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid *BioFactors*, 13, 225-230.
- 11 Indian Ministry of Health and Family Welfare, 2004. *The Ayurvedic Pharmacopoeia of India, Vol IV*. Government of India, New Dehli, India.
- 12 InteliHealth, *Boswellia serrata*
<http://www.intelihealth.com/IH/ihtIH/WSSAN028/8513/31402/348745.html?d=dmContent>.

- 13 Kimmatkar N, Thawani V, Hingorani L, Khiyani R, 2003. Efficacy and tolerability of *Boswellia serrata* extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. *Phytomedicine*, 10, 3-7.
- 14 Mills S and Bone K Elsevier, 2005. *The Essential Guide to Herbal Safety*. Churchill Livingstone, London, Edinburgh.
- 15 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 16 Reddy GK, Chandrakasan G, Dhar SC, 1989. Studies on the metabolism of glycosaminoglycans under the influence of new herbal anti-inflammatory agents. *Biochem Pharmacol*, 38, 3527-3534.
- 17 Reichling J, Schmokel H, Fitz J, Bucher S, Saller R, 2004. Dietary support with *Boswellia* resin in canine inflammatory joint and spinal disease. *Schweiz Arch Tierheilkd*, 146, 71-79.
- 18 Sabinsa Corporation, *Boswellin*, www.boswellin.com.
- 19 Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP, 1992. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. *J Pharmacol Exp Ther*, 261, 1143-1146.
- 20 Sander O, Herborn G, Rau R, 1998. [Is H15 (resin extract of *Boswellia serrata*, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study]. *Z Rheumatol*, 57, 11-16.
- 21 Sharma PC, Yelne MB, Dennis TJ, 2000. *Database on Medical Plants used in Ayurveda*. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 22 Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R, 2004. Pharmacokinetic study of 11-Keto beta-Boswellic acid. *Phytomedicine*, 11, 255-260.
- 23 Sitaram B, 2006. *Bhavaprakasa of Bhavamisra : Original Text Along With Commentary and Translation : Including Nighantu Portion*. Chaukhambha Orientalia, Varanasi, India.
- 24 Sterk V, Buchele B, Simmet T, 2004. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. *Planta Med*, 70, 1155-1160.
- 25 Takada Y, Ichikawa H, Badmaev V, Aggarwal BB, 2006. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. *J Immunol*, 176, 3127-3140.
- 26 Weber CC, Reising K, Muller WE, Schubert-Zsilavec M, Abdel-Tawab M, 2006. Modulation of Pgp function by boswellic acids. *Planta Med*, 72, 507-513.
- 27 Williamson EM, 2002. *Major Herbs of Ayurveda*. Churchill Livingstone, London, Edinburgh.
- 28 Yuan G, Wahlqvist ML, He G, Yang M, Li D, 2006. Natural products and anti-inflammatory activity. *Asia Pac J Clin Nutr*, 15, 143-152.

ID 2649: “ginger extract (*Zingiberis officinale*)” and “helps to maintai mobility of joints”

- 1 Ahmed S, Anuntiyo J, Malemud CJ, Haqqi TM, 2005. Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. *Evid Based Complement Alternat Med*, 2, 301-308.
- 2 Altman RD and Marcussen KC, 2001. Effects of a ginger extract on knee pain in patients with osteoarthritis. *Arthritis Rheum*, 44, 2531-2538.
- 3 Ameye LG and Chee WS, 2006. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. *Arthritis Res Ther*, 8, R127.
- 4 *Zingiber officinale* (ginger). Monograph, 2003. *Altern Med Rev*, 8, 331-335.
- 5 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.

- 6 Bliddal H, Rosetzky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt HH, Christensen K, Jensen ON, Barslev J, 2000. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. *Osteoarthritis Cartilage*, 8, 9-12.
- 7 Chrubasik S, Pittler MH, Roufogalis BD, 2005. *Zingiberis rhizoma*: a comprehensive review on the ginger effect and efficacy profiles. *Phytomedicine*, 12, 684-701.
- 8 Gogte VVM, 2000. *Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants*. Bharatiya Vidya Bhavan, Mumbai.
- 9 Grzanna R, Lindmark L, Frondoza CG, 2005. Ginger--an herbal medicinal product with broad anti-inflammatory actions. *J Med Food*, 8, 125-132.
- 10 Haghghi M, Khalvat A, Toliat T, Jallaei S, 2005. Comparing the effects of ginger (*Zingiber officinale*) extract and ibuprofen on patients with osteoarthritis. *Arch Iranian Med*, 8, 267-271.
- 11 Indian Ministry of Health and Family Welfare, 2001. *The Ayurvedic Pharmacopoeia of India, Vol I*. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 12 Lans C, Turner N, Brauer G, Lourenco G, Georges K, 2006. Ethnoveterinary medicines used for horses in Trinidad and in British Columbia, Canada. *J Ethnobiol Ethnomed*, 2, 31.
- 13 Lantz RC, Chen GJ, Sarihan M, Solyom AM, Jolad SD, Timmermann BN, 2007. The effect of extracts from ginger rhizome on inflammatory mediator production. *Phytomedicine*, 14, 123-128.
- 14 Levy AS, Simon O, Shelly J, Gardener M, 2006. 6-Shogaol reduced chronic inflammatory response in the knees of rats treated with complete Freund's adjuvant. *BMC Pharmacol*, 6, 12.
- 15 Micklefield GH, Redeker Y, Meister V, Jung O, Greving I, May B, 1999. Effects of ginger on gastroduodenal motility. *Int J Clin Pharmacol Ther*, 37, 341-346.
- 16 Miller LG, 1998. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med*, 158, 2200-2211.
- 17 Newall CA, Anderson LA, Phillipson JD, 1996. *Herbal Medicines: A Guide for Health-care Professionals*. The Pharmaceutical Press, London.
- 18 Ojewole JA, 2006. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of *Zingiber officinale* (Roscoe) rhizomes (*Zingiberaceae*) in mice and rats. *Phytother Res*, 20, 764-772.
- 19 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 20 Sharma PC, Yelne MB, Dennis TJ, 2000. *Database on Medical Plants used in Ayurveda*. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 21 Shen CL, Hong KJ, Kim SW, 2005. Comparative effects of ginger root (*Zingiber officinale* Rosc.) on the production of inflammatory mediators in normal and osteoarthrotic sow chondrocytes. *J Med Food*, 8, 149-153.
- 22 Shishodia S, Gethi G, Aggarwal BB, 2005. Curcumin: Getting back to the roots. *The annals of the New York Academy of Sciences*, 1056, 206-217.
- 23 Sitaram B, 2006. *Bhavaprakasa of Bhavamisra : Original Text Along With Commentary and Translation : Including Nighantu Portion*. Chaukhambha Orientalia, Varanasi, India.
- 24 Srivastava KC and Mustafa T, 1992. Ginger (*Zingiber officinale*) in rheumatism and musculoskeletal disorders. *Med Hypotheses*, 39, 342-348.
- 25 Tao QF, Xu Y, Lam RY, Schneider B, Dou H, Leung PS, Shi SY, Zhou CX, Yang LX, Zhang RP, Xiao YC, Wu X, Stockigt J, Zeng S, Cheng CH, Zhao Y, 2008. Diarylheptanoids and a monoterpenoid from the rhizomes of *Zingiber officinale*: antioxidant and cytoprotective properties. *J Nat Prod*, 71, 12-17.
- 26 WHO (World Health Organization), 1999. *WHO Monographs on Selected Medicinal Plants*. WHO (World Health Organization), Geneva.

ID 2651: “Extract from Garcinia cambogia (60% HCA) - (-)-Hydroxycitric acid” and “HCA is an inhibitor of ATP-citrate lyase, which is involved in fatty acid synthesis”

- 1 Jena BS, Jayaprakasha GK, Singh RP, Sakariah KK, 2002. Chemistry and biochemistry of (-)-hydroxycitric acid from Garcinia. *J Agric Food Chem*, 50, 10-22.
- 2 Joyal SV, 2004. A perspective on the current strategies for the treatment of obesity. *Curr Drug Targets CNS Neurol Disord*, 3, 341-356.
- 3 Opala T, Rzymyski P, Pischel I, Wilczak M, Wozniak J, 2006. Efficacy of 12 weeks supplementation of a botanical extract-based weight loss formula on body weight, body composition and blood chemistry in healthy, overweight subjects--a randomised double-blind placebo-controlled clinical trial. *Eur J Med Res*, 11, 343-350.
- 4 Shara M, Ohia SE, Yasmin T, Zardetto-Smith A, Kincaid A, Bagchi M, Chatterjee A, Bagchi D, Stohs SJ, 2003. Dose- and time-dependent effects of a novel (-)-hydroxycitric acid extract on body weight, hepatic and testicular lipid peroxidation, DNA fragmentation and histopathological data over a period of 90 days. *Mol Cell Biochem*, 254, 339-346.
- 5 Toromanyan E, Aslanyan G, Amroyan E, Gabrielyan E, Panossian A, 2007. Efficacy of Slim339 in reducing body weight of overweight and obese human subjects. *Phytother Res*, 21, 1177-1181.
- 6 Yamada T, Hida H, Yamada Y, 2007. Chemistry, physiological properties, and microbial production of hydroxycitric acid. *Appl Microbiol Biotechnol*, 75, 977-982.

ID 2652: “Extract from Aronia melanocarpa” and “antioxidant effects”

- 1 Kowalczyk E, Fijalkowski P, Kura M, Krzesinski P, Blaszczyk J, Kowalski J, Smigielski J, Rutkowski M, Kopff M, 2005. The influence of anthocyanins from Aronia melanocarpa on selected parameters of oxidative stress and microelements contents in men with hypercholesterolemia. *Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego*, 19, 651.
- 2 Valcheva-Kuzmanova SV and Belcheva A, 2006. Current knowledge of Aronia melanocarpa as a medicinal plant. *Folia medica*, 48, 11.
- 3 Valcheva-Kuzmanova S, Kuzmanov K, Mihova V, Krasnaliev I, Borisova P, Belcheva A, 2007. Antihyperlipidemic effect of Aronia melanocarpa fruit juice in rats fed a high-cholesterol diet. *Plant Foods for Human Nutrition*, 62, 19-24.

ID 2653: “Extract from the red grapes skin” and “antioxidant effects”

- 1 Dani C, Oliboni LS, Vanderlinde R, Bonatto D, Salvador M, Henriques JA, 2007. Phenolic content and antioxidant activities of white and purple juices manufactured with organically- or conventionally-produced grapes. *Food Chem Toxicol*, 45, 2574-2580.
- 2 Mattivi F, Guzzon R, Vrhovsek U, Stefanini M, Velasco R, 2006. Metabolite profiling of grape: Flavonols and anthocyanins. *J Agric Food Chem*, 54, 7692-7702.
- 3 Monagas M, Hernandez-Ledesma B, Gomez-Cordoves C, Bartolome B, 2006. Commercial dietary ingredients from Vitis vinifera L. leaves and grape skins: antioxidant and chemical characterization. *J Agric Food Chem*, 54, 319-327.
- 4 Zern TL, West KL, Fernandez ML, 2003. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. *J Nutr*, 133, 2268-2272.

- 5 Zern TL, Wood RJ, Greene C, West KL, Liu Y, Aggarwal D, Shachter NS, Fernandez ML, 2005. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. *J Nutr*, 135, 1911-1917.

ID 2654: “Extract from Hibiscus Chinensis” and “antioxidant effects”

- 1 Gauthaman KK, Saleem MT, Thanislas PT, Prabhu VV, Krishnamoorthy KK, Devaraj NS, Somasundaram JS, 2006. Cardioprotective effect of the Hibiscus rosa sinensis flowers in an oxidative stress model of myocardial ischemic reperfusion injury in rat. *BMC Complement Altern Med*, 6, 32.
- 2 Yamasaki H, Uefuji H, Sakihama Y, 1996. Bleaching of the red anthocyanin induced by superoxide radical. *Arch Biochem Biophys*, 332, 183-186.

ID 2657: “green tea extract (Camelia sinensis)” and “helps to keep elasticity of vessels”

- 1 Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM, 2004. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. *J Pharmacol Exp Ther*, 308, 767-773.
- 2 Hamblin T, 2006. Natural products and the treatment of leukemia. *Leuk Res*, 30, 649-650.
- 3 Kazi A, Smith DM, Daniel K, Zhong S, Gupta P, Bosley ME, Dou QP, 2002. Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. *In Vivo*, 16, 397-403.
- 4 Kemberling JK, Hampton JA, Keck RW, Gomez MA, Selman SH, 2003. Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. *J Urol*, 170, 773-776.
- 5 Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC, Zhao J, 2003. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. *Arch Intern Med*, 163, 1448-1453.
- 6 Moyers SB and Kumar NB, 2004. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. *Nutr Rev*, 62, 204-211.
- 7 Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J, 2005. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. *J Neurosci*, 25, 8807-8814.
- 8 Skrzydlewska E, Ostrowska J, Farbiszewski R, Michalak K, 2002. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. *Phytomedicine*, 9, 232-238.
- 9 Yokozawa T, Nakagawa T, Kitani K, 2002. Antioxidative activity of green tea polyphenol in cholesterol-fed rats. *J Agric Food Chem*, 50, 3549-3552.

ID 2658: “nettle extract (Urtica dioica), dandelion extract (Taraxum officinale), birch extract (Betula pendula),parsley extract (Petroselinum crispum)” and “has diuretic effect , helps to maintain proper function of urinary system, diureticum”

- 1 Akbay P, Basaran AA, Undeger U, Basaran N, 2003. In vitro immunomodulatory activity of flavonoid glycosides from *Urtica dioica* L. *Phytother Res*, 17, 34-37.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 3 Carnat A, Lacouture I, Fraisse D, Lamaison JL, 1996. [Standardization of the birch leaf]. *Ann Pharm Fr*, 54, 231-235.
- 4 Golyshenkov PP, 1978. [Therapeutic properties of a birch leaf infusion]. *Veterinariia*, 97-99.

- 5 Grases F, Melero G, Costa-Bauza A, Prieto R, March JG, 1994. Urolithiasis and phytotherapy. *International urology and nephrology*, 26, 507-511.
- 6 Gulcin I, Kufrevioglu OI, Oktay M, Buyukokuroglu ME, 2004. Antioxidant, antimicrobial, antiulcer and analgesic activities of nettle (*Urtica dioica* L.). *J Ethnopharmacol*, 90, 205-215.
- 7 Hu C and Kitts DD, 2003. Antioxidant, prooxidant, and cytotoxic activities of solvent-fractionated dandelion (*Taraxacum officinale*) flower extracts in vitro. *J Agric Food Chem*, 51, 301-310.
- 8 Konrad L, Muller HH, Lenz C, Laubinger H, Aumuller G, Lichius JJ, 2000. Antiproliferative effect on human prostate cancer cells by a stinging nettle root (*Urtica dioica*) extract. *Planta Med*, 66, 44-47.
- 9 Randall C, Meethan K, Randall H, Dobbs F, 1999. Nettle sting of *Urtica dioica* for joint pain--an exploratory study of this complementary therapy. *Complement Ther Med*, 7, 126-131.
- 10 Riehemann K, Behnke B, Schulze-Osthoff K, 1999. Plant extracts from stinging nettle (*Urtica dioica*), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-kappaB. *FEBS Lett*, 442, 89-94.
- 11 Schutz K, Carle R, Schieber A, 2006. *Taraxacum*--a review on its phytochemical and pharmacological profile. *J Ethnopharmacol*, 107, 313-323.
- 12 Testai L, Chericoni S, Calderone V, Nencioni G, Nieri P, Morelli I, Martinotti E, 2002. Cardiovascular effects of *Urtica dioica* L. (*Urticaceae*) roots extracts: in vitro and in vivo pharmacological studies. *J Ethnopharmacol*, 81, 105-109.
- 13 Valkama E, Salminen JP, Koricheva J, Pihlaja K, 2003. Comparative analysis of leaf trichome structure and composition of epicuticular flavonoids in Finnish birch species. *Ann Bot (Lond)*, 91, 643-655.
- 14 Williams CA, Goldstone F, Greenham J, 1996. Flavonoids, cinnamic acids and coumarins from the different tissues and medicinal preparations of *Taraxacum officinale*. *Phytochemistry*, 42, 121-127.
- 15 Yarnell E, 2002. Botanical medicines for the urinary tract. *World J Urol*, 20, 285-293.

ID 2660: “Evening primrose oil (*Oenothera biennis*) contains gamalinolenic acid” and “helps to maintain elasticity, tenderness and health of skin, structure and function of skin and mucose membrane”

- 1 Brosche T and Platt D, 2000. Effect of borage oil consumption on fatty acid metabolism, transepidermal water loss and skin parameters in elderly people. *Arch Gerontol Geriatr*, 30, 139-150.
- 2 Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R, 1997. Premenstrual symptoms in general practice patients. Prevalence and treatment. *J Reprod Med*, 42, 637-646.
- 3 Das UN, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P, 1998. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? *Prostaglandins Leukot Essent Fatty Acids*, 58, 39-54.
- 4 Fan YY and Chapkin RS, 1998. Importance of dietary gamma-linolenic acid in human health and nutrition. *J Nutr*, 128, 1411-1414.
- 5 Fukushima M, Matsuda T, Yamagishi K, Nakano M, 1997. Comparative hypocholesterolemic effects of six dietary oils in cholesterol-fed rats after long-term feeding. *Lipids*, 32, 1069-1074.
- 6 Granlund H, 2002. Treatment of childhood eczema. *Paediatr Drugs*, 4, 729-735.
- 7 Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton FH, 1997. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. *J Nutr*, 127, 1435-1444.
- 8 Leventhal LJ, Boyce EG, Zurier RB, 1993. Treatment of rheumatoid arthritis with gammalinolenic acid. *Ann Intern Med*, 119, 867-873.
- 9 Muggli R, 2005. Systemic evening primrose oil improves the biophysical skin parameters of healthy adults. *Int J Cosmet Sci*, 27, 243-249.
- 10 Muggli R, 2007. Systemic evening primrose oil for irritated skin care. *Cosmetics and toiletries*, 122, 42-56.

- 11 Rothman D, DeLuca P, Zurier RB, 1995. Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. *Semin Arthritis Rheum*, 25, 87-96.
- 12 Samson S, Rawlings AV, Guyonnet D, Lassel T, 2007. Improvements in stratum corneum barrier function from a probiotic yogurt containing borage oil, green tea polyphenols and vitamin E. *Journal of Investigative Dermatology*, 27, S65.
- 13 Soeken KL, Miller SA, Ernst E, 2003. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. *Rheumatology (Oxford)*, 42, 652-659.
- 14 Vassilopoulos D, Zurier RB, Rossetti RG, Tsokos GC, 1997. Gammalinolenic acid and dihomogammalinolenic acid suppress the CD3-mediated signal transduction pathway in human T cells. *Clin Immunol Immunopathol*, 83, 237-244.
- 15 Yoon S, Lee J, Lee S, 2002. The therapeutic effect of evening primrose oil in atopic dermatitis patients with dry scaly skin lesions is associated with the normalization of serum gamma-interferon levels. *Skin Pharmacol Appl Skin Physiol*, 15, 20-25.

ID 2661: “Evening primrose oil (*Oenothera biennis*) contains gamalinolenic acid” and “helps to keep normal blood cholesterol”

- 1 Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R, 1997. Premenstrual symptoms in general practice patients. Prevalence and treatment. *J Reprod Med*, 42, 637-646.
- 2 Das U, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P, 1998. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? *Prostaglandins Leukot Essent Fatty Acids*, 58, 39-54.
- 3 Fan YY and Chapkin RS, 1998. Importance of dietary gamma-linolenic acid in human health and nutrition. *J Nutr*, 128, 1411-1414.
- 4 Fukushima M, Matsuda T, Yamagishi K, Nakano M, 1997. Comparative hypocholesterolemic effects of six dietary oils in cholesterol-fed rats after long-term feeding. *Lipids*, 32, 1069-1074.
- 5 Granlund H, 2002. Treatment of childhood eczema. *Paediatr Drugs*, 4, 729-735.
- 6 Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton FH, 1997. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. *J Nutr*, 127, 1435-1444.
- 7 Leventhal LJ, Boyce EG, Zurier RB, 1993. Treatment of rheumatoid arthritis with gammalinolenic acid. *Ann Intern Med*, 119, 867-873.
- 8 Rothman D, DeLuca P, Zurier RB, 1995. Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. *Semin Arthritis Rheum*, 25, 87-96.
- 9 Soeken KL, Miller SA, Ernst E, 2003. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. *Rheumatology (Oxford)*, 42, 652-659.
- 10 Vassilopoulos D, Zurier RB, Rossetti RG, Tsokos GC, 1997. Gammalinolenic acid and dihomogammalinolenic acid suppress the CD3-mediated signal transduction pathway in human T cells. *Clin Immunol Immunopathol*, 83, 237-244.
- 11 Yoon S, Lee J, Lee S, 2002. The therapeutic effect of evening primrose oil in atopic dermatitis patients with dry scaly skin lesions is associated with the normalization of serum gamma-interferon levels. *Skin Pharmacol Appl Skin Physiol*, 15, 20-25.

ID 2662: “Evening primrose oil (*Oenothera biennis*) contains gamalinolenic acid” and “helps to keep normal blood pressure”

- 1 Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R, 1997. Premenstrual symptoms in general practice patients. Prevalence and treatment. *J Reprod Med*, 42, 637-646.

- 2 Das U, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P, 1998. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? *Prostaglandins Leukot Essent Fatty Acids*, 58, 39-54.
- 3 Fan YY and Chapkin RS, 1998. Importance of dietary gamma-linolenic acid in human health and nutrition. *J Nutr*, 128, 1411-1414.
- 4 Fukushima M, Matsuda T, Yamagishi K, Nakano M, 1997. Comparative hypocholesterolemic effects of six dietary oils in cholesterol-fed rats after long-term feeding. *Lipids*, 32, 1069-1074.
- 5 Granlund H, 2002. Treatment of childhood eczema. *Paediatr Drugs*, 4, 729-735.
- 6 Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton FH, 1997. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. *J Nutr*, 127, 1435-1444.
- 7 Leventhal LJ, Boyce EG, Zurier RB, 1993. Treatment of rheumatoid arthritis with gammalinolenic acid. *Ann Intern Med*, 119, 867-873.
- 8 Rothman D, DeLuca P, Zurier RB, 1995. Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. *Semin Arthritis Rheum*, 25, 87-96.
- 9 Soeken KL, Miller SA, Ernst E, 2003. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. *Rheumatology (Oxford)*, 42, 652-659.
- 10 Vassilopoulos D, Zurier RB, Rossetti RG, Tsokos GC, 1997. Gammalinolenic acid and dihomogammalinolenic acid suppress the CD3-mediated signal transduction pathway in human T cells. *Clin Immunol Immunopathol*, 83, 237-244.
- 11 Yoon S, Lee J, Lee S, 2002. The therapeutic effect of evening primrose oil in atopic dermatitis patients with dry scaly skin lesions is associated with the normalization of serum gamma-interferon levels. *Skin Pharmacol Appl Skin Physiol*, 15, 20-25.

ID 2663: “extract of guarana (*Paullinia cupana*)” and “natural antioxidant”

- 1 Andersen T and Fogh J, 2001. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. *J Hum Nutr Diet*, 14, 243-250.
- 2 Espinola EB, Dias RF, Mattei R, Carlini EA, 1997. Pharmacological activity of Guarana (*Paullinia cupana* Mart.) in laboratory animals. *J Ethnopharmacol*, 55, 223-229.
- 3 Galduroz JC and Carlini Ede A, 1994. Acute effects of the *Paulinia cupana*, "Guarana" on the cognition of normal volunteers. *Sao Paulo Med J*, 112, 607-611.
- 4 Galduroz JC and Carlini EA, 1996. The effects of long-term administration of guarana on the cognition of normal, elderly volunteers. *Sao Paulo Med J*, 114, 1073-1078.
- 5 Lima WP, Carnevali LC, Jr., Eder R, Costa Rosa LF, Bacchi EM, Seelaender MC, 2005. Lipid metabolism in trained rats: effect of guarana (*Paullinia cupana* Mart.) supplementation. *Clin Nutr*, 24, 1019-1028.
- 6 Mattei R, Dias RF, Espinola EB, Carlini EA, Barros SB, 1998. Guarana (*Paullinia cupana*): toxic behavioral effects in laboratory animals and antioxidants activity in vitro. *J Ethnopharmacol*, 60, 111-116.
- 7 Santa Maria A, Lopez A, Diaz MM, Munoz-Mingarro D, Pozuelo JM, 1998. Evaluation of the toxicity of guarana with in vitro bioassays. *Ecotoxicol Environ Saf*, 39, 164-167.

ID 2664: “green tea extract (*Camelia sinensis*)” and “natural antioxidant”

- 1 Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM, 2004. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. *J Pharmacol Exp Ther*, 308, 767-773.
- 2 Hamblin T, 2005. Natural products and the treatment of leukemia. *Leuk Res*, 30, 649-650.

- 3 Kazi A, Smith DM, Daniel K, Zhong S, Gupta P, Bosley ME, Dou QP, 2002. Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. *In Vivo*, 16, 397-403.
- 4 Kemberling JK, Hampton JA, Keck RW, Gomez MA, Selman SH, 2003. Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. *J Urol*, 170, 773-776.
- 5 Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC, Zhao J, 2003. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. *Arch Intern Med*, 163, 1448-1453.
- 6 Moyers SB and Kumar NB, 2004. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. *Nutr Rev*, 62, 204-211.
- 7 Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J, 2005. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. *J Neurosci*, 25, 8807-8814.
- 8 Skrzydlewska E, Ostrowska J, Farbiszewski R, Michalak K, 2002. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. *Phytomedicine*, 9, 232-238.
- 9 Yokozawa T, Nakagawa T, Kitani K, 2002. Antioxidative activity of green tea polyphenol in cholesterol-fed rats. *J Agric Food Chem*, 50, 3549-3552.

ID 2665: “Mucuna pruriens” and “Metabolism of testosterone”

- 1 Ahmad MK, Mahdi AA, Shukla KK, Islam N, Jaiswar SP, Ahmad S, 2008. Effect of *Mucuna pruriens* on semen profile and biochemical parameters in seminal plasma of infertile men. *Fertil Steril*, 90, 627-635.
- 2 Misra L and Wagner H, 2007. Extraction of bioactive principles from *Mucuna pruriens* seeds. *Indian J Biochem Biophys*, 44, 56-60.

ID 2668: “Extract of olive leaves (oleuropein)” and “natural antioxidant protect organism from oxidative damage powerful antioxidants beneficial to human health”

- 1 Al-Azzawie HF and Alhamdani MS, 2006. Hypoglycemic and antioxidant effect of oleuropein in alloxan-diabetic rabbits. *Life Sci*, 78, 1371-1377.
- 2 Andreadou I, Iliodromitis EK, Mikros E, Constantinou M, Agalias A, Magiatis P, Skaltsounis AL, Kamber E, Tsantili-Kakoulidou A, Kremastinos DT, 2006. The olive constituent oleuropein exhibits anti-ischemic, antioxidative, and hypolipidemic effects in anesthetized rabbits. *J Nutr*, 136, 2213-2219.
- 3 Hamdi HK and Castellon R, 2005. Oleuropein, a non-toxic olive iridoid, is an anti-tumor agent and cytoskeleton disruptor. *Biochem Biophys Res Commun*, 334, 769-778.
- 4 Khayyal MT, el-Ghazaly MA, Abdallah DM, Nassar NN, Okpanyi SN, Kreuter MH, 2002. Blood pressure lowering effect of an olive leaf extract (*Olea europaea*) in L-NAME induced hypertension in rats. *Arzneimittelforschung*, 52, 797-802.
- 5 Micol V, Caturla N, Perez-Fons L, Mas V, Perez L, Estepa A, 2005. The olive leaf extract exhibits antiviral activity against viral haemorrhagic septicaemia rhabdovirus (VHSV). *Antiviral Res*, 66, 129-136.
- 6 Puel C, Quintin A, Agalias A, Mathey J, Obled C, Mazur A, Davicco MJ, Lebecque P, Skaltsounis AL, Coxam V, 2004. Olive oil and its main phenolic micronutrient (oleuropein) prevent inflammation-induced bone loss in the ovariectomised rat. *Br J Nutr*, 92, 119-127.
- 7 Turner R, Etienne N, Alonso MG, de Pascual-Teresa S, Minihane AM, Weinberg PD, Rimbach G, 2005. Antioxidant and anti-atherogenic activities of olive oil phenolics. *Int J Vitam Nutr Res*, 75, 61-70.
- 8 Visioli F, Bellosta S, Galli C, 1998. Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages. *Life Sci*, 62, 541-546.

- 9 Visioli F and Galli C, 2002. Biological properties of olive oil phytochemicals. *Crit Rev Food Sci Nutr*, 42, 209-221.

ID 2672: “Ginseng, extract from root” and “Effective substances, ginsenosides”

- 1 Bahrke MS and Morgan WR, 2000. Evaluation of the ergogenic properties of ginseng: an update. *Sports Med*, 29, 113-133.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 5 Bucci LR, 2000. Selected herbals and human exercise performance. *Am J Clin Nutr*, 72, 624S-636S.
- 6 Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ, 2006. Systematic review of the effects of ginseng on cardiovascular risk factors. *Ann Pharmacother*, 40, 83-95.
- 7 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 8 Coleman CI, Hebert JH, Reddy P, 2003. The effects of Panax ginseng on quality of life. *J Clin Pharm Ther*, 28, 5-15.
- 9 Commissie Keuring Fytproducten, 2007. Master file Ginseng Radix.
- 10 Coon JT and Ernst E, 2002. Panax ginseng: a systematic review of adverse effects and drug interactions. *Drug Saf*, 25, 323-344.
- 11 Council of Europe, *European Pharmacopoeia*.
- 12 Delgoda R and Westlake AC, 2004. Herbal interactions involving cytochrome p450 enzymes: a mini review. *Toxicol Rev*, 23, 239-249.
- 13 EBSCO CAM Review Board, 2006. Ginseng.
- 14 Engels HJ, Fahlman MM, Wirth JC, 2003. Effects of ginseng on secretory IgA, performance, and recovery from interval exercise. *Med Sci Sports Exerc*, 35, 690-696.
- 15 Ernst E, 2002. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. *Ann Intern Med*, 136, 42-53.
- 16 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 17 Fulder S, 2002. *O ženšenu*. Pragma, Prague.
- 18 Glenn MB and Lexell J, 2003. Ginseng. *J Head Trauma Rehabil*, 18, 196-200.
- 19 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY, 2002. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. *Clin Pharmacol Ther*, 72, 276-287.
- 20 He N and Edeki T, 2004. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. *Am J Ther*, 11, 206-212.
- 21 Helms S, 2004. Cancer prevention and therapeutics: Panax ginseng. *Altern Med Rev*, 9, 259-274.
- 22 Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S, 2005. Herb-drug interactions: a literature review. *Drugs*, 65, 1239-1282.
- 23 Ioannides C, 2002. Pharmacokinetic interactions between herbal remedies and medicinal drugs. *Xenobiotica*, 32, 451-478.

- 24 Izzo AA, Di Carlo G, Borrelli F, Ernst E, 2005. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. *Int J Cardiol*, 98, 1-14.
- 25 Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ, 2004. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol*, 57, 592-599.
- 26 Kakizoe T, 2000. Asian studies of cancer chemoprevention: latest clinical results. *Eur J Cancer*, 36, 1303-1309.
- 27 Kameníková D, 2000. *Zdravotnické noviny*
- 28 Kaneko H and Nakanishi K, 2004. Proof of the mysterious efficacy of ginseng: basic and clinical trials: clinical effects of medical ginseng, korean red ginseng: specifically, its anti-stress action for prevention of disease. *J Pharmacol Sci*, 95, 158-162.
- 29 Kennedy DO and Scholey AB, 2003a. Ginseng: potential for the enhancement of cognitive performance and mood. *Pharmacol Biochem Behav*, 75, 687-700.
- 30 Kennedy DO, Scholey AB, Drewery L, Marsh VR, Moore B, Ashton H, 2003b. Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. *Pharmacol Biochem Behav*, 75, 701-709.
- 31 Kennedy DO, Haskell CF, Wesnes KA, Scholey AB, 2004. Improved cognitive performance in human volunteers following administration of guarana (*Paullinia cupana*) extract: comparison and interaction with Panax ginseng. *Pharmacol Biochem Behav*, 79, 401-411.
- 32 Kiefer D and Pantuso T, 2003. Panax ginseng. *Am Fam Physician*, 68, 1539-1542.
- 33 Kim SH and Park KS, 2003. Effects of Panax ginseng extract on lipid metabolism in humans. *Pharmacol Res*, 48, 511-513.
- 34 Kim SH, Park KS, Chang MJ, Sung JH, 2005. Effects of Panax ginseng extract on exercise-induced oxidative stress. *J Sports Med Phys Fitness*, 45, 178-182.
- 35 Lee TK, Johnke RM, Allison RR, O'Brien KF, Dobbs LJ, Jr., 2005. Radioprotective potential of ginseng. *Mutagenesis*, 20, 237-243.
- 36 Liu JP, Yang M, Du XM, 2004. Herbal medicines for viral myocarditis. *Cochrane Database Syst Rev*, CD003711.
- 37 McGuffin M, Hobbs C, Upton R, Goldberg A, 1997. Botanical safety handbook. American Herbal Products Association. CRC Press, Boca Raton.
- 38 MedlinePlus, Ginseng (American ginseng, Asian ginseng, Chinese ginseng, Korean red ginseng, Panax ginseng: Panax spp., including *P. ginseng* C.C. Meyer and *P. quinquefolius* L., excluding *Eleutherococcus senticosus*), <http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-ginseng.html>.
- 39 Reay JL, Kennedy DO, Scholey AB, 2005. Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity. *J Psychopharmacol*, 19, 357-365.
- 40 Schwenk TL and Costley CD, 2002. When food becomes a drug: nonanabolic nutritional supplement use in athletes. *Am J Sports Med*, 30, 907-916.
- 41 Shin HR, Kim JY, Yun TK, Morgan G, Vainio H, 2000. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. *Cancer Causes Control*, 11, 565-576.
- 42 Sparreboom A, Cox MC, Acharya MR, Figg WD, 2004. Herbal remedies in the United States: potential adverse interactions with anticancer agents. *J Clin Oncol*, 22, 2489-2503.
- 43 UMMC (University of Maryland Medical Centre), Asian Ginseng.
- 44 Vaes LP and Chyka PA, 2000. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. *Ann Pharmacother*, 34, 1478-1482.

- 45 Vogler BK, Pittler MH, Ernst E, 1999. The efficacy of ginseng. A systematic review of randomised clinical trials. *Eur J Clin Pharmacol*, 55, 567-575.
- 46 Vuksan V and Sievenpiper JL, 2005. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. *Nutr Metab Cardiovasc Dis*, 15, 149-160.
- 47 WHO (World Health Organization), 2002. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.
- 48 Wichtl M, 1994. *Herbal Drugs and Phytopharmaceuticals*. Medpharm, Stuttgart.
- 49 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 50 Xie JT, McHendale S, Yuan CS, 2005. Ginseng and diabetes. *Am J Chin Med*, 33, 397-404.
- 51 Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS, 2003. Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care*, 26, 1277-1294.
- 52 Yun TK, 2001. Panax ginseng--a non-organ-specific cancer preventive? *Lancet Oncol*, 2, 49-55.
- 53 Yun TK, 2003. Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. *Mutat Res*, 523-524, 63-74.
- 54 Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen CJ, 2004. Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. *Med Sci Monit*, 10, RA187-192.

ID 2673: “Ginseng, extract from root” and “Acting as antioxidants”

- 1 Fulder S, 2002. *O ženšenu*. Pragma, Prague.
- 2 Kameníková D, 2000. *Zdravotnické noviny*

ID 2674: “Eucalyptol” and “Antiseptic properties”

- 1 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 3 Cermelli C, Fabio A, Fabio G, Quaglio P, 2008. Effect of eucalyptus essential oil on respiratory bacteria and viruses. *Curr Microbiol*, 56, 89-92.
- 4 Cimanga K, Kambu K, Tona L, Apers S, De Bruyne T, Hermans N, Totte J, Pieters L, Vlietinck AJ, 2002. Correlation between chemical composition and antibacterial activity of essential oils of some aromatic medicinal plants growing in the Democratic Republic of Congo. *J Ethnopharmacol*, 79, 213-220.
- 5 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 6 Grassmann J, Hippeli S, Dornisch K, Rohnert U, Beuscher N, Elstner EF, 2000. Antioxidant properties of essential oils. Possible explanations for their anti-inflammatory effects. *Arzneimittelforschung*, 50, 135-139.
- 7 Hoppe HA, 1977. *Eucalyptus*. In: *Drogenkunde*. Ealter de Gruyter & Co, Berlin.
- 8 Juergens UR, Stober M, Vetter H, 1998. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro. *Eur J Med Res*, 3, 508-510.
- 9 Lu XQ, Tang FD, Wang Y, Zhao T, Bian RL, 2004. [Effect of Eucalyptus globulus oil on lipopolysaccharide-induced chronic bronchitis and mucin hypersecretion in rats]. *Zhongguo Zhong Yao Za Zhi*, 29, 168-171.

- 10 Reynolds JEF, 1993. Martindale: The Extra Pharmacopoeia. The Pharmaceutical Press, London.
- 11 Salari MH, Amine G, Shirazi MH, Hafezi R, Mohammadypour M, 2006. Antibacterial effects of Eucalyptus globulus leaf extract on pathogenic bacteria isolated from specimens of patients with respiratory tract disorders. Clin Microbiol Infect, 12, 194-196.
- 12 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- 13 WHO (World Health Organization), 1999. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.
- 14 Wichtl M, 2004. Herbal Drugs and Phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart.

ID 2675: “Menthol” and “Influence of nasal airflow”

- 1 Eccles R, Jawad MS, Morris S, 1990. The effects of oral administration of (-)-menthol on nasal resistance to airflow and nasal sensation of airflow in subjects suffering from nasal congestion associated with the common cold. J Pharm Pharmacol, 42, 652-654.

ID 2676: “Ginseng ” and “Erection”

- 1 Choi HK, Seong DH, Rha KH, 1995. Clinical efficacy of Korean red ginseng for erectile dysfunction. Int J Impot Res, 7, 181-186.
- 2 Choi YD, Rha KH, Choi HK, 1999. In vitro and in vivo experimental effect of Korean red ginseng on erection. J Urol, 162, 1508-1511.
- 3 de Andrade E, de Mesquita AA, Claro Jde A, de Andrade PM, Ortiz V, Paranhos M, Srougi M, 2007. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian J Androl, 9, 241-244.
- 4 Hong B, Ji YH, Hong JH, Nam KY, Ahn TY, 2002. A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol, 168, 2070-2073.
- 5 Murphy LL and Lee TJ, 2002. Ginseng, sex behavior, and nitric oxide. Ann NY Acad Sci, 962, 372-377.
- 6 Salvati G, Genovesi G, Marcellini L, Paolini P, De Nuccio I, Pepe M, Re M, 1996. Effects of Panax Ginseng C.A. Meyer saponins on male fertility. Panminerva Med, 38, 249-254.

ID 2677: “Elder Flower (Sambucus nigra)” and “Supports body’s renal elimination of water”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. Les plantes dans la thérapeutique moderne. Maloine, Paris.
- 2 BHMA (British Herbal Medicine Association), 1996. British Herbal Pharmacopoeia. British Herbal Medicine Association, Exeter.
- 3 Bradley P, 1992. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Leclerc H, 1994. Précis de phytothérapie. Masson, Paris.
- 7 WHO (World Health Organization), 2005. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.
- 8 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2680: “Valerian-hops combination (*Humulus lupulus*, *Valeriana officinalis*)” and “Sleep”

- 1 Bent S, Padula A, Moore D, Patterson M, Mehling W, 2006. Valerian for sleep: a systematic review and meta-analysis. *Am J Med*, 119, 1005-1012.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, 1975. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 3 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 4 BHMA (British Herbal Medicine Association), 1983. *British Herbal Pharmacopoeia*. Bournemouth British Herbal Medicine Association, Exeter.
- 5 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 6 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 7 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 8 Bradley P, 1992. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 9 Brendler T, Gruenwald J, Jaenicke C, 1997. *Herbal Remedies: Heilpflanzen*. Deutscher Apotheker Verlag, Stuttgart.
- 10 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 11 Cahier de l'Agence, 1998. *Médicaments à base de plantes: Cahiers de l'Agence no 3*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 12 Cerny A and Schmid K, 1999. Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study). *Fitoterapia*, 70, 221-228.
- 13 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 14 Fernandez S, Wasowski C, Paladini AC, Marder M, 2004. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from *Valeriana officinalis*. *Pharmacol Biochem Behav*, 77, 399-404.
- 15 Garnier G, Bézanger-Beauquesne L, Debraux G, Souèges R, Dol G, 1961. *Ressources médicinales de la flore française*. Vigot, Paris.
- 16 Gerhard U, Linnenbrink N, Georghiadou C, Hobi V, 1996. [Vigilance-decreasing effects of 2 plant-derived sedatives]. *Praxis (Bern 1994)*, 85, 473-481.
- 17 Leung AY and Foster S, 1996. *Encyclopedia of common natural ingredients used in food, drugs, and cosmetics*. John Wiley & Sons, New York.
- 18 Morin CM, Koetter U, Bastien C, Ware JC, Wooten V, 2005. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. *Sleep*, 28, 1465-1471.
- 19 Paris R and Myose H, 1981. *Précis de Matière Médicale, Tome II, Pharmacognosie spéciale*. Masson, Paris.
- 20 Rombi M, 1991. *Cent plantes médicinales*. Romart, Nice.
- 21 Schellenberg R, Sauer S, Abourashed EA, Koetter U, Brattstrom A, 2004. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. *Planta Med*, 70, 594-597.
- 22 Schmitz M and Jackel M, 1998. [Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valerian preparation and a benzodiazepine drug]. *Wien Med Wochenschr*, 148, 291-298.

- 23 Schwander J and Mann C, 1999. The pupil unrest index as a measure of sleep restoration in patients with psychophysiological insomnia.
- 24 Valnet J, 1976. Phytothérapie. Traitement des maladies par les plantes. Maloine, Paris.
- 25 Van Hellemont J, 1986. Compendium de phytothérapie. Association Pharmaceutique Belge, Bruxelles.
- 26 Vonderheid-Guth B, Todorova A, Brattstrom A, Dimpfel W, 2000. Pharmacodynamic effects of valerian and hops extract combination (Ze 91019) on the quantitative-topographical EEG in healthy volunteers. Eur J Med Res, 5, 139-144.
- 27 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 28 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.
- 29 Wren RC, 1975. Potter's new cyclopaedia of botanical drugs and preparations. Health Science Press, Saffron Walden.

ID 2681: “Caraway fruit (*Carum carvi*)” and “Spasmolytic effect”

- 1 BHMA (British Herbal Medicine Association), 1996. British Herbal Pharmacopoeia. British Herbal Medicine Association, Exeter.
- 2 Bisset NG and Wichtl M, 2001. Herbal Drugs and Phytopharmaceuticals Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 3 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 7 Forster HB, Niklas H, Lutz S, 1980. Antispasmodic effects of some medicinal plants. Planta Med, 40, 309-319.
- 8 Teuscher E, Anton R, Lobstein A, Plantes aromatiques: épices, aromates, condiments et huiles essentielles. Tec & Doc Lavoisier; Ed. médicales internationales.
- 9 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2684: “Aniseed (*Pimpinella anisum*)” and “Stimulates secretion of all glands, including lacteal ones”

- 1 Bruckner C, 1989. [Use and value of common European lactation-promoting medicinal plants (galactagogues)]. Padiatr Grenzgeb, 28, 403-410.
- 2 Hiller K and Melzig MF, 2003. Lexikon der Arzneipflanzen und Drogen. Spektrum Akademischer Verlag, Heidelberg.
- 3 Hoppe HA, 1977. Drogenkunde. Ealter de Gruyter & Co, Berlin.
- 4 Schönfelder I and Schönfelder P, 2004. Das neue Handbuch der Heilpflanzen: Botanik, Arzneidrogen, Wirkstoffe, Anwendungen Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 5 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2687: “Common Thyme (*Thymus vulgaris*, *Thymus zygis*)” and “Supports secretion of mucus in the upper respiratory tract”

- 1 WHO (World Health Organization), 1999. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.

ID 2690: “Lime Tree (*Tilia cordata*, *Tilia platyphyllos*)” and “Supports expectoration”

- 1 Bradley P, 1992. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.

ID 2691: “Lime Tree (*Tilia cordata*, *Tilia platyphyllos*)” and “Supports body’s renal elimination of water”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.

ID 2692: “Fennel (*Foeniculum vulgare*)” and “Spasmolytic and carminative effect”

- 1 Alexandrovich I, Rakovitskaya O, Kolmo E, Sidorova T, Shushunov S, 2003. The effect of fennel (*Foeniculum Vulgare*) seed oil emulsion in infantile colic: a randomized, placebo-controlled study. *Altern Ther Health Med*, 9, 58-61.
- 2 Billore KV, Yelne MB, Dennis TJ, Chaudhari BG, 2005. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 3 Birdane FM, Cemek M, Birdane YO, Gulcin I, Buyukokuroglu ME, 2007. Beneficial effects of *Foeniculum vulgare* on ethanol-induced acute gastric mucosal injury in rats. *World J Gastroenterol*, 13, 607-611.
- 4 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 5 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 6 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 7 Bruckner C, 1989. Anwendung und Wert in Europa gebräuchlicher lactationsfordernder Heilpflanzen (*Galactogoga*). *Padiatr. Grenzgeb.*, 28, 403-410.
- 8 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 9 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 10 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 11 Franke W, 1997. *Nutzpflanzenkunde*. Thieme, Stuttgart.
- 12 Gogte VVM, 2000. *Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants*. Bharatiya Vidya Bhavan, Mumbai.
- 13 Indian Ministry of Health and Family Welfare, 2001. *The Ayurvedic Pharmacopoeia of India*. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 14 Kapoor LD, 1990. *Handbook of Ayurvedic Medicinal Plants*. CRC Press, Boca Raton.

- 15 Kwon YS, Choi WG, Kim WJ, Kim WK, Kim MJ, Kang WH, Kim CM, 2002. Antimicrobial constituents of *Foeniculum vulgare*. *Arch Pharm Res*, 25, 154-157.
- 16 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 17 Savino F, Cresi F, Castagno E, Silvestro L, Oggero R, 2005. A randomized double-blind placebo-controlled trial of a standardized extract of *Matricariae recutita*, *Foeniculum vulgare* and *Melissa officinalis* (ColiMil) in the treatment of breastfed colicky infants. *Phytother Res*, 19, 335-340.
- 18 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 19 Weizman Z, Alkrinawi S, Goldfarb D, Bitran C, 1993. Efficacy of herbal tea preparation in infantile colic. *J Pediatr*, 122, 650-652.
- 20 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2694: “German Chamomile (*Matricaria/Chamomills recutita* L.)” and “Spasmolytic effect”

- 1 Bradley P, 1992. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 2 Carle R and Gomaa K, 1992. Chamomile: a pharmacological and clinical profile. *Drugs of today*, 28, 559–565.
- 3 Savino F, Cresi F, Castagno E, Silvestro L, Oggero R, 2005. A randomized double-blind placebo-controlled trial of a standardized extract of *Matricariae recutita*, *Foeniculum vulgare* and *Melissa officinalis* (ColiMil) in the treatment of breastfed colicky infants. *Phytother Res*, 19, 335-340.
- 4 Weizman Z, Alkrinawi S, Goldfarb D, Bitran C, 1993. Efficacy of herbal tea preparation in infantile colic. *J Pediatr*, 122, 650-652.

ID 2696: “Peppermint (*Mentha piperita*)” and “Carminative effect”

- 1 Aktug SE and Karapinar M, 1986. Sensitivity of some common food-positioning bacteria to thyme, mint and bay leaves. *International Journal of Food Microbiology*, 3, 349-354.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Bradley P, 1993. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 4 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 5 Harries N, James KC, Pugh WK, 1977. Antifoaming and Carminative Actions of Volatile Oils. *Journal of Clinical Pharmacy and Therapeutics*, 2, 171-177.
- 6 McKay DL and Blumberg JB, 2006. A review of the bioactivity and potential health benefits of peppermint tea (*Mentha piperita* L.). *Phytother Res*, 20, 619-633.
- 7 WHO (World Health Organization), 2002. *WHO Monographs on Selected Medicinal Plants*. WHO (World Health Organization), Geneva.

ID 2699: “Goat’s rue (*Galega officinalis*)” and “Supports activity of lacteal glands”

- 1 Typl H, 1961 The galactagogue effect of *Galega officinalis*. *Zentralbl Gynakol*, 83, 713-716

ID 2701: “Chicory (*Cichorium intybus* L.)” and “Urinary elimination”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. Les plantes dans la thérapeutique moderne. Maloine, Paris.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Boullard B, 2001. Plantes médicinales du monde: croyances et réalités. Estem, Paris.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- 7 Garnier G, Bézanger-Beauquesne L, Debraux G, Souèges R, Dol G, 1961. Ressources médicinales de la flore française. Vigot, Paris.
- 8 Girre L, 2001. Les plantes et les médicaments: L'origine végétale de nos médicaments. Delachaux et Niestlé, Lausanne.
- 9 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 10 Leclerc H, 1976. Précis de phytothérapie. Essais de thérapeutique par les plantes françaises. Masson, Paris.
- 11 Leung AY and Foster S, 1996. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. John Wiley & Sons, New York.
- 12 Loeper M and Lesure J, 1960. Formulaire pratique de thérapeutique et de pharmacologie. Doin, Paris.
- 13 Roberfroid MB, 1999. Concepts in functional foods: the case of inulin and oligofructose. *J Nutr*, 129, 1398S-1401S.
- 14 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? *Am J Clin Nutr*, 71, 1682S-1687S; discussion 1688S-1690S.
- 15 Thom E, 2000. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. *J Int Med Res*, 28, 229-233.
- 16 Van Hellemont J, 1986. Compendium de Phytothérapie. Association Pharmaceutique Belge, Bruxelles.
- 17 Wren RC Potters, 1988. Potter's New Cyclopaedia of Botanical Drugs and Preparations. C.W. Daniel, Saffron Walden.

ID 2702: “Chicory (*Cichorium intybus* L.)” and “Slimming aid/ Weight control”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Roberfroid MB, 1999. Concepts in functional foods: the case of inulin and oligofructose. *J Nutr*, 129, 1398S-1401S.
- 4 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? *Am J Clin Nutr*, 71, 1682S-1687S; discussion 1688S-1690S.
- 5 Thom E, 2000. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. *J Int Med Res*, 28, 229-233.

ID 2703: “Carob (*Ceratonia siliqua* L.)” and “Satiety/ weight control”

- 1 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 2 Corcoran MR, 1966. Reduction of alpha-Amylase by an Inhibitor from Carob. *Plant Physiol*, 41, 1265-1267.
- 3 Couplan F, 1998. Le guide nutritionnel des plantes sauvages et cultivées. Delachaux et Niestlé, Lausanne (Suisse).
- 4 Hulshof T, De Graaf C, Weststrate JA, 1993. The effects of preloads varying in physical state and fat content on satiety and energy intake. *Appetite*, 21, 273-286.
- 5 Ollier C, 2001. Minceur et Phytothérapie. *Le Moniteur des Pharmacies et des Laboratoires Cahier Conseil II* du n°2393, 51, 1-16.
- 6 Videment E, 2006 Minceur et compléments alimentaires. *Le Moniteur des Pharmacies et des Laboratoires. Cahier Conseil II* du n°2626, 78, 1-15.

ID 2704 : “Artichoke (leaf) *Cynara scolymus*” and “Health of lower urinary tract”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 2 Boni U and Patri G, 1977. *Scoprire, riconoscere, usare le Erbe*. Fabbri Editori, Milano.
- 3 Bradley P, 2006. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 4 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Capasso F, Gaginella TS, Grandolini G, Izzo AA, 2003. *Phytotherapy: a quick reference to herbal medicine*. Springer, Berlin.
- 7 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 8 Paris RR and Myose H, 1971. *Précis de matière Médicale, Tome III*. Masson, Paris.

ID 2705: “Cherry Peduncle. *Prunus avium*, *Prunus cerasus*” and “Health of lower urinary tract”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 3 Boni U and Patri G, 1977. *Scoprire, Riconoscere, Usare le Erbe*. Fabbri Editori, Milano.
- 4 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 7 Leclerc H, 1983. *Precis de Phytotherapie*. Masson, Paris.
- 8 Lievre H, 1980. Les thérapeutiques végétales de l'appareil urinaire. *La revue du jeune médecin*, 50, 91-107.
- 9 Loeper M and Lesure J, 1960. *Formulaire pratique de thérapeutique et de pharmacologie*. Doin, Paris.
- 10 Olivier JF, 60 fruits et légumes qui guérissent. *La vie Médicale*, 40.

- 11 Paris R and Myose H, 1976. Précis de Matière Médicale. Masson, Paris.
- 12 Scimeca D and Tétau M, 2006. Le Guide de Phytothérapie. La santé par les plantes. Alpen, Monaco.
- 13 Videment E, 2006. Minceur et compléments alimentaires. Cahier Conseil II du n°2626, 1-13.

ID 2707: “Guarana (seed) Paullinia cupana” and “Weight control and fat metabolism”

- 1 Andersen T and Fogh J, 2001. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. *J Hum Nutr Diet*, 14, 243-250.
- 2 Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J, 1990. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. *Am J Clin Nutr*, 51, 759-767.
- 3 Astrup A, Toubro S, Cannon S, Hein P, Madsen J, 1991. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. *Metabolism*, 40, 323-329.
- 4 Belza A, Frandsen E, Kondrup J, 2007. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. *Int J Obes (Lond)*, 31, 121-130.
- 5 Belza A, Toubro S, Astrup A, 2009. The effect of caffeine, green tea and tyrosine on thermogenesis and energy intake. *Eur J Clin Nutr*, 63, 57-64.
- 6 Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL, 2001. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. *Int J Obes Relat Metab Disord*, 25, 316-324.
- 7 Boullard B, 2001. Plantes médicinales du monde: Réalités & Croyances. Estem.
- 8 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 9 Cahier de l'Agence, 1998. Médicaments à base de plantes: Cahiers de l'Agence no 3. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 10 Capasso F, Gaginella TS, Grandolini G, Izzo AA, 2003. Phytotherapy: a quick reference to herbal medicine. Springer.
- 11 Carlini EA, 2003. Plants and the central nervous system. *Pharmacol Biochem Behav*, 75, 501-512.
- 12 Couturier C, Janvier B, Girlich D, Bereziat G, Andreani-Mangeney M, 1998. Effects of caffeine on lipoprotein lipase gene expression during the adipocyte differentiation process. *Lipids*, 33, 455-460.
- 13 Fallet C, 1994. Cellulite et amincissement. *Le Moniteur des Pharmacies*, 2073, 1-8.
- 14 Greenway FL, 2001. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. *Obes Rev*, 2, 199-211.
- 15 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 16 Henry A, 1998. Mince pour être belle et bien dans sa peau. *Le Trébuchet*, 179, 15-26.
- 17 Kobayashi-Hattori K, Mogi A, Matsumoto Y, Takita T, 2005. Effect of caffeine on the body fat and lipid metabolism of rats fed on a high-fat diet. *Bioscience, biotechnology, and biochemistry*, 69, 2219-2223.
- 18 Leung AY and Foster S, 1996. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. John Wiley & Sons, New York.
- 19 Lima WP, Carnevali LC, Jr., Eder R, Costa Rosa LF, Bacchi EM, Seelaender MC, 2005. Lipid metabolism in trained rats: effect of guarana (*Paullinia cupana* Mart.) supplementation. *Clin Nutr*, 24, 1019-1028.
- 20 Mason P, 2001. Dietary Supplements. Pharmaceutical Press, London.
- 21 Morelli V and Zoorob RJ, 2000. Alternative therapies: Part I. Depression, diabetes, obesity. *Am Fam Physician*, 62, 1051-1060.

- 22 Moro CO and Basile G, 2000. Obesity and medicinal plants. *Fitoterapia*, 71 Suppl 1, S73-82.
- 23 Ollier C, 2001. Minceur et phytothérapie. *Le Moniteur des Pharmacies*, 2393.
- 24 Roberts AT, de Jonge-Levitan L, Parker CC, Greenway F, 2005. The effect of an herbal supplement containing black tea and caffeine on metabolic parameters in humans. *Altern Med Rev*, 10, 321-325.
- 25 Roux D, 2005. *Les nouvelles plantes qui soignent*. Editions Alpen.
- 26 Videment E, 2006. Minceur et compléments alimentaires. *Le Moniteur des Pharmacies et des Laboratoires. Cahier Conseil II no 2626*, 51, 1-13.
- 27 Westerterp-Plantenga MS, Lejeune MP, Kovacs EM, 2005. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. *Obes Res*, 13, 1195-1204.
- 28 Wichtl M and Anton R, 1999. *Plantes thérapeutiques : tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 29 Wichtl M and Anton R, 2003. *Plantes thérapeutiques : tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 30 Wichtl M, 2004. *Herbal Drugs and Phytopharmaceuticals*. Medpharm Scientific Publishers, Stuttgart.

ID 2708: “Heather (blossoming top). *Calluna vulgaris*” and “Health of lower urinary tract”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Rapport allégations plantes du 27 février 2003.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 3 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1990. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 4 Boni U and Patri G, 1986. *Scoprire, Riconoscere, Usare le Erbe*. Fabbri Editori, Milano.
- 5 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 6 Cahiers de l'Agence, 1997. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 7 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 8 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 9 Paris RR and Myose H, 1971. *Précis de matière Médicale*. Masson, Paris.
- 10 Valnet J, 1983. *Phytothérapie. Traitement des maladies par les plantes*. Livre de Poche / Maloine, Paris.
- 11 Van Hellemont J, 1986. *Compendium de Phytothérapie*. Association Pharmaceutique Belge, Bruxelles.

ID 2709: “Mallow (leaf and flower) *Malva sylvestris*” and “Pharyngeal health / Softening throat”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 2 Blumenthal M, 1988. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 3 Boni U and Patri G, 1997. *Scoprire, riconoscere, usare le erbe*. Gulliver libri.
- 4 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.

- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Capasso F, Gaginella TS, Grandolini G, Izzo AA, 2003. Phytotherapy: a quick reference to herbal medicine. Springer.
- 7 Dorvault FLM, 1850. L'Officine ou Répertoire général de pharmacie pratique. Labé, Paris.
- 8 Paris R and Myose H, 1981. Précis de Matière Médicale, Tome II, Pharmacognosie spéciale. Masson, Paris.
- 9 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2710: “Papaya (leaf) *Carica papaya*” and “Body fat reduction”

- 1 Blumenthal M, 1987. Papaya leaf. In: The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 3 Dorvault F, 1995. Papaye. In: L'officine. Vigot, Paris, 1204.
- 4 Leung AY and Foster S, 1996. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. John Wiley & Sons, New York.
- 5 Moro CO and Basile G, 2000. Obesity and medicinal plants. *Fitoterapia*, 71 Suppl 1, S73-82.
- 6 Paris R and Myose H, 1981. Précis de Matière Médicale, Tome II, Pharmacognosie spéciale. Masson, Paris.
- 7 Zucker S, Buttle DJ, Nicklin MJ, Barrett AJ, 1985. The proteolytic activities of chymopapain, papain, and papaya proteinase III. *Biochim Biophys Acta*, 828, 196-204.

ID 2713: “*Pyrus malus* (Common Name Apple) extract powder containing polyphenols” and “Blood glucose control”

- 1 DianaNaturals, *Malus domestica* (apple), <http://www.diananaturals.com/pages/product.php?SELECTPDT=3>.
- 2 Ehrenkranz JR, Lewis NG, Kahn CR, Roth J, 2005. Phlorizin: a review. *Diabetes Metab Res Rev*, 21, 31-38.
- 3 Johnston KL, Clifford MN, Morgan LM, 2002. Possible role for apple juice phenolic compounds in the acute modification of glucose tolerance and gastrointestinal hormone secretion in humans. *J Sci Food Agric*, 82, 1800-1805.

ID 2715: “*Borago officinalis* - common name : Borage” and “Renal elimination / organism draining”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. Les plantes dans la thérapeutique moderne. Maloine, Paris.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 3 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 4 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 5 Leclerc H, 1994. Précis de phytothérapie. Masson, Paris.

ID 2716: “Camellia sinensis - common name : tea” and “Control of weight”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2717: “Ribes nigrum - nom commun : blackcurrant” and “Control of weight”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahier de l'Agence, 1998. Médicaments à base de plantes: Cahiers de l'Agence no 3. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Wichtl M and Anton R, 2003. Plantes thérapeutiques : tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2718: “Sambucus nigra - common name : black elder, European elder” and “Control of weight”

- 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 3 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2719: “Armorica rusticana - common name : Horseradish” and “Renal elimination / Organism draining”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.

ID 2722: “Alfalfa. (Medicago sativa L.)” and “Hair and nails health”

- 1 Rombi M, Robert D, Guedon D, Rosier-Sala C, Renzacci E, 2007. 120 plantes médicinales : Composition, mode d'action et intérêt thérapeutique ... de l'Ail à la Vigne rouge. Alpen Editions Monaco.
- 2 Scimeca D and Tetau M, 2006. Alfalfa. In: Le guide de phytothérapie. Alpen editions, Monaco.

ID 2723: “Bamboo (Bambusa arundinacea)” and “Bones and joints health”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris.

- 2 Calomme MR and Vanden Berghe DA, 1997. Supplementation of calves with stabilized orthosilicic acid. Effect on the Si, Ca, Mg, and P concentrations in serum and the collagen concentration in skin and cartilage. *Biol Trace Elem Res*, 56, 153-165.
- 3 Eisinger J and Clairet D, 1993. Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. *Magnes Res*, 6, 247-249.
- 4 EVM (Expert Group on Vitamins and Minerals), 2003. Safe Upper Levels for Vitamins and Minerals. Food Standards Agency, London.
- 5 Food Standards Agency, Silicon, <http://www.eatwell.gov.uk/healthydiet/nutritionessentials/vitaminsandminerals/silicon/>.
- 6 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 7 IoM (Institute of Medicine), 2000. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC.
- 8 Jugdaohsingh R, Tucker KL, Qiao N, Cupples LA, Kiel DP, Powell JJ, 2004. Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort. *J Bone Miner Res*, 19, 297-307.
- 9 Jugdaohsingh R, 2007. Silicon and bone health. *J Nutr Health Aging*, 11, 99-110.
- 10 Martin KR, 2007. The chemistry of silica and its potential health benefits. *J Nutr Health Aging*, 11, 94-97.
- 11 Reffitt DM, Ogston N, Jugdaohsingh R, Cheung HF, Evans BA, Thompson RP, Powell JJ, Hampson GN, 2003. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. *Bone*, 32, 127-135.
- 12 Rombi M, Robert D, Guedon D, Rosier-Sala C, Renzacci E, 2007. 120 plantes médicinales : Composition, mode d'action et intérêt thérapeutique ... de l'Ail à la Vigne rouge. Alpen Editions Monaco.
- 13 Schiano A, Eisinger F, Detolle P, Laponche AM, Brisou B, Eisinger J, 1979. Silicon, bone tissue and immunity. *Rev Rhum Mal Osteoartic*, 46, 483-486.
- 14 Seaborn CD and Nielsen FH, 2002. Dietary silicon and arginine affect mineral element composition of rat femur and vertebra. *Biol Trace Elem Res*, 89, 239-250.
- 15 Seaborn CD and Nielsen FH, 2002. Silicon deprivation decreases collagen formation in wounds and bone, and ornithine transaminase enzyme activity in liver. *Biol Trace Elem Res*, 89, 251-261.

ID 2724: “Cocoa (*Theobroma cacao* L.)” and “Slimming / lipids metabolism”

- 1 Dulloo AG, Seydoux J, Girardier L, 1992. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? *Metabolism*, 41, 1233-1241.
- 2 Fredholm BB and Lindgren E, 1984. The effect of alkylxanthines and other phosphodiesterase inhibitors on adenosine-receptor mediated decrease in lipolysis and cyclic AMP accumulation in rat fat cells. *Acta Pharmacol Toxicol (Copenh)*, 54, 64-71.
- 3 Inoue H, Kobayashi-Hattori K, Horiuchi Y, Oishi Y, Arai S, Takita T, 2006. Regulation of the body fat percentage in developmental-stage rats by methylxanthine derivatives in a high-fat diet. *Biosci Biotechnol Biochem*, 70, 1134-1139.
- 4 Matsui N, Ito R, Nishimura E, Yoshikawa M, Kato M, Kamei M, Shibata H, Matsumoto I, Abe K, Hashizume S, 2005. Ingested cocoa can prevent high-fat diet-induced obesity by regulating the expression of genes for fatty acid metabolism. *Nutrition*, 21, 594-601.
- 5 SFA (Societe Francaise des Antioxydants), 2005. Etat actuel de la recherche scientifique sur les ingrédients minceur – Dernières avancées dans le domaine de la perte de poids. La théobromine.

ID 2725: “Cola (Cola nitida)” and “Weight control”

- 1 Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J, 1990. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. *Am J Clin Nutr*, 51, 759-767.
- 2 Blecher M, Merlino NS, Ro'Ane JT, 1968. Control of the metabolism and lipolytic effects of cyclic 3',5'-adenosine monophosphate in adipose tissue by insulin, methyl xanthines, and nicotinic acid. *J Biol Chem*, 243, 3973-3977.
- 3 Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y, 1995. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. *Am J Physiol*, 269, E671-678.
- 4 Couturier C, Janvier B, Girlich D, Bereziat G, Andreani-Mangeny M, 1998. Effects of caffeine on lipoprotein lipase gene expression during the adipocyte differentiation process. *Lipids*, 33, 455-460.
- 5 Fallet C, 1995. Minceur et fermeté. *Le Moniteur des Pharmacies et des Laboratoires. Cahier cosméto-pratique* du n°2117 1-8.
- 6 Greenway FL, De Jonge L, Blanchard D, Frisard M, Smith SR, 2004. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. *Obes Res*, 12, 1152-1157.
- 7 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 8 Roberts AT, de Jonge-Levitan L, Parker CC, Greenway F, 2005. The effect of an herbal supplement containing black tea and caffeine on metabolic parameters in humans. *Altern Med Rev*, 10, 321-325.
- 9 SFA (Société Française des Antioxydants), 2005. Les ingrédients minceur : Dernières avancées scientifiques dans le domaine de la perte de poids. *La caféine*.
- 10 Videment E, 2006. Minceur et compléments alimentaires. *Le Moniteur des Pharmacies et des Laboratoires. Cahier Conseil II* du n°2626, 1-13.

ID 2727: “Grape (Vitis vinifera L)” and “Weight control”

- 1 Ardevol A, Blade C, Salvado MJ, Arola L, 2000. Changes in lipolysis and hormone-sensitive lipase expression caused by procyanidins in 3T3-L1 adipocytes. *Int J Obes Relat Metab Disord*, 24, 319-324.
- 2 Dabis G and Siou A, 1988. Microcirculation et lipodystrophie segmentaire: application à l'étude des OPC(Endotelon®). *Gazette médicale de France*, 95, 66-70.
- 3 Delaby M, 1989. Endotelon® en pratique quotidienne: désorganisation de l'unité circulatoire et O. P. C. *Gazette médicale de France*, 96, 18-32.
- 4 Delacroix P, 1981. Etude en double aveugle de l'endotelon dans l'insuffisance veineuse chronique. *La revue de médecine*, 27-28, 1793-1802.
- 5 Houdret JC, 1989. De l'utilité du « marc de raisin » dans le traitement de l'obésité et de la cellulite. *Médecines Naturelles Actualités* 2, 26-27.
- 6 Juhel C, Armand M, Lairon D, 1999. Effet inhibiteur d'un extrait du proaffinol (extrait de raisin) sur la lipase gastrique et la lipase pancréatique. *INSERM-U476, Arkopharma*, 1-12.
- 7 Moreno DA, Ilic N, Poulev A, Brasaemle DL, Fried SK, Raskin I, 2003. Inhibitory effects of grape seed extract on lipases. *Nutrition*, 19, 876-879.
- 8 Rombi M, Robert D, Guedon D, Rosier-Sala C, Renzacci E, 2007. 120 plantes médicinales : Composition, mode d'action et intérêt thérapeutique ... de l'Ail à la Vigne rouge. *Alpen Editions Monaco*.
- 9 Tsuda T, Horio F, Uchida K, Aoki H, Osawa T, 2003. Dietary cyanidin 3-O-beta-D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. *J Nutr*, 133, 2125-2130.

- 10 Tsuda T, Ueno Y, Aoki H, Koda T, Horio F, Takahashi N, Kawada T, Osawa T, 2004. Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes. *Biochem Biophys Res Commun*, 316, 149-157.
- 11 Vogels N, Nijs IM, Westerterp-Plantenga MS, 2004. The effect of grape-seed extract on 24 h energy intake in humans. *Eur J Clin Nutr*, 58, 667-673.

ID 2728: “Grapefruit (*Citrus paradisi* Mact. = *C. decumana* L., *C. grandis* Osbeck ; *Citrus maxima*)” and “Purifying/ detoxifying properties”

- 1 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 2 Cho J, 2006. Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. *Arch Pharm Res*, 29, 699-706.
- 3 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 4 Gorinstein S, Caspi A, Libman I, Katrich E, Lerner HT, Trakhtenberg S, 2004. Fresh israeli jaffa sweetie juice consumption improves lipid metabolism and increases antioxidant capacity in hypercholesterolemic patients suffering from coronary artery disease: studies in vitro and in humans and positive changes in albumin and fibrinogen fractions. *J Agric Food Chem*, 52, 5215-5222.
- 5 Jagetia GC, Venkatesha VA, Reddy TK, 2003. Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow. *Mutagenesis*, 18, 337-343.
- 6 JHCI (Joint Health Claims Initiative), 2003. *Final Technical Report A List of Well Established Nutrient Function Statements*.
- 7 Mason P, 2001. *Dietary Supplements*. Pharmaceutical Press, London.
- 8 Pari L and Gnanasoundari M, 2006. Influence of naringenin on oxytetracycline mediated oxidative damage in rat liver. *Basic Clin Pharmacol Toxicol*, 98, 456-461.
- 9 Paris RR and Moyse H, 1981. Citrus divers à fruits alimentaires. In: *Précis de Matière Médicale. Pharmacognosie spéciale*. Masson, Paris, 301.
- 10 Remesy C, Manach C, Demigne C, Texier O, Regerat F, 1996. Intérêt nutritionnel des flavonoïdes. *Médecine et nutrition* 32, 17-27.
- 11 Tirillini B, 2000. Grapefruit: the last decade acquisitions. *Fitoterapia*, 71 Suppl 1, S29-37.
- 12 Wilmsen PK, Spada DS, Salvador M, 2005. Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. *J Agric Food Chem*, 53, 4757-4761.

ID 2730: “Larch tree (*Larix decidua*)” and “Immune health”

- 1 Larch Arabinogalactan. Monograph. 2000. *Altern Med Rev*, 5, 463-466.
- 2 Gruenwald J, Brendler T, Jaenicke C, 2004. Larch tree (*Larix decidua*). In: *PDR for herbal medicines*. Thomson Reuters, Montvale.
- 3 Kelly GS, 1999. Larch arabinogalactan : clinical relevance of a novel immune-enhancing polysaccharide. *Altern Med Rev.*, 4, 96-103.
- 4 Kim LS, Waters RF, Burkholder PM, 2002. Immunological activity of larch arabinogalactan and echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. *Altern Med Rev*, 7, 138-149.
- 5 Roxas M and Jurenka J, 2007. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. *Altern Med Rev*, 12, 25-48.
- 6 Scimeca D and Tetau M, 2006. Mélèze. In: *Le Guide de Phytothérapie. La santé par les plantes*. Alpen éditions, Monaco.

ID 2731: “Lithothamnium calcareum (calcium carbonate)” and “Bone health - mineralization”

- 1 Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian FA, 1994. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. *Ann Intern Med*, 120, 97-103.
- 2 Dorvault FLM, 1996. *L'Officine*. Vigot, Paris.
- 3 Eklou-Kalonji E, Zerath E, Colin C, Lacroix C, Holy X, Denis I, Pointillart A, 1999. Calcium-regulating hormones, bone mineral content, breaking load and trabecular remodeling are altered in growing pigs fed calcium-deficient diets. *J Nutr*, 129, 188-193.
- 4 FDA (Food and Drug Administration), 2007. FDA updates health claim for calcium and osteoporosis. P07-02.
- 5 NIH (National Institute of Health), 1994. Optimal calcium intake. *NIH Consens Statement*, 12, 1-31.
- 6 NIH (National Institute of Health), 2000. Osteoporosis Prevention, Diagnosis, and Therapy. *NIH Consens Statement*, 17, 1-36.
- 7 Peterson CA, Eurell JA, Erdman JW, Jr., 1995. Alterations in calcium intake on peak bone mass in the female rat. *J Bone Miner Res*, 10, 81-95.
- 8 Prince RL, Devine A, Dhaliwal SS, Dick IM, 2006. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. *Arch Intern Med*, 166, 869-875.
- 9 Stear SJ, Prentice A, Jones SC, Cole TJ, 2003. Effect of a calcium and exercise intervention on the bone mineral status of 16-18-y-old adolescent girls. *Am J Clin Nutr*, 77, 985-992.
- 10 Storm D, Eslin R, Porter ES, Musgrave K, Vereault D, Patton C, Kessenich C, Mohan S, Chen T, Holick MF, Rosen CJ, 1998. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. *J Clin Endocrinol Metab*, 83, 3817-3825.
- 11 Sweetman S, 2002. *Martindale: The Complete Drug Reference*. Pharmaceutical Press, London.

ID 2733: “Nopal (*Opuntia ficus indica*)” and “Weight control”

- 1 Ennouri M, Fetoui H, Bourret E, Zeghal N, Attia H, 2006. Evaluation of some biological parameters of *Opuntia ficus indica*. 1. Influence of a seed oil supplemented diet on rats. *Bioresour Technol*, 97, 1382-1386.
- 2 Ennouri M, Fetoui H, Bourret E, Zeghal N, Guermazi F, Attia H, 2006. Evaluation of some biological parameters of *Opuntia ficus indica*. 2. Influence of seed supplemented diet on rats. *Bioresour Technol*, 97, 2136-2140.
- 3 Fernandez ML, Trejo A, McNamara DJ, 1990. Pectin isolated from prickly pear (*Opuntia* sp.) modifies low density lipoprotein metabolism in cholesterol-fed guinea pigs. *J Nutr*, 120, 1283-1290.
- 4 Feugang JM, Konarski P, Zou D, Stintzing FC, Zou C, 2006. Nutritional and medicinal use of Cactus pear (*Opuntia* spp.) cladodes and fruits. *Front Biosci*, 11, 2574-2589.
- 5 Frati AC, Gordillo BE, Altamirano P, Ariza CR, Cortes-Franco R, Chavez-Negrete A, Islas-Andrade S, 1991. Influence of nopal intake upon fasting glycemia in type II diabetics and healthy subjects. *Arch Invest Med (Mex)*, 22, 51-56.
- 6 Frati-Munari AC, Fernandez-Harp JA, de la Riva H, Ariza-Andraca R, del Carmen Torres M, 1983. Effects of nopal (*Opuntia* sp.) on serum lipids, glycemia and body weight. *Arch Invest Med (Mex)*, 14, 117-125.
- 7 Frati-Munari AC, Gordillo BE, Altamirano P, Ariza CR, 1988. Hypoglycemic effect of *Opuntia streptacantha* Lemaire in NIDDM. *Diabetes Care*, 11, 63-66.

- 8 Frati-Munari AC, Altamirano-Bustamante E, Rodriguez-Barcenas N, Ariza-Andraca R, Lopez-Ledesma R, 1989. [Hypoglycemic action of *Opuntia streptacantha* Lemaire: study using raw extracts]. *Arch Invest Med (Mex)*, 20, 321-325.
- 9 Frati-Munari AC, Del Valle-Martinez LM, Ariza-Andraca CR, Islas-Andrade S, Chavez-Negrete A, 1989. [Hypoglycemic action of different doses of nopal (*Opuntia streptacantha* Lemaire) in patients with type II diabetes mellitus]. *Arch Invest Med (Mex)*, 20, 197-201.
- 10 Frati-Munari AC, Rios Gil U, Ariza-Andraca CR, Islas Andrade S, Lopez Ledesma R, 1989. [Duration of the hypoglycemic action of *Opuntia streptacantha* Lem.]. *Arch Invest Med (Mex)*, 20, 297-300.
- 11 Frati-Munari AC, Licona-Quesada R, Araiza-Andraca CR, Lopez-Ledesma R, Chavez-Negrete A, 1990. [Activity of *Opuntia streptacantha* in healthy individuals with induced hyperglycemia]. *Arch Invest Med (Mex)*, 21, 99-102.
- 12 Laurenz JC, Collier CC, Kuti JO, 2003. Hypoglycaemic effect of *Opuntia lindheimeri* Englem in a diabetic pig model. *Phytother Res*, 17, 26-29.
- 13 Li CY, Cheng XS, Cui MZ, Yan YG, 2005. [Regulative effect of *Opuntia* powder on blood lipids in rats and its mechanism]. *Zhongguo Zhong Yao Za Zhi*, 30, 694-696.
- 14 Shapiro K and Gong WC, 2002. Natural products used for diabetes. *J Am Pharm Assoc (Wash)*, 42, 217-226.
- 15 Trejo-Gonzalez A, Gabriel-Ortiz G, Puebla-Perez AM, Huizar-Contreras MD, Munguia-Mazariegos MR, Mejia-Arreguin S, Calva E, 1996. A purified extract from prickly pear cactus (*Opuntia fuliginosa*) controls experimentally induced diabetes in rats. *J Ethnopharmacol*, 55, 27-33.
- 16 Wolfram RM, Kritz H, Efthimiou Y, Stomatopoulos J, Sinzinger H, 2002. Effect of prickly pear (*Opuntia robusta*) on glucose- and lipid-metabolism in non-diabetics with hyperlipidemia--a pilot study. *Wien Klin Wochenschr*, 114, 840-846.

ID 2734: “Purslane (*Portulaca oleracea* L.)” and “Antioxidant properties”

- 1 Arruda SF, Siqueira EM, Souza EM, 2004. Malanga (*Xanthosoma sagittifolium*) and purslane (*Portulaca oleracea*) leaves reduce oxidative stress in vitamin A-deficient rats. *Ann Nutr Metab*, 48, 288-295.
- 2 Charleux JL, 1996. Beta-carotene, vitamin C, and vitamin E: the protective micronutrients. *Nutr Rev*, 54, S109-114.
- 3 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 4 Huang Z, Wang B, Eaves DH, Shikany JM, Pace RD, 2007. Total phenolics and antioxidant capacity of indigenous vegetables in the southeast United States: Alabama Collaboration for Cardiovascular Equality Project. *Int J Food Sci Nutr*, 1-9.
- 5 JHCI (Joint Health Claims Initiative), 2003. Joint Health Claims Initiative Final Technical Report A List of Well Established Nutrient Function Statements . "Antioxidant activity in cell membrane : Vitamin E is necessary for protecting cell membranes from some type of damage caused by free radicals".
- 6 JHCI (Joint Health Claims Initiative), 2003. Joint Health Claims Initiative Final Technical Report A List of Well Established Nutrient Function Statements. "Antioxidant activity : Vitamin C contributes to cell protection from the damage caused by free radicals.".
- 7 Lim YY and Quah EPL, 2007. Antioxidant properties of different cultivars of *Portulaca oleracea*. *Food Chemistry*, 103, 734-740.
- 8 Liu L, Howe P, Zhou YF, Xu ZQ, Hocart C, Zhan R, 2000. Fatty acids and beta-carotene in australian purslane (*Portulaca oleracea*) varieties. *J Chromatogr A*, 893, 207-213.
- 9 Nemeth E, Feher J, Nagy V, Lengyel G, 2006. [The role of antioxidants in prevention]. *Orv Hetil*, 147, 603-607.

- 10 Nutranews-Science, Nutrition, Prévention et Santé,, 2005. Les caroténoïdes, des nutriments antioxydants fortement protecteur.
- 11 Palaniswamy UR, McAvoy RJ, Bible BB, 2001. Stage of harvest and polyunsaturated essential fatty acid concentrations in purslane (*Portulaca oleraceae*) leaves. *J Agric Food Chem*, 49, 3490-3493.
- 12 Regnault C, Postaire ER, Rousset GJ, Bejot M, Hazebroucq GF, 1993. Influence of beta carotene, vitamin E, and vitamin C on endogenous antioxidant defenses in erythrocytes. *Ann Pharmacother*, 27, 1349-1350.
- 13 Scimeca D and Tetau M, 2006. Pourpier. In: *Le guide de phytothérapie*. Alpen editions, Monaco.
- 14 Simopoulos AP and Salem N, Jr., 1986. Purslane: a terrestrial source of omega-3 fatty acids. *N Engl J Med*, 315, 833.
- 15 Simopoulos AP, 1991. Omega-3 fatty acids in health and disease and in growth and development. *Am J Clin Nutr*, 54, 438-463.
- 16 Simopoulos AP, Norman HA, Gillaspie JE, Duke JA, 1992. Common purslane: a source of omega-3 fatty acids and antioxidants. *J Am Coll Nutr*, 11, 374-382.
- 17 Simopoulos AP, 2004. Omega-3 fatty acids and antioxidants in edible wild plants. *Biol Res*, 37, 263-277.
- 18 Simopoulos AP, Tan DX, Manchester LC, Reiter RJ, 2005. Purslane: a plant source of omega-3 fatty acids and melatonin. *J Pineal Res*, 39, 331-332.
- 19 Willson RL, 1983. Free radical protection: why vitamin E, not vitamin C, beta-carotene or glutathione? *Ciba Found Symp*, 101, 19-44.
- 20 Zeng X, 1999. [A study of scavenging action of purslane aqueous extracts on oxygen free radical]. *Hunan Yi Ke Da Xue Xue Bao*, 24, 133-135.

ID 2735: “Red Vine (*Vitis vinifera* L.)” and “Weight control/cellulitis”

- 1 Ardevol A, Blade C, Salvado MJ, Arola L, 2000. Changes in lipolysis and hormone-sensitive lipase expression caused by procyanidins in 3T3-L1 adipocytes. *Int J Obes Relat Metab Disord*, 24, 319-324.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 3 Dabis G and Siou A, 1988. Microcirculation et lipodystrophie segmentaire: application à l'étude des OPC(Endotelon®). *Gazette médicale de France*, 95, 66-70.
- 4 Delaby M, 1989. Endotelon® en pratique quotidienne: désorganisation de l'unité circulatoire et O. P. C. *Gazette médicale de France*, 96, 18-32.
- 5 Delacroix P, 1981. Etude en double aveugle de l'endotelon dans l'insuffisance veineuse chronique. *La revue de médecine*, 27-28, 1793-1802.
- 6 Juhel C, Armand M, Lairon D, 1999. Effet inhibiteur d'un extrait du proaffinol (extrait de raisin) sur la lipase gastrique et la lipase pancréatique. *INSERM-U476, Arkopharma*, 1-12.
- 7 Thebaut JB, Thebaut P, Vin F, 1985. Etude de l'Endotélon® dans les manifestations fonctionnelles de l'insuffisance veineuse périphérique. Résultats d'une étude en double aveugle portant sur 92 patients. *Gazette Médicale*, 92, 96-100.
- 8 Videment E, 2006. Minceur et compléments alimentaires. *Le Moniteur des Pharmacies et des Laboratoires. Cahier Conseil II du n°2626*, 1-13.

ID 2736: “Sage (*Salvia lavandulaefolia* Vahl.)” and “Mental health/ cognitive functions”

- 1 Howes MJ, Perry NS, Houghton PJ, 2003. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. *Phytother Res*, 17, 1-18.

- 2 Kennedy DO and Scholey AB, 2006. The psychopharmacology of European herbs with cognition-enhancing properties. *Curr Pharm Des*, 12, 4613-4623.
- 3 Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS, 1999. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. *J Pharm Pharmacol*, 51, 527-534.
- 4 Perry NS, Houghton PJ, Sampson J, Theobald AE, Hart S, Lis-Balchin M, Houlst JR, Evans P, Jenner P, Milligan S, Perry EK, 2001. In-vitro activity of *S. lavandulaefolia* (Spanish sage) relevant to treatment of Alzheimer's disease. *J Pharm Pharmacol*, 53, 1347-1356.
- 5 Perry NS, Houghton PJ, Jenner P, Keith A, Perry EK, 2002. *Salvia lavandulaefolia* essential oil inhibits cholinesterase in vivo. *Phytomedicine*, 9, 48-51.
- 6 Savelev S, Okello E, Perry NS, Wilkins RM, Perry EK, 2003. Synergistic and antagonistic interactions of anticholinesterase terpenoids in *Salvia lavandulaefolia* essential oil. *Pharmacol Biochem Behav*, 75, 661-668.
- 7 Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB, 2003. *Salvia lavandulaefolia* (Spanish sage) enhances memory in healthy young volunteers. *Pharmacol Biochem Behav*, 75, 669-674.
- 8 Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB, 2005. Positive modulation of mood and cognitive performance following administration of acute doses of *Salvia lavandulaefolia* essential oil to healthy young volunteers. *Physiol Behav*, 83, 699-709.
- 9 Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E, 2000. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. *J Ethnopharmacol*, 69, 105-114.

ID 2739: “Corn silk (*Zea mays* L.)” and “Health of urinary and digestive function”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Rapport allégations plantes du 27 février 2003.
- 2 Barnes J, Anderson LA, Phillipson JD, 2002. *Herbal Medicines, A guide for healthcare professionals*. Pharmaceutical Press, London.
- 3 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 4 Bisset NG and Wichtl M, 1994. *Herbal Drugs and Phytopharmaceuticals*. Medpharm GmbH Scientific Publishers, Stuttgart, Germany.
- 5 Bradley P, 2006. *British Herbal Compendium*. British Herbal Medicine Association, Bournemouth.
- 6 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 7 Ebadi M, 2002. *Pharmacodynamic basis of herbal medicine*. CRC Press, Boca Raton.
- 8 Kerhard J and Adam JG, 1974. *La Pharmacopée sénégalaise traditionnelle, plantes médicinales et toxiques*. Vigot, Paris.
- 9 Leclerc H, 1994. *Precis de Phytothérapie*. Masson, Paris.
- 10 Leung AY and Foster S, 1996. *Encyclopedia of common natural ingredients used in food, drugs, and cosmetics*. John Wiley & Sons, New York.
- 11 Maksimovic Z, Dobric S, Kovacevic N, Milovanovic Z, 2004. Diuretic activity of *Maydis stigma* extract in rats. *Pharmazie*, 59, 967-971.
- 12 Mills S and Bone K, 2000. *Principles and Practices of Phytothérapie: Modern Herbal Medecine*. Churchill Livingstone, London, Edinburgh.
- 13 Sweetman S, 2002. *Martindale: The Complete Drug Reference*. Pharmaceutical Press, London.

- 14 Velazquez DV, Xavier HS, Batista JE, de Castro-Chaves C, 2005. Zea mays L. extracts modify glomerular function and potassium urinary excretion in conscious rats. *Phytomedicine*, 12, 363-369.
- 15 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2740: “Couchgrass (*Agropyron repens L.*)” and “Detoxification”

- 1 Larousse L'encyclopédie des plantes médicinales 2001. Larousse, Paris.
- 2 Barnes J, Anderson LA, Phillipson JD, 2002. *Herbal Medicines*. Pharmaceutical Press, London.
- 3 Bézanger-Beauquesne L, Pinkas M, Torck M, 1975. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 4 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes Médicinales des Régions Tempérées*. Maloine, Paris.
- 5 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 6 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 7 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 8 Boullard B, 2001. *Plantes médicinales du monde: croyances et réalités*. Estem, Paris.
- 9 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 10 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 11 Crellin JK and Philpott J, 1990. *A reference guide to medicinal plants. Herbal Medicine Past and Present*. Duke University Press, Durham, London.
- 12 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 13 Garnier G, Bezanger-Beauquesne L, Debraux G, 1961. *Ressources médicinales de la Flore Française Tom. 1-2*. Vigot, Paris.
- 14 Girre L, 2001. *Les plantes et les médicaments Delachaux et Niestlé*, Paris.
- 15 Gruenwald J, Brendler T, Jaenicke C, 1998. *PDR for herbal medicines*. Medical Economics Company, Montvale, New Jersey.
- 16 Leclerc H, 1994. *Precis de Phytothérapie*. Masson, Paris.
- 17 Leung AY and Foster S, 1996. *Encyclopedia of common natural ingredients used in food, drugs, and cosmetics*. John Wiley & Sons, New York.
- 18 Leung A and Foster S, 2003. *Encyclopedia of common natural ingredients used in food, drugs, and cosmetics*. Wiley-Interscience, New York.
- 19 Mills S and Bone K, 2000. *Principles and Practices of Phytotherapie: Modern Herbal Medecine*. Churchill Livingstone, London, Edinburgh.
- 20 No authors listed, 1983. *Résumé de phytothérapie*. Edition de l'Herboristerie, Nice.
- 21 Paris R and Myose H, 1981. *Précis de Matière Médicale, Tome II, Pharmacognosie spéciale*. Masson, Paris.
- 22 Rombi M, Guedon D, Robert D, Rosier-sala C, Renzacci E, 2007. *120 plantes médicinales: Composition, mode d'action et intérêt thérapeutique*. Alpen, Monaco.
- 23 Sweetman S, 2002. *Martindale: The Complete Drug Reference*. Pharmaceutical Press, London.

- 24 Valnet J, 1976. *Phytothérapie. Traitement des maladies par les plantes*. Maloine, Paris.
- 25 Van Hellemont J, 1986. *Compendium de Phytothérapie*. Association Pharmaceutique Belge, Bruxelles.
- 26 Videment E, 2006. *Minceur et compléments alimentaires*. *Le Moniteur des Pharmacies et des Laboratoires*, 78, 1-13.
- 27 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 28 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 29 Wren RC Potters, 1980. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. Health Science Press, Bradford.
- 30 Wren RC, 1988. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. C.W. Daniel, Saffron Walden.

ID 2742: “Fennel (*Foeniculum vulgare*)” and “Urinary elimination - Detoxification”

- 1 Larousse L'encyclopédie des plantes médicinales 2001. Larousse, Paris.
- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, Trotin F, 1980. *Plantes médicinales des régions tempérées*. Maloine, Paris.
- 3 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 4 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 5 Blumenthal M, 1986. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines* The American Botanical Council, Austin, TX.
- 6 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 7 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 8 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 9 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 10 Fournier P, 1948. *Le livre des plantes médicinales et vénéneuses de France*. Paul Le Chevalier, Paris.
- 11 Girre L, 2001. *Les plantes et les médicaments : L'origine végétale de nos médicaments*. Delachaux et Niestlé, Lausanne.
- 12 Leclerc H, 1976. *Précis de phytothérapie. Essais de thérapeutique par les plantes françaises*. Masson, Paris.
- 13 Loeper M and Lesure J, 1960. *Formulaire pratique de thérapeutique et de pharmacologie*. Doin, Paris.
- 14 Mills S and Bone K, 2005. *The Essential Guide to Herbal Safety*. Churchill Livingstone London, Edinburgh.
- 15 Moatti R, 1993. *Le guide complet des plantes pour se soigner*. Editions Du Rocher, Paris.
- 16 Van Hellemont J, 1986. *Compendium de Phytothérapie*. Association Pharmaceutique Belge, Bruxelles.
- 17 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.
- 18 Wright CI, Van-Buren L, Kroner CI, Koning MM, 2007. *Herbal medicines as diuretics: a review of the scientific evidence*. *J Ethnopharmacol*, 114, 1-31.

ID 2743: “Papaya (*Carica papaya* L.)” and “Skin curves/Cellulitis”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 3 Leung AY and Foster S, 1996. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. John Wiley & Sons, New York.
- 4 Miller JM, Papastrat CJ, Ginsberg M, 1958. The administration of papain buccally in the treatment of inflammation and edema. *Antibiotic Med Clin Ther*, 5, 720-722.
- 5 Moro CO and Basile G, 2000. Obesity and medicinal plants. *Fitoterapia*, 71 Suppl 1, S73-82.
- 6 Passeport Santé, Passeport Santé, www.passeportsante.net.
- 7 Rombi M, 1991. Cent plantes médicinales: Composition, mode d'action et intérêt thérapeutique. Romart, Paris.
- 8 Rombi M, Guedon D, Robert D, Rosier-sala C, Renzacci E, 2007. 120 plantes médicinales: Composition, mode d'action et intérêt thérapeutique. Alpen, Monaco.

ID 2744: “Turmeric (*Curcuma longa* L.)” and “Stimulation of appetite”

- 1 Ammon HP and Wahl MA, 1991. Pharmacology of *Curcuma longa*. *Planta Med*, 57, 1-7.
- 2 Araujo CC and Leon LL, 2001. Biological activities of *Curcuma longa* L. *Mem Inst Oswaldo Cruz*, 96, 723-728.
- 3 Blumenthal M, Goldberg A, Brinckmann J, 2000. Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Gautam SC, Gao X, Dulchavsky S, 2007. Immunomodulation by curcumin. *Adv Exp Med Biol*, 595, 321-341.
- 7 Grant KL and Schneider CD, 2000. Turmeric. *Am J Health Syst Pharm*, 57, 1121-1122.
- 8 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 9 Rombi M, Robert D, Guedon D, Rosier-Sala C, Renzacci E, 2007. 120 plantes médicinales : Composition, mode d'action et intérêt thérapeutique ... de l'Ail à la Vigne rouge. Alpen Editions Monaco.
- 10 Roux D and Danielle R, 2005. Les nouvelles plantes qui soignent: découvrez les pouvoirs naturels des plantes médicinales. Alpen Editions, Monaco.
- 11 Shishodia S, Singh T, Chaturvedi MM, 2007. Modulation of transcription factors by curcumin. *Adv Exp Med Biol*, 595, 127-148.
- 12 Tirkey N, Kaur G, Vij G, Chopra K, 2005. Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. *BMC Pharmacol*, 5, 15.

ID 2746: “Quinoa (*Chenopodium quinoa*)” and “Hair growth”

- 1 Reis PJ, 1992. Length growth and diameter relationships of Merino wool fibres. *Wool technology and Sheep breeding*, 40, 52.

- 2 Ruales J, de Grijalva Y, Lopez-Jaramillo P, Nair BM, 2002. The nutritional quality of an infant food from quinoa and its effect on the plasma level of insulin-like growth factor-1 (IGF-1) in undernourished children. *Int J Food Sci Nutr*, 53, 143-154.

ID 2747: “Roquette (Eruca sativa): dry hydroethanolic extract ” and “Hair growth”

- 1 Takahashi T, Kamiya T, Hasegawa A, Yokoo Y, 1999. Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells in vitro and activate hair follicle growth in vivo. *J Invest Dermatol*, 112, 310-316.
- 2 Vallette G, Tenaud I, Branka JE, Jarry A, Sainte-Marie I, Dreno B, Laboisse CL, 1998. Control of growth and differentiation of normal human epithelial cells through the manipulation of reactive nitrogen species. *Biochem J*, 331 (Pt 3), 713-717.

ID 2748: “Huile de carthame (safflower oil)” and “Skin care”

- 1 Cosgrove MC, Franco OH, Granger SP, Murray PG, Mayes AE, 2007. Dietary nutrient intakes and skin-aging appearance among middle-aged American women. *Am J Clin Nutr*, 86, 1225-1231.
- 2 Hansen HS and Jensen B, 1985. Essential function of linoleic acid esterified in acylglucosylceramide and acylceramide in maintaining the epidermal water permeability barrier. Evidence from feeding studies with oleate, linoleate, arachidonate, columbinate and alpha-linolenate. *Biochim Biophys Acta*, 834, 357-363.
- 3 Marsh KA, Ruedisueli FL, Coe SL, Watson TGD, 2000. Effects of zinc and linoleic acid supplementation on the skin and coat quality of dogs receiving a complete and balanced diet. *Vet. Derm.*, 11, 277-284.
- 4 Rondinone R, 1991. Peau et apport lipidique. *Lexicon Vevy Europe, skin care instant reports*, 8, 179-183.
- 5 Wright S, 1991. Essential fatty acids and the skin. *Br J Dermatol*, 125, 503-515.

ID 2749: “Huile de noisettes : Hazel nut (Corylus avellana) oil” and “Skin care”

- 1 Breiden B, Gallala H, Doering T, Sandhoff K, 2007. Optimization of submerged keratinocyte cultures for the synthesis of barrier ceramides. *Eur J Cell Biol*, 86, 657-673.
- 2 Elias PM, Brown BE, Ziboh VA, 1980. The permeability barrier in essential fatty acid deficiency: evidence for a direct role for linoleic acid in barrier function. *J Invest Dermatol*, 74, 230-233.
- 3 Hansen HS and Jensen B, 1985. Essential function of linoleic acid esterified in acylglucosylceramide and acylceramide in maintaining the epidermal water permeability barrier. Evidence from feeding studies with oleate, linoleate, arachidonate, columbinate and alpha-linolenate. *Biochim Biophys Acta*, 834, 357-363.
- 4 Oikawa D, Nakanishi T, Nakamura YN, Yamamoto T, Yamaguchi A, Shiba N, Iwamoto H, Tachibana T, Furuse M, 2005. Modification of skin composition by conjugated linoleic acid alone or with combination of other fatty acids in mice. *Br J Nutr*, 94, 275-281.
- 5 Wertz PW, Cho ES, Downing DT, 1983. Effect of essential fatty acid deficiency on the epidermal sphingolipids of the rat. *Biochim Biophys Acta*, 753, 350-355.

ID 2750: “Cassis : Dry extract of Ribes Nigrum fruit standardized at 7% of anthocyanosides” and “Eye health”

- 1 Canter PH and Ernst E, 2004. Anthocyanosides of *Vaccinium myrtillus* (bilberry) for night vision--a systematic review of placebo-controlled trials. *Surv Ophthalmol*, 49, 38-50.

- 2 Ghosh D and Konishi T, 2007. Anthocyanins and anthocyanin-rich extracts: role in diabetes and eye function. *Asia Pac J Clin Nutr*, 16, 200-208.
- 3 Kahkonen MP, Hopia AI, Vuorela HJ, Rauha JP, Pihlaja K, Kujala TS, Heinonen M, 1999. Antioxidant activity of plant extracts containing phenolic compounds. *J Agric Food Chem*, 47, 3954-3962.
- 4 Maher P and Hanneken A, 2005. Flavonoids protect retinal ganglion cells from oxidative stress-induced death. *Invest Ophthalmol Vis Sci*, 46, 4796-4803.
- 5 Matsumoto H, Nakamura Y, Tachibanaki S, Kawamura S, Hirayama M, 2003. Stimulatory effect of cyanidin 3-glycosides on the regeneration of rhodopsin. *J Agric Food Chem*, 51, 3560-3563.
- 6 Matsumoto H, Nakamura Y, Iida H, Ito K, Ohguro H, 2006. Comparative assessment of distribution of blackcurrant anthocyanins in rabbit and rat ocular tissues. *Exp Eye Res*, 83, 348-356.
- 7 Nakaishi H, Matsumoto H, Tominaga S, Hirayama M, 2000. Effects of black current anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans. *Altern Med Rev*, 5, 553-562.
- 8 Nakajima JI, Tanaka I, Seo S, Yamazaki M, Saito K, 2004. LC/PDA/ESI-MS Profiling and Radical Scavenging Activity of Anthocyanins in Various Berries. *J Biomed Biotechnol*, 2004, 241-247.

ID 2751: “Curcuma: *Curcuma longa*” and “Liver lipids”

- 1 Asai A, Nakagawa K, Miyazawa T, 1999. Antioxidative effects of turmeric, rosemary and capsicum extracts on membrane phospholipid peroxidation and liver lipid metabolism in mice. *Biosci Biotechnol Biochem*, 63, 2118-2122.
- 2 Asai A and Miyazawa T, 2001. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. *J Nutr*, 131, 2932-2935.
- 3 Deshpande UR, Joseph LJ, Manjure SS, Samuel AM, Pillai D, Bhide SV, 1997. Effects of turmeric extract on lipid profile in human subjects. *Medical Science Research*, 25, 695-698.
- 4 Gogte VVM, 2000. *Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants*. Bharatiya Vidya Bhavan, Mumbai.
- 5 Kapoor LD, 1990. *Handbook of Ayurvedic Medicinal Plants*. CRC Press, Boca Raton.
- 6 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 7 Rukkumani R, Aruna K, Varma PS, Rajasekaran KN, Menon VP, 2005. Comparative effects of curcumin and its analog on alcohol- and polyunsaturated fatty acid-induced alterations in circulatory lipid profiles. *J Med Food*, 8, 256-260.
- 8 Sharma PC, Yelne MB, Dennis TJ, 2000. *Database on Medical Plants used in Ayurveda*. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 9 WHO (World Health Organization), 1999. *WHO Monographs on Selected Medicinal Plants*. WHO (World Health Organization), Geneva.
- 10 Williamson EM, 2002. *Major Herbs of Ayurveda*. Churchill Livingstone, London, Edinburgh.

ID 2752: “Radis noir: *Raphanus niger* (Black radish)” and “Improve digestion/transit”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.

- 3 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Rombi M, 1991. Cent plantes médicinales: Composition, mode d'action et intérêt thérapeutique. Romart, Paris.
- 5 Schauenberg P and Paris F, 1977. Guide des plantes médicinales. Analyse, description et utilisation de 400 plantes. Lutterworth Press, Guildford.

ID 2753 : “Sureau: Elder berry (dry aqueous extract)” and “Veinous system”

- 1 Bell DR and Burt TD, 2007. Phenolic acids contained in anthocyanin enriched extracts from Elderberry, Bilberry and Chokeberry possess endothelium dependent and independent vasorelaxation properties in porcine coronary arteries. *FASEB Journal*, 21(5), 366.
- 2 Youdim KA, Martin A, Joseph JA, 2000. Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress. *Free Radic Biol Med*, 29, 51-60.

ID 2755: “Myrtille: Extract of Vaccinium Myrtillus (bilberries)” and “Hairs and nails care”

- 1 Bilberry. 1996. In: Encyclopedia of common natural ingredients used in food, drugs and cosmetics. Leung A and Foster S (eds.). Wiley-Interscience, New York.
- 2 Vaccinium myrtillus (bilberry). 1999. In: Textbook of natural medicine. Pizzorno J and Murray M (eds.). Churchill Livingstone, London, Edinburgh.
- 3 Allaert FA, Vin F, Levardon M, 1992. [Comparative study of the effectiveness of continuous or intermittent courses of a phlebotonic drug on venous disorders disclosed or aggravated by oral, estrogen-progesterone contraceptives]. *Phlebologie*, 45, 167-173.
- 4 Amouretti M, 1972. [Therapeutic value of Vaccinium myrtillus anthocyanosides in an internal medicine department]. *Therapeutique*, 48, 579-581.
- 5 Antignani PL and Caliumi C, 2007. Medical treatment of chronic venous insufficiency. *Vasc Dis Prev*, 4, 117-124.
- 6 Bell DR and Gochenaur K, 2006. Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts. *J Appl Physiol*, 100, 1164-1170.
- 7 Bertuglia S, Malandrino S, Colantuoni A, 1995. Effect of Vaccinium myrtillus anthocyanosides on ischaemia reperfusion injury in hamster cheek pouch microcirculation. *Pharmacol Res*, 31, 183-187.
- 8 Costantini A, De Bernardi T, Gotti A, 1999. [Clinical and capillaroscopic evaluation of chronic uncomplicated venous insufficiency with procyanidins extracted from vitis vinifera]. *Minerva Cardioangiol*, 47, 39-46.
- 9 Kay CD, Kris-Etherton PM, West SG, 2006. Effects of antioxidant-rich foods on vascular reactivity: review of the clinical evidence. *Curr Atheroscler Rep*, 8, 510-522.
- 10 Lietti A, Cristoni A, Picci M, 1976. Studies on Vaccinium myrtillus anthocyanosides. I. Vasoprotective and antiinflammatory activity. *Arzneimittelforschung*, 26, 829-832.
- 11 Serraino I, Dugo L, Dugo P, Mondello L, Mazzon E, Dugo G, Caputi AP, Cuzzocrea S, 2003. Protective effects of cyanidin-3-O-glucoside from blackberry extract against peroxynitrite-induced endothelial dysfunction and vascular failure. *Life Sci*, 73, 1097-1114.
- 12 Youdim KA, McDonald J, Kalt W, Joseph JA, 2002. Potential role of dietary flavonoids in reducing microvascular endothelium vulnerability to oxidative and inflammatory insults (small star, filled). *J Nutr Biochem*, 13, 282-288.

ID 2757: “Ascophyllum (*Ascophyllum nodosum*) dry water extract” and “Action on fats”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1975. Les plantes dans la thérapeutique moderne. Maloine, Paris.
- 2 BHMA (British Herbal Medicine Association), 1996. British Herbal Pharmacopoeia. British Herbal Medicine Association, Exeter.
- 3 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 4 Bradley P, 2006. British Herbal Compendium. British Herbal Medicine Association, Bournemouth.
- 5 Brendler T, Gruenwald J, Jaenicke C, 1997. Herbal Remedies: Heilpflanzen. Deutscher Apotheker Verlag, Stuttgart.
- 6 Cahiers de L'Agence, 1998. Les Cahiers de l'agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 7 Donadieu Y and Basire J, 1985. Les Algues Les Therapeutiques Naturelles. Maloine, Paris.
- 8 Wichtl M and Anton R, 2003. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2758: “Spiruline (dry extract of *Spirulina maxima*)” and “Amino acid supplementation”

- 1 Clement G, Giddey C, Menzi R, 1967. Amino acid composition and nutritive value of the alga *Spirulina maxima*. J Sci Food Agric, 18, 497-501.
- 2 Clement G, 1975. [Production and characteristic constituents of the algae *Spirulina platensis* and *maxima*]. Ann Nutr Aliment, 29, 477-488.
- 3 Clement O, 1978. A new resource, the spirulina alga. Bull soc phycol Fr, 23, 57-58.
- 4 Garson J, Maigrot M, Busson F, 1969. [Cyanophyceae usable in human nutrition]. Med Trop (Mars), 29, 536-538.
- 5 Holt TK and Krogmann DW, 1981. A carotenoid protein from cyanobacteria. Biochim. Biophys. Acta, 637, 408-414.
- 6 Kaempfel U, Berghausen KH, Liefländer M, 1995. Eignen sich Cyanobakterien für die menschliche Ernährung? Ein Beitrag über die essentiellen Aminosäuren von Cyanobakterien. Deutsche Lebensmittel-Rundschau, 91, 50-52.
- 7 Kataoka N and Misaki A, 1983. Glycolipids isolated from *Spirulina maxima*: structure and fatty acid composition. Agricultural and Biological Chemistry, 47, 2349-2355.
- 8 Lacaz-Ruiz R and Mos EN, 1990. Produção de biomassa de *Spirulina maxima* para alimentação humana e animal. Revista de Microbiologia (Sao Paulo), 16, 132-137.
- 9 LiChuan Q, 2004. Study on nutritional ingredients of *Spirulina major*. Acta Botanica Boreali-Occidentalia Sinica, 24, 1520-1522.
- 10 Maranesi M, Barzanti V, Carenini G, Gentili P, 1984. Nutritional studies on *Spirulina maxima*. Acta Vitaminol Enzymol, 6, 295-304.
- 11 Meza-Calix A and Jacobs Jaime A, 1977. Effect of growing factors present in *Spirulina maxima* on swine. Canadian Journal of Animal Science, 57, 833.
- 12 Olguin EJ, Hernández B, Araus A, Camacho R, González R, Ramirez ME, Galicia S, Mercado G, 1994. Simultaneous high-biomass protein production and nutrient removal using *Spirulina maxima* in sea water supplemented with anaerobic effluents. World Journal of Microbiology and Biotechnology, 10, 576-578.

- 13 Ötles S and Pire R, 2001. Fatty acid composition of *Chlorella* and *Spirulina* microalgae species. *Journal of AOAC International*, 84, 1708-1714.
- 14 Vermorel M, Toullec G, Dumond D, Pion R, 1975. [Protein and energy value of spiruline blue algae supplemented by amino acids: digestive and metabolic utilization by the growing rat]. *Ann Nutr Aliment*, 29, 535-552.

ID 2759: “Brocoli: Dry extract of concentrated *Brassica oleracea* inflorescences juice” and “Gastric acidities”

- 1 Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A, 2002. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of *Helicobacter pylori* and prevents benzo[a]pyrene-induced stomach tumors. *Proc Natl Acad Sci USA*, 99, 7610-7615.
- 2 Galan MV, Kishan AA, Silverman AL, 2004. Oral broccoli sprouts for the treatment of *Helicobacter pylori* infection: a preliminary report. *Dig Dis Sci*, 49, 1088-1090.
- 3 Haristoy X, Angioi-Duprez K, Duprez A, Lozniewski A, 2003. Efficacy of sulforaphane in eradicating *Helicobacter pylori* in human gastric xenografts implanted in nude mice. *Antimicrob Agents Chemother*, 47, 3982-3984.
- 4 Johnson IT, 2002. Glucosinolates: bioavailability and importance to health. *Int J Vitam Nutr Res*, 72, 26-31.
- 5 Keck AS and Finley JW, 2004. Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. *Integr Cancer Ther*, 3, 5-12.
- 6 Yanaka A, Zhang S, Tauchi M, Suzuki H, Nakahara A, Tanaka N, Yamamoto M, 2005. Daily Intake of Sulforaphane-Rich Broccoli Sprouts Suppresses *H. Pylori* Colonization and Attenuates Gastritis in *H. Pylori*-infected Human Subjects. *Gastroenterology*, 128, A64.

ID 2765: “Plante : Thé vert *Camellia sinensis* (Green tea)” and “Elimination rénale de l’eau”

- 1 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. *Les plantes dans la thérapeutique moderne*. Maloine, Paris.
- 2 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de l'Agence, 1998. *Les Cahiers de l'Agence n°3. Médicaments à base de plantes*. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Hiller K and Melzig MF, 2003. *Lexikon der Arzneipflanzen und Drogen*. Spektrum Akademischer Verlag, Heidelberg.
- 5 Leung A and Foster S, 2003. *Encyclopedia of common natural ingredients used in food, drugs, and cosmetics*. Wiley-Interscience, New York.
- 6 Paris R and Myose H, 1981. *Précis de Matière Médicale, Tome II, Pharmacognosie spéciale*. Masson, Paris.
- 7 Rombi M, 1991. *Cent plantes médicinales: Composition Mode D'action et Interet Therapeutique*. Romart, Pris.
- 8 Valnet J, 1976. *Phytothérapie. Traitement des maladies par les plantes*. Maloine, Paris.
- 9 Wichtl M and Anton R, 2003. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2767: “Plante: Frêne *Fraxinus excelsior* (ash)” and “Elimination rénale de l’eau – Fonctions d’élimination de l’organisme”

- 1 Larousse L'encyclopédie des plantes médicinales. 2001. Larousse, Paris.

- 2 Bézanger-Beauquesne L, Pinkas M, Torck M, 1986. Les plantes dans la thérapeutique moderne. Maloine, Paris.
- 3 Boullard B, 2001. Plantes médicinales du monde. Estem, Paris.
- 4 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 5 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 6 Casadebaig J, Jacob M, Cassanas G, Gaudy D, Baylac G, Puech A, 1989. Physicochemical and pharmacological properties of spray-dried powders from *Fraxinus excelsior* leaf extracts. *J Ethnopharmacol*, 26, 211-216.
- 7 Girre L, 2001. Les plantes et les médicaments: L'origine végétale de nos médicaments. Delachaux et Niestlé, Lausanne.
- 8 Gruenwald J, Brendler T, Jaenicke C, 2004. PDR for herbal medicines. Thomson Reuters, Montvale.
- 9 Kowalczyk B and Olechnowicz-Stepien W, 1990. A further contribution to the lipophilic constituents of *Fraxinus excelsior* leaves. *Planta Med*, 56, 561-562.
- 10 Leclerc H, 1994. *Precis de Phytothérapie*. Masson, Paris.
- 11 Paris RR and Myose H, 1971. *Précis de matière Médicale*, Tome III. Masson, Paris.

ID 2770: “Food supplement /Food ingredient: Whole cranberry powder from North American Cranberry (*Vaccinium macrocarpon*) Early Black species” and “Health of the lower urinary tract”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2004. Avis d'évaluation des justificatifs concernant l'allégation « contribue à diminuer la fixation de certaines bactéries *E. coli* sur les parois urinaires » pour un nectar/cocktail de jus de cranberry/canneberge. Maisons-Alfort, le 3 décembre 2004. Saisine n° 2004-SA-214. Saisine liée n°2003-SA-0056 et 2003-SA-0352.
- 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2004. Avis relatif à l'évaluation des justificatifs concernant l'allégation « contribue à diminuer la fixation de certaines bactéries *E.coli* sur les parois des voies urinaires » et sur l'emploi de la « cranberry/canneberge » ou « *Vaccinium macrocarpon* » dans des jus concentrés, des compléments alimentaires et un cocktail/nectar de jus. Maisons-Alfort le 6 avril 2004. Saisine n°2003-SA-0352, Saisine liée n°2003-SA-0056.
- 3 American Herbal Pharmacopoeia, 2002. Cranberry fruit. *Vaccinium macrocarpon* Aiton. Standards of Analysis, Quality Control. American Herbal Pharmacopoeia.
- 4 Battle M, Martin T, Fulton J, 2001. Lactulose may help prevent urinary tract infections. *BMJ*, 323, 936.
- 5 Blumenthal M, 2003. *The ABC Clinical Guide to Herbs*. American Botanical Council, Austin, TX.
- 6 Brigham and Women's Hospital, Cranberry, <http://healthlibrary.brighamandwomens.org/Search/19,Cranberry>.
- 7 Bruyere F, 2006. [Use of cranberry in chronic urinary tract infections]. *Med Mal Infect*, 36, 358-363.
- 8 Di Martino P, Agniel R, David K, Templer C, Gaillard JL, Denys P, Botto H, 2006. Reduction of *Escherichia coli* adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial. *World J Urol*, 24, 21-27.
- 9 Donabedian H, 2006. Nutritional therapy and infectious diseases: a two-edged sword. *Nutr J*, 5, 21.
- 10 Goodine W, 2002. Regular drinking of cranberry-lingonberry juice concentrate reduced recurrent urinary tract infections in women. *Evid Based Nurs*, 5, 43.
- 11 Harvard Medical School, Consumer health information. Cranberry (*Vaccinium macrocarpon*), www.intelihealth.com.

- 12 Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M, 2005. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. *Phytochemistry*, 66, 2281-2291.
- 13 Hutchinson J, 2005. Do cranberries help prevent urinary tract infections? *Nurs Times*, 101, 38-40.
- 14 Jepson RG, Mihaljevic L, Craig J, 2004. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*, CD001321.
- 15 Jepson RG and Craig JC, 2008. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*, CD001321.
- 16 Kemper KJ, 1999. Cranberry (*Vaccinium macrocarpon*). The Longwood Herbal Task Force and The Center for Holistic Pediatric Education and Research.
- 17 Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M, 2001. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. *BMJ*, 322, 1571.
- 18 Lynch DM, 2004. Cranberry for prevention of urinary tract infections. *Am Fam Physician*, 70, 2175-2177.
- 19 Mayo Clinic, Cranberry (*Vaccinium macrocarpon*), http://www.mayoclinic.com/health/cranberry/NS_patient-cranberry.
- 20 McMurdo MET, Bissett LY, Price RJG, Phillips G, Crombie IK, 2005. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. *Age Ageing*, 34, 256-261.
- 21 MedlinePlus, Cranberry (*Vaccinium macrocarpon*), <http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-cranberry.html>.
- 22 National Center for Complementary and Alternative Medicine, Herbs at a glance: Cranberry, <http://nccam.nih.gov/health/cranberry/>.
- 23 Netzel M, Strass G, Herbst M, Dietrich H, Bitsch R, Bitsch I, Frank T, 2005. The excretion and biological antioxidant activity of elderberry antioxidants in healthy humans. *Food Research International*, 38, 905-910.
- 24 Sengupta K, Alluri KV, Golakoti T, Gottumukkala GV, Raavi J, Kotchrlakota L, Sigalan SC, Dey D, Ghosh S, Chatterjee A, A randomized, double blind, controlled, dose dependent clinical trial to evaluate the efficacy of a proanthocyanidin standardized whole cranberry (*Vaccinium macrocarpon*) powder on infections of the urinary tract. (Unpublished study).
- 25 Sobota AE, 1984. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. *J Urol*, 131, 1013-1016.
- 26 Supplement Watch, Supplement Watch, <http://www.supplementwatch.com/>.
- 27 Therapeutic Research Faculty, Cranberry Monograph. Natural Medicines Comprehensive Database.
- 28 Turner A, Chen SN, Joike MK, Pendland SL, Pauli GF, Farnsworth NR, 2005. Inhibition of uropathogenic *Escherichia coli* by cranberry juice: a new antiadherence assay. *J Agric Food Chem*, 53, 8940-8947.

ID 2772: “Valerian extract [Dry extract from roots of *Valeriana officinalis* L., drug/native extract ratio(3 - 6): 1, solvent of extraction Ethanol/Water, min 0.3% valerenic acid]” and “For isomnia and mental health”

- 1 Cerny A and Schmid K, 1999. Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study). *Fitoterapia*, 70, 221-228.
- 2 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 3 Schwander J and Mann C, 1999. The pupil unrest index as a measure of sleep restoration in patients with psychophysiological insomnia.

- 4 WHO (World Health Organization), 1999. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.

ID 2773: “Graines de brocoli et extraits de graines de brocoli: Sulforaphane” and “Santé de la prostate”

- 1 Brooks JD, Paton VG, Vidanes G, 2001. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. *Cancer Epidemiol Biomarkers Prev*, 10, 949-954.
- 2 Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, Conaway CC, 2002. Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. *Int J Oncol*, 20, 631-636.
- 3 Chiao JW, Wu H, Ramaswamy G, Conaway CC, Chung FL, Wang L, Liu D, 2004. Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. *Carcinogenesis*, 25, 1403-1408.
- 4 Dashwood RH, Myzak MC, Ho E, 2006. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? *Carcinogenesis*, 27, 344-349.
- 5 Dashwood RH and Ho E, 2007. Dietary histone deacetylase inhibitors: from cells to mice to man. *Semin Cancer Biol*, 17, 363-369.
- 6 Hanlon N, Coldham N, Gielbert A, Kuhnert N, Sauer MJ, King LJ, Ioannides C, 2008. Absolute bioavailability and dose-dependent pharmacokinetic behaviour of dietary doses of the chemopreventive isothiocyanate sulforaphane in rat. *Br J Nutr*, 99, 559-564.
- 7 Herman-Antosiewicz A, Xiao H, Lew KL, Singh SV, 2007. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line. *Mol Cancer Ther*, 6, 1673-1681.
- 8 Higdon JV, Delage B, Williams DE, Dashwood RH, 2007. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. *Pharmacol Res*, 55, 224-236.
- 9 Hu R, Hebbar V, Kim BR, Chen C, Winnik B, Buckley B, Soteropoulos P, Toliás P, Hart RP, Kong AN, 2004. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. *J Pharmacol Exp Ther*, 310, 263-271.
- 10 Jones SB and Brooks JD, 2006. Modest induction of phase 2 enzyme activity in the F-344 rat prostate. *BMC Cancer*, 6, 62.
- 11 Juge N, Mithen RF, Traka M, 2007. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. *Cell Mol Life Sci*, 64, 1105-1127.
- 12 Keck AS, Qiao Q, Jeffery EH, 2003. Food matrix effects on bioactivity of broccoli-derived sulforaphane in liver and colon of F344 rats. *J Agric Food Chem*, 51, 3320-3327.
- 13 Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB, 2007. Prospective study of fruit and vegetable intake and risk of prostate cancer. *J Natl Cancer Inst*, 99, 1200-1209.
- 14 Lai RH, Keck AS, Wallig MA, West LG, Jeffery EH, 2008. Evaluation of the safety and bioactivity of purified and semi-purified glucoraphanin. *Food Chem Toxicol*, 46, 195-202.
- 15 Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH, 2006. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. *FASEB J*, 20, 506-508.
- 16 Singh AV, Xiao D, Lew KL, Dhir R, Singh SV, 2004. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. *Carcinogenesis*, 25, 83-90.
- 17 Wang L, Liu D, Ahmed T, Chung FL, Conaway C, Chiao JW, 2004. Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. *Int J Oncol*, 24, 187-192.
- 18 Zhang Y, Munday R, Jobson HE, Munday CM, Lister C, Wilson P, Fahey JW, Mhaweche-Fauceglia P, 2006. Induction of GST and NQO1 in cultured bladder cells and in the urinary bladders of rats by an extract of broccoli (*Brassica oleracea italica*) sprouts. *J Agric Food Chem*, 54, 9370-9376.

ID 2774: “Fumaria officinalis, fumitory, nom français : fumeterre” and “elimination”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
- 2 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 3 Cahiers de L'Agence, 1998. Les Cahiers de l'agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 4 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- 5 Valnet J, 1983. Phytothérapie. Traitement des maladies par les plantes. Livre de Poche / Maloine, Paris.
- 6 Van Hellemont J, 1986. Compendium de phytothérapie. Association Pharmaceutique Belge, Bruxelles.
- 7 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2778: “Artemisia vulgaris L. ; Common name : Armoise commune” and “appétit”

- 1 AFSSA (Agence française de sécurité sanitaire des aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).

ID 2780: “Combretum micranthum G. Don; Common name: Kinkéliba” and “elimination”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).

ID 2782: “Equisetum arvense L.; Common name: Prêle des champs” and “élimination”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).
- 2 Blumenthal M, 1986. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines The American Botanical Council, Austin.
- 3 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- 4 Cahiers de L'Agence, 1997. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 5 Capasso F, Gaginella TS, Grandolini G, Izzo AA, 2003. Phytotherapy: A Quick Reference to Herbal Medicine. Springer Verlag, Berlin, Heidelberg, New York.
- 6 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- 7 Valnet J, 1983. Phytothérapie. Traitement des maladies par les plantes. Livre de Poche / Maloine, Paris.
- 8 Van Hellemont J, 1986. Compendium de Phytothérapie. Association Pharmaceutique Belge, Bruxelles.

- 9 Wichtl M and Anton R, 1999. Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique. Ed. Tec & Doc, Lavoisier, Paris.

ID 2783: “Equisetum arvense L. ; Common name : Prêle des champs; Common name : Armoise commune” and “ amincissement”

- 1 AFSSA (Agence française de sécurité sanitaire des aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).

ID 2784: “Hieracium pilosella L.; Common name: Piloselle” and “élimination”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).
- 2 Beaux D, Fleurentin J, Mortier F, 1999. Effect of extracts of Orthosiphon stamineus Benth, Hieracium pilosella L., Sambucus nigra L. and Arctostaphylos uva-ursi (L.) Spreng. in rats. Phytother Res, 13, 222-225.
- 3 Depoërs P, Ledoux F, Meurin P, 2002. La phytothérapie entre science et tradition Amyris, Paris.

ID 2785: “Ononis spinosa L.; Common name: Bugrane ” and “élimination”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).

ID 2787: “Urtica dioica L.; Common name: Ortie dioïque” and “élimination”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).

ID 2788: “Zea mays L.; Common name: Maïs” and “amincissement”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2003. Démarche d'évaluation de la sécurité, de l'intérêt et de l'allégation des denrées alimentaires, contenant des plantes, destinées à la consommation humaine (Framework for the evaluation of the safety, the effect and the claims of foodstuff, made from plants, for the human diet).

ID 2792: “Ajuga extract” and “Trophism of skin and related tissues”

- 1 Calcagno MP, Camps F, Coll J, Mele E, Messeguer J, Tomas YJ, 1994. Sengosterone, an ecdysteroid present in Ajuga reptans L. Anales de Quimica, 90, 483-486.

- 2 Camps F, Coll J, Cortel A, Messeguer A, 1979. Ajugareptansin, a new diterpenoid from *Ajuga reptans* (L.). *Tetrahedron Letters*, 19, 1709-1712.
- 3 Marzani B, Giardina S, Benedusi A, Marzatico F, 2005. Antioxidant and anti-inflammatory activities of *Ajuga reptans* extract. Verona International Joint Meeting on Foods, Phytotherapeutic Compounds and Health.
- 4 Nikolova M and Asenov A, 2006. Surface flavonoid aglycones in newly studied plant species. *Natural product research*, 20, 103-106.

ID 2793: “Alfalfa” and “Cardiovascular system”

- 1 Boue SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA, Cleveland TE, 2003. Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. *J Agric Food Chem*, 51, 2193-2199.
- 2 Esper E, Barichello AW, Chan EK, Matts JP, Buchwald H, 1987. Synergistic lipid-lowering effects of alfalfa meal as an adjuvant to the partial ileal bypass operation. *Surgery*, 102, 39-51.
- 3 Hwang J, Hodis HN, Sevanian A, 2001. Soy and alfalfa phytoestrogen extracts become potent low-density lipoprotein antioxidants in the presence of acerola cherry extract. *J Agric Food Chem*, 49, 308-314.
- 4 Malinow MR, McLaughlin P, Naito HK, Lewis LA, McNulty WP, 1978. Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys. *Atherosclerosis*, 30, 27-43.
- 5 Malinow MR, McLaughlin P, Stafford C, Livingston AL, Kohler GO, 1980. Alfalfa saponins and alfalfa seeds. Dietary effects in cholesterol-fed rabbits. *Atherosclerosis*, 37, 433-438.
- 6 Malinow MR, 1983. Experimental models of atherosclerosis regression. *Atherosclerosis*, 48, 105-118.
- 7 Molgaard J, von Schenck H, Olsson AG, 1987. Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with type II hyperlipoproteinemia. *Atherosclerosis*, 65, 173-179.
- 8 Pierre S, Crosbie L, Duttaroy AK, 2005. Inhibitory effect of aqueous extracts of some herbs on human platelet aggregation in vitro. *Platelets*, 16, 469-473.

ID 2794: “Avocado-soy extract” and “Joints”

- 1 Altinel L, Saritas ZK, Kose KC, Pamuk K, Aksoy Y, Serteser M, 2007. Treatment with unsaponifiable extracts of avocado and soybean increases TGF-beta1 and TGF-beta2 levels in canine joint fluid. *Tohoku J Exp Med*, 211, 181-186.
- 2 Appelboom T, Schuermans J, Verbruggen G, Henrotin Y, Reginster JY, 2001. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. *Scand J Rheumatol*, 30, 242-247.
- 3 Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A, 1997. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. *Rev Rhum Engl Ed*, 64, 825-834.
- 4 Boumediene K, Felisaz N, Bogdanowicz P, Galera P, Guillou GB, Pujol JP, 1999. Avocado/soya unsaponifiables enhance the expression of transforming growth factor beta1 and beta2 in cultured articular chondrocytes. *Arthritis Rheum*, 42, 148-156.
- 5 Cake MA, Read RA, Guillou B, Ghosh P, 2000. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). *Osteoarthritis Cartilage*, 8, 404-411.
- 6 Henrotin YE, Sanchez C, Deberg MA, Piccardi N, Guillou GB, Msika P, Reginster JY, 2003. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. *J Rheumatol*, 30, 1825-1834.

- 7 Henrotin YE, Deberg MA, Crielaard JM, Piccardi N, Msika P, Sanchez C, 2006. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. *J Rheumatol*, 33, 1668-1678.
- 8 Khayyal MT and el-Ghazaly MA, 1998. The possible "chondroprotective" effect of the unsaponifiable constituents of avocado and soya in vivo. *Drugs Exp Clin Res*, 24, 41-50.
- 9 Kut C, Assoumou A, Dridi M, Bonnefoix M, Gogly B, Pellat B, Guillou GB, Godeau G, 1998. Morphometric analysis of human gingival elastic fibres degradation by human leukocyte elastase protective effect of avocado and soybean unsaponifiables (ASU). *Pathol Biol (Paris)*, 46, 571-576.
- 10 Kut-Lasserre C, Miller CC, Ejeil AL, Gogly B, Dridi M, Piccardi N, Guillou B, Pellat B, Godeau G, 2001. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP-2), stromelysin 1 (MMP-3), and tissue inhibitors of matrix metalloproteinase (TIMP- 1 and TIMP-2) secretion by human fibroblasts in culture. *J Periodontol*, 72, 1685-1694.
- 11 Lequesne M, Maheu E, Cadet C, Dreiser RL, 2002. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. *Arthritis Rheum*, 47, 50-58.
- 12 Little CV and Parsons T, 2001. Herbal therapy for treating osteoarthritis. *Cochrane Database Syst Rev*, CD002947.
- 13 Maheu E, Mazieres B, Valat JP, Loyau G, Le Loet X, Bourgeois P, Grouin JM, Rozenberg S, 1998. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. *Arthritis Rheum*, 41, 81-91.

ID 2795: “Bilberry / flavonols + anthocyanidines” and “Antioxidativity Cardiovascular system”

- 1 Bagchi D, Sen CK, Bagchi M, Atalay M, 2004. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*, 69, 75-80, 71 p preceding 75.
- 2 Bravo L, 1998. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. *Nutr Rev*, 56, 317-333.
- 3 Eastwood MA, 1999. Interaction of dietary antioxidants in vivo: how fruit and vegetables prevent disease? *QJM*, 92, 527-530.
- 4 Heinonen IM, Lehtonen PJ, Hopia AI, 1998. Antioxidant Activity of Berry and Fruit Wines and Liquors. *J Agric Food Chem*, 46, 25-31.
- 5 Heinonen IM, Meyer AS, Frankel EN, 1998. Antioxidant activity of berry phenolics on human low-density lipoprotein and liposome oxidation. *J Agric Food Chem*, 46, 4107-4112.
- 6 Hertog MGL, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic SI, Pekkarinen M, Simic BS, Toshima H, Feskens EJM, Hollman PCH, Katan MB, 1995. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. *Arch Intern Med*, 155, 381-386.
- 7 Kähkönen MP, Heinämäki J, Ollilainen V, Heinonen M, 2001. Berry anthocyanins: isolation, identification and antioxidant activities. *Journal of the Science of Food and Agriculture*, 83, 1403-1411.
- 8 Middleton E, Jr., Kandaswami C, Theoharides TC, 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol Rev*, 52, 673-751.
- 9 Newport A and Lockwood B, 2005. Use of Nutraceuticals for eye health. *Pharmaceutical Journal*, 275, 261-264.
- 10 Peterson J and Dwyer J, 1998. Flavonoids: dietary occurrence and biochemical activity. *Nutrition Research*, 18, 1995-2018.

- 11 Prior RL, 2003. Fruits and vegetables in the prevention of cellular oxidative damage. *Am J Clin Nutr*, 78, 570S-578S.
- 12 Reed J, 2002. Cranberry flavonoids, atherosclerosis and cardiovascular health. *Crit Rev Food Sci Nutr*, 42, 301-316.
- 13 Zheng W and Wang SY, 2003. Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries. *J Agric Food Chem*, 51, 502-509.

ID 2796: “Bilberry and anthocyanins from blackcurrant” and “Eyes”

- 1 Bilberry Fruit. 2000. In: *Principles and Practice of Phytotherapy: Modern Herbal Medicine*. Mills S and Bone K (eds.). Churchill Livingstone, London, Edinburgh, 297-302.
- 2 *Vaccinium myrtillus* (bilberry). Monograph, 2001. *Altern Med Rev*, 6, 500-504.
- 3 Prévenir le Déclin de la vision lié au Vieillissement. 2001. *Nutanews -Science, Nutrition, Prévention et Santé*, Mai.
- 4 Barnes J, Anderson LA, Phillipson JD, 2003. *Herbal Medicines*. Pharmaceutical Press, London.
- 5 Bastide P, Rouher F, Tronche P, 1968. Rhodosine et anthocyanosides. A propos de quelques faits expérimentaux. *Bull. Soc. Ophtalm. Fran*, 68, 801-807.
- 6 Bruneton J, 1999. *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris.
- 7 Canter PH and Ernst E, 2004. Anthocyanosides of *Vaccinium myrtillus* (bilberry) for night vision--a systematic review of placebo-controlled trials. *Surv Ophthalmol*, 49, 38-50.
- 8 Delaveau P, 1984. Myrtille. *Concours médical*, 106, 4129-4130.
- 9 Dorvault FLM, 1867. *L'Officine*. Asselin, Paris.
- 10 Dorvault FLM, 1995. *L'Officine*. Vigot, Paris.
- 11 Head K, 2001. Natural therapies for ocular disorders part two: Cataracts and glaucoma. *Alternative Medicine Review*, 6, 141-166.
- 12 Jayle GE, Aubry M, Gavini H, 1965. Etude concernant l'action sur la vision nocturne des anthocyanosides extrait du *Vaccinium myrtillus*. *Ann Ocul*, 198, 556-562.
- 13 Lee J, Lee HK, Kim CY, Hong YJ, Choe CM, You TW, Seong GJ, 2005. Purified high-dose anthocyanoside oligomer administration improves nocturnal vision and clinical symptoms in myopia subjects. *Br J Nutr*, 93, 895-899.
- 14 Mercier A, Perdriel G, Rozier J, Chevaleraud J, 1965. [Note concerning the action of anthocyanin glycosides on the human electroretinogram]. *Bull Soc Ophtalmol Fr*, 65, 1049-1053.
- 15 Nakaishi H, Matsumoto H, Tominaga S, Hirayama M, 2000. Effects of black current anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans. *Altern Med Rev*, 5, 553-562.
- 16 Vasco C, Riihinen K, Ruales J, Kamal-Eldin A, 2009. Phenolic compounds in Rosaceae fruits from Ecuador. *J Agric Food Chem*, 57, 1204-1212.
- 17 Weisel T, Baum M, Eisenbrand G, Dietrich H, Will F, Stockis JP, Kulling S, Rufer C, Johannes C, Janzowski C, 2006. An anthocyanin/polyphenolic-rich fruit juice reduces oxidative DNA damage and increases glutathione level in healthy probands. *Biotechnol J*, 1, 388-397.
- 18 Wichtl M and Anton R, 1999. *Plantes thérapeutiques: tradition, pratique officinale, science et thérapeutique*. Ed. Tec & Doc, Lavoisier, Paris.

ID 2798: “Bilberry + pine bark” and “Musculoskeletal system”

- 1 Ahotupa M, 1996. Tutkimusraportti, Havupuu-uutteen ja Pycnogenolin antioksidatiiviset vaikutukset. MCA Tutkimuslaboratorio, Turku.
- 2 Bravetti G, 1989. Preventive medical treatment of senile cataract with vitamin E and anthocyanosides: clinical evaluation. *Ann Ottalmol Clin Ocul*, 115, 109.
- 3 Canter PH and Ernst E, 2004. Anthocyanosides of *Vaccinium myrtillus* (bilberry) for night vision--a systematic review of placebo-controlled trials. *Surv Ophthalmol*, 49, 38-50.
- 4 Cignarella A, Nastasi M, Cavalli E, Puglisi L, 1996. Novel lipid-lowering properties of *Vaccinium myrtillus* L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate. *Thromb Res*, 84, 311-322.
- 5 Fursova A, Gesarevich OG, Gonchar AM, Trofimova NA, Kolosova NG, 2005. [Dietary supplementation with bilberry extract prevents macular degeneration and cataracts in senesce-accelerated OXYS rats]. *Adv Gerontol*, 16, 76-79.
- 6 Head KA, 2001. Natural therapies for ocular disorders, part two: cataracts and glaucoma. *Altern Med Rev*, 6, 141-166.
- 7 Kamuren ZT, McPeck CG, Sanders RA, Watkins JB, 3rd, 2006. Effects of low-carbohydrate diet and Pycnogenol treatment on retinal antioxidant enzymes in normal and diabetic rats. *J Ocul Pharmacol Ther*, 22, 10-18.
- 8 Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P, 2004. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. *Life Sci*, 75, 2505-2513.
- 9 Schonlau F and Rohdewald P, 2001. Pycnogenol for diabetic retinopathy. A review. *Int Ophthalmol*, 24, 161-171.
- 10 Sivonova M, Waczulikova I, Kilanczyk E, Hrnčiarova M, Bryszewska M, Klajnert B, Durackova Z, 2004. The effect of Pycnogenol on the erythrocyte membrane fluidity. *Gen Physiol Biophys*, 23, 39-51.

ID 2800: “Bilberry + pine bark” and “Antioxidativity”

- 1 Ahotupa M, 1996. Tutkimusraportti, Havupuu-uutteen ja Pycnogenolin antioksidatiiviset vaikutukset. MCA Tutkimuslaboratorio, Turku.
- 2 Bravetti G, 1989. Preventive medical treatment of senile cataract with vitamin E and anthocyanosides: clinical evaluation. *Ann Ottalmol Clin Ocul*, 115, 109.
- 3 Canter PH and Ernst E, 2004. Anthocyanosides of *Vaccinium myrtillus* (bilberry) for night vision--a systematic review of placebo-controlled trials. *Surv Ophthalmol*, 49, 38-50.
- 4 Cignarella A, Nastasi M, Cavalli E, Puglisi L, 1996. Novel lipid-lowering properties of *Vaccinium myrtillus* L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate. *Thromb Res*, 84, 311-322.
- 5 Fursova A, Gesarevich OG, Gonchar AM, Trofimova NA, Kolosova NG, 2005. [Dietary supplementation with bilberry extract prevents macular degeneration and cataracts in senesce-accelerated OXYS rats]. *Adv Gerontol*, 16, 76-79.
- 6 Head KA, 2001. Natural therapies for ocular disorders, part two: cataracts and glaucoma. *Altern Med Rev*, 6, 141-166.
- 7 Kamuren ZT, McPeck CG, Sanders RA, Watkins JB, 3rd, 2006. Effects of low-carbohydrate diet and Pycnogenol treatment on retinal antioxidant enzymes in normal and diabetic rats. *J Ocul Pharmacol Ther*, 22, 10-18.
- 8 Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P, 2004. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. *Life Sci*, 75, 2505-2513.

- 9 Schonlau F and Rohdewald P, 2001. Pycnogenol for diabetic retinopathy. A review. *Int Ophthalmol*, 24, 161-171.
- 10 Sivonova M, Waczulikova I, Kilanczyk E, Hrnciarova M, Bryszewska M, Klajnert B, Durackova Z, 2004. The effect of Pycnogenol on the erythrocyte membrane fluidity. *Gen Physiol Biophys*, 23, 39-51.

ID 2803: “Dandelion root extract” and “Cardiovascular system”

- 1 Cho SY, Park JY, Park EM, Choi MS, Lee MK, Jeon SM, Jang MK, Kim MJ, Park YB, 2002. Alternation of hepatic antioxidant enzyme activities and lipid profile in streptozotocin-induced diabetic rats by supplementation of dandelion water extract. *Clin Chim Acta*, 317, 109-117.
- 2 Sweeney B, Vora M, Ulbricht C, Basch E, 2005. Evidence-based systematic review of dandelion (*Taraxacum officinale*) by natural standard research collaboration. *J Herb Pharmacother*, 5, 79-93.

ID 2805: “Garlic” and “Carbohydrate metabolism and insulin sensitivity.”

- 1 Cicero AF, Derosa G, Gaddi A, 2004. What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. *Acta Diabetol*, 41, 91-98.
- 2 Kieseewetter H, Jung F, Pindur G, Jung EM, Mrowietz C, Wenzel E, 1991. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. *Int J Clin Pharmacol Ther Toxicol*, 29, 151-155.

ID 2807: “Ginkgo tree (*Ginkgo biloba*)” and “Cardiovascular system. Eyes. Ears”

- 1 Liste der in der Schweiz zulässigen Anpreisungen für Vitamine und Mineralstoffe.
- 2 Burschka MA, Hassan HA, Reineke T, van Bebbler L, Caird DM, Mosges R, 2001. Effect of treatment with *Ginkgo biloba* extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients. *Eur Arch Otorhinolaryngol*, 258, 213-219.
- 3 Cieza A, Maier P, Poppel E, 2003. Effects of *Ginkgo biloba* on mental functioning in healthy volunteers. *Arch Med Res*, 34, 373-381.
- 4 D-A-CH (Deutsche Gesellschaft für Ernährung - Österreichische Gesellschaft für Ernährung - Schweizerische Gesellschaft für Ernährungsforschung - Schweizerische Vereinigung für Ernährung), 2000. Referenzwerte für die Nährstoffzufuhr. Umschau Braus Verlag, Frankfurt am Main.
- 5 Diamond BJ, Shiflett SC, Feiwei N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE, 2000. *Ginkgo biloba* extract: mechanisms and clinical indications. *Arch Phys Med Rehabil*, 81, 668-678.
- 6 Gertz HJ and Kiefer M, 2004. Review about *Ginkgo biloba* special extract EGb 761 (*Ginkgo*). *Curr Pharm Des*, 10, 261-264.
- 7 Gröber U, 2002. *Orthomolekulare Medizin*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- 8 Loew D, 2002. [Value of *Ginkgo biloba* in treatment of Alzheimer dementia]. *Wien Med Wochenschr*, 152, 418-422.
- 9 Mason P, 2001. *Dietary Supplements*. Pharmaceutical Press, London.
- 10 McKenna DJ, Jones K, Hughes K, 2001. Efficacy, safety, and use of *ginkgo biloba* in clinical and preclinical applications. *Altern Ther Health Med*, 7, 70-86, 88-90.
- 11 Morgenstern C and Biermann E, 2002. The efficacy of *Ginkgo* special extract EGb 761 in patients with tinnitus. *Int J Clin Pharmacol Ther*, 40, 188-197.
- 12 Reisser CH and Weidauer H, 2001. *Ginkgo biloba* extract EGb 761 or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, double-blind study. *Acta Otolaryngol*, 121, 579-584.

- 13 Ritch R, 2005. Complementary therapy for the treatment of glaucoma: a perspective. *Ophthalmol Clin North Am*, 18, 597-609.

ID 2808: “Ginseng” and “Physical performance and condition.”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 3 Branth S and Gruber P, 1990. Ginseng förbättrar prestationen! *Biomed*, 3, 14-17.
- 4 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 5 Sørensen H and Sonne J, 1996. A double-masked study of the effects of ginseng on cognitive functions. *Current Therapeutic Research*, 57, 959-968.
- 6 Sotaniemi EA, Haapakoski E, Rautio A, 1995. Ginseng therapy in non-insulin-dependent diabetic patients. *Diabetes Care*, 18, 1373-1375.
- 7 WHO (World Health Organization), 1999. *WHO Monographs on Selected Medicinal Plants*. WHO (World Health Organization), Geneva.

ID 2809: “Ginseng” and “Mental state and performance”

- 1 Attele AS, Wu JA, Yuan CS, 1999. Ginseng pharmacology: multiple constituents and multiple actions. *Biochem Pharmacol*, 58, 1685-1693.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 3 Branth S and Gruber P, 1990. Ginseng förbättrar prestationen! *Biomed*, 3, 14-17.
- 4 Caso Marasco A, Vargas Ruiz R, Salas Villagomez A, Begona Infante C, 1996. Double-blind study of a multivitamin complex supplemented with ginseng extract. *Drugs Exp Clin Res*, 22, 323-329.
- 5 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 6 Kennedy DO and Scholey AB, 2003. Ginseng: potential for the enhancement of cognitive performance and mood. *Pharmacol Biochem Behav*, 75, 687-700.
- 7 Kiefer D and Pantuso T, 2003. Panax ginseng. *Am Fam Physician*, 68, 1539-1542.
- 8 Le Gal M, Cathebras P, Strüby K, 1996. Pharmaton capsules in the treatment of functional fatigue : a double-blind study versus placebo evaluated by a new methodology. *PTR. Phytotherapy research* 10, 49-53.
- 9 Perialisi G, Ripari P, Vecchiet L, 1991. Effects of a standardized ginseng extract combined with dimethylaminoethanol bitartrate, vitamins, minerals, and trace elements on physical performance during exercise. *Clin Ther*, 13, 373-382.
- 10 Sørensen H and Sonne J, 1996. A double-masked study of the effects of ginseng on cognitive functions. *Current Therapeutic Research*, 57, 959-968.
- 11 Tode T, Kikuchi Y, Hirata J, Kita T, Nakata H, Nagata I, 1999. Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes. *Int J Gynaecol Obstet*, 67, 169-174.

- 12 Ussher J, Dewberry C, Malson H, Noakes J, 1995. The relationship between health related quality of life and dietary supplementation in british middle managers: A double blind placebo controlled study *Psychology & Health*, 10, 97-111.
- 13 Wesnes K, Luthringer R, Ambrosetti L, Edgar C, Petrini O, 2003. The effects of a combination of Panax ginseng, vitamins and minerals on mental performance, mood and physical fatigue in nurses working night shifts: a double-blind, placebo controlled trial. *Current Topics in Nutraceutical Research*, 1, 169-176.
- 14 WHO (World Health Organization), 1999. WHO Monographs on Selected Medicinal Plants. WHO (World Health Organization), Geneva.

ID 2812: “Green tea extract” and “Mental state and performance”

- 1 Hanley JL, 1999. Attention Deficit Disorder. Impakt Communications Inc, Green Bay, WI.
- 2 Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, Awata S, Nagatomi R, Arai H, Tsuji I, 2006. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. *Am J Clin Nutr*, 83, 355-361.

ID 2813: “Green tea extract” and “Mouth”

- 1 Hirasawa M, Takada K, Otake S, 2006. Inhibition of acid production in dental plaque bacteria by green tea catechins. *Caries Res*, 40, 265-270.

ID 2814: “Green tea, green tea extract” and “Cardiovascular system”

- 1 Clark J and You M, 2006. Chemoprevention of lung cancer by tea. *Mol Nutr Food Res*, 50, 144-151.
- 2 Cooper R, Morre DJ, Morre DM, 2005. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. *J Altern Complement Med*, 11, 521-528.
- 3 Cooper R, Morre DJ, Morre DM, 2005. Medicinal benefits of green tea: part II. review of anticancer properties. *J Altern Complement Med*, 11, 639-652.
- 4 Hoensch HP and Kirch W, 2005. Potential role of flavonoids in the prevention of intestinal neoplasia: a review of their mode of action and their clinical perspectives. *Int J Gastrointest Cancer*, 35, 187-195.
- 5 Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB, 2006. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. *Mol Nutr Food Res*, 50, 229-234.
- 6 Siddiqui IA, Adhami VM, Saleem M, Mukhtar H, 2006. Beneficial effects of tea and its polyphenols against prostate cancer. *Mol Nutr Food Res*, 50, 130-143.
- 7 Stangl V, Lorenz M, Stangl K, 2006. The role of tea and tea flavonoids in cardiovascular health. *Mol Nutr Food Res*, 50, 218-228.
- 8 Zaveri NT, 2006. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. *Life Sci*, 78, 2073-2080.

ID 2815: “Heather blossom extract” and “Mental state and performance”

- 1 Girau Bach L, 1955. [Pharmacognosia of *Calluna vulgaris* (L.) Hull (common heath) of the northeast region of Spain.]. *Farmacognosia*, 15, 49-144.
- 2 Plants For A Future, *Calluna vulgaris*, http://www.ibiblio.org/pfaf/cgi-bin/arr_html?Calluna+vulgaris.

- 3 Tunon H, Olavsdotter C, Bohlin L, 1995. Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. *J Ethnopharmacol*, 48, 61-76.

ID 2816: “Dry extract of common horsetail summer shoots + dry extract of dandelion root” and “Fluid and electrolyte balance”

- 1 Hagers Handbuch der pharmazeutischen Praxis. 1992. Springer Verlag, Berlin.
- 2 BHMA (British Herbal Medicine Association), 1983. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 3 BHMA (British Herbal Medicine Association), 1996. *British Herbal Pharmacopoeia*. British Herbal Medicine Association, Exeter.
- 4 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.
- 5 Evans WC and Trease GE, 1989. *Trease and Evans' pharmacognosy*. Baillière Tindall, London, Philadelphia.
- 6 Wichtl M, 1994. *Herbal Drugs and Phytopharmaceuticals*. Medpharm, Stuttgart.
- 7 Widmaier W, 1986. *Pflanzenheilkunde. Geschichte-Praxis-Rezepturen*. WEB Biologisch-Medizinische Verlagsgesellschaft, Schorndorf.
- 8 Wren RC Potters, 1980. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. Health Science Press, Bradford.

ID 2817: “Iceland moss extract (*Cetraria islandica*)” and “Antioxidativity”

- 1 Gulcin I, Oktay M, Kufrevioglu OI, Aslan A, 2002. Determination of antioxidant activity of lichen *Cetraria islandica* (L) Ach. *J Ethnopharmacol*, 79, 325-329.
- 2 Ingolfssdottir K, Jurcic K, Fischer B, Wagner H, 1994. Immunologically active polysaccharide from *Cetraria islandica*. *Planta Med*, 60, 527-531.
- 3 Kempe C, Gruning H, Stasche N, Hormann K, 1997. [Icelandic moss lozenges in the prevention or treatment of oral mucosa irritation and dried out throat mucosa]. *Laryngorhinootologie*, 76, 186-188.
- 4 Olafsdottir ES, Ingolfssdottir K, Barsett H, Paulsen BS, Jurcic K, Wagner H, 1999. Immunologically active (1->3)-(1->4)-alpha-D-glucan from *Cetraria islandica*. *Phytomedicine*, 6, 33-39.
- 5 Puodziuniene G, Janulis V, Milasius A, Budnikas V, 2005. [Development of cough-relieving herbal teas]. *Medicina (Kaunas)*, 41, 500-505.

ID 2819: “Jerusalem artichoke” and “Gut health”

- 1 Cummings JH, Macfarlane GT, Englyst HN, 2001. Prebiotic digestion and fermentation. *Am J Clin Nutr*, 73, 415S-420S.
- 2 Kaur N and Gupta AK, 2002. Applications of inulin and oligofructose in health and nutrition. *J Biosci*, 27, 703-714.
- 3 Rumessen JJ, Bode S, Hamberg O, Gudmand-Hoyer E, 1990. Fructans of Jerusalem artichokes: intestinal transport, absorption, fermentation, and influence on blood glucose, insulin, and C-peptide responses in healthy subjects. *Am J Clin Nutr*, 52, 675-681.

- 4 Zhuk EA and Zelenkov VN, 1997. [Topinambur concentrate in the treatment of patients with insulin-dependent diabetes mellitus]. *Vopr Pitan*, 34-36.

ID 2820: “Jerusalem artichoke” and “Gut health”

- 1 Cummings JH, Macfarlane GT, Englyst HN, 2001. Prebiotic digestion and fermentation. *Am J Clin Nutr*, 73, 415S-420S.
- 2 Kaur N and Gupta AK, 2002. Applications of inulin and oligofructose in health and nutrition. *J Biosci*, 27, 703-714.
- 3 Rumessen JJ, Bode S, Hamberg O, Gudmand-Hoyer E, 1990. Fructans of Jerusalem artichokes: intestinal transport, absorption, fermentation, and influence on blood glucose, insulin, and C-peptide responses in healthy subjects. *Am J Clin Nutr*, 52, 675-681.
- 4 Zhuk EA and Zelenkov VN, 1997. [Topinambur concentrate in the treatment of patients with insulin-dependent diabetes mellitus]. *Vopr Pitan*, 34-36.

ID 2821: “Nettle” and “Bone, nails, hair”

- 1 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 2 Frater M and Halasz S, 1991. Experiences with Urticalcin® for the prevention of tooth decay, brittle nails, problems with hair growth and other indications. *Bioforce*.
- 3 Hiltunen R and Holm Y, 1994. *Luonnonlääkkeet*. Painotalo Miktor, Helsinki.
- 4 Weiss RF and Fintelmann V, 2000. *Weiss's Herbal Medicine*. Thieme, Stuttgart.

ID 2823: “Oregano (*Origanum vulgare*)” and “Antioxidativity”

- 1 Baricevic D and Bartol T, 2002. Bibliometric analysis of agricultural and biomedical bibliographic databases with regard to medicinal plants genera *Origanum* and *Lippia* in the period 1981-1998. In: *Oregano: the genera Origanum and Lippia. Medicinal and Aromatic Plants - Industrial Profiles*. Kintzios SE (ed.) Taylor and Francis, London, New York, 245-268.
- 2 Burt SA and Reinders RD, 2003. Antibacterial activity of selected plant essential oils against *Escherichia coli* O157:H7. *Lett Appl Microbiol*, 36, 162-167.
- 3 Dorman HJ and Deans SG, 2000. Antimicrobial agents from plants: antibacterial activity of plant volatile oils. *J Appl Microbiol*, 88, 308-316.
- 4 el-Ashmawy IM, el-Nahas AF, Salama OM, 2005. Protective effect of volatile oil, alcoholic and aqueous extracts of *Origanum majorana* on lead acetate toxicity in mice. *Basic Clin Pharmacol Toxicol*, 97, 238-243.
- 5 Elgayyar M, Draughon FA, Golden DA, Mount JR, 2001. Antimicrobial activity of essential oils from plants against selected pathogenic and saprophytic microorganisms. *J Food Prot*, 64, 1019-1024.
- 6 Hammer KA, Carson CF, Riley TV, 1999. Antimicrobial activity of essential oils and other plant extracts. *J Appl Microbiol*, 86, 985-990.
- 7 Jin Jun W, Kyung Han B, Won Yu K, Sung Kim M, Seop Chang I, Yun Kim H, Yon Cho H, 2001. Antioxidant effects of *Origanum majorana* L. on superoxide anion radicals. *Food Chemistry*, 75, 439-444.
- 8 Lopez V, Akerreta S, Casanova E, Garcia-Mina JM, Caverro RY, Calvo MI, 2007. In vitro antioxidant and anti-rhizopus activities of Lamiaceae herbal extracts. *Plant Foods Hum Nutr*, 62, 151-155.
- 9 Mejlholm O and Dalgaard P, 2002. Antimicrobial effect of essential oils on the seafood spoilage micro-organism *Photobacterium phosphoreum* in liquid media and fish products. *Lett Appl Microbiol*, 34, 27-31.

- 10 Nevas M, Korhonen AR, Lindstrom M, Turkki P, Korkeala H, 2004. Antibacterial efficiency of Finnish spice essential oils against pathogenic and spoilage bacteria. *J Food Prot*, 67, 199-202.
- 11 Ninfali P, Mea G, Giorgini S, Rocchi M, Bacchiocca M, 2005. Antioxidant capacity of vegetables, spices and dressings relevant to nutrition. *Br J Nutr*, 93, 257-266.
- 12 O'Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, Vaira D, Holton J, Basset C, 2005. Bactericidal and anti-adhesive properties of culinary and medicinal plants against *Helicobacter pylori*. *World J Gastroenterol*, 11, 7499-7507.
- 13 Oussalah M, Caillet S, Lacroix M, 2006. Mechanism of action of Spanish oregano, Chinese cinnamon, and savory essential oils against cell membranes and walls of *Escherichia coli* O157:H7 and *Listeria monocytogenes*. *J Food Prot*, 69, 1046-1055.
- 14 Srihari T, Sengottuvelan M, Nalini N, 2008. Dose-dependent effect of oregano (*Origanum vulgare* L.) on lipid peroxidation and antioxidant status in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. *J Pharm Pharmacol*, 60, 787-794.
- 15 Tognolini M, Barocelli E, Ballabeni V, Bruni R, Bianchi A, Chiavarini M, Impicciatore M, 2006. Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity. *Life Sci*, 78, 1419-1432.
- 16 Ultee A, Gorris LG, Smid EJ, 1998. Bactericidal activity of carvacrol towards the food-borne pathogen *Bacillus cereus*. *J Appl Microbiol*, 85, 211-218.

ID 2825: “Papaya” and “Digestion”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. Papaya leaf. In: *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX, 361.
- 2 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. Papain. In: *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX, 360-361.
- 3 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 4 Bruneton J, 1999. Papayer. In: *Pharmacognosie Phytochimie plantes médicinales*. Tec & Doc, Lavoisier, Paris, 221-223.
- 5 Bruneton J, 2002. Plantes et système digestif. In: *Phytothérapie, les données de l'évaluation*. Tec & Doc, Lavoisier, Paris, 218-220.
- 6 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- 7 Duke JA, 1985. *Carica papaya* L. (Caricaceae) – Papaya. In: *Handbook of Medicinal Herbs*. CRC Press, Boca Raton, 100-101.
- 8 Gruenwald J, Brendler T, Jaenicke C, 2004. Papaya. In: *PDR for herbal medicines*. Thomson Reuters, Montvale, 614-615.
- 9 Lassoudiere A, 1969. La papaïne. *Fruits*, 21, 503-530.
- 10 Lefrancois P and Ruby F, Papaïne, www.passeportsante.net.
- 11 Leung AY and Foster S, 1996. Papain. In: *Encyclopedia of common natural ingredients used in food, drugs, and cosmetics*. John Wiley & Sons, New York, 402-405.
- 12 Paris R and Myose H, 1981. Papayer. In: *Précis de Matière Médicale, Tome II*. Masson, Paris, 460-464.
- 13 Perrot EM, 1943-1944. Papayer. In: *Matières premières usuelles du règne végétal, Thérapeutique, Hygiène, Industrie*. Masson et Cie Editeurs, Paris, 1619-1623.

- 14 Rakhimov MR, 2000. [Pharmacological study of papain from the papaya plant cultivated in Uzbekistan]. *Eksp Klin Farmakol*, 63, 55-57.
- 15 Rombi M, Guedon D, Robert D, Rosier-sala C, Renzacci E, 2007. 120 plantes médicinales: Composition, mode d'action et intérêt thérapeutique. Alpen, Monaco.
- 16 Sweetman S, 2002. Papain. In: Martindale: The Complete Drug Reference. Pharmaceutical Press, London, 1647-1648.
- 17 Weiss RF, 2001. Herbal Medicine (Translated from the sixth German edition of *Lehrbuch der Phytotherapie*, Ab Arcanum, Gothenburg, Sweden, 1988). Thieme Medical Publishers.
- 18 Zucker S, Buttle DJ, Nicklin MJ, Barrett AJ, 1985. The proteolytic activities of chymopapain, papain, and papaya proteinase III. *Biochim Biophys Acta*, 828, 196-204.

ID 2827: “Pine shoot (fresh) (*Picea abies*)” and “Respiratory passages”

- 1 Hiltunen R and Holm Y, 1994. Luonnonlääkkeet. Painotalo Miktor, Helsinki.
- 2 Lagoni N, 2004. Arzneiliche Anmerkungen zur Tanne, *Abies alba* MILL. In: LWF Wissen: Beiträge zur Tanne. Bayrische Landesanstalt für Wald und Forstwirtschaft (ed.) 83-86.

ID 2829: “Roseroot (*Rhodiola rosea*)” and “Physical performance and condition. Antioxidativity”

- 1 *Rhodiola rosea*. Monograph. 2002. *Altern Med Rev*, 7, 421-423.
- 2 Abidov M, Crendal F, Grachev S, Seifulla R, Ziegenfuss T, 2003. Effect of extracts from *Rhodiola rosea* and *Rhodiola crenulata* (Crassulaceae) roots on ATP content in mitochondria of skeletal muscles. *Bull Exp Biol Med*, 136, 585-587.
- 3 Abidov M, Grachev S, Seifulla RD, Ziegenfuss TN, 2004. Extract of *Rhodiola rosea* radix reduces the level of C-reactive protein and creatinine kinase in the blood. *Bull Exp Biol Med*, 138, 63-64.
- 4 Brown RP, Gerbarg P, Ramazanov Z, 2002. *Rhodiola rosea*: A Phytomedicinal Overview. *HerbalGram*, 56, 40-52.
- 5 De Bock K, Eijnde BO, Ramaekers M, Hespel P, 2004. Acute *Rhodiola rosea* intake can improve endurance exercise performance. *International journal of sport nutrition and exercise metabolism*, 14, 298-307.
- 6 Furmanowa M, Skopinska-Rozewska E, Rogala E, Hartwich M, 1998. *Rhodiola rosea* in vitro culture: phytochemical analysis and antioxidant action. *Acta societatis botanicorum Poloniae*, 67, 69-73.
- 7 Kelly GS, 2001. *Rhodiola rosea*: a possible plant adaptogen. *Altern Med Rev*, 6, 293-302.
- 8 Kucinskaite A, Briedis V, Savickas A, 2004. [Experimental analysis of therapeutic properties of *Rhodiola rosea* L. and its possible application in medicine]. *Medicina (Kaunas)*, 40, 614-619.
- 9 Oliff H, 2004. Optimum Dosage of *Rhodiola rosea* Extract for Antifatigue Effects and Improved Mental Performance. *HerbalGram*, 63.

ID 2830: “Suma (*Pfaffia paniculata*) –phospholipid compound” and “Mental state and performance Physical performance and condition.”

- 1 Ballas SK, 2000. Hydration of sickle erythrocytes using a herbal extract (*Pfaffia paniculata*) in vitro. *Br J Haematol*, 111, 359-362.
- 2 Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC, 1991. Effects of phosphatidylserine in age-associated memory impairment. *Neurology*, 41, 644-649.

- 3 De Oliveira FG, 1980. Contribution to the Pharmacognostic Study of Brazilian Ginseng *Pfaffia paniculata*. *An Farm Chim*, 20, 277-361.
- 4 De Oliveira F, 1986. *Pfaffia paniculata* (Martius) Kuntze-Brazilian Ginseng. *Rev Bras Farmacog*, 1, 86-92.
- 5 Engel RR, Satzger W, Gunther W, Kathmann N, Bove D, Gerke S, Munch U, Hippus H, 1992. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. *Eur Neuropsychopharmacol*, 2, 149-155.
- 6 Gindin J, Novikov M, Kedar D, Walter-Ginzburg A, Nacr S, Karta O, Zur E, Levi S, 1995. The effect of plant phosphatidylserine on age-associated memory impairment and mood in the functioning elderly. Rehovot, Israel: Geriatric Institute for Education and Research, and Department of Geriatrics, Kaplan Hospital.
- 7 Maggioni M, Picotti GB, Bondiolotti GP, Panerai A, Cenacchi T, Nobile P, Brambilla F, 1990. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. *Acta Psychiatr Scand*, 81, 265-270.
- 8 Mazzanti G and Braghiroli L, 1994. Analgesic antiinflammatory action of *Pfaffia paniculata* (Martius) Kuntze. *Phytotherapy Research*, 8, 413-416.

ID 2831: “*Tribulus terrestris*” and “Sexual organs and/or hormone activity”

- 1 Adaikan PG, Gauthaman K, Prasad RN, Ng SC, 2000. Proerectile pharmacological effects of *Tribulus terrestris* extract on the rabbit corpus cavernosum. *Ann Acad Med Singapore*, 29, 22-26.
- 2 Adimoelja A, Setiawan L, Djojotananjo T, 1996. *Tribulus terrestris* (protodioscin) in the treatment of male infertility with idiopathic oligoasthenoterato-zoospermia. *Proceedings of the First International Conference of Medical Plants for Reproductive Medicine*, Taipei, Taiwan.
- 3 Adimoelja A, 2000. Phytochemicals and the breakthrough of traditional herbs in the management of sexual dysfunctions. *Int J Androl*, 23 Suppl 2, 82-84.
- 4 Al-Ali M, Wahbi S, Twajj H, Al-Badr A, 2003. *Tribulus terrestris*: preliminary study of its diuretic and contractile effects and comparison with *Zea mays*. *J Ethnopharmacol*, 85, 257-260.
- 5 Frawley D and Lad V, 1986. *The yoga of herbs: an Ayurvedic guide to herbal medicine*. Lotus Press, Bramsche.
- 6 Gauthaman K, Adaikan PG, Prasad RN, 2002. Aphrodisiac properties of *Tribulus Terrestris* extract (Protodioscin) in normal and castrated rats. *Life Sci*, 71, 1385-1396.
- 7 Gauthaman K, Ganesan AP, Prasad RN, 2003. Sexual effects of puncturevine (*Tribulus terrestris*) extract (protodioscin): an evaluation using a rat model. *J Altern Complement Med*, 9, 257-265.
- 8 Gauthaman K and Adaikan PG, 2005. Effect of *Tribulus terrestris* on nicotinamide adenine dinucleotide phosphate-diaphorase activity and androgen receptors in rat brain. *J Ethnopharmacol*, 96, 127-132.
- 9 Kistanova E, Zlatev H, Karcheva V, Kolev A, 2005. Effect of plant *Tribulus terrestris* extract on reproductive performances of rams. *Biotechnology in Animal Husbandry*, 21, 55-63.
- 10 Kumanov F, Bozadjieva E, Platonova M, Ankov V, *Clinical Testing of Tribestan*. Institute of Endocrinology, Gerontology, Geriatrics and HMML.
- 11 MacKay D, 2004. Nutrients and botanicals for erectile dysfunction: examining the evidence. *Alternative medicine review*, 9, 4-16.
- 12 Neychev VK and Mitev VI, 2005. The aphrodisiac herb *Tribulus terrestris* does not influence the androgen production in young men. *J Ethnopharmacol*, 101, 319-323.
- 13 Obreshkova D, Pangarova T, Mitkov S, Dinchev D, 1998. Comparative analytical investigation of *tribulus terrestris* preparations. *Farmacija (Sofija)*, 45, 10-12.

- 14 Rowland DL and Tai W, 2003. A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions. *J Sex Marital Ther*, 29, 185-205.
- 15 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 16 Sopharma USA Corporation, Tribestan®, www.tribulus.eu.com.
- 17 Traish AM and Guay AT, 2006. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. *J Sex Med*, 3, 382-404; discussion 404-387.
- 18 Wikipedia, Tribulus, <http://en.wikipedia.org/wiki/Tribulus>.
- 19 Zarkova S, 1981. Tribestan: experimental and clinical investigations. Sopharma Chemical Pharmaceutical Research Institute, Sofia, Bulgaria.

ID 2832: “Wheat sprouts” and “Antioxidativity”

- 1 Marsili V, Calzuola I, Gianfranceschi GL, 2004. Nutritional relevance of wheat sprouts containing high levels of organic phosphates and antioxidant compounds. *J Clin Gastroenterol*, 38, S123-126.
- 2 Peryt B, Szymczyk T, Lesca P, 1992. Mechanism of antimutagenicity of wheat sprout extracts. *Mutat Res*, 269, 201-215.

ID 2833: “Wheat sprouts” and “Eyes”

- 1 Marsili V, Calzuola I, Gianfranceschi GL, 2004. Nutritional relevance of wheat sprouts containing high levels of organic phosphates and antioxidant compounds. *J Clin Gastroenterol*, 38, S123-126.
- 2 Peryt B, Szymczyk T, Lesca P, 1992. Mechanism of antimutagenicity of wheat sprout extracts. *Mutat Res*, 269, 201-215.

ID 2835: “Yerba mate extract (*Ilex paraguarensis*)” and “Antioxidativity”

- 1 Bixby M, Spieler L, Menini T, Gugliucci A, 2005. *Ilex paraguariensis* extracts are potent inhibitors of nitrosative stress: A comparative study with green tea and wines using a protein nitration model and mammalian cell cytotoxicity. *Life Sciences*, 77, 345-358.
- 2 Bracesco N, Dell M, Rocha A, Behtash S, Menini T, Gugliucci A, Nunes E, 2003. Antioxidant activity of a botanical extract preparation of *Ilex paraguariensis*: Prevention of DNA double-strand breaks in *Saccharomyces cerevisiae* and human low-density lipoprotein oxidation. *Journal of Alternative and Complementary Medicine*, 9, 379-387.
- 3 Gugliucci A and Stahl AJC, 1995. Low-Density-Lipoprotein Oxidation Is Inhibited by Extracts of *Ilex Paraguariensis*. *Biochemistry and Molecular Biology International*, 35, 47-56.
- 4 Gugliucci A, 1996. Antioxidant effects of *Ilex paraguariensis*: Induction of decreased oxidability of human LDL in vivo. *Biochemical and Biophysical Research Communications*, 224, 338-344.
- 5 Mosimann ALP, Wilhelm D, da Silva EL, 2006. Aqueous extract of *Ilex paraguariensis* attenuates the progression of atherosclerosis in cholesterol-fed rabbits. *Biofactors*, 26, 59-70.
- 6 Schinella GR, Troiani G, Davila V, de Buschiazzo PM, Tournier HA, 2000. Antioxidant effects of an aqueous extract of *Ilex paraguariensis*. *Biochemical and Biophysical Research Communications*, 269, 357-360.
- 7 Schinella G, Fantinelli JC, Mosca SM, 2005. Cardioprotective effects of *Ilex paraguariensis* extract: evidence for a nitric oxide-dependent mechanism. *Clinical Nutrition*, 24, 360-366.

ID 2844: “Brassica oleracea var italica (broccoli)” and “Immune system”.

- 1 Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG, 2004. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. *J Nutr*, 134, 1134-1138.
- 2 Bacon JR, Williamson G, Garner RC, Lappin G, Langouet S, Bao Y, 2003. Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes. *Carcinogenesis*, 24, 1903-1911.
- 3 Bacon JR, Plumb GW, Howie AF, Beckett GJ, Wang W, Bao Y, 2007. Dual action of sulforaphane in the regulation of thioredoxin reductase and thioredoxin in human HepG2 and Caco-2 cells. *J Agric Food Chem*, 55, 1170-1176.
- 4 Barcelo S, Mace K, Pfeifer AM, Chipman JK, 1998. Production of DNA strand breaks by N-nitrosodimethylamine and 2-amino-3-methylimidazo[4,5-f]quinoline in THLE cells expressing human CYP isoenzymes and inhibition by sulforaphane. *Mutat Res*, 402, 111-120.
- 5 Basten GP, Bao Y, Williamson G, 2002. Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells. *Carcinogenesis*, 23, 1399-1404.
- 6 Bertl E, Bartsch H, Gerhauser C, 2006. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. *Mol Cancer Ther*, 5, 575-585.
- 7 Brooks JD and Paton V, 1999. Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent. *Prostate Cancer Prostatic Dis*, 2, S8.
- 8 Brooks JD, Paton VG, Vidanes G, 2001. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. *Cancer Epidemiol Biomarkers Prev*, 10, 949-954.
- 9 Callaway EC, Zhang Y, Chew W, Chow HH, 2004. Cellular accumulation of dietary anticarcinogenic isothiocyanates is followed by transporter-mediated export as dithiocarbamates. *Cancer Lett*, 204, 23-31.
- 10 Campbell L, Howie F, Arthur JR, Nicol F, Beckett G, 2007. Selenium and sulforaphane modify the expression of selenoenzymes in the human endothelial cell line EAhy926 and protect cells from oxidative damage. *Nutrition*, 23, 138-144.
- 11 Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, Brown CK, Singh SV, 2007. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. *Carcinogenesis*, 28, 151-162.
- 12 Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D, McIntee EJ, Hecht SS, Chung FL, 2005. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. *Cancer Res*, 65, 8548-8557.
- 13 Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K, 2007. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. *Carcinogenesis*, 28, 1485-1490.
- 14 Dinkova-Kostova AT, Jenkins SN, Fahey JW, Ye L, Wehage SL, Liby KT, Stephenson KK, Wade KL, Talalay P, 2006. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. *Cancer Lett*, 240, 243-252.
- 15 Fahey JW, Zhang Y, Talalay P, 1997. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. *Proc Natl Acad Sci U S A*, 94, 10367-10372.
- 16 Fahey JW and Stephenson KK, 1999. Cancer Chemoprotective Effects of Cruciferous Vegetables. *HortScience*, 34, 1159-1163.
- 17 Fahey JW and Talalay P, 1999. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. *Food Chem Toxicol*, 37, 973-979.
- 18 Fahey JW and Kensler TW, 2007. Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. *Chem Res Toxicol*, 20, 572-576.

- 19 Farnham M, Stephenson K, Fahey J, 2000. Capacity of broccoli to induce a mammalian chemoprotective enzyme varies among inbred lines. *Journal of the American Society of Horticultural Science* 125, 482-488.
- 20 Farnham WW, Wilson PE, Stephenson KK, Fahey JW, 2004. Genetic & environmental effects on glucosinolate content & chemoprotective potency of broccoli. *Plant Breeding*, 123, 60-65.
- 21 Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P, 2002. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. *Carcinogenesis*, 23, 581-586.
- 22 Fimognari C, Berti F, Cantelli-Forti G, Hrelia P, 2005. Effect of sulforaphane on micronucleus induction in cultured human lymphocytes by four different mutagens. *Environ Mol Mutagen*, 46, 260-267.
- 23 Fimognari C, Nusse M, Lenzi M, Sciuscio D, Cantelli-Forti G, Hrelia P, 2006. Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. *Mutat Res*, 601, 92-101.
- 24 Fimognari C and Hrelia P, 2007. Sulforaphane as a promising molecule for fighting cancer. *Mutat Res*, 635, 90-104.
- 25 Finley JW, Davis CD, Feng Y, 2000. Selenium from high selenium broccoli protects rats from colon cancer. *J Nutr*, 130, 2384-2389.
- 26 Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W, 2003. Urinary isothiocyanate levels, brassica, and human breast cancer. *Cancer Res*, 63, 3980-3986.
- 27 Frydoonfar HR, McGrath DR, Spigelman AD, 2003. The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. *ANZ J Surg*, 73, 154-156.
- 28 Gamet-Payraastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc N, Tulliez J, Terce F, 2000. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. *Cancer Res*, 60, 1426-1433.
- 29 Gao X, Dinkova-Kostova AT, Talalay P, 2001. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. *Proc Natl Acad Sci U S A*, 98, 15221-15226.
- 30 Han JM, Lee YJ, Lee SY, Kim EM, Moon Y, Kim HW, Hwang O, 2007. Protective effect of sulforaphane against dopaminergic cell death. *J Pharmacol Exp Ther*, 321, 249-256.
- 31 Hecht SS, 1999. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. *J Nutr*, 129, 768S-774S.
- 32 Herman-Antosiewicz A, Johnson DE, Singh SV, 2006. Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. *Cancer Res*, 66, 5828-5835.
- 33 Higdon JV, Delage B, Williams DE, Dashwood RH, 2007. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. *Pharmacol Res*, 55, 224-236.
- 34 Hu R, Khor TO, Shen G, Jeong WS, Hebbar V, Chen C, Xu C, Reddy B, Chada K, Kong AN, 2006. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. *Carcinogenesis*, 27, 2038-2046.
- 35 IARC (The International Agency for Research on Cancer), 2004. Cruciferous Vegetables, Isothiocyanates and Indoles (IARC Handbooks of Cancer Prevention). World Health Organization, Cedex, France.
- 36 Jackson SJ and Singletary KW, 2004. Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. *J Nutr*, 134, 2229-2236.
- 37 Jackson SJ, Singletary KW, Venema RC, 2007. Sulforaphane suppresses angiogenesis and disrupts endothelial mitotic progression and microtubule polymerization. *Vascul Pharmacol*, 46, 77-84.
- 38 Johnson IT, 2002. Glucosinolates: bioavailability and importance to health. *Int J Vitam Nutr Res*, 72, 26-31.
- 39 Juge N, Mithen RF, Traka M, 2007. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. *Cell Mol Life Sci*, 64, 1105-1127.

- 40 Kensler TW, Chen JG, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, Ye L, Coady JL, Wang JB, Wu Y, Sun Y, Zhang QN, Zhang BC, Zhu YR, Qian GS, Carmella SG, Hecht SS, Benning L, Gange SJ, Groopman JD, Talalay P, 2005. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. *Cancer Epidemiol Biomarkers Prev*, 14, 2605-2613.
- 41 Khor TO, Hu R, Shen G, Jeong WS, Hebbar V, Chen C, Xu C, Nair S, Reddy B, Chada K, Kong AN, 2006. Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. *Biopharm Drug Dispos*, 27, 407-420.
- 42 Kim BR, Hu R, Keum YS, Hebbar V, Shen G, Nair SS, Kong AN, 2003. Effects of glutathione on antioxidant response element-mediated gene expression and apoptosis elicited by sulforaphane. *Cancer Res*, 63, 7520-7525.
- 43 Kristal AR and Lampe JW, 2002. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. *Nutr Cancer*, 42, 1-9.
- 44 Kuroiwa Y, Nishikawa A, Kitamura Y, Kanki K, Ishii Y, Umemura T, Hirose M, 2006. Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. *Cancer Lett*, 241, 275-280.
- 45 Langouet S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP, 2000. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. *Chem Res Toxicol*, 13, 245-252.
- 46 Leoni O, Iori R, Palmieri S, Esposito E, Menegatti E, Cortesi R, Nastruzzi C, 1997. Myrosinase-generated isothiocyanate from glucosinolates: isolation, characterization and in vitro antiproliferative studies. *Bioorg Med Chem*, 5, 1799-1806.
- 47 Lund EK, Smith TK, Clarke RG, Johnson IT, 2001. Cell death in the colorectal cancer cell line HT29 in response to glucosinolate metabolites. *Journal of the Science of Food and Agriculture*, 81, 959-961.
- 48 Maheo K, Morel F, Langouet S, Kramer H, Le Ferrec E, Ketterer B, Guillouzo A, 1997. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. *Cancer Res*, 57, 3649-3652.
- 49 Matusheski NV and Jeffery EH, 2001. Comparison of the bioactivity of two glucoraphanin hydrolysis products found in broccoli, sulforaphane and sulforaphane nitrile. *J Agric Food Chem*, 49, 5743-5749.
- 50 McWalter GK, Higgins LG, McLellan LI, Henderson CJ, Song L, Thornalley PJ, Itoh K, Yamamoto M, Hayes JD, 2004. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. *J Nutr*, 134, 3499S-3506S.
- 51 Misiewicz I, Skupinska K, Kasprzycka-Guttman T, 2003. Sulforaphane and 2-oxohexyl isothiocyanate induce cell growth arrest and apoptosis in L-1210 leukemia and ME-18 melanoma cells. *Oncol Rep*, 10, 2045-2050.
- 52 Mithen R, Faulkner K, Magrath R, Rose P, Williamson G, Marquez J, 2003. Development of isothiocyanate-enriched broccoli, and its enhanced ability to induce phase 2 detoxification enzymes in mammalian cells. *Theor Appl Genet*, 106, 727-734.
- 53 Munday R and Munday CM, 2002. Selective induction of phase II enzymes in the urinary bladder of rats by allyl isothiocyanate, a compound derived from Brassica vegetables. *Nutr Cancer*, 44, 52-59.
- 54 Murashima M, Watanabe S, Zhuo XG, Uehara M, Kurashige A, 2004. Phase 1 study of multiple biomarkers for metabolism and oxidative stress after one-week intake of broccoli sprouts. *Biofactors*, 22, 271-275.
- 55 Myzak MC and Dashwood RH, 2006. Chemoprotection by sulforaphane: keep one eye beyond Keap1. *Cancer Lett*, 233, 208-218.
- 56 Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH, 2006-a. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. *FASEB J*, 20, 506-508.

- 57 Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E, 2006-b. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. *Carcinogenesis*, 27, 811-819.
- 58 Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E, 2007. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. *Exp Biol Med (Maywood)*, 232, 227-234.
- 59 Parnaud G, Li P, Cassar G, Rouimi P, Tulliez J, Combaret L, Gamet-Payrastrre L, 2004. Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. *Nutr Cancer*, 48, 198-206.
- 60 Pereira FM, Rosa E, Fahey JW, Stephenson KK, Carvalho R, Aires A, 2002. Influence of temperature and ontogeny on the levels of glucosinolates in broccoli (*Brassica oleracea* Var. *italica*) sprouts and their effect on the induction of mammalian phase 2 enzymes. *J Agric Food Chem*, 50, 6239-6244.
- 61 Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, Knutson L, Forsell P, Eriksson T, Lennernas H, Williamson G, 2003. Absorption/Metabolism of Sulforaphane and Quercetin, and regulation of phase II enzymes, in human jejunum in vivo. *Drug Metabolism and Disposition*, 31, 805-813.
- 62 Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW, 2004. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. *Mol Cancer Ther*, 3, 1239-1248.
- 63 Pledge-Tracy A, Sobolewski MD, Davidson NE, 2007. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. *Mol Cancer Ther*, 6, 1013-1021.
- 64 Ritz SA, Wan J, Diaz-Sanchez D, 2007. Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract. *Am J Physiol Lung Cell Mol Physiol*, 292, L33-39.
- 65 Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P, 1998. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. *Cancer Epidemiol Biomarkers Prev*, 7, 1091-1100.
- 66 Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P, 2001. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. *Cancer Epidemiol Biomarkers Prev*, 10, 501-508.
- 67 Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P, 2006. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. *Nutr Cancer*, 55, 53-62.
- 68 Talalay P, 2000. Chemoprotection against cancer by induction of phase 2 enzymes. *Biofactors*, 12, 5-11.
- 69 Talalay P and Fahey JW, 2001. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. *J Nutr*, 131, 3027S-3033S.
- 70 Tang L and Zhang Y, 2004-a. Dietary isothiocyanates inhibit the growth of human bladder carcinoma cells. *J Nutr*, 134, 2004-2010.
- 71 Tang L and Zhang Y, 2004-b. Isothiocyanates in the chemoprevention of bladder cancer. *Curr Drug Metab*, 5, 193-201.
- 72 Tang L, Li G, Song L, Zhang Y, 2006. The principal urinary metabolites of dietary isothiocyanates, N-acetylcysteine conjugates, elicit the same anti-proliferative response as their parent compounds in human bladder cancer cells. *Anticancer Drugs*, 17, 297-305.
- 73 Tang L, Zhang Y, Jobson HE, Li J, Stephenson KK, Wade KL, Fahey JW, 2006. Potent activation of mitochondria-mediated apoptosis and arrest in S and M phases of cancer cells by a broccoli sprout extract. *Mol Cancer Ther*, 5, 935-944.
- 74 Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A, Yodoi J, 2005. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. *Invest Ophthalmol Vis Sci*, 46, 979-987.

- 75 Thejass P and Kuttan G, 2006. Antimetastatic activity of Sulforaphane. *Life Sci*, 78, 3043-3050.
- 76 Thejass P and Kuttan G, 2007. Immunomodulatory activity of Sulforaphane, a naturally occurring isothiocyanate from broccoli (*Brassica oleracea*). *Phytomedicine*, 14, 538-545.
- 77 Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S, 2002. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. *Cancer Res*, 62, 5196-5203.
- 78 van Lieshout EM, Bedaf MM, Pieter M, Ekkel C, Nijhoff WA, Peters WH, 1998-a. Effects of dietary anticarcinogens on rat gastrointestinal glutathione S-transferase theta 1-1 levels. *Carcinogenesis*, 19, 2055-2057.
- 79 van Lieshout EM, Posner GH, Woodard BT, Peters WH, 1998-b. Effects of the sulforaphane analog compound 30, indole-3-carbinol, D-limonene or relafen on glutathione S-transferases and glutathione peroxidase of the rat digestive tract. *Biochim Biophys Acta*, 1379, 325-336.
- 80 Vermeulen M, van den Berg R, Freidig AP, van Bladeren PJ, Vaes WH, 2006. Association between consumption of cruciferous vegetables and condiments and excretion in urine of isothiocyanate mercapturic acids. *J Agric Food Chem*, 54, 5350-5358.
- 81 Wang W, Wang S, Howie AF, Beckett GJ, Mithen R, Bao Y, 2005. Sulforaphane, erucin, and iberin up-regulate thioredoxin reductase 1 expression in human MCF-7 cells. *J Agric Food Chem*, 53, 1417-1421.
- 82 Wu L and Juurlink BH, 2001. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. *J Hypertens*, 19, 1819-1825.
- 83 Wu HT, Lin SH, Chen YH, 2005. Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetables. *J Agric Food Chem*, 53, 5164-5169.
- 84 Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, Conney AH, Kong AN, 2006. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. *Cancer Res*, 66, 8293-8296.
- 85 Ye L and Zhang Y, 2001. Total intracellular accumulation levels of dietary isothiocyanates determine their activity in elevation of cellular glutathione and induction of Phase 2 detoxification enzymes. *Carcinogenesis*, 22, 1987-1992.
- 86 Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P, 2002. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. *Clin Chim Acta*, 316, 43-53.
- 87 Yeh CT and Yen GC, 2005. Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells. *Carcinogenesis*, 26, 2138-2148.
- 88 Yoxall V, Kentish P, Coldham N, Kuhnert N, Sauer MJ, Ioannides C, 2005. Modulation of hepatic cytochromes P450 and phase II enzymes by dietary doses of sulforaphane in rats: Implications for its chemopreventive activity. *Int J Cancer*, 117, 356-362.
- 89 Zhang Y and Talalay P, 1998. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. *Cancer Res*, 58, 4632-4639.
- 90 Zhang Y, 2000. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. *Carcinogenesis*, 21, 1175-1182.
- 91 Zhang Y and Callaway EC, 2002. High cellular accumulation of sulforaphane, a dietary anticarcinogen, is followed by rapid transporter-mediated export as a glutathione conjugate. *Biochem J*, 364, 301-307.
- 92 Zhang Y, 2004. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. *Mutat Res*, 555, 173-190.
- 93 Zhang Y, Yao S, Li J, 2006. Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action. *Proc Nutr Soc*, 65, 68-75.

- 94 Zhao B, Seow A, Lee EJ, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Yu MC, Lee HP, 2001. Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. *Cancer Epidemiol Biomarkers Prev*, 10, 1063-1067.
- 95 Zhao J, Kobori N, Aronowski J, Dash PK, 2006. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. *Neurosci Lett*, 393, 108-112.
- 96 Zhou C, Poulton EJ, Grun F, Bammler TK, Blumberg B, Thummel KE, Eaton DL, 2007. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. *Mol Pharmacol*, 71, 220-229.

ID 2845: “*Brassica oleracea var italica* (broccoli)” and “Antioxidant properties and cell protection”

- 1 Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG, 2004. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. *J Nutr*, 134, 1134-1138.
- 2 Bacon JR, Williamson G, Garner RC, Lappin G, Langouet S, Bao Y, 2003. Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes. *Carcinogenesis*, 24, 1903-1911.
- 3 Bacon JR, Plumb GW, Howie AF, Beckett GJ, Wang W, Bao Y, 2007. Dual action of sulforaphane in the regulation of thioredoxin reductase and thioredoxin in human HepG2 and Caco-2 cells. *J Agric Food Chem*, 55, 1170-1176.
- 4 Barcelo S, Mace K, Pfeifer AM, Chipman JK, 1998. Production of DNA strand breaks by N-nitrosodimethylamine and 2-amino-3-methylimidazo[4,5-f]quinoline in THLE cells expressing human CYP isoenzymes and inhibition by sulforaphane. *Mutat Res*, 402, 111-120.
- 5 Basten GP, Bao Y, Williamson G, 2002. Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells. *Carcinogenesis*, 23, 1399-1404.
- 6 Bertl E, Bartsch H, Gerhauser C, 2006. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. *Mol Cancer Ther*, 5, 575-585.
- 7 Brooks JD and Paton V, 1999. Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent. *Prostate Cancer Prostatic Dis*, 2, S8.
- 8 Brooks JD, Paton VG, Vidanes G, 2001. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. *Cancer Epidemiol Biomarkers Prev*, 10, 949-954.
- 9 Callaway EC, Zhang Y, Chew W, Chow HH, 2004. Cellular accumulation of dietary anticarcinogenic isothiocyanates is followed by transporter-mediated export as dithiocarbamates. *Cancer Lett*, 204, 23-31.
- 10 Campbell L, Howie F, Arthur JR, Nicol F, Beckett G, 2007. Selenium and sulforaphane modify the expression of selenoenzymes in the human endothelial cell line EAhy926 and protect cells from oxidative damage. *Nutrition*, 23, 138-144.
- 11 Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, Brown CK, Singh SV, 2007. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. *Carcinogenesis*, 28, 151-162.
- 12 Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D, McIntee EJ, Hecht SS, Chung FL, 2005. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. *Cancer Res*, 65, 8548-8557.
- 13 Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K, 2007. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. *Carcinogenesis*, 28, 1485-1490.

- 14 Dinkova-Kostova AT, Jenkins SN, Fahey JW, Ye L, Wehage SL, Liby KT, Stephenson KK, Wade KL, Talalay P, 2006. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. *Cancer Lett*, 240, 243-252.
- 15 Fahey JW, Zhang Y, Talalay P, 1997. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. *Proc Natl Acad Sci USA*, 94, 10367-10372.
- 16 Fahey JW and Stephenson KK, 1999. Cancer chemoprotective effects of cruciferous vegetables. *HortScience*, 34, 1159-1163.
- 17 Fahey JW and Talalay P, 1999. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. *Food Chem Toxicol*, 37, 973-979.
- 18 Fahey JW and Kensler TW, 2007. Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. *Chem Res Toxicol*, 20, 572-576.
- 19 Farnham MW, Stephenson KK, Fahey JW, 2000. Capacity of broccoli to induce a mammalian chemoprotective enzyme varies among inbred lines. *HortScience*, 125, 482-488.
- 20 Farnham MW, Wilson PE, Stephenson KK, Fahey JW, 2004. Genetic and environmental effects on glucosinolate content and chemoprotective potency of broccoli. *Plant Breeding*, 123, 60-65.
- 21 Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P, 2002. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. *Carcinogenesis*, 23, 581-586.
- 22 Fimognari C, Berti F, Cantelli-Forti G, Hrelia P, 2005. Effect of sulforaphane on micronucleus induction in cultured human lymphocytes by four different mutagens. *Environ Mol Mutagen*, 46, 260-267.
- 23 Fimognari C, Nusse M, Lenzi M, Sciuscio D, Cantelli-Forti G, Hrelia P, 2006. Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. *Mutat Res*, 601, 92-101.
- 24 Fimognari C and Hrelia P, 2007. Sulforaphane as a promising molecule for fighting cancer. *Mutat Res*, 635, 90-104.
- 25 Finley JW, Davis CD, Feng Y, 2000. Selenium from high selenium broccoli protects rats from colon cancer. *J Nutr*, 130, 2384-2389.
- 26 Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W, 2003. Urinary isothiocyanate levels, brassica, and human breast cancer. *Cancer Res*, 63, 3980-3986.
- 27 Frydoonfar HR, McGrath DR, Spigelman AD, 2003. The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. *ANZ J Surg*, 73, 154-156.
- 28 Gamet-Payraastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc N, Tulliez J, Terce F, 2000. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. *Cancer Res*, 60, 1426-1433.
- 29 Gao X, Dinkova-Kostova AT, Talalay P, 2001. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. *Proc Natl Acad Sci USA*, 98, 15221-15226.
- 30 Han JM, Lee YJ, Lee SY, Kim EM, Moon Y, Kim HW, Hwang O, 2007. Protective effect of sulforaphane against dopaminergic cell death. *J Pharmacol Exp Ther*, 321, 249-256.
- 31 Hecht SS, 1999. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. *J Nutr*, 129, 768S-774S.
- 32 Herman-Antosiewicz A, Johnson DE, Singh SV, 2006. Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. *Cancer Res*, 66, 5828-5835.
- 33 Higdon JV, Delage B, Williams DE, Dashwood RH, 2007. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. *Pharmacol Res*, 55, 224-236.
- 34 Hu R, Khor TO, Shen G, Jeong WS, Hebbar V, Chen C, Xu C, Reddy B, Chada K, Kong AN, 2006. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. *Carcinogenesis*, 27, 2038-2046.

- 35 International Agency for Research on Cancer, 2004. Cruciferous Vegetables, Isothiocyanates and Indoles. IARC Handbook of Cancer Prevention. IARC Press, Lyon.
- 36 Jackson SJ and Singletary KW, 2004. Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. *J Nutr*, 134, 2229-2236.
- 37 Jackson SJ, Singletary KW, Venema RC, 2007. Sulforaphane suppresses angiogenesis and disrupts endothelial mitotic progression and microtubule polymerization. *Vascul Pharmacol*, 46, 77-84.
- 38 Johnson IT, 2002. Glucosinolates: bioavailability and importance to health. *Int J Vitam Nutr Res*, 72, 26-31.
- 39 Juge N, Mithen RF, Traka M, 2007. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. *Cell Mol Life Sci*, 64, 1105-1127.
- 40 Kensler TW, Chen JG, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, Ye L, Coady JL, Wang JB, Wu Y, Sun Y, Zhang QN, Zhang BC, Zhu YR, Qian GS, Carmella SG, Hecht SS, Benning L, Gange SJ, Groopman JD, Talalay P, 2005. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. *Cancer Epidemiol Biomarkers Prev*, 14, 2605-2613.
- 41 Khor TO, Hu R, Shen G, Jeong WS, Hebbar V, Chen C, Xu C, Nair S, Reddy B, Chada K, Kong AN, 2006. Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. *Biopharm Drug Dispos*, 27, 407-420.
- 42 Kim BR, Hu R, Keum YS, Hebbar V, Shen G, Nair SS, Kong AN, 2003. Effects of glutathione on antioxidant response element-mediated gene expression and apoptosis elicited by sulforaphane. *Cancer Res*, 63, 7520-7525.
- 43 Kristal AR and Lampe JW, 2002. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. *Nutr Cancer*, 42, 1-9.
- 44 Kuroiwa Y, Nishikawa A, Kitamura Y, Kanki K, Ishii Y, Umemura T, Hirose M, 2006. Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. *Cancer Lett*, 241, 275-280.
- 45 Langouet S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP, 2000. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. *Chem Res Toxicol*, 13, 245-252.
- 46 Leoni O, Iori R, Palmieri S, Esposito E, Menegatti E, Cortesi R, Nastruzzi C, 1997. Myrosinase-generated isothiocyanate from glucosinolates: isolation, characterization and in vitro antiproliferative studies. *Bioorg Med Chem*, 5, 1799-1806.
- 47 Lund EK, Smith TK, Clarke RG, Johnson IT, 2001. Cell death in the colorectal cancer cell line HT29 in response to glucosinolate metabolites. *Journal of the Science of Food and Agriculture*, 81, 959-961.
- 48 Maheo K, Morel F, Langouet S, Kramer H, Le Ferrec E, Ketterer B, Guillouzo A, 1997. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. *Cancer Res*, 57, 3649-3652.
- 49 Matusheski NV and Jeffery EH, 2001. Comparison of the bioactivity of two glucoraphanin hydrolysis products found in broccoli, sulforaphane and sulforaphane nitrile. *J Agric Food Chem*, 49, 5743-5749.
- 50 McWalter GK, Higgins LG, McLellan LI, Henderson CJ, Song L, Thornalley PJ, Itoh K, Yamamoto M, Hayes JD, 2004. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. *J Nutr*, 134, 3499S-3506S.
- 51 Misiewicz I, Skupinska K, Kasprzycka-Guttman T, 2003. Sulforaphane and 2-oxohexyl isothiocyanate induce cell growth arrest and apoptosis in L-1210 leukemia and ME-18 melanoma cells. *Oncol Rep*, 10, 2045-2050.
- 52 Mithen R, Faulkner K, Magrath R, Rose P, Williamson G, Marquez J, 2003. Development of isothiocyanate-enriched broccoli, and its enhanced ability to induce phase 2 detoxification enzymes in mammalian cells. *Theor Appl Genet*, 106, 727-734.

- 53 Munday R and Munday CM, 2002. Selective induction of phase II enzymes in the urinary bladder of rats by allyl isothiocyanate, a compound derived from Brassica vegetables. *Nutr Cancer*, 44, 52-59.
- 54 Murashima M, Watanabe S, Zhuo XG, Uehara M, Kurashige A, 2004. Phase I study of multiple biomarkers for metabolism and oxidative stress after one-week intake of broccoli sprouts. *Biofactors*, 22, 271-275.
- 55 Myzak MC and Dashwood RH, 2006. Chemoprotection by sulforaphane: keep one eye beyond Keap1. *Cancer Lett*, 233, 208-218.
- 56 Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH, 2006. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. *FASEB J*, 20, 506-508.
- 57 Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E, 2006. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. *Carcinogenesis*, 27, 811-819.
- 58 Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E, 2007. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. *Exp Biol Med (Maywood)*, 232, 227-234.
- 59 Parnaud G, Li P, Cassar G, Rouimi P, Tulliez J, Combaret L, Gamet-Payrastre L, 2004. Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. *Nutr Cancer*, 48, 198-206.
- 60 Pereira FM, Rosa E, Fahey JW, Stephenson KK, Carvalho R, Aires A, 2002. Influence of temperature and ontogeny on the levels of glucosinolates in broccoli (*Brassica oleracea* Var. *italica*) sprouts and their effect on the induction of mammalian phase 2 enzymes. *J Agric Food Chem*, 50, 6239-6244.
- 61 Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, Knutson L, Forsell P, Eriksson T, Lennernas H, Williamson G, 2003. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. *Drug Metab Dispos*, 31, 805-813.
- 62 Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW, 2004. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. *Mol Cancer Ther*, 3, 1239-1248.
- 63 Pledge-Tracy A, Sobolewski MD, Davidson NE, 2007. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. *Mol Cancer Ther*, 6, 1013-1021.
- 64 Ritz SA, Wan J, Diaz-Sanchez D, 2007. Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract. *Am J Physiol Lung Cell Mol Physiol*, 292, L33-39.
- 65 Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P, 1998. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. *Cancer Epidemiol Biomarkers Prev*, 7, 1091-1100.
- 66 Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P, 2001. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. *Cancer Epidemiol Biomarkers Prev*, 10, 501-508.
- 67 Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P, 2006. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. *Nutr Cancer*, 55, 53-62.
- 68 Talalay P, 2000. Chemoprotection against cancer by induction of phase 2 enzymes. *Biofactors*, 12, 5-11.
- 69 Talalay P and Fahey JW, 2001. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. *J Nutr*, 131, 3027S-3033S.
- 70 Tang L and Zhang Y, 2004. Dietary isothiocyanates inhibit the growth of human bladder carcinoma cells. *J Nutr*, 134, 2004-2010.
- 71 Tang L and Zhang Y, 2004. Isothiocyanates in the chemoprevention of bladder cancer. *Curr Drug Metab*, 5, 193-201.

- 72 Tang L, Li G, Song L, Zhang Y, 2006. The principal urinary metabolites of dietary isothiocyanates, N-acetylcysteine conjugates, elicit the same anti-proliferative response as their parent compounds in human bladder cancer cells. *Anticancer Drugs*, 17, 297-305.
- 73 Tang L, Zhang Y, Jobson HE, Li J, Stephenson KK, Wade KL, Fahey JW, 2006. Potent activation of mitochondria-mediated apoptosis and arrest in S and M phases of cancer cells by a broccoli sprout extract. *Mol Cancer Ther*, 5, 935-944.
- 74 Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A, Yodoi J, 2005. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. *Invest Ophthalmol Vis Sci*, 46, 979-987.
- 75 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- 76 Thejass P and Kuttan G, 2006. Antimetastatic activity of Sulforaphane. *Life Sci*, 78, 3043-3050.
- 77 Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S, 2002. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. *Cancer Res*, 62, 5196-5203.
- 78 van Lieshout EM, Bedaf MM, Pieter M, Ekkel C, Nijhoff WA, Peters WH, 1998. Effects of dietary anticarcinogens on rat gastrointestinal glutathione S-transferase theta 1-1 levels. *Carcinogenesis*, 19, 2055-2057.
- 79 van Lieshout EM, Posner GH, Woodard BT, Peters WH, 1998. Effects of the sulforaphane analog compound 30, indole-3-carbinol, D-limonene or relafen on glutathione S-transferases and glutathione peroxidase of the rat digestive tract. *Biochim Biophys Acta*, 1379, 325-336.
- 80 Vermeulen M, van den Berg R, Freidig AP, van Bladeren PJ, Vaes WH, 2006. Association between consumption of cruciferous vegetables and condiments and excretion in urine of isothiocyanate mercapturic acids. *J Agric Food Chem*, 54, 5350-5358.
- 81 Wang W, Wang S, Howie AF, Beckett GJ, Mithen R, Bao Y, 2005. Sulforaphane, erucin, and iberin up-regulate thioredoxin reductase 1 expression in human MCF-7 cells. *J Agric Food Chem*, 53, 1417-1421.
- 82 Wu L and Juurlink BH, 2001. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. *J Hypertens*, 19, 1819-1825.
- 83 Wu L, Noyan Ashraf MH, Facci M, Wang R, Paterson PG, Ferrie A, Juurlink BH, 2004. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. *Proc Natl Acad Sci USA*, 101, 7094-7099.
- 84 Wu HT, Lin SH, Chen YH, 2005. Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetables. *J Agric Food Chem*, 53, 5164-5169.
- 85 Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, Conney AH, Kong AN, 2006. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. *Cancer Res*, 66, 8293-8296.
- 86 Ye L and Zhang Y, 2001. Total intracellular accumulation levels of dietary isothiocyanates determine their activity in elevation of cellular glutathione and induction of Phase 2 detoxification enzymes. *Carcinogenesis*, 22, 1987-1992.
- 87 Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P, 2002. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. *Clin Chim Acta*, 316, 43-53.
- 88 Yeh CT and Yen GC, 2005. Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells. *Carcinogenesis*, 26, 2138-2148.
- 89 Yoxall V, Kentish P, Coldham N, Kuhnert N, Sauer MJ, Ioannides C, 2005. Modulation of hepatic cytochromes P450 and phase II enzymes by dietary doses of sulforaphane in rats: Implications for its chemopreventive activity. *Int J Cancer*, 117, 356-362.

- 90 Zhang Y and Talalay P, 1998. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. *Cancer Res*, 58, 4632-4639.
- 91 Zhang Y, 2000. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. *Carcinogenesis*, 21, 1175-1182.
- 92 Zhang Y and Callaway EC, 2002. High cellular accumulation of sulphoraphane, a dietary anticarcinogen, is followed by rapid transporter-mediated export as a glutathione conjugate. *Biochem J*, 364, 301-307.
- 93 Zhang Y, 2004. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. *Mutat Res*, 555, 173-190.
- 94 Zhang Y, Yao S, Li J, 2006. Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action. *Proc Nutr Soc*, 65, 68-75.
- 95 Zhao B, Seow A, Lee EJ, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Yu MC, Lee HP, 2001. Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. *Cancer Epidemiol Biomarkers Prev*, 10, 1063-1067.
- 96 Zhao J, Kobori N, Aronowski J, Dash PK, 2006. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. *Neurosci Lett*, 393, 108-112.
- 97 Zhou C, Poulton EJ, Grun F, Bammler TK, Blumberg B, Thummel KE, Eaton DL, 2007. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. *Mol Pharmacol*, 71, 220-229.

ID 2847: “Malva sylvestris L. (Common name: Mallow)” and “-Respiratory health”

- 1 Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C, Rister R, 1998. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, TX.

ID 2848: “Melissa extract [Dry extract from leaves of *Melissa officinalis* L., drug/native extract ratio (4 - 6) : 1, solvent of extraction Methanol/Water , min 1.8% rosmarinic acid]” and “-For mental health”

- 1 Cerny A and Schmid K, 1999. Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study). *Fitoterapia*, 70, 221-228.
- 2 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. *ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products*. Thieme, Stuttgart.
- 3 Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA, 2002. Modulation of mood and cognitive performance following acute administration of *Melissa officinalis* (lemon balm). *Pharmacol Biochem Behav*, 72, 953-964.
- 4 Kennedy DO, Wake G, Savelev S, Tildesley NT, Perry EK, Wesnes KA, Scholey AB, 2003. Modulation of mood and cognitive performance following acute administration of single doses of *Melissa officinalis* (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. *Neuropsychopharmacology*, 28, 1871-1881.
- 5 Kennedy DO, Little W, Scholey AB, 2004. Attenuation of laboratory-induced stress in humans after acute administration of *Melissa officinalis* (Lemon Balm). *Psychosom Med*, 66, 607-613.
- 6 Kennedy DO, Little W, Haskell CF, Scholey AB, 2006. Anxiolytic effects of a combination of *Melissa officinalis* and *Valeriana officinalis* during laboratory induced stress. *Phytother Res*, 20, 96-102.
- 7 Schwander J and Mann C, 1999. The pupil unrest index as a measure of sleep restoration in patients with psychophysiological insomnia.
- 8 WHO (World Health Organization), 2002. *WHO Monographs on Selected Medicinal Plants*. WHO (World Health Organization), Geneva.

ID 2849: “Natural Grape Extract From grape seed Solvent free” and “-- Rich in polyphenols- Act as antioxidants - Antioxidant is a compound able to scavenge free radicals in the body and stop the oxidative chain reaction”

- 1 Dani C, Oliboni LS, Vanderlinde R, Bonatto D, Salvador M, Henriques JA, 2007. Phenolic content and antioxidant activities of white and purple juices manufactured with organically- or conventionally-produced grapes. *Food Chem Toxicol*, 45, 2574-2580.
- 2 Mattivi F, Guzzon R, Vrhovsek U, Stefanini M, Velasco R, 2006. Metabolite profiling of grape: Flavonols and anthocyanins. *J Agric Food Chem*, 54, 7692-7702.
- 3 Monagas M, Hernandez-Ledesma B, Gomez-Cordoves C, Bartolome B, 2006. Commercial dietary ingredients from *Vitis vinifera* L. leaves and grape skins: antioxidant and chemical characterization. *J Agric Food Chem*, 54, 319-327.
- 4 Zern TL, West KL, Fernandez ML, 2003. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. *J Nutr*, 133, 2268-2272.
- 5 Zern TL, Wood RJ, Greene C, West KL, Liu Y, Aggarwal D, Shachter NS, Fernandez ML, 2005. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. *J Nutr*, 135, 1911-1917.

ID 2850: “Ocimum sanctum LEAF” and “Antioxidant. Immunity”

- 1 Anandjiwala S, Kalola J, Rajani M, 2006. Quantification of eugenol, luteolin, ursolic acid, and oleanolic acid in black (Krishna Tulasi) and green (Sri Tulasi) varieties of *Ocimum sanctum* Linn. using high-performance thin-layer chromatography. *J AOAC Int*, 89, 1467-1474.
- 2 Arjuman A, Nair V, Gopalakrishna HN, Nandini M, 2007. Evaluation of the antioxidant potential of NR-ANX-C (a polyherbal formulation) and its individual constituents in reversing haloperidol-induced catalepsy in mice. *Indian Journal of Pharmacology*, 39, 151.
- 3 Asad M and Harish MS, 1998. Effect of eumil, a herbal immunomodulatory product on granulocyte phagocytosis. *Indian of Pharmacology* 30, 116-117.
- 4 Babu K and Uma Maheswari KC, 2006. In vivo studies on the effect of *Ocimum sanctum* L. leaf extract in modifying the genotoxicity induced by chromium and mercury in *Allium* root meristems. *J Environ Biol*, 27, 93-95.
- 5 Bhattacharya SK, Bhattacharya A, Das K, Muruganandam AV, Sairam K, 2001. Further investigations on the antioxidant activity of *Ocimum sanctum* using different paradigms of oxidative stress in rats. *Journal of Natural Remedies* 1.
- 6 Billore KV, Yelne MB, Dennis TJ, Chaudhari BG, 2005. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 7 Chatterjee S and Das SN, 1996. Effect of Immue-21 on Murine Peritoneal Macrophages and Splenic Lymphocytes. *Ancient Science of Life*, 15, 250-253.
- 8 Chatterjee S and Das SN, 1997. Immunopotentiality by IMMU-21 in immunocompromised rats. *Ancient Science of Life*, 16, 200-205.
- 9 Ganasoundari A, Devi PU, Rao MN, 1997. Protection against radiation-induced chromosome damage in mouse bone marrow by *Ocimum sanctum*. *Mutat Res*, 373, 271-276.
- 10 Geeta, Vasudevan DM, Kedlaya R, Deepa S, Ballal M, 2001. Activity of *Ocimum sanctum* (the traditional Indian medicinal plant) against the enteric pathogens. *Indian J Med Sci*, 55, 434-438, 472.
- 11 Gogte VVM, 2000. *Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants*. Bharatiya Vidya Bhavan, Mumbai.

- 12 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 13 Kath RK and Gupta RK, 2006. Antioxidant activity of hydroalcoholic leaf extract of *ocimum sanctum* in animal models of peptic ulcer. *Indian J Physiol Pharmacol*, 50, 391-396.
- 14 Kelm MA, Nair MG, Strasburg GM, DeWitt DL, 2000. Antioxidant and cyclooxygenase inhibitory phenolic compounds from *Ocimum sanctum* Linn. *Phytomedicine*, 7, 7-13.
- 15 Mukherjee R, Dash PK, Ram GC, 2005. Immunotherapeutic potential of *Ocimum sanctum* (L) in bovine subclinical mastitis. *Res Vet Sci*, 79, 37-43.
- 16 Prakash P and Gupta N, 2005. Therapeutic uses of *Ocimum sanctum* Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. *Indian J Physiol Pharmacol*, 49, 125-131.
- 17 Samson J, Sheeladevi R, Ravindran R, 2007. Oxidative stress in brain and antioxidant activity of *Ocimum sanctum* in noise exposure. *Neurotoxicology*, 28, 679-685.
- 18 Sato K, Krist S, Buchbauer G, 2006. Antimicrobial effect of trans-cinnamaldehyde, (-)-perillaldehyde, (-)-citronellal, citral, eugenol and carvacrol on airborne microbes using an airwasher. *Biol Pharm Bull*, 29, 2292-2294.
- 19 Sood S, Narang D, Thomas MK, Gupta YK, Maulik SK, 2006. Effect of *Ocimum sanctum* Linn. on cardiac changes in rats subjected to chronic restraint stress. *J Ethnopharmacol*, 108, 423-427.
- 20 Subramanian M, Chintalwar GJ, Chattopadhyay S, 2005. Antioxidant and radioprotective properties of an *Ocimum sanctum* polysaccharide. *Redox Rep*, 10, 257-264.

ID 2854: “Bilberry *Vaccinium myrtillus*” and “Function as antioxidant”

- 1 *Vaccinium myrtillus* (bilberry). Monograph, 2001. *Altern Med Rev*, 6, 500-504.
- 2 Blumenthal M, Goldberg A, Brinckmann J, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX.
- 3 Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, Wold AB, Haffner K, Baugerod H, Andersen LF, Moskaug O, Jacobs DR, Jr., Blomhoff R, 2002. A systematic screening of total antioxidants in dietary plants. *J Nutr*, 132, 461-471.
- 4 Kalkan Yildirim H, 2006. Evaluation of colour parameters and antioxidant activities of fruit wines. *Int J Food Sci Nutr*, 57, 47-63.

ID 2855: “Blackcurrant *Ribes nigrum*” and “Antioxidant properties”

- 1 Anttonen MJ and Karjalainen RO, 2006. High-performance liquid chromatography analysis of black currant (*Ribes nigrum* L.) fruit phenolics grown either conventionally or organically. *J Agric Food Chem*, 54, 7530-7538.
- 2 Bässler KH, Golly I, Loew D, Pietrzik K, 1997. *Vitamin-Lexikon für Ärzte, Apotheker und Ernährungswissenschaftler*. Urban & Fischer, München.
- 3 Biesalski H-K, Köhrle J, Schümann K, 2002. *Vitamine, Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen*. Thieme, Stuttgart.
- 4 Biesalski HK, Fürst P, Kasper H, Kluthe R, Pöler W, Puchstein C, Stählin HB, 2004. *Ernährungsmedizin*. Thieme, Stuttgart.
- 5 Costantino L, Albasini A, Rastelli G, Benvenuti S, 1992. Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. *Planta Med*, 58, 342-344.

- 6 Garrow JS, James WPT, Ralph A, 2000. Human Nutrition and Dietetics. Churchill Livingstone, London, Edinburgh.
- 7 Hahn A, 2006. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- 8 Heinonen IM, Lehtonen PJ, Hopia AI, 1998. Antioxidant Activity of Berry and Fruit Wines and Liquors. J Agric Food Chem, 46, 25-31.
- 9 Kapasakalidis PG, Rastall RA, Gordon MH, 2006. Extraction of polyphenols from processed black currant (*Ribes nigrum* L.) residues. J Agric Food Chem, 54, 4016-4021.
- 10 Matsumoto H, Nakamura Y, Hirayama M, Yoshiki Y, Okubo K, 2002. Antioxidant activity of black currant anthocyanin aglycons and their glycosides measured by chemiluminescence in a neutral pH region and in human plasma. J Agric Food Chem, 50, 5034-5037.
- 11 Matsumoto H, Nakamura Y, Iida H, Ito K, Ohguro H, 2006. Comparative assessment of distribution of blackcurrant anthocyanins in rabbit and rat ocular tissues. Exp Eye Res, 83, 348-356.
- 12 *Vaccinium myrtillus* (bilberry). Monograph, 2001. Altern Med Rev, 6, 500-504.
- 13 Nakajima JI, Tanaka I, Seo S, Yamazaki M, Saito K, 2004. LC/PDA/ESI-MS Profiling and Radical Scavenging Activity of Anthocyanins in Various Berries. J Biomed Biotechnol, 2004, 241-247.
- 14 Nielsen IL, Haren GR, Magnussen EL, Dragsted LO, Rasmussen SE, 2003. Quantification of anthocyanins in commercial black currant juices by simple high-performance liquid chromatography. Investigation of their pH stability and antioxidative potency. J Agric Food Chem, 51, 5861-5866.
- 15 Wang J and Mazza G, 2002. Effects of anthocyanins and other phenolic compounds on the production of tumor necrosis factor alpha in LPS/IFN-gamma-activated RAW 264.7 macrophages. J Agric Food Chem, 50, 4183-4189.
- 16 Xiong S, Melton LD, Easteal AJ, Siew D, 2006. Stability and antioxidant activity of black currant anthocyanins in solution and encapsulated in glucan gel. J Agric Food Chem, 54, 6201-6208.

ID 2857: “Ecklonia cava Kjellman (brown seaweed) extract” and “Antioxidant effects”

- 1 Athukorala Y, Kim KN, Jeon YJ, 2006. Antiproliferative and antioxidant properties of an enzymatic hydrolysate from brown alga, *Ecklonia cava*. Food Chem Toxicol, 44, 1065-1074.
- 2 Kang K, Hwang HJ, Hong DH, Park Y, Kim SH, Lee BH, Shin HC, 2004. Antioxidant and antiinflammatory activities of ventol, a phlorotannin-rich natural agent derived from *Ecklonia cava*, and its effect on proteoglycan degradation in cartilage explant culture. Res Commun Mol Pathol Pharmacol, 115-116, 77-95.
- 3 Kang KA, Zhang R, Lee KH, Chae S, Kim BJ, Kwak YS, Park JW, Lee NH, Hyun JW, 2006. Protective effect of triphlorethol-A from *Ecklonia cava* against ionizing radiation in vitro. J Radiat Res (Tokyo), 47, 61-68.
- 4 Shin HC, Hwang HJ, Kang KJ, Lee BH, 2006. An antioxidative and antiinflammatory agent for potential treatment of osteoarthritis from *Ecklonia cava*. Arch Pharm Res, 29, 165-171.

ID 2858: “Emblica officinalis” and “Immunity/digestion”

- 1 Chawla Y, Dubey P, Singh R, Nundy S, Tandon B, 1982. Treatment of dyspepsia with Amalaki (*Emblica officinalis* Linn.)-an Ayurvedic drug. Indian J Med Res, 76 Suppl, 95-98.
- 2 Gogte VVM, 2000. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants. Bharatiya Vidya Bhavan, Mumbai.

- 3 Indian Ministry of Health and Family Welfare, 2001. The Ayurvedic Pharmacopoeia of India. Government of India, Ministry of Health and Family Welfare, Department of Indian Systems of Medicine and Homeopathy, New Dehli, India.
- 4 Kapoor LD, 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton.
- 5 Manjunatha S, Jaryal AK, Bijlani RL, Sachdeva U, Gupta SK, 2001. Effect of Chyawanprash and vitamin C on glucose tolerance and lipoprotein profile. *Indian J Physiol Pharmacol*, 45, 71-79.
- 6 Pole S, 2006. *Ayurvedic Medicine: The Principles of Traditional Practice*. Churchill Livingstone, London, Edinburgh.
- 7 Sharma PC, Yelne MB, Dennis TJ, 2000. Database on Medical Plants used in Ayurveda. Central Council for Research in Ayurveda & Siddha, New Dehli.
- 8 Williamson EM, 2002. *Major Herbs of Ayurveda*. Churchill Livingstone, London, Edinburgh.

ID 2859: “Mangosteen (*Garcinia mangostana* L) fruits and extracts derived from the fruits” and “Immune support”

- 1 Chanarat P, Chanarat N, Fujihara M, Nagumo T, 1997. Immunopharmacological activity of polysaccharide from the pericarb of mangosteen *garcinia*: phagocytic intracellular killing activities. *J Med Assoc Thai*, 80 Suppl 1, S149-154.
- 2 Gopalakrishnan C, Shankaranarayanan D, Kameswaran L, Nazimudeen SK, 1980. Effect of mangostin, a xanthone from *Garcinia mangostana* Linn. in immunopathological & inflammatory reactions. *Indian J Exp Biol*, 18, 843-846.
- 3 Muruganandan S, Lal J, Gupta PK, 2005. Immunotherapeutic effects of mangiferin mediated by the inhibition of oxidative stress to activated lymphocytes, neutrophils and macrophages. *Toxicology*, 215, 57-68.
- 4 Osman MB and Milan AR, 2006. Mangosteen. *Garcinia mangostana* L. International Centre for Underutilised Crops, Southampton, UK.
- 5 Shaneyfelt ME, Burke AD, Graff JW, Jutila MA, Hardy ME, 2006. Natural products that reduce rotavirus infectivity identified by a cell-based moderate-throughput screening assay. *Virology*, 3, 68.
- 6 Shankaranarayan D, Gopalakrishnan C, Kameswaran L, 1979. Pharmacological profile of mangostin and its derivatives. *Arch Int Pharmacodyn Ther*, 239, 257-269.

ID 2860: “Mangosteen (*Garcinia mangostana* L) fruits and extracts derived from the fruits” and “Antioxidant”

- 1 Fu C, Loo AE, Chia FP, Huang D, 2007. Oligomeric proanthocyanidins from mangosteen pericarps. *J Agric Food Chem*, 55, 7689-7694.
- 2 Haruenkit R, Poovarodom S, Leontowicz H, Leontowicz M, Sajewicz M, Kowalska T, Delgado-Licon E, Rocha-Guzman NE, Gallegos-Infante JA, Trakhtenberg S, Gorinstein S, 2007. Comparative study of health properties and nutritional value of durian, mangosteen, and snake fruit: experiments in vitro and in vivo. *J Agric Food Chem*, 55, 5842-5849.
- 3 Jung HA, Su BN, Keller WJ, Mehta RG, Kinghorn AD, 2006. Antioxidant xanthones from the pericarp of *Garcinia mangostana* (Mangosteen). *J Agric Food Chem*, 54, 2077-2082.
- 4 Moongkarndi P, Kosem N, Kaslungka S, Luanratana O, Pongpan N, Neungton N, 2004. Antiproliferation, antioxidation and induction of apoptosis by *Garcinia mangostana* (mangosteen) on SKBR3 human breast cancer cell line. *J Ethnopharmacol*, 90, 161-166.
- 5 Osman MB and Milan AR, 2005. Mangosteen. *Garcinia mangostana* L. International Centre for Underutilised Crops, Southampton, UK.

- 6 Weecharangsan W, Opanasopit P, Sukma M, Ngawhirunpat T, Sotanaphun U, Siripong P, 2006. Antioxidative and neuroprotective activities of extracts from the fruit hull of mangosteen (*Garcinia mangostana* Linn.). *Med Princ Pract*, 15, 281-287.
- 7 Williams P, Ongsakul M, Proudfoot J, Croft K, Beilin L, 1995. Mangostin inhibits the oxidative modification of human low density lipoprotein. *Free Radic Res*, 23, 175-184.

ID 2861: “Mangosteen (*Garcinia mangostana* L) fruits and extracts derived from the fruits” and “Control of blood lipids”

- 1 Fu C, Loo AE, Chia FP, Huang D, 2007. Oligomeric proanthocyanidins from mangosteen pericarps. *J Agric Food Chem*, 55, 7689-7694.
- 2 Haruenkit R, Poovarodom S, Leontowicz H, Leontowicz M, Sajewicz M, Kowalska T, Delgado-Licon E, Rocha-Guzman NE, Gallegos-Infante JA, Trakhtenberg S, Gorinstein S, 2007. Comparative study of health properties and nutritional value of durian, mangosteen, and snake fruit: experiments in vitro and in vivo. *J Agric Food Chem*, 55, 5842-5849.
- 3 Jung HA, Su BN, Keller WJ, Mehta RG, Kinghorn AD, 2006. Antioxidant xanthenes from the pericarp of *Garcinia mangostana* (Mangosteen). *J Agric Food Chem*, 54, 2077-2082.
- 4 Moongkarndi P, Kosem N, Kaslungka S, Luanratana O, Pongpan N, Neungton N, 2004. Antiproliferation, antioxidation and induction of apoptosis by *Garcinia mangostana* (mangosteen) on SKBR3 human breast cancer cell line. *J Ethnopharmacol*, 90, 161-166.
- 5 Osman MB and Milan AR, 2006. Mangosteen. *Garcinia mangostana* L. International Centre for Underutilised Crops, Southampton, UK.
- 6 Weecharangsan W, Opanasopit P, Sukma M, Ngawhirunpat T, Sotanaphun U, Siripong P, 2006. Antioxidative and neuroprotective activities of extracts from the fruit hull of mangosteen (*Garcinia mangostana* Linn.). *Med Princ Pract*, 15, 281-287.
- 7 Williams P, Ongsakul M, Proudfoot J, Croft K, Beilin L, 1995. Mangostin inhibits the oxidative modification of human low density lipoprotein. *Free Radic Res*, 23, 175-184.

ID 2862: “Mangosteen (*Garcinia mangostana* L) fruits and extracts derived from the fruits” and “Regulation of inflammatory responses in the body”

- 1 Chairungsrilerd N, Furukawa K, Ohta T, Nozoe S, Ohizumi Y, 1996. Pharmacological properties of alpha-mangostin, a novel histamine H1 receptor antagonist. *Eur J Pharmacol*, 314, 351-356.
- 2 Chairungsrilerd N, Furukawa K, Ohta T, Nozoe S, Ohizumi Y, 1996. Histaminergic and serotonergic receptor blocking substances from the medicinal plant *Garcinia mangostana*. *Planta Med*, 62, 471-472.
- 3 Chairungsrilerd N, Furukawa KI, Ohta T, Nozoe S, Ohizumi Y, 1998. Gamma-mangostin, a novel type of 5-hydroxytryptamine 2A receptor antagonist. *Naunyn Schmiedebergs Arch Pharmacol*, 357, 25-31.
- 4 Chomnawang MT, Surassmo S, Nukoolkarn VS, Gritsanapan W, 2007. Effect of *Garcinia mangostana* on inflammation caused by *Propionibacterium acnes*. *Fitoterapia*, 78, 401-408.
- 5 Dharmaratne HR, Piyasena KG, Tennakoon SB, 2005. A geranylated biphenyl derivative from *Garcinia mangostana*. *Nat Prod Res*, 19, 239-243.
- 6 Furukawa K, Chairungsrilerd N, Ohta T, Nozoe S, Ohizumi Y, 1997. [Novel types of receptor antagonists from the medicinal plant *Garcinia mangostana*]. *Nippon Yakurigaku Zasshi*, 110 Suppl 1, 153P-158P.
- 7 Gopalakrishnan C, Shankaranarayanan D, Kameswaran L, Nazimudeen SK, 1980. Effect of mangostin, a xanthone from *Garcinia mangostana* Linn. in immunopathological & inflammatory reactions. *Indian J Exp Biol*, 18, 843-846.

- 8 Marona H, Pekala E, Filipek B, Maciag D, Szneler E, 2001. Pharmacological properties of some aminoalkanoic derivatives of xanthone. *Pharmazie*, 56, 567-572.
- 9 Nakatani K, Yamakuni T, Kondo N, Arakawa T, Oosawa K, Shimura S, Inoue H, Ohizumi Y, 2004. gamma-Mangostin inhibits inhibitor-kappaB kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells. *Mol Pharmacol*, 66, 667-674.
- 10 Osman MB and Milan AR, 2006. Mangosteen. *Garcinia mangostana* L. International Centre for Underutilised Crops, Southampton, UK.
- 11 Shaneyfelt ME, Burke AD, Graff JW, Jutila MA, Hardy ME, 2006. Natural products that reduce rotavirus infectivity identified by a cell-based moderate-throughput screening assay. *Virology*, 3, 68.
- 12 Shankaranarayan D, Gopalakrishnan C, Kameswaran L, 1979. Pharmacological profile of mangostin and its derivatives. *Arch Int Pharmacodyn Ther*, 239, 257-269.
- 13 Yamakuni T, Aoki K, Nakatani K, Kondo N, Oku H, Ishiguro K, Ohizumi Y, 2006. Garcinone B reduces prostaglandin E2 release and NF-kappaB-mediated transcription in C6 rat glioma cells. *Neurosci Lett*, 394, 206-210.

ID 2865: “Polyphenols (from *Olea europaea* extract)” and “Antioxidant properties”

- 1 Aldini G, Piccoli A, Beretta G, Morazzoni P, Riva A, Marinello C, Maffei Facino R, 2006. Antioxidant activity of polyphenols from solid olive residues of c.v. Coratina. *Fitoterapia*, 77, 121-128.
- 2 Liu MJ, Li JX, Guo HZ, Lee KM, Qin L, Chan KM, 2003. The effects of verbascoside on plasma lipid peroxidation level and erythrocyte membrane fluidity during immobilization in rabbits: a time course study. *Life Sci*, 73, 883-892.

ID 2866: “Rosemary. *Rosmarinus officinalis*” and “Antioxidant properties”

- 1 al-Sereiti MR, Abu-Amer KM, Sen P, 1999. Pharmacology of rosemary (*Rosmarinus officinalis* Linn.) and its therapeutic potentials. *Indian J Exp Biol*, 37, 124-130.
- 2 Cheung S and Tai J, 2007. Anti-proliferative and antioxidant properties of rosemary *Rosmarinus officinalis*. *Oncol Rep*, 17, 1525-1531.
- 3 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Thieme, Stuttgart.
- 4 Nakatani N, 2000. Phenolic antioxidants from herbs and spices. *Biofactors*, 13, 141-146.
- 5 Perez-Fons L, Aranda FJ, Guillen J, Villalain J, Micol V, 2006. Rosemary (*Rosmarinus officinalis*) diterpenes affect lipid polymorphism and fluidity in phospholipid membranes. *Arch Biochem Biophys*, 453, 224-236.
- 6 Wijeratne SS and Cuppett SL, 2007. Potential of rosemary (*Rosmarinus officinalis* L.) diterpenes in preventing lipid hydroperoxide-mediated oxidative stress in Caco-2 cells. *J Agric Food Chem*, 55, 1193-1199.

ID 2867: “Zingiber officinale” and “Blood sugar metabolism”

- 1 Akhani SP, Vishwakarma SL, Goyal RK, 2004. Anti-diabetic activity of *Zingiber officinale* in streptozotocin-induced type I diabetic rats. *J Pharm Pharmacol*, 56, 101-105.
- 2 Ojewole JA, 2006. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of *Zingiber officinale* (Roscoe) rhizomes (*Zingiberaceae*) in mice and rats. *Phytother Res*, 20, 764-772.

- 3 Srinivasan K, 2005. Plant foods in the management of diabetes mellitus: spices as beneficial antidiabetic food adjuncts. *Int J Food Sci Nutr*, 56, 399-414.

ID 2870: “Standardisierter Kartoffelextrakt” and “Sättigung/ Gewichtsmanagement / Förderung der CCK-Ausschüttung”

- 1 Crawley JN and Corwin RL, 1994. Biological Actions of Cholecystokinin. *Peptides*, 15, 731-755.
- 2 Dana S, 2005. An open label phase II study of Satise® for appetite control and weight loss. *Kemin Consumer Care White Paper*. Kemin Industries, Inc.
- 3 Gibbs J, Falasco JD, Mchugh PR, 1976. Cholecystokinin-Decreased Food-Intake in Rhesus-Monkeys. *American Journal of Physiology*, 230, 15-18.
- 4 Gumbmann MR, Dugan GM, Spangler WL, Baker EC, Rackis JJ, 1989. Pancreatic Response in Rats and Mice to Trypsin-Inhibitors from Soy and Potato after Short-Term and Long-Term Dietary Exposure. *Journal of Nutrition*, 119, 1598-1609.
- 5 Gutzwiller JP, Drewe J, Ketterer S, Hildebrand P, Krautheim A, Beglinger C, 2000. Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans. *American Journal of Physiology-Regulatory Integrative and Comparative Physiology*, 279, R189-R195.
- 6 Halford JCG, 2001. Pharmacology of appetite suppression: Implication for the treatment of obesity. *Current Drug Targets*, 2, 353-370.
- 7 Herzig KH, Schon I, Tatemoto K, Ohe Y, Li Y, Folsch UR, Owyang C, 1996. Diazepam binding inhibitor is a potent cholecystokinin releasing peptide in the intestine (vol 93, pg 7927, 1996). *Proceedings of the National Academy of Sciences of the United States of America*, 93, 14214-14214.
- 8 Hill AJ, Peikin SR, Ryan CA, Blundell JE, 1990. Oral-Administration of Proteinase Inhibitor-Ii from Potatoes Reduces Energy-Intake in Man. *Physiology & Behavior*, 48, 241-246.
- 9 Hu J, Dana S, Radosevich J, 2004. A randomized, double-blind, placebo-controlled clinical study demonstrates proteinase inhibitor II is a safe and effective tool for promoting weight reduction. *Kemin Consumer Care White Paper*. Kemin Industries, Inc.
- 10 Jensen RT, 2002. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. *Pharmacology & toxicology*, 91, 333-350.
- 11 Liddle RA, Rushakoff RJ, Morita ET, Beccaria L, Carter JD, Goldfine ID, 1988. Physiological-Role for Cholecystokinin in Reducing Postprandial Hyperglycemia in Humans. *Journal of Clinical Investigation*, 81, 1675-1681.
- 12 Liddle RA, 1995. Regulation of Cholecystokinin Secretion by Intraluminal Releasing Factors. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 32, G319-G327.
- 13 Liddle RA, 2000. Regulation of cholecystokinin secretion in humans. *Journal of Gastroenterology*, 35, 181-187.
- 14 Ludwig DDS, 2002. The glycemic index - Physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. *Jama-Journal of the American Medical Association*, 287, 2414-2423.
- 15 Matson CA, Reid DF, Cannon TA, Ritter RC, 2000. Cholecystokinin and leptin act synergistically to reduce body weight. *American Journal of Physiology-Regulatory Integrative and Comparative Physiology*, 278, R882-R890.
- 16 Mclaughlin CL, Peikin SR, Baile CA, 1983. Food-Intake Response to Modulation of Secretion of Cholecystokinin in Zucker Rats. *American Journal of Physiology*, 244, R676-R685.
- 17 Melton PM, Kissileff HR, Pisunyer FX, 1992. Cholecystokinin (Cck-8) Affects Gastric Pressure and Ratings of Hunger and Fullness in Women. *American Journal of Physiology*, 263, R452-R456.
- 18 Miyasaka K and Funakoshi A, 1998. Luminal feedback regulation, monitor peptide, CCK-releasing peptide, and CCK receptors. *Pancreas*, 16, 277-283.

- 19 Owyang C, 1999. Discovery of a cholecystokinin-releasing peptide: Biochemical characterization and physiological implications. *Chinese Journal of Physiology*, 42, 113-120.
- 20 Peikin S, Springer C, Dockray G, et al 1987. Oral administration of protease inhibitor potato II stimulates the release of cholecystokinin in man. *Gastroenterology* 92 (A1570).
- 21 Phillips WT, Schwartz JG, McMahan CA, 1993. Reduced Postprandial Blood-Glucose Levels in Recently Diagnosed Non-Insulin-Dependent Diabetics Secondary to Pharmacologically Induced Delayed Gastric-Emptying. *Digestive Diseases and Sciences*, 38, 51-58.
- 22 Ritter RC, Covasa M, Matson CA, 1999. Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. *Neuropeptides*, 33, 387-399.
- 23 Schwartz JG, Guan D, Green GM, Phillips WT, 1994. Treatment with an Oral Proteinase-Inhibitor Slows Gastric-Emptying and Acutely Reduces Glucose and Insulin Levels after a Liquid Meal in Type-II Diabetic-Patients. *Diabetes Care*, 17, 255-262.
- 24 Spiegel T, Hubert C, Peikin S, 1999. Effect of a premeal beverage containing a protease inhibitor from potatoes on satiety in dieting overweight women. *North American Association for the Study of Obesity (NAASO) Annual Meeting*.
- 25 Spreadbury D, Shao AE, Essmann MK, 2003. A proteinase inhibitor extract from potatoes reduces post-prandial blood glucose in human subjects. *JANA*, 6, 29-38.
- 26 Vasselli J, Greenfield D, Schwartz L, Heymsfield S, 1999. Protease inhibitor from potatoes decreases hunger and increases fullness in overweight subjects following a meal. *North American Association for the study of obesity (NAASO) Annual Meeting*.
- 27 Wolever TMS, Jenkins DJA, Vuksan V, Jenkins AL, Wong GS, Josse RG, 1992. Beneficial Effect of Low-Glycemic Index Diet in Overweight Niddm Subjects. *Diabetes Care*, 15, 562-564.
- 28 Woods SC, Schwartz MW, Baskin DG, Seeley RJ, 2000. Food intake and the regulation of body weight. *Annual Review of Psychology*, 51, 255-277.

ID 2872: “Combination of Vitamin C, Selenium and Vitamin E” and “Anti-oxidant properties”

- 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris.
- 2 Combs GF, 1992. The vitamins: fundamental aspects in nutrition and health. Academic Press, New York.
- 3 IoM (Institute of Medicine), 2000. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academies Press, Washington DC.
- 4 Knight JA, Blaylock RC, Searles DA, 1993. The effect of vitamins C and E on lipid peroxidation in stored erythrocytes. *Ann Clin Lab Sci*, 23, 51-56.
- 5 Le Grusse J and Watier B, 1993. Les vitamines. Centre d'étude et d'information sur les vitamines. Produits Roche, Neuillysur-Seine, France.
- 6 Lederer J, 1986. Sélénium et vitamine E: les deux pompiers de l'organisme. Nauwelaerts Maloine, Paris.
- 7 Packer L, Weber SU, Rimbach G, 2001. Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling. *J Nutr*, 131, 369S-373S.
- 8 Packer L, Traber MG, Kraemer K, Frei B, 2002. The antioxidant vitamins C and E. AOCS Press, Champaign, IL.
- 9 Rayman MP, 2000. The importance of selenium to human health. *The Lancet*, 356, 233-241.

ID 2873: “Vitamin E acetate (D,L-alpha tocopherol acetate)” and “Health of the scalp”

- 1 Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT, 2000. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. *J Am Coll Cardiol*, 36, 94-102.
- 2 Wu D, Liu L, Meydani M, Meydani SN, 2005. Vitamin E increases production of vasodilator prostanoids in human aortic endothelial cells through opposing effects on cyclooxygenase-2 and phospholipase A2. *J Nutr*, 135, 1847-1853.

ID 2874: “Vitamines du groupe B : B-group vitamins (especially vitamin B5 and vitamin B8)” and “Hairs and nails care”

- 1 Budde J, Tronnier H, Rahlfs VW, Frei-Kleiner S, 1993. [Systemic therapy of diffuse effluvium and hair structure damage]. *Hautarzt*, 44, 380-384.
- 2 Dethlefs J and Schneider W, 1977. [Effect of a combination of vitamin and amino acid on the hair growth]. *ZFA (Stuttgart)*, 53, 684-688.
- 3 Floersheim GL, 1992. [An examination of the effect of biotin on alopecia and hair quality]. *H&G Zeitschrift für Hautkrankheiten*, 67, 246-255.
- 4 Petri H, Pierchalla P, Tronnier H, 1990. [The efficacy of drug therapy in structural lesions of the hair and in diffuse effluvium--comparative double blind study]. *Schweiz Rundsch Med Prax*, 79, 1457-1462.

ID 2875: “Vitamine B3” and “Hairs and nails care”

- 1 Aikawa H and Suzuki K, 1986. Lesions in the skin, intestine, and central nervous system induced by an antimetabolite of niacin. *Am J Pathol*, 122, 335-342.
- 2 BIAM, Nicotinique acide, www.biam2.org.
- 3 El-Fekih N, Badri T, Kharfi M, Zeglaoui F, Fazaa B, Gaiji S, Kamoun MR, 2005. Diffuse alopecia and diet. *Dermatol Clin*, 25, 101-105.
- 4 EVM (Expert Group on Vitamins and Minerals), 2003. Safe Upper Levels for Vitamins and Minerals. Food Standards Agency, London.
- 5 Gupte SA, Rupawalla T, Mohazzab HK, Wolin MS, 1999. Regulation of NO-elicited pulmonary artery relaxation and guanylate cyclase activation by NADH oxidase and SOD. *Am J Physiol*, 276, H1535-1542.
- 6 Gupte SA, Rupawalla T, Phillibert D, Jr., Wolin MS, 1999. NADPH and heme redox modulate pulmonary artery relaxation and guanylate cyclase activation by NO. *Am J Physiol*, 277, L1124-1132.
- 7 Gupte SA, Li KX, Okada T, Sato K, Oka M, 2002. Inhibitors of pentose phosphate pathway cause vasodilation: involvement of voltage-gated potassium channels. *J Pharmacol Exp Ther*, 301, 299-305.

ID 2876: “Vitamine B8 (biotin)” and “Hair loss and regrowth”

- 1 Bryant KL, Kornegay ET, Knight JW, Veit HP, Notter DR, 1985. Supplemental biotin for swine. III. Influence of supplementation to corn- and wheat-based diets on the incidence and severity of toe lesions, hair and skin characteristics and structural soundness of sows housed in confinement during four parities. *J Anim Sci*, 60, 154-162.
- 2 Charles BM, Hosking G, Green A, Pollitt R, Bartlett K, Taitz LS, 1979. Biotin-responsive alopecia and developmental regression. *Lancet*, 2, 118-120.
- 3 Chelrif-Cheikh JL and Hincky M, 1977. Recrudescence de l'alopecie. *Concours Médical*, 99, 4461-4464.

- 4 Dijkstra AC, Goos CM, Cunliffe WJ, Sultan C, Vermorcken AJ, 1987. Is increased 5 alpha-reductase activity a primary phenomenon in androgen-dependent skin disorders? *J Invest Dermatol*, 89, 87-92.
- 5 Fabre P, 1987. Les alopecies, leur traitement par vitaminothérapie: Vitamine B5 et biotine. *Tempo médical*, 274.
- 6 Falcone G, Bianchini P, Boldrini E, 2006. Current concepts and new therapeutic indications about biotin. *Prog Nutr*, 8, 3-10.
- 7 Floersheim GL, 1992. An examination of the effect of biotin on alopecia and hair quality. *Zeitschrift für Hautkrankheiten*, 67, 246-255.
- 8 Hincky M, 1980. Diagnosis and treatment of diffuse alopecias. *Rev Med*, 21, 1855-1864.
- 9 Jacquet A, 1999. Evaluation of Nutricap® for men dietary supplement for hair complaints. *Nouv Dermatol*, 18, 680-683.
- 10 Le Grusse J and Watier B, 1993. Les vitamines. Centre d'études et d'information sur les vitamines, Produits Roche.
- 11 Liang T and Liao S, 1992. Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids. *Biochem J*, 285 (Pt 2), 557-562.
- 12 Mercurio MG and Gogstetter DS, 2000. Androgen physiology and the cutaneous pilosebaceous unit. *J Gend Specif Med*, 3, 59-64.
- 13 Miller SJ, 1989. Nutritional deficiency and the skin. *J Am Acad Dermatol*, 21, 1-30.
- 14 Munnich A, Saudubray JM, Ogier H, Marsac C, Charpentier C, Frezal J, 1980. [Alopecia, chronic candidodis, mental retardation and repeated ketoacidotic comas curable by biotin administration: multiple carboxylases deficiency (author's transl)]. *Ann Med Interne (Paris)*, 131, 435-437.
- 15 Proud VK, Rizzo WB, Patterson JW, Heard GS, Wolf B, 1990. Fatty acid alterations and carboxylase deficiencies in the skin of biotin-deficient rats. *Am J Clin Nutr*, 51, 853-858.
- 16 Shelley WB and Shelley ED, 1985. Uncombable hair syndrome: observations on response to biotin and occurrence in siblings with ectodermal dysplasia. *J Am Acad Dermatol*, 13, 97-102.

ID 2877: “Vitamine B8 : Vitamin B8 or vitamin H (biotin)” and “Resistance and strength of the nails”

- 1 Colombo VE, Gerber F, Bronhofer M, Floersheim GL, 1990. Treatment of brittle fingernails and onychoschizia with biotin: scanning electron microscopy. *J Am Acad Dermatol*, 23, 1127-1132.
- 2 Floersheim GL, 1989. [Treatment of brittle fingernails with biotin]. *Z Hautkr*, 64, 41-48.
- 3 Floersheim GL, 1992. An examination of the effect of biotin on alopecia and hair quality. *Zeitschrift für Hautkrankheiten*, 67, 246-255.
- 4 Gehring W, 1996. Biotin: The Influence of Biotin on Nails of Reduced Quality. *Aktuelle Dermatologie*, 22, 20-24.
- 5 Hochman LG, Scher RK, Meyerson MS, 1993. Brittle nails: response to daily biotin supplementation. *Cutis*, 51, 303-305.

ID 2878: “Vitamine B5 (Pantothenic acid)” and “Skin care”

- 1 Hurley LS and Mackenzie JB, 1954. Adrenal function in the pantothenic acid-deficient rat; liver glycogen, blood glucose, adrenal cholesterol and adrenal ascorbic acid levels. *J Nutr*, 54, 403-415.
- 2 Perry WF, Hawkins WW, Cumming GR, 1953. Adrenal function in pantothenic acid deficiency. *Am J Physiol*, 172, 259-264.

- 3 Tarasov Iu A, Sheibak VM, Moiseenok AG, 1985. [Adrenal cortex functional activity in pantothenate deficiency and the administration of the vitamin or its derivatives]. *Vopr Pitan*, 51-54.
- 4 Wirtschafter ZT and Walsh JR, 1963. Adrenocortical alterations induced by deficiency and excess of pantothenic acid. *Endocrinology*, 72, 725-734.

ID 2879: “Menaquinone-7 (MK-7, a form of vitamin K2)” and “Bone health”

- 1 PDR for Nonprescription Drugs, Dietary Supplements and Herbs: The Definitive Guide to OTC Medications. 2007. Thomson, Montvale, NJ.
- 2 Akiyama Y, Hara K, Ohkawa I, Tajima T, 1993. Effects of menatetrenone on bone loss induced by ovariectomy in rats. *Jpn J Pharmacol*, 62, 145-153.
- 3 Akiyama Y, Hara K, Kobayashi M, Tomiuga T, Nakamura T, 1999. Inhibitory effect of vitamin K2 (menatetrenone) on bone resorption in ovariectomized rats: a histomorphometric and dual energy X-ray absorptiometric study. *Jpn J Pharmacol*, 80, 67-74.
- 4 Asawa Y, Amizuka N, Hara K, Kobayashi M, Aita M, Li M, Kenmotsu S, Oda K, Akiyama Y, Ozawa H, 2004. Histochemical evaluation for the biological effect of menatetrenone on metaphyseal trabeculae of ovariectomized rats. *Bone*, 35, 870-880.
- 5 Bugel S, 2003. Vitamin K and bone health. *Proc Nutr Soc*, 62, 839-843.
- 6 Bunyaratavej N, Penkitti P, Kittimanon N, Boonsangsom P, Bonjongsat A, Yuno S, 2001. Efficacy and safety of Menatetrenone-4 postmenopausal Thai women. *J Med Assoc Thai*, 84 Suppl 2, S553-559.
- 7 FNFC/FOSHU (Food with Nutrient Functional Claims/Foods for Specified Health Use), Ministry of Health, Labour, and Welfare, Japan : Food with Health Claims, Food for Special Dietary Uses, and Nutrition Labeling <http://www.mhlw.go.jp/english/topics/foodsafety/fhc/index.html>.
- 8 Hara K, Akiyama Y, Ohkawa I, Tajima T, 1993. Effects of menatetrenone on prednisolone-induced bone loss in rats. *Bone*, 14, 813-818.
- 9 Hara K, Kobayashi M, Akiyama Y, 2002. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. *Bone*, 31, 575-581.
- 10 Hodges SJ, Pilkington MJ, Stamp TC, Catterall A, Shearer MJ, Bitensky L, Chayen J, 1991. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. *Bone*, 12, 387-389.
- 11 Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD, 1993. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. *J Bone Miner Res*, 8, 1241-1245.
- 12 Ikeda Y, Iki M, Morita A, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H, 2006. Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study. *J Nutr*, 136, 1323-1328.
- 13 IoM (Institute of Medicine), 2000. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC.
- 14 Ishida Y and Kawai S, 2004. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. *Am J Med*, 117, 549-555.
- 15 Iwamoto I, Kosha S, Noguchi S, Murakami M, Fujino T, Douchi T, Nagata Y, 1999. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy. *Maturitas*, 31, 161-164.
- 16 Iwamoto J, Takeda T, Ichimura S, 2000. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. *J Orthop Sci*, 5, 546-551.

- 17 Iwamoto J, Takeda T, Ichimura S, 2001. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. *J Orthop Sci*, 6, 487-492.
- 18 Iwamoto J, Yeh JK, Takeda T, 2003. Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats. *J Bone Miner Res*, 18, 776-783.
- 19 Iwamoto J, Yeh JK, Takeda T, Ichimura S, Sato Y, 2003. Comparative effects of vitamin K and vitamin D supplementation on prevention of osteopenia in calcium-deficient young rats. *Bone*, 33, 557-566.
- 20 Iwamoto J, Takeda T, Sato Y, 2004. Effects of vitamin K2 on osteoporosis. *Curr Pharm Des*, 10, 2557-2576.
- 21 Iwamoto J, Takeda T, Sato Y, 2006. Effects of vitamin K2 on the development of osteopenia in rats as the models of osteoporosis. *Yonsei Med J*, 47, 157-166.
- 22 Iwasaki Y, Yamato H, Murayama H, Sato M, Takahashi T, Ezawa I, Kurokawa K, Fukagawa M, 2002. Maintenance of trabecular structure and bone volume by vitamin K(2) in mature rats with long-term tail suspension. *J Bone Miner Metab*, 20, 216-222.
- 23 Iwasaki Y, Yamato H, Murayama H, Takahashi T, Ezawa I, Kurokawa K, Fukagawa M, 2002. Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. *Jpn J Pharmacol*, 90, 88-93.
- 24 Iwasaki-Ishizuka Y, Yamato H, Murayama H, Abe M, Takahashi K, Kurokawa K, Fukagawa M, Ezawa I, 2003. Menatetrenone ameliorates reduction in bone mineral density and bone strength in sciatic neurectomized rats. *J Nutr Sci Vitaminol (Tokyo)*, 49, 256-261.
- 25 Iwasaki-Ishizuka Y, Yamato H, Murayama H, Ezawa I, Kurokawa K, Fukagawa M, 2005. Menatetrenone rescues bone loss by improving osteoblast dysfunction in rats immobilized by sciatic neurectomy. *Life Sci*, 76, 1721-1734.
- 26 JHCI (Joint Health Claims Initiative), 2003. Final Technical Report A List of Well Established Nutrient Function Statements.
- 27 Kanai T, Takagi T, Masuhiro K, Nakamura M, Iwata M, Saji F, 1997. Serum vitamin K level and bone mineral density in post-menopausal women. *Int J Gynaecol Obstet*, 56, 25-30.
- 28 Kaneki M, Hodges SJ, Hosoi T, Fujiwara S, Lyons A, Crean SJ, Ishida N, Nakagawa M, Takechi M, Sano Y, Mizuno Y, Hoshino S, Miyao M, Inoue S, Horiki K, Shiraki M, Ouchi Y, Orimo H, 2001. Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. *Nutrition*, 17, 315-321.
- 29 Katsuyama H, Ideguchi S, Fukunaga M, Saijoh K, Sunami S, 2002. Usual dietary intake of fermented soybeans (Natto) is associated with bone mineral density in premenopausal women. *J Nutr Sci Vitaminol (Tokyo)*, 48, 207-215.
- 30 Katsuyama H, Ideguchi S, Fukunaga M, Fukunaga T, Saijoh K, Sunami S, 2004. Promotion of bone formation by fermented soybean (Natto) intake in premenopausal women. *J Nutr Sci Vitaminol (Tokyo)*, 50, 114-120.
- 31 Knapen MH, Schurgers LJ, Vermeer C, 2007. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. *Osteoporos Int*, 18, 963-972.
- 32 Kobayashi M, Hara K, Akiyama Y, 2002. Effects of vitamin K2 (menatetrenone) on calcium balance in ovariectomized rats. *Jpn J Pharmacol*, 88, 55-61.
- 33 Kobayashi M, Hara K, Akiyama Y, 2004. Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet. *Bone*, 35, 1136-1143.
- 34 Kobayashi M, Hara K, Akiyama Y, 2007. Infrared analysis of bones in magnesium-deficient rats treated with vitamin K2. *J Bone Miner Metab*, 25, 12-18.
- 35 Mawatari T, Miura H, Higaki H, Moro-Oka T, Kurata K, Murakami T, Iwamoto Y, 2000. Effect of vitamin K2 on three-dimensional trabecular microarchitecture in ovariectomized rats. *J Bone Miner Res*, 15, 1810-1817.

- 36 Miki T, Nakatsuka K, Naka H, Kitatani K, Saito S, Masaki H, Tomiyoshi Y, Morii H, Nishizawa Y, 2003. Vitamin K(2) (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. *J Bone Miner Metab*, 21, 161-165.
- 37 Orimo H, Shiraki M, Tomita A, Morii A, Fujita T, Ohata M, 1998. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: A double-blinded placebo-controlled study. *Journal of Bone and Mineral Metabolism*, 16, 106-112.
- 38 Ozuru R, Sugimoto T, Yamaguchi T, Chihara K, 2002. Time-dependent effects of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. *Endocr J*, 49, 363-370.
- 39 Schurgers LJ, Teunissen KJ, Hamulyak K, Knapen MH, Vik H, Vermeer C, 2007. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. *Blood*, 109, 3279-3283.
- 40 Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T, 2002. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. *Calcif Tissue Int*, 71, 69-79.
- 41 Shiraki M, Shiraki Y, Aoki C, Miura M, 2000. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res*, 15, 515-521.
- 42 Tamatani M, Morimoto S, Nakajima M, Fukuo K, Onishi T, Kitano S, Niinobu T, Ogihara T, 1998. Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. *Metabolism*, 47, 195-199.
- 43 Tomiuga T, Kobayashi M, Nakajima Y, Bessho M, Katoh Y, Hara K, Akiyama Y, Nakamura T, Tajima T, 1994. Effects of menatetrenone on the decrease in calcium balance induced by vitamin K-deficient diet and sodium loading in rats. *Jpn J Pharmacol*, 65, 35-43.
- 44 Tsugawa N, Shiraki M, Suhara Y, Kamao M, Tanaka K, Okano T, 2006. Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. *Am J Clin Nutr*, 83, 380-386.
- 45 Tsukamoto Y, Ichise H, Kakuda H, Yamaguchi M, 2000. Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and gamma-carboxylated osteocalcin concentration in normal individuals. *J Bone Miner Metab*, 18, 216-222.
- 46 Tsukamoto Y, Ichise H, Yamaguchi M, 2000. Prolonged Intake of Dietary Fermented Soybeans (Natto) with the Reinforced Vitamin K2 (Menaquinone-7) Enhances Circulating γ -Carboxylated Osteocalcin Concentration in Normal Individuals. *J Health Science*, 46, 317-321.
- 47 Tsukamoto Y, 2004. Studies on action of menaquinone-7 in regulation of bone metabolism and its preventive role of osteoporosis. *Biofactors*, 22, 5-19.
- 48 Ushiroyama T, Ikeda A, Ueki M, 2002. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. *Maturitas*, 41, 211-221.
- 49 Vermeer C, Shearer MJ, Zittermann A, Bolton-Smith C, Szulc P, Hodges S, Walter P, Rambeck W, Stocklin E, Weber P, 2004. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. *Eur J Nutr*, 43, 325-335.
- 50 Yamaguchi M, Taguchi H, Gao YH, Igarashi A, Tsukamoto Y, 1999. Effect of vitamin K2 (menaquinone-7) in fermented soybean (natto) on bone loss in ovariectomized rats. *J Bone Miner Metab*, 17, 23-29.
- 51 Yamaguchi M, Kakuda H, Gao YH, Tsukamoto Y, 2000. Prolonged intake of fermented soybean (natto) diets containing vitamin K2 (menaquinone-7) prevents bone loss in ovariectomized rats. *J Bone Miner Metab*, 18, 71-76.
- 52 Yamaguchi M, 2006. Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis. *Yakugaku Zasshi*, 126, 1117-1137.

- 53 Zhong Jie Ma, Aki Igarashi, Konosuke Yamakawa, Yamaguchi M, 2001. Enhancing Effect of Zinc and Vitamin K2 (Menaquinone-7) on Bone Components in the Femoral Tissue of Female Elderly Rats. *J. Health Sci.*, 47, 40-45.

ID 2880: “Menaquinone-7 (MK-7, a form of vitamin K2)” and “Cardiovascular Health”

- 1 PDR for Nonprescription Drugs, Dietary Supplements and Herbs: The Definitive Guide to OTC Medications. 2007. Thomson, Montvale, NJ.
- 2 Adams J and Pepping J, 2005. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. *Am J Health Syst Pharm*, 62, 1574-1581.
- 3 Berkner KL and Runge KW, 2004. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. *J Thromb Haemost*, 2, 2118-2132.
- 4 Booth SL, 2007. Vitamin K status in the elderly. *Curr Opin Clin Nutr Metab Care*, 10, 20-23.
- 5 Braam LA, Dissel P, Gijsbers BL, Spronk HM, Hamulyak K, Soute BA, Debie W, Vermeer C, 2000. Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. *Arterioscler Thromb Vasc Biol*, 20, 1257-1261.
- 6 Cranenburg EC, Schurgers LJ, Vermeer C, 2007. Vitamin K: the coagulation vitamin that became omnipotent. *Thromb Haemost*, 98, 120-125.
- 7 Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC, 2004. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. *J Nutr*, 134, 3100-3105.
- 8 IoM (Institute of Medicine), 2000. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC.
- 9 JHCI (Joint Health Claims Initiative), 2003. Final Technical Report A List of Well Established Nutrient Function Statements.
- 10 Jie KS, Bots ML, Vermeer C, Witteman JC, Grobbee DE, 1995. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. *Atherosclerosis*, 116, 117-123.
- 11 Kaneki M, Hosoi T, Ouchi Y, Orimo H, 2006. Pleiotropic actions of vitamin K: protector of bone health and beyond? *Nutrition*, 22, 845-852.
- 12 Kawashima H, Nakajima Y, Matubara Y, Nakanowatari J, Fukuta T, Mizuno S, Takahashi S, Tajima T, Nakamura T, 1997. Effects of vitamin K2 (menatetrenone) on atherosclerosis and blood coagulation in hypercholesterolemic rabbits. *Jpn J Pharmacol*, 75, 135-143.
- 13 Koos R, Mahnken AH, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger JE, Kuhl HP, 2005. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. *Am J Cardiol*, 96, 747-749.
- 14 Maas AH, van der Schouw YT, Beijerinck D, Deurenberg JJ, Mali WP, Grobbee DE, van der Graaf Y, 2007. Vitamin K intake and calcifications in breast arteries. *Maturitas*, 56, 273-279.
- 15 Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C, 2007a. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. *Blood*, 109, 2823-2831.
- 16 Schurgers LJ, Teunissen KJ, Hamulyak K, Knapen MH, Vik H, Vermeer C, 2007b. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. *Blood*, 109, 3279-3283.
- 17 Seyama Y, Horiuchi M, Hayashi M, Kanke Y, 1996. Effect of vitamin K2 on experimental calcinosis induced by vitamin D2 in rat soft tissue. *Int J Vitam Nutr Res*, 66, 36-38.
- 18 Seyama Y, Hayashi M, Takegami H, Usami E, 1999. Comparative effects of vitamin K2 and vitamin E on experimental arteriosclerosis. *Int J Vitam Nutr Res*, 69, 23-26.

- 19 Seyama Y, Kimoto S, Marukawa Y, Horiuchi M, Hayashi M, Usami E, 2000. Comparative effects of vitamin K2 and estradiol on experimental arteriosclerosis with diabetes mellitus. *Int J Vitam Nutr Res*, 70, 301-304.
- 20 Shearer MJ, 2000a. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. *Curr Opin Clin Nutr Metab Care*, 3, 433-438.
- 21 Shearer MJ and Bolton-Smith C, 2000b. The UK food data-base for vitamin K and why we need it. *Food Chemistry*, 68, 213-218.
- 22 Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C, 2003. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. *J Vasc Res*, 40, 531-537.
- 23 Suzuki Y, Kondo K, Ichise H, Tsukamoto Y, Urano T, Umemura K, 2003a. Dietary supplementation with fermented soybeans suppresses intimal thickening. *Nutrition*, 19, 261-264.
- 24 Suzuki Y, Kondo K, Matsumoto Y, Zhao BQ, Otsuguro K, Maeda T, Tsukamoto Y, Urano T, Umemura K, 2003b. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. *Life Sci*, 73, 1289-1298.
- 25 Vermeer C and Braam L, 2001. Role of K vitamins in the regulation of tissue calcification. *J Bone Miner Metab*, 19, 201-206.
- 26 Vermeer C, Shearer MJ, Zittermann A, Bolton-Smith C, Szulc P, Hodges S, Walter P, Rambeck W, Stocklin E, Weber P, 2004. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. *Eur J Nutr*, 43, 325-335.

ID 2881: “Folate/ Folic acid (Vitamin B9)” and “Cell division/multiplication: Nucleic acids and amino acids synthesis (such as in the gastrointestinal tract) “

- 1 CEDAP (Commission Interministérielle d’Etude des Produits Destinés à une Alimentation Particulière), 1996. Avis de la commission interministérielle d’étude des produits destinés à une alimentation particulière (CEDAP) en date du 18 décembre 1996 sur les recommandations relatives au caractère non trompeur des seuils des allégations nutritionnelles fonctionnelles (repris dans le BOCCRF du 7 octobre 1997) dressant une liste indicative des allégations.
- 2 COMA (Committee on Medical Aspects of Food and Nutrition Policy), 2000. Folic acid and the prevention of disease. The Stationary Office, London.
- 3 EDA (European Dairy Association), 2007. List of EDA Health Claims under Article 13 Regulation EC No 1924/2006 on Nutrition and Health Claims Made on Food.
- 4 EVM (Expert Group on Vitamins and Minerals), 2002. Review of Folic Acid. EVM/00/18.REVISED AUG 2002.
- 5 Garrow JS, James WPT, Ralph A, 2000. Human Nutrition and Dietetics. Churchill Livingstone, London, Edinburgh.
- 6 Gibney MJ, Vorster H, Kok F, 2002. Introduction to Human Nutrition (The Nutrition Society Textbook). Wiley-Blackwell, Chichester.
- 7 IoM (Institute of Medicine), 1998. Dietary Reference Intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. National Academies Press, Washington DC.
- 8 JHCI (Joint Health Claims Initiative), 2003. Final Technical Report A List of Well Established Nutrient Function Statements. JHCI Ref: JHCI/76/03.
- 9 Mann J and Truswell AS, 2002. Essentials of Human Nutrition. Oxford University Press, New York.
- 10 Sadler MJ, Strain JJ, Caballero B, 1999. Encyclopedia of Human Nutrition. Academic Press, San Diego.
- 11 SCF (Scientific Committee on Food), 2000. Opinion on the Tolerable Upper Intake Level of Folate. SCF/CS/NUT/UPPLEV/18 Final.

ID 2882: “Folate/Folic acid” and “Effect on a normal pregnancy target group: women planning to become pregnant and pregnant”

- 1 Liste der in der Schweiz zulässigen Anpreisungen für Vitamine und Mineralstoffe.
- 2 ANZFA (Food Standards Australia New Zealand), A Pilot For A Health Claims System-Using Folate/Neural Tube Defects Health Claims.
- 3 Blot I, Diallo D, Tchernia G, 1999. Iron deficiency in pregnancy: effects on the newborn. *Curr Opin Hematol*, 6, 65-70.
- 4 Bothwell TH, 2000. Iron requirements in pregnancy and strategies to meet them. *Am J Clin Nutr*, 72, 257S-264S.
- 5 Bruinse HW and van den Berg H, 1995. Changes of some vitamin levels during and after normal pregnancy. *Eur J Obstet Gynecol Reprod Biol*, 61, 31-37.
- 6 Dhur A and Herberg S, 1989. Prevalence of iron deficiency in France and southern Europe. *Bibl Nutr Dieta*, 44, 106-113.
- 7 Ek J and Magnus EM, 1981. Plasma and red blood cell folate during normal pregnancies. *Acta Obstet Gynecol Scand*, 60, 247-251.
- 8 Hallberg L and Hultén L, 1996. Iron requirements, iron balance and iron deficiency in menstruating and pregnant women. In: *Iron nutrition in health and disease*. Hallberg L and Asp NG (eds.). John Libby, London, 165-182.
- 9 Halliday H and McMaster D, 1988. Does iron supplementation reduce zinc bioavailability in preterm infants? In: *Vitamins and minerals in pregnancy and lactation*. Berger H (ed.) Nestlé Nutrition Workshop series, Raven Press, New York.
- 10 Haste FM, Anderson HR, Brooke OG, Bland JM, Peacock JL, 1991. The effects of smoking and drinking on the anthropometric measurements of neonates. *Paediatr Perinat Epidemiol*, 5, 83-92.
- 11 Haste FM, Brooke OG, Anderson HR, Bland JM, 1991. The effect of nutritional intake on outcome of pregnancy in smokers and non-smokers. *Br J Nutr*, 65, 347-354.
- 12 Hindmarsh PC, Geary MP, Rodeck CH, Jackson MR, Kingdom JC, 2000. Effect of early maternal iron stores on placental weight and structure. *Lancet*, 356, 719-723.
- 13 JHCI (Joint Health Claims Initiative), 2003. Final Technical Report A List of Well Established Nutrient Function Statements.
- 14 Kadyrov M, Kosanke G, Kingdom J, Kaufmann P, 1998. Increased fetoplacental angiogenesis during first trimester in anaemic women. *Lancet*, 352, 1747-1749.
- 15 Kilpatrick S and Laro SR, 2004. Maternal Hematologic Disorders. In: *Maternal-fetal medicine: principles and practice*. Creasy RK and Resnik R (eds.). WB Saunders Company, London.
- 16 Koletzko B and Pietrzik K, 2004. Gesundheitliche Bedeutung der Folsäurezufuhr. *Deutsches Ärzteblatt*, 101, 1670-1681.
- 17 Mahomed K, 2000. Iron and folate supplementation in pregnancy. *Cochrane Database Syst Rev*, CD001135.
- 18 Mahomed K, 2000. Iron supplementation in pregnancy. *Cochrane Database Syst Rev*, CD000117.
- 19 Mahomed K, 2000. Folate supplementation in pregnancy. *Cochrane Database Syst Rev*, CD000183.
- 20 Martinez O and Roe DA, 1977. Effect of oral contraceptives on blood folate levels in pregnancy. *Am J Obstet Gynecol*, 128, 255-261.
- 21 Mc Ganty WJ, Dawson EB, Fogelman A, 1994. Nutrition in pregnancy and lactation. In: *Modern Nutrition in Health and Disease*. Shils M, Olson JA, Shike M (eds.). Lea and Febiger, Philadelphia, 705-727.
- 22 Milman N, Bergholt T, Byg KE, Eriksen L, Graudal N, 1999. Iron status and iron balance during pregnancy. A critical reappraisal of iron supplementation. *Acta Obstet Gynecol Scand*, 78, 749-757.

- 23 Pena-Rosas JP and Viteri FE, 2006. Effects of routine oral iron supplementation with or without folic acid for women during pregnancy. *Cochrane Database Syst Rev*, 3, CD004736.
- 24 Rolschau J, Date J, Kristoffersen K, 1979. Folic acid supplement and intrauterine growth. *Acta Obstet Gynecol Scand*, 58, 343-346.

ID 2884: “Calcium” and “Gut flora / Natural defences”

- 1 Bovee-Oudenhoven IM, Termont DS, Heidt PJ, Van der Meer R, 1997. Increasing the intestinal resistance of rats to the invasive pathogen *Salmonella enteritidis*: additive effects of dietary lactulose and calcium. *Gut*, 40, 497-504.
- 2 Bovee-Oudenhoven IM, Termont DS, Weerkamp AH, Faassen-Peters MA, Van der Meer R, 1997. Dietary calcium inhibits the intestinal colonization and translocation of *Salmonella* in rats. *Gastroenterology*, 113, 550-557.
- 3 Bovee-Oudenhoven IM, Wissink ML, Wouters JT, Van der Meer R, 1999. Dietary calcium phosphate stimulates intestinal lactobacilli and decreases the severity of a salmonella infection in rats. *J Nutr*, 129, 607-612.
- 4 Bovee-Oudenhoven IM, Lettink-Wissink ML, Van Doesburg W, Witteman BJ, Van Der Meer R, 2003. Diarrhea caused by enterotoxigenic *Escherichia coli* infection of humans is inhibited by dietary calcium. *Gastroenterology*, 125, 469-476.
- 5 Rademaker JLW, Snel H, Hoolwerf J, Peinhopf M, Huijsdens X, Savelkoul P, Van der Meer R, 2005. Influence of dietary calcium on the composition of the fecal microflora in human volunteers. Poster at the 4th NIZO Dairy Conference, Arnhem.

ID 2885: “Natural mineral water: Sulphates as Mg-, Na- salts: MgSO₄, Na₂SO₄” and “Digestion/Intestinal tract”

- 1 [Gutenbrunner C and Hildebrandt G, 1994. Handbuch der Heilwassertrinkkuren. Sonntag Verlag, Stuttgart.](#)
- 2 [No authors listed, 1990. Monograph on water containing sulphate. Federal Gazette \(Slovenia\), 115, 3239.](#)

ID 2886: “Natural mineral water: Hydrogencarbonates as Na-, Mg-, Ca-, salts: NaHCO₃, Mg(HCO₃)₂, Ca(HCO₃)₂” and “Stomach acid in digestion”

- 1 [Gutenbrunner C and Hildebrandt G, 1994. Handbuch der Heilwassertrinkkuren. Sonntag Verlag, Stuttgart.](#)
- 2 [No authors listed, 1990. Monograph on water containing sulphate. Federal Gazette \(Slovenia\), 115, 3239.](#)

ID 2887: “Sodium phosphate” and “Supports an increase in VO₂max”

- 1 Cade R, Conte M, Zauner C, Mars D, Peterson J, Lunne D, Hommen N, Packer D, 1984. Effects of phosphate loading on 2,3-diphosphoglycerate and maximal oxygen uptake. *Med Sci Sports Exerc*, 16, 263-268.
- 2 Kreider RB, Miller GW, Williams MH, Somma CT, Nasser TA, 1990. Effects of phosphate loading on oxygen uptake, ventilatory anaerobic threshold, and run performance. *Med Sci Sports Exerc*, 22, 250-256.
- 3 Kreider RB, Miller GW, Schenck D, Cortes CW, Miriel V, Somma CT, Rowland P, Turner C, Hill D, 1992. Effects of phosphate loading on metabolic and myocardial responses to maximal and endurance exercise. *Int J Sport Nutr*, 2, 20-47.

- 4 Stewart I, McNaughton L, Davies P, Tristram S, 1990. Phosphate loading and the effects on VO₂max in trained cyclists. *Res Q Exerc Sport*, 61, 80-84.

ID 2888: “zeaxantin” and “helps to preserve elasticity and permeability of capillars of retina and supports good blood circulation in eyes”

- 1 Lutein and zeaxanthin. Monograph, 2005. *Altern Med Rev*, 10, 128-135.
- 2 Bhosale P and Bernstein PS, 2005. Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation. *Biochim Biophys Acta*, 1740, 116-121.
- 3 Krinsky NI, 2002. Possible biologic mechanisms for a protective role of xanthophylls. *J Nutr*, 132, 540S-542S.

ID 2889: “Fer” and “lutte contre l'anémie/ la fatigue”

- 1 Edgerton VR, Gardner GW, Ohira Y, Gunawardena KA, Senewiratne B, 1979. Iron-deficiency anaemia and its effect on worker productivity and activity patterns. *Br Med J*, 2, 1546-1549.
- 2 Gasche C, Lomer MC, Cavill I, Weiss G, 2004. Iron, anaemia, and inflammatory bowel diseases. *Gut*, 53, 1190-1197.
- 3 Hurtado EK, Claussen AH, Scott KG, 1999. Early childhood anemia and mild or moderate mental retardation. *Am J Clin Nutr*, 69, 115-119.

ID 2890: “Zinc” and “Le zinc est un élément ou cofacteur de différentes enzymes des métabolismes protéiques, glucidique et lipidiques ainsi que des acides nucléiques : alcool déshydrogénase, superoxyde dismutase, ADN polymérase, ARN polymérase, phosphatases alcalines, carboxy”

- 1 Liste der in der Schweiz zulässigen Anpreisungen für Vitamine und Mineralstoffe.
- 2 Ordonnance du Conseil Fédéral Suisse du 23 novembre 2005 sur les denrées alimentaires et les objets usuels (ODAIUOs).
- 3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris.
- 4 Basdevant A, Laville M, Lerebours E, 2001. *Traité de nutrition clinique de l'adulte*. Flammarion Médecine-Sciences, Paris.
- 5 D-A-CH (Deutsche Gesellschaft für Ernährung - Österreichische Gesellschaft für Ernährung - Schweizerische Gesellschaft für Ernährungsforschung - Schweizerische Vereinigung für Ernährung), 2000. Referenzwerte für die Nährstoffzufuhr. Umschau Braus Verlag, Frankfurt am Main.
- 6 Gröber U, 2002. *Orthomolekulare Medizin: ein Leitfaden für Apotheker und Ärzte*. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

ID 2891: “Lactotriptides” and “Blood pressure”

- 1 Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y, 2005. Effect of powdered fermented milk with *Lactobacillus helveticus* on subjects with high-normal blood pressure or mild hypertension. *J Am Coll Nutr*, 24, 257-265.
- 2 De Leeuw P, Van der Zander K, Kroon A, Rennenberg R, Koning M, 2006. Dairy peptides: a dose dependent effect on blood pressure. Poster at the 16th European Meeting on Hypertension, Madrid.

- 3 FitzGerald RJ and Meisel H, 2000. Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. *Br J Nutr*, 84 Suppl 1, S33-37.
- 4 Foltz M, Meynen EE, Bianco V, van Platerink C, Koning TM, Kloek J, 2007. Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. *J Nutr*, 137, 953-958.
- 5 Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T, 1996. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *Am J Clin Nutr*, 64, 767-771.
- 6 Hirata H, Nakamura Y, Yada H, Moriguchi S, Kajimoto O, Takahashi T, 2002. Clinical effects of new sour milk drink in mild or moderate hypertensive subjects. *J. New Rem. & Clin*, 51, 60-69.
- 7 Huth PJ, DiRienzo DB, Miller GD, 2006. Major scientific advances with dairy foods in nutrition and health. *J Dairy Sci*, 89, 1207-1221.
- 8 Itakura H, Ikemoto S, Terada S, Kondo K, 2001. The effect of sour milk on blood pressure in untreated hypertensive and normotensive subjects. *Journal of Japanese Society of Clinical Nutrition*, 23, 26-31.
- 9 Jauhiainen T, Collin M, Narva M, ZhongJian C, Poussa T, Vapaatalo H, Korpela R, 2005. Effect of long-term intake of milk peptides and minerals on blood pressure and arterial function in spontaneously hypertensive rats. *Milchwissenschaft*, 60, 358-363.
- 10 Jauhiainen T, Vapaatalo H, Poussa T, Kyronpalo S, Rasmussen M, Korpela R, 2005. *Lactobacillus helveticus* fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. *Am J Hypertens*, 18, 1600-1605.
- 11 Jauhiainen T, Pilvi T, Jian C, Vapaatalo H, Korpela R, Mervaala E, 2006. Antihypertensive mechanism behind blood pressure lowering biological active tripeptides. Poster at the 16th European Meeting on Hypertension, Madrid.
- 12 Jauhiainen T and Korpela R, 2007. Milk peptides and blood pressure. *J Nutr*, 137, 825S-829S.
- 13 Jauhiainen T, Rönback M, Vapaatalo H, Wuolle K, Kautiainen H, Groop P-H, Korpela R, (Unpublished). Long-term intervention with *Lactobacillus helveticus* fermented milk improves arterial stiffness in hypertensive subjects.
- 14 Kajimoto O, Aihara K, Hirata H, Takahashi R, Nakamura Y, 2001. Hypotensive effects of the tablets containing "lactotripeptides (VPP, IPP)". *Journal of Nutritional Food*, 4, 51-61.
- 15 Kajimoto O, Nakamura Y, Yada H, Moriguchi S, Hirata H, Takahashi T, 2001. Hypotensive effects of sour milk in subjects with mild or moderate hypertension. *J. Jpn. Soc. Nutr. Food Sci*, 54, 347-354.
- 16 Kajimoto O, Kurosaki T, Mizutani J, Ikeda N, Kaneko K, Yabune M, Nakamura Y, 2002. Antihypertensive effects of the liquid yogurt containing "lactotripeptides (VPP, IPP)" in mild hypertensive subjects. *J. Nutr. Food*, 5, 55-66.
- 17 Masuda O, Nakamura Y, Takano T, 1996. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. *J Nutr*, 126, 3063-3068.
- 18 Meisel H, 1998. Overview on Milk Protein-derived Peptides. *International Dairy Journal*, 8, 363-373.
- 19 Mizuno S, Matsuura K, Gotou T, Nishimura S, Kajimoto O, Yabune M, Kajimoto Y, Yamamoto N, 2005. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. *Br J Nutr*, 94, 84-91.
- 20 Mizushima S, Ohshige K, Watanabe J, Kimura M, Kadowaki T, Nakamura Y, Tochikubo O, Ueshima H, 2004. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. *Am J Hypertens*, 17, 701-706.
- 21 Nakamura Y, Yamamoto N, Sakai K, Takano T, 1995. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. *J Dairy Sci*, 78, 1253-1257.

- 22 Nakamura Y, Kajimoto O, Kaneko K, Aihara K, Mizutani J, Ikeda N, Kajimoto Y, 2004. Effects of the liquid yogurts containing “lactotripeptide (VPP, IPP)” on high-normal blood pressure. *J Nutr Food*, 7, 123-137.
- 23 Neutel J, Nonaka M, Hendler M, Weber MA, 2006. The use of Amealpeptide in the treatment of patients with stage I and stage II hypertension - data from the AHEAD Study. Poster at the 16th European Meeting on Hypertension, Madrid.
- 24 Sano J, Ohki K, Higuchi T, Aihara K, Mizuno S, Kajimoto O, Nakagawa S, Kajimoto Y, Nakamura Y, 2005. Effect of casein hydrolysate, prepared with protease derived from *Aspergillus oryzae*, on subjects with high-normal blood pressure or mild hypertension. *J Med Food*, 8, 423-430.
- 25 Seppo L, Kerojoki O, Suomalainen T, Korpela R, 2002. The effect of a *Lactobacillus helveticus* LBK-16 H fermented milk on hypertension- a pilot study on humans. *Milchwissenschaft*, 57, 124-127.
- 26 Seppo L, Jauhiainen T, Poussa T, Korpela R, 2003. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. *Am J Clin Nutr*, 77, 326-330.
- 27 Sipola M, Finckenberg P, Santisteban J, Korpela R, Vapaatalo H, Nurminen ML, 2001. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. *J Physiol Pharmacol*, 52, 745-754.
- 28 Sipola M, Finckenberg P, Korpela R, Vapaatalo H, Nurminen ML, 2002. Effect of long-term intake of milk products on blood pressure in hypertensive rats. *J Dairy Res*, 69, 103-111.
- 29 Tuomilehto J, Lindstrom J, Hyyrynen J, Korpela R, Karhunen ML, Mikkola L, Jauhiainen T, Seppo L, Nissinen A, 2004. Effect of ingesting sour milk fermented using *Lactobacillus helveticus* bacteria producing tripeptides on blood pressure in subjects with mild hypertension. *J Hum Hypertens*, 18, 795-802.
- 30 Van der Zander K, Jäkel M, Bianco V, Koning M, 2006. The effect of fermented dairy peptides on daytime blood pressure. Poster at the 16th European Meeting on Hypertension, Madrid.
- 31 Visser F, Kocks M, Kluppel C, Van der Zander K, Koning M, Navis G, 2006. Acute ACE inhibiting effects of the lactotripeptide IPP in rats. Poster at the 16th European Meeting on Hypertension, Madrid.

ID 2892: “Conjugated Linoleic acid (cis-9, trans-11 and trans-10, cis-12)” and “weight management, fat metabolism enhancement”

- 1 Atkinson R, 1999. Clinical implications for conjugated linoleic acid (CLA) in the treatment of obesity. *Lipidforum*, the 21st Symposium, Kolding, Danmark.
- 2 Berven G, Bye A, Hals O, Blankson H, Fagertun H, Thom E, Wadstein J, Gudmundsen O, 2000. Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers. *Eur J Lipid Sci Technol*, 102, 455-462.
- 3 Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O, 2000. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. *J Nutr*, 130, 2943-2948.
- 4 Gaullier JM, Berven G, Blankson H, Gudmundsen O, 2002. Clinical trial results support a preference for using CLA preparations enriched with two isomers rather than four isomers in human studies. *Lipids*, 37, 1019-1025.
- 5 Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O, 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. *Am J Clin Nutr*, 79, 1118-1125.
- 6 Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O, 2005. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. *J Nutr*, 135, 778-784.
- 7 Gaullier JM, Halse J, Hoivik HO, Hoye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O, 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. *Br J Nutr*, 97, 550-560.

- 8 Kamphuis MM, Lejeune MP, Saris WH, Westerterp-Plantenga MS, 2003. Effect of conjugated linoleic acid supplementation after weight loss on appetite and food intake in overweight subjects. *Eur J Clin Nutr*, 57, 1268-1274.
- 9 Kamphuis MM, Lejeune MP, Saris WH, Westerterp-Plantenga MS, 2003. The effect of conjugated linoleic acid supplementation after weight loss on body weight regain, body composition, and resting metabolic rate in overweight subjects. *Int J Obes Relat Metab Disord*, 27, 840-847.
- 10 Kreider RB, Ferreira MP, Greenwood M, Wilson M, Almada AL, 2002. Effects of conjugated linoleic acid supplementation during resistance training on body composition, bone density, strength, and selected hematological markers. *J Strength Cond Res*, 16, 325-334.
- 11 Larsen TM, Toubro S, Gudmundsen O, Astrup A, 2006. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. *Am J Clin Nutr*, 83, 606-612.
- 12 Mougios V, Matsakas A, Petridou A, Ring S, Sagredos A, Melissopoulou A, Tsigilis N, Nikolaidis M, 2001. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. *J Nutr Biochem*, 12, 585-594.
- 13 Pinkoski C, Chilibeck PD, Candow DG, Esliger D, Ewaschuk JB, Facci M, Farthing JP, Zello GA, 2006. The effects of conjugated linoleic acid supplementation during resistance training. *Med Sci Sports Exerc*, 38, 339-348.
- 14 Riserus U, Berglund L, Vessby B, 2001. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. *Int J Obes Relat Metab Disord*, 25, 1129-1135.
- 15 Smedman A and Vessby B, 2001. Conjugated linoleic acid supplementation in humans--metabolic effects. *Lipids*, 36, 773-781.
- 16 Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP, 2006. Conjugated linoleic acid impairs endothelial function. *Arterioscler Thromb Vasc Biol*, 26, 307-312.
- 17 Thom E, Wadstein J, Gudmundsen O, 2001. Conjugated linoleic acid reduces body fat in healthy exercising humans. *J Int Med Res*, 29, 392-396.
- 18 Watras AC, Buchholz AC, Close RN, Zhang Z, Schoeller DA, 2007. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain. *Int J Obes (Lond)*, 31, 481-487.
- 19 Whigham LD, O'Shea M, Mohede ICM, Walaski HP, Atkinson RL, 2004. Safety profile of conjugated linoleic acid in a 12-month trial in obese humans. *Food and Chemical Toxicology*, 42, 1701-1709.
- 20 Whigham LD, Watras AC, Schoeller DA, 2007. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. *Am J Clin Nutr*, 85, 1203-1211.
- 21 Zambell KL, Keim NL, Van Loan MD, Gale B, Benito P, Kelley DS, Nelson GJ, 2000. Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure. *Lipids*, 35, 777-782.

ID 2893: “Whey protein concentrate rich in alpha-lactalbumin” and “Cognition / memory”

- 1 Booiij L, Merens W, Markus CR, Van der Does AJW, 2006. Diet rich in a-lactalbumin improves memory in unmedicated recovered depressed patients and matched controls. *Journal of Psychopharmacology*, 20, 526-535.
- 2 Markus CR, Klöpping-Ketelaars WI, Pasma W, Klarenbeek B, Berg HVD, 2000. Dose-Dependent Effect of -Lactalbumin in Combination with Two Different Doses of Glucose on the Plasma Trp/LNAA Ratio. *Nutritional Neuroscience*, 3, 345-355.
- 3 Markus CR, Olivier B, de Haan EH, 2002. Whey protein rich in alpha-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. *Am J Clin Nutr*, 75, 1051-1056.

- 4 Markus CR, Jonkman LM, Lammers JH, Deutz NE, Messer MH, Rigtering N, 2005. Evening intake of alpha-lactalbumin increases plasma tryptophan availability and improves morning alertness and brain measures of attention. *Am J Clin Nutr*, 81, 1026-1033.
- 5 Markus CR and Jonkman LM, 2007. Attention switching after dietary brain 5-HT challenge in high impulsive subjects. *J Psychopharmacol*, 21, 700-708.
- 6 Schmitt JA, Jorissen BL, Dye L, Markus CR, Deutz NE, Riedel WJ, 2005. Memory function in women with premenstrual complaints and the effect of serotonergic stimulation by acute administration of an alpha-lactalbumin protein. *J Psychopharmacol*, 19, 375-384.

ID 2894: “Potato protein isolate” and “satiety”

- 1 Belitz HD, Lynen F, Weder JK, 1982. Comparative studies of the inhibitory action of some legume seeds, potato tubers, and bran against human and bovine proteinases. *Z Lebensm Unters Forsch*, 174, 442-446.
- 2 Erdmann J, Hebeisen Y, Lippl F, Wagenpfeil S, Schusdziarra V, 2007. Food intake and plasma ghrelin response during potato-, rice- and pasta-rich test meals. *Eur J Nutr*, 46, 196-203.
- 3 Fear G, Komarnytsky S, Raskin I, 2007. Protease inhibitors and their peptidomimetic derivatives as potential drugs. *Pharmacol Ther*, 113, 354-368.
- 4 Hill AJ, Peikin SR, Ryan CA, Blundell JE, 1990. Oral administration of proteinase inhibitor II from potatoes reduces energy intake in man. *Physiol Behav*, 48, 241-246.
- 5 Holt SH, Miller JC, Petocz P, Farmakalidis E, 1995. A satiety index of common foods. *Eur J Clin Nutr*, 49, 675-690.
- 6 Kaplan RJ and Greenwood CE, 2002. Influence of dietary carbohydrates and glycaemic response on subjective appetite and food intake in healthy elderly persons. *Int J Food Sci Nutr*, 53, 305-316.
- 7 Kemin Foods, 2004. Method for the elimination of Kunitz and Bowman-Birk trypsin inhibitors and carboxypeptidase inhibitor from potato proteins, United States patent US 6686456 B2.
- 8 Liddle RA, 1995. Regulation of cholecystokinin secretion by intraluminal releasing factors. *Am J Physiol*, 269, G319-327.
- 9 Liddle RA, 2000. Regulation of cholecystokinin secretion in humans. *J Gastroenterol*, 35, 181-187.
- 10 Liener IE, Goodale RL, Deshmukh A, Satterberg TL, Ward G, DiPietro CM, Bankey PE, Borner JW, 1988. Effect of a trypsin inhibitor from soybeans (Bowman-Birk) on the secretory activity of the human pancreas. *Gastroenterology*, 94, 419-427.
- 11 McLaughlin CL, Peikin SR, Baile CA, 1983. Food intake response to modulation of secretion of cholecystokinin in Zucker rats. *American Journal of Physiology- Regulatory, Integrative and Comparative Physiology*, 244, 676-685.
- 12 McLaughlin CL, Peikin SR, Baile CA, 1983. Trypsin inhibitor effects on food intake and weight gain in Zucker rats. *Physiol Behav*, 31, 487-491.
- 13 Mineo H, Ishida K, Morikawa N, Ohmi S, Machida A, Noda T, Fukushima M, Chiji H, 2007. Ingestion of potato starch decreases chymotrypsin but does not affect trypsin, amylase, or lipase activity in the pancreas in rats. *Nutrition Research*, 27, 113-118.
- 14 Owyang C, Louie DS, Tatum D, 1986. Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin. *J Clin Invest*, 77, 2042-2047.
- 15 Owyang C, 1994. Negative feedback control of exocrine pancreatic secretion: role of cholecystokinin and cholinergic pathway. *J Nutr*, 124, 1321S-1326S.
- 16 Peikin SR, 1985. Method of stimulating satiety in mammals, United States Patent 4491578.

- 17 Peikin SR, C.J. Springer, G.J. Dockray, J.E. Blundell, A.J. Hill, Calam J, Ryan CA, 1987. Oral administration of proteinase inhibitor II from potatoes stimulates release of cholecystokinin in men. *Gastroenterology*, 92, A1570-A1576.
- 18 Pouvreau L, Gruppen H, Piersma SR, van den Broek LA, van Koningsveld GA, Voragen AG, 2001. Relative abundance and inhibitory distribution of protease inhibitors in potato juice from cv. Elkana. *J Agric Food Chem*, 49, 2864-2874.
- 19 Pouvreau LAM, 2004. Occurrence and physico-chemical properties of protease inhibitors from potato tuber (*Solanum tuberosum*). PhD Thesis, Wageningen University.
- 20 Reseland JE, Holm H, Jacobsen MB, Jenssen TG, Hanssen LE, 1996. Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. *J Nutr*, 126, 634-642.
- 21 Schwartz JG, Guan D, Green GM, Phillips WT, 1994. Treatment with an oral proteinase inhibitor slows gastric emptying and acutely reduces glucose and insulin levels after a liquid meal in type II diabetic patients. *Diabetes Care*, 17, 255-262.
- 22 Spiegel TA, Hubert C, Peikin SR, 1999. Effect of a Premeal Beverage Containing a Protease Inhibitor from Potatoes on Satiety in Dieting Overweight Women. *Obesity Research*, 7, Supplement 1.
- 23 van Koningsveld G, 2001. Physico-chemical and functional properties of potato proteins. PhD Thesis, Wageningen University.
- 24 Vasselli JR, Greenfield D, Schwartz L, Heymsfield SB, 1999. Consumption of Pre-Meal Drink Containing Protease Inhibitor from Potatoes Decreases Hunger and Increases Fullness in Overweight Subjects Following a Meal. *Obesity Research*, 7, Supplement 1.

ID 2895: “Enova™ Oil (diacylglycerol oil of plant origin –Min 80% diacylglycerols)” and “Weight maintenance”

- 1 FNFC/FOSHU (Food with Nutrient Functional Claims/Foods for Specified Health Use), Ministry of Health, Labour, and Welfare, Japan : Food with Health Claims, Food for Special Dietary Uses, and Nutrition Labeling <http://www.mhlw.go.jp/english/topics/foodsafety/fhc/index.html>.
- 2 Kamphuis MM, Mela DJ, Westerterp-Plantenga MS, 2003. Diacylglycerols affect substrate oxidation and appetite in humans. *Am J Clin Nutr*, 77, 1133-1139.
- 3 Katsuragi T, Toi T, Yasukawa T, 1999. Effects of dietary diacylglycerol on obesity and hyperlipidemia. *Jap Soc Human Dry Dock*, 14, 12-16.
- 4 Katsuragi Y, Yasukawa T, Matsuo N, Flickinger BD, Tokimitsu I, Matlock MG, 2004. Diacylglycerol oil. AOCS Press, Champaign, IL.
- 5 Maki KC, Davidson MH, Tsushima R, Matsuo N, Tokimitsu I, Umporowicz DM, Dicklin MR, Foster GS, Ingram KA, Anderson BD, Frost SD, Bell M, 2002. Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. *Am J Clin Nutr*, 76, 1230-1236.
- 6 Nagao T, Watanabe H, Goto N, Onizawa K, Taguchi H, Matsuo N, Yasukawa T, Tsushima R, Shimasaki H, Itakura H, 2000. Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial. *J Nutr*, 130, 792-797.
- 7 Saito S, Tomonobu K, Hase T, Tokimitsu I, 2006. Effects of diacylglycerol on postprandial energy expenditure and respiratory quotient in healthy subjects. *Nutrition*, 22, 30-35.
- 8 Takei A, Toi T, Takahashi H, Takeda Y, Moriwaki J, Takase H, Katsuragi Y, 2001. Effects of diacylglycerol containing mayonnaise on lipid metabolism and body fat in humans. *J Nutr Food*, 4, 89-101.
- 9 Teramoto T, Watanabe H, Ito K, Omata Y, Furukawa T, Shimoda K, Hoshino M, Nagao T, Naito S, 2004. Significant effects of diacylglycerol on body fat and lipid metabolism in patients on hemodialysis. *Clin Nutr*, 23, 1122-1126.

ID 2896: “Enova™ Oil (diacylglycerol oil of plant origin –Min 80% diacylglycerols)” and “Postprandial serum triglyceride”

- 1 FNFC/FOSHU (Food with Nutrient Functional Claims/Foods for Specified Health Use), Ministry of Health, Labour, and Welfare, Japan : Food with Health Claims, Food for Special Dietary Uses, and Nutrition Labeling <http://www.mhlw.go.jp/english/topics/foodsafety/fhc/index.html>.
- 2 Katsuragi Y, Yasukawa T, Matsuo N, Flickinger BD, Tokimitsu I, Matlock MG, 2004. Diacylglycerol oil. AOCS Press, Champaign, IL.
- 3 Tada N, Watanabe H, Matsuo N, Tokimitsu I, Okazaki M, 2001. Dynamics of postprandial remnant-like lipoprotein particles in serum after loading of diacylglycerols. *Clin Chim Acta*, 311, 109-117.
- 4 Tada N, Shoji K, Takeshita M, Watanabe H, Yoshida H, Hase T, Matsuo N, Tokimitsu I, 2005. Effects of diacylglycerol ingestion on postprandial hyperlipidemia in diabetes. *Clin Chim Acta*, 353, 87-94.
- 5 Taguchi H, Watanabe H, Onizawa K, Nagao T, Gotoh N, Yasukawa T, Tsushima R, Shimasaki H, Itakura H, 2000. Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans. *J Am Coll Nutr*, 19, 789-796.
- 6 Takase H, Shoji K, Hase T, Tokimitsu I, 2005. Effect of diacylglycerol on postprandial lipid metabolism in non-diabetic subjects with and without insulin resistance. *Atherosclerosis*, 180, 197-204.
- 7 Tomonobu K, Hase T, Tokimitsu I, 2006. Dietary diacylglycerol in a typical meal suppresses postprandial increases in serum lipid levels compared with dietary triacylglycerol. *Nutrition*, 22, 128-135.
- 8 Yamamoto K, Asakawa H, Tokunaga K, Meguro S, Watanabe H, Tokimitsu I, Yagi N, 2005. Effects of diacylglycerol administration on serum triacylglycerol in a patient homozygous for complete lipoprotein lipase deletion. *Metabolism*, 54, 67-71.

ID 2897: “Essential fatty acid Linoleic Acid (LA - omega 6)” and “Brain development and maturation of neurosensorial functions”

- 1 Garrow JS, James WPT, Ralph A, 2000. *Human Nutrition and Dietetics*. Churchill Livingstone, London, Edinburgh.
- 2 Gibney MJ, Vorster H, Kok F, 2002. *Introduction to Human Nutrition (The Nutrition Society Textbook)*. Wiley-Blackwell, Chichester.
- 3 Mann J and Truswell AS, 2002. *Essentials of human nutrition*. Oxford University Press, Oxford.

ID 2898: “Essential fatty acid Linoleic Acid (LA - omega 6)” and “Growth and development and maintenance of body functions”

- 1 Garrow JS, James WPT, Ralph A, 2000. *Human Nutrition and Dietetics*. Churchill Livingstone, London, Edinburgh.
- 2 Gibney MJ, Vorster H, Kok F, 2002. *Introduction to Human Nutrition (The Nutrition Society Textbook)*. Wiley-Blackwell, Chichester.
- 3 IoM (Institute of Medicine), 2005. *Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids*. National Academies Press, Washington DC.
- 4 Mann J and Truswell AS, 2002. *Essentials of Human Nutrition*. Oxford University Press, New York.

ID 2899: “Essential fatty acid Linoleic Acid (LA - omega 6)” and “Artery/Heart health”

- 1 Agmon Y, Khandheria BK, Meissner I, Schwartz GL, Petterson TM, O'Fallon WM, Whisnant JP, Wiebers DO, Seward JB, 2002. Relation of coronary artery disease and cerebrovascular disease with atherosclerosis of the thoracic aorta in the general population. *Am J Cardiol*, 89, 262-267.
- 2 Arntzenius AC, Kromhout D, Barth JD, Reiber JH, Brusckhe AV, Buis B, van Gent CM, Kempen-Voogd N, Strikwerda S, van der Velde EA, 1985. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. *N Engl J Med*, 312, 805-811.
- 3 British Nutrition Foundation, 2005. *Cardiovascular Disease: Diet, Nutrition and Emerging Risk Factors*. Blackwell Publishing, Oxford.
- 4 Brouwer IA, Katan MB, Zock PL, 2004. Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. *J Nutr*, 134, 919-922.
- 5 Brown AA and Hu FB, 2001. Dietary modulation of endothelial function: implications for cardiovascular disease. *Am J Clin Nutr*, 73, 673-686.
- 6 Dayton S, Pearce ML, Hashimoto SAM, Dixon WJ, Tomiyasu U, 1969. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. *Circulation*, 40 (Suppl 2), 1-63.
- 7 de Lorgeril M and Salen P, 2005. Dietary prevention of coronary heart disease: the Lyon diet heart study and after. *World Rev Nutr Diet*, 95, 103-114.
- 8 EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to nutrition claims concerning omega-3 fatty acids, monounsaturated fat, polyunsaturated fat and unsaturated fat (Request N°EFSA-Q-2004-107). *The EFSA Journal*, 253, 1-29.
- 9 FDA (US Food and Drug Administration), 2003. Monounsaturated Fatty Acids from Olive Oil and Coronary Heart Disease (Docket No 2003Q-0559). Letter Responding to Health Claim Petition dated August 28, 2003.
- 10 Finnegan YE, Minihane AM, Leigh-Firbank EC, Kew S, Meijer GW, Muggli R, Calder PC, Williams CM, 2003. Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. *Am J Clin Nutr*, 77, 783-795.
- 11 Frantz ID, Jr., Dawson EA, Ashman PL, Gatewood LC, Bartsch GE, Kuba K, Brewer ER, 1989. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. *Arteriosclerosis*, 9, 129-135.
- 12 Goyens PL and Mensink RP, 2005. The dietary alpha-linolenic acid to linoleic acid ratio does not affect the serum lipoprotein profile in humans. *J Nutr*, 135, 2799-2804.
- 13 Hutter CM, Austin MA, Humphries SE, 2004. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. *Am J Epidemiol*, 160, 430-435.
- 14 IoM (Institute of Medicine), 2005. *Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids*. National Academies Press, Washington DC.
- 15 Law MR, Wald NJ, Thompson SG, 1994. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *BMJ*, 308, 367-372.
- 16 Leren P, 1970. The Oslo diet-heart study. Eleven-year report. *Circulation*, 42, 935-942.
- 17 Matsushima Y, Kawano H, Koide Y, Baba T, Toda G, Seto S, Yano K, 2004. Relationship of carotid intima-media thickness, pulse wave velocity, and ankle brachial index to the severity of coronary artery atherosclerosis. *Clin Cardiol*, 27, 629-634.
- 18 Mensink RP, Zock PL, Kester AD, Katan MB, 2003. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr*, 77, 1146-1155.

- 19 National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002. Final Report.
- 20 Nicolosi RJ, Wilson TA, Rogers EJ, Kritchevsky D, 1998. Effects of specific fatty acids (8:0, 14:0, cis-18:1, trans-18:1) on plasma lipoproteins, early atherogenic potential, and LDL oxidative properties in the hamster. *J Lipid Res*, 39, 1972-1980.
- 21 No authors listed, 1995. Experimental mechanism: formation of atheroma. *Am J Clin Nutr*, 62, 689S-692S.
- 22 Taniguchi H, Momiyama Y, Fayad ZA, Ohmori R, Ashida K, Kihara T, Hara A, Arakawa K, Kameyama A, Noya K, Nagata M, Nakamura H, Ohsuzu F, 2004. In vivo magnetic resonance evaluation of associations between aortic atherosclerosis and both risk factors and coronary artery disease in patients referred for coronary angiography. *Am Heart J*, 148, 137-143.
- 23 Turpeinen O, Karvonen MJ, Pekkarinen M, Miettinen M, Elosuo R, Paavilainen E, 1979. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. *Int J Epidemiol*, 8, 99-118.
- 24 Watts GF, Jackson P, Burke V, Lewis B, 1996. Dietary fatty acids and progression of coronary artery disease in men. *Am J Clin Nutr*, 64, 202-209.
- 25 WHO (World Health Organization), 2003. Diet, Nutrition and the Prevention of Chronic Diseases. Technical Report No. 916.

ID 2900: “Fats” and “Cell growth/cell functioning and structure”

- 1 Garrow JS, James WPT, Ralph A, 2000. *Human Nutrition and Dietetics*. Churchill Livingstone, London, Edinburgh.
- 2 Gibney MJ, Vorster H, Kok F, 2002. *Introduction to Human Nutrition (The Nutrition Society Textbook)*. Wiley-Blackwell, Chichester.
- 3 IoM (Institute of Medicine), 2005. *Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids*. National Academies Press, Washington DC.
- 4 Mann J and Truswell AS, 2002. *Essentials of Human Nutrition*. Oxford University Press, New York.

ID 2901: “Fats (containing EFA)” and “Essential fatty acids (EFA) supply”

- 1 Garrow JS, James WPT, Ralph A, 2000. *Human Nutrition and Dietetics*. Churchill Livingstone, London, Edinburgh.
- 2 Gibney MJ, Vorster H, Kok F, 2002. *Introduction to Human Nutrition (The Nutrition Society Textbook)*. Wiley-Blackwell, Chichester.
- 3 IoM (Institute of Medicine), 2005. *Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids*. National Academies Press, Washington DC.
- 4 Mann J and Truswell AS, 2002. *Essentials of Human Nutrition*. Oxford University Press, New York.

ID 2902: “Fats (fatty acids higher than c-10)” and “Absorption of fat soluble vitamins”

- 1 Garrow JS, James WPT, Ralph A, 2000. *Human Nutrition and Dietetics*. Churchill Livingstone, London, Edinburgh.
- 2 Gibney MJ, Vorster H, Kok F, 2002. *Introduction to Human Nutrition (The Nutrition Society Textbook)*. Wiley-Blackwell, Chichester.
- 3 IoM (Institute of Medicine), 2005. *Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids*. National Academies Press, Washington DC.

4 Mann J and Truswell AS, 2002. Essentials of human nutrition. Oxford University Press, Oxford.

ID 2903: “Isomaltulose (or trademark Palatinose)” and “Reduced speed of digestion and absorption results in lower glycemic response”

- 1 Commission Decision 2005/581/EC of 25 July 2005 authorising the placing on the market of isomaltulose as a novel food or novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council
- 2 Achten J, Jentjens RL, Brouns F, Jeukendrup AE, 2007. Exogenous oxidation of isomaltulose is lower than that of sucrose during exercise in men. *J Nutr*, 137, 1143-1148.
- 3 Arai H, Mizuno A, Sakuma M, Fukaya M, Matsuo K, Muto K, Sasaki H, Matsuura M, Okumura H, Yamamoto H, Taketani Y, Doi T, Takeda E, 2007. Effects of a palatinose-based liquid diet (Inslow) on glycemic control and the second-meal effect in healthy men. *Metabolism*, 56, 115-121.
- 4 Dahlqvist A, 1961. Hydrolysis of palatinose (isomaltulose) by pig intestinal glycosidases. *Acta chem. Scand*, 15, 808-816.
- 5 German Federal Institute for Risk Assessment (BfR), 2004. Initial assessment report on the application made by Sudzucker AG to place on the market the novel food ingredient isomaltulose (Palatinose(TM)) in accordance with Article 6 of Regulation (EC) No 258/97.
- 6 Gostner A, Holub I, Theis S, Volk A, Kozianowski G, Scheppach W, 2006. Intestinal digestibility of isomaltulose (Palatinose™) in patients with ileostoma [Intestinale Verdaulichkeit von Isomaltulose (Palatinose™) bei Patienten mit Ileostoma] [Abstract P 18]. *Z Gastroenterol*, 44, 1073-1094.
- 7 Grupp U and Siebert G, 1978. Metabolism of hydrogenated palatinose, an equimolar mixture of alpha-D-glucopyranosido-1,6-sorbitol and alpha-D-glucopyranosido-1,6-mannitol. *Res Exp Med (Berl)*, 173, 261-278.
- 8 Heinz F, 1987. The enzymatic splitting of sugar substitutes by isolated enzymes and enzyme complexes from the small intestinal mucosa. Research Project No. 6539.
- 9 Irwin WE and Strater PJ, 2001. Isomaltulose. In: Handbook of Sweeteners. Nabors LO (ed.) Marcel Dekker, New York, 413-421.
- 10 Kawai K, Okuda Y, Yamashita K, 1985. Changes in blood glucose and insulin after an oral palatinose administration in normal subjects. *Endocrinol Jpn*, 32, 933-936.
- 11 Kawai K, Yoshikawa H, Murayama Y, Okuda Y, Yamashita K, 1989. Usefulness of palatinose as a caloric sweetener for diabetic patients. *Horm Metab Res*, 21, 338-340.
- 12 König L, Polland T, Kozianowski B, 2007. Metabolic effects of low-glycemic Palatinose™ during long-lasting endurance exercise. *Ann Nutr Metab*, 51, 69.
- 13 Liao ZH, Li YB, Yao B, Fan HD, Hu GL, Weng JP, 2001. The effects of isomaltulose on blood glucose and lipids for diabetic subjects. *Diabetes*, 50, A366.
- 14 Lina BA, Jonker D, Kozianowski G, 2002. Isomaltulose (Palatinose): a review of biological and toxicological studies. *Food Chem Toxicol*, 40, 1375-1381.
- 15 Livesey G, (unpublished). Glycaemic and insulinaemic response curves to isomaltulose in healthy humans.
- 16 MacDonald I and Daniel JW, 1983. The bio-availability of isomaltulose in man and rat. *Nutrition reports international*, 28, 1083-1090.
- 17 SUGiRS, (unpublished). Glycaemic Index Report - Isomalt. Sydney University's GI Database.
- 18 Suzuki, Tsuyuki, Taihichi, Watanabe, Mizutani, 2000. Method for continuing oxidative metabolism accompanying to exercise and food and drink for sport, Patent Publication JP2000300212.
- 19 Tsuji Y, Yamada K, Hosoya N, Moriuchi S, 1986. Digestion and absorption of sugars and sugar substitutes in rat small intestine. *J Nutr Sci Vitaminol (Tokyo)*, 32, 93-100.

- 20 Van Weerden EJ, Huisman J, Van Leeuwen P, (unpublished). Digestion processes of Palatinose and saccharose in the small and large intestine of the pig. ILOB-Report No. 520.
- 21 Yamada K, Shinohara H, Hosoya N, 1985. Hydrolysis of 1- α -D-glucopyranosyl-D-fructofuranose by rat intestinal sucrase-isomaltase complex. *Nutr Rep Int*, 32, 1211-1220.
- 22 Ziesenitz SC, 1986. Zur Verwertung des Zuckeraustauschstoffs Palatinit® im Stoffwechsel. Beiträge zu Infusionstherapie und Klinische Ernährung, 16.
- 23 Ziesenitz SC, 1986. Stufenweises Prüfschema für Zuckeraustauschstoffe – Vorprüfung mittels Enzymen. 3. Carbohydrasen aus Jejunal mucosa des Menschen. *Z Ernährungswiss*, 25, 253-258.

ID 2905: “Long-chain omega-3 (n-3) polyunsaturated fatty acids (LC omega-3 PUFA, LC n-3 PUFA) or docosahexaenoic acid or eicosapentaenoic acid or omega-3 fish oils” and “Building block for lipids in the retina’s photoreceptors; Eye Health”

- 1 Anderson GJ, Connor WE, Corliss JD, 1990. Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina. *Pediatr Res*, 27, 89-97.
- 2 Auestad N, Scott DT, Janowsky JS, Jacobsen C, Carroll RE, Montalto MB, Halter R, Qiu W, Jacobs JR, Connor WE, Connor SL, Taylor JA, Neuringer M, Fitzgerald KM, Hall RT, 2003. Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. *Pediatrics*, 112, e177-183.
- 3 Birch EE, Hoffman DR, Castaneda YS, Fawcett SL, Birch DG, Uauy RD, 2002. A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. *Am J Clin Nutr*, 75, 570-580.
- 4 Birch EE, Garfield S, Castaneda Y, Hughbanks-Wheaton D, Uauy R, Hoffman D, 2007. Visual acuity and cognitive outcomes at 4 years of age in a double-blind, randomized trial of long-chain polyunsaturated fatty acid-supplemented infant formula. *Early Hum Dev*, 83, 279-284.
- 5 Cheatham CL, Colombo J, Carlson SE, 2006. N-3 fatty acids and cognitive and visual acuity development: methodologic and conceptual considerations. *Am J Clin Nutr*, 83, 1458S-1466S.
- 6 Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N, Jr., Serhan CN, Smith LE, 2007. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. *Nat Med*, 13, 868-873.
- 7 Diau GY, Loew ER, Wijendran V, Sarkadi-Nagy E, Nathanielsz PW, Brenna JT, 2003. Docosahexaenoic and arachidonic acid influence on preterm baboon retinal composition and function. *Invest Ophthalmol Vis Sci*, 44, 4559-4566.
- 8 Fliesler SJ and Anderson RE, 1983. Chemistry and metabolism of lipids in the vertebrate retina. *Prog Lipid Res*, 22, 79-131.
- 9 Innis SM, 1993. Essential fatty acid requirements in human nutrition. *Can J Physiol Pharmacol*, 71, 699-706.
- 10 Innis SM, Nelson CM, Rioux MF, King DJ, 1994. Development of visual acuity in relation to plasma and erythrocyte omega-6 and omega-3 fatty acids in healthy term gestation infants. *Am J Clin Nutr*, 60, 347-352.
- 11 Jeffrey BG, Weisinger HS, Neuringer M, Mitchell DC, 2001. The role of docosahexaenoic acid in retinal function. *Lipids*, 36, 859-871.
- 12 Jensen CL, Voigt RG, Prager TC, Zou YL, Fraley JK, Rozelle JC, Turcich MR, Llorente AM, Anderson RE, Heird WC, 2005. Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants. *Am J Clin Nutr*, 82, 125-132.
- 13 Johnson EJ and Schaefer EJ, 2006. Potential role of dietary n-3 fatty acids in the prevention of dementia and macular degeneration. *Am J Clin Nutr*, 83, 1494S-1498S.

- 14 Judge MP, Harel O, Lammi-Keefe CJ, 2007. A docosahexaenoic acid-functional food during pregnancy benefits infant visual acuity at four but not six months of age. *Lipids*, 42, 117-122.
- 15 Koletzko B, Cetin I, Brenna JT, 2007. Dietary fat intakes for pregnant and lactating women. *Br J Nutr*, 98, 873-877.
- 16 Larque E, Demmelmair H, Koletzko B, 2002. Perinatal supply and metabolism of long-chain polyunsaturated fatty acids: importance for the early development of the nervous system. *Ann NY Acad Sci*, 967, 299-310.
- 17 Lauritzen L, Jorgensen MH, Mikkelsen TB, Skovgaard M, Straarup EM, Olsen SF, Hoy CE, Michaelsen KF, 2004. Maternal fish oil supplementation in lactation: effect on visual acuity and n-3 fatty acid content of infant erythrocytes. *Lipids*, 39, 195-206.
- 18 Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA, 1994. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. *Am J Clin Nutr*, 60, 189-194.
- 19 Malcolm CA, Hamilton R, McCulloch DL, Montgomery C, Weaver LT, 2003. Scotopic electroretinogram in term infants born of mothers supplemented with docosahexaenoic acid during pregnancy. *Invest Ophthalmol Vis Sci*, 44, 3685-3691.
- 20 Montgomery C, Speake BK, Cameron A, Sattar N, Weaver LT, 2003. Maternal docosahexaenoic acid supplementation and fetal accretion. *Br J Nutr*, 90, 135-145.
- 21 Rojas CV, Martinez JI, Flores I, Hoffman DR, Uauy R, 2003. Gene expression analysis in human fetal retinal explants treated with docosahexaenoic acid. *Invest Ophthalmol Vis Sci*, 44, 3170-3177.
- 22 SanGiovanni JP and Chew EY, 2005. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. *Prog Retin Eye Res*, 24, 87-138.
- 23 Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE, 2001. Essential fatty acids in visual and brain development. *Lipids*, 36, 885-895.
- 24 Williams C, Birch EE, Emmett PM, Northstone K, 2001. Stereoacuity at age 3.5 y in children born full-term is associated with prenatal and postnatal dietary factors: a report from a population-based cohort study. *Am J Clin Nutr*, 73, 316-322.

ID 2906: “Low or reduced saturated fat (hard fat) or replacement of saturated fat with MUFA PUFA (soft fat) low cholesterol” and “Maintains healthy LDL cholesterol levels Arterial/Heart Health”

- 1 Arntzenius AC, Kromhout D, Barth JD, Reiber JH, Brusckhe AV, Buis B, van Gent CM, Kempen-Voogd N, Strikwerda S, van der Velde EA, 1985. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. *N Engl J Med*, 312, 805-811.
- 2 Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U, 1969. A Controlled Clinical Trial of a Diet High in Unsaturated Fat in Preventing Complications of Atherosclerosis. *Circulation*, 40 (Suppl 2), 1-63.
- 3 JHCI (Joint Health Claims Initiative), 2003. Final Technical Report. A List of Well Established Nutrient Function Statements. JHCI/76/03.
- 4 Law MR, Wald NJ, Thompson SG, 1994. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *BMJ*, 308, 367-372.
- 5 Leren P, 1970. The Oslo diet-heart study. Eleven-year report. *Circulation*, 42, 935-942.
- 6 Mensink RP, Zock PL, Kester AD, Katan MB, 2003. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr*, 77, 1146-1155.
- 7 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002. Final Report. NIH Publication No. 02-5215.

- 8 NFA (Finnish National Food Authority), 2002. Terveysväitteiden valvontaopas. Control guides number 2/2002.
- 9 SNF (Swedish Nutrition Foundation), 2004. Health claims in the labelling and marketing of food products. The food sector's code of practice. 2004:1.
- 10 Turpeinen O, Karvonen MJ, Pekkarinen M, Miettinen M, Elosuo R, Paavilainen E, 1979. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. *Int J Epidemiol*, 8, 99-118.
- 11 Watts GF, Jackson P, Burke V, Lewis B, 1996. Dietary fatty acids and progression of coronary artery disease in men. *Am J Clin Nutr*, 64, 202-209.
- 12 WHO (World Health Organization), 2003. Diet, Nutrition and the Prevention of Chronic Diseases. Technical Report No. 916.

ID 2907: “Polyols” and “Remineralisation of teeth”

- 1 Barber LR and Wilkins EM, 2002. Evidence-based prevention, management, and monitoring of dental caries. *J Dent Hyg*, 76, 270-275.
- 2 Birkhed D, 1994. Cariologic aspects of xylitol and its use in chewing gum: a review. *Acta Odontol Scand*, 52, 116-127.
- 3 Dawes C and Macpherson LM, 1992. Effects of nine different chewing-gums and lozenges on salivary flow rate and pH. *Caries Res*, 26, 176-182.
- 4 Edgar WM, 1990. Saliva and dental health. Clinical implications of saliva: report of a consensus meeting. *Br Dent J*, 169, 96-98.
- 5 Edgar WM, 1998. Sugar substitutes, chewing gum and dental caries--a review. *Br Dent J*, 184, 29-32.
- 6 Featherstone JD, 2000. The science and practice of caries prevention. *J Am Dent Assoc*, 131, 887-899.
- 7 Imfeld TN, 1994. Clinical caries studies with polyalcohols. A literature review. *Schweiz Monatsschr Zahnmed*, 104, 941-945.
- 8 Imfeld T, 1999. Chewing gum--facts and fiction: a review of gum-chewing and oral health. *Crit Rev Oral Biol Med*, 10, 405-419.
- 9 Itthagarun A and Wei SH, 1997. Chewing gum and saliva in oral health. *J Clin Dent*, 8, 159-162.
- 10 Kandelman D, 1997. Sugar, alternative sweeteners and meal frequency in relation to caries prevention: new perspectives. *Br J Nutr*, 77 Suppl 1, S121-128.
- 11 Leach SA, 1987. Sugar substitutes and remineralization. *Dtsch Zahnarzt Z*, 42, S135-138.
- 12 Lingstrom P and Moynihan P, 2003. Nutrition, saliva, and oral health. *Nutrition*, 19, 567-569.
- 13 Rigmont Barber L, 2002. Evidence based prevention, management and monitoring of dental caries. *The Journal of Dental Hygiene*, 76.
- 14 Sentko A, Tietze W, Stößer L, 2006. Zuckerfreie Süßwaren in der Kariesprophylaxe. *Prophylaxe impuls*, 10, 174-183.
- 15 Stösser L, Tietze W, Sentko A, 2006. Sugar-free sweets and their role in caries prevention.
- 16 Takatsuka T, 2000. Influence of Palatinit® and xylitol on demineralisation/remineralisation on bovine enamel. *Cariology Today*, 1, 27-40.
- 17 Takatsuka T, 2002. Enamel remineralisation by isomalt-toothpaste in situ. *J Dent Res*, 81 Supplement, Seq No 259, Presentation 2815.
- 18 Van Loveren C, 2004. Sugar alcohols: what is the evidence for caries-preventive and caries-therapeutic effects? *Caries Res*, 38, 286-293.

- 19 WHO/FAO (World Health Organization and Food and Agriculture Organization), 2003. Expert Report: Diet, nutrition and prevention of chronic diseases. Report of a Joint WHO/FAO Expert Consultation. WHO Technical Report Series 916.

ID 2908: “Polyols” and “Low glyceic properties”

- 1 European Parliament and Council Directive 94/35/EC of 30 June 1994 on sweeteners for use in foodstuffs. OJ L 237, 10.9.1994, p. 3–12
- 2 Foster-Powell K, Holt SH, Brand-Miller JC, 2002. International table of glyceic index and glyceic load values: 2002. *Am J Clin Nutr*, 76, 5-56.
- 3 Gee JM, Cooke D, Gorick S, Wortley GM, Greenwood RH, Zumbé A, Johnson IT, 1991. Effects of conventional sucrose-based, fructose-based and isomalt-based chocolates on postprandial metabolism in non-insulin-dependent diabetics. *Eur J Clin Nutr*, 45, 561-566.
- 4 Gostner A, Schaffer V, Theis S, Menzel T, Luhrs H, Melcher R, Schauber J, Kudlich T, Dusel G, Dorbath D, Kozianowski G, Scheppach W, 2005. Effects of isomalt consumption on gastrointestinal and metabolic parameters in healthy volunteers. *Br J Nutr*, 94, 575-581.
- 5 Livesey G, 2003. Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties. *Nutr Res Rev*, 16, 163-191.
- 6 Livesey G, 2005. Low-glycaemic diets and health: implications for obesity. *Proc Nutr Soc*, 64, 105-113.
- 7 Pometta D, Trabichet C, Spengler M, 1985. Effects of a 12-week administration of isomalt (Palatinit®) on metabolic control in type-II-diabetics. *Aktuelle Ernährungsmedizin*, 10, 174-177.
- 8 Thiebaud D, Jacot E, Schmitz H, Spengler M, Felber JP, 1984. Comparative study of isomalt and sucrose by means of continuous indirect calorimetry. *Metabolism*, 33, 808-813.

ID 2909: “Sterols/ stanols and their esters” and “Heart health and artery health because of LDL cholesterol maintenance”

- 1 Commission Regulation (EC) No 608/2004 of 31 March 2004 concerning the labelling of foods and food ingredients with added phytosterols, phytosterol esters, phytostanols and/or phytostanol esters. OJ L 97, 1.4.2004, p. 44–45.
- 2 Food labeling: health claims; plant sterol/stanol esters and coronary heart disease. Food and Drug Administration, HHS. Interim final rule. 2000. *Fed Regist*, 65, 54686-54739.
- 3 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*, 285, 2486-2497.
- 4 Lipid management guidelines--2001. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. 2001. *Med J Aust*, 175 Suppl, S57-85.
- 5 Flemish Dietetic Association, 2002. Intervention protocol for dyslipidemia published by the VVVD.
- 6 IAS (International Atherosclerosis Society), 2003. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease.
- 7 JHCI (Joint Health Claims Initiative), 2003. Final Technical Report A List of Well Established Nutrient Function Statements.
- 8 Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R, 2003. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. *Mayo Clin Proc*, 78, 965-978.

- 9 Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J, 2006. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation*, 114, 82-96.
- 10 SCF (Scientific Committee on Food), 2002. General view on the long-term effects of the intake of elevated levels of phytosterols from multiple dietary sources, with particular attention to the effects on R-carotene.
- 11 SNF (Swedish Nutrition Foundation), Product-specific physiological claims (PPF).

ID 2910: “Unsaturated fats/ fatty acids (poly and/or monounsaturates)” and “Blood cholesterol and artery/heart health”

- 1 Brouwer IA, Katan MB, Zock PL, 2004. Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. *J Nutr*, 134, 919-922.
- 2 De Lorgeril M and Salen P, 2005. Dietary prevention of coronary heart disease: the Lyon diet heart study and after. *World Rev Nutr Diet*, 95, 103-114.
- 3 EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to nutrition claims concerning omega-3 fatty acids, monounsaturated fat, polyunsaturated fat and unsaturated fat (Request N°EFSA-Q-2004-107). *The EFSA Journal*, 253, 1-29.
- 4 FDA (US Food and Drug Administration), 2003. Monounsaturated Fatty Acids from Olive Oil and Coronary Heart Disease (Docket No 2003Q-0559). Letter Responding to Health Claim Petition dated August 28, 2003.
- 5 Finnegan YE, Minihaue AM, Leigh-Firbank EC, Kew S, Meijer GW, Muggli R, Calder PC, Williams CM, 2003. Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. *Am J Clin Nutr*, 77, 783-795.
- 6 Goyens PLL and Mensink RP, 2005. The Dietary a-Linolenic Acid to Linoleic Acid Ratio Does Not Affect the Serum Lipoprotein Profile in Humans. *J Nutr*, 135, 2799-2804.
- 7 IoM (Institute of Medicine), 2002. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty acids, Cholesterol, Protein, and Amino Acids. National Academies Press, Washington D.C.
- 8 Mensink RP, Zock PL, Kester AD, Katan MB, 2003. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr*, 77, 1146-1155.
- 9 Stanner S, 2005. Cardiovascular Disease: Diet, Nutrition and Emerging Risk Factors. Blackwell Publishing, Oxford.
- 10 WHO (World Health Organization), 2003. Diet, Nutrition and the Prevention of Chronic Diseases. Technical Report No. 916.

ID 2911: “Unsaturated fats/fatty acids” and “Function of the cell membrane”

- 1 Garrow JS, James WPT, Ralph A, 2000. Human Nutrition and Dietetics. Churchill Livingstone, London, Edinburgh.
- 2 Gibney MJ, Vorster H, Kok F, 2002. Introduction to Human Nutrition (The Nutrition Society Textbook). Wiley-Blackwell, Chichester.
- 3 IoM (Institute of Medicine), 2005. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. National Academies Press, Washington DC.
- 4 Mann J and Truswell AS, 2002. Essentials of human nutrition. Oxford University Press, Oxford.

ID 2912: “Carbohydrates in dairy products” and “Foods with a low glycemic index (GI) give a low and slow blood glucose response”

- 1 Foster-Powell K, Holt SH, Brand-Miller JC, 2002. International table of glycemic index and glycemic load values: 2002. *Am J Clin Nutr*, 76, 5-56.

ID 2913: “L-methionine” and “Improvement of protein quality. Modulation of lipids metabolism”

- 1 Di Buono M, Wykes LJ, Cole DE, Ball RO, Pencharz PB, 2003. Regulation of sulfur amino acid metabolism in men in response to changes in sulfur amino acid intakes. *J Nutr*, 133, 733-739.
- 2 Fomon SJ, Ziegler EE, Filer LJ, Jr., Nelson SE, Edwards BB, 1979. Methionine fortification of a soy protein formula fed to infants. *Am J Clin Nutr*, 32, 2460-2471.
- 3 Fujisawa K, Yagasaki K, Funabiki R, 1995. Reduction of hyperlipidemia and proteinuria without growth retardation in nephritic rats by a methionine-supplemented, low-soy-protein diet. *Am J Clin Nutr*, 61, 603-606.
- 4 Fukagawa NK, 2006. Sparing of methionine requirements: evaluation of human data takes sulfur amino acids beyond protein. *J Nutr*, 136, 1676S-1681S.
- 5 Garlick PJ, 2006. Toxicity of methionine in humans. *J Nutr*, 136, 1722S-1725S.
- 6 Harvey Mudd S, Braverman N, Pomper M, Tezcan K, Kronick J, Jayakar P, Garganta C, Ampola MG, Levy HL, McCandless SE, Wiltse H, Stabler SP, Allen RH, Wagner C, Borschel MW, 2003. Infantile hypermethioninemia and hyperhomocysteinemia due to high methionine intake: a diagnostic trap. *Mol Genet Metab*, 79, 6-16.
- 7 Oda H, 2006. Functions of sulfur-containing amino acids in lipid metabolism. *J Nutr*, 136, 1666S-1669S.
- 8 Raguso CA, Regan MM, Young VR, 2000. Cysteine kinetics and oxidation at different intakes of methionine and cystine in young adults. *Am J Clin Nutr*, 71, 491-499.
- 9 van de Poll MC, Dejong CH, Soeters PB, 2006. Adequate range for sulfur-containing amino acids and biomarkers for their excess: lessons from enteral and parenteral nutrition. *J Nutr*, 136, 1694S-1700S.

ID 2914: “Long chain Omega 3 fatty acids” and “Normal immune system function”

- 1 Calder PC, 2001. omega 3 polyunsaturated fatty acids, inflammation and immunity. *World Rev Nutr Diet*, 88, 109-116.
- 2 Calder PC, 2002. Dietary modification of inflammation with lipids. *Proc Nutr Soc*, 61, 345-358.
- 3 Calder PC, 2005. Polyunsaturated fatty acids and inflammation. *Biochem Soc Trans*, 33, 423-427.

ID 2915: “Olibra™/Fabules™ (Oil-in-water emulsion, containing 40% fractionated palm oil, 2,5% oats oil and water; no preservatives or stabilisers added.)” and “Fabules™ prolonges the feeling of satiety.”

- 1 Burns AA, Livingstone MB, Welch RW, Dunne A, Rowland IR, 2002. Dose-response effects of a novel fat emulsion (Olibra) on energy and macronutrient intakes up to 36 h post-consumption. *Eur J Clin Nutr*, 56, 368-377.

ID 2916: “Indole-3-carbinol” and “Cell metabolism - positively affects the fission of cells their immunity and regeneration”

- 1 Meng Q, Yuan F, Goldberg ID, Rosen EM, Auburn K, Fan S, 2000. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. *J Nutr*, 130, 2927-2931.
- 2 Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A, 2005. A phase I study of indole-3-carbinol in women: tolerability and effects. *Cancer Epidemiol Biomarkers Prev*, 14, 1953-1960.

ID 2917: “Indole-3-carbinol” and “Induction of apoptosis of transformed and damaged cells”

- 1 Fan S, Meng Q, Auburn K, Carter T, Rosen EM, 2006. BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. *Br J Cancer*, 94, 407-426.

ID 2919: “Formulated emulsion of palm oil, oat oil and water (Patent: WO 99/02041 Satiety Product)” and “Prolongs the feeling of satiety and contributes to a reduced calorie intake at the next meal. Less sensation of hunger between the meals and less need for snacking”

- 1 Burns AA, Livingstone MB, Welch RW, Dunne A, Robson PJ, Lindmark L, Reid CA, Mullaney U, Rowland IR, 2000. Short-term effects of yoghurt containing a novel fat emulsion on energy and macronutrient intakes in non-obese subjects. *Int J Obes Relat Metab Disord*, 24, 1419-1425.
- 2 Burns AA, Livingstone MB, Welch RW, Dunne A, Reid CA, Rowland IR, 2001. The effects of yoghurt containing a novel fat emulsion on energy and macronutrient intakes in non-overweight, overweight and obese subjects. *Int J Obes Relat Metab Disord*, 25, 1487-1496.
- 3 Burns AA, Livingstone MB, Welch RW, Dunne A, Rowland IR, 2002. Dose-response effects of a novel fat emulsion (Olibra) on energy and macronutrient intakes up to 36 h post-consumption. *Eur J Clin Nutr*, 56, 368-377.
- 4 Logan CM, McCaffrey TA, Wallace JM, Robson PJ, Welch RW, Dunne A, Livingstone MB, 2006. Investigation of the medium-term effects of Olibratrade mark fat emulsion on food intake in non-obese subjects. *Eur J Clin Nutr*, 60, 1081-1091.

ID 2920: “Isomalt” and “Low glyceimic properties”

- 1 European Parliament and Council Directive 94/35/EC of 30 June 1994 on sweeteners for use in foodstuffs. *OJ L 237*, 10.9.1994, p. 3-12.
- 2 Gee JM, Cooke D, Gorick S, Wortley GM, Greenwood RH, Zumbe A, Johnson IT, 1991. Effects of conventional sucrose-based, fructose-based and isomalt-based chocolates on postprandial metabolism in non-insulin-dependent diabetics. *Eur J Clin Nutr*, 45, 561-566.
- 3 Gostner A, Schaffer V, Theis S, Menzel T, Luhrs H, Melcher R, Schauber J, Kudlich T, Dusel G, Dorbath D, Kozianowski G, Scheppach W, 2005. Effects of isomalt consumption on gastrointestinal and metabolic parameters in healthy volunteers. *Br J Nutr*, 94, 575-581.
- 4 Holub I, Gostner A, Hessdoerfer S, Theis S, Bender G, Willinger B, Allolio B, Kozianowski G, Scheppach W, 2006. Influence of low-glycaemic sweetener isomalt on metabolic variables and vascular risk factors in patients with type 2 diabetes. *Diabetes and Vascular Disease Research*, 4, 183.
- 5 Livesey G, 2003. Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties. *Nutr Res Rev*, 16, 163-191.
- 6 Livesey G, 2005. Low-glycaemic diets and health: implications for obesity. *Proc Nutr Soc*, 64, 105-113.

- 7 Thiebaud D, Jacot E, Schmitz H, Spengler M, Felber JP, 1984. Comparative study of isomalt and sucrose by means of continuous indirect calorimetry. *Metabolism*, 33, 808-813.

ID 2921: “Isomalt” and “Dental health - General”

- 1 European Parliament and Council Directive 94/35/EC of 30 June 1994 on sweeteners for use in foodstuffs. OJ L 237, 10.9.1994, p. 3-12.
- 2 Title 21, Food and Drugs. Chapter I Food and Drug Administration Departement of Health and Human Services. Subchapter B Food for Human Consumption Part 101 Food labeling: Health claims: dietary noncariogenic carbohydrate sweeteners and dental caries. Code of Federal Regulations (Revised 2008).
- 3 Featherstone JDB, 1994. Effects of Isomalt Sweetener on the Caries Process. *Journal of Clinical Dentistry*, 5, 82-82.
- 4 FNFC/FOSHU (Food with Nutrient Functional Claims/Foods for Specified Health Use), Ministry of Health, Labour, and Welfare, Japan : Food with Health Claims, Food for Special Dietary Uses, and Nutrition Labeling <http://www.mhlw.go.jp/english/topics/foodsafety/fhc/index.html>.
- 5 Grenby TH and Mistry M, 1996. Laboratory studies of sweets re-formulated to improve their dental properties. *Oral Dis*, 2, 32-40.
- 6 Imfeld T and Muhlemann HR, 1978. Cariogenicity and acidogenicity of food, confectionery and beverages. *Pharmacol Ther Dent*, 3, 53-68.
- 7 Imfeld TN, 1983. Identification of low caries risk dietary components. *Monographs in Oral Science*, 11, 1-198.
- 8 Imfeld TN, 1994. Clinical caries studies with polyalcohols. A literature review. *Schweiz Monatsschr Zahnmed*, 104, 941-945.
- 9 SCMPMD (Scientific Committee on Medical Products and Medical Devices), 2002. Revision of the scientific opinion on the effects of xylitol and other polyols on caries development adopted by the Scientific Committee on Medicinal Products and Medical Devices on 2 June 1999.
- 10 van der Hoeven JS, 1979. Influence of disaccharide alcohols on the oral microflora. *Caries Res*, 13, 301-306.
- 11 van der Hoeven JS, 1980. Cariogenicity of disaccharide alcohols in rats. *Caries Res*, 14, 61-66.
- 12 Van Loveren C, 2004. Sugar alcohols: what is the evidence for caries-preventive and caries-therapeutic effects? *Caries Res*, 38, 286-293.

ID 2922: “Inulin/oligofructose from chicory” and “Satiety”

- 1 Archer BJ, Johnson SK, Devereux HM, Baxter AL, 2004. Effect of fat replacement by inulin or lupin-kernel fibre on sausage patty acceptability, post-meal perceptions of satiety and food intake in men. *Br J Nutr*, 91, 591-599.
- 2 Benini L, Rigo L, Tacchella N, Marangoni E, Deiorio F, Ghirelli F, Santi R, Martini R, Vantini I, 2004. Fructo-oligosaccharides eaten at breakfast delay gastric emptying of the main meal. *Gastroenterology* 126 (4, Suppl. 2) A399.
- 3 Cani PD, Dewever C, Delzenne NM, 2004. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. *Br J Nutr*, 92, 521-526.
- 4 Cani PD, Neyrinck AM, Maton N, Delzenne NM, 2005. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1. *Obes Res*, 13, 1000-1007.
- 5 Cani PD, Joly E, Horsmans Y, Delzenne NM, 2006. Oligofructose promotes satiety in healthy human: a pilot study. *Eur J Clin Nutr*, 60, 567-572.

- 6 Cani PD, Hoste S, Guiot Y, Delzenne NM, 2007. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. *Br J Nutr*, 98, 32-37.
- 7 Delmee E, Cani PD, Gual G, Knauf C, Burcelin R, Maton N, Delzenne NM, 2006. Relation between colonic proglucagon expression and metabolic response to oligofructose in high fat diet-fed mice. *Life Sci*, 79, 1007-1013.
- 8 Delzenne NM and Cani PD, 2005. A place for dietary fibre in the management of the metabolic syndrome. *Curr Opin Clin Nutr Metab Care*, 8, 636-640.
- 9 Delzenne NM, Cani PD, Daubioul C, Neyrinck AM, 2005. Impact of inulin and oligofructose on gastrointestinal peptides. *Br J Nutr*, 93 Suppl 1, S157-161.
- 10 Slavin J and Green H, 2007. Dietary fibre and satiety. *Nutrition Bulletin* 32: 32–42.
- 11 Ten Bruggencate. et al, 2007. Dietary oligofructose increases satiety in rats by modulating blood gut hormones and their colonic gene expression. Confidential report: NIZO Food Research (manuscript in preparation).
- 12 Whelan K, Efthymiou L, Judd PA, Preedy VR, Taylor MA, 2006. Appetite during consumption of enteral formula as a sole source of nutrition: the effect of supplementing pea-fibre and fructo-oligosaccharides. *Br J Nutr*, 96, 350-356.

ID 2923: “Galacto-oligosaccharides (GOS)” and “Calcium absorption”

- 1 Bongers A and Heuvel EHM, 2003. Prebiotics and the bioavailability of minerals and trace elements. *Food Reviews International*, 19, 397-422.
- 2 Chonan O, Matsumoto K, Watanuki M, 1995. Effect of galactooligosaccharides on calcium absorption and preventing bone loss in ovariectomized rats. *Biosci Biotechnol Biochem*, 59, 236-239.
- 3 Chonan O and Watanuki M, 1995. Effect of galactooligosaccharides on calcium absorption in rats. *J Nutr Sci Vitaminol (Tokyo)*, 41, 95-104.
- 4 Chonan O, Takahashi R, Yasui H, Watanuki M, 1996. Effects of beta 1-->4 linked galactooligosaccharides on use of magnesium and calcification of the kidney and heart in rats fed excess dietary phosphorous and calcium. *Biosci Biotechnol Biochem*, 60, 1735-1737.
- 5 Chonan O and Watanuki M, 1996. The effect of 6'-galactooligosaccharides on bone mineralization of rats adapted to different levels of dietary calcium. *Int J Vitam Nutr Res*, 66, 244-249.
- 6 Perez-Conesa D, Lopez G, Abellan P, Ros G, 2006. Bioavailability of calcium, magnesium and phosphorus in rats fed probiotic, prebiotic and synbiotic powder follow-up infant formulas and their effect on physiological and nutritional parameters. *Journal of the Science of Food and Agriculture*, 86, 2327-2336.
- 7 Sako T, Matsumoto K, Tanaka R, 1999. Recent progress on research and applications of non-digestible galacto-oligosaccharides. *International Dairy Journal*, 9, 69-80.
- 8 Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Acil Y, Gluer CC, Schrezenmeir J, 2007. Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. *J Nutr*, 137, 838S-846S.
- 9 Schoterman HC, 2001. Galacto-oligosaccharides: properties and health aspects. In: *Advanced Dietary Fibre Technology*. McCleary BV and Prosky L (eds.). Blackwell Science, Malden, MA, 494-502.
- 10 van den Heuvel EG, Schoterman MH, Muijs T, 2000. Transgalactooligosaccharides stimulate calcium absorption in postmenopausal women. *J Nutr*, 130, 2938-2942.
- 11 Yanahira S, Morita M, Aoe S, Suguri T, Takada Y, Miura S, Nakajima I, 1997. Effects of lactitol-oligosaccharides on calcium and magnesium absorption in rats. *J Nutr Sci Vitaminol (Tokyo)*, 43, 123-132.

ID 2925: “Alpha-cyclodextrin (a soluble dietary fiber)” and “Weight management”

- 1 Artiss JD, Brogan K, Brucal M, Moghaddam M, Jen KL, 2006. The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. *Metabolism*, 55, 195-202.
- 2 Gallaher DD, Gallaher CM, Plank DW, 2007. Alpha-cyclodextrin selectively increases fecal excretion of saturated fats. *FASEB J.*, 21, A730.
- 3 Grunberger G, Jen KL, Artiss JD, 2007. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. *Diabetes Metab Res Rev*, 23, 56-62.
- 4 Wagner EM, Jen K-LC, Artiss JD, Remaley AT, 2007. Effects of FBCx on lipid lowering in LDLr-KO mice. *FASEB J.*, 21, A341.

ID 2926: “Alpha-cyclodextrin (a soluble dietary fiber)” and “Glucose homeostasis”

- 1 Buckley JD, Thorp AA, Murphy KJ, Howe PR, 2006. Dose-dependent inhibition of the post-prandial glycaemic response to a standard carbohydrate meal following incorporation of alpha-cyclodextrin. *Ann Nutr Metab*, 50, 108-114.
- 2 Diamantis I and Bär A, 2002. Effect of alpha-cyclodextrin on the glycemic index (GI) and insulinemic index (II) of starch in human volunteers. Unpublished study report (included in the novel food application for alpha-cyclodextrin).

ID 2927: “Fibersol-2 (a resistant dextrin, i.e. a soluble dietary fiber)” and “Vascular/heart health;Blood lipids”

- 1 Fujiwara K and Matsuoka A, 1993. Continuous administration tests of indigestible dextrin; II. *Japanese Journal of Clinical Nutrition*, 83, 301–305.
- 2 Kajimoto O, 2002. Effects of a tea beverage containing indigestible dextrin on the serum triglyceride level in subjects with mild hypertriglyceridemia. *J Nutritional Food*, 5, 117-130.
- 3 Kawasaki F, 2000. Efficacy of tea drinking containing indigestible dextrin. *J Nutritional Food*, 3, 65-72.
- 4 Kishimoto Y, Wakabayashi S, Tokunaga K, 2000. Effects of long-term administration of indigestible dextrin on visceral fat accumulation. *J Jpn Assoc Dietary Fiber Res*, 4, 59-65.
- 5 Kishimoto Y, Wakabayashi S, Yuba K, 2000. Effects of instant miso-soup containing dextrin on moderating the rise of postprandial blood glucose levels, and safety of long-term administration. *J Nutritional Food*, 3, 19-27.
- 6 Kishimoto Y, Oga H, Tagami H, Okuma K, Gordon DT, 2007. Suppressive effect of resistant maltodextrin on postprandial blood triacylglycerol elevation. *Eur J Nutr*, 46, 133-138.
- 7 Konnya H, (Unpublished). Effects of drinks containing indigestible dextrin on insulin and secretion of GLP-1. Study report submitted in support of FOSHU application.
- 8 Mizushima N, 2000. Effect of long-term ingestion of indigestible dextrin-containing soft drinks on safety and blood glucose levels. *J Nutritional Food*, 3, 75-82.
- 9 Nomura M, Nakajima Y, Abe H, 1992. Effects of long-term administration of indigestible dextrin as soluble dietary fiber on lipid and glucose metabolism. *Journal of Japanese Society of Nutrition and Food Science*, 45, 21-25.
- 10 Sekizaki K and Yonezawa H, 2001. Efficacy of packed boiled rice containing indigestible dextrin on moderating the rise of postprandial blood glucose levels, and safety of long-term administration. *J Nutritional Food*, 4, 81-88.

- 11 Tokunaga K and Matsuoka A, 1999. Effects of a FOSHU (food for specified health use) containing indigestible dextrin as a functional component on glucose and fat metabolisms. *J Jpn Diabetes Soc*, 42, 61-63.

ID 2929: “Sunfiber (enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity In healthy people”

- 1 DeLegge MH, Marx SC, Gohman SM, Patrick PG, Greenberg NA, 1995. The effect of partially hydrolyzed guar gum (PHGG) on the use of laxative agents in an elderly nursing home population. *Gastroenterology*, 108 (Suppl.), A722.
- 2 Patrick PG, Gohman SM, Marx SC, DeLegge MH, Greenberg NA, 1998. Effect of supplements of partially hydrolyzed guar gum on the occurrence of constipation and use of laxative agents. *J Am Diet Assoc*, 98, 912-914.
- 3 Takahashi H, Yang SIL, Hayashi C, Kim M, Yamanaka J, Yamamoto T, 1993. Effect of partially hydrolyzed guar gum on fecal output in human volunteers. *Nutrition research*, 13, 649-657.
- 4 Takahashi H, Wako N, Okubo T, Ishihara N, Yamanaka J, Yamamoto T, 1994. Influence of Partially Hydrolyzed Guar Gum on Constipation in Women. *Journal of Nutritional Science and Vitaminology*, 40, 251-251.

ID 2930: “Sunfiber (enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity In people with irritable bowel syndrom”

- 1 Giaccari S, Grasso G, Tronci S, Allegretta L, Sponziello G, Montefusco A, Siciliano IG, Guarisco R, Candiani C, Chiri S, 2001. Partially hydrolyzed guar gum: a fiber as coadjuvant in the irritable colon syndrome. *Clin Ter*, 152, 21-25.
- 2 Giannini EG, Mansi C, Dulbecco P, Savarino V, 2006. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. *Nutrition*, 22, 334-342.
- 3 Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, Battaglia G, Desideri S, Faedo A, Marzolino C, Tonon A, Ermani M, Leandro G, 2002. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). *Dig Dis Sci*, 47, 1697-1704.
- 4 Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, Marino M, Pantalena M, Tafner G, Verdianelli G, 2005. Treatment Effects of Partially Hydrolyzed Guar Gum on Symptoms and Quality of Life of Patients with Irritable Bowel Syndrome. A Multicenter Randomized Open Trial. *Digestive Diseases and Sciences*, 50, 1107-1112.

ID 2931: “Sunfiber (enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity In people receiving total or supplemental enteral nutrition”

- 1 Alam NH, Meier R, Schneider H, Sarker SA, Bardhan PK, Mahalanabis D, Fuchs GJ, Gyr N, 2000. Partially Hydrolyzed Guar Gum-Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhea in Children. *Journal of Pediatric Gastroenterology and Nutrition*, 31, 503.
- 2 Homann HH, Kemen M, Fuessenich C, Senkal M, Zumtobel V, 1994. Reduction in diarrhea incidence by soluble fiber in patients receiving total or supplemental enteral nutrition. *JPEN J Parenter Enteral Nutr*, 18, 486-490.
- 3 Nakao M, Ogura Y, Satake S, Ito I, Iguchi A, Takagi K, Nabeshima T, 2002. Usefulness of soluble dietary fiber for the treatment of diarrhea during enteral nutrition in elderly patients. *Nutrition*, 18, 35-39.

- 4 Shankardass K, Chuchmach S, Chelswick K, Stefanovich C, Spurr S, Brooks J, Tsai M, Saibil FG, Cohen LB, Edington JD, 1990. Bowel function of long-term tube-fed patients consuming formulae with and without dietary fiber. *JPEN J Parenter Enteral Nutr*, 14, 508-512.
- 5 Spapen H, Diltoer M, Van Malderen C, Opdenacker G, Suys E, Huyghens L, 2001. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double-blind, randomized, and controlled trial. *Clinical Nutrition*, 20, 301-305.

ID 2932: “Sunfiber™ (syn.: Benefiber™) (enzymatically partially depolymerised guar gum)” and “Postprandial blood glucose”

- 1 Golay A, Schneider H, Bloise D, Vadas L, Assal J, 1995. The effect of a liquid supplement containing guar gum and fructose on glucose tolerance in non-insulin-dependent diabetic patients. *Nutr. Metab. Cardiovasc. Dis*, 5, 141-148.
- 2 Gu Y, Yamashita T, Suzuki I, Raj Juneja L, Yokawa T, 2003. Effects of enzyme hydrolyzed guar gum on the elevation of blood glucose levels after meal. *Medicine and Biology*, 147, 19-24.
- 3 Kondo S, Xiao JZ, Takahashi N, Miyaji K, Iwatsuki K, Kokubo S, 2004. Suppressive effects of dietary fiber in yogurt on the postprandial serum lipid levels in healthy adult male volunteers. *Biosci Biotechnol Biochem*, 68, 1135-1138.
- 4 Trinidad T, Perez E, Loyola A, Mallillin A, Encabo R, Yokawa T, Aoyama N, Juneja L, 2004. Short communication. Glycemic index of Sunfibre (*Cyamoposis tetragonolobus*) products in normal and diabetic subjects. *International Journal of Food Science and Technology*, 39, 1093-1098.

ID 2933: “Hydroxypropyl methylcellulose (HPMC) Voedingsvezel” and “Verzadiging”

- 1 Astrup A, Vrist E, Quaade F, 1990. Dietary fibre added to very low calorie diet reduces hunger and alleviates constipation. *Int J Obes*, 14, 105-112.
- 2 Blundell JE and Burley VJ, 1987. Satiation, satiety and the action of fibre on food intake. *Int J Obes*, 11 Suppl 1, 9-25.
- 3 Bolton RP, Heaton KW, Burroughs LF, 1981. The role of dietary fiber in satiety, glucose, and insulin: studies with fruit and fruit juice. *Am J Clin Nutr*, 34, 211-217.
- 4 Briony T, 2001. *Manual of Dietetic Practice*. Blackwell Science, Chichester.
- 5 Burley VJ, Leeds AR, Blundell JE, 1987. The effect of high and low-fibre breakfasts on hunger, satiety and food intake in a subsequent meal. *Int J Obes*, 11 Suppl 1, 87-93.
- 6 Burley VJ, Paul AW, Blundell JE, 1992. An Investigation of a Sugar Beet Fibre-Supplemented Breakfast on Energy Intake in Young Non-Obese Subjects. *International Journal of Obesity*, 16, 53.
- 7 Burton-Freeman B, 2000. Dietary fiber and energy regulation. *J Nutr*, 130, 272S-275S.
- 8 Burton-Freeman B, 2000. Dietary fiber and energy regulation. *J Nutr*, 130, 272S-275S.
- 9 Committee on Diet and Health Food and Nutrition Board Commission on Life Sciences National Research Council, 1989. *Diet and health: implications for reducing chronic disease risk*. National Academies Press, Washington D.C.
- 10 Delargy HJ, O'Sullivan KR, Fletcher RJ, Blundell JE, 1997. Effects of amount and type of dietary fibre (soluble and insoluble) on short-term control of appetite. *Int J Food Sci Nutr*, 48, 67-77.
- 11 Ellis PR, Apling EC, Leeds AR, Peterson DB, Jepson EM, 1985. Guar bread and satiety: effects of an acceptable new product in overweight diabetic patients and normal subjects. *J Plant Foods*, 6, 253-262.
- 12 Garrow JS and James WPT, 1996. *Human Nutrition and Dietetics*. Churchill Livingstone, Edinburgh.

- 13 Gibney M, Vorster H, Kok F, 2002. *Introduction to Human Nutrition (The Nutrition Society Textbook)*. Wiley-Blackwell, Chichester.
- 14 Gustafsson K, Asp NG, Hagander B, Nyman M, 1995. Satiety effects of spinach in mixed meals: comparison with other vegetables. *Int J Food Sci Nutr*, 46, 327-334.
- 15 Health Council of the Netherlands, 2006. Guidelines for dietary fiber intake.
- 16 Hulshof T, De Graaf C, Weststrate JA, 1993. The effects of preloads varying in physical state and fat content on satiety and energy intake. *Appetite*, 21, 273-286.
- 17 Hylander B and Rossner S, 1983. Effects of dietary fiber intake before meals on weight loss and hunger in a weight-reducing club. *Acta Med Scand*, 213, 217-220.
- 18 Pasma WJ, Saris WH, Wauters MA, Westterp-Plantenga MS, 1997. Effect of one week of fibre supplementation on hunger and satiety ratings and energy intake. *Appetite*, 29, 77-87.
- 19 Raben A, Christensen NJ, Madsen J, Holst JJ, Astrup A, 1994. Decreased postprandial thermogenesis and fat oxidation but increased fullness after a high-fiber meal compared with a low-fiber meal. *Am J Clin Nutr*, 59, 1386-1394.
- 20 Rytting KR, Larsen S, Haegh L, 1985. Treatment of slightly to moderately overweight persons. A double blind placebo-controlled investigation with diet and fiber tablets (DumoVital). *Tidsskr Nor Laegeforen*, 104, 989-991.
- 21 Tiwary CM, Ward JA, Jackson BA, 1997. Effect of pectin on satiety in healthy US Army adults. *J Am Coll Nutr*, 16, 423-428.
- 22 Turnbull WH, Walton J, Leeds AR, 1993. Acute effects of mycoprotein on subsequent energy intake and appetite variables. *Am J Clin Nutr*, 58, 507-512.
- 23 Van Itallie TB, 1978. Dietary fiber and obesity. *Am J Clin Nutr*, 31, S43-52.
- 24 Wilmhurst P and Crawley JC, 1980. The measurement of gastric transit time in obese subjects using ²⁴Na and the effects of energy content and guar gum on gastric emptying and satiety. *Br J Nutr*, 44, 1-6.

ID 2934: “CalorieControl Trim® Oat Bran 20%” and “Contribution to the maintenance of healthy blood cholesterol levels”

- 1 Title 21, Food and Drugs. Chapter I Food and Drug Administration Departement of Health and Human Services. Subchapter B Food for Human Consumption Part 101 Food labeling Health Claims; Oats and Coronary Heart Disease. Code of Federal Regulations (Revised 2008).
- 2 Behall KM, Scholfield DJ, Hallfrisch J, 1997. Effect of beta-glucan level in oat fiber extracts on blood lipids in men and women. *J Am Coll Nutr*, 16, 46-51.
- 3 Behall KM, Scholfield DJ, Hallfrisch J, 2004. Diets containing barley significantly reduce lipids in mildly hypercholesterolemic men and women. *Am J Clin Nutr*, 80, 1185-1193.
- 4 Kays SE and Barton FE, 2nd, 2002. Near-infrared analysis of soluble and insoluble dietary fiber fractions of cereal food products. *J Agric Food Chem*, 50, 3024-3029.
- 5 McCarty MF, 2005. Nutraceutical resources for diabetes prevention--an update. *Med Hypotheses*, 64, 151-158.
- 6 Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher RG, Slavin JL, 2007. Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. *Nutr J*, 6, 6.
- 7 Reyna-Villasmil N, Bermudez-Pirela V, Mengual-Moreno E, Arias N, Cano-Ponce C, Leal-Gonzalez E, Souki A, Inglett GE, Israili ZH, Hernandez-Hernandez R, Valasco M, Arraiz N, 2007. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia. *Am J Ther*, 14, 203-212.

8 United States Patent and Trademark Office, Homepage, <http://www.uspto.gov/>.

ID 2935: “CalorieControl Trim® Oat Bran” and “insulin_glucose response”

- 1 Title 21, Food and Drugs. Chapter I Food and Drug Administration Departement of Health and Human Services. Subchapter B Food for Human Consumption Part 101 Food labeling Health Claims; Oats and Coronary Heart Disease. Code of Federal Regulations (Revised 2008).
- 2 Hallfrisch J, Scholfield DJ, Behall KM, 1995. Diets containing soluble oat extracts improve glucose and insulin responses of moderately hypercholesterolemic men and women. *Am J Clin Nutr*, 61, 379-384.
- 3 Jenkins AL, Jenkins DJ, Zdravkovic U, Wursch P, Vuksan V, 2002. Depression of the glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. *Eur J Clin Nutr*, 56, 622-628.
- 4 United States Patent and Trademark Office, Homepage, <http://www.uspto.gov/>.

ID 2936: “Bifidobacterium breve BR 03 (DSM 16604)” and “Microflora / intestinal transit”

- 1 Del Piano M, Montino F, Carmagnola S, Anderloni A, Orsello M, Garelo E, Sforza F, Ballare M, 2005. The use of probiotics in the treatment of constipation in the elderly. *Cibus*, 1, 23-30.

ID 2937: “Bifidobacterium breve BL 03 (DSM 16603)” and “Microflora / intestinal transit”

- 1 Del Piano M, Montino F, Carmagnola S, Anderloni A, Orsello M, Garelo E, Sforza F, Ballare M, 2005. The use of probiotics in the treatment of constipation in the elderly. *Cibus*, 1, 23-30.

ID 2938: “Bifidobacterium breve BR 03 (DSM 16604) +Lactobacillus plantarum LP 01 (LMG P-21021)” and “Microflora / intestinal transit”

- 1 Saggiaro A, 2004. Probiotics in the treatment of Irritable Bowel Syndrome. *Journal of Clinical Gastroenerology*, 38, 104-106.

ID 2939: “Bifidobacterium infantis Bi1 (LMG P-17502), Bifidobacterium breve Bbr8 (LMG P-17501) and Bifidobacterium longum Bl10 (LMG P-17500)” and “he bacteria take part in the commensal gastrointestina flora. They survive in the gastrointestinal tract and counteract unwanted bacteria, promoting the intestinal healt”

- 1 Bazzocchi G, Gionchetti P, Swennen E, Matteuzzi D, Campieri M, 1998. Ruolo della flora batterica nella sindrome dell'intestino irritabile: un nuovo approccio terapeutico. *Argomenti di Gastroenterologia Clinica*, 11 (Suppl 1), 17-21.
- 2 Bianchi-Salvadori B, Vesely R, Ferrari A, Canzi E, Casiraghi C, Brighenti F, 2001. Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements. *Microbiologica*, 24, 23-33.
- 3 Bottazzi V, 1987. Aggiornamento di microbiologia dei batteri lattici. Centro Sperimentale del Latte S.p.A, Milano.
- 4 Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D, 2001. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. *Res Microbiol*, 152, 735-741.

- 5 Campieri M, 1999. Studio clinico per la valutazione comparativa in termini di efficacia e tollerabilità di VSL/3 forte in confronto a placebo in soggetti affetti da sindromi diarroiche di varia origine.
- 6 De Simone C, Famularo G, Birillo E, Vesely R, Bianchi Salvadori B, Santini G, 1995. Rethinking the role of probiotics for the prevention and treatment of enteropathies. In: Old Herborn University Seminar Monograph 8. Probiotics: prospects of use in opportunistic infections. Fuller R, Heidt PJ, Rusch V, Van Der Waaij D (eds.). Institute for Microbiology and Biochemistry, Herborn-Dill, 67-80.
- 7 De Simone C, Famularo G, Bianchi Salvadori B, Vesely R, 1998. Prospettive terapeutiche dei batteri lattici - Teoria e applicazioni nel dismicrobismo intestinale. Piccin Nuova Libreria S.p.A, Padova.
- 8 Faustini M, Bianchi Salvadori B, Giardini A, Vesely R, Maffeo G, Russo V, 1994. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto, 2004. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto. Cibus, 8, 1-9.
- 9 Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M, 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology, 119, 305-309.
- 10 Mogensen G, Salminen S, O'Brien J, Owehand A, Holzapfel W, Shortt C, Fonden R, Miller GD, Donohue D, Playne M, Crittenden R, Bianchi Salvadori B, Zink R, 2002. Inventory of microorganisms with a documented history of use in food. Bull Int Dairy Fed, 377, 10-19.
- 11 Naidu AS, Bidlack WR, Clemens RA, 1999. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr, 39, 13-126.
- 12 Ouwehand A, Bianchi Salvadori B, Fondén R, Mogensen G, Salminen S, Sellars R, 2003. Health effects of probiotics and culture-containing dairy products in humans. IDF Bulletin, 380, 4-19.
- 13 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr, 71, 1682S-1687S; discussion 1688S-1690S.
- 14 Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M, 1999. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther, 13, 1103-1108.

ID 2940: “Bifidobacterium lactis BS 01 (LMG P-21384)” and “Intestinal transit”

- 1 Del Piano M, Montino F, Carmagnola S, Anderloni A, Orsello M, Garello E, Sforza F, Ballare M, 2005. The use of probiotics in the treatment of constipation in the elderly. Cibus, 1, 23-30.

ID 2941: “Bifidobacterium lactis BS 01 (LMG P-21384)+Lactobacillus rhamnosus LR 04 (DSM 16605)+Lactobacillus plantarum LP 02(LMG P-21020)” and “Natural defences / immune system / intestinal discomfort”

- 1 Pregliasco F, et al., (Unpublished). Clinical efficacy of administration of new synbiotics formulation (Lactobacillus plantarum, Lactobacillus casei subsp. rhamnosus, Bifidobacterium lactis and FOS-s.c.) in the prevention of respiratory tract infection and in the improvement of the intestinal function.

ID 2942: “Lactobacillus acidophilus bar 13 (CNCM-I-3857) and Bifidobacterium longum bar 33 (CNCM-I-3858)- mix 1:1” and “immune modulation”

- 1 Deposit certificates for Bar 13 and Bar 33 (CONFIDENTIAL). 2007.
- 2 Bifidobacterium longum R0175 - Antibiotic Profile (CONFIDENTIAL). 2008.
- 3 Lactobacillus helveticus R0052 - Antibiotic Profile (CONFIDENTIAL). 2008.

- 4 Certificate from Lallemand regarding the denomination of the strains (CONFIDENTIAL). 2008.
- 5 Brigidi P, 2008. Genetic identification certificates for Bar 13 and Bar 33 (CONFIDENTIAL).
- 6 Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, Rizzello F, Campieri M, Brigidi P, 2008. Interaction of probiotic *Lactobacillus* and *Bifidobacterium* strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. *Int J Food Microbiol*, 125, 286-292.
- 7 Mengheri E, 2008. Health, probiotics, and inflammation. *J Clin Gastroenterol*, 42 Suppl 3 Pt 2, S177-178.
- 8 Roselli M, Finamore A, Nuccitelli S, Carnevali P, Brigidi P, Vitali B, Nobili F, Rami R, Garaguso I, Mengheri E, 2009. Prevention of TNBS-induced colitis by different *Lactobacillus* and *Bifidobacterium* strains is associated with an expansion of $\gamma\delta$ T and regulatory T cells of intestinal intraepithelial lymphocytes. *Inflammatory Bowel Disease*, Published Online ahead of print: 5 June 2009.

ID 2943: “*Lactobacillus acidophilus* K8 (LMG P-17503)” and “The strain takes part in the normal vaginal flora. It colonize the vagina. It counteract unwanted bacteria and yeasts, promoting the vaginal health”

- 1 Bottazzi V, 1987. Aggiornamento di microbiologia dei batteri lattici. Centro Sperimentale del Latte S.p.A, Milano.
- 2 De Simone C, Bianchi Salvadori B, Negri R, Terrazzi M, Baldinelli L, Vesely R, 1986. The adjuvant effect of yogurt on production of gamma-interferon by Con A-stimulated human peripheral blood lymphocytes. *Nutrition Reports International*, 33, 419-433.
- 3 De Simone C, Famularo G, Birillo E, Vesely R, Bianchi Salvadori B, Santini G, 1995. Rethinking the role of probiotics for the prevention and treatment of enteropathies. In: Old Herborn University Seminar Monograph 8. Probiotics: prospects of use in opportunistic infections. Fuller R, Heidt PJ, Rusch V, Van Der Waaij D (eds.). Institute for Microbiology and Biochemistry, Herborn-Dill, 67-80.
- 4 De Simone C, Famularo G, Bianchi Salvadori B, Vesely R, 1998. Prospettive terapeutiche dei batteri lattici - Teoria e applicazioni nel dismicrobismo intestinale. Piccin Nuova Libreria S.p.A, Padova.
- 5 Di Silverio F, Von Heland M, Macrì D, Flammia G, 1998. Il ruolo della microflora intestinale nelle cistiti urinarie e sindrome colon-pelvica. *Argomenti di Gastroenterologia Clinica*, 11 Suppl.1, 23-27.
- 6 Faustini M, Bianchi Salvadori B, Giardini A, Vesely R, Maffeo G, Russo V, 1994. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto, 2004. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto. *Cibus*, 8, 1-9.
- 7 Mastromarino P, Petruzzello R, Macchia S, 1998. Adesione dei batteri lattici alle cellule HeLa. In: Prospettive terapeutiche dei batteri lattici - Teoria e applicazioni nel dismicrobismo intestinale. De Simone C, Famularo G, Bianchi Salvadori B, Vesely R (eds.). Piccin Nuova Libreria S.p.A, Padova, 133-150.
- 8 Mogensen G, Salminen S, O'Brien J, Ouwehand A, Holzapfel W, Shortt C, Fondén R, Miller GD, Donohue D, Playne M, Crittenden R, Bianchi Salvadori B, Zink R, 2002. Inventory of Microorganisms with a documented history of use in food *IDF Bulletin*, 377, 10-19.
- 9 Naidu AS, Bidlack WR, Clemens RA, 1999. Probiotic spectra of lactic acid bacteria (LAB). *Crit Rev Food Sci Nutr*, 39, 13-126.
- 10 Ouwehand A, Bianchi Salvadori B, Fondén R, Mogensen G, Salminen S, Sellars R, 2003. Health effects of probiotics and culture-containing dairy products in humans. *IDF Bulletin*, 380, 4-19.
- 11 Reid G and Bruce AW, 2003. Urogenital infections in women: can probiotics help? *Postgrad Med J*, 79, 428-432.
- 12 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? *Am J Clin Nutr*, 71, 1682S-1687S; discussion 1688S-1690S.

ID 2944: “Lactobacillus acidophilus LA 02 (LMG P-21381)+Lactobacillus plantarum LP 01 (LMG P-21021)” and “Microflora / intestinal transit”

- 1 Saggiaro A, 2004. Probiotics in the treatment of irritable bowel syndrome. *Journal of clinical gastroenterology*, 38, 104-106.

ID 2945: “Lactobacillus acidophilus LA1 (LMG P-21904)” and “Intestinal flora / gut health”

- 1 Bottazzi V, 1987. Aggiornamento di microbiologia dei batteri lattici. Centro Sperimentale del Latte S.p.A, Milano.
- 2 Camaschella P and Bianchi Salvadori B, 1987. Distribuzione del *Lactobacillus acidophilus* nel lume intestinale di animali gnotocenici trattati con *Streptococcus faecium*. *Obiettivi e Documenti Veterinari*, VIII, 67-69.
- 3 Campieri M, 1999. Clinical trial for a comparative versus placebo evaluation of efficacy and tolerability of a new product (VSL3 Forte) in subjects affected by diarrhoeic syndrome of various origin. Scientific report of the University of Bologna.
- 4 De Simone C, Famularo G, Birillo E, Vesely R, Bianchi Salvadori B, Santini G, 1995. Rethinking the role of probiotics for the prevention and treatment of enteropathies. In: *Prospects of Use un Opportunistic Infections*. Old Herborn University Seminar Monograph. Fuller R, Heidt PJ, Rusch V, Van DerWaaaj D (eds.). 67-80.
- 5 De Simone C, Famularo G, Bianchi Salvadori B, Vesely R, 1998. Prospettive terapeutiche dei batteri lattici – Teoria e applicazioni nel dismicrobismo intestinale. Piccin Nuova Libreria S.p.A., Padova.
- 6 EFFCA (European food and feed cultures association), Inventory of Microorganisms with a documented history of use in food, http://www.effca.com/anglais/pages/statique/11_list_of_microorg.htm.
- 7 Faustini M, Bianchi Salvadori B, Giardini A, Vesely R, Maffeo G, Russo V, 1994. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto. *Cibus*, 1.
- 8 Naidu AS, Bidlack WR, Clemens RA, 1999. Probiotic spectra of lactic acid bacteria (LAB). *Crit Rev Food Sci Nutr*, 39, 13-126.
- 9 Ouwehand A, Bianchi Salvadori B, Fondén R, Mogensen G, Salminen S, Sellars R, 2003. Health effects of probiotics and culture-containing dairy products in humans. *Bulletin - International Dairy Federation*, 380, 4-19.
- 10 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? *Am J Clin Nutr*, 71, 1682S-1687S; discussion 1688S-1690S.
- 11 Zoppi G, Cinquetti M, Benini A, Bonamini E, Minelli EB, 2001. Modulation of the intestinal ecosystem by probiotics and lactulose in children during treatment with ceftriaxone. *Current Therapeutic Research*, 62, 418-435.

ID 2946: “Lactobacillus acidophilus P 18806” and “Benessere generale del tratto gastro-intestinale”

- 1 Dondi G, 2000. Method for the selection of adhesive lactobacilli strains having therapeutical properties and strains obtained by said method, European Patent EP1046713, European Patent Office.
- 2 Elli M, Callegari ML, Ferrari S, Bessi E, Cattivelli D, Soldi S, Morelli L, Goupil Feuillerat N, Antoine JM, 2006. Survival of yogurt bacteria in the human gut. *Appl Environ Microbiol*, 72, 5113-5117.
- 3 Proge Farm, 1999. Determination of carbohydrate fermentation pattern SDS-PAGE protein profiling report 04/02/99.

ID 2947: “Lactobacillus acidophilus P 18806” and “Rinforzo delle difese naturali”

- 1 Mastrandrea F, Coradduzza G, Serio G, Minardi A, Manelli M, Ardito S, Muratore L, 2004. Probiotics reduce the CD34+ hemopoietic precursor cell increased traffic in allergic subjects. *Eur Ann Allergy Clin Immunol*, 36, 118-122.

ID 2948: “Lactobacillus acidophilus, Bifidobacterium (BB46); Bifidobacterium (BB02), Bifidobacterium Breve (Bbr8 LMG P-17501) CSL, Lactobacillus Rhamnosus ATC C53103 (LGG), Lactobacillus casei 101/37 (Img P-17504), Lactobacillus delbrueckii spp bulgaricus AY/CSL (LMG P1)” and “Intestinal microflora - Natural defences - immune response”

No references provided

ID 2949: “Lactobacillus casei CNCM I-1572 DG” and “Intestinal flora”

- 1 Drago L, De Vecchi E, Valli M, Nicola L, Lomabardi A, Gismondo MR, 2002. Colonizzazione intestinale di *Lactobacillus casei* subsp. casei I-1572 CNCM (*L. casei* DG) in volontari sani e in topi *germ-free*. *Farmaci e terapia*, 19, 72-76.

ID 2950: “Lactobacillus crispatus P 17631” and “Benessere della microflora vaginale”

- 1 Lattobacilli ad usoetc. Università degli Studi del Piemonte Orientale.
- 2 Dondi G and Morelli L, 1998. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures, European Patent 0949330A3.
- 3 Dondi G and Morelli L, 2002. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures, United States Patent 6342366.
- 4 Gianella C, 2003. Activity and tolerability study of lactobacillus crispatus P 17631 vaginal capsules administered in repeated dose regimen to 24 females suffering from vaginal infections. Institute for Pharmacokinetic and Analytical Studies, Ligornetto, Switzerland.
- 5 Pietronave S, Bonetti A, Martinotti MG, 2003. Caratterizzazione delle proprietà probiotiche di alcuni ceppi del genere *Lactobacillus* spp. Atti del 5° Congresso Federazione Italiana Scienze della Vita (FISV), Rimini, 168.

ID 2951: “Lactobacillus delbrueckii P18805” and “Benessere generale del tratto gastro-intestinale”

- 1 BCCM-LMG (Belgian co-ordinated collections of micro-organisms - Laboratorium voor Microbiologie Universiteit Gent), 1997. Identification of 3 bacterial isolates reported 29/01/97.
- 2 Dondi G, 2000. Method for the selection of adhesive lactobacilli strains having therapeutical properties and strains obtained by said method, European Patent EP1046713, Office EP.
- 3 Elli M, Callegari ML, Ferrari S, Bessi E, Cattivelli D, Soldi S, Morelli L, Goupil Feuillerat N, Antoine JM, 2006. Survival of yogurt bacteria in the human gut. *Appl Environ Microbiol*, 72, 5113-5117.
- 4 Proge Farm, 1999. Determination of carbohydrate fermentation pattern SDS-PAGE protein profiling report 04/02/99.

ID 2952: “Lactobacillus delbrueckii P18805” and “Rinforzo delle difese naturali”

- 1 Mastrandrea F, Coradduzza G, Serio G, Minardi A, Manelli M, Ardito S, Muratore L, 2004. Probiotics reduce the CD34+ hemopoietic precursor cell increased traffic in allergic subjects. *Eur Ann Allergy Clin Immunol*, 36, 118-122.

ID 2953: “Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG-P 17224) and Streptococcus thermophilus 9Y/CSL (LMG-P 17225)” and “Intestinal microflora”

- 1 Bianchi Salvadori B, Brughera F, Salvadori P, 1967. Studio sulle variazioni coprocolturali nel lattante in rapporto alla somministrazione di yoghurt. *Min Diet*, 7, 176-180.
- 2 Bianchi Salvadori B, Gotti M, Brughera F, Polinelli U, 1978. Etude sur les variations de la flore lactique et bifide intestinale par rapport à l'administration des cellules lactiques du yaourt. *Le Lait*, 58, 17-42.
- 3 Bianchi Salvadori B, Camaschella P, Bazzigaluppi E, 1984. Distribution and adherence of *Lactobacillus bulgaricus* in the gastroenteric tract of germ-free animals. *Milchwissenschaft*, 39, 387-391.
- 4 Bianchi Salvadori B and Camaschella P, 1986. Yogurt as re-equilibration agent of the intestinal flora of dispeptic babies. *Annali Ist. Sup. Sanità*, 22, 1149-1152.
- 5 Bianchi Salvadori B, Camaschella P, Cislighi S, 1989. Effect of yogurt lactic acid bacteria and Bifidobacteria on translocation of *Escherichia coli* in the lymph system. *Microecol Therapy*, 18, 137-142.
- 6 Bianchi Salvadori B, Vesely R, Ferrari A, Canzi E, Casiraghi C, Brighenti F, 2001. Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements. *New Microbiol*, 24, 23-33.
- 7 Bottazzi V, 1987. *Aggiornamenti di Microbiologia dei batteri lattici*. Centro Sperimentale del Latte, Milano.
- 8 Camaschella P, Cislighi S, Bianchi Salvadori B, 1988. Proprietà probiotiche dei batteri lattici dello yogurt e fenomeno di traslocazione batterica. *Proceedings of Recenti progressi in gastroenterologia e nutrizione pediatrica*, Napoli, 115-124.
- 9 Campieri M, 1999. Clinical trial for a comparative versus placebo evaluation of efficacy and tolerability of a new product (VSL3 Forte) in subjects affected by diarrhoeic syndrome of various origin. University of Bologna.
- 10 Canzi E, Casiraghi MC, Zanchi R, Gandolfi R, Ferrari A, Brighenti F, Bosia R, Crippa A, Maestri P, Vesely R, 2002. Yogurt in the diet of the elderly: a preliminary investigation into its effect on the gut ecosystem and lipid metabolism. *Le Lait*, 82, 713-723.
- 11 De Simone C, Famularo G, Birillo E, Vesely R, Bianchi Salvadori B, Santini G, 1995. Rethinking the role of probiotics for the prevention and treatment of enteropathies. In: *Prospects of Use in Opportunistic Infections*. Old Herborn University Seminar Monograph. Fuller R, Heidt PJ, Rusch V, Van DerWaij D (eds.). 67-80.
- 12 De Simone C, Famularo G, Bianchi Salvadori B, Vesely R, 1998. Prospettive terapeutiche dei batteri lattici: teoria e applicazioni nel dismicrobismo intestinale. *Piccin Nuova Libreria*, Padova.
- 13 EFFCA (European food and feed cultures association), Inventory of Microorganisms with a documented history of use in food, http://www.effca.com/anglais/pages/statique/11_list_of_microorg.htm.
- 14 Faustini M, Bianchi Salvadori B, Giardini A, Vesely R, Maffeo G, Russo V, 2004. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto. *Cibus*, 8, 1-9.
- 15 Naidu AS, Bidlack WR, Clemens RA, 1999. Probiotic spectra of lactic acid bacteria (LAB). *Crit Rev Food Sci Nutr*, 39, 13-126.
- 16 Ouwehand AC, Bianchi Salvadori B, Fonden R, Mogensen G, Salminen S, Sellars R, 2003. Health effects of probiotics and culture-containing dairy products in humans. *Bulletin- International Dairy Federation*, 4-19.

- 17 Pacini N, Ferrari A, Canzi E, Bianchi Salvadori B, 1979. Etude sur la microflore intestinale et sur les transformations biliaries chez des souris alimentés avec du yaourt. *Le Lait*, LIX, 589-590, 615-624.
- 18 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? *Am J Clin Nutr*, 71, 1682S-1687S; discussion 1688S-1690S.
- 19 Salvadori P and Bianchi Salvadori B, 1973. Studio sulle variazioni coprocolturali nell'uomo in rapporto alla somministrazione di yogurt. *Minerva Dietologica*, 13, 8-12.
- 20 Zanini K, Marzotto M, Castellazzi A, Borsari A, Dellaglio F, Torriani S, 2007. The effects of fermented milks with simple and complex probiotic mixtures on the intestinal microbiota and immune response of healthy adults and children. *International Dairy Journal*, 17, 1332-1343.

ID 2954: “Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG-P 17224) and Streptococcus thermophilus 9Y/CSL (LMG-P 17225)” and “Natural defence - immune response (Svolgono un'attività immunostimulante e immunomodulante verificato in individui adulti e bambini)”

- 1 Bianchi Salvadori B, Camaschella P, Bazzigaluppi E, 1984. Distribution and adherence of *Lactobacillus bulgaricus* in the gastroenteric tract of germ-free animals. *Milchwissenschaft*, 39, 387-391.
- 2 Bottazzi V, 1987. Aggiornamenti di Microbiologia dei batteri lattici. Centro Sperimentale del Latte, Milano.
- 3 Campieri M, 1999. Clinical trial for a comparative versus placebo evaluation of efficacy and tolerability of a new product (VSL3 Forte) in subjects affected by diarrhoeic syndrome of various origin. University of Bologna.
- 4 De Simone C, Bianchi Salvadori B, Negri R, Ferrazzi M, Baldinelli L, Vesely R, 1986. The adjuvant effect of yogurt on production of gamma interferon by con A-stimulated human peripheral blood lymphocytes. *Nutrition reports international*, 33, 419-433.
- 5 De Simone C, Grassi PP, Bianchi-Salvadori B, Miragliotta G, Vesely R, Jirillo E, 1988. Adherence of specific yogurt micro-organisms to human peripheral blood lymphocytes. *Microbios*, 55, 49.
- 6 De Simone C, Tzantzoglou S, Baldinelli L, Difabio S, Bianchi-Salvadori B, Jirillo E, Vesely R, 1988. Enhancement of host resistance against *Salmonella typhimurium* infection by a diet supplemented with yogurt. *Immunopharmacology and Immunotoxicology*, 10, 399-415.
- 7 De Simone C, Bianchi Salvadori B, Jirillo E, Baldinelli L, Di Fabio S, Vessely R, 1989. Yogurt and the immune response. *Les Laits Fermentés: actualités de la recherche*, Congrès International, Paris.
- 8 De Simone C, Bianchi Salvadori B, Tzantzoglou S, Jirillo E, Camaschella P, Cislighi S, Ciardi A, Vesely R, 1992. Bacterial translocation and immunological responses in mice monoassociated or biassociated with *Lactobacillus bulgaricus* and *Escherichia coli*. *Dynamic Nutrition Research*, 1, 57-65.
- 9 De Simone C, Famularo G, Birillo E, Vesely R, Bianchi Salvadori B, Santini G, 1995. Rethinking the role of probiotics for the prevention and treatment of enteropathies. In: *Prospects of Use in Opportunistic Infections*. Old Herborn University Seminar Monograph. Fuller R, Heidt PJ, Rusch V, Van DerWaaaj D (eds.). 67-80.
- 10 De Simone C, Famularo G, Bianchi Salvadori B, Vesely R, 1998. Prospettive terapeutiche dei batteri lattici: teoria e applicazioni nel dismicrobismo intestinale. *Piccin Nuova Libreria*, Padova.
- 11 EFFCA (European food and feed cultures association), Inventory of Microorganisms with a documented history of use in food, http://www.effca.com/anglais/pages/statique/11_list_of_microorg.htm.
- 12 Faustini M, Bianchi Salvadori B, Giardini A, Vesely R, Maffeo G, Russo V, 2004. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto. *Cibus*, 8, 1-9.
- 13 Naidu AS, Bidlack WR, Clemens RA, 1999. Probiotic spectra of lactic acid bacteria (LAB). *Crit Rev Food Sci Nutr*, 39, 13-126.
- 14 Ouwehand AC, Bianchi Salvadori B, Fonden R, Mogensen G, Salminen S, Sellars R, 2003. Health effects of probiotics and culture-containing dairy products in humans. *Bulletin- International Dairy Federation*, 4-19.

- 15 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? *Am J Clin Nutr*, 71, 1682S-1687S; discussion 1688S-1690S.
- 16 Simone CD, Vesely R, Negri R, Salvadori BB, Zanzoglu S, Cilli A, Lucci L, 1987. Enhancement of immune response of murine Peyer's patches by a diet supplemented with yogurt. *Immunopharmacology and Immunotoxicology*, 9, 87-100.
- 17 Simone C, Baldinelli L, Di Fabio S, Tzantzoglou S, Jirillo E, Bianchi Salvadori B, Vesely R, 1988. Lactobacilli feeding increases NK cells and gamma-IFN levels in humans. *Dietetics in the 90s. Role of the dietitian/nutritionist*, 1.
- 18 Vesely R, Negri R, Bianchi Salvadori B, Lavezzari D, De Simone C, 1985. Influence of diet addition with yogurt on the mouse immune system. *Journal of Immunology and Immunopharmacology*, 5, 30-35.
- 19 Zanini K, Marzotto M, Castellazzi A, Borsari A, Dellaglio F, Torriani S, 2007. The effects of fermented milks with simple and complex probiotic mixtures on the intestinal microbiota and immune response of healthy adults and children. *International Dairy Journal*, 17, 1332-1343.

ID 2955: “Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG-P 17224) and Streptococcus thermophilus 9Y/CSL (LMG-P 17225)” and “Lactose digestion”

- 1 Bianchi Salvadori B, Camaschella P, Bazzigaluppi E, 1984. Distribution and adherence of *Lactobacillus bulgaricus* in the gastroenteric tract of germ free-animals. *Milchwissenschaft*, 39, 387-391.
- 2 Bottazzi V, 1987. Aggiornamento di microbiologia dei batteri lattici. Centro Sperimentale del Latte S.p.A., Milano.
- 3 Campieri M, 1999. Clinical trial for a comparative versus placebo evaluation of efficacy and tolerability of a new product (VSL3 Forte) in subjects affected by diarrhoeic syndrome of various origin. University of Bologna.
- 4 De Simone C, Famularo G, Birillo E, Vesely R, Bianchi Salvadori B, Santini G, 1995. Rethinking the role of probiotics for the prevention and treatment of enteropathies. In: *Prospects of Use in Opportunistic Infections*. Old Herborn University Seminar Monograph. Fuller R, Heidt PJ, Rusch V, Van DerWaaaj D (eds.). 67-80.
- 5 De Simone C, Famularo G, Bianchi Salvadori B, Vesely R, 1998. Prospettive terapeutiche dei batteri lattici - Teoria e applicazioni nel dismicrobismo intestinale. Piccin Nuova Libreria S.p.A., Padova.
- 6 Ecuba P, Zambrini AV, Camaschella P, Cislaghi S, Pannone P, Di Martino L, Pettoello M, Guandalini S, 1992. Valutazione dell'uso dello yogurt nel malassorbimento di lattosio in età pediatrica. *Riv Ital Pediatr*, 18, 254-259.
- 7 EFFCA (European food and feed cultures association), Inventory of Microorganisms with a documented history of use in food, http://www.effca.com/anglais/pages/statique/11_list_of_microorg.htm.
- 8 Faustini M, Bianchi Salvadori B, Giardini A, Vesely R, Maffeo G, Russo V, 1994. Valutazione della sicurezza di una miscela di batteri probiotici nel ratto. *Cibus*, 8, 1-9.
- 9 Naidu AS, Bidlack WR, Clemens RA, 1999. Probiotic spectra of lactic acid bacteria (LAB). *Crit Rev Food Sci Nutr*, 39, 13-126.
- 10 Ouwehand AC, Bianchi Salvadori B, Fonden R, Mogensen G, Salminen S, Sellars R, 2003. Health effects of probiotics and culture-containing dairy products in humans. *Bulletin- International Dairy Federation*, 4-19.
- 11 Roberfroid MB, 2000. Prebiotics and probiotics: are they functional foods? *Am J Clin Nutr*, 71, 1682S-1687S; discussion 1688S-1690S.

ID 2956: “Lactobacillus gasseri P 17632” and “Benessere generale del tratto gastro-intestinale”

- 1 BCCM-LMG (Belgian Co-ordinated Collections of Micro-organisms - Laboratorium voor Microbiologie), 1997. Identification of 3 bacterial isolates reported 29/01/97.
- 2 Dondi G, 2000. Use of agent active against Candida in the treatment of disorders of the oral and intestinal mucosa, United States Patent Application Publication US2004/0043011A1.
- 3 Dondi G, 2000. Method for the selection of adhesive lactobacilli strains having therapeutical properties and strains obtained by said method, European Patent EP1046713, European Patent Office.
- 4 Dondi G and Morelli L, 2002. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures, United States Patent 6,342,366 B1.
- 5 Dondi G, 2007. Use of agent active against Candida in the treatment of disorders of the oral and intestinal mucosa, European Patent 1339419 B1, European Patent Office.
- 6 Lattobacilli ad usoetc. Università degli Studi del Piemonte Orientale.
- 7 Morelli L, 1997. Microbiological analysis of 6 strains of lactobacillus for a patent deposit. Università Cattolica del sacro Cuore di Piacenza.
- 8 Pietronave S, Bonetti A, Martinotti MG, 2003. Caratterizzazione delle proprietà probiotiche di alcuni ceppi del genere Lactobacillus spp. Atti del 5° Congresso Federazione Italiana Scienze della Vita (FISV), Rimini, 168.
- 9 Pietronave. S, Malfa P, Martinotti M, 2004. Lactobacillus gasseri P 17632: a potencial probiotic strain. Atti del 6° Congresso Federazione Italiana Scienze della Vita (FISV), Riva del Garda, 473.
- 10 Proge Farm, 1997. Identification of 3 bacterial isolates Report 29/01/1997.

ID 2957: “Lactobacillus gasseri P 18137” and “Benessere della microflora vaginale”

- 1 Lattobacilli ad usoetc. Università degli Studi del Piemonte Orientale.
- 2 Dondi G and Morelli L, 1998. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures, European Patent 0949330A3.
- 3 Dondi G and Morelli L, 2002. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures, United States Patent 6,342,366 B1.
- 4 Pietronave S, Bonetti A, Martinotti MG, 2003. Caratterizzazione delle proprietà probiotiche di alcuni ceppi del genere Lactobacillus spp. Atti del 5° Congresso Federazione Italiana Scienze della Vita (FISV), Rimini, 168.

ID 2958: “Lactobacillus gasseri P 18137” and “Benessere generale del tratto gastro-intestinale”

- 1 Lattobacilli ad usoetc. Università degli Studi del Piemonte Orientale.
- 2 BCCM-LMG (Belgian Co-ordinated Collections of Micro-organisms - Laboratorium voor Microbiologie), 1998. Determination of carbohydrate fermentation pattern.
- 3 Dondi G and Morelli L, 1998. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures, European Patent 0949330A3.

- 4 Dondi G and Morelli L, 2002. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures, United States Patent 6342366.
- 5 Pietronave S, Bonetti A, Martinotti MG, 2003. Caratterizzazione delle proprietà probiotiche di alcuni ceppi del genere *Lactobacillus* spp. Atti del 5° Congresso Federazione Italiana Scienze della Vita (FISV), Rimini, 168.

ID 2959: “*Lactobacillus paracasei* B21060” and “Funzione intestinale”

- 1 Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, Federico A, Chilovi F, Milandri GL, De Bona M, Cavenati S, Gullini S, Abbiati R, Garbagna N, Cerutti R, Grossi E, 2008. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. *J Clin Gastroenterol*, 42 Suppl 3 Pt 2, S218-223.
- 2 Drago L, Gismondo MR, Lombardi A, de Haen C, Gozzini L, 1997. Inhibition of in vitro growth of enteropathogens by new *Lactobacillus* isolates of human intestinal origin. *FEMS Microbiol Lett*, 153, 455-463.
- 3 Federico A, Tuccillo C, Grossi E, Abbiati R, Garbagna N, Salerno R, Mucherino C, Tiso A, Romano M, Del Vecchio Blanco C, Loguercio C, 2007. The role of a synbiotic (FLORTEC, Bracco SpA, Italy) on the plasma levels and peripheral blood mononuclear cell expression of cytokines in patients with ulcerative colitis: a pilot study. 4th Probiotics and Prebiotics New Foods jointly with XXX International Congress on Microbial Ecology and Disease (SOMED), Rome.
- 4 Morelli L, Cesena C, de Haen C, Gozzini L, 1998. Taxonomic *Lactobacillus* Composition of Feces from Human Newborns during the First Few Days. *Microb Ecol*, 35, 205-212.
- 5 Morelli L, Zonenschain D, Callegari ML, Grossi E, Maisano F, Fusillo M, 2003. Assessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous flora. *Nutr J*, 2, 11.
- 6 Morelli L, Garbagna N, Rizzello F, Zonenschain D, Grossi E, 2006. In vivo association to human colon of *Lactobacillus paracasei* B21060: map from biopsies. *Dig Liver Dis*, 38, 894-898.
- 7 Peluso I, Fina D, Caruso R, Stolfi C, Caprioli F, Fantini MC, Caspani G, Grossi E, Di Iorio L, Paone FM, Pallone F, Monteleone G, 2007. *Lactobacillus paracasei* subsp. *paracasei* B21060 suppresses human T-cell proliferation. *Infect Immun*, 75, 1730-1737.

ID 2960: “*Lactobacillus paracasei* CNCM I 1687” and “Supports your natural (immune) defence system by increasing the IL-10 production and enhancing NK cell activity in peripheral blood mononuclear cells (PBMC). Necessary to maintain the natural defences/helps to maintain a balanced immune system (increasing the IL-10 production and enhancing NK cell activity)”

- 1 Castellazzi A, 2007. Studio in vitro sulle proprietà immunomodulanti del ceppo batterico *Lactobacillus paracasei* I 1687. Final report.

ID 2961: “*Lactobacillus paracasei* CNCM I 1687” and “Is a probiotic; contributes to a healthy digestive system by supporting the gut flora through an increased number of positive lactobacillus in the intestine; useful to maintain an healthy intestinal flora adhering to the mucosa; improves intestinal barrier function by competition (steric encumbrance) against pathogens; reduces gastro-intestinal discomfort; necessary to maintain a healthy digestive system by production of specific enzymes (e.g. beta-galactosidase)”

- 1 Morelli L, 1996. Identification of two strains of *Lactobacillus* for a patent deposit. Final Report.
- 2 Morelli L, 1997. Microbiological analysis of 6 strains of *Lactobacillus* for a patent deposit. Final Report.

- 3 Pedraglio G, 2004. Novel lactobacilli strains useful in the treatment of disorders of the gastrointestinal system, 0861905B1, Office EP.

ID 2962: “Lactobacillus paracasei I1688” and “Rinforzo delle difese naturali”

- 1 Castellazzi A, Avanzini MA, Oliveri M, Valsecchi C, Malfa P, Marseglia G, 2006. "In vitro" and "in Vivo" immunomodulant activity of PSMIX (Lactobacillus paracasei I 1688 and Lactobacillus salivarius I 1794). Poster at the 6th Annual Meeting of the Federation of Clinical Immunology Societies, San Francisco.
- 2 Castellazzi AM, 2007. Final report on Florilac Trial. University of Pavia.
- 3 Castellazzi AM, Valsecchi C, Montagna L, Malfa P, Ciprandi G, Avanzini MA, Marseglia GL, 2007. In vitro activation of mononuclear cells by two probiotics: Lactobacillus paracasei I 1688, Lactobacillus salivarius I 1794, and their mixture (PSMIX). Immunological Investigations, 36, 413-421.
- 4 Dondi G and Malfa P, 2007. Use of Specific Lactic Bacteria for the Preparation of Immunomodulating Compositions, WO/2007/015132.

ID 2963: “Lactobacillus paracasei I1688” and “Benessere generale del tratto gastro-intestinale”

- 1 Bonetti A, 2002. Assessment of the persistence in the human intestinal tract of two probiotic lactobacilli Lactobacillus salivarius I 1794 and Lactobacillus paracasei I 1688. Microbial Ecology in Health and Disease, 14, 229-233.
- 2 Morelli L, 1996. Identification of two strains of lactobacillus for a patent deposit.
- 3 Morelli L, 1997. Microbiological analysis of 6 strains of lactobacillus for a patent deposit. Università Cattolica del sacro Cuore di Piacenza.
- 4 Pedraglio G, 2004. Novel lactobacilli strains useful in the treatment of disorders of the gastrointestinal system, European Patent EP0861905, European Patent Office.

ID 2964: “Lactobacillus paracasei LMG P-22043” and “Intestinal flora”

- 1 Lavermicocca P, Valerio F, Lonigro SL, De Angelis M, Morelli L, Callegari ML, Rizzello CG, Visconti A, 2005. Study of adhesion and survival of lactobacilli and bifidobacteria on table olives with the aim of formulating a new probiotic food. Appl Environ Microbiol, 71, 4233-4240.
- 2 Lavermicocca P, 2006. Highlights on new food research. Dig Liver Dis, 38 Suppl 2, S295-299.
- 3 Lavermicocca P, Valerio F, Lonigro SL, Di Leo A, Visconti A, 2008. Antagonistic activity of potential probiotic Lactobacilli against the ureolytic pathogen Yersinia enterocolitica. Curr Microbiol, 56, 175-181.
- 4 Ministero della Salute, 2007. Oggetto: Arricchimento con probiotici di prodotti orticoli - su richiesta della Copaim. (Lettera del 23/05/2007).
- 5 Valerio F, De Bellis P, Lonigro SL, Morelli L, Visconti A, Lavermicocca P, 2006. In vitro and in vivo survival and transit tolerance of potentially probiotic strains carried by artichokes in the gastrointestinal tract. Appl Environ Microbiol, 72, 3042-3045.

ID 2965: “Lactobacillus plantarum LP 01 (LMG P-21021)” and “Microflora / intestinal transit”

- 1 Del Piano M, Montino F, Carmagnola S, Anderloni A, Orsello M, Garelo E, Sforza F, Ballare M, 2005. The use of probiotics in the treatment of constipation in the elderly. Cibus, 1, 23-30.

ID 2966: “Lactobacillus plantarum P 17630” and “Benessere del tratto intestinale”

- 1 BCCM-LMG (Belgian Co-ordinated Collections of Micro-organisms - Laboratorium voor Microbiologie), 1997. Identification of 3 bacterial isolates reported 29/01/97.
- 2 Dho G, Marchese A, Debbia E, 2003. Caratteristiche microbiologiche di Lactobacillus Plantarum P17630 contenuto in un preparato probiotico per uso vaginale. Giornale Italiano di Microbiologia Medica Odontoiatrica e Clinica, 7, 102-108.
- 3 Dondi G and It P, 1999. Method for the selection of adhesive lactobacilli strains having therapeutical properties and strains obtained by said method, European Patent EP 1046713A2, European Patent Office.
- 4 Morelli L, 1997. Microbiological analysis of 6 strains of lactobacillus for a patent deposit. Università Cattolica del sacro Cuore di Piacenza.
- 5 Morelli L, 2000. Microbiological characteristics of Lactobacillus Plantarum P17630 contained in vaginal suppositories. Università Cattolica del sacro Cuore di Piacenza.
- 6 Pietronave S, Bonetti A, Martinotti MG, 2003. Caratterizzazione delle proprietà probiotiche di alcuni ceppi del genere Lactobacillus spp. Atti del 5° Congresso Federazione Italiana Scienze della Vita (FISV), Rimini, 168.

ID 2967: “Lactobacillus plantarum P 17630” and “Benessere della microflora vaginale”

- 1 Bonetti A, Morelli L, Campominosi E, Ganora E, Sforza F, 2003. Adherence of Lactobacillus plantarum P 17630 in soft-gel capsule formulation versus Doderlein's bacillus in tablet formulation to vaginal epithelial cells. Minerva Ginecol, 55, 279-284, 284-277.
- 2 Carriero C, Lezzi V, Mancini T, Selvaggi L, 2007. Vaginal capsules of Lactobacillus plantarum P 17630 for prevention of relapse of candida vulvovaginitis: an Italian multicentre observational study. Int. J. Probiotics and Prebiotics, 2, 155-162.
- 3 Culici M, Dal Sasso M, Braga P, 2004. L'adesione del Lactobacillus plantarum P 17630 alle cellule vaginali inibisce l'adesività della Candida albicans. Giornale Italiano di Microbiologia Medica Odontoiatrica e Clinica, 8, 34-41.
- 4 Dondi G and It P, 1999. Method for the selection of adhesive lactobacilli strains having therapeutical properties and strains obtained by said method, European Patent EP 1046713A2, European Patent Office.
- 5 Escorsell J, 2007. Lactobacillus plantarum P 17630: Eficacia y tolerabilidad en el tratamiento y la prevención de la vaginitis recurrente. Drugs of Today, 43 (supl. 5), 1-14.
- 6 Nava S, Garone GP, Colombo D, Mongelli L, 2002. Considerazioni sull'impiego del Lactobacillus plantarum P17630 nella patologia vaginale su base infettivo-infiammatoria. Riv. Ostetr. Ginecol. Pratica e Med. Perin, 17, 14-19.

ID 2968: “Lactobacillus rhamnosus” and “Promotes the well being of the intestin improving skin, scalp and hair health.”

No references provided.

ID 2969: “Lactobacillus rhamnosus LR 04 (DSM 16605)” and “Microflora / intestinal transit”

- 1 Dezi A, Carmagnola S, Ballarè M, Orsello M, Del Piano M, Capurso L, 2004. Probiotics and chronic diarrhoea in the elderly. Cibus, 8, 58-64.

ID 2970: “Lactobacillus salivarius I1794” and “Benessere generale del tratto gastro-intestinale”

- 1 Bonetti A, 2002. Assessment of the persistence in the human intestinal tract of two probiotic lactobacilli Lactobacillus salivarius I 1794 and Lactobacillus paracasei I 1688. *Microbial Ecology in Health and Disease*, 14, 229-233.
- 2 Dondi G, 2000. Use of agents active against Candida in the treatment of disorders of the oral and intestinal mucosa, United States Patent Application Publication US2004/0043011A1.
- 3 Dondi G, 2007. Use of agents active against Candida in the treatment of disorders of the oral and intestinal mucosa, European Patent EP1339419B1.
- 4 Morelli L, 1996. Identification of two strains of lactobacillus for a patent deposit. Università Cattolica del sacro Cuore di Piacenza.
- 5 Morelli L, 1997. Microbiological analysis of 6 strains of lactobacillus for a patent deposit. Università Cattolica del sacro Cuore di Piacenza.
- 6 Pedraglio G, 2004. Novel lactobacilli strains useful in the treatment of disorders of the gastrointestinal system, European Patent EP 0861905, European Patent Office.

ID 2971: “Lactobacillus salivarius I1794” and “Rinforzo delle difese naturali”

- 1 Castellazzi A, Avanzini MA, Oliveri M, Valsecchi C, Malfa P, Marseglia G, 2006. "In vitro" and "in vivo" immunomodulant activity of PSMIX (Lactobacillus paracasei I 1688 and Lactobacillus salivarius I 1794). Poster at the 6th Annual Meeting of the Federation of Clinical Immunology Societies, San Francisco.
- 2 Castellazzi A, 2007. Final report on Florilac Trial. University of Pavia.
- 3 Castellazzi AM, Valsecchi C, Montagna L, Malfa P, Ciprandi G, Avanzini MA, Marseglia GL, 2007. In vitro activation of mononuclear cells by two probiotics: Lactobacillus paracasei I 1688, Lactobacillus salivarius I 1794, and their mixture (PSMIX). *Immunological Investigations*, 36, 413-421.
- 4 Dondi G and Malfa P, 2007. Use of Specific Lactic Bacteria for the Preparation of Immunomodulating Compositions, WO/2007/015132.

ID 2972: “PSMIX®, miscela di Lactobacillus paracasei I1688 e Lactobacillus salivarius I1794” and “Benessere generale del tratto gastro-intestinale”

- 1 Bonetti A, 2002. Assessment of the persistence in the human intestinal tract of two probiotic lactobacilli Lactobacillus salivarius I 1794 and Lactobacillus paracasei I 1688. *Microbial Ecology in Health and Disease*, 14, 229-233.
- 2 Dondi G, 2000. Use of agents active against Candida in the treatment of disorders of the oral and intestinal mucosa, United States Patent Application Publication US2004/0043011A1.
- 3 Dondi G, 2007. Use of agents active against Candida in the treatment of disorders of the oral and intestinal mucosa, European Patent EP1339419B1.
- 4 Morelli L, 1996. Identification of two strains of lactobacillus for a patent deposit. Università Cattolica del sacro Cuore di Piacenza.
- 5 Morelli L, 1997. Microbiological analysis of 6 strains of lactobacillus for a patent deposit. Università Cattolica del sacro Cuore di Piacenza.
- 6 Pedraglio G, 2004. Novel lactobacilli strains useful in the treatment of disorders of the gastrointestinal system, European Patent EP 0861905, European Patent Office.

ID 2973: “PSMIX®, miscela di Lactobacillus paracasei I1688 e Lactobacillus salivarius I1794” and “Rinforzo delle difese naturali”

- 1 Castellazzi A, Avanzini MA, Oliveri M, Valsecchi C, Malfa P, Marseglia G, 2006. "In vitro" and "in vivo" immunomodulant activity of PSMIX (Lactobacillus paracasei I 1688 and Lactobacillus salivarius I 1794). Poster at the 6th Annual Meeting of the Federation of Clinical Immunology Societies, San Francisco.
- 2 Castellazzi A, 2007. Final report on Florilac Trial. University of Pavia.
- 3 Castellazzi AM, Valsecchi C, Montagna L, Malfa P, Ciprandi G, Avanzini MA, Marseglia GL, 2007. In vitro activation of mononuclear cells by two probiotics: Lactobacillus paracasei I 1688, Lactobacillus salivarius I 1794, and their mixture (PSMIX). Immunological Investigations, 36, 413-421.
- 4 Dondi G and Malfa P, 2007. Use of Specific Lactic Bacteria for the Preparation of Immunomodulating Compositions, WO/2007/015132.

ID 2974: “Streptococcus thermophilus LMG P 18807” and “Is a probiotic contributes to a healthy digestive system by supporting the gut flora through an increased number of positive lactobacillus in the intestine; useful to maintain a healthy intestinal flora adhering to the mucosa; improves intestinal barrier function by competition (steric encumbrance) against pathogens; reduces gastro-intestinal discomfort; necessary to maintain a healthy digestive system by production of specific enzymes (e.g. beta-galactosidase)”

- 1 BCCM-LMG (Belgian co-ordinated collections of micro-organisms - Laboratorium voor Microbiologie Universiteit Gent), 1999. Determination of carbohydrate fermentation pattern SDS-PAGE protein profiling report 4/2/1999.
- 2 Dondi G and It P, 1999. Method for the selection of adhesive lactobacilli strains having therapeutical properties and strains obtained by said method, European Patent EP 1046713A2, European Patent Office.
- 3 Elli M, Callegari ML, Ferrari S, Bessi E, Cattivelli D, Soldi S, Morelli L, Goupil Feuillerat N, Antoine JM, 2006. Survival of yogurt bacteria in the human gut. Appl Environ Microbiol, 72, 5113-5117.

ID 2975: “Streptococcus thermophilus LMG P 18807” and “Increases the immune defences/response by reducing the CD34+ cells. As recommended by PASSCLAIM, the functional capacity of the immune system has been assessed by: - measuring specific cell function in vivo e.g. production of cytokines or response to antigens - determining the incidence and severity of infection. Necessary to maintain the natural defences/helps to maintain a balanced immune system (reducing the CD34+ cells)”

- 1 Mastrandrea F, Coradduzza G, Serio G, Minardi A, Manelli M, Ardito S, Muratore L, 2004. Probiotics reduce the CD34+ hemopoietic precursor cell increased traffic in allergic subjects. Eur Ann Allergy Clin Immunol, 36, 118-122.

ID 2976: “Yoghurt cultures (live)” and “Lactose digestion”

- 1 Adolfsson O, Meydani SN, Russell RM, 2004. Yogurt and gut function. Am J Clin Nutr, 80, 245-256.
- 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2005. Effets des probiotiques et prébiotiques sur la flore et l'immunité de l'homme adulte (Effects of probiotics and prebiotics on flora and immunity in adults).
- 3 Conway PL, Gorbach SL, Goldin BR, 1987. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci, 70, 1-12.
- 4 de Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir J, 2001. Probiotics--compensation for lactase insufficiency. Am J Clin Nutr, 73, 421S-429S.

- 5 Dewit O, Pochart P, Desjeux JF, 1988. Breath hydrogen concentration and plasma glucose, insulin and free fatty acid levels after lactose, milk, fresh or heated yogurt ingestion by healthy young adults with or without lactose malabsorption. *Nutrition*, 4, 131-135.
- 6 DGCCRF (Direction Générale de la Concurrence de la Consommation et de la Répression des Fraudes), 2005. Allegations "ferments lactiques vivants du yaourt / digestion du lactose" (Claims "live ferments of yoghurt / lactose digestion").
- 7 Drouault S, Corthier G, Ehrlich SD, Renault P, 1999. Survival, physiology, and lysis of *Lactococcus lactis* in the digestive tract. *Appl Environ Microbiol*, 65, 4881-4886.
- 8 Drouault S, Anba J, Corthier G, 2002. *Streptococcus thermophilus* is able to produce a beta-galactosidase active during its transit in the digestive tract of germ-free mice. *Appl Environ Microbiol*, 68, 938-941.
- 9 Greenberg NA and Mahoney RR, 1982. Production and Characterization of β -Galactosidase from *Streptococcus thermophilus*. *Journal of Food Science*, 47, 1824 - 1835.
- 10 Guarner F, Perdigon G, Corthier G, Salminen S, Koletzko B, Morelli L, 2005. Should yoghurt cultures be considered probiotic? *Br J Nutr*, 93, 783-786.
- 11 Klaenhammer TR and Kullen MJ, 1999. Selection and design of probiotics. *Int J Food Microbiol*, 50, 45-57.
- 12 Kolars JC, Levitt MD, Aouji M, Savaiano DA, 1984. Yogurt--an autodigesting source of lactose. *N Engl J Med*, 310, 1-3.
- 13 Lerebours E, N'Djitoyap Ndam C, Lavoine A, Hellot MF, Antoine JM, Colin R, 1989. Yogurt and fermented-then-pasteurized milk: effects of short-term and long-term ingestion on lactose absorption and mucosal lactase activity in lactase-deficient subjects. *Am J Clin Nutr*, 49, 823-827.
- 14 Lin MY, Yen CL, Chen SH, 1998. Management of lactose maldigestion by consuming milk containing lactobacilli. *Dig Dis Sci*, 43, 133-137.
- 15 Marteau P, Flourie B, Pochart P, Chastang C, Desjeux JF, Rambaud JC, 1990. Effect of the microbial lactase (EC 3.2.1.23) activity in yoghurt on the intestinal absorption of lactose: an in vivo study in lactase-deficient humans. *Br J Nutr*, 64, 71-79.
- 16 Martini MC, Bollweg GL, Levitt MD, Savaiano DA, 1987. Lactose digestion by yogurt beta-galactosidase: influence of pH and microbial cell integrity. *Am J Clin Nutr*, 45, 432-436.
- 17 Martini MC, Lerebours EC, Lin WJ, Harlander SK, Berrada NM, Antoine JM, Savaiano DA, 1991. Strains and species of lactic acid bacteria in fermented milks (yogurts): effect on in vivo lactose digestion. *Am J Clin Nutr*, 54, 1041-1046.
- 18 Mater DD, Bretigny L, Firmesse O, Flores MJ, Mogenet A, Bresson JL, Corthier G, 2005. *Streptococcus thermophilus* and *Lactobacillus delbrueckii* subsp. *bulgaricus* survive gastrointestinal transit of healthy volunteers consuming yogurt. *FEMS Microbiol Lett*, 250, 185-187.
- 19 Montes RG, Bayless TM, Saavedra JM, Perman JA, 1995. Effect of milks inoculated with *Lactobacillus acidophilus* or a yogurt starter culture in lactose-maldigesting children. *J Dairy Sci*, 78, 1657-1664.
- 20 Newcomer AD, Park HS, O'Brien PC, McGill DB, 1983. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. *Am J Clin Nutr*, 38, 257-263.
- 21 Onwulata CI, Rao DR, Vankineni P, 1989. Relative efficiency of yogurt, sweet acidophilus milk, hydrolyzed-lactose milk, and a commercial lactase tablet in alleviating lactose maldigestion. *Am J Clin Nutr*, 49, 1233-1237.
- 22 Payne DL, Welsh JD, Manion CV, Tsegaye A, Herd LD, 1981. Effectiveness of milk products in dietary management of lactose malabsorption. *Am J Clin Nutr*, 34, 2711-2715.
- 23 Pelletier X, Laure-Boussuge S, Donazzolo Y, 2001. Hydrogen excretion upon ingestion of dairy products in lactose-intolerant male subjects: importance of the live flora. *Eur J Clin Nutr*, 55, 509-512.
- 24 Piaia M, Antoine J, Mateos-guardia J, Leplingard A, Lenoir-wijnkoop I, 2003. Assessment of the benefits of live yogurt: methods and markers for in vivo studies of the physiological effects of yogurt cultures (+

Commentaries in the same issue: Yoghurt – Dead or alive?). *Microbial Ecology in Health and Disease*, 15, 79-87.

- 25 Pochart P, Bisetti N, Bourlioux P, Desjeux JF, 1989. Effect of daily consumption of fresh or pasteurized yoghurt on intestinal lactose utilisation in lactose malabsorbers. *Microecol Ther*, 18, 105–110.
- 26 Rizkalla SW, Luo J, Kabir M, Chevalier A, Pacher N, Slama G, 2000. Chronic consumption of fresh but not heated yogurt improves breath-hydrogen status and short-chain fatty acid profiles: a controlled study in healthy men with or without lactose maldigestion. *Am J Clin Nutr*, 72, 1474-1479.
- 27 Rosado JL, Solomons NW, Allen LH, 1992. Lactose digestion from unmodified, low-fat and lactose-hydrolyzed yogurt in adult lactose-maldigesters. *Eur J Clin Nutr*, 46, 61-67.
- 28 Saltzman JR, Russell RM, Golner B, Barakat S, Dallal GE, Goldin BR, 1999. A randomized trial of *Lactobacillus acidophilus* BG2FO4 to treat lactose intolerance. *Am J Clin Nutr*, 69, 140-146.
- 29 Shermak MA, Saavedra JM, Jackson TL, Huang SS, Bayless TM, Perman JA, 1995. Effect of yogurt on symptoms and kinetics of hydrogen production in lactose-malabsorbing children. *Am J Clin Nutr*, 62, 1003-1006.
- 30 Speck ML and Geoffrion JW, 1980. Lactase and starter culture survival in heated and frozen yogurts. *J. Food Prot*, 1, 26-29.
- 31 Varela-Moreiras G, Antoine JM, Ruiz-Roso B, Varela G, 1992. Effects of yogurt and fermented-then-pasteurized milk on lactose absorption in an institutionalized elderly group. *J Am Coll Nutr*, 11, 168-171.

ID 2977: “Probiotic strain: *Lactobacillus salivarius* W24” and “Intestinal microbiota”

- 1 Coomans M, Hazen M, Jonkers D, Maes J, Stobberingh E, 2002. De invloed van een probioticum versus een placebo op de fecale flora. External report, University of Maastricht, Dept of Medical Microbiology.
- 2 Koning C, Jonkers D, Stobberingh E, Stockbrugger R, 2005. The effect of a multispecies probiotic on the intestinal flora and bowel habits in healthy volunteers treated with amoxicillin. *European Journal of Gastroenterology & Hepatology*, 17, A62.
- 3 Koning CJM, Jonkers DMAE, Stobberingh EE, Smidt H, Stockbrügger RW, 2005. The effect of a multispecies probiotic on the composition of the dominant faecal flora in healthy volunteers treated with amoxicillin. *Gut* 54 (suppl VII), A234.
- 4 Koning CJM, Jonkers D, Stobberingh EE, Mulder L, Rombouts FM, Stockbrügger RW, 2007. The Effect of a Multispecies Probiotic on the Intestinal Microbiota and Bowel Movements in Healthy Volunteers Taking the Antibiotic Amoxicillin. *Am J Gastroenterol*, 10, 1-12.
- 5 Kuipers M, Timmerman H, Willems R, Rijkers GT, Wamel WJBv, 2006. Selected probiotic bacteria disrupt biofilm development of vancomycin-resistant *Enterococcus faecium*. Abstracts of an international conference: Biofilms II: Attachment and detachment in pure and mixed cultures, Leipzig.
- 6 Mulder L, 2007. In vitro inhibition of *Candida* sp. by *L. salivarius* W24. Internal report, Winlove Bio Industries, Amsterdam, The Netherlands.
- 7 Mulder L, 2007. In vitro inhibition of several potential pathogenic bacteria by *L.salivarius* W24. Internal report, Winlove Bio Industries, Amsterdam, The Netherlands.
- 8 Mulder L, 2007. Production of hydrogen peroxide by *L.salivarius* W24. Internal report, Winlove Bio Industries, Amsterdam, The Netherlands.
- 9 No authors listed, 2004. Survival of bifidobacteria in the GI tract. External report. Wageningen University, Molecular Ecology Group.
- 10 No authors listed, 2007. In vitro inhibition of *Clostridium difficile* ribotype 027 by *L.salivarius* W24. Internal report, Winlove Bio Industries, Amsterdam, The Netherlands.

- 11 Ridwan BU, Koning CJM, Besselink MGH, Timmerman HM, Brouwer EC, Verhoef J, Gooszen HG, Akkermans LMA, 2008. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. *Lett Appl Microbiol*, 46, 61-67.
- 12 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.
- 13 van Bindsbergen L, Ridwan BU, Besselink MGH, Timmerman HM, Verhoef J, Gooszen HG, Akkermans LMA, 2005. Can probiotics inhibit the growth of antibiotic resistant micro-organisms? In-vitro study. Najaarsvergadering Nederlandse En Vlaamse Verenigingen Voor Gastroenterologie, Nederlandse Vereniging Voor Hepatologie, Nederlandse Vereniging Voor Gastrointestinale Chirurgie, Nederlands Genootschap Van Maag-Darm-Leverartsen, Veldhoven.

ID 2978: “Probiotic strain: *Lactobacillus salivarius* W24” and “Beneficially affects the oral ecology measured by increased numbers of positive lactobacilli in the oral microbiota”

- 1 Caglar E, Kargul B, Tanboga I, 2005. Bacteriotherapy and probiotics' role on oral health. *Oral Dis*, 11, 131-137.
- 2 Koll-Klais P, Mandar R, Leibur E, Marcotte H, Hammarstrom L, Mikelsaar M, 2005. Oral lactobacilli in chronic periodontitis and periodontal health: species composition and antimicrobial activity. *Oral Microbiol Immunol*, 20, 354-361.
- 3 Kuipers MI, 2007. The effect of probiotics on the growth and development of saliva biofilms. Internal report.
- 4 Meurman JH, 2005. Probiotics: do they have a role in oral medicine and dentistry? *Eur J Oral Sci*, 113, 188-196.
- 5 Zaura E, Buijs MJ, Kuipers MI, Crielaard W, ten Cate JM, Effects of probiotics on dental plaque ecology. (CONFIDENTIAL).

ID 2979: “Probiotic strain: *Lactobacillus salivarius* W24” and “Gut barrier function”

- 1 Koning C, Jonkers D, Stobberingh E, Out T, Stockbrugger R, 2007. Amoxycillin and multispecies probiotic intake affect cytokine production in healthy volunteers. *Gastroenterology*, 132 (Suppl2), A209.
- 2 Lutgendorff F, van Minnen L, Timmerman H, Gooszen H, Akermans L, 2006. Prophylactic probiotics reduce bacterial translocation in experimental pancreatitis. *European Journal of Gastroenterology & Hepatology*, 18, A2-A3.
- 3 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Rijkers GT, Timmerman HM, Gooszen HG, Akkermans LMA, Söderholm JD, 2007. Probiotics reduce mucosal barrier failure in the early phase of acute pancreatitis.
- 4 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Timmerman HM, Gooszen HG, Akkermans LMA, JD S, 2007. Prophylactic probiotics reduce intestinal permeability in early phase experimental pancreatitis.
- 5 Niers LE, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NO, Knol EF, Kapsenberg ML, Kimpen JL, Hoekstra MO, 2005. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. *Clin Exp Allergy*, 35, 1481-1489.
- 6 Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, Kimpen JL, Rijkers GT, 2007. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. *Clin Exp Immunol*, 149, 344-352.
- 7 Timmerman HM, 2006. Multispecies probiotics - Composition and Functionality. Thesis, Utrecht University.

- 8 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.
- 9 van Minnen LP, 2006. Acute Pancreatitis: Surgery, Pathophysiology and probiotic prophylaxis. Thesis, Utrecht University.
- 10 van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, Smidt H, Visser MR, Rijkers GT, Gooszen HG, Akkermans LM, 2007. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. *Surgery*, 141, 470-480.

ID 2980: “Probiotic strain: *Lactobacillus salivarius* W24” and “Balances/supports the immune system measured by increased levels of regulatory cytokines and sIgA”

- 1 Koning CJM, Jonkers DMAE, Stobberingh EE, Out TA, Stockbrügger RW, 2005. The effect of a multispecies probiotic on components of the mucosal and systemic immune system in healthy volunteers treated with amoxicillin. *Gut*, 54 Suppl VII, A260.
- 2 Koning CJM, Jonkers D, Stobberingh E, Out T, Stockbrügger R, 2007. Amoxycillin and multispecies probiotic intake affect cytokine production. *Gastroenterology*, 132 Suppl 2, A209.
- 3 Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbrügger RW, 2008. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxicillin. *Am J Gastroenterol*, 103, 178-189.
- 4 Niers LE, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NO, Knol EF, Kapsenberg ML, Kimpen JL, Hoekstra MO, 2005. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. *Clin Exp Allergy*, 35, 1481-1489.
- 5 Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, Kimpen JL, Rijkers GT, 2007. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. *Clin Exp Immunol*, 149, 344-352.
- 6 Timmerman HM, 2006. Multispecies probiotics - Composition and Functionality. (Thesis), Utrecht University.
- 7 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.
- 8 Timmerman HM, van Minnen LP, de Jager W, Konstantinov SR, Lutgendorff F, Verheem A, Harmsen W, Visser MR, Smidt H, Gooszen HG, Akkermans LMA, Rijkers GT, 2007. The systemic cytokine response during experimental acute pancreatitis: impact of enteral probiotics Chapter 10 and 12.

ID 2981: “Probiotic strain: *Lactobacillus casei* W56” and “Intestinal microbiota”

- 1 Kuipers M, Timmerman H, Willems R, Rijkers GT, Wamel WJBv, 2006. Selected probiotic bacteria disrupt biofilm development of vancomycin-resistant *Enterococcus faecium*. Abstracts of an international conference: Biofilms II: Attachment and detachment in pure and mixed cultures, Leipzig.
- 2 Mulder L, 2007. Production of hydrogen peroxide by *L.salivarius* W24. Internal report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 3 Mulder L, 2007. In vitro inhibition of several potential pathogenic bacteria by *L.salivarius* W24. Internal report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 4 Ridwan BU, Koning CJM, Besselink MGH, Timmerman HM, Brouwer EC, Verhoef J, Gooszen HG, Akkermans LMA, 2008. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. *Lett Appl Microbiol*, 46, 61-67.

- 5 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.
- 6 van Bindsbergen L, Ridwan BU, Besselink MGH, Timmerman HM, Verhoef J, Gooszen HG, Akkermans LMA, 2005. Can probiotics inhibit the growth of antibiotic resistant micro-organisms? In-vitro study. Najaarsvergadering Nederlandse En Vlaamse Verenigingen Voor Gastroenterologie, Nederlandse Vereniging Voor Hepatologie, Nederlandse Vereniging Voor Gastrointestinale Chirurgie, Nederlands Genootschap Van Maag-Darm-Leverartsen, Veldhoven.

ID 2982: “Probiotic strain: *Lactobacillus casei* W58” and “Gut barrier function”

- 1 Lutgendorff F, van Minnen L, Timmerman H, Gooszen H, Akermans L, 2006. Prophylactic probiotics reduce bacterial translocation in experimental pancreatitis. *European Journal of Gastroenterology & Hepatology*, 18, A2-A3.
- 2 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Rijkers GT, Timmerman HM, Gooszen HG, Akkermans LMA, Söderholm JD, 2007. Probiotics reduce mucosal barrier failure in the early phase of acute pancreatitis.
- 3 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Timmerman HM, Gooszen HG, Akkermans LMA, JD S, 2007. Prophylactic probiotics reduce intestinal permeability in early phase experimental pancreatitis.
- 4 van Minnen LP, 2006. Acute Pancreatitis: Surgery, Pathophysiology and probiotic prophylaxis. Thesis, Utrecht University.
- 5 van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, Smidt H, Visser MR, Rijkers GT, Gooszen HG, Akkermans LM, 2007. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. *Surgery*, 141, 470-480.

ID 2983: “Probiotic strain: *Lactobacillus casei* W61” and “Balances/supports the immune system measured by increased levels of regulatory cytokines and sIgA”

- 1 Niers LE, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NO, Knol EF, Kapsenberg ML, Kimpen JL, Hoekstra MO, 2005. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. *Clin Exp Allergy*, 35, 1481-1489.
- 2 Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, Kimpen JL, Rijkers GT, 2007. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. *Clin Exp Immunol*, 149, 344-352.
- 3 Roll H, Rosler P, Lachtermann E, Jung K, 2000. Beeinflussung von sekretorischen IgA-Defiziten bei Sportstudenten durch Nahrungsergänzungsmittel. *Erfahrungsheilkunde*, 8, 489-494.
- 4 Timmerman HM, 2006. Multispecies probiotics - Composition and Functionality. (Thesis), Utrecht University.
- 5 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.

ID 2984: “Probiotic strain: *Lactococcus lactis* W58” and “Intestinal microbiota”

- 1 Beasley SS and Saris PEJ, 2004. Nisin-producing *Lactococcus lactis* strains isolated from human milk. *Am Soc Microbiol*, 70, 5051-5053.

- 2 Kuipers M, Timmerman H, Willems R, Rijkers GT, Wamel WJBv, 2006. Selected probiotic bacteria disrupt biofilm development of vancomycin-resistant *Enterococcus faecium*. Abstracts of an international conference: Biofilms II: Attachment and detachment in pure and mixed cultures, Leipzig.
- 3 Martin R, Heilig HG, Zoetendal EG, Jimenez E, Fernandez L, Smidt H, Rodriguez JM, 2007. Cultivation-independent assessment of the bacterial diversity of breast milk among healthy women. *Res Microbiol*, 158, 31-37.
- 4 Mulder L, 2007. In vitro inhibition of *Candida* sp. by *Lc. lactis* W58. Internal report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 5 Mulder L, 2007. In vitro inhibition of *Clostridium difficile* by *Lc. lactis* W58. Internal report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 6 Ridwan BU, Koning CJ, Besselink MG, Timmerman HM, Brouwer EC, Verhoef J, Gooszen HG, Akkermans LM, 2008. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. *Lett Appl Microbiol*, 46, 61-67.
- 7 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.
- 8 van Bindsbergen L, Ridwan BU, Besselink MGH, Timmerman HM, Verhoef J, Gooszen HG, Akkermans LMA, 2005. Can probiotics inhibit the growth of antibiotic resistant micro-organisms? In-vitro study. Najaarsvergadering Nederlandse En Vlaamse Verenigingen Voor Gastroenterologie, Nederlandse Vereniging Voor Hepatologie, Nederlandse Vereniging Voor Gastrointestinale Chirurgie, Nederlands Genootschap Van Maag-Darm-Leverartsen, Veldhoven.

ID 2985: “Probiotic strain: *Lactococcus lactis* W61” and “Gut barrier function”

- 1 Lutgendorff F, van Minnen L, Timmerman H, Gooszen H, Akermans L, 2006. Prophylactic probiotics reduce bacterial translocation in experimental pancreatitis. *European Journal of Gastroenterology & Hepatology*, 18, A2-A3.
- 2 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Rijkers GT, Timmerman HM, Gooszen HG, Akkermans LMA, Söderholm JD, 2007. Probiotics reduce mucosal barrier failure in the early phase of acute pancreatitis.
- 3 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Timmerman HM, Gooszen HG, Akkermans LMA, JD S, 2007. Prophylactic probiotics reduce intestinal permeability in early phase experimental pancreatitis.
- 4 Mulder L, 2007. The effect of probiotic strain *Lc. lactis* W58 on the transepithelial electrical resistance (TEER) of Caco-2 cells in the presence of *Salmonella*. Internal Report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 5 van Minnen LP, 2006. Acute Pancreatitis: Surgery, Pathophysiology and probiotic prophylaxis. Thesis, Utrecht University.
- 6 van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, Smidt H, Visser MR, Rijkers GT, Gooszen HG, Akkermans LM, 2007. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. *Surgery*, 141, 470-480.

ID 2986: “Probiotic strain: Lactococcus lactis W64” and “Balances/supports the immune system measured by increased levels of regulatory cytokines and sIgA”

- 1 Niers LE, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NO, Knol EF, Kapsenberg ML, Kimpen JL, Hoekstra MO, 2005. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. *Clin Exp Allergy*, 35, 1481-1489.
- 2 Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, Kimpen JL, Rijkers GT, 2007. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. *Clin Exp Immunol*, 149, 344-352.
- 3 Timmerman HM, 2006. Multispecies probiotics - Composition and Functionality. (Thesis), Utrecht University.
- 4 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.

ID 2987: “Probiotic strain: Bifidobacterium lactis W52 (Formerly known as Bifidobacterium infantis W52)” and “Intestinal microbiota”

- 1 Collins MD and Gibson GR, 1999. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. *Am J Clin Nutr*, 69, 1052S-1057S.
- 2 Coomans M, Hazen M, Jonkers D, Maes J, Stobberingh E, 2002. De invloed van een probioticum versus een placebo op de fecale flora. External report, University of Maastricht, Dept of Medical Microbiology.
- 3 Edwards CA and Parrett AM, 2002. Intestinal flora during the first months of life: new perspectives. *Br J Nutr*, 88 Suppl 1, S11-18.
- 4 Fanaro S, Chierici R, Guerrini P, Vigi V, 2003. Intestinal microflora in early infancy: composition and development. *Acta Paediatr Suppl*, 91, 48-55.
- 5 Kuipers M, Timmerman H, Willems R, Rijkers GT, Wamel WJBv, 2006. Selected probiotic bacteria disrupt biofilm development of vancomycin-resistant *Enterococcus faecium*. Abstracts of an international conference: Biofilms II: Attachment and detachment in pure and mixed cultures, Leipzig.
- 6 Mackie RI, Sghir A, Gaskins HR, 1999. Developmental microbial ecology of the neonatal gastrointestinal tract. *Am J Clin Nutr*, 69, 1035S-1045S.
- 7 Mountzouris KC, McCartney AL, Gibson GR, 2002. Intestinal microflora of human infants and current trends for its nutritional modulation. *Br J Nutr*, 87, 405-420.
- 8 No authors listed, 2004. Survival of bifidobacteria in the GI tract. External report. Wageningen University, Molecular Ecology Group.
- 9 Ridwan BU, Koning CJ, Besselink MG, Timmerman HM, Brouwer EC, Verhoef J, Gooszen HG, Akkermans LM, 2008. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. *Lett Appl Microbiol*, 46, 61-67.
- 10 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.
- 11 van Bindsbergen L, Ridwan BU, Besselink MGH, Timmerman HM, Verhoef J, Gooszen HG, Akkermans LMA, 2005. Can probiotics inhibit the growth of antibiotic resistant micro-organisms? In-vitro study. Najaarsvergadering Nederlandse En Vlaamse Verenigingen Voor Gastroenterologie, Nederlandse Vereniging Voor Hepatologie, Nederlandse Vereniging Voor Gastrointestinale Chirurgie, Nederlands Genootschap Van Maag-Darm-Leverartsen, Veldhoven.
- 12 van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, Smidt H, Visser MR, Rijkers GT, Gooszen HG, Akkermans LM, 2007. Modification of intestinal flora with

multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. *Surgery*, 141, 470-480.

ID 2988: “Probiotic strain: *Bifidobacterium lactis* W52 (Formerly known as *Bifidobacterium infantis* W52)” and “Gut barrier function”

- 1 Lutgendorff F, van Minnen L, Timmerman H, Gooszen H, Akermans L, 2006. Prophylactic probiotics reduce bacterial translocation in experimental pancreatitis. *European Journal of Gastroenterology & Hepatology*, 18, A2-A3.
- 2 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Rijkers GT, Timmerman HM, Gooszen HG, Akkermans LMA, Söderholm JD, 2007. Probiotics reduce mucosal barrier failure in the early phase of acute pancreatitis.
- 3 Lutgendorff F, Sandström PA, Trulsson LM, van Minnen LP, Timmerman HM, Gooszen HG, Akkermans LMA, JD S, 2007. Prophylactic probiotics reduce intestinal permeability in early phase experimental pancreatitis.
- 4 Mulder L, 2007. The effect of probiotic strain *Lc.lactis* W58 on the transepithelial electrical resistance (TEER) of Caco-2 cells in the presence of *Salmonella*. Internal Report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 5 van Minnen LP, 2006. Acute Pancreatitis: Surgery, Pathophysiology and probiotic prophylaxis. Thesis, Utrecht University.
- 6 van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, Smidt H, Visser MR, Rijkers GT, Gooszen HG, Akkermans LM, 2007. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. *Surgery*, 141, 470-480.

ID 2989: “Probiotic strain: *Bifidobacterium lactis* W52 (Formerly known as *Bifidobacterium infantis* W52)” and “Balances/supports the immune system measured by increased levels of regulatory cytokines”

- 1 Niers LE, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NO, Knol EF, Kapsenberg ML, Kimpfen JL, Hoekstra MO, 2005. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. *Clin Exp Allergy*, 35, 1481-1489.
- 2 Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, Kimpfen JL, Rijkers GT, 2007. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. *Clin Exp Immunol*, 149, 344-352.
- 3 Timmerman HM, 2006. Multispecies probiotics - Composition and Functionality. (Thesis), Utrecht University.
- 4 Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT, 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. *Clin Nutr*, 26, 450-459.
- 5 Timmerman HM, van Minnen LP, de Jager W, Konstantinov SR, Lutgendorff F, Verheem A, Harmsen W, Visser MR, Smidt H, Gooszen HG, Akkermans LMA, Rijkers GT, 2007. The systemic cytokine response during experimental acute pancreatitis: impact of enteral probiotics Chapter 10 and 12.

ID 2990: “Probiotic strain: Bifidobacterium lactis W52 (Formerly known as Bifidobacterium infantis W52)” and “Supports/maintains abdominal well-being and gastro-intestinal comfort measured by an improved intestinal passage”

- 1 Bekkali NL, Bongers ME, Van den Berg MM, Liem O, Benninga MA, 2007. The role of a probiotics mixture in the treatment of childhood constipation: a pilot study. *Nutr J*, 6, 17.

ID 2991: “Probiotic strain: Lactobacillus salivarius LS-33” and “Intestinal microbiota”

- 1 Daniel C, Poiret S, Goudercourt D, Dennin V, Leyer G, Pot B, 2006. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. *Appl Environ Microbiol*, 72, 5799-5805.
- 2 Engelbrektsen A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL, 2009. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. *J Med Microbiol*, 58, 663-670.
- 3 Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, Dewulf J, Brassart D, Mercenier A, Pot B, 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. *World J Gastroenterol*, 13, 236-243.
- 4 Foligne B, Zoumpopoulou G, Dewulf J, Ben Younes A, Chareyre F, Sirard JC, Pot B, Grangette C, 2007. A key role of dendritic cells in probiotic functionality. *PLoS ONE*, 2, e313.

ID 2992: Probiotic strain: “Bifidobacterium lactis BI-07 (Formerly known as Bifidobacterium infantis BI-07)” and “Promotes the restoration of the intestinal microbiota during and after antibiotic use measured by increased levels of bifidobacteria and reduced levels of non-beneficial bacteria in the intestine thereby improving a normal intestinal passage”

- 1 Engelbrektsen AL, Korzenik JR, Sanders ME, Clement BG, Leyer G, Klaenhammer TR, Kitts CL, 2006. Analysis of treatment effects on the microbial ecology of the human intestine. *FEMS Microbiol Ecol*, 57, 239-250.
- 2 Engelbrektsen A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL, 2009. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. *Journal of Medical Microbiology*, 58, 663.
- 3 Halpin-Dohnalek MI, Hilty MD, Bynum DG, 1999. Method and formula for the prevention of diarrhea 5902578 United States Patent Office.
- 4 Ruiz-Palacios GF, Guerrero M, Hilty M, et al, 1996. Feeding of a probiotic for the prevention of community acquired diarrhoea in young Mexican children. *Pediatr Res*, 39, 104.
- 5 Wagner RD, Pierson C, Warner T, Dohnalek M, Farmer J, Roberts L, Hilty M, Balish E, 1997. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. *Infect Immun*, 65, 4165-4172.

ID 2993: “Positively affects the immune response” and “Probiotic strain: Bifidobacterium lactis BI-07 (Formerly known as Bifidobacterium infantis BI-07)”

- 1 Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, Dewulf J, Brassart D, Mercenier A, Pot B, 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. *World J Gastroenterol*, 13, 236-243.

ID 2994: “Probiotic strain: Bifidobacterium lactis BI-04 (Formerly known as Bifidobacterium lactis BL-01 and Bifidobacterium longum BI-04)” and “Promotes the restoration of the intestinal microbiota during and after antibiotic use measured by enhanced levels of bifidobacteria in the intestine”

- 1 Bartosch S, Woodmansey EJ, Paterson JC, McMurdo ME, Macfarlane GT, 2005. Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis, 40, 28-37.
- 2 Engelbrektsen AL, Korzenik JR, Sanders ME, Clement BG, Leyer G, Klaenhammer TR, Kitts CL, 2006. Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol Ecol, 57, 239-250.
- 3 Engelbrektsen A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL, 2009. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. Journal of Medical Microbiology, 58, 663.

ID 2995: “Probiotic strain: Bifidobacterium lactis BI-04 (Formerly known as Bifidobacterium lactis BL-01 and Bifidobacterium longum BI-04)” and “Positively affects the immune response”

- 1 Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, Dewulf J, Brassart D, Mercenier A, Pot B, 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol, 13, 236-243.

ID 2996: “Probiotic supplement: Winclove 500” and “Intestinal microbiota”

- 1 Coomans M, Hazen M, Jonkers D, Maes J, Stobberingh E, 2002. De invloed van een probioticum versus een placebo op de fecale flora. External report, University of Maastricht, Dept of Medical Microbiology.
- 2 No authors listed, 2004. Survival of bifidobacteria in the GI tract. External report. Wageningen University, Molecular Ecology group.

ID 2997: “Probiotic supplement: Lactobact omni FOS” and “Intestinal microbiota”

- 1 Mulder L, 2007. In vitro inhibition of several potential pathogenic bacteria by probiotic strains in Lactobact omni FOS. Internal report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 2 Mulder L, 2007. Production of hydrogen peroxide by L. salivarius W24. Internal report, Winclove Bio Industries, Amsterdam, The Netherlands.
- 3 Müller M, Rathmann S, Grathwohl D, König D, Staats R, Moch K, Berg A, Intake of a probiotic food supplement changes fecal microflora and exercise-induced NK-cell decrease in endurance athletes. Freiburg University, Center for Internal Medicine, Dept. of Prevention, Rehabilitation and Sports Medicine, Gießen University, Institut für Ernährungswissenschaften, Germany.

ID 2998: “Probiotic supplement: Lactobact omni FOS” and “Reduces stress-induced immune responses measured by the suppression of Th2 cytokines and increased levels of sIgA, thereby promoting resistance to viral infections”

- 1 Müller M, Rathmann S, Grathwohl D, König D, Staats R, Moch K, Berg A, Intake of a probiotic food supplement changes fecal microflora and exercise-induced NK-cell decrease in endurance athletes. Freiburg University, Center for Internal Medicine, Dept. of Prevention, Rehabilitation and Sports Medicine, Gießen University, Institut für Ernährungswissenschaften, Germany.

- 2 Roll H, Rosler P, Lachtermann E, Jung K, 2000. Beeinflussung von sekretorischen IgA-Defiziten bei Sportstudenten durch Nahrungsergänzungsmittel. *Erfahrungsheilkunde*, 8, 489-494.
- 3 Van Uden N, 2006. Ex vivo production of several cytokines by probiotic strains in Lactobact omni FOS (Internal report). Winlove Bio Industries, Amsterdam, The Netherlands.

ID 2999: “Probiotic strain: Lactobacillus acidophilus LA-5” and “Lactose intolerance”

- 1 Jiang TY and Savaiano DA, 1993. Impact of lactobacilli supplements on colonic fermentation of lactose in vitro. Dept of Food Science and Nutrition, University of Minnesota.
- 2 Jiang T and Savaiano DA, 1997. In vitro lactose fermentation by human colonic bacteria is modified by Lactobacillus acidophilus supplementation. *J Nutr*, 127, 1489-1495.
- 3 Lin MY, Savaiano D, Harlander S, 1991. Influence of nonfermented dairy products containing bacterial starter cultures on lactose maldigestion in humans. *J Dairy Sci*, 74, 87-95.
- 4 Virta P, Otterstrom K, Niemi L, Wieser-Aho MT, Lahteenmaki AL, Leppanen T, 1993. The Effect of a Preparation Containing Freeze-Dried Lactic Acid Bacteria [L. acidophilus LA-5 (LA-1) and Bifidobacterium TB-12] on Lactose Intolerance. External Report, Pharmacia, Finland.

ID 3000: “Probiotic strain: Lactobacillus acidophilus LA-5” and “Contributes to gastro-intestinal well-being measured by the improvement of natural bowel movements and a normal intestinal passage”

- 1 Alm L, Ryd-Kjellen E, Setterberg G, Blomquist L, 1993. Effect of a new fermented milkproduct “Cultura” on constipation in geriatric patients. 1st Lactic acid bacteria computer conference proceedings.
- 2 Sagen OB, 1989. Treatment of functional disturbance in the intestine by administration of lactic acid bacteria. Internal report.